{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "accelerator": "GPU",
    "colab": {
      "name": "BERT_Innitial_Reranking.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "language": "python",
      "name": "python3"
    },
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "96472b679850423f99e8caa2d426cd16": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "state": {
            "_view_name": "HBoxView",
            "_dom_classes": [],
            "_model_name": "HBoxModel",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "box_style": "",
            "layout": "IPY_MODEL_4c38a03b3c724be781679004fd371968",
            "_model_module": "@jupyter-widgets/controls",
            "children": [
              "IPY_MODEL_63e5e89fce084a4b83342c5ab54d1774",
              "IPY_MODEL_582f22d8ef7245afb1ec581364b20d91"
            ]
          }
        },
        "4c38a03b3c724be781679004fd371968": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "63e5e89fce084a4b83342c5ab54d1774": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "state": {
            "_view_name": "ProgressView",
            "style": "IPY_MODEL_39c9bcbc0ed84577a3483e2a33263d36",
            "_dom_classes": [],
            "description": "Batches: 100%",
            "_model_name": "FloatProgressModel",
            "bar_style": "success",
            "max": 2657,
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": 2657,
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "orientation": "horizontal",
            "min": 0,
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_6041a6d8f1594273a0452bcee41bf0fb"
          }
        },
        "582f22d8ef7245afb1ec581364b20d91": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "state": {
            "_view_name": "HTMLView",
            "style": "IPY_MODEL_751bea229047417c908b64e260f222a1",
            "_dom_classes": [],
            "description": "",
            "_model_name": "HTMLModel",
            "placeholder": "​",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": " 2657/2657 [09:46&lt;00:00,  4.53it/s]",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_0d0385b1e85544b5983a373a2cab3a68"
          }
        },
        "39c9bcbc0ed84577a3483e2a33263d36": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "ProgressStyleModel",
            "description_width": "initial",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "bar_color": null,
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "6041a6d8f1594273a0452bcee41bf0fb": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "751bea229047417c908b64e260f222a1": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "DescriptionStyleModel",
            "description_width": "",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "0d0385b1e85544b5983a373a2cab3a68": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/HuyenNguyenHelen/MyTREC_2021/blob/main/BERT_Innitial_Reranking.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "X2R9TjVzNV_E",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "62cbae13-b213-4350-d356-945d4ded3ef7"
      },
      "source": [
        "!pip install -U sentence-transformers rank_bm25"
      ],
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Collecting sentence-transformers\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/3b/fd/8a81047bbd9fa134a3f27e12937d2a487bd49d353a038916a5d7ed4e5543/sentence-transformers-2.0.0.tar.gz (85kB)\n",
            "\r\u001b[K     |███▉                            | 10kB 25.3MB/s eta 0:00:01\r\u001b[K     |███████▋                        | 20kB 16.3MB/s eta 0:00:01\r\u001b[K     |███████████▌                    | 30kB 13.7MB/s eta 0:00:01\r\u001b[K     |███████████████▎                | 40kB 6.9MB/s eta 0:00:01\r\u001b[K     |███████████████████▏            | 51kB 7.6MB/s eta 0:00:01\r\u001b[K     |███████████████████████         | 61kB 7.9MB/s eta 0:00:01\r\u001b[K     |██████████████████████████▉     | 71kB 8.2MB/s eta 0:00:01\r\u001b[K     |██████████████████████████████▋ | 81kB 9.1MB/s eta 0:00:01\r\u001b[K     |████████████████████████████████| 92kB 6.4MB/s \n",
            "\u001b[?25hCollecting rank_bm25\n",
            "  Downloading https://files.pythonhosted.org/packages/16/5a/23ed3132063a0684ea66fb410260c71c4ffda3b99f8f1c021d1e245401b5/rank_bm25-0.2.1-py3-none-any.whl\n",
            "Collecting transformers<5.0.0,>=4.6.0\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/fd/1a/41c644c963249fd7f3836d926afa1e3f1cc234a1c40d80c5f03ad8f6f1b2/transformers-4.8.2-py3-none-any.whl (2.5MB)\n",
            "\u001b[K     |████████████████████████████████| 2.5MB 14.1MB/s \n",
            "\u001b[?25hRequirement already satisfied, skipping upgrade: tqdm in /usr/local/lib/python3.7/dist-packages (from sentence-transformers) (4.41.1)\n",
            "Requirement already satisfied, skipping upgrade: torch>=1.6.0 in /usr/local/lib/python3.7/dist-packages (from sentence-transformers) (1.9.0+cu102)\n",
            "Requirement already satisfied, skipping upgrade: torchvision in /usr/local/lib/python3.7/dist-packages (from sentence-transformers) (0.10.0+cu102)\n",
            "Requirement already satisfied, skipping upgrade: numpy in /usr/local/lib/python3.7/dist-packages (from sentence-transformers) (1.19.5)\n",
            "Requirement already satisfied, skipping upgrade: scikit-learn in /usr/local/lib/python3.7/dist-packages (from sentence-transformers) (0.22.2.post1)\n",
            "Requirement already satisfied, skipping upgrade: scipy in /usr/local/lib/python3.7/dist-packages (from sentence-transformers) (1.4.1)\n",
            "Requirement already satisfied, skipping upgrade: nltk in /usr/local/lib/python3.7/dist-packages (from sentence-transformers) (3.2.5)\n",
            "Collecting sentencepiece\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/ac/aa/1437691b0c7c83086ebb79ce2da16e00bef024f24fec2a5161c35476f499/sentencepiece-0.1.96-cp37-cp37m-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.2MB)\n",
            "\u001b[K     |████████████████████████████████| 1.2MB 47.0MB/s \n",
            "\u001b[?25hCollecting huggingface-hub\n",
            "  Downloading https://files.pythonhosted.org/packages/35/03/071adc023c0a7e540cf4652fa9cad13ab32e6ae469bf0cc0262045244812/huggingface_hub-0.0.13-py3-none-any.whl\n",
            "Collecting tokenizers<0.11,>=0.10.1\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/d4/e2/df3543e8ffdab68f5acc73f613de9c2b155ac47f162e725dcac87c521c11/tokenizers-0.10.3-cp37-cp37m-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_12_x86_64.manylinux2010_x86_64.whl (3.3MB)\n",
            "\u001b[K     |████████████████████████████████| 3.3MB 47.9MB/s \n",
            "\u001b[?25hRequirement already satisfied, skipping upgrade: importlib-metadata; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers) (4.5.0)\n",
            "Collecting sacremoses\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/75/ee/67241dc87f266093c533a2d4d3d69438e57d7a90abb216fa076e7d475d4a/sacremoses-0.0.45-py3-none-any.whl (895kB)\n",
            "\u001b[K     |████████████████████████████████| 901kB 46.1MB/s \n",
            "\u001b[?25hRequirement already satisfied, skipping upgrade: filelock in /usr/local/lib/python3.7/dist-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers) (3.0.12)\n",
            "Requirement already satisfied, skipping upgrade: requests in /usr/local/lib/python3.7/dist-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers) (2.23.0)\n",
            "Requirement already satisfied, skipping upgrade: packaging in /usr/local/lib/python3.7/dist-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers) (20.9)\n",
            "Requirement already satisfied, skipping upgrade: regex!=2019.12.17 in /usr/local/lib/python3.7/dist-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers) (2019.12.20)\n",
            "Requirement already satisfied, skipping upgrade: pyyaml in /usr/local/lib/python3.7/dist-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers) (3.13)\n",
            "Requirement already satisfied, skipping upgrade: typing-extensions in /usr/local/lib/python3.7/dist-packages (from torch>=1.6.0->sentence-transformers) (3.7.4.3)\n",
            "Requirement already satisfied, skipping upgrade: pillow>=5.3.0 in /usr/local/lib/python3.7/dist-packages (from torchvision->sentence-transformers) (7.1.2)\n",
            "Requirement already satisfied, skipping upgrade: joblib>=0.11 in /usr/local/lib/python3.7/dist-packages (from scikit-learn->sentence-transformers) (1.0.1)\n",
            "Requirement already satisfied, skipping upgrade: six in /usr/local/lib/python3.7/dist-packages (from nltk->sentence-transformers) (1.15.0)\n",
            "Requirement already satisfied, skipping upgrade: zipp>=0.5 in /usr/local/lib/python3.7/dist-packages (from importlib-metadata; python_version < \"3.8\"->transformers<5.0.0,>=4.6.0->sentence-transformers) (3.4.1)\n",
            "Requirement already satisfied, skipping upgrade: click in /usr/local/lib/python3.7/dist-packages (from sacremoses->transformers<5.0.0,>=4.6.0->sentence-transformers) (7.1.2)\n",
            "Requirement already satisfied, skipping upgrade: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests->transformers<5.0.0,>=4.6.0->sentence-transformers) (1.24.3)\n",
            "Requirement already satisfied, skipping upgrade: chardet<4,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests->transformers<5.0.0,>=4.6.0->sentence-transformers) (3.0.4)\n",
            "Requirement already satisfied, skipping upgrade: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests->transformers<5.0.0,>=4.6.0->sentence-transformers) (2021.5.30)\n",
            "Requirement already satisfied, skipping upgrade: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests->transformers<5.0.0,>=4.6.0->sentence-transformers) (2.10)\n",
            "Requirement already satisfied, skipping upgrade: pyparsing>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from packaging->transformers<5.0.0,>=4.6.0->sentence-transformers) (2.4.7)\n",
            "Building wheels for collected packages: sentence-transformers\n",
            "  Building wheel for sentence-transformers (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for sentence-transformers: filename=sentence_transformers-2.0.0-cp37-none-any.whl size=126711 sha256=16b8f27468b660d120d753beea9226c1704427e4598b2ede1245c508338e7548\n",
            "  Stored in directory: /root/.cache/pip/wheels/38/d2/98/d191289a877a34c68aa67e05179521e060f96394a3e9336be6\n",
            "Successfully built sentence-transformers\n",
            "\u001b[31mERROR: transformers 4.8.2 has requirement huggingface-hub==0.0.12, but you'll have huggingface-hub 0.0.13 which is incompatible.\u001b[0m\n",
            "Installing collected packages: tokenizers, sacremoses, huggingface-hub, transformers, sentencepiece, sentence-transformers, rank-bm25\n",
            "Successfully installed huggingface-hub-0.0.13 rank-bm25-0.2.1 sacremoses-0.0.45 sentence-transformers-2.0.0 sentencepiece-0.1.96 tokenizers-0.10.3 transformers-4.8.2\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "KWjIyYfctOmC"
      },
      "source": [
        "# Documents and Query processing"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "SuK0bdCvHgho"
      },
      "source": [
        "### Documents"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 202
        },
        "id": "GvuFFbNItLua",
        "outputId": "904717b4-7ae6-4d70-a8f0-04e917ac7290"
      },
      "source": [
        "import pandas as pd\n",
        "path = r\"/content/Text_New_Summary_OR_NER-BERN_Query2016_gene-disease-drug_2016(1).csv\"\n",
        "with open(path, 'r', encoding = 'utf-8' ) as f:\n",
        "    data = pd.read_csv(f, header = None, delimiter='\\t')\n",
        "data.columns = ['queryID','docID', 'score', 'concat_str']\n",
        "data.head()\n",
        "\n",
        "# column_names = [name.split(':')[0].replace('\\'', '') for name in data.columns]\n",
        "# column_names = [name.split(':')[0].replace(' ', '') for name in column_names]\n",
        "# data.columns = column_names\n",
        "# print(data.columns )\n",
        "\n",
        "# # Creating new data with some txt fields\n",
        "# new_data = data[['brief_title', 'official_title', 'brief_summary_text_block', 'concat_string']]\n",
        "# new_data['brief_summary_text_block'] = new_data['brief_summary_text_block'].apply(lambda x: x.split(':')[1].replace(\"'\",''))\n",
        "# new_data['brief_summary_text_block'].head()"
      ],
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>queryID</th>\n",
              "      <th>docID</th>\n",
              "      <th>score</th>\n",
              "      <th>concat_str</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1</td>\n",
              "      <td>4391998</td>\n",
              "      <td>16.155838</td>\n",
              "      <td>avail urea nitrogencreatinin gastrointestin bl...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>4529650</td>\n",
              "      <td>15.569978</td>\n",
              "      <td>duoden adenocarcinoma melena duoden melena mic...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>1</td>\n",
              "      <td>4798841</td>\n",
              "      <td>15.293642</td>\n",
              "      <td>preoper cavern hemangioma present melena wirel...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>1</td>\n",
              "      <td>3999026</td>\n",
              "      <td>15.052819</td>\n",
              "      <td>anemia melena pyeloduoden fistula stoneassoci ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>1</td>\n",
              "      <td>3113951</td>\n",
              "      <td>14.672893</td>\n",
              "      <td>ultrasonograph cow abomas lymphosarcoma descri...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "   queryID  ...                                         concat_str\n",
              "0        1  ...  avail urea nitrogencreatinin gastrointestin bl...\n",
              "1        1  ...  duoden adenocarcinoma melena duoden melena mic...\n",
              "2        1  ...  preoper cavern hemangioma present melena wirel...\n",
              "3        1  ...  anemia melena pyeloduoden fistula stoneassoci ...\n",
              "4        1  ...  ultrasonograph cow abomas lymphosarcoma descri...\n",
              "\n",
              "[5 rows x 4 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 13
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "cuovq0Vd9S6V"
      },
      "source": [
        "doc_txt = data['concat_str'].values.tolist()"
      ],
      "execution_count": 14,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "MsvRfiUbHluN"
      },
      "source": [
        "### Query"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 202
        },
        "id": "3jCKOV4_HpK4",
        "outputId": "72fca593-d20d-4219-8ea4-455422ead060"
      },
      "source": [
        "# Raw query\n",
        "'''\n",
        "# Loading the Query [2016/2021]\n",
        "## Query 2016\n",
        "import pandas as pd\n",
        "import xml.etree.ElementTree as ET\n",
        "\n",
        "tree = ET.parse(r\"/content/topics2016.xml\")\n",
        "root = tree.getroot()\n",
        "\n",
        "queryID, note, description, summary=[],[],[], []\n",
        "\n",
        " \n",
        "i=0\n",
        "while i<len(root):\n",
        "    queryID.append(i+1)\n",
        "    for j in range (len(root[i])):\n",
        "        if root[i][j].tag == 'note':\n",
        "            note.append(root[i][j].text.replace('\\n',''))\n",
        "        if root[i][j].tag == 'summary':\n",
        "            summary.append(root[i][j].text)\n",
        "        if root[i][j].tag == 'description':\n",
        "            description.append(root[i][j].text)\n",
        "  \n",
        "    i+=1\n",
        "    \n",
        "queries = pd.DataFrame(zip(queryID, note, description, summary), columns =['queryID', 'note', 'description', 'summary'] )\n",
        "queries.head()\n",
        "'''"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>queryID</th>\n",
              "      <th>note</th>\n",
              "      <th>description</th>\n",
              "      <th>summary</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>1</td>\n",
              "      <td>78 M w/ pmh of CABG in early [**Month (only...</td>\n",
              "      <td>78 M transferred to nursing home for rehab aft...</td>\n",
              "      <td>A 78 year old male presents with frequent stoo...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>2</td>\n",
              "      <td>Ms [**Known patient lastname 241**] is a [*...</td>\n",
              "      <td>An elderly female with past medical history of...</td>\n",
              "      <td>An elderly female with past medical history of...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>3</td>\n",
              "      <td>Pt is a 75F with a PMHx significant for sev...</td>\n",
              "      <td>A 75F with a PMHx significant for severe PVD, ...</td>\n",
              "      <td>A 75F found to be hypoglycemic with hypotensio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>4</td>\n",
              "      <td>The patient is an 87 yo woman with h/o oste...</td>\n",
              "      <td>An 87 yo woman with h/o osteoporosis, multiple...</td>\n",
              "      <td>An 87 yo woman with h/o osteoporosis, DM2, dem...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>5</td>\n",
              "      <td>An 82 M with COPD, s/p bioprosthetic AVR fo...</td>\n",
              "      <td>An 82 man with chronic obstructive pulmonary d...</td>\n",
              "      <td>An 82 man with multiple chronic conditions and...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "   queryID  ...                                            summary\n",
              "0        1  ...  A 78 year old male presents with frequent stoo...\n",
              "1        2  ...  An elderly female with past medical history of...\n",
              "2        3  ...  A 75F found to be hypoglycemic with hypotensio...\n",
              "3        4  ...  An 87 yo woman with h/o osteoporosis, DM2, dem...\n",
              "4        5  ...  An 82 man with multiple chronic conditions and...\n",
              "\n",
              "[5 rows x 4 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 302
        },
        "id": "kUa7kVrradSD",
        "outputId": "1ad7c10f-0f92-489c-a215-3fe83f4cd161"
      },
      "source": [
        "# Processed query 2016\n",
        "path = r\"/content/NER-BERN_Query2021_gene-disease-drug.csv\"\n",
        "with open(path, 'r', encoding = 'utf-8' ) as f:\n",
        "    query = pd.read_csv(f)\n",
        "query['NERgdd'] = query['NERgdd'].apply(labda x: ''.join([i for i in x.split(',')]))\n",
        "query.head()\n"
      ],
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Unnamed: 0</th>\n",
              "      <th>QueryID</th>\n",
              "      <th>Age</th>\n",
              "      <th>Gender</th>\n",
              "      <th>Main_text</th>\n",
              "      <th>Main_text_NER</th>\n",
              "      <th>NERgdd</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>45</td>\n",
              "      <td>Male</td>\n",
              "      <td>Patient is a 45-year-old man with a history of...</td>\n",
              "      <td>{'disease': 'anaplastic astrocytoma of the spi...</td>\n",
              "      <td>anaplastic astrocytoma of the spine,temozolomide</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>48</td>\n",
              "      <td>Male</td>\n",
              "      <td>48 M with a h/o HTN hyperlipidemia, bicuspid a...</td>\n",
              "      <td>{'disease': 'HTN hyperlipidemia', 'gene': 'EF'...</td>\n",
              "      <td>HTN hyperlipidemia,EF,Lasix</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2</td>\n",
              "      <td>3</td>\n",
              "      <td>32</td>\n",
              "      <td>Female</td>\n",
              "      <td>A 32 yo woman who presents following a severe ...</td>\n",
              "      <td>{'disease': 'intraventricular hemorrhage', 'sp...</td>\n",
              "      <td>intraventricular hemorrhage</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>3</td>\n",
              "      <td>4</td>\n",
              "      <td>44</td>\n",
              "      <td>Female</td>\n",
              "      <td>This is a 44 year old female with PMH of PCOS,...</td>\n",
              "      <td>{'disease': 'PMH', 'gene': 'kappa light chain'}</td>\n",
              "      <td>PMH,kappa light chain</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>4</td>\n",
              "      <td>5</td>\n",
              "      <td>74</td>\n",
              "      <td>Male</td>\n",
              "      <td>74M hx of CAD s/p CABG, EF 60% prior CVA (no r...</td>\n",
              "      <td>{'disease': 'CAD', 'species': 'patient'}</td>\n",
              "      <td>CAD</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "   Unnamed: 0  ...                                            NERgdd\n",
              "0           0  ...  anaplastic astrocytoma of the spine,temozolomide\n",
              "1           1  ...                       HTN hyperlipidemia,EF,Lasix\n",
              "2           2  ...                       intraventricular hemorrhage\n",
              "3           3  ...                             PMH,kappa light chain\n",
              "4           4  ...                                               CAD\n",
              "\n",
              "[5 rows x 7 columns]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 17
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 128
        },
        "id": "9Czir6DohIlH",
        "outputId": "ae285220-ce01-477a-ca54-343ed8254af5"
      },
      "source": [
        "# Processing query"
      ],
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "error",
          "ename": "IndentationError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;36m  File \u001b[0;32m\"<ipython-input-23-153d06b60a3a>\"\u001b[0;36m, line \u001b[0;32m12\u001b[0m\n\u001b[0;31m    '''\u001b[0m\n\u001b[0m        ^\u001b[0m\n\u001b[0;31mIndentationError\u001b[0m\u001b[0;31m:\u001b[0m unindent does not match any outer indentation level\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "ZyP3dXRfcXLa"
      },
      "source": [
        "# Question-Answering using Simple Wikipedia Index\n",
        "\n",
        "This examples demonstrates the setup for Query / Question-Answer-Retrieval.\n",
        "\n",
        "You can input a query or a question. The script then uses semantic search\n",
        "to find relevant passages in Simple English Wikipedia (as it is smaller and fits better in RAM).\n",
        "\n",
        "For semantic search, we use SentenceTransformer('msmarco-distilbert-base-v2') and retrieve\n",
        "100 potentially passages that answer the input query.\n",
        "\n",
        "Next, we use a more powerful CrossEncoder (cross_encoder = CrossEncoder('cross-encoder/ms-marco-TinyBERT-L-6')) that\n",
        "scores the query and all retrieved passages for their relevancy. The cross-encoder is neccessary to filter out certain noise\n",
        "that might be retrieved from the semantic search step.\n"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 199,
          "referenced_widgets": [
            "96472b679850423f99e8caa2d426cd16",
            "4c38a03b3c724be781679004fd371968",
            "63e5e89fce084a4b83342c5ab54d1774",
            "582f22d8ef7245afb1ec581364b20d91",
            "39c9bcbc0ed84577a3483e2a33263d36",
            "6041a6d8f1594273a0452bcee41bf0fb",
            "751bea229047417c908b64e260f222a1",
            "0d0385b1e85544b5983a373a2cab3a68"
          ]
        },
        "id": "D_hDi8KzNgMM",
        "outputId": "6549eb2a-5804-49b2-d7ff-281375b76856"
      },
      "source": [
        "import json\n",
        "from sentence_transformers import SentenceTransformer, CrossEncoder, util\n",
        "import time\n",
        "import gzip\n",
        "import os\n",
        "import torch\n",
        "\n",
        "if not torch.cuda.is_available():\n",
        "    print(\"Warning: No GPU found. Please add GPU to your notebook\")\n",
        "\n",
        "# We use the Bi-Encoder to encode all passages, so that we can use it with sematic search\n",
        "model_name = 'msmarco-MiniLM-L-6-v3'\n",
        "bi_encoder = SentenceTransformer(model_name)\n",
        "top_k = 100  # Number of passages we want to retrieve with the bi-encoder\n",
        "\n",
        "# The bi-encoder will retrieve 100 documents. We use a cross-encoder, to re-rank the results list to improve the quality\n",
        "cross_encoder = CrossEncoder('cross-encoder/ms-marco-MiniLM-L-6-v2')\n",
        "        \n",
        "# Here, we compute the corpus_embeddings from scratch (which can take a while depending on the GPU)\n",
        "corpus_embeddings = bi_encoder.encode(doc_txt, convert_to_tensor=True, show_progress_bar=True)\n",
        "print(corpus_embeddings)"
      ],
      "execution_count": 19,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "96472b679850423f99e8caa2d426cd16",
              "version_minor": 0,
              "version_major": 2
            },
            "text/plain": [
              "HBox(children=(FloatProgress(value=0.0, description='Batches', max=2657.0, style=ProgressStyle(description_wid…"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "stream",
          "text": [
            "\n",
            "tensor([[ 0.3816,  0.0557,  0.1371,  ..., -0.0199,  0.4855,  0.2420],\n",
            "        [ 0.0024, -0.2993,  0.0318,  ..., -0.3888, -0.2327,  0.1130],\n",
            "        [ 0.0950,  0.0926,  0.4330,  ..., -0.4781,  0.3871,  0.3569],\n",
            "        ...,\n",
            "        [-0.4757, -0.4969, -0.2152,  ..., -0.0865,  0.4372, -0.4299],\n",
            "        [-0.1003, -0.0306,  0.1446,  ..., -0.1608,  0.4007,  0.2513],\n",
            "        [-0.3700, -0.0859, -0.0194,  ..., -0.1801, -0.0886,  0.5117]],\n",
            "       device='cuda:0')\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "UlArb7kqN3Re"
      },
      "source": [
        "# This function will search all wikipedia articles for passages that\n",
        "# answer the query\n",
        "def search(query):\n",
        "\n",
        "    ##### Sematic Search #####\n",
        "    # Encode the query using the bi-encoder and find potentially relevant passages\n",
        "    question_embedding = bi_encoder.encode(query, convert_to_tensor=True)\n",
        "    question_embedding = question_embedding.cuda()\n",
        "    hits = util.semantic_search(question_embedding, corpus_embeddings, top_k=top_k)\n",
        "    hits = hits[0]  # Get the hits for the first query\n",
        "\n",
        "    ##### Re-Ranking #####\n",
        "    # Now, score all retrieved passages with the cross_encoder\n",
        "    cross_inp = [[query, doc_txt[hit['corpus_id']]] for hit in hits]\n",
        "    cross_scores = cross_encoder.predict(cross_inp)\n",
        "\n",
        "    # Sort results by the cross-encoder scores\n",
        "    for idx in range(len(cross_scores)):\n",
        "        hits[idx]['cross-score'] = cross_scores[idx]\n",
        "\n",
        "    # Output of top-5 hits from bi-encoder\n",
        "    print(\"\\n-------------------------\\n\")\n",
        "    print(\"Top-3 Bi-Encoder Retrieval hits\")\n",
        "    hits_en = sorted(hits, key=lambda x: x['score'], reverse=True)\n",
        "    for hit in hits_en[0:3]:\n",
        "         print(\"\\t{:.3f}\\t{}\".format(hit['score'], doc_txt[hit['corpus_id']].replace(\"\\n\", \" \")))\n",
        "\n",
        "    # Output of top-5 hits from re-ranker\n",
        "    print(\"\\n-------------------------\\n\")\n",
        "    print(\"Top-3 Cross-Encoder Re-ranker hits\")\n",
        "    hits_re = sorted(hits, key=lambda x: x['cross-score'], reverse=True)\n",
        "    for hit in hits_re[0:3]:\n",
        "        print(\"\\t{:.3f}\\t{}\".format(hit['cross-score'], doc_txt[hit['corpus_id']].replace(\"\\n\", \" \")))\n",
        "    #return hits_re['cross-score'], doc_txt[int(hits_re['corpus_id'])]\n",
        "\n",
        "\n",
        "\n",
        "\n"
      ],
      "execution_count": 20,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2J0Zxgw0artg",
        "outputId": "ba35d740-76a7-4062-9e22-130532a51475"
      },
      "source": [
        "search(query = \"A 78 year old male presents with frequent stools and melena\")"
      ],
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.436\tsolitari peutzjegh polyp jejunum yearold 19year old melena anemia duodenoscopi abnorm bowel xray jejun polyp cm polyp visualis perop bowel endoscopi subsequ surgic remov polyp characterist histolog appear peutzjegh polyp sign peutzjegh characterist mucocutan pigment polyp remov polyp melena recur hemoglobin normal altogeth fulfil peutzjegh solitari jejun peutzjegh polyp polyp  backgroundcas presentationdiscussionconclusionabbreviationscompet interestsauthor contributionscons peutzjegh pj famili occurr gastrointestin hamartomat polyp mucocutan hyperpigment pj histolog peutzjegh polyp pjp pjp pj characterist promin mucocutan pigment pj pjp characterist promin mucocutan pigment pj gastrointestin extraintestin malign gastrointestin hamartomat polyp pj histolog appear interdigit smooth fiber form characterist branch tree arbor polyp pj solitari pjp typic mucocutan pj except 22year old solitari pjp yearold present melena bleed pjp jejunum bleed solitari pjp jejunum typic pj consider younger solitari pjp abbrevi\n",
            "\t0.363\tmeasur old portug crosssect age 75 ensur becam aim elderli 75 urban set cross section qol portugues version easycar descript inferenti eighti elderli diabet 809 43 old widow marri educ live urban mediumlow incom 112 101 antidiabet glycem excess uncontrol notic perceiv worst perceiv wellb sociodemograph gender monthli incom live arrang interf modestli urban set treat elderli glycem paid qol incom diabet live arrang thoroughli wellb elderlyqu lifetyp diabetesprimari backgroundmethodsstudi participantsmeasuresdata collectiondata analysiseth considerationsresultssampl characterizationperceiv lifeanalysi sociodemograph perceiv lifediscussionconclusioncompet interestsauthor contribut th centuri age demograph featur elderli repres 600 million 2045 surpass worldwid grow billion concern repercuss age societi worldwid promot idea elderli take mainten mobil independ age multitud isn consensu definit old multidimension holist concept includ healthrel age rise oldold 75 likelihood next decad ill elect prioriti provid comprehens personcentr biggest challeng centuri warrant elderli deal old accept elderli diabet set geriatr syndrom hypoglycemia live home independ qol aim perceiv qol age 75 urban unit analys sociodemograph profil qol purpos easycar instrument recommend establish link concept subject wellb enabl multidimension comprehens systemat set believ contribut urban set treat elderli glycem paid qol incom diabet live arrang thoroughli wellb compet interest\n",
            "\t0.363\tmeasur old portug crosssect age 75 ensur becam aim elderli 75 urban set cross section qol portugues version easycar descript inferenti eighti elderli diabet 809 43 old widow marri educ live urban mediumlow incom 112 101 antidiabet glycem excess uncontrol notic perceiv worst perceiv wellb sociodemograph gender monthli incom live arrang interf modestli urban set treat elderli glycem paid qol incom diabet live arrang thoroughli wellb elderlyqu lifetyp diabetesprimari backgroundmethodsstudi participantsmeasuresdata collectiondata analysiseth considerationsresultssampl characterizationperceiv lifeanalysi sociodemograph perceiv lifediscussionconclusioncompet interestsauthor contribut th centuri age demograph featur elderli repres 600 million 2045 surpass worldwid grow billion concern repercuss age societi worldwid promot idea elderli take mainten mobil independ age multitud isn consensu definit old multidimension holist concept includ healthrel age rise oldold 75 likelihood next decad ill elect prioriti provid comprehens personcentr biggest challeng centuri warrant elderli deal old accept elderli diabet set geriatr syndrom hypoglycemia live home independ qol aim perceiv qol age 75 urban unit analys sociodemograph profil qol purpos easycar instrument recommend establish link concept subject wellb enabl multidimension comprehens systemat set believ contribut urban set treat elderli glycem paid qol incom diabet live arrang thoroughli wellb compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.025\tsolitari peutzjegh polyp jejunum yearold 19year old melena anemia duodenoscopi abnorm bowel xray jejun polyp cm polyp visualis perop bowel endoscopi subsequ surgic remov polyp characterist histolog appear peutzjegh polyp sign peutzjegh characterist mucocutan pigment polyp remov polyp melena recur hemoglobin normal altogeth fulfil peutzjegh solitari jejun peutzjegh polyp polyp  backgroundcas presentationdiscussionconclusionabbreviationscompet interestsauthor contributionscons peutzjegh pj famili occurr gastrointestin hamartomat polyp mucocutan hyperpigment pj histolog peutzjegh polyp pjp pjp pj characterist promin mucocutan pigment pj pjp characterist promin mucocutan pigment pj gastrointestin extraintestin malign gastrointestin hamartomat polyp pj histolog appear interdigit smooth fiber form characterist branch tree arbor polyp pj solitari pjp typic mucocutan pj except 22year old solitari pjp yearold present melena bleed pjp jejunum bleed solitari pjp jejunum typic pj consider younger solitari pjp abbrevi\n",
            "\t-5.316\tintussuscept intestin melanoma gastrointestin tract fairli frequent melanoma metastas bowel intussuscept melanoma 77yearold man admit epigastr melena anaemia radiolog workup jejun intussuscept exploratori laparoscopi aris jejunum cm distal angl treitz bowel resect endtoend anastomosi histolog intestin melanoma theori concern origin malign melanoma bowel intestin normal contain melanocyt occasion alimentari tract lymph node support theori origin melanoma solitari intestin lesion cutan melanoma conclud melanoma intestin  introductioncas reportdiscussionconclus melanoma intestin metastas cutan complic occlus bleed anaemia perfor intestin bowel intussuscept 84836 melanoma 912 cutan 52 ocular origin gastrointestin mucosa malign melanoma gastrointestin tract lesion extrem melanoma gastrointestin tract extrem neoplast lesion unusu intussuscept regardless exact origin melanot lesion choic extens resect wedg resect mesenteri\n",
            "\t-5.953\tcathet ablat atrial fibril elderli atrial fibril af cathet ablat emerg promis af adopt elderli aim af cathet ablat elderli consist 316 paroxysm af underw atrial ablat ninetyf 65 48 male 689 old 221 65 old 130 male 525 104 old 340 151 55 579 elderli arrhythmia recurr 149 674 younger 0169 procedur uncommon logist regress atrial diamet 0003 0001 dyslipidemia 0039 coronari arteri 0018 predictor af recurr elderli cathet ablat af safe invas choic symptomat elderli af ablationatri fibrillationth elderli introductionmethodspatientscathet ablat procedurepostabl followupstatist analysisresultsclin echocardiograph procedur age 65 65 oldclin echocardiograph procedur age 65 old af recurr cathet ablationsummari atrial fibril cathet ablat elderlydiscuss atrial fibril af arrhythmia reach age 80 af 2030 europ million af 120000 215000 expect af elderli becom concern af comorbid obstruct place thromboembol antiarrhythm predict age frequent proarrhythmia af cathet ablat adopt elderli elderli initi exclud cathet ablat concern progress cathet ablat elderli option af aim af cathet ablat predictor af recurr cathet ablat af safe elderli success differ younger younger display term lad dyslipidemia cad predictor af recurr cathet ablat elderli atrial ablat come younger comorbid radiofrequ cathet ablat elderli corrado success 73 75 zado atrial ablat 65 65 74 75 89 84 86 bhargava success younger kusumoto success 84 age 65 75 old month tan success af cathet ablat respect 70 80 72 7079 74 69 bunch success 78 octogenarian month chine af cathet ablat exhibit success elderli 773 younger one 793 lin present af cathet ablat premenopaus 94 435 70 old postmenopaus 649 642 74 old 43 success respect 543 premenopaus 542 postmenopaus promis cryoballoon ablat age 70 115 47 ablat 62 recurr atrial arrhythmia display success younger one 579 674 didnt reach signific predictor arrhythmia recurr elderli younger elderli complic atrial ablat younger accord cathet ablat elimin vein trigger atrial substrat quit elderli electrophysiolog promin atrial fibrosi atrial atrophi connect age reduct atrial voltag atrial refractori conduct slow recurr af display la voltag la scar electrophysiolog arrhythmia recurr cathet ablat elderli tradit dyslipidemia predictor af recurr quit term success cathet ablat af safe reason offer modal elderli excess bradycardia rhythm antiarrhythm proarrhythmia invas choic symptomat elderli af asymptomat episod af recogn af recurr ambulatori adopt success overestim asymptomat episod paroxysm af elderli valid\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "uOPVUKkxea_h",
        "outputId": "a5d9a2d7-f707-46b2-c42a-c4d20005b428"
      },
      "source": [
        "f = open(r'temp1.txt','w')\n",
        "for q1,q2 in zip(query['QueryID'], query['NERgdd']):\n",
        "  output1 = {}\n",
        "  output2 = {}\n",
        "  output1[q2] = search(q2)\n",
        "  output2[q1] = search(q2)\n",
        "  for k, v in output1.items():\n",
        "    print(k, v)\n"
      ],
      "execution_count": 25,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.447\tamylas polymorph drosophila melanogast haplotyp frequenc tropic african american    full articl plea pdf \n",
            "\t0.445\tbench bedsid everolimu subependym giant astrocytoma tuber sclerosi optic regener cytotoxin glioma  axon regenerationneuroscienceneurosurgerytuber sclerosi complextarget cytotoxin everolimu subependym giantcel astrocytoma tuber sclerosi pointstun arous optogenet modul locu coeruleu pointslongdist axon regener matur optic contribut oncomodulin camp pten delet pointsgen therapymedi cytotoxin glioma therapeut point  \n",
            "\t0.421\tsuperparamagnet bifunct bisphosphon nanoparticl mri agent osteoporosi nanosystem magnet agent magnet reson mri agent bisphosphon nanoplatform consist superparamagnet fe nanoparticl conjug 15dihydroxy155trisphosphonopentylphosphon dihmbp bisphosphon outer nanoparticl assynthes nanoparticl mri agent adsorpt onto hydroxyapatit mri measur adsorpt bisphosphon nanoparticl hydroxyapatit mri t2 agent osteosarcoma mg63 fe dihmbp hybrid nanomateri citox viabil  introduction2 methods21 reagent22 15dihydroxy155trisphosphonopentylphosphon dihmbps23 dihmbp nanocrystals24 nanocryst characterization25 charg dihmbp nanocrystals26 calcium complexometr titration27 magnet magnet reson imaging28 hydroxyapatit targeting29 viability210 labelling3 discussion4  bonetarget mri agent superparamagnet nanoparticl bisphosphon moieti hmbp function exhibit iron calcium complex feasibl nanosystem complex hydroxyapatit miner osteoporot fractur superparamagnet nanoparticl mri agent osteoporosi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.442\tanaplast medullari ependymoma present subarachnoid hemorrhag a41year old man violent thunderclap headach bilater propriocept sensibl deficit upper limb cerebr ct scan mri lumbar punctur subarachnoid hemorrhag sah cerebr angiographi paraparesi thorough workup diffus anaplast extramedullari c7d10 ependymoma mening carcinomatosi hemorrhag went d5d8 laminectomi temozolomid radiotherapi situat remain emphas spinal mass sah aneurysm arterioven malform  introduction2 presentation3 discus subarachnoid hemorrhag sah normal intracrani mostli aneurysm malform sah spinal mostli consequ spinal trauma arterioven malform spinal mass minor sah ependymoma meningioma hemangioblastoma consid propos clearer concern workup subarachnoid hemorrhag lumbar punctur ct scan sah investig spinal mass cerebr angiographi emphas investig spinal column subarachnoid hemorrhag cerebr angiographi present insidi prolong state repeat angiographi modal reveal thrombos aneurysm mri flair convex hemorrhag ct scan lumbar punctur cervicodorsolumbar mri reward spinal neoplast ulrich ependymoma present sah myxopapillari ependymoma lumbar spine conu medullari matter workup spinal axi alway sah cerebr angiographi\n",
            "\t-6.168\tbench bedsid everolimu subependym giant astrocytoma tuber sclerosi optic regener cytotoxin glioma  axon regenerationneuroscienceneurosurgerytuber sclerosi complextarget cytotoxin everolimu subependym giantcel astrocytoma tuber sclerosi pointstun arous optogenet modul locu coeruleu pointslongdist axon regener matur optic contribut oncomodulin camp pten delet pointsgen therapymedi cytotoxin glioma therapeut point  \n",
            "\t-7.067\tanatom guidanc ablat atrial flutter fibril outflow tract ventricular tachycardia document excel radiofrequ ablat increasingli situat arrhythmia circumst accur anatom ablat maintain discus anatomi electrophysiolog typic atrial flutter atrial fibril outflow tract ventricular tachycardia pediatr maintain know neighbor region anatomi arrhythmogen substrat arrhythmia go prevent atrial flutteratri fibrillationanatomyablationelectrophysiolog introductiontyp atrial flutterregion anatomysubeustachian ridgesubeustachian pouchespromin pectin musclesatyp flutter atyp situat cvtidepend flutter occursatri fibrillationpulmonari vein ostiumarteri atrial ablationth esophagusoutflow tract ventricular tachycardiaanatom overlap structuresavoid arteri injuryth conduct autonom innvervationconclus perhap subspecialti cardiolog requir appreci detail region anatomi electrophysiolog hardli arrhythmia ablat anatomi appreci perform arrhythmia anatom becom mandatori anatom present ablat atrial flutter atrial fibril outflow tract ventricular tachycardia anatomi avoid pediatr emphas arrhythmia arrhythmia serv templat student electrophysiolog appreci region anatomi guid safe ablat\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.447\tamylas polymorph drosophila melanogast haplotyp frequenc tropic african american    full articl plea pdf \n",
            "\t0.445\tbench bedsid everolimu subependym giant astrocytoma tuber sclerosi optic regener cytotoxin glioma  axon regenerationneuroscienceneurosurgerytuber sclerosi complextarget cytotoxin everolimu subependym giantcel astrocytoma tuber sclerosi pointstun arous optogenet modul locu coeruleu pointslongdist axon regener matur optic contribut oncomodulin camp pten delet pointsgen therapymedi cytotoxin glioma therapeut point  \n",
            "\t0.421\tsuperparamagnet bifunct bisphosphon nanoparticl mri agent osteoporosi nanosystem magnet agent magnet reson mri agent bisphosphon nanoplatform consist superparamagnet fe nanoparticl conjug 15dihydroxy155trisphosphonopentylphosphon dihmbp bisphosphon outer nanoparticl assynthes nanoparticl mri agent adsorpt onto hydroxyapatit mri measur adsorpt bisphosphon nanoparticl hydroxyapatit mri t2 agent osteosarcoma mg63 fe dihmbp hybrid nanomateri citox viabil  introduction2 methods21 reagent22 15dihydroxy155trisphosphonopentylphosphon dihmbps23 dihmbp nanocrystals24 nanocryst characterization25 charg dihmbp nanocrystals26 calcium complexometr titration27 magnet magnet reson imaging28 hydroxyapatit targeting29 viability210 labelling3 discussion4  bonetarget mri agent superparamagnet nanoparticl bisphosphon moieti hmbp function exhibit iron calcium complex feasibl nanosystem complex hydroxyapatit miner osteoporot fractur superparamagnet nanoparticl mri agent osteoporosi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.442\tanaplast medullari ependymoma present subarachnoid hemorrhag a41year old man violent thunderclap headach bilater propriocept sensibl deficit upper limb cerebr ct scan mri lumbar punctur subarachnoid hemorrhag sah cerebr angiographi paraparesi thorough workup diffus anaplast extramedullari c7d10 ependymoma mening carcinomatosi hemorrhag went d5d8 laminectomi temozolomid radiotherapi situat remain emphas spinal mass sah aneurysm arterioven malform  introduction2 presentation3 discus subarachnoid hemorrhag sah normal intracrani mostli aneurysm malform sah spinal mostli consequ spinal trauma arterioven malform spinal mass minor sah ependymoma meningioma hemangioblastoma consid propos clearer concern workup subarachnoid hemorrhag lumbar punctur ct scan sah investig spinal mass cerebr angiographi emphas investig spinal column subarachnoid hemorrhag cerebr angiographi present insidi prolong state repeat angiographi modal reveal thrombos aneurysm mri flair convex hemorrhag ct scan lumbar punctur cervicodorsolumbar mri reward spinal neoplast ulrich ependymoma present sah myxopapillari ependymoma lumbar spine conu medullari matter workup spinal axi alway sah cerebr angiographi\n",
            "\t-6.168\tbench bedsid everolimu subependym giant astrocytoma tuber sclerosi optic regener cytotoxin glioma  axon regenerationneuroscienceneurosurgerytuber sclerosi complextarget cytotoxin everolimu subependym giantcel astrocytoma tuber sclerosi pointstun arous optogenet modul locu coeruleu pointslongdist axon regener matur optic contribut oncomodulin camp pten delet pointsgen therapymedi cytotoxin glioma therapeut point  \n",
            "\t-7.067\tanatom guidanc ablat atrial flutter fibril outflow tract ventricular tachycardia document excel radiofrequ ablat increasingli situat arrhythmia circumst accur anatom ablat maintain discus anatomi electrophysiolog typic atrial flutter atrial fibril outflow tract ventricular tachycardia pediatr maintain know neighbor region anatomi arrhythmogen substrat arrhythmia go prevent atrial flutteratri fibrillationanatomyablationelectrophysiolog introductiontyp atrial flutterregion anatomysubeustachian ridgesubeustachian pouchespromin pectin musclesatyp flutter atyp situat cvtidepend flutter occursatri fibrillationpulmonari vein ostiumarteri atrial ablationth esophagusoutflow tract ventricular tachycardiaanatom overlap structuresavoid arteri injuryth conduct autonom innvervationconclus perhap subspecialti cardiolog requir appreci detail region anatomi electrophysiolog hardli arrhythmia ablat anatomi appreci perform arrhythmia anatom becom mandatori anatom present ablat atrial flutter atrial fibril outflow tract ventricular tachycardia anatomi avoid pediatr emphas arrhythmia arrhythmia serv templat student electrophysiolog appreci region anatomi guid safe ablat\n",
            "anaplastic astrocytoma of the spine,temozolomide None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.518\thypercalcemia dissemin paracoccidioidomycosi hypercalcemia granulomat sarcoidosi tuberculosi berylliosi leprosi fungal paracoccidioid brasiliensi hypercalcemia neither document etiolog hypercalcemia 22yearold man dissemin paracoccidioidomycosi hypercalcemia 125dihydroxyvitamin suppress parathyroid hormon indic hypercalcemia parathyroid hormon 125dihydroxyvitamin episod resolv readili corticosteroid hypercalcemia origin receiv antifung brasiliensi calcium remain  introductioncas presentationdiscussionconclusionabbreviationscompet interestsauthor contributionscons hypercalcemia granulomat sarcoidosi tuberculosi berylliosi leprosi fungal fungal dissemin candidiasi histoplasmosi cryptococcosi coccidioidomycosi rare implic hypercalcemia hypercalcemia dissemin paracoccidioid brasiliensi 125dihydroxyvitamin hypercalcemia dissemin brasiliensi 125dihydroxyvitamin abbrevi\n",
            "\t0.434\tesophag cryoballoon ablat paroxysm atrial fibril lgemri   backgroundmethodsresultsconclusionsfund esophag wall thermal cryoballoon ablat seriou complic lategadolinium enhanc mri lgemri accur noninvas compar relationsship esophag lgemri vein isol pvi arctic front af artic front afa cryoballoon paroxysm atrial fibril paf preliminari esophag lgemri cryoballoon ablat anatom esophagu atrium cryoballoon anatom locat esophagu easili as mri ablat fund\n",
            "\t0.434\tesophag cryoballoon ablat paroxysm atrial fibril lgemri   backgroundmethodsresultsconclusionsfund esophag wall thermal cryoballoon ablat seriou complic lategadolinium enhanc mri lgemri accur noninvas compar relationsship esophag lgemri vein isol pvi arctic front af artic front afa cryoballoon paroxysm atrial fibril paf preliminari esophag lgemri cryoballoon ablat anatom esophagu atrium cryoballoon anatom locat esophagu easili as mri ablat fund\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.332\tsterol marinederiv omega3 fatti ingredi frontier treat hyperlipidemia hyperlipidemia hypercholesterolemia hc hypertriglyceridemia htn continu north america healthcar continu seek efficaci safe therapi complement evergrow food nutraceut ffn hyperlipidemia recept amongst implement ffn guidelin continu lag demonstr ffn modul perpetu hyperlipidemia consist combin ffn marinederiv omega3 fatti sterolsstanol statin enhanc triglycerid cholesterollow purpos commentari contend efficaci ffn hc htg boost lipidlow hypolipidem editori aim guidelin emphas efficaci ffn hyperlipidemia adjunct pharmacotherapi  introductionclin food nutraceut treat hyperlipidemiafunct food nutraceut modul endpointsfunct food nutraceut adjunct therapiesfutur direct incorpor food nutraceut hyperlipidem guidelinesconclusionsabbreviationscompet interestsauthor contributionsauthor hyperlipidemia hypercholesterolemia hc hypertriglyceridemia htg form burden north america american meet extraordinarili hc htg amongst 69 65 hyperlipidemia atherosclerosi lifestyl hc htg lifestyl ineffect begin exhibit healthcar practition turn lipidlow said food nutraceut ffn grow genr therapi hyperlipidemia administ nonetheless question ffn posit guidelin hc htg decad consider amongst direct toward enhanc ffn therapi lifestylerel worsen advanc discount ffn diseasethwart hypercholesterolemia escal ldlc cholesterol ncep describ sterolsstanol p option circul ldlc plethora peerreview articl demonstr reduct ldlc p ncep p fortifi food constitu lifestyl p emphas latter introduc regimen similarli marin omega3 fatti mom3 fiber nut soy endpoint htg hc p adopt regimen demonstr ffn p mom3 complement produc pharmacomonotherapi food nutraceut mere lifestyl ffn contain bioactiv substanc administ dose modul foster gap exist ffn close ffn implement guidelin hyperlipidemia optim throughout sterol marinederiv omega3 fatti insolubl fibr dyslipidemia sterol p displac dietari cholesterol mix micel absorb p activ lxr atpbind cassett transport abcg pump absorb p back intestin lumen marinederiv omega3 fatti mom3 peroxisom prolifer ppar farnesol fxr hepatocyt nuclear4 hnf4 lxr altogeth modul mom3 triglycerid oxid lipoprotein lipas lpl alongsid triglycerid shortchain fatti scfa colon ferment insolubl fibr adipos lipolyisi circul nonesterifi fatti nefa insolubl fiber inhibit excess hypothes propag hepat forkhead foxa2 peroxisom proliferatoractiv ppar coactiv pgc1 ppar hepat triglycerid oxid food nutraceut ffn adjunct pharmacotherapi hyperlipidemia depict guidelin deemphas ffn hyperlipidemia progress incorpor notion ffn emphas hyperlipidemia dosag ffn effect modul foster hyperlipidemia ffn continu overshadow progress consecut demonstr ffn efficaci adjunct pharmacotherapi hyperlipidemia imper develop ffn incorpor guidelin treat hc htg wake hyperlipidemia amongst ffn serv efficaci adjunct pharmotherapi abbrevi\n",
            "\t-2.382\tprevent   introductionmodifi lifestyl highrisk hypertensionmetaanalysesdiabet mellitusdiabet statinsadherenceconclus hf epidem affect worldwid 51 million project 2030 lifetim hf aggress hf ahaacc hf guidelin introduc concept hf goal outlin hf hf endpoint symptomat hf hf hospit endpoint articl updat review hf discus modifi highlight pivot review metaanalys pharmacolog live lifestyl treat hf thiazid diuret choic acei arb atherosclerot plu beta blocker cardioselect prefer calcium channel blocker nondihydropyridin diltiazem verapamil hf altern alpha blocker avoid altogeth adher hf\n",
            "\t-2.693\tapolipoprotein genotyp hyperlipidem apolipoprotein apo apo 229 polypeptid classifi isoform e2 e3 e4 112 158 apo e3 isoform preval apo e2 e4 hyperlipoproteinemia apo isoform korean apo genotyp amplif apo polymeras restrict isotyp done cleavag restrict hha polyacrylamid gel electrophoresi apo allel 73 48 e2 849 e3 103 e4 hyperlipoproteinemia apo allel 63 e2 810 e3 127 e4 apo isoform diabet hyperlipidemia apo e4 allel 200 103 0005 apo e3 isoform apo e2 isoform caucasian japanes somewhat apo e4 allel hypercholesterolemia apo isoform determin hyperlipoproteinemia apo genotyp    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.518\thypercalcemia dissemin paracoccidioidomycosi hypercalcemia granulomat sarcoidosi tuberculosi berylliosi leprosi fungal paracoccidioid brasiliensi hypercalcemia neither document etiolog hypercalcemia 22yearold man dissemin paracoccidioidomycosi hypercalcemia 125dihydroxyvitamin suppress parathyroid hormon indic hypercalcemia parathyroid hormon 125dihydroxyvitamin episod resolv readili corticosteroid hypercalcemia origin receiv antifung brasiliensi calcium remain  introductioncas presentationdiscussionconclusionabbreviationscompet interestsauthor contributionscons hypercalcemia granulomat sarcoidosi tuberculosi berylliosi leprosi fungal fungal dissemin candidiasi histoplasmosi cryptococcosi coccidioidomycosi rare implic hypercalcemia hypercalcemia dissemin paracoccidioid brasiliensi 125dihydroxyvitamin hypercalcemia dissemin brasiliensi 125dihydroxyvitamin abbrevi\n",
            "\t0.434\tesophag cryoballoon ablat paroxysm atrial fibril lgemri   backgroundmethodsresultsconclusionsfund esophag wall thermal cryoballoon ablat seriou complic lategadolinium enhanc mri lgemri accur noninvas compar relationsship esophag lgemri vein isol pvi arctic front af artic front afa cryoballoon paroxysm atrial fibril paf preliminari esophag lgemri cryoballoon ablat anatom esophagu atrium cryoballoon anatom locat esophagu easili as mri ablat fund\n",
            "\t0.434\tesophag cryoballoon ablat paroxysm atrial fibril lgemri   backgroundmethodsresultsconclusionsfund esophag wall thermal cryoballoon ablat seriou complic lategadolinium enhanc mri lgemri accur noninvas compar relationsship esophag lgemri vein isol pvi arctic front af artic front afa cryoballoon paroxysm atrial fibril paf preliminari esophag lgemri cryoballoon ablat anatom esophagu atrium cryoballoon anatom locat esophagu easili as mri ablat fund\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.332\tsterol marinederiv omega3 fatti ingredi frontier treat hyperlipidemia hyperlipidemia hypercholesterolemia hc hypertriglyceridemia htn continu north america healthcar continu seek efficaci safe therapi complement evergrow food nutraceut ffn hyperlipidemia recept amongst implement ffn guidelin continu lag demonstr ffn modul perpetu hyperlipidemia consist combin ffn marinederiv omega3 fatti sterolsstanol statin enhanc triglycerid cholesterollow purpos commentari contend efficaci ffn hc htg boost lipidlow hypolipidem editori aim guidelin emphas efficaci ffn hyperlipidemia adjunct pharmacotherapi  introductionclin food nutraceut treat hyperlipidemiafunct food nutraceut modul endpointsfunct food nutraceut adjunct therapiesfutur direct incorpor food nutraceut hyperlipidem guidelinesconclusionsabbreviationscompet interestsauthor contributionsauthor hyperlipidemia hypercholesterolemia hc hypertriglyceridemia htg form burden north america american meet extraordinarili hc htg amongst 69 65 hyperlipidemia atherosclerosi lifestyl hc htg lifestyl ineffect begin exhibit healthcar practition turn lipidlow said food nutraceut ffn grow genr therapi hyperlipidemia administ nonetheless question ffn posit guidelin hc htg decad consider amongst direct toward enhanc ffn therapi lifestylerel worsen advanc discount ffn diseasethwart hypercholesterolemia escal ldlc cholesterol ncep describ sterolsstanol p option circul ldlc plethora peerreview articl demonstr reduct ldlc p ncep p fortifi food constitu lifestyl p emphas latter introduc regimen similarli marin omega3 fatti mom3 fiber nut soy endpoint htg hc p adopt regimen demonstr ffn p mom3 complement produc pharmacomonotherapi food nutraceut mere lifestyl ffn contain bioactiv substanc administ dose modul foster gap exist ffn close ffn implement guidelin hyperlipidemia optim throughout sterol marinederiv omega3 fatti insolubl fibr dyslipidemia sterol p displac dietari cholesterol mix micel absorb p activ lxr atpbind cassett transport abcg pump absorb p back intestin lumen marinederiv omega3 fatti mom3 peroxisom prolifer ppar farnesol fxr hepatocyt nuclear4 hnf4 lxr altogeth modul mom3 triglycerid oxid lipoprotein lipas lpl alongsid triglycerid shortchain fatti scfa colon ferment insolubl fibr adipos lipolyisi circul nonesterifi fatti nefa insolubl fiber inhibit excess hypothes propag hepat forkhead foxa2 peroxisom proliferatoractiv ppar coactiv pgc1 ppar hepat triglycerid oxid food nutraceut ffn adjunct pharmacotherapi hyperlipidemia depict guidelin deemphas ffn hyperlipidemia progress incorpor notion ffn emphas hyperlipidemia dosag ffn effect modul foster hyperlipidemia ffn continu overshadow progress consecut demonstr ffn efficaci adjunct pharmacotherapi hyperlipidemia imper develop ffn incorpor guidelin treat hc htg wake hyperlipidemia amongst ffn serv efficaci adjunct pharmotherapi abbrevi\n",
            "\t-2.382\tprevent   introductionmodifi lifestyl highrisk hypertensionmetaanalysesdiabet mellitusdiabet statinsadherenceconclus hf epidem affect worldwid 51 million project 2030 lifetim hf aggress hf ahaacc hf guidelin introduc concept hf goal outlin hf hf endpoint symptomat hf hf hospit endpoint articl updat review hf discus modifi highlight pivot review metaanalys pharmacolog live lifestyl treat hf thiazid diuret choic acei arb atherosclerot plu beta blocker cardioselect prefer calcium channel blocker nondihydropyridin diltiazem verapamil hf altern alpha blocker avoid altogeth adher hf\n",
            "\t-2.693\tapolipoprotein genotyp hyperlipidem apolipoprotein apo apo 229 polypeptid classifi isoform e2 e3 e4 112 158 apo e3 isoform preval apo e2 e4 hyperlipoproteinemia apo isoform korean apo genotyp amplif apo polymeras restrict isotyp done cleavag restrict hha polyacrylamid gel electrophoresi apo allel 73 48 e2 849 e3 103 e4 hyperlipoproteinemia apo allel 63 e2 810 e3 127 e4 apo isoform diabet hyperlipidemia apo e4 allel 200 103 0005 apo e3 isoform apo e2 isoform caucasian japanes somewhat apo e4 allel hypercholesterolemia apo isoform determin hyperlipoproteinemia apo genotyp    \n",
            "HTN hyperlipidemia,EF,Lasix None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.578\tintracerebr hematoma     \n",
            "\t0.570\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\t0.570\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t4.620\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\t4.620\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\t4.620\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.578\tintracerebr hematoma     \n",
            "\t0.570\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\t0.570\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t4.620\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\t4.620\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "\t4.620\tspontan intraventricular hemorrhag   introduction2 methods21 analysis3 results4 discus intraventricular hemorrhag complic parenchym intracerebr hemorrhag subarachnoid hemorrhag spontan intraventricular hemorrhag recogniz parenchym noncontrastenhanc comput tomographi ct magnet reson mri extrem spontan intraventricular hemorrhag partial rariti intracerebr hemorrhag hemorrhag spectrum intracerebr hemorrhag reason bleed hemorrhag thalamu basal ganglion intern wellknown supratentori cerebr hemorrhag subcort topographi topographi lobar cerebellar brainstem intraventricular hemorrhag singlecent retrospect aim character intraventricular hemorrhag object intraventricular hemorrhag subcort hemorrhag prospect hospitalbas registri barcelona spain intraventricular hemorrhag hospitalbas registri scarc intraventricular hemorrhag subgroup hemorrhag account 031 33 intracerebr hemorrhag intraventricular hemorrhag intracerebr hemorrhag vari hame ara subsampl 551 hemorrhag flint intraventricular hemorrhag intraventricular hemorrhag subcort haemorrhag profil 85 old atrial fibril headach conscious frequent intraventricular hemorrhag remark intraventricular hemorrhag 789 417 age 85 subcort hemorrhag 722 intraventricular hemorrhag mart brega 56 hame 85 intraventricular hemorrhag aspect oldest old segment elderli receiv suboptim neuroimag old carri prospect registri ensur independ present underw protocol workup note review intraventricular hemorrhag limit practic chang rariti intraventricular hemorrhag interpret take limit appli multivari atrial fibril frequent intraventricular hemorrhag subcort hemorrhag occurr atrial fibril attribut atrial fibril rise 59 old 235 age 80 89 headach frequent hemorrhag ischem intraventricular hemorrhag subcort hemorrhag headach intracrani experienc 78 angelopoulo alert featur correl hemorrhag alert intracerebr hemorrhag gener intracrani compromis hemispher reticular activ bilater brainstem tegmentum intraventricular haemorrhag inhospit 417 83 symptomfre discharg passero angelopoulo verma fatal 43 36 333 rang 45 figur tembl inhospit hemorrhag lacunar old subtyp poorer younger 85 agreement daverat el predictor spontan intracerebr hemorrhag massiv intraventricular hemorrhag produc fourth ventricular distens periventricular cerebr compress omin sign advanc neurolog deterior age 85 femal percentag oldest old old wors none symptomfre discharg inhospit subgroup 286 remain decompress intraventricular hemorrhag recommend clot remov consequ intraventricular extens intracerebr hemorrhag minim invas coupl recombin plasminogen activatormedi clot lysi thrombolyt administ intraventricularli extern ventricular drain lyse intraventricular clot safe morbid intracerebr hemorrhag ultraearli clot remov thrombolyt cerebr infarct care monitor special unit paramount intracerebr hemorrhag summari 33 hemorrhag intraventricular hemorrhag intraventricular hemorrhag classic subcort hemorrhag present old demograph featur intraventricular haemorrhag inhospit 417\n",
            "intraventricular hemorrhage None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.390\tphorbol myrist acet stimul phagosomelysosom fusion phorbol myrist acet pma phagosomelysosom pl fusion fluoresc 0110 microgram pmaml strike pl fusion phorbol myrist monoest pma reproduc pretreat express maxim pl fusion maintain return pmafre medium catalas superoxid dismutas indomethacin hydrocortison block pma h2o2 o2 prostaglandin plasminogen activ pl fusion pma proteinsynthesi puromycin cycloheximid block pma fusion 4d label pma rapidli plateau return pmafre medium cel label rapidli releas return background releas label metabolit pma thinlay chromatographi product migrat monoest phorbol12myrist phorbol pma macrophag j774 lesser embryo fibroblast    \n",
            "\t0.387\tmll ell fusion transcript childhood myeloid leukemia myeloid sarcoma chromosom transloc t1119q23p13 breakpoint subband 19p131 myeloid leukemia aml mll ell fusion variat mll ell seem leukemogen potenc fusion lie behind mll ell signific fusion cytogenet done marrow 20monthold boy unusu myelomonocyt aml myeloid sarcoma infiltr soft gband fish yield karyotyp 47xi 6t81911q24p13q23 fish mll split rnasequenc transloc mll ell chimera exon mll nt 4241 access nm0059333 fuse exon ell nt 817 access nm0065323 rtpcr sanger verifi abovement fusion transcript specul myelomonoblast aml extramedullari typic mll ell fusion transcript onlin version articl doi101186s4016401600372 author user  backgroundcas presentationeth statementclin presentationiniti rtpcr experimentsrnasequencingmolecular confirm fusionconclus chromosom transloc t1119q23p13 myeloid aml lymphoblast leukemia breakpoint subband 19p133 primarili infant aml transloc t1119q23p133 fusion mll mllt1 enl ltg19 yeats1 gener mll mllt1 fusion breakpoint subband 19p131 mostli aml transloc t1119q23p131 mll ell fusion mll ell fusion biphenotyp leukemia mll fusion t1119posit aml recurr mll myo1f fusion infant aml mll sh3gl1 fusion childhood aml mll ell fusion transcript exon mll fuse exon ell variant mll ell fusion transcript myelomonocyt leukemia mll exon exon nilson fuse ell exon congenit monoblast leukemia threeway transloc t11911p36p131q23 braekel breakpoint mll ell intron leukemogen potenc mll ell fusion murin variant mll ell impair transform variat mll ell leukemogen potenc fusion hint variabl behind mll ell signific rarer fusion childhood leukemia threeway transloc fusion exon mll exon ell exon ell fuse mll aml genet threeway transloc t81911q24p13q23 rearrang mll chimer mll ell transcript fusion mll exon ell exon rtpcr amplif reli forward primer exon mll revers primer exon ell choic mll fuse exon ell pcr primer set mll3878fell498r1 nest primer mll3947f1ell415r fail amplifi cdna fragment band cytogenet fish rnasequenc help mll exon ell exon fusion gband appear regular chromosom transloc t1119q23p13 wellknown leukemia fish mll split distal move deriv surprisingli arm rnasequenc exon mll fuse exon ell rtpcr revers primer exon ell primer ell1044r1 mll3878f ell1044r1 primer fusion transcript braekel cowork congenit monoblast leukemia threeway transloc t11911p36p1311q23 mll mll ell fusion ident hitherto exon ell fuse mll certainli intrigu threeway transloc unusu phenomenon behind mll rearrang hint hidden behind aml mll exon ell exon fusion actual underestim rtpcr amplif primer set hitherto situat remedi rtpcr includ primer fusion mll exon ell hold mll ell fusion transcript ell exon fuse mll myelomonocyt leukemia cmml transform aml exon ell fuse mll threeway transloc fusion exon ell mll mllell fusion contain aminotermin mll includ hook methyltransferas repress ell ideogram locat ell subband 19p1311 vertic red exon intron ell vertic box exon breakpoint bp intron vertic arrow bp centromer cen telomer tel diagram ell access nm0065323 exon code black vertic arrow fusion point mll ell fusion transcript diagram ell fp1 fp2 fp3 fusion point mll mllell fusion mllell retain occludin homolog smcproka local unusu conspicu widespread pain soft interpret myeloid sarcoma extens infarct mere marrow infiltr valid support gradual protract resolut take place aml display myelomonocyt myeloid sarcoma mll ell fusion cytogenet mll ell fusion threeway transloc gener mll ell fusion t81911q24p13q23 newborn t11911p36p1311q23 threemonthold boy t61911p22p13q23 none mll ell fusion t11911p36p1311q23 mll exon ell exon fusion transcript twomonthold child braekel breakpoint mll ell mll exon ell exon fusion transcript threemonthold boy t61911p22p13q23 transloc mll exon ell exon fusion transcript imposs definit statement nevertheless carri mll ell fusion seem encourag newborn receiv antileukem die birth went remiss seem survivor remiss clone 7q delet emerg remiss unclear recurr cytogenet abnorm sometim aml remiss persist marrow leukemia waitandse prudent\n",
            "\t0.381\tchang landscap pmscl autoantibodi autoantibodi polymyositisscleroderma pmscl sclerosi pmscl overlap hank colleagu issu arthriti separ antipmscl75c pmscl100 autoantibodi manifest sclerosi paramount agreement antipmscl sclerosi manifest hope trigger systemat multicentr confirm elucid immunoassay  backgrounddetect pmscl antibodiesmajor pmscl epitopecom hank colleaguesclin antipmscl autoantibodiescomparison pmscl100conclusionabbreviationscompet interest characterist featur sclerosi ssc scleroderma scl antinucleolar anoa autoantibodi aab exosom polymyositisscleroderma pmscl antipmscl reactiv direct pmscl75c pmscl100 nine core exosom albeit appar hank colleagu put relev compar lia multicentr systemat myositi consensu pmscl pmscl75c aab abbrevi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.445\tpsychometr instrument crosssect pmh instrument valid pmh dimens multiethn crosssect examin psychometr instrument ass pmh helpseek pmh instrument 360 outpati schizophrenia anxieti spectrum seek tertiari psychiatr affili clinic singapor complet pmh instrument satisfact happi reliabl intern consist construct exploratori equat model esem criterion converg diverg valid pmh instrument item item theori item function irtdif esem pmh instrument fit reflect cope person autonomi spiritu interperson skill emot intern consist cronbach alpha 085 instrument subscal pmh instrument fulfil correl construct adequ item discrimin difficulti estim dif note item gender ethnic pmh instrument reliabl valid instrument measur pmh dimens dif pmh implic shift just immens routin polici make  backgroundmethodsethicsset participantsmeasuresstatist analysisresultsesemirtdif analysesreliabilitycorrel measuresdiscussionconclus ass wellb gain momentum politician economist polici maker profession effort concept wellb relat happi satisfact product citizen grow wellb pose conceptu challeng firstli constitut countri secondli wellb mere opposit ill organis wellb realiz abil cope stress product fruit contribut just ill wellb tradit conceptu subject wellb frequent emot mood satisfact psycholog wellb focus function cognit skill pana affectomet subject wellb ryff psycholog wellb scale concept past wellb larg divid theoret construct ryan deci composit theori grant equal subject transient psycholog eudemon wellb optim function selfdetermin theori autonomi compet related satisfact psycholog wellb expert combin construct wellb pmh pmh fundament wellb famili societi refer emot attribut selfreport sen wellb cope skill definit interpret pmh vari extant definit pmh jahoba person matter involv mind attitud take come wellb satisfact selfesteem purpos sen hope vital explor concept pmh multiethn asian singapor pmh constitut broader construct build maintain relationship cope interperson skill receiv emot pursu person autonomi particip religi spiritu practic pmh exert power physiolog ill grow benefici pmh recoveri ill overlap ill pmh adequ explor pmh ill warwick edinburgh wellb wemwb europ routin ass wellb survey pilot aim evalu psycholog psychosi larg western psychometr ill pmh instrument valid pmh multiethn asian singapor mix instrument guid qualit investig psychometr instrument definit pmh investig chine malay indian ethnic singapor pmh instrument selfadminist 47item cover cultur dimens cope emot spiritu interperson skill person autonomi compar gender ethnic instrument sixfactor intern consist cronbach alpha coeffici 096 full 089 093 094 089 089 089 cope person autonomi spiritu interperson skill emot support subscal pmh instrument valid aim explor psychometr pmh instrument seek tertiari psychiatr affili clinic singapor hypothes sixfactor gold pmh converg diverg valid wellb pmh instrument hypothes pmh subscal posit moder wellb satisfact happi function moder anxieti item item theori item function irtdif establish reliabl valid pmh instrument make suitabl pmh valid multifactori pmh toward multidimension wellb design evalu implic shift ass immens routin polici make\n",
            "\t-4.605\tperpendicularli orient sub10nm block copolym lamella atmospher thermal anneal minut direct selfassembl dsa block copolym bcp realiz nextgener lithographi semiconductor soft imper simultan achiev requir resolut orient microdomain etch select mild anneal compat manufactur suitabl bcp modifi polysiloxanebas bcp sub10nmwid perpendicularli orient lamellar thin film hydroxyl chain introduc polysiloxan block balanc polystyren therebi perpendicular orient orient complet minut 130 air atmospher etch thin film achiev width 85 nm  discussionmethodsprepar polystyren methyl vinyl siloxan p pmvsprepar thiol modifi bcpsprepar rcpscharacter bulkcharacter thin filmsolv annealingaddit informationsupplementari materialsupplementari polystyren methyl vinyl siloxan p pmv bcp precursor bcp weight unit ratio synthes anion polymer styren 135trimethyl135trivinyl cyclotrisiloxan vinyl siloxan unit modifi thiol reagent polystyren substitut siloxan name p pmhx p pmhxoh hx hxoh methyl hexyl hexanol scheme 1a detail character bcp bcp summar bcp bulk morpholog bcp smallangl xray scatter sax bcp p 130 pmhx 44 subscript repeat monom unit react 1melcapt hexan exhibit peak order form introduc alkyl repuls p block bcp exhibit peak higherord bcp p pmhxoh hydroxyl exhibit peak sidechain affect microphas separ sax space p pmhxoh nm morpholog lamellar selfassembl thin film form lamellar carri p pmhxoh space nm sax neutral layer film thick bcp anneal cast solvent firstli optimum neutral layer bcp nonsicontain random copolym rcp summar classic neutral layer rcp monom bcp crosslink coval bondabl sicontain bcp sicontain neutral layer etch etch ideal substrat detail polymethacryl methacryl pmma pma act neutral layer p pmhxoh terrac half bulk period 05l height pmma pma crosssect profil 2bgl secondli filmthick depend rcp film thick 10l 20l pmma pma exhibit fingerprint perpendicular orient flat surfac film thick 10l 20l p pma p pma p preferenti parallel lamellar form thick 10l 20l p block cover bcp contactangl assum surfac consist psblock wet layer equival p homopolym film consist fingerprint exhibit thirdli anneal orient p pmhxoh pmma pma film experi anneal fix minut view throughput fingerprint anneal enough anneal 130 min becam becam anneal 140 min terrac fingerprint anneal 150 min 130 min anneal p pmhxoh experi anneal execut p pmhxoh s8 p pmhxoh perpendicularli orient lamellar pmma pma note suitabl anneal shift 150 160 anneal milder anneal p pmma typic 200 min attract achiev manufactur anneal microphas separ anneal anneal drastic orient transform block cover bcp film form terrac p wet layer cast solvent experi except cast solvent bcp film cast propylen glycol monomethyl ether acet pgmea exhibit fingerprintlik prepattern bcp film cast toluen chloroform exhibit anneal 130 min film cast pgmea exhibit fingerprint bcp anneal pgmea boil pgmea slowli evapor bcp film spin coat microdomain assembl top bcp film solvent anneal 29 p pmhxoh perpendicular lamella solvent anneal toluen chloroform pmma pma perpendicular lamella solvent anneal pgmea pgmea solvent realiz perpendicular orient p pmhxoh pgmea cast solvent industri uniform thin film cast pgmea dewet thermal anneal dsa technolog etch select bcp bcp consist block etch select polysiloxan exhibit etch etch hydrocarbon polym p pmma p pmhxoh pmhxoh block etch p block orient perfect disloc pmhxoh block etch barrier substrat exact orient achiev success orient bcp bcp bcp perpendicular thermal anneal sfe block bcp achiev smaller featur size p pmma suitabl neutral layer atom forc microscopi afm imag crosssect scan electron microscopi sem imag 32nmthick 20l p pmhxoh film anneal 130 min pmma pma oxygenplasma reactiveion etch rie 90 afm imag exhibit etch crosssect afm support perpendicular orient order period 85nmwide rie sem imag evidenc perpendicular form near insid film perpendicular orient anneal 130 min homopolym etch p remov faster etch etch p 025 nm ideal bcp dsa etch select perpendicular substrat thermal anneal mild resolut bcp space nm desir p pmma classic achiev smaller featur repuls introduc sicontain block polym orient horizont orient sfe block overcom bcp optim achiev p pmhxoh form perpendicular lamella 85nmwide pmma pma anneal 130 min etch success remov p block rie achiev polym pmhxoh consist polysiloxan hydrophob p block hydroxyl pmhxoh exhibit hydrophil pmhxoh block amphipath molecul hydroxyl form wet layer hydroxyl polysiloxan chain repuls p block enabl smallerfeatur microphas separ pmhx alkyl repuls p block p 130 pmhx 44 smaller microphasesepar polym expand achiev smallerfeatur orient simultan industri nanofabr attract basic polym scienc academ \n",
            "\t-4.619\tpsychometr pmhscale increasingli recogn pmh pmhscale propos unidimension consist likerttyp item psychometr pmhscale student 5406 1547 3204 factori equival invari analys maximum likelihood intern consist cronbach alpha testretest reliabl converg diverg valid pearson unidimension scalar invari intern consist retestreli converg discrimin valid pmhscale concept compar pmhscale brief easi interpret instrument measur pmh  backgroundmethodssampl proceduresstud sampleretest 1retest 3patient sampledresden samplest healthyincidencest mental illremissioninstrumentsstatist analysesresultsdescript statisticsstudi equival pmhscale groupsstudi equival pmhscale timestudi testretest reliabl intern consistencytestretest reliabilityintern consistencyacross correlationstudi construct converg discrimin valid pmhscalestudi changediscussionconclus tradit psychopatholog mental ill presum mental increasingli recogn pmh concept view pmh refer wellb refer psychopatholog wellb ass integr dualfactor theori domin pmh hedon tradit deal emot mood lifesatisfact eudaimon tradit focus optim function everyday take hedon eudaimon pmh emot psycholog wellb pmh instrument comprehens questionnair dimens pmh continuumshort mhcsf item relat pmh psychopatholog questionnair ghq pmhscale lutz 1992a unpublish manuscript brief unidimension personcentr questionnair unidimension ensur concept postul holist concept pmh personcentr item advantag statement consist crosssitu judgment particip predict behaviour situat freiburg person inventori fpi formul item item pmhscale item correspond definit pmh crosssitu personcentr personcentr item consist person characterist situat behaviourcentr item instead behaviour situat pmhscale construct inner emot psycholog suppos outer partnership unidimension selfreport brief easi pmhscale lutz 1992a unpublish manuscript item item pool pool german languag instrument met trier person inventori freiburg person inventori berne questionnair subject wellb final version lutz 1992a unpublish manuscript nine item rate likert true true item pmhscale origin item origin item carefre spirit trierer person inventori tpf enjoy item lutz item pool satisfi freiburg person inventori fpir confid spg manag fulfil trier person inventori tpf emot trier person inventori tpf actual equip deal difficulti trier person inventori tpf bring joy spg calm balanc trier person inventori tpf version pmhscale predictor remiss phobia dresden predictor broad predictor remiss phobia 137 protect satisfact predict remiss protect selfefficaci vulner twelvemonth cope skill style psychopatholog phobia predict phobia recoveri phobia 91 psychopatholog anxieti hassl multivari regress adjust salient predictor recoveri strongest predictor recoveri phobia promot salutogenet concern tradit pathogenet pmhscale wish receiv pension lutz michalak unpublish manuscript predict success behaviour inpati encourag psychometr use nineitem version pmhscale detail purpos build drawn 1547 5406 3204 object overview object nine item pmhscale load equival pmhscale pmhscale invari requir usag estim testretest reliabl intern consist establish construct valid ass converg discrimin valid pmhscale instrument pmh mentalhealth pmhscale quick pmh scalar invari pmhscale determin pmh\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.390\tphorbol myrist acet stimul phagosomelysosom fusion phorbol myrist acet pma phagosomelysosom pl fusion fluoresc 0110 microgram pmaml strike pl fusion phorbol myrist monoest pma reproduc pretreat express maxim pl fusion maintain return pmafre medium catalas superoxid dismutas indomethacin hydrocortison block pma h2o2 o2 prostaglandin plasminogen activ pl fusion pma proteinsynthesi puromycin cycloheximid block pma fusion 4d label pma rapidli plateau return pmafre medium cel label rapidli releas return background releas label metabolit pma thinlay chromatographi product migrat monoest phorbol12myrist phorbol pma macrophag j774 lesser embryo fibroblast    \n",
            "\t0.387\tmll ell fusion transcript childhood myeloid leukemia myeloid sarcoma chromosom transloc t1119q23p13 breakpoint subband 19p131 myeloid leukemia aml mll ell fusion variat mll ell seem leukemogen potenc fusion lie behind mll ell signific fusion cytogenet done marrow 20monthold boy unusu myelomonocyt aml myeloid sarcoma infiltr soft gband fish yield karyotyp 47xi 6t81911q24p13q23 fish mll split rnasequenc transloc mll ell chimera exon mll nt 4241 access nm0059333 fuse exon ell nt 817 access nm0065323 rtpcr sanger verifi abovement fusion transcript specul myelomonoblast aml extramedullari typic mll ell fusion transcript onlin version articl doi101186s4016401600372 author user  backgroundcas presentationeth statementclin presentationiniti rtpcr experimentsrnasequencingmolecular confirm fusionconclus chromosom transloc t1119q23p13 myeloid aml lymphoblast leukemia breakpoint subband 19p133 primarili infant aml transloc t1119q23p133 fusion mll mllt1 enl ltg19 yeats1 gener mll mllt1 fusion breakpoint subband 19p131 mostli aml transloc t1119q23p131 mll ell fusion mll ell fusion biphenotyp leukemia mll fusion t1119posit aml recurr mll myo1f fusion infant aml mll sh3gl1 fusion childhood aml mll ell fusion transcript exon mll fuse exon ell variant mll ell fusion transcript myelomonocyt leukemia mll exon exon nilson fuse ell exon congenit monoblast leukemia threeway transloc t11911p36p131q23 braekel breakpoint mll ell intron leukemogen potenc mll ell fusion murin variant mll ell impair transform variat mll ell leukemogen potenc fusion hint variabl behind mll ell signific rarer fusion childhood leukemia threeway transloc fusion exon mll exon ell exon ell fuse mll aml genet threeway transloc t81911q24p13q23 rearrang mll chimer mll ell transcript fusion mll exon ell exon rtpcr amplif reli forward primer exon mll revers primer exon ell choic mll fuse exon ell pcr primer set mll3878fell498r1 nest primer mll3947f1ell415r fail amplifi cdna fragment band cytogenet fish rnasequenc help mll exon ell exon fusion gband appear regular chromosom transloc t1119q23p13 wellknown leukemia fish mll split distal move deriv surprisingli arm rnasequenc exon mll fuse exon ell rtpcr revers primer exon ell primer ell1044r1 mll3878f ell1044r1 primer fusion transcript braekel cowork congenit monoblast leukemia threeway transloc t11911p36p1311q23 mll mll ell fusion ident hitherto exon ell fuse mll certainli intrigu threeway transloc unusu phenomenon behind mll rearrang hint hidden behind aml mll exon ell exon fusion actual underestim rtpcr amplif primer set hitherto situat remedi rtpcr includ primer fusion mll exon ell hold mll ell fusion transcript ell exon fuse mll myelomonocyt leukemia cmml transform aml exon ell fuse mll threeway transloc fusion exon ell mll mllell fusion contain aminotermin mll includ hook methyltransferas repress ell ideogram locat ell subband 19p1311 vertic red exon intron ell vertic box exon breakpoint bp intron vertic arrow bp centromer cen telomer tel diagram ell access nm0065323 exon code black vertic arrow fusion point mll ell fusion transcript diagram ell fp1 fp2 fp3 fusion point mll mllell fusion mllell retain occludin homolog smcproka local unusu conspicu widespread pain soft interpret myeloid sarcoma extens infarct mere marrow infiltr valid support gradual protract resolut take place aml display myelomonocyt myeloid sarcoma mll ell fusion cytogenet mll ell fusion threeway transloc gener mll ell fusion t81911q24p13q23 newborn t11911p36p1311q23 threemonthold boy t61911p22p13q23 none mll ell fusion t11911p36p1311q23 mll exon ell exon fusion transcript twomonthold child braekel breakpoint mll ell mll exon ell exon fusion transcript threemonthold boy t61911p22p13q23 transloc mll exon ell exon fusion transcript imposs definit statement nevertheless carri mll ell fusion seem encourag newborn receiv antileukem die birth went remiss seem survivor remiss clone 7q delet emerg remiss unclear recurr cytogenet abnorm sometim aml remiss persist marrow leukemia waitandse prudent\n",
            "\t0.381\tchang landscap pmscl autoantibodi autoantibodi polymyositisscleroderma pmscl sclerosi pmscl overlap hank colleagu issu arthriti separ antipmscl75c pmscl100 autoantibodi manifest sclerosi paramount agreement antipmscl sclerosi manifest hope trigger systemat multicentr confirm elucid immunoassay  backgrounddetect pmscl antibodiesmajor pmscl epitopecom hank colleaguesclin antipmscl autoantibodiescomparison pmscl100conclusionabbreviationscompet interest characterist featur sclerosi ssc scleroderma scl antinucleolar anoa autoantibodi aab exosom polymyositisscleroderma pmscl antipmscl reactiv direct pmscl75c pmscl100 nine core exosom albeit appar hank colleagu put relev compar lia multicentr systemat myositi consensu pmscl pmscl75c aab abbrevi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.445\tpsychometr instrument crosssect pmh instrument valid pmh dimens multiethn crosssect examin psychometr instrument ass pmh helpseek pmh instrument 360 outpati schizophrenia anxieti spectrum seek tertiari psychiatr affili clinic singapor complet pmh instrument satisfact happi reliabl intern consist construct exploratori equat model esem criterion converg diverg valid pmh instrument item item theori item function irtdif esem pmh instrument fit reflect cope person autonomi spiritu interperson skill emot intern consist cronbach alpha 085 instrument subscal pmh instrument fulfil correl construct adequ item discrimin difficulti estim dif note item gender ethnic pmh instrument reliabl valid instrument measur pmh dimens dif pmh implic shift just immens routin polici make  backgroundmethodsethicsset participantsmeasuresstatist analysisresultsesemirtdif analysesreliabilitycorrel measuresdiscussionconclus ass wellb gain momentum politician economist polici maker profession effort concept wellb relat happi satisfact product citizen grow wellb pose conceptu challeng firstli constitut countri secondli wellb mere opposit ill organis wellb realiz abil cope stress product fruit contribut just ill wellb tradit conceptu subject wellb frequent emot mood satisfact psycholog wellb focus function cognit skill pana affectomet subject wellb ryff psycholog wellb scale concept past wellb larg divid theoret construct ryan deci composit theori grant equal subject transient psycholog eudemon wellb optim function selfdetermin theori autonomi compet related satisfact psycholog wellb expert combin construct wellb pmh pmh fundament wellb famili societi refer emot attribut selfreport sen wellb cope skill definit interpret pmh vari extant definit pmh jahoba person matter involv mind attitud take come wellb satisfact selfesteem purpos sen hope vital explor concept pmh multiethn asian singapor pmh constitut broader construct build maintain relationship cope interperson skill receiv emot pursu person autonomi particip religi spiritu practic pmh exert power physiolog ill grow benefici pmh recoveri ill overlap ill pmh adequ explor pmh ill warwick edinburgh wellb wemwb europ routin ass wellb survey pilot aim evalu psycholog psychosi larg western psychometr ill pmh instrument valid pmh multiethn asian singapor mix instrument guid qualit investig psychometr instrument definit pmh investig chine malay indian ethnic singapor pmh instrument selfadminist 47item cover cultur dimens cope emot spiritu interperson skill person autonomi compar gender ethnic instrument sixfactor intern consist cronbach alpha coeffici 096 full 089 093 094 089 089 089 cope person autonomi spiritu interperson skill emot support subscal pmh instrument valid aim explor psychometr pmh instrument seek tertiari psychiatr affili clinic singapor hypothes sixfactor gold pmh converg diverg valid wellb pmh instrument hypothes pmh subscal posit moder wellb satisfact happi function moder anxieti item item theori item function irtdif establish reliabl valid pmh instrument make suitabl pmh valid multifactori pmh toward multidimension wellb design evalu implic shift ass immens routin polici make\n",
            "\t-4.605\tperpendicularli orient sub10nm block copolym lamella atmospher thermal anneal minut direct selfassembl dsa block copolym bcp realiz nextgener lithographi semiconductor soft imper simultan achiev requir resolut orient microdomain etch select mild anneal compat manufactur suitabl bcp modifi polysiloxanebas bcp sub10nmwid perpendicularli orient lamellar thin film hydroxyl chain introduc polysiloxan block balanc polystyren therebi perpendicular orient orient complet minut 130 air atmospher etch thin film achiev width 85 nm  discussionmethodsprepar polystyren methyl vinyl siloxan p pmvsprepar thiol modifi bcpsprepar rcpscharacter bulkcharacter thin filmsolv annealingaddit informationsupplementari materialsupplementari polystyren methyl vinyl siloxan p pmv bcp precursor bcp weight unit ratio synthes anion polymer styren 135trimethyl135trivinyl cyclotrisiloxan vinyl siloxan unit modifi thiol reagent polystyren substitut siloxan name p pmhx p pmhxoh hx hxoh methyl hexyl hexanol scheme 1a detail character bcp bcp summar bcp bulk morpholog bcp smallangl xray scatter sax bcp p 130 pmhx 44 subscript repeat monom unit react 1melcapt hexan exhibit peak order form introduc alkyl repuls p block bcp exhibit peak higherord bcp p pmhxoh hydroxyl exhibit peak sidechain affect microphas separ sax space p pmhxoh nm morpholog lamellar selfassembl thin film form lamellar carri p pmhxoh space nm sax neutral layer film thick bcp anneal cast solvent firstli optimum neutral layer bcp nonsicontain random copolym rcp summar classic neutral layer rcp monom bcp crosslink coval bondabl sicontain bcp sicontain neutral layer etch etch ideal substrat detail polymethacryl methacryl pmma pma act neutral layer p pmhxoh terrac half bulk period 05l height pmma pma crosssect profil 2bgl secondli filmthick depend rcp film thick 10l 20l pmma pma exhibit fingerprint perpendicular orient flat surfac film thick 10l 20l p pma p pma p preferenti parallel lamellar form thick 10l 20l p block cover bcp contactangl assum surfac consist psblock wet layer equival p homopolym film consist fingerprint exhibit thirdli anneal orient p pmhxoh pmma pma film experi anneal fix minut view throughput fingerprint anneal enough anneal 130 min becam becam anneal 140 min terrac fingerprint anneal 150 min 130 min anneal p pmhxoh experi anneal execut p pmhxoh s8 p pmhxoh perpendicularli orient lamellar pmma pma note suitabl anneal shift 150 160 anneal milder anneal p pmma typic 200 min attract achiev manufactur anneal microphas separ anneal anneal drastic orient transform block cover bcp film form terrac p wet layer cast solvent experi except cast solvent bcp film cast propylen glycol monomethyl ether acet pgmea exhibit fingerprintlik prepattern bcp film cast toluen chloroform exhibit anneal 130 min film cast pgmea exhibit fingerprint bcp anneal pgmea boil pgmea slowli evapor bcp film spin coat microdomain assembl top bcp film solvent anneal 29 p pmhxoh perpendicular lamella solvent anneal toluen chloroform pmma pma perpendicular lamella solvent anneal pgmea pgmea solvent realiz perpendicular orient p pmhxoh pgmea cast solvent industri uniform thin film cast pgmea dewet thermal anneal dsa technolog etch select bcp bcp consist block etch select polysiloxan exhibit etch etch hydrocarbon polym p pmma p pmhxoh pmhxoh block etch p block orient perfect disloc pmhxoh block etch barrier substrat exact orient achiev success orient bcp bcp bcp perpendicular thermal anneal sfe block bcp achiev smaller featur size p pmma suitabl neutral layer atom forc microscopi afm imag crosssect scan electron microscopi sem imag 32nmthick 20l p pmhxoh film anneal 130 min pmma pma oxygenplasma reactiveion etch rie 90 afm imag exhibit etch crosssect afm support perpendicular orient order period 85nmwide rie sem imag evidenc perpendicular form near insid film perpendicular orient anneal 130 min homopolym etch p remov faster etch etch p 025 nm ideal bcp dsa etch select perpendicular substrat thermal anneal mild resolut bcp space nm desir p pmma classic achiev smaller featur repuls introduc sicontain block polym orient horizont orient sfe block overcom bcp optim achiev p pmhxoh form perpendicular lamella 85nmwide pmma pma anneal 130 min etch success remov p block rie achiev polym pmhxoh consist polysiloxan hydrophob p block hydroxyl pmhxoh exhibit hydrophil pmhxoh block amphipath molecul hydroxyl form wet layer hydroxyl polysiloxan chain repuls p block enabl smallerfeatur microphas separ pmhx alkyl repuls p block p 130 pmhx 44 smaller microphasesepar polym expand achiev smallerfeatur orient simultan industri nanofabr attract basic polym scienc academ \n",
            "\t-4.619\tpsychometr pmhscale increasingli recogn pmh pmhscale propos unidimension consist likerttyp item psychometr pmhscale student 5406 1547 3204 factori equival invari analys maximum likelihood intern consist cronbach alpha testretest reliabl converg diverg valid pearson unidimension scalar invari intern consist retestreli converg discrimin valid pmhscale concept compar pmhscale brief easi interpret instrument measur pmh  backgroundmethodssampl proceduresstud sampleretest 1retest 3patient sampledresden samplest healthyincidencest mental illremissioninstrumentsstatist analysesresultsdescript statisticsstudi equival pmhscale groupsstudi equival pmhscale timestudi testretest reliabl intern consistencytestretest reliabilityintern consistencyacross correlationstudi construct converg discrimin valid pmhscalestudi changediscussionconclus tradit psychopatholog mental ill presum mental increasingli recogn pmh concept view pmh refer wellb refer psychopatholog wellb ass integr dualfactor theori domin pmh hedon tradit deal emot mood lifesatisfact eudaimon tradit focus optim function everyday take hedon eudaimon pmh emot psycholog wellb pmh instrument comprehens questionnair dimens pmh continuumshort mhcsf item relat pmh psychopatholog questionnair ghq pmhscale lutz 1992a unpublish manuscript brief unidimension personcentr questionnair unidimension ensur concept postul holist concept pmh personcentr item advantag statement consist crosssitu judgment particip predict behaviour situat freiburg person inventori fpi formul item item pmhscale item correspond definit pmh crosssitu personcentr personcentr item consist person characterist situat behaviourcentr item instead behaviour situat pmhscale construct inner emot psycholog suppos outer partnership unidimension selfreport brief easi pmhscale lutz 1992a unpublish manuscript item item pool pool german languag instrument met trier person inventori freiburg person inventori berne questionnair subject wellb final version lutz 1992a unpublish manuscript nine item rate likert true true item pmhscale origin item origin item carefre spirit trierer person inventori tpf enjoy item lutz item pool satisfi freiburg person inventori fpir confid spg manag fulfil trier person inventori tpf emot trier person inventori tpf actual equip deal difficulti trier person inventori tpf bring joy spg calm balanc trier person inventori tpf version pmhscale predictor remiss phobia dresden predictor broad predictor remiss phobia 137 protect satisfact predict remiss protect selfefficaci vulner twelvemonth cope skill style psychopatholog phobia predict phobia recoveri phobia 91 psychopatholog anxieti hassl multivari regress adjust salient predictor recoveri strongest predictor recoveri phobia promot salutogenet concern tradit pathogenet pmhscale wish receiv pension lutz michalak unpublish manuscript predict success behaviour inpati encourag psychometr use nineitem version pmhscale detail purpos build drawn 1547 5406 3204 object overview object nine item pmhscale load equival pmhscale pmhscale invari requir usag estim testretest reliabl intern consist establish construct valid ass converg discrimin valid pmhscale instrument pmh mentalhealth pmhscale quick pmh scalar invari pmhscale determin pmh\n",
            "PMH,kappa light chain None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t1.708\tcomputeraid cad    cad place prompt alert reader reader decid initi commerci cad prompt 94 984 microcalcif 89 mass prompt miss prompt 52 77 evalu cad extrapol assum reader respond appropri everi correct prompt initi recal real reader rang fals prompt uk reader dismiss 1000 fals prompt everi true prompt decis make discrimin investig miss reader dismiss true prompt cad read recal offset reimburs cad read uk cad technolog improv shortli benefici uk unproven \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t1.708\tcomputeraid cad    cad place prompt alert reader reader decid initi commerci cad prompt 94 984 microcalcif 89 mass prompt miss prompt 52 77 evalu cad extrapol assum reader respond appropri everi correct prompt initi recal real reader rang fals prompt uk reader dismiss 1000 fals prompt everi true prompt decis make discrimin investig miss reader dismiss true prompt cad read recal offset reimburs cad read uk cad technolog improv shortli benefici uk unproven \n",
            "CAD None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.427\tosteomyel endstag initi atherosclerosi neg acceler endstag esrd osteomyel com esrd explor com esrd com taiwan insur claim 1997 24267 newli com 97068 sexmatch noncom risk esrd com adjust comorbid name coronari arteri congest hyperlipidemia esrd 201fold confid interv 181 225 com noncom joint com comorbid esrd 157fold 123 200 com comorbid 225 197 257 com comorbid agespecif adjust esrd com hazard 178 518 614 age 34 com esrd comorbid younger  introductionmateri methodsdata sourcestudi patientsoutcom measuresstatist analysisresultsdiscuss endstag esrd becom concern worldwid esrd impair interfer product esrd financi burden esrd diminish econom past decad identifi esrd coronari arteri cad congest chf esrd esrd pathophysiolog explan esrd unresolv involv atherosclerosi explor evalu esrd risk inflammationrel elucid esrd osteomyel com last bone typic evok intens boni nearbi soft com erad typic com cad dementia epilepsi cad esrd investig com esrd warrant connect com esrd nationwid databas com risk esrd link hepat hepat gout periodont 29 herp zoster esrd suspect esrd nation repres nhird compar com 1997 com esrd numer causal link esrd old 31 33 33 34 33 hyperlipidemia 34 36 cad 37 chf 38 com comorbid esrd noncom comorbid com comorbid esrd com match comorbid differ com esrd physiopatholo account com esrd noncom infectionassoci glomerulonephr predispos nephron glomerulosclerosi declin reserv antibiot treat com nephrotox interact toxic com prospect com biopsi clarifi causal com esrd old recogn crucial esrd 39 com subgroup age 34 178fold esrd noncom subgroup age 34 attribut compet esrd elderli younger elderli initi dialysi elderli refus dialysi consider lifespan comorbid 41 retrospect strict enrol com esrd com age 34 bia strength retrospect strict catastroph ill registr esrd strict definit esrd strengthen severitydepend com esrd com sexmatch dataset exceed million enrolle encompass 99 taiwan neartotalpopul coupl strict casetocontrol generaliz precis reliabl nhi audit implement supervis insur claim overdiagnosi resourc wast nhi surveil ensur valid recogn comorbid esrd hyperlipidemia chf cad hyperuricemia gout proteinuria adjust com esrd note definit lipid confound variabl bia limit databas lifestyl person behavior drink esrd insur claim calcul esrd com refus dialysi com underestim overestim com esrd bia minim nhi cover 99 taiwan com esrd com esrd esrd com comorbid cad chf hyperlipidemia hyperuricemia gout proteinuria younger com esrd prompt alert com younger\n",
            "\t0.427\tosteomyel endstag initi atherosclerosi neg acceler endstag esrd osteomyel com esrd explor com esrd com taiwan insur claim 1997 24267 newli com 97068 sexmatch noncom risk esrd com adjust comorbid name coronari arteri congest hyperlipidemia esrd 201fold confid interv 181 225 com noncom joint com comorbid esrd 157fold 123 200 com comorbid 225 197 257 com comorbid agespecif adjust esrd com hazard 178 518 614 age 34 com esrd comorbid younger  introductionmateri methodsdata sourcestudi patientsoutcom measuresstatist analysisresultsdiscuss endstag esrd becom concern worldwid esrd impair interfer product esrd financi burden esrd diminish econom past decad identifi esrd coronari arteri cad congest chf esrd esrd pathophysiolog explan esrd unresolv involv atherosclerosi explor evalu esrd risk inflammationrel elucid esrd osteomyel com last bone typic evok intens boni nearbi soft com erad typic com cad dementia epilepsi cad esrd investig com esrd warrant connect com esrd nationwid databas com risk esrd link hepat hepat gout periodont 29 herp zoster esrd suspect esrd nation repres nhird compar com 1997 com esrd numer causal link esrd old 31 33 33 34 33 hyperlipidemia 34 36 cad 37 chf 38 com comorbid esrd noncom comorbid com comorbid esrd com match comorbid differ com esrd physiopatholo account com esrd noncom infectionassoci glomerulonephr predispos nephron glomerulosclerosi declin reserv antibiot treat com nephrotox interact toxic com prospect com biopsi clarifi causal com esrd old recogn crucial esrd 39 com subgroup age 34 178fold esrd noncom subgroup age 34 attribut compet esrd elderli younger elderli initi dialysi elderli refus dialysi consider lifespan comorbid 41 retrospect strict enrol com esrd com age 34 bia strength retrospect strict catastroph ill registr esrd strict definit esrd strengthen severitydepend com esrd com sexmatch dataset exceed million enrolle encompass 99 taiwan neartotalpopul coupl strict casetocontrol generaliz precis reliabl nhi audit implement supervis insur claim overdiagnosi resourc wast nhi surveil ensur valid recogn comorbid esrd hyperlipidemia chf cad hyperuricemia gout proteinuria adjust com esrd note definit lipid confound variabl bia limit databas lifestyl person behavior drink esrd insur claim calcul esrd com refus dialysi com underestim overestim com esrd bia minim nhi cover 99 taiwan com esrd com esrd esrd com comorbid cad chf hyperlipidemia hyperuricemia gout proteinuria younger com esrd prompt alert com younger\n",
            "\t0.398\tdiffer myocardi session hemodialysi endstag mellitu coronari arteri hemodialysi hd acut improv background coronari arteri cad dm set endstag esrd veloc echocardiographi tve offer fast choic follow myocardi hd esrd concomit dm cad 46 esrd dm dmcad underw tve shortli hd besid doppler region myocardi systol diastol veloc systol post process prehd posthd kg 51 48 62 vs59 61 58 001 ventricular diastol dimens post hd 46 42 53 51 47 001 region longitudin peak systol veloc septum cm posthd 157 72 0001 remain unchang trend note ventricular wall myocardi veloc cm comput global 63 79 0001 region diastol veloc cm remain unchang 359 41 001 systol 1sec remain unchang 087 04 094 03 n hd session improv lv esrd coexist dm cad dialysisdepend load coexist background myocardi hd  backgroundmethodsstudi designstandard echocardiographi protocoltissu veloc echocardiographystrain imaginghemodialysiscoronari angiographystatist methodsresultsradi tve datasystol diastol interv lv fill tei indexdiscussionconclusionstudi limitationsclin implicationscompet interestsauthor contribut mellitu dm endstag esrd great coexist coronari arteri cad esrd coronari event die detail behind death exact region contractil behavior ventricl lv esrd ongo replac hemodialysi hd destin temporarili remov excess fluid toxin undergo hd concomit tve load depend esrd coexist dm cad region myocardi systol diastol veloc diminish differ myocardi dialysisdepend preload longitudin myocardi tve hd quantit differ set irrespect load hd session improv lv esrd comorbid dm myocardi continu diminish irrespect concomit cad minor compensatori overact systol radial motion latter possibl region cad hdinduc tve depend preexist myocardi hemodynam milieu\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.713\tendstag articl concept nephropathi hypertens nephropathi endstag esrd search pubm embas scopu iran medex januari 1990 decemb 2014 manuscript english persian languag fulltext articl abstract diabet mainten replac hemodialysi hd periton dialysi pd transplant nondiabet esrd esrd partli suscept foot ulcer hemodynam instabl hd transplant esrd transplant prefer replac esrd dialysi nephropathyendstag diseaseren replac therapyhemodialysi implic policypracticeresearchmed educationintroductionmateri methodsdiabet esrdsurviv esrddialysi modal diabeticsdialysi transplantationpreempt transplantationconclusionauthor contributionconflict interesteth considerationsfundingsupport implic policypracticeresearchmed nephropathi hypertens nephropathi endstag esrd reflect catastroph squeal silent killer esrd worldwid enorm financi burden healthcar introduct nephropathi classic proteinuria percent formerli call insulindepend formerli call noninsulindepend mellitu dm dm pancreat pancreatectomi dm longsenough glycemia enough dm microalbuminuria half progress macroalbuminuria call overt nephropathi overt nephropathi substanti progress endstag esrd dm progress equival proteinuria esrd proteinuria investig nephropathi retard normal prefer blockad reninangiotensin ra angiotensin convert acei angiotensin blocker arb agent spironolacton aldosteron antagonist pentoxifyllin nonselect phosphodiesteras strict substanti progress esrd esrd worldwid enorm financi burden healthcar dm complic articl esrd requir replac esrd hemodialysi hd periton dialysi pd dialysi transplant search pubm embas scopu iran medex januari 1990 decemb 2014the search combin word equival esrd hemodialysi dialysi periton dialysi transplant nephropathi manuscript english persian languag fulltext articl abstract unfortun search confer proceed manuscript languag esrd done esrd past decad glomerulonephr gn initi esrd aggress gn possibl nephropathi hypertens nephropathi esrd esrd account 45 note european 34 requir replac germani australia esrd stabil denmark widespread implement intens renoprotect glycem etiolog esrd esrd reflect catastroph sequela silent killer iran 1997 percentag requir replac attribut nephropathi twofold 1997 31 iran dm esrd account age nephropathi hypertens nephrosclerosi 55 caus esrd esrd nephropathi wakeel dm commonest esrd 266 nephrosclerosi saudi arabia preval comorbid 59 327 dm arab 212 kuwait egypt 468 lebanon esrd mainten dialysi prevent uremia expect esrd introduct dialysi 1960 diabet mainten dialysi hd pd nondiabet esrd esrd usrd esrd catastroph initi hd 10year esrd mainten hd 79 53 112 remain span age 44 age 64 chantrel esrd center franc requir dialysi die 211 esrd mainten dialysi done exist iran dialysi catastroph nondiabet esrd 185 esrd intermitt hd oneyear nondiabet 5year 522 738 5year 569 1861 esrd multicent hd southwest iran nondiabet 15year nondiabet 792 85 323 115 58 04 summari dialysi nondiabet question surviv dialysi dm esrd dialysi dm comorbid compar issu dialysi intern european associationeuropean dialysi transplant registri schroijen compar 419 dialysi 3624 dialysi 1193 dialysi comorbid 602 dialysi dialysi nondiabet adjust countri malign dialysi comorbid esrd lifetim arterioven fistula suscept fungal foot ulcer hemodynam instabl hd autonom neuropathi dialysi modal diabet choic dialysi modal hd ambulatori periton dialysi capd autom periton dialysi apd diabet influenc consider appli nondiabet avail conveni comorbid socioeconom dialysi center independ motiv toler shift vasculatur creat adequ hd abdomen pd 29 39 old vessel limit creat sustain adequ arterioven fistula hd autonom neuropathi frequent hypotens episod hd ultrafiltr dialysi fluid remov goal intradialyt hypotens necessit intraven fluid replac overload hypotens episod hd necessit discontinu hd inadequ dialysi complic 33 39 pd hd advantag modal complic dialysi initi undergo pd hd ensu pd hd pd preserv residu shortterm usrd pd dialysi lost 34 dialysi transplant transplant esrd nondiabet transplant recipi posttranspl fungal posttranspl urinari tract nondiabet transplant recipi esrd glycem transplant immunosuppress regimen transplant detriment pancreat beta glycem achiev transplant recurr transplant 44 challeng transplant prefer replac esrd transplant dialysi 41 42 usrd shortterm transplant recipi dialysi 7200 transplant recipi transplant 73 000 place wait list transplant 027 024030 project expect underw transplant diabet waitlist 43 scotland 1732 waitlist transplant posttransplant 250 underw transplant project diabet dialysi 41 dialysi underw transplant dialysi fatal nonfat 44 preemptiv transplant ckd advantag preemptiv transplant dialysi initi dialysi transplant preemptiv transplant recommend transplant dialysi 45 46 ckd preemptiv transplant initi dialysi transplant prefer substanti improv usrd preemptiv transplant transplant 41 53 72 73 103 000 wait 36 36 48 48 graft dialysi esrd 45 allograft preemptiv transplant esrd live donor deceas donor kidney meierkriesch 45 preemptiv transplant allograft live deceas donor becker 46 retrospect 000 preemptiv transplant live donor recipi esrd underw preemptiv transplant live donor risk 057 065 recipi recipi cadaver donor kidney percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut sbg ssbm search gather s hf sbg prepar draft ssbm edit manuscript conflict declar compet interest ethic consider ethic issu plagiar fabric doubl public complet author fundingsupport none percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut\n",
            "\t-2.713\tendstag articl concept nephropathi hypertens nephropathi endstag esrd search pubm embas scopu iran medex januari 1990 decemb 2014 manuscript english persian languag fulltext articl abstract diabet mainten replac hemodialysi hd periton dialysi pd transplant nondiabet esrd esrd partli suscept foot ulcer hemodynam instabl hd transplant esrd transplant prefer replac esrd dialysi nephropathyendstag diseaseren replac therapyhemodialysi implic policypracticeresearchmed educationintroductionmateri methodsdiabet esrdsurviv esrddialysi modal diabeticsdialysi transplantationpreempt transplantationconclusionauthor contributionconflict interesteth considerationsfundingsupport implic policypracticeresearchmed nephropathi hypertens nephropathi endstag esrd reflect catastroph squeal silent killer esrd worldwid enorm financi burden healthcar introduct nephropathi classic proteinuria percent formerli call insulindepend formerli call noninsulindepend mellitu dm dm pancreat pancreatectomi dm longsenough glycemia enough dm microalbuminuria half progress macroalbuminuria call overt nephropathi overt nephropathi substanti progress endstag esrd dm progress equival proteinuria esrd proteinuria investig nephropathi retard normal prefer blockad reninangiotensin ra angiotensin convert acei angiotensin blocker arb agent spironolacton aldosteron antagonist pentoxifyllin nonselect phosphodiesteras strict substanti progress esrd esrd worldwid enorm financi burden healthcar dm complic articl esrd requir replac esrd hemodialysi hd periton dialysi pd dialysi transplant search pubm embas scopu iran medex januari 1990 decemb 2014the search combin word equival esrd hemodialysi dialysi periton dialysi transplant nephropathi manuscript english persian languag fulltext articl abstract unfortun search confer proceed manuscript languag esrd done esrd past decad glomerulonephr gn initi esrd aggress gn possibl nephropathi hypertens nephropathi esrd esrd account 45 note european 34 requir replac germani australia esrd stabil denmark widespread implement intens renoprotect glycem etiolog esrd esrd reflect catastroph sequela silent killer iran 1997 percentag requir replac attribut nephropathi twofold 1997 31 iran dm esrd account age nephropathi hypertens nephrosclerosi 55 caus esrd esrd nephropathi wakeel dm commonest esrd 266 nephrosclerosi saudi arabia preval comorbid 59 327 dm arab 212 kuwait egypt 468 lebanon esrd mainten dialysi prevent uremia expect esrd introduct dialysi 1960 diabet mainten dialysi hd pd nondiabet esrd esrd usrd esrd catastroph initi hd 10year esrd mainten hd 79 53 112 remain span age 44 age 64 chantrel esrd center franc requir dialysi die 211 esrd mainten dialysi done exist iran dialysi catastroph nondiabet esrd 185 esrd intermitt hd oneyear nondiabet 5year 522 738 5year 569 1861 esrd multicent hd southwest iran nondiabet 15year nondiabet 792 85 323 115 58 04 summari dialysi nondiabet question surviv dialysi dm esrd dialysi dm comorbid compar issu dialysi intern european associationeuropean dialysi transplant registri schroijen compar 419 dialysi 3624 dialysi 1193 dialysi comorbid 602 dialysi dialysi nondiabet adjust countri malign dialysi comorbid esrd lifetim arterioven fistula suscept fungal foot ulcer hemodynam instabl hd autonom neuropathi dialysi modal diabet choic dialysi modal hd ambulatori periton dialysi capd autom periton dialysi apd diabet influenc consider appli nondiabet avail conveni comorbid socioeconom dialysi center independ motiv toler shift vasculatur creat adequ hd abdomen pd 29 39 old vessel limit creat sustain adequ arterioven fistula hd autonom neuropathi frequent hypotens episod hd ultrafiltr dialysi fluid remov goal intradialyt hypotens necessit intraven fluid replac overload hypotens episod hd necessit discontinu hd inadequ dialysi complic 33 39 pd hd advantag modal complic dialysi initi undergo pd hd ensu pd hd pd preserv residu shortterm usrd pd dialysi lost 34 dialysi transplant transplant esrd nondiabet transplant recipi posttranspl fungal posttranspl urinari tract nondiabet transplant recipi esrd glycem transplant immunosuppress regimen transplant detriment pancreat beta glycem achiev transplant recurr transplant 44 challeng transplant prefer replac esrd transplant dialysi 41 42 usrd shortterm transplant recipi dialysi 7200 transplant recipi transplant 73 000 place wait list transplant 027 024030 project expect underw transplant diabet waitlist 43 scotland 1732 waitlist transplant posttransplant 250 underw transplant project diabet dialysi 41 dialysi underw transplant dialysi fatal nonfat 44 preemptiv transplant ckd advantag preemptiv transplant dialysi initi dialysi transplant preemptiv transplant recommend transplant dialysi 45 46 ckd preemptiv transplant initi dialysi transplant prefer substanti improv usrd preemptiv transplant transplant 41 53 72 73 103 000 wait 36 36 48 48 graft dialysi esrd 45 allograft preemptiv transplant esrd live donor deceas donor kidney meierkriesch 45 preemptiv transplant allograft live deceas donor becker 46 retrospect 000 preemptiv transplant live donor recipi esrd underw preemptiv transplant live donor risk 057 065 recipi recipi cadaver donor kidney percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut sbg ssbm search gather s hf sbg prepar draft ssbm edit manuscript conflict declar compet interest ethic consider ethic issu plagiar fabric doubl public complet author fundingsupport none percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut\n",
            "\t-2.795\tconduct veloc endstag nervou preval endstag esrd esrd elucid purpos connect conduct veloc hundr ninetyeight 68 esrd undergo hemodialysi esrd enrol conduct hour hemodialysi orthodrom sensori potenti compound potenti record median ulnar radial nerv hemoglobincorrect esrd 91 gdl 59 gdl 0001 324 68 esrd mellitu poorer sensori conduct veloc 0001 predictor conduct veloc 005 esrd declin mellitu neuropathi esrd leadkidney chronicendstag diseaseneur conductiondiabet mellitusperipher nervou introductionmateri methodssubjectsmeasur conduct velocitymeasur concentrationstatist analysisresultsdiscuss assum 150 250 ingest ten percent absorb poison leadsold kettl can leadglaz potteri acid fluid store cook equilibr organ kinet consist pool skeleton divid labil deep pool organ excret pool burden tendenc accumul skeleton act reservoir mobil patholog lactat osteoporosi endstag esrd hyperparathyroid abnorm vitamin consequ osteoporosi excret stimul resorpt esrd aggrav urem neuropathi anemia classic manifest industri poison colic anemia neuropathi encephalopathi impair reproduct disabl widespread clinic evid spectrum insuffici obviou sign premis exist asymptot subclin counterpart clinic obviou manifest poison anemia neuropathi lie upper covert heme excret uric slow conduct subclin correl nervou preval neurolog esrd nonetheless challeng catalogu neuropathi extens esrd electrophysiolog neuropathi pathophysiolog urem neuropathi theori slowli dializ substanc intermedi alter axon eventu degener neuropathi esrd mellitu pharmaceut neurotoxin alcoholnutrit neuropathi industri neurotoxin mercuri arsen thallium investig elucid purpos endstag valid relat sensori conduct veloc correl poison asymptomat poison colic neuropathi minor cramp paresthesia intermitt limb abdomin digest disturb easi defin esrd uremia aggrav poison esrd enabl discus overload esrd determin epidemiolog rigor methodolog twice 91 gdl 59 gdl esrd contrari expect conduct influenc conduct esrd electrophysiolog neuropathi pathophysiolog urem neuropathi slowli dializ substanc intermedi pathogen axon eventu degener view heterogen adequaci hemodialysi conduct ktv 130 027 ktv conduct conduct carpal tunnel esrd esrd apt carpal tunnel mask conduct carpal tunnel microglobulin normal catabol substanc amyloid deposit throughout consequ deposit carpal tunnel transvers carpal ligament profound ischem neuropathi refer ischem monomel neuropathi limb ischemia shunt neuropathi sensat weak distal arm suppli shunt vessel avoid carpal tunnel ischem neuropathi conduct conduct wristelbow segment median ulnar nerv sensori conduct radial arm arm exclud alcohol nutrit neuropathi esrd sensori potenti compound potenti suppress mellitu nondiabet mellitu nutrit npcr 103 038 albumin 37 04 gdl homogen hemodialysi npcr ulnar conduct guess malnutrit conduct esrd npcr prognost conduct neuropathi esrd pharmaceut neurotoxin industri neurotoxin mercuri arsen thallium metal neuropathi esrd enough neuropathi esrd nervou axon princip leadinduc patholog fiber segment demyelin axon degener 29 nerv person electrophysiolog probe covert abnorm slow conduct fiber ulnar neurotox ulnar conduct veloc depress gdl conjunct reveal esrd induc neuropathi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.427\tosteomyel endstag initi atherosclerosi neg acceler endstag esrd osteomyel com esrd explor com esrd com taiwan insur claim 1997 24267 newli com 97068 sexmatch noncom risk esrd com adjust comorbid name coronari arteri congest hyperlipidemia esrd 201fold confid interv 181 225 com noncom joint com comorbid esrd 157fold 123 200 com comorbid 225 197 257 com comorbid agespecif adjust esrd com hazard 178 518 614 age 34 com esrd comorbid younger  introductionmateri methodsdata sourcestudi patientsoutcom measuresstatist analysisresultsdiscuss endstag esrd becom concern worldwid esrd impair interfer product esrd financi burden esrd diminish econom past decad identifi esrd coronari arteri cad congest chf esrd esrd pathophysiolog explan esrd unresolv involv atherosclerosi explor evalu esrd risk inflammationrel elucid esrd osteomyel com last bone typic evok intens boni nearbi soft com erad typic com cad dementia epilepsi cad esrd investig com esrd warrant connect com esrd nationwid databas com risk esrd link hepat hepat gout periodont 29 herp zoster esrd suspect esrd nation repres nhird compar com 1997 com esrd numer causal link esrd old 31 33 33 34 33 hyperlipidemia 34 36 cad 37 chf 38 com comorbid esrd noncom comorbid com comorbid esrd com match comorbid differ com esrd physiopatholo account com esrd noncom infectionassoci glomerulonephr predispos nephron glomerulosclerosi declin reserv antibiot treat com nephrotox interact toxic com prospect com biopsi clarifi causal com esrd old recogn crucial esrd 39 com subgroup age 34 178fold esrd noncom subgroup age 34 attribut compet esrd elderli younger elderli initi dialysi elderli refus dialysi consider lifespan comorbid 41 retrospect strict enrol com esrd com age 34 bia strength retrospect strict catastroph ill registr esrd strict definit esrd strengthen severitydepend com esrd com sexmatch dataset exceed million enrolle encompass 99 taiwan neartotalpopul coupl strict casetocontrol generaliz precis reliabl nhi audit implement supervis insur claim overdiagnosi resourc wast nhi surveil ensur valid recogn comorbid esrd hyperlipidemia chf cad hyperuricemia gout proteinuria adjust com esrd note definit lipid confound variabl bia limit databas lifestyl person behavior drink esrd insur claim calcul esrd com refus dialysi com underestim overestim com esrd bia minim nhi cover 99 taiwan com esrd com esrd esrd com comorbid cad chf hyperlipidemia hyperuricemia gout proteinuria younger com esrd prompt alert com younger\n",
            "\t0.427\tosteomyel endstag initi atherosclerosi neg acceler endstag esrd osteomyel com esrd explor com esrd com taiwan insur claim 1997 24267 newli com 97068 sexmatch noncom risk esrd com adjust comorbid name coronari arteri congest hyperlipidemia esrd 201fold confid interv 181 225 com noncom joint com comorbid esrd 157fold 123 200 com comorbid 225 197 257 com comorbid agespecif adjust esrd com hazard 178 518 614 age 34 com esrd comorbid younger  introductionmateri methodsdata sourcestudi patientsoutcom measuresstatist analysisresultsdiscuss endstag esrd becom concern worldwid esrd impair interfer product esrd financi burden esrd diminish econom past decad identifi esrd coronari arteri cad congest chf esrd esrd pathophysiolog explan esrd unresolv involv atherosclerosi explor evalu esrd risk inflammationrel elucid esrd osteomyel com last bone typic evok intens boni nearbi soft com erad typic com cad dementia epilepsi cad esrd investig com esrd warrant connect com esrd nationwid databas com risk esrd link hepat hepat gout periodont 29 herp zoster esrd suspect esrd nation repres nhird compar com 1997 com esrd numer causal link esrd old 31 33 33 34 33 hyperlipidemia 34 36 cad 37 chf 38 com comorbid esrd noncom comorbid com comorbid esrd com match comorbid differ com esrd physiopatholo account com esrd noncom infectionassoci glomerulonephr predispos nephron glomerulosclerosi declin reserv antibiot treat com nephrotox interact toxic com prospect com biopsi clarifi causal com esrd old recogn crucial esrd 39 com subgroup age 34 178fold esrd noncom subgroup age 34 attribut compet esrd elderli younger elderli initi dialysi elderli refus dialysi consider lifespan comorbid 41 retrospect strict enrol com esrd com age 34 bia strength retrospect strict catastroph ill registr esrd strict definit esrd strengthen severitydepend com esrd com sexmatch dataset exceed million enrolle encompass 99 taiwan neartotalpopul coupl strict casetocontrol generaliz precis reliabl nhi audit implement supervis insur claim overdiagnosi resourc wast nhi surveil ensur valid recogn comorbid esrd hyperlipidemia chf cad hyperuricemia gout proteinuria adjust com esrd note definit lipid confound variabl bia limit databas lifestyl person behavior drink esrd insur claim calcul esrd com refus dialysi com underestim overestim com esrd bia minim nhi cover 99 taiwan com esrd com esrd esrd com comorbid cad chf hyperlipidemia hyperuricemia gout proteinuria younger com esrd prompt alert com younger\n",
            "\t0.398\tdiffer myocardi session hemodialysi endstag mellitu coronari arteri hemodialysi hd acut improv background coronari arteri cad dm set endstag esrd veloc echocardiographi tve offer fast choic follow myocardi hd esrd concomit dm cad 46 esrd dm dmcad underw tve shortli hd besid doppler region myocardi systol diastol veloc systol post process prehd posthd kg 51 48 62 vs59 61 58 001 ventricular diastol dimens post hd 46 42 53 51 47 001 region longitudin peak systol veloc septum cm posthd 157 72 0001 remain unchang trend note ventricular wall myocardi veloc cm comput global 63 79 0001 region diastol veloc cm remain unchang 359 41 001 systol 1sec remain unchang 087 04 094 03 n hd session improv lv esrd coexist dm cad dialysisdepend load coexist background myocardi hd  backgroundmethodsstudi designstandard echocardiographi protocoltissu veloc echocardiographystrain imaginghemodialysiscoronari angiographystatist methodsresultsradi tve datasystol diastol interv lv fill tei indexdiscussionconclusionstudi limitationsclin implicationscompet interestsauthor contribut mellitu dm endstag esrd great coexist coronari arteri cad esrd coronari event die detail behind death exact region contractil behavior ventricl lv esrd ongo replac hemodialysi hd destin temporarili remov excess fluid toxin undergo hd concomit tve load depend esrd coexist dm cad region myocardi systol diastol veloc diminish differ myocardi dialysisdepend preload longitudin myocardi tve hd quantit differ set irrespect load hd session improv lv esrd comorbid dm myocardi continu diminish irrespect concomit cad minor compensatori overact systol radial motion latter possibl region cad hdinduc tve depend preexist myocardi hemodynam milieu\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.713\tendstag articl concept nephropathi hypertens nephropathi endstag esrd search pubm embas scopu iran medex januari 1990 decemb 2014 manuscript english persian languag fulltext articl abstract diabet mainten replac hemodialysi hd periton dialysi pd transplant nondiabet esrd esrd partli suscept foot ulcer hemodynam instabl hd transplant esrd transplant prefer replac esrd dialysi nephropathyendstag diseaseren replac therapyhemodialysi implic policypracticeresearchmed educationintroductionmateri methodsdiabet esrdsurviv esrddialysi modal diabeticsdialysi transplantationpreempt transplantationconclusionauthor contributionconflict interesteth considerationsfundingsupport implic policypracticeresearchmed nephropathi hypertens nephropathi endstag esrd reflect catastroph squeal silent killer esrd worldwid enorm financi burden healthcar introduct nephropathi classic proteinuria percent formerli call insulindepend formerli call noninsulindepend mellitu dm dm pancreat pancreatectomi dm longsenough glycemia enough dm microalbuminuria half progress macroalbuminuria call overt nephropathi overt nephropathi substanti progress endstag esrd dm progress equival proteinuria esrd proteinuria investig nephropathi retard normal prefer blockad reninangiotensin ra angiotensin convert acei angiotensin blocker arb agent spironolacton aldosteron antagonist pentoxifyllin nonselect phosphodiesteras strict substanti progress esrd esrd worldwid enorm financi burden healthcar dm complic articl esrd requir replac esrd hemodialysi hd periton dialysi pd dialysi transplant search pubm embas scopu iran medex januari 1990 decemb 2014the search combin word equival esrd hemodialysi dialysi periton dialysi transplant nephropathi manuscript english persian languag fulltext articl abstract unfortun search confer proceed manuscript languag esrd done esrd past decad glomerulonephr gn initi esrd aggress gn possibl nephropathi hypertens nephropathi esrd esrd account 45 note european 34 requir replac germani australia esrd stabil denmark widespread implement intens renoprotect glycem etiolog esrd esrd reflect catastroph sequela silent killer iran 1997 percentag requir replac attribut nephropathi twofold 1997 31 iran dm esrd account age nephropathi hypertens nephrosclerosi 55 caus esrd esrd nephropathi wakeel dm commonest esrd 266 nephrosclerosi saudi arabia preval comorbid 59 327 dm arab 212 kuwait egypt 468 lebanon esrd mainten dialysi prevent uremia expect esrd introduct dialysi 1960 diabet mainten dialysi hd pd nondiabet esrd esrd usrd esrd catastroph initi hd 10year esrd mainten hd 79 53 112 remain span age 44 age 64 chantrel esrd center franc requir dialysi die 211 esrd mainten dialysi done exist iran dialysi catastroph nondiabet esrd 185 esrd intermitt hd oneyear nondiabet 5year 522 738 5year 569 1861 esrd multicent hd southwest iran nondiabet 15year nondiabet 792 85 323 115 58 04 summari dialysi nondiabet question surviv dialysi dm esrd dialysi dm comorbid compar issu dialysi intern european associationeuropean dialysi transplant registri schroijen compar 419 dialysi 3624 dialysi 1193 dialysi comorbid 602 dialysi dialysi nondiabet adjust countri malign dialysi comorbid esrd lifetim arterioven fistula suscept fungal foot ulcer hemodynam instabl hd autonom neuropathi dialysi modal diabet choic dialysi modal hd ambulatori periton dialysi capd autom periton dialysi apd diabet influenc consider appli nondiabet avail conveni comorbid socioeconom dialysi center independ motiv toler shift vasculatur creat adequ hd abdomen pd 29 39 old vessel limit creat sustain adequ arterioven fistula hd autonom neuropathi frequent hypotens episod hd ultrafiltr dialysi fluid remov goal intradialyt hypotens necessit intraven fluid replac overload hypotens episod hd necessit discontinu hd inadequ dialysi complic 33 39 pd hd advantag modal complic dialysi initi undergo pd hd ensu pd hd pd preserv residu shortterm usrd pd dialysi lost 34 dialysi transplant transplant esrd nondiabet transplant recipi posttranspl fungal posttranspl urinari tract nondiabet transplant recipi esrd glycem transplant immunosuppress regimen transplant detriment pancreat beta glycem achiev transplant recurr transplant 44 challeng transplant prefer replac esrd transplant dialysi 41 42 usrd shortterm transplant recipi dialysi 7200 transplant recipi transplant 73 000 place wait list transplant 027 024030 project expect underw transplant diabet waitlist 43 scotland 1732 waitlist transplant posttransplant 250 underw transplant project diabet dialysi 41 dialysi underw transplant dialysi fatal nonfat 44 preemptiv transplant ckd advantag preemptiv transplant dialysi initi dialysi transplant preemptiv transplant recommend transplant dialysi 45 46 ckd preemptiv transplant initi dialysi transplant prefer substanti improv usrd preemptiv transplant transplant 41 53 72 73 103 000 wait 36 36 48 48 graft dialysi esrd 45 allograft preemptiv transplant esrd live donor deceas donor kidney meierkriesch 45 preemptiv transplant allograft live deceas donor becker 46 retrospect 000 preemptiv transplant live donor recipi esrd underw preemptiv transplant live donor risk 057 065 recipi recipi cadaver donor kidney percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut sbg ssbm search gather s hf sbg prepar draft ssbm edit manuscript conflict declar compet interest ethic consider ethic issu plagiar fabric doubl public complet author fundingsupport none percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut\n",
            "\t-2.713\tendstag articl concept nephropathi hypertens nephropathi endstag esrd search pubm embas scopu iran medex januari 1990 decemb 2014 manuscript english persian languag fulltext articl abstract diabet mainten replac hemodialysi hd periton dialysi pd transplant nondiabet esrd esrd partli suscept foot ulcer hemodynam instabl hd transplant esrd transplant prefer replac esrd dialysi nephropathyendstag diseaseren replac therapyhemodialysi implic policypracticeresearchmed educationintroductionmateri methodsdiabet esrdsurviv esrddialysi modal diabeticsdialysi transplantationpreempt transplantationconclusionauthor contributionconflict interesteth considerationsfundingsupport implic policypracticeresearchmed nephropathi hypertens nephropathi endstag esrd reflect catastroph squeal silent killer esrd worldwid enorm financi burden healthcar introduct nephropathi classic proteinuria percent formerli call insulindepend formerli call noninsulindepend mellitu dm dm pancreat pancreatectomi dm longsenough glycemia enough dm microalbuminuria half progress macroalbuminuria call overt nephropathi overt nephropathi substanti progress endstag esrd dm progress equival proteinuria esrd proteinuria investig nephropathi retard normal prefer blockad reninangiotensin ra angiotensin convert acei angiotensin blocker arb agent spironolacton aldosteron antagonist pentoxifyllin nonselect phosphodiesteras strict substanti progress esrd esrd worldwid enorm financi burden healthcar dm complic articl esrd requir replac esrd hemodialysi hd periton dialysi pd dialysi transplant search pubm embas scopu iran medex januari 1990 decemb 2014the search combin word equival esrd hemodialysi dialysi periton dialysi transplant nephropathi manuscript english persian languag fulltext articl abstract unfortun search confer proceed manuscript languag esrd done esrd past decad glomerulonephr gn initi esrd aggress gn possibl nephropathi hypertens nephropathi esrd esrd account 45 note european 34 requir replac germani australia esrd stabil denmark widespread implement intens renoprotect glycem etiolog esrd esrd reflect catastroph sequela silent killer iran 1997 percentag requir replac attribut nephropathi twofold 1997 31 iran dm esrd account age nephropathi hypertens nephrosclerosi 55 caus esrd esrd nephropathi wakeel dm commonest esrd 266 nephrosclerosi saudi arabia preval comorbid 59 327 dm arab 212 kuwait egypt 468 lebanon esrd mainten dialysi prevent uremia expect esrd introduct dialysi 1960 diabet mainten dialysi hd pd nondiabet esrd esrd usrd esrd catastroph initi hd 10year esrd mainten hd 79 53 112 remain span age 44 age 64 chantrel esrd center franc requir dialysi die 211 esrd mainten dialysi done exist iran dialysi catastroph nondiabet esrd 185 esrd intermitt hd oneyear nondiabet 5year 522 738 5year 569 1861 esrd multicent hd southwest iran nondiabet 15year nondiabet 792 85 323 115 58 04 summari dialysi nondiabet question surviv dialysi dm esrd dialysi dm comorbid compar issu dialysi intern european associationeuropean dialysi transplant registri schroijen compar 419 dialysi 3624 dialysi 1193 dialysi comorbid 602 dialysi dialysi nondiabet adjust countri malign dialysi comorbid esrd lifetim arterioven fistula suscept fungal foot ulcer hemodynam instabl hd autonom neuropathi dialysi modal diabet choic dialysi modal hd ambulatori periton dialysi capd autom periton dialysi apd diabet influenc consider appli nondiabet avail conveni comorbid socioeconom dialysi center independ motiv toler shift vasculatur creat adequ hd abdomen pd 29 39 old vessel limit creat sustain adequ arterioven fistula hd autonom neuropathi frequent hypotens episod hd ultrafiltr dialysi fluid remov goal intradialyt hypotens necessit intraven fluid replac overload hypotens episod hd necessit discontinu hd inadequ dialysi complic 33 39 pd hd advantag modal complic dialysi initi undergo pd hd ensu pd hd pd preserv residu shortterm usrd pd dialysi lost 34 dialysi transplant transplant esrd nondiabet transplant recipi posttranspl fungal posttranspl urinari tract nondiabet transplant recipi esrd glycem transplant immunosuppress regimen transplant detriment pancreat beta glycem achiev transplant recurr transplant 44 challeng transplant prefer replac esrd transplant dialysi 41 42 usrd shortterm transplant recipi dialysi 7200 transplant recipi transplant 73 000 place wait list transplant 027 024030 project expect underw transplant diabet waitlist 43 scotland 1732 waitlist transplant posttransplant 250 underw transplant project diabet dialysi 41 dialysi underw transplant dialysi fatal nonfat 44 preemptiv transplant ckd advantag preemptiv transplant dialysi initi dialysi transplant preemptiv transplant recommend transplant dialysi 45 46 ckd preemptiv transplant initi dialysi transplant prefer substanti improv usrd preemptiv transplant transplant 41 53 72 73 103 000 wait 36 36 48 48 graft dialysi esrd 45 allograft preemptiv transplant esrd live donor deceas donor kidney meierkriesch 45 preemptiv transplant allograft live deceas donor becker 46 retrospect 000 preemptiv transplant live donor recipi esrd underw preemptiv transplant live donor risk 057 065 recipi recipi cadaver donor kidney percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut sbg ssbm search gather s hf sbg prepar draft ssbm edit manuscript conflict declar compet interest ethic consider ethic issu plagiar fabric doubl public complet author fundingsupport none percentag dm progress equival esrd proteinuria nephropathi hypertens nephropathi esrd reflect catastroph sequela silent killer diabet mainten dialysi hd pd nondiabet esrd dialysi comorbid pd hd dialysi initi undergo pd preserv residu shortterm pd pd dialysi lost transplant esrd transplant prefer replac esrd dialysi ckd ckd advantag preemptiv transplant initi dialysi transplant recommend transplant dialysi allograft preemptiv transplant esrd live donor deceas donor kidney contribut\n",
            "\t-2.795\tconduct veloc endstag nervou preval endstag esrd esrd elucid purpos connect conduct veloc hundr ninetyeight 68 esrd undergo hemodialysi esrd enrol conduct hour hemodialysi orthodrom sensori potenti compound potenti record median ulnar radial nerv hemoglobincorrect esrd 91 gdl 59 gdl 0001 324 68 esrd mellitu poorer sensori conduct veloc 0001 predictor conduct veloc 005 esrd declin mellitu neuropathi esrd leadkidney chronicendstag diseaseneur conductiondiabet mellitusperipher nervou introductionmateri methodssubjectsmeasur conduct velocitymeasur concentrationstatist analysisresultsdiscuss assum 150 250 ingest ten percent absorb poison leadsold kettl can leadglaz potteri acid fluid store cook equilibr organ kinet consist pool skeleton divid labil deep pool organ excret pool burden tendenc accumul skeleton act reservoir mobil patholog lactat osteoporosi endstag esrd hyperparathyroid abnorm vitamin consequ osteoporosi excret stimul resorpt esrd aggrav urem neuropathi anemia classic manifest industri poison colic anemia neuropathi encephalopathi impair reproduct disabl widespread clinic evid spectrum insuffici obviou sign premis exist asymptot subclin counterpart clinic obviou manifest poison anemia neuropathi lie upper covert heme excret uric slow conduct subclin correl nervou preval neurolog esrd nonetheless challeng catalogu neuropathi extens esrd electrophysiolog neuropathi pathophysiolog urem neuropathi theori slowli dializ substanc intermedi alter axon eventu degener neuropathi esrd mellitu pharmaceut neurotoxin alcoholnutrit neuropathi industri neurotoxin mercuri arsen thallium investig elucid purpos endstag valid relat sensori conduct veloc correl poison asymptomat poison colic neuropathi minor cramp paresthesia intermitt limb abdomin digest disturb easi defin esrd uremia aggrav poison esrd enabl discus overload esrd determin epidemiolog rigor methodolog twice 91 gdl 59 gdl esrd contrari expect conduct influenc conduct esrd electrophysiolog neuropathi pathophysiolog urem neuropathi slowli dializ substanc intermedi pathogen axon eventu degener view heterogen adequaci hemodialysi conduct ktv 130 027 ktv conduct conduct carpal tunnel esrd esrd apt carpal tunnel mask conduct carpal tunnel microglobulin normal catabol substanc amyloid deposit throughout consequ deposit carpal tunnel transvers carpal ligament profound ischem neuropathi refer ischem monomel neuropathi limb ischemia shunt neuropathi sensat weak distal arm suppli shunt vessel avoid carpal tunnel ischem neuropathi conduct conduct wristelbow segment median ulnar nerv sensori conduct radial arm arm exclud alcohol nutrit neuropathi esrd sensori potenti compound potenti suppress mellitu nondiabet mellitu nutrit npcr 103 038 albumin 37 04 gdl homogen hemodialysi npcr ulnar conduct guess malnutrit conduct esrd npcr prognost conduct neuropathi esrd pharmaceut neurotoxin industri neurotoxin mercuri arsen thallium metal neuropathi esrd enough neuropathi esrd nervou axon princip leadinduc patholog fiber segment demyelin axon degener 29 nerv person electrophysiolog probe covert abnorm slow conduct fiber ulnar neurotox ulnar conduct veloc depress gdl conjunct reveal esrd induc neuropathi\n",
            "ESRD,vanco None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.441\tlocal fate escherichia coli hematogen pyelonephr hematogen coli pyelonephr local organ persist antigen fluoresc histolog bacteriolog salient sequenti follow organ pas vessel wall interstitium began multipl subsequ evok leucocyt multipl glomerulus tubular tubular lumen microabscess interstitium bacteriuria appear repres invas filtrat organ heal spontan steril parenchym scar contain amount residu persist continu progress scar persist antigen postul constitut antigen stimulu immun hematogen pyelonephr    \n",
            "\t0.431\therp enceph herp simplex enceph myeliti suckl routin titrat fluoresc stain intracerebr inocul dispers rapidli cerebrospin fluid csf multipli mening ependyma invad parenchyma infect glia extraneur inocul gain nervou cn hematogen intraperiton intranas inocul multipli viscera viremia focus cn cerebr vessel subcutan intranas inocul spread correspond cranial nerv spread centripet endoneur schwann fibroblast axon correspond ganglion perikaryon spread cn unrel tract axon spread hostviru discus relat theori bloodbrain barrier    \n",
            "\t0.416\tmultipl newcastl virushela hundredfold viruscel multipl newcastl ndv hela phase reproduct consequ multipl hour inocul multipl appear newli infect hemadsorb mitosi mark doubl hela ndv nw fluoresc establish interfer nw multipl ndv inocul multipl newli appear infect particl infect rapidli reach peak declin continu hour declin infect begun fraction incorpor infect particl maxim yield particl hela cent cellassoci neutral antiserum disrupt mitosi releas infect ndv progress mitot continu mark cytopath mitot ndv inhibit mitosi hela discus    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.941\thepatocellular cirrhosi hepat    editor 65yearold refer king faisal centr jaundic fever abdomin discomfort biochem hepat hcv hepat histolog cirrhosi hcv polymeras hcv quantit 4682 copiesml lft alt 225 iul 560 iul ast 104 iul 543 iul bilirubin mll 51170 moll inr 0911 albumin 38 gl 3550 gl biopsi hepat grade portal fibrosi cirrhosi alphafetoprotein gml complet full pegul interferon million unit subcutan timesweek ribavirin 1000 mg oral lft sustain virolog sustain detect antivir discharg clinic instruct ct scan discharg imag refer back huge hypochondri jaundic fever cm diamet separ illdefin lobul hard basic cbc alt iul 560 iul ast iul 543 iul alp 75 iul 30120 iul bilirubin mll 51170 moll inr 0911 albumin 42 gl 3550 gl afp gml carcinoembryon cea gml ultrasound abdomen huge 8cm 11cm portal vein branch visual distal ct abdomen segment hepatocellullar hcc classic triphas heterogen enhanc arteri washout portalven leav hcc lesion hypodens surround underw remov segment histopatholog hcc stain hcc pseudoglandular trabecular extens lymphovascul invas immunohistochem stain cd34 wrap cluster rest nonneoplast liver mild steatosi cirrhosi trichrom stain triphas ct scan abdomen segment arteri portalven hematoxylin eosin stain hcc classic pseudoglandular trabecular trichrom stain nonneoplast mild steatosi cirrhosi hcc aris hepatocyt malign aris cirrhot hcv cirrhosi worldwid afp cirrhosi achiev sustain hcc afp occas okanou 1246 hcv pegul interferon interferon hcc interferon lower hcc sustain transient biochem respond none respond hcc omata interferon hcc hcv hcc fibrosi gender interferon prevent sustain respond untreat hcc offer surveil ultrasound 34 monthli interv doubl hcc hcc absent insuffici abnorm triphas ct mri confirm ct interv 34 litertur hcc cirrhosi porphyria cutanea tarda epidemiolog hcc hcv cirrhosi coinfect hbv rest alcohol alcohol 80 gday knowldg coinfect hcc apart hcv hcc hcv interferonalpha sustain virolog afp exclud hcc surveil hcc \n",
            "\t-1.631\tadminstr peginterferon ulcer coliti hepat colon revers th1th2 ratio 42yearold man hepat ulcer coliti uc refer august bloodi diarrhea clinic endoscop flare uc inform consent pegifn 2a initi pegifn abdomin gradual subsid cytokin thelper th ifnth il4 start colonoscopi mucos unev pegifn 2a novemb remiss uc cytokin alter th1th2 cytokin balanc intestin uc regard uc refractori therapi  reportdiscuss 42yearold man hcv refer august diarrhea bloodi stool ten admiss uc endoscop histolog 3000 mg mesalazin admiss mild tender abdomen colonoscop reddish edemat mucosa eros entir colon 1a sutherland score thrombocytopenia 57000mm3 aspar aminotransferas ast 124 iul alanin aminotransferas alt 110 iul hepat hcv genotyp ib 757 kiuml biopsi hcv f3a2 refus corticosteroid leukocytapheresi inform consent pegifn 2a 90 gweek improv colon initi pegifn abdomin gradual subsid cytokin thelper th ifnth interleukin il4 402 274 2a il10 start colonoscopi mucos 1b dai score unev pegifn 2a novemb remiss uc hcvrna suggest sustain virolog inf immunomodulatori inf pathophysiolog ibd ibd imbal th1th2 cytokin inf trigger th1relat intestin celiac crohn inf th1 pathophysiolog uc th2 regard inf benefici excess th2 uc seem success uc inf uc controversi provok exacerb uc inf th1th2 inf cytokin th1th2 suggest shift cytokin toward th1 pegifn 2a il10 uc specul judg alter th1th2 cytokin balanc alter th1th2 cytokin balanc biomark interferon uc uc refractori therapi practic biomark\n",
            "\t-3.219\tuntangl etiolog ascit 72 final amyloidosi biopsi specialti gastroenterolog hepatolog unusu amyloidosi vast organ infiltr amyloidosi typic cirrhosi typic present includ hepatomegali mild abnorm 72yearold man 2week worsen abdomin scrotal extrem swell endors melanot stool intermitt dizzi 10pound gain vital 8257 mmhg pul 83 beatsmin orthostat mild bibasilar crackl note abdomen moder distend fluid wave hepatosplenomegali note display anasarca extrem scrotal edema jaundic telangiectasia stigma bilirubin mgdl 02 mgdl ast 111 iul 34 iul alt 51 iul 55 iul ggt 583 ul 64 ul alkalin phosphatas 645 ul 150 ul periton fluid portal atyp present cirrhosi unclear etiolog biopsi amyloid deposit etiolog ambigu typic etiolog atyp present hepat amyloidosi discov ascit typic hepatomegali  backgroundcas reportdiscussionconclus amyloidosi date back 1854 rudolph virchow deposit abnorm proteinac organ organ involv gastrointestin tract marrow infiltr hepat present hepatomegali abnorm alkalin phosphatas ascit hepat amyloidosi etiolog ascit cirrhosi typic predict highlight atyp present amyloidosi untangl clue proteinuria alkalin phosphatas elev accompani\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.441\tlocal fate escherichia coli hematogen pyelonephr hematogen coli pyelonephr local organ persist antigen fluoresc histolog bacteriolog salient sequenti follow organ pas vessel wall interstitium began multipl subsequ evok leucocyt multipl glomerulus tubular tubular lumen microabscess interstitium bacteriuria appear repres invas filtrat organ heal spontan steril parenchym scar contain amount residu persist continu progress scar persist antigen postul constitut antigen stimulu immun hematogen pyelonephr    \n",
            "\t0.431\therp enceph herp simplex enceph myeliti suckl routin titrat fluoresc stain intracerebr inocul dispers rapidli cerebrospin fluid csf multipli mening ependyma invad parenchyma infect glia extraneur inocul gain nervou cn hematogen intraperiton intranas inocul multipli viscera viremia focus cn cerebr vessel subcutan intranas inocul spread correspond cranial nerv spread centripet endoneur schwann fibroblast axon correspond ganglion perikaryon spread cn unrel tract axon spread hostviru discus relat theori bloodbrain barrier    \n",
            "\t0.416\tmultipl newcastl virushela hundredfold viruscel multipl newcastl ndv hela phase reproduct consequ multipl hour inocul multipl appear newli infect hemadsorb mitosi mark doubl hela ndv nw fluoresc establish interfer nw multipl ndv inocul multipl newli appear infect particl infect rapidli reach peak declin continu hour declin infect begun fraction incorpor infect particl maxim yield particl hela cent cellassoci neutral antiserum disrupt mitosi releas infect ndv progress mitot continu mark cytopath mitot ndv inhibit mitosi hela discus    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.941\thepatocellular cirrhosi hepat    editor 65yearold refer king faisal centr jaundic fever abdomin discomfort biochem hepat hcv hepat histolog cirrhosi hcv polymeras hcv quantit 4682 copiesml lft alt 225 iul 560 iul ast 104 iul 543 iul bilirubin mll 51170 moll inr 0911 albumin 38 gl 3550 gl biopsi hepat grade portal fibrosi cirrhosi alphafetoprotein gml complet full pegul interferon million unit subcutan timesweek ribavirin 1000 mg oral lft sustain virolog sustain detect antivir discharg clinic instruct ct scan discharg imag refer back huge hypochondri jaundic fever cm diamet separ illdefin lobul hard basic cbc alt iul 560 iul ast iul 543 iul alp 75 iul 30120 iul bilirubin mll 51170 moll inr 0911 albumin 42 gl 3550 gl afp gml carcinoembryon cea gml ultrasound abdomen huge 8cm 11cm portal vein branch visual distal ct abdomen segment hepatocellullar hcc classic triphas heterogen enhanc arteri washout portalven leav hcc lesion hypodens surround underw remov segment histopatholog hcc stain hcc pseudoglandular trabecular extens lymphovascul invas immunohistochem stain cd34 wrap cluster rest nonneoplast liver mild steatosi cirrhosi trichrom stain triphas ct scan abdomen segment arteri portalven hematoxylin eosin stain hcc classic pseudoglandular trabecular trichrom stain nonneoplast mild steatosi cirrhosi hcc aris hepatocyt malign aris cirrhot hcv cirrhosi worldwid afp cirrhosi achiev sustain hcc afp occas okanou 1246 hcv pegul interferon interferon hcc interferon lower hcc sustain transient biochem respond none respond hcc omata interferon hcc hcv hcc fibrosi gender interferon prevent sustain respond untreat hcc offer surveil ultrasound 34 monthli interv doubl hcc hcc absent insuffici abnorm triphas ct mri confirm ct interv 34 litertur hcc cirrhosi porphyria cutanea tarda epidemiolog hcc hcv cirrhosi coinfect hbv rest alcohol alcohol 80 gday knowldg coinfect hcc apart hcv hcc hcv interferonalpha sustain virolog afp exclud hcc surveil hcc \n",
            "\t-1.631\tadminstr peginterferon ulcer coliti hepat colon revers th1th2 ratio 42yearold man hepat ulcer coliti uc refer august bloodi diarrhea clinic endoscop flare uc inform consent pegifn 2a initi pegifn abdomin gradual subsid cytokin thelper th ifnth il4 start colonoscopi mucos unev pegifn 2a novemb remiss uc cytokin alter th1th2 cytokin balanc intestin uc regard uc refractori therapi  reportdiscuss 42yearold man hcv refer august diarrhea bloodi stool ten admiss uc endoscop histolog 3000 mg mesalazin admiss mild tender abdomen colonoscop reddish edemat mucosa eros entir colon 1a sutherland score thrombocytopenia 57000mm3 aspar aminotransferas ast 124 iul alanin aminotransferas alt 110 iul hepat hcv genotyp ib 757 kiuml biopsi hcv f3a2 refus corticosteroid leukocytapheresi inform consent pegifn 2a 90 gweek improv colon initi pegifn abdomin gradual subsid cytokin thelper th ifnth interleukin il4 402 274 2a il10 start colonoscopi mucos 1b dai score unev pegifn 2a novemb remiss uc hcvrna suggest sustain virolog inf immunomodulatori inf pathophysiolog ibd ibd imbal th1th2 cytokin inf trigger th1relat intestin celiac crohn inf th1 pathophysiolog uc th2 regard inf benefici excess th2 uc seem success uc inf uc controversi provok exacerb uc inf th1th2 inf cytokin th1th2 suggest shift cytokin toward th1 pegifn 2a il10 uc specul judg alter th1th2 cytokin balanc alter th1th2 cytokin balanc biomark interferon uc uc refractori therapi practic biomark\n",
            "\t-3.219\tuntangl etiolog ascit 72 final amyloidosi biopsi specialti gastroenterolog hepatolog unusu amyloidosi vast organ infiltr amyloidosi typic cirrhosi typic present includ hepatomegali mild abnorm 72yearold man 2week worsen abdomin scrotal extrem swell endors melanot stool intermitt dizzi 10pound gain vital 8257 mmhg pul 83 beatsmin orthostat mild bibasilar crackl note abdomen moder distend fluid wave hepatosplenomegali note display anasarca extrem scrotal edema jaundic telangiectasia stigma bilirubin mgdl 02 mgdl ast 111 iul 34 iul alt 51 iul 55 iul ggt 583 ul 64 ul alkalin phosphatas 645 ul 150 ul periton fluid portal atyp present cirrhosi unclear etiolog biopsi amyloid deposit etiolog ambigu typic etiolog atyp present hepat amyloidosi discov ascit typic hepatomegali  backgroundcas reportdiscussionconclus amyloidosi date back 1854 rudolph virchow deposit abnorm proteinac organ organ involv gastrointestin tract marrow infiltr hepat present hepatomegali abnorm alkalin phosphatas ascit hepat amyloidosi etiolog ascit cirrhosi typic predict highlight atyp present amyloidosi untangl clue proteinuria alkalin phosphatas elev accompani\n",
            "Hep C cirrhosis,interferon,ETOH None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.580\tlipid apolipoprotein coronari arteri proatherogen lowdens lipoprotein cholesterol ldlc antiatherogen highdens lipoprotein cholesterol hdlc controversi aris coronari arteri cad goal cad 1916 cad 85 cox proport hazard regress estim ratio allcaus cvd median 31 147 death record 113 cvd categor hdlc ushap allcaus cvd adjust cvd ldlc apob ldlhdl apobapoai posit apoai invers cvd pairwis lipidrel ldlhdl ldlc stronger allcaus cvd proatherogen chine cad  introduction2 methods21 participants22 measurements23 prospect followup24 analysis3 results31 relationship categor lipid mortality32 pairwis comparison relationship continu lipid mortality4 discussion5 conclus  chine cad hdlc allcaus cvd ldlc proper predictor cad ldlhdl strengthen besid apob apobapoai apoai cvd cad\n",
            "\t0.580\tlipid apolipoprotein coronari arteri proatherogen lowdens lipoprotein cholesterol ldlc antiatherogen highdens lipoprotein cholesterol hdlc controversi aris coronari arteri cad goal cad 1916 cad 85 cox proport hazard regress estim ratio allcaus cvd median 31 147 death record 113 cvd categor hdlc ushap allcaus cvd adjust cvd ldlc apob ldlhdl apobapoai posit apoai invers cvd pairwis lipidrel ldlhdl ldlc stronger allcaus cvd proatherogen chine cad  introduction2 methods21 participants22 measurements23 prospect followup24 analysis3 results31 relationship categor lipid mortality32 pairwis comparison relationship continu lipid mortality4 discussion5 conclus  chine cad hdlc allcaus cvd ldlc proper predictor cad ldlhdl strengthen besid apob apobapoai apoai cvd cad\n",
            "\t0.570\tden ldl famili hyperlipidemia n291 polymorph lipoprotein lipas predomin den ldl cholesterol particl famili hyperlipidemia fch lipoprotein lipas exert circumst ldl lipid n291 polymorph lipoprotein lipas lpl fch apolipoprotein diamet ldl n291 polymorph 93 fch 286 fch n291 polymorph diamet ldl fch ldl triglycerid vldlc nonhdlc apo b100 hdlc fch polymorph 875 125 polymorph 692 308 statist 0004 fch 97 n291 fch 93 dutch fchl caucasian polymorph fch ldl posse atherogen den ldl n291  backgroundmateri methodsdna rflp lplstudi designstatisticsresultsdiscussionabbreviationscompet interestsauthor contributionsacknowledg dyslipemia mellitu famili hyperlipidemia constitut atherogen lipoprotein triglycerid ldl particl hdl cholesterol triad prematur coronari den ldl particl form larg triglycerid coronari ldl particl bimod peak separ phenotyp buoyant ldl predomin smaller den ldl predomin cholesterol atp consid den ldl famili hyperlipidemia fch mim 144250 frequent hyperlipemia tendenc appear coronari prematur coronari fch present complet understood vari rel atherogen lipoprotein apolipoprotein b100 relat fch polygen fch lipoprotein lipas lpl ec 31134 glycoprot catabol lipoprotein rich triglycerid chylomicron lipoprotein vldl lpl take place surround lumen capillari vessel adher heparan sulphat proteoglycan 80 lpl 1500 heterozyg n291 local exon lpl analyz atherogen lipoprotein predomin den ldl n291 lpl polymorph spanish fch valencia respect fch complet understood dyslipem disturb lipoprotein fraction abnorm elev vldl overproduct defect catabol den ldl final catabol particl easili oxid display affin retent arteri wall normal counterpart den ldl accept emerg cholesterol programm panel predomin particl classic fch ldl atherogen hypolipidem modifi ldl subclass atherogen lipoprotein potent lipidlow therapi fch heterogen oligogen exert lipoprotein lipas codon polymorph lpl alter triglyceriderich lipoprotein frequent polymorph exon rs268 1128 n291 fch 97 93 dutch fch consider caucasian polymorph reflect carrier n291 frequent fch postprandi lipemia alter enzymat vldl particl apo b100 appear den ldl particl final catabol triglyceriderich lipoprotein particl fch polymorph neg postprandi fatrich meal initi normolipem coincid polymorphismcarri smaller ldl diamet atherogen alter triglyceriderich particl fch polymorph ischem cardiopathi n291 polymorph smaller ldl diamet correspond constitut final alter triglyceriderich particl repres polymorph constitut awar relat polymorph unfortun make conduct permit draw solid conclus said fch ldl atherogen den ldl allel encod n291 lpl percentag fch disrupt alter clearanc triglyceriderich lipoprotein atherogen fch autonom valencia ldl carri polymorph consider rigor hyperlipemia abbrevi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.484\tldl cholesterol chromosom locu 1p133 coronari arteri   introduction2 methods21 subjects3 measurements31 measurements32 biochem assays33 genotyp polymorph rs599839 rs646776 rs4970834331 amplification34 analysis35 calculations4 results41 biochem patients411 linkag disequilibrium ld snp rs599839 rs646776 rs4970834 cad 42 profile421 genotyp 3422 ldlc genotyp cad 443 rs599839 rs64776 rs4970834 genotyp angiograph cad patients431 snp genotyp coronari stenosi 5432 haplotyp 644 ldlc 1p13 loco stenosi ac odd ac discussion6 summari cvd morbid worldwid ldl cholesterol contribut epidemiolog lowdens lipoprotein cholesterol ldlc prematur atherosclerosi lowdens lipoprotein cholesterol carrier cholesterol implic buildup cholesterol atherosclerot plaqu postul ldl atherosclerosi oxid ldlc numer biolog pathogenet acceler cytotox chemotact monocyt arteri wall den ldlc particl endotheliumdepend vasodil acetylcholin decreas ldl cholesterol cvd morbid ldl cholesterol repres intervent hazard cvd coronari arteri cad consequ atherosclerot coronari arteri ischem ihd polymorph encod isoform atherosclerosi genomewid gwa candid locus confer protect cad myocardi infarct mi genomewid gwa discov hypercholesterolemia myocardi infarct polymorph 1p133 prolineserinerich coiledcoil psrc1 cadherin egf lag sevenpass gtype celsr2 myosin hlike mybphl sortilin sort1 apolipoprotein apo b100 sortilin encod sort1 interact apob100 golgi apparatu acceler hepat export apob100contain lipoprotein regul circul ldlc knockout sortilin reduc lipoprotein hypercholesterolemia atherosclerot plaqu ldl receptordefici sortilin acceler hepat lipoprotein circul ldl promis candid locus chromosom locat 1p133 consist ldlc paramet wellestablish cad gwa rs599839 rs646776 rs4970834 chromosom locat 1p133 determin ldl success replic cad polymorph 1p133 97 kb block linkag disequilibrium variant rs599839 untransl psrc1 linkag disequilibrium snp ld block rs599839 snp cad ldlc minor allel european maf033 hapmap ceu httpwwwncbinlmnihgovprojectssnp cad ldlc equival arab polymorph modul ldlc cad snp rs599839 rs646776 rs4970834 1p133 locu ldl cholesterol cad ldl wellcharacter consecut coronari arteri ac underw coronari angiographi polymorph rs599839 ldlc variant rs599839 atherosclerot lesion coronari vessel polymorph rs599839 rs646776 rs4970834 locu 1p133 antagon stenosi ldlc longitudin qatari explor locu atherogenesi\n",
            "\t-0.484\tldl cholesterol chromosom locu 1p133 coronari arteri   introduction2 methods21 subjects3 measurements31 measurements32 biochem assays33 genotyp polymorph rs599839 rs646776 rs4970834331 amplification34 analysis35 calculations4 results41 biochem patients411 linkag disequilibrium ld snp rs599839 rs646776 rs4970834 cad 42 profile421 genotyp 3422 ldlc genotyp cad 443 rs599839 rs64776 rs4970834 genotyp angiograph cad patients431 snp genotyp coronari stenosi 5432 haplotyp 644 ldlc 1p13 loco stenosi ac odd ac discussion6 summari cvd morbid worldwid ldl cholesterol contribut epidemiolog lowdens lipoprotein cholesterol ldlc prematur atherosclerosi lowdens lipoprotein cholesterol carrier cholesterol implic buildup cholesterol atherosclerot plaqu postul ldl atherosclerosi oxid ldlc numer biolog pathogenet acceler cytotox chemotact monocyt arteri wall den ldlc particl endotheliumdepend vasodil acetylcholin decreas ldl cholesterol cvd morbid ldl cholesterol repres intervent hazard cvd coronari arteri cad consequ atherosclerot coronari arteri ischem ihd polymorph encod isoform atherosclerosi genomewid gwa candid locus confer protect cad myocardi infarct mi genomewid gwa discov hypercholesterolemia myocardi infarct polymorph 1p133 prolineserinerich coiledcoil psrc1 cadherin egf lag sevenpass gtype celsr2 myosin hlike mybphl sortilin sort1 apolipoprotein apo b100 sortilin encod sort1 interact apob100 golgi apparatu acceler hepat export apob100contain lipoprotein regul circul ldlc knockout sortilin reduc lipoprotein hypercholesterolemia atherosclerot plaqu ldl receptordefici sortilin acceler hepat lipoprotein circul ldl promis candid locus chromosom locat 1p133 consist ldlc paramet wellestablish cad gwa rs599839 rs646776 rs4970834 chromosom locat 1p133 determin ldl success replic cad polymorph 1p133 97 kb block linkag disequilibrium variant rs599839 untransl psrc1 linkag disequilibrium snp ld block rs599839 snp cad ldlc minor allel european maf033 hapmap ceu httpwwwncbinlmnihgovprojectssnp cad ldlc equival arab polymorph modul ldlc cad snp rs599839 rs646776 rs4970834 1p133 locu ldl cholesterol cad ldl wellcharacter consecut coronari arteri ac underw coronari angiographi polymorph rs599839 ldlc variant rs599839 atherosclerot lesion coronari vessel polymorph rs599839 rs646776 rs4970834 locu 1p133 antagon stenosi ldlc longitudin qatari explor locu atherogenesi\n",
            "\t-3.102\tcircul oxid ldl biomark crosssect navajo preval cvd t2d navajo nativ american decad oxid lowdens lipoprotein oxldl cvd biomark never navajo oxldl cvd t2d biomark crosssect navajo crosssect 252 navajo commun din project oxldl sandwich enzymelink immunosorb univari multivari oxldl oxid nonoxid lipoprotein ratio glycat hemoglobin hba1c creactiv crp interleukin il6 demograph preval navajo hba1c crp bmi highdens lipoprotein triglycerid cvd t2d median oxldl 47 368 57 ul correl oxldl hba1c oxldlhdl oxldlldl crp hba1c oxldl oxldlhdl oxldlldl crp multivari triglycerid predictor oxldl oxldlhdl oxldlldl oxldl trend hba1c reach signific hba1c predictor oxldlhdl crp trend oxldlhdl weak predictor oxldlldl navajo subset oxldl compar cvd t2d abnorm biomark hba1c navajo worsen cvd  introductionmethodsstudi methodsbiomark measurementsstatist analysisresultsclin navajo populationcharacterist navajo subset origin dineh participantslevel biomark cvd t2dfrequenc histogram selfreport plot actual hba1c levelsoxid ldl interactionsunivari relationship cvd biomark oxldl oxldlhdl oxldlldl biomark crp il6 hba1c cvd t2d selfreport conditionsmultivari analysiscoeffici estim final oxldl oxldlhdl oxldlldldiscussionstudi limitationsconclusionssupport informationcomparison navajo subset oxldl bmi hba1c monoclon 4e6 circul oxldl cvd t2d rare navajo 1930 decad preval t2d overweight cvd nonaccident navajo nativ american wellestablish cvd navajo t2d 1997 comprehens look navajospecif navajo nutrit nearli navajo 45 t2d center t2d american indianalaskan nativ youth age ethnic race t2d concern increasingli cvd clinic numer circul biomark creactiv crp interleukin6 il6 predict cvd ass crp il6 proinflammatori cytokin induc regul biomark cvd emerg oxid ldl oxldl cholesterol oxldl subclin atherosclerosi stronger predictor coronari arteri cad oxldl reportedli distinguish cad cohort serv predictor myocardi infarct unstabl cad oxid ldl t2d establish oxldl clinic biomark oxldl cvd biomark navajo t2d purpos character cvd biomark crosssect navajo oxldl hba1c accept biomark glycem ultim metric trend understudi ethnic navajo face dramat cvd greatli cvdrelat cvd oxldl navajo trend indic t2d cohort oxldl absolut cvd prediabet underserv ethnic unclear ongo explor exposur socioeconom lifestyl contribut cardiometabol\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.580\tlipid apolipoprotein coronari arteri proatherogen lowdens lipoprotein cholesterol ldlc antiatherogen highdens lipoprotein cholesterol hdlc controversi aris coronari arteri cad goal cad 1916 cad 85 cox proport hazard regress estim ratio allcaus cvd median 31 147 death record 113 cvd categor hdlc ushap allcaus cvd adjust cvd ldlc apob ldlhdl apobapoai posit apoai invers cvd pairwis lipidrel ldlhdl ldlc stronger allcaus cvd proatherogen chine cad  introduction2 methods21 participants22 measurements23 prospect followup24 analysis3 results31 relationship categor lipid mortality32 pairwis comparison relationship continu lipid mortality4 discussion5 conclus  chine cad hdlc allcaus cvd ldlc proper predictor cad ldlhdl strengthen besid apob apobapoai apoai cvd cad\n",
            "\t0.580\tlipid apolipoprotein coronari arteri proatherogen lowdens lipoprotein cholesterol ldlc antiatherogen highdens lipoprotein cholesterol hdlc controversi aris coronari arteri cad goal cad 1916 cad 85 cox proport hazard regress estim ratio allcaus cvd median 31 147 death record 113 cvd categor hdlc ushap allcaus cvd adjust cvd ldlc apob ldlhdl apobapoai posit apoai invers cvd pairwis lipidrel ldlhdl ldlc stronger allcaus cvd proatherogen chine cad  introduction2 methods21 participants22 measurements23 prospect followup24 analysis3 results31 relationship categor lipid mortality32 pairwis comparison relationship continu lipid mortality4 discussion5 conclus  chine cad hdlc allcaus cvd ldlc proper predictor cad ldlhdl strengthen besid apob apobapoai apoai cvd cad\n",
            "\t0.570\tden ldl famili hyperlipidemia n291 polymorph lipoprotein lipas predomin den ldl cholesterol particl famili hyperlipidemia fch lipoprotein lipas exert circumst ldl lipid n291 polymorph lipoprotein lipas lpl fch apolipoprotein diamet ldl n291 polymorph 93 fch 286 fch n291 polymorph diamet ldl fch ldl triglycerid vldlc nonhdlc apo b100 hdlc fch polymorph 875 125 polymorph 692 308 statist 0004 fch 97 n291 fch 93 dutch fchl caucasian polymorph fch ldl posse atherogen den ldl n291  backgroundmateri methodsdna rflp lplstudi designstatisticsresultsdiscussionabbreviationscompet interestsauthor contributionsacknowledg dyslipemia mellitu famili hyperlipidemia constitut atherogen lipoprotein triglycerid ldl particl hdl cholesterol triad prematur coronari den ldl particl form larg triglycerid coronari ldl particl bimod peak separ phenotyp buoyant ldl predomin smaller den ldl predomin cholesterol atp consid den ldl famili hyperlipidemia fch mim 144250 frequent hyperlipemia tendenc appear coronari prematur coronari fch present complet understood vari rel atherogen lipoprotein apolipoprotein b100 relat fch polygen fch lipoprotein lipas lpl ec 31134 glycoprot catabol lipoprotein rich triglycerid chylomicron lipoprotein vldl lpl take place surround lumen capillari vessel adher heparan sulphat proteoglycan 80 lpl 1500 heterozyg n291 local exon lpl analyz atherogen lipoprotein predomin den ldl n291 lpl polymorph spanish fch valencia respect fch complet understood dyslipem disturb lipoprotein fraction abnorm elev vldl overproduct defect catabol den ldl final catabol particl easili oxid display affin retent arteri wall normal counterpart den ldl accept emerg cholesterol programm panel predomin particl classic fch ldl atherogen hypolipidem modifi ldl subclass atherogen lipoprotein potent lipidlow therapi fch heterogen oligogen exert lipoprotein lipas codon polymorph lpl alter triglyceriderich lipoprotein frequent polymorph exon rs268 1128 n291 fch 97 93 dutch fch consider caucasian polymorph reflect carrier n291 frequent fch postprandi lipemia alter enzymat vldl particl apo b100 appear den ldl particl final catabol triglyceriderich lipoprotein particl fch polymorph neg postprandi fatrich meal initi normolipem coincid polymorphismcarri smaller ldl diamet atherogen alter triglyceriderich particl fch polymorph ischem cardiopathi n291 polymorph smaller ldl diamet correspond constitut final alter triglyceriderich particl repres polymorph constitut awar relat polymorph unfortun make conduct permit draw solid conclus said fch ldl atherogen den ldl allel encod n291 lpl percentag fch disrupt alter clearanc triglyceriderich lipoprotein atherogen fch autonom valencia ldl carri polymorph consider rigor hyperlipemia abbrevi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.484\tldl cholesterol chromosom locu 1p133 coronari arteri   introduction2 methods21 subjects3 measurements31 measurements32 biochem assays33 genotyp polymorph rs599839 rs646776 rs4970834331 amplification34 analysis35 calculations4 results41 biochem patients411 linkag disequilibrium ld snp rs599839 rs646776 rs4970834 cad 42 profile421 genotyp 3422 ldlc genotyp cad 443 rs599839 rs64776 rs4970834 genotyp angiograph cad patients431 snp genotyp coronari stenosi 5432 haplotyp 644 ldlc 1p13 loco stenosi ac odd ac discussion6 summari cvd morbid worldwid ldl cholesterol contribut epidemiolog lowdens lipoprotein cholesterol ldlc prematur atherosclerosi lowdens lipoprotein cholesterol carrier cholesterol implic buildup cholesterol atherosclerot plaqu postul ldl atherosclerosi oxid ldlc numer biolog pathogenet acceler cytotox chemotact monocyt arteri wall den ldlc particl endotheliumdepend vasodil acetylcholin decreas ldl cholesterol cvd morbid ldl cholesterol repres intervent hazard cvd coronari arteri cad consequ atherosclerot coronari arteri ischem ihd polymorph encod isoform atherosclerosi genomewid gwa candid locus confer protect cad myocardi infarct mi genomewid gwa discov hypercholesterolemia myocardi infarct polymorph 1p133 prolineserinerich coiledcoil psrc1 cadherin egf lag sevenpass gtype celsr2 myosin hlike mybphl sortilin sort1 apolipoprotein apo b100 sortilin encod sort1 interact apob100 golgi apparatu acceler hepat export apob100contain lipoprotein regul circul ldlc knockout sortilin reduc lipoprotein hypercholesterolemia atherosclerot plaqu ldl receptordefici sortilin acceler hepat lipoprotein circul ldl promis candid locus chromosom locat 1p133 consist ldlc paramet wellestablish cad gwa rs599839 rs646776 rs4970834 chromosom locat 1p133 determin ldl success replic cad polymorph 1p133 97 kb block linkag disequilibrium variant rs599839 untransl psrc1 linkag disequilibrium snp ld block rs599839 snp cad ldlc minor allel european maf033 hapmap ceu httpwwwncbinlmnihgovprojectssnp cad ldlc equival arab polymorph modul ldlc cad snp rs599839 rs646776 rs4970834 1p133 locu ldl cholesterol cad ldl wellcharacter consecut coronari arteri ac underw coronari angiographi polymorph rs599839 ldlc variant rs599839 atherosclerot lesion coronari vessel polymorph rs599839 rs646776 rs4970834 locu 1p133 antagon stenosi ldlc longitudin qatari explor locu atherogenesi\n",
            "\t-0.484\tldl cholesterol chromosom locu 1p133 coronari arteri   introduction2 methods21 subjects3 measurements31 measurements32 biochem assays33 genotyp polymorph rs599839 rs646776 rs4970834331 amplification34 analysis35 calculations4 results41 biochem patients411 linkag disequilibrium ld snp rs599839 rs646776 rs4970834 cad 42 profile421 genotyp 3422 ldlc genotyp cad 443 rs599839 rs64776 rs4970834 genotyp angiograph cad patients431 snp genotyp coronari stenosi 5432 haplotyp 644 ldlc 1p13 loco stenosi ac odd ac discussion6 summari cvd morbid worldwid ldl cholesterol contribut epidemiolog lowdens lipoprotein cholesterol ldlc prematur atherosclerosi lowdens lipoprotein cholesterol carrier cholesterol implic buildup cholesterol atherosclerot plaqu postul ldl atherosclerosi oxid ldlc numer biolog pathogenet acceler cytotox chemotact monocyt arteri wall den ldlc particl endotheliumdepend vasodil acetylcholin decreas ldl cholesterol cvd morbid ldl cholesterol repres intervent hazard cvd coronari arteri cad consequ atherosclerot coronari arteri ischem ihd polymorph encod isoform atherosclerosi genomewid gwa candid locus confer protect cad myocardi infarct mi genomewid gwa discov hypercholesterolemia myocardi infarct polymorph 1p133 prolineserinerich coiledcoil psrc1 cadherin egf lag sevenpass gtype celsr2 myosin hlike mybphl sortilin sort1 apolipoprotein apo b100 sortilin encod sort1 interact apob100 golgi apparatu acceler hepat export apob100contain lipoprotein regul circul ldlc knockout sortilin reduc lipoprotein hypercholesterolemia atherosclerot plaqu ldl receptordefici sortilin acceler hepat lipoprotein circul ldl promis candid locus chromosom locat 1p133 consist ldlc paramet wellestablish cad gwa rs599839 rs646776 rs4970834 chromosom locat 1p133 determin ldl success replic cad polymorph 1p133 97 kb block linkag disequilibrium variant rs599839 untransl psrc1 linkag disequilibrium snp ld block rs599839 snp cad ldlc minor allel european maf033 hapmap ceu httpwwwncbinlmnihgovprojectssnp cad ldlc equival arab polymorph modul ldlc cad snp rs599839 rs646776 rs4970834 1p133 locu ldl cholesterol cad ldl wellcharacter consecut coronari arteri ac underw coronari angiographi polymorph rs599839 ldlc variant rs599839 atherosclerot lesion coronari vessel polymorph rs599839 rs646776 rs4970834 locu 1p133 antagon stenosi ldlc longitudin qatari explor locu atherogenesi\n",
            "\t-3.102\tcircul oxid ldl biomark crosssect navajo preval cvd t2d navajo nativ american decad oxid lowdens lipoprotein oxldl cvd biomark never navajo oxldl cvd t2d biomark crosssect navajo crosssect 252 navajo commun din project oxldl sandwich enzymelink immunosorb univari multivari oxldl oxid nonoxid lipoprotein ratio glycat hemoglobin hba1c creactiv crp interleukin il6 demograph preval navajo hba1c crp bmi highdens lipoprotein triglycerid cvd t2d median oxldl 47 368 57 ul correl oxldl hba1c oxldlhdl oxldlldl crp hba1c oxldl oxldlhdl oxldlldl crp multivari triglycerid predictor oxldl oxldlhdl oxldlldl oxldl trend hba1c reach signific hba1c predictor oxldlhdl crp trend oxldlhdl weak predictor oxldlldl navajo subset oxldl compar cvd t2d abnorm biomark hba1c navajo worsen cvd  introductionmethodsstudi methodsbiomark measurementsstatist analysisresultsclin navajo populationcharacterist navajo subset origin dineh participantslevel biomark cvd t2dfrequenc histogram selfreport plot actual hba1c levelsoxid ldl interactionsunivari relationship cvd biomark oxldl oxldlhdl oxldlldl biomark crp il6 hba1c cvd t2d selfreport conditionsmultivari analysiscoeffici estim final oxldl oxldlhdl oxldlldldiscussionstudi limitationsconclusionssupport informationcomparison navajo subset oxldl bmi hba1c monoclon 4e6 circul oxldl cvd t2d rare navajo 1930 decad preval t2d overweight cvd nonaccident navajo nativ american wellestablish cvd navajo t2d 1997 comprehens look navajospecif navajo nutrit nearli navajo 45 t2d center t2d american indianalaskan nativ youth age ethnic race t2d concern increasingli cvd clinic numer circul biomark creactiv crp interleukin6 il6 predict cvd ass crp il6 proinflammatori cytokin induc regul biomark cvd emerg oxid ldl oxldl cholesterol oxldl subclin atherosclerosi stronger predictor coronari arteri cad oxldl reportedli distinguish cad cohort serv predictor myocardi infarct unstabl cad oxid ldl t2d establish oxldl clinic biomark oxldl cvd biomark navajo t2d purpos character cvd biomark crosssect navajo oxldl hba1c accept biomark glycem ultim metric trend understudi ethnic navajo face dramat cvd greatli cvdrelat cvd oxldl navajo trend indic t2d cohort oxldl absolut cvd prediabet underserv ethnic unclear ongo explor exposur socioeconom lifestyl contribut cardiometabol\n",
            "CLL,LDH,R-CVP None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.379\tvalproic acidinduc hyperammonemia elderli valproic deriv treat psychiatr elderli hyperammonemia elderli vulner systemat hyperammonemia valproic deriv  introduction2 ammonia hyperammonemia hyperammonem encephalopathy3 methods4 results5 discussion6 valproic broadspectrum antiepilept approv seizur bipolar schizoaffect phobia neuropath prophylaxi migrain headach valproic deriv safe bipolar affect agit dementia refractori anxieti elderli hyperammonemia encephalopathi come younger highlight complic elderli occurr valproic acidinduc hyperammonemia elderli elderli valproic acidinduc hyperammonemia assum signific comorbid grow valproic mood stabil psychiatr elderli clinician awar uncommon valproat systemat document hyperammonemia valproic deriv elderli valproat seizur fourth elderli man success bipolar ill divalproex valproat hyperammonemia multifactori vigil elderli comorbid concurr ammonia intuit diagnos hyperammonemia ammonia asymptomat recommend routin check ammonia elderli valproat unavail ammonia check close monitor elderli valproat regardless period ill eeg ct mri scan symptomat inconclus hyperammonemia valproic deriv discontinu supplement lcarnitin provid symptomat meantim continu care elderli valproat deriv side hyperammonemia\n",
            "\t0.371\tintraven sodium valproat phenytoin firstlin epilepticu epilepticu se seriou neurolog prompt sodium valproat treat se success firstlin antiepilept a controversi intraven sodium valproat noninferior intraven phenytoin se se intraven sodium valproat intraven phenytoin firstlin enrol se record sodium valproat phenytoin descript statist 37 se intraven phenytoin intraven sodium valproat firstlin diazepam mg intraven rescu start antiepilept uncontrol except sodium valproat phenytoin sodium valproat clinicallycontrol seizur nondepend seizur hospit seriou cardiovascular event hypotens intraven sodium valproat noninferior intraven phenytoin firstlin se compromis phenytoinsodium valproateefficacystatu epilepticuscomparison backgroundmethodsresultsdiscussionconclusioncompet interestsauthor contributionsprepubl epilepticu se emerg proper prompt morbid intraven phenytoin treat se antiepilept a sodium valproat lacosamid levetiracetam topiram benefit se intraven sodium valproat a se firstlin a se seizur unlik phenytoin sodium valproat safe compromis arrhythmia hypotens sodium valproat firstlin se metaanalysi randomizedcontrol intraven phenytoin sodium valproat se aim se firstlin a add se intraven sodium valproat noninferior intraven phenytoin se intraven sodium valproat noninferior intraven phenytoin firstlin se compromis compet interest\n",
            "\t0.357\tvalacyclovir neurotox dialysi    sir 58yearold admit complaint sensorium irrit drowsi began start drowsi restless talk irrelevantli confus drowsi worsen herpet abdomen back start valacyclovir 500 mg ckd mainten dialysi hypertens admiss afebril pul 120 bpm 210110 mmhg record sign pallor unremark admit intens unit monitor manag valacyclovir stop magnet reson mri electroencephalographi eeg gener slow wave epilept discharg cerebrospin fluid csf essenti remain drowsi disori underw dialysi markedli derang neurotox nd dialysi recoveri conscious plan dialysi regain sensorium valacyclovir prodrug act inhibit deoxyribonucl polymeras introduc acyclovir dose superior bioavail neuropsychiatr manifest valacyclovir frequent manifest confus dizzi irrit ataxia tremor seizur myoclonu hallucin initi resolv 57 stop dug hemodialysi modal filter csf comput tomographymri unremark correl eeg encount diffus gener slow past occurr valacyclovir neurotox van elderli rang 500 3000 mg frequent ckd success discontinu requir hemodialysi middl age ladi dialysi valacyclovir 500 mg od adjust neurotox sideeffect requir hospit discontinu dialysi sensorium got valacyclovir pose dilemma clinician herp zoster enceph van share disturb sensorium frequent manifest awar neurotox valacyclovir adjust prompt discontinu dialysi improv valacyclovir neurotox \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.648\tnonhyperammonem valproat encephalopathi 21yearold hypothyroid seizur sequela old trauma receiv sodium valproat clobazam phenobarbiton gener tonic clonic seizur neurolog opd sensorium gait unsteadi week hike valproat drowsi neurolog unremark except gait unsteadi ataxia admit worsen biochem count routin urin arteri ga urin csf repeat mri done depict old fresh worsen sensorium eeg suggest diffus encephalopathi thyroid valproat encephalopathi suspect valproat empir stop put levetiracetam phenytoin sensorium rapidli stoppag valproat normal eeg valproat ammonia infer nonhyperammoneam valproat encephalopathi highlight exist nonhyperammonem valproat encephalopathi hyperammonemia encephalopathi  introductioncas reportdiscuss valproic versatil gener tonicclon myoclon seizur nonepilept migrain bipolar tremor gain abnorm hair valproic encephalopathi hyperammonemia asymptomat hyperammonemia symptomat rare valproat encephalopathi hyperammonemia encount valproateinduc encephalopathi hyperammonemia strengthen encephalopathi uncommon sodium valproat present valproateinduc encephalopathi vari includ irrit agit drowsi coma occasion paradox seizur appetit nausea vomit drowsi disorient local sign focal neurodeficit convuls seizur eeg drowsi mark diffus background slow inter mix 225 hz highamplitud slow wave synchron hemispher epileptiform iv diazepam gener encephalopathi exclud nonconvuls epilepticu investig exclud encephalopathi csf exclus valproat encephalopathi relat hike valproat naranjo suggest stoppag valproat normal eeg valproateinduc encephalopathi hyperammonemia hyperammonemia develop initi urea defici predispos valproateinduc hyperammonemia valproat valproat concomit topiram electroencephalogram complet welldevelop wave posterior head regionsarrow valproateinduc encephalopathi unclear conscious hyperammonemia toxic metabolit sodium valproat organ latter encephalopathi ammonia valproateinduc encephalopathi typic substanti elev ammonia fold upper limit exhibit typic valproateinduc encephalopathi slightli ammonia ammonia seem unabl encephalopath valproic valproateinduc encephalopathi multifactori hyperammonemia ammoniuminduc coma stephen sodium valproat ammonia coma valproic dual encephalopathi besid hyperammonem cortic enhanc encephalopathi ammonia ammonia hyperammonemia believ encephalopathi glutam astrocyt glutam excitotox cerebr edema possibl seizur hyperammonemia discus hyperammonemiamayb nonhyperammonem valproat encephalopathi prompt discontinu sodium valproat alway subsid manifest nevertheless pitfal delay misdiagnosi nontox valproat valproat help establish encephalopathi mistaken postict confusion help characterist eeg encompass diffus background slow intermix highamplitud slow wave triphas wave sign encephalopathi valproateinduc encephalopathi suspect valproat sensorium take valproic mild mark encephalopath sign progress lethargi stupor subtl behavior avoid reward valproateinduc encephalopathi valproat dosag relat valproat revers conscious withdraw establish\n",
            "\t-6.166\tvalproic acidinduc myoclonu dement valproic deriv treat psychiatr elderli elderli suscept neuropsychiatr 66yearold woman earlyonset alzheim dementia myoclonu valproic prepar behavior disturb dementia  introduction2 report3 discus origin anticonvuls valproic vpa psychiatr concern antipsychot dementia mood stabil anticonvuls dement agit behavior report woman earlyonset alzheim dementia valproic prepar treat behavior dementia myoclonu ammonemia valproic 42yearold depress vpa myoclonu valproic dementia treat behavior disturb vpa fatti disrupt urea caus impair bodi usual fatti disrupt urea ammonia encephalopathi hyperammonemia vpa encephalopathi myoclonu vpa ammonia ammonia vpa discontinu vpa resolut myoclonu vpa normal myoclonu valproic toxin myoclonu ammonia delirium behavior disturb give dementia complet essenti delirium remain fluctuat conscious infecti behavior issu came record pressur stay unit care conclud autonom dementia psychotrop take record hospit record pressur discharg rang 103 10763 69 hg unclear elderli suscept neuropsychiatr sideeffect vpa elderli vpa close monitor regardless period ill myoclonu close vpa discontinu immedi elderli anticonvuls mood stabil vpa attempt avoid extrapyramid cerebrovascular antipsychot profil vpa control agit behavior disturb untoward myoclonu psychotrop help bpsd none proven benign sideeffect profil elderli comorbid take put sideeffect drugdrug profil issu give dementia\n",
            "\t-6.220\tvalproat monotherapi induceddelirium hyperammonemia present valproat delirium hyperammonemia report interest present valproat monotherapi valproateinduc delirium mistaken psychosi worsen mania improp ammonia deliri valproat discontinu valproat electroencephalogram derang rechalleng valproat prove valproat hyperammonemia ammonia monitor routin receiv valproat hyperammonemiaplasma ammoniavalproateinduc delirium introductioncas reportcas 1case 2case 3discuss valproat 2propyl pentano anticonvuls mood stabil mania bipolar valproateinduc delirium hyperammonemia vidh interest valproat vidh lft electroencephalogram eeg eight genuin vidh report present valproat monotherapi lft eeg dilemma busi clinician rechalleng valproat prove valproat delirium valproateinduc hyperammonemia transient asymptomat phenomenon undetect manifest lethargi disorient revers deficit progress mark sedat coma vidh hepat extens pediatr vidh topiram phenytoin ad valproat vidh valproat receiv valproat monotherapi gradual soon valproat discontinu ammonia correspond normal resolv present lab investig electrophysiolog resolut rechalleng valproat prove valproat delirium hyperammonemia spite investig mild elev lft triphas wave eeg initi dose probabl delirium valproateinduc hyperammonemia vidh hyperammonemia valproateinduc carnitin defici decreas biosynthesi carbamoyl phosphat synthetas urea replac carnitin option glutam astrocyt perhap cerebr edema glutamin inhibit caus osmol promot influx result astrocyt swell swell compromis astrocyt cerebr edema intracrani kidney vidh glutam ammonia kidney glutaminas mitochondrion valproat concomit antiepilept topiram aspirin cimetidin elev fraction valproat hyperammonemia comorbid hypoalbuminemia vidh clinician consid hyperammonemia delirium receiv valproat monotherapi busi clinician mistak worsen manic sedat ammonia done lft discontinu valproat prompt revers dietari carnitin supplement gday help hyperammonemia valproat confirm\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.379\tvalproic acidinduc hyperammonemia elderli valproic deriv treat psychiatr elderli hyperammonemia elderli vulner systemat hyperammonemia valproic deriv  introduction2 ammonia hyperammonemia hyperammonem encephalopathy3 methods4 results5 discussion6 valproic broadspectrum antiepilept approv seizur bipolar schizoaffect phobia neuropath prophylaxi migrain headach valproic deriv safe bipolar affect agit dementia refractori anxieti elderli hyperammonemia encephalopathi come younger highlight complic elderli occurr valproic acidinduc hyperammonemia elderli elderli valproic acidinduc hyperammonemia assum signific comorbid grow valproic mood stabil psychiatr elderli clinician awar uncommon valproat systemat document hyperammonemia valproic deriv elderli valproat seizur fourth elderli man success bipolar ill divalproex valproat hyperammonemia multifactori vigil elderli comorbid concurr ammonia intuit diagnos hyperammonemia ammonia asymptomat recommend routin check ammonia elderli valproat unavail ammonia check close monitor elderli valproat regardless period ill eeg ct mri scan symptomat inconclus hyperammonemia valproic deriv discontinu supplement lcarnitin provid symptomat meantim continu care elderli valproat deriv side hyperammonemia\n",
            "\t0.371\tintraven sodium valproat phenytoin firstlin epilepticu epilepticu se seriou neurolog prompt sodium valproat treat se success firstlin antiepilept a controversi intraven sodium valproat noninferior intraven phenytoin se se intraven sodium valproat intraven phenytoin firstlin enrol se record sodium valproat phenytoin descript statist 37 se intraven phenytoin intraven sodium valproat firstlin diazepam mg intraven rescu start antiepilept uncontrol except sodium valproat phenytoin sodium valproat clinicallycontrol seizur nondepend seizur hospit seriou cardiovascular event hypotens intraven sodium valproat noninferior intraven phenytoin firstlin se compromis phenytoinsodium valproateefficacystatu epilepticuscomparison backgroundmethodsresultsdiscussionconclusioncompet interestsauthor contributionsprepubl epilepticu se emerg proper prompt morbid intraven phenytoin treat se antiepilept a sodium valproat lacosamid levetiracetam topiram benefit se intraven sodium valproat a se firstlin a se seizur unlik phenytoin sodium valproat safe compromis arrhythmia hypotens sodium valproat firstlin se metaanalysi randomizedcontrol intraven phenytoin sodium valproat se aim se firstlin a add se intraven sodium valproat noninferior intraven phenytoin se intraven sodium valproat noninferior intraven phenytoin firstlin se compromis compet interest\n",
            "\t0.357\tvalacyclovir neurotox dialysi    sir 58yearold admit complaint sensorium irrit drowsi began start drowsi restless talk irrelevantli confus drowsi worsen herpet abdomen back start valacyclovir 500 mg ckd mainten dialysi hypertens admiss afebril pul 120 bpm 210110 mmhg record sign pallor unremark admit intens unit monitor manag valacyclovir stop magnet reson mri electroencephalographi eeg gener slow wave epilept discharg cerebrospin fluid csf essenti remain drowsi disori underw dialysi markedli derang neurotox nd dialysi recoveri conscious plan dialysi regain sensorium valacyclovir prodrug act inhibit deoxyribonucl polymeras introduc acyclovir dose superior bioavail neuropsychiatr manifest valacyclovir frequent manifest confus dizzi irrit ataxia tremor seizur myoclonu hallucin initi resolv 57 stop dug hemodialysi modal filter csf comput tomographymri unremark correl eeg encount diffus gener slow past occurr valacyclovir neurotox van elderli rang 500 3000 mg frequent ckd success discontinu requir hemodialysi middl age ladi dialysi valacyclovir 500 mg od adjust neurotox sideeffect requir hospit discontinu dialysi sensorium got valacyclovir pose dilemma clinician herp zoster enceph van share disturb sensorium frequent manifest awar neurotox valacyclovir adjust prompt discontinu dialysi improv valacyclovir neurotox \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.648\tnonhyperammonem valproat encephalopathi 21yearold hypothyroid seizur sequela old trauma receiv sodium valproat clobazam phenobarbiton gener tonic clonic seizur neurolog opd sensorium gait unsteadi week hike valproat drowsi neurolog unremark except gait unsteadi ataxia admit worsen biochem count routin urin arteri ga urin csf repeat mri done depict old fresh worsen sensorium eeg suggest diffus encephalopathi thyroid valproat encephalopathi suspect valproat empir stop put levetiracetam phenytoin sensorium rapidli stoppag valproat normal eeg valproat ammonia infer nonhyperammoneam valproat encephalopathi highlight exist nonhyperammonem valproat encephalopathi hyperammonemia encephalopathi  introductioncas reportdiscuss valproic versatil gener tonicclon myoclon seizur nonepilept migrain bipolar tremor gain abnorm hair valproic encephalopathi hyperammonemia asymptomat hyperammonemia symptomat rare valproat encephalopathi hyperammonemia encount valproateinduc encephalopathi hyperammonemia strengthen encephalopathi uncommon sodium valproat present valproateinduc encephalopathi vari includ irrit agit drowsi coma occasion paradox seizur appetit nausea vomit drowsi disorient local sign focal neurodeficit convuls seizur eeg drowsi mark diffus background slow inter mix 225 hz highamplitud slow wave synchron hemispher epileptiform iv diazepam gener encephalopathi exclud nonconvuls epilepticu investig exclud encephalopathi csf exclus valproat encephalopathi relat hike valproat naranjo suggest stoppag valproat normal eeg valproateinduc encephalopathi hyperammonemia hyperammonemia develop initi urea defici predispos valproateinduc hyperammonemia valproat valproat concomit topiram electroencephalogram complet welldevelop wave posterior head regionsarrow valproateinduc encephalopathi unclear conscious hyperammonemia toxic metabolit sodium valproat organ latter encephalopathi ammonia valproateinduc encephalopathi typic substanti elev ammonia fold upper limit exhibit typic valproateinduc encephalopathi slightli ammonia ammonia seem unabl encephalopath valproic valproateinduc encephalopathi multifactori hyperammonemia ammoniuminduc coma stephen sodium valproat ammonia coma valproic dual encephalopathi besid hyperammonem cortic enhanc encephalopathi ammonia ammonia hyperammonemia believ encephalopathi glutam astrocyt glutam excitotox cerebr edema possibl seizur hyperammonemia discus hyperammonemiamayb nonhyperammonem valproat encephalopathi prompt discontinu sodium valproat alway subsid manifest nevertheless pitfal delay misdiagnosi nontox valproat valproat help establish encephalopathi mistaken postict confusion help characterist eeg encompass diffus background slow intermix highamplitud slow wave triphas wave sign encephalopathi valproateinduc encephalopathi suspect valproat sensorium take valproic mild mark encephalopath sign progress lethargi stupor subtl behavior avoid reward valproateinduc encephalopathi valproat dosag relat valproat revers conscious withdraw establish\n",
            "\t-6.166\tvalproic acidinduc myoclonu dement valproic deriv treat psychiatr elderli elderli suscept neuropsychiatr 66yearold woman earlyonset alzheim dementia myoclonu valproic prepar behavior disturb dementia  introduction2 report3 discus origin anticonvuls valproic vpa psychiatr concern antipsychot dementia mood stabil anticonvuls dement agit behavior report woman earlyonset alzheim dementia valproic prepar treat behavior dementia myoclonu ammonemia valproic 42yearold depress vpa myoclonu valproic dementia treat behavior disturb vpa fatti disrupt urea caus impair bodi usual fatti disrupt urea ammonia encephalopathi hyperammonemia vpa encephalopathi myoclonu vpa ammonia ammonia vpa discontinu vpa resolut myoclonu vpa normal myoclonu valproic toxin myoclonu ammonia delirium behavior disturb give dementia complet essenti delirium remain fluctuat conscious infecti behavior issu came record pressur stay unit care conclud autonom dementia psychotrop take record hospit record pressur discharg rang 103 10763 69 hg unclear elderli suscept neuropsychiatr sideeffect vpa elderli vpa close monitor regardless period ill myoclonu close vpa discontinu immedi elderli anticonvuls mood stabil vpa attempt avoid extrapyramid cerebrovascular antipsychot profil vpa control agit behavior disturb untoward myoclonu psychotrop help bpsd none proven benign sideeffect profil elderli comorbid take put sideeffect drugdrug profil issu give dementia\n",
            "\t-6.220\tvalproat monotherapi induceddelirium hyperammonemia present valproat delirium hyperammonemia report interest present valproat monotherapi valproateinduc delirium mistaken psychosi worsen mania improp ammonia deliri valproat discontinu valproat electroencephalogram derang rechalleng valproat prove valproat hyperammonemia ammonia monitor routin receiv valproat hyperammonemiaplasma ammoniavalproateinduc delirium introductioncas reportcas 1case 2case 3discuss valproat 2propyl pentano anticonvuls mood stabil mania bipolar valproateinduc delirium hyperammonemia vidh interest valproat vidh lft electroencephalogram eeg eight genuin vidh report present valproat monotherapi lft eeg dilemma busi clinician rechalleng valproat prove valproat delirium valproateinduc hyperammonemia transient asymptomat phenomenon undetect manifest lethargi disorient revers deficit progress mark sedat coma vidh hepat extens pediatr vidh topiram phenytoin ad valproat vidh valproat receiv valproat monotherapi gradual soon valproat discontinu ammonia correspond normal resolv present lab investig electrophysiolog resolut rechalleng valproat prove valproat delirium hyperammonemia spite investig mild elev lft triphas wave eeg initi dose probabl delirium valproateinduc hyperammonemia vidh hyperammonemia valproateinduc carnitin defici decreas biosynthesi carbamoyl phosphat synthetas urea replac carnitin option glutam astrocyt perhap cerebr edema glutamin inhibit caus osmol promot influx result astrocyt swell swell compromis astrocyt cerebr edema intracrani kidney vidh glutam ammonia kidney glutaminas mitochondrion valproat concomit antiepilept topiram aspirin cimetidin elev fraction valproat hyperammonemia comorbid hypoalbuminemia vidh clinician consid hyperammonemia delirium receiv valproat monotherapi busi clinician mistak worsen manic sedat ammonia done lft discontinu valproat prompt revers dietari carnitin supplement gday help hyperammonemia valproat confirm\n",
            "intellectual disability,valium None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.462\tcircul metalloproteinase4 timp4 sclerosi arteri metalloproteinas mmp excess timp dysregul turnov sclerosi ssc crosssect 106 ssc timp4 preferenti search correl simultan echocardiographi arteri systol pasp myocardi timp4 mmp9 rais ssc subgroup pasp mmhg 69 timp4 compar irrespect diffus fibrosi pasp suggest timp4 03 independ sclerosi fibrosi cardiopulmonari vasculaturespecif timp4 ssc  introduction2 methods21 population22 circul timp4 mmp9 bnp molecules23 analysis3 results31 circul mmp9 timp4 fibrosi ssc32 arteri ssc timp4 levels4 discussion5  herein timp4 perhap mmp stiffen cardiopulmonari vasculatur ssc abnorm deserv timp4 candid ssc pilot pool prospect timp4 highrisk ssc cardiopulmonari perhap biomark warrant\n",
            "\t0.457\tunusu spontan bleed intens unit mastocytosi 39year old anaphylactoid shock diffus bleed prolong partial thromboplastin emerg room aggress mastocytosi suspect rais tryptas mastocyt infiltr marrow favor support antihistamin imatinib mesyl  backgroundcas presentationconclusionabbreviationscompet interestsauthor contributionscons mastocytosi heterogen excess mast organ marrow mast degranul heparin mediat releas mast spontan bleed rare mastocytosi mastocytosi abnorm mast organ follow benign indol invalid lifethreaten hypotens syncop flush urticaria bronchospasm peptic ulcer diarrhea malabsorpt osteoporosi weigh fatigu aggress mastocytosi enlarg spleen lymph node eosinophilia mastocytosi demonstr mast infiltr marrow special stain cytometri tryptas mastocytosi tryptas exceed ngml depend mast burden organ clinic mediat histamin leukotrien tryptas heparin kinet clot fibrinogenolyt anticoagul tryptas heparin bleed mastocytosi heparinlik anticoagul emerg room mastocytosi avoid trigger heat cold alcohol aspirin nsaid symptomat h1 h2 antihistamin proton pump antileukotrien anticholinerg glucocortico d epinephrin hypotens aggress mastocytosi interferon alpha cladribin imatinib mesyl imatinib d816v ckit abbrevi\n",
            "\t0.442\tmetalloproteinas sclerosi abnorm timp2 sclerosi ssc explor 42 ssc equal ct chest ecg echocardiographi timp2 elisa timp2 005 ct dssc timp2 dssc 013 timp2 diastol 80 lssc 133 014 involv point probabl timp2 dssc lssc equal  backgroundmateri methodspatientsdoppl echocardiographyhighresolut comput tomographystatist analysisresultstimp2 dssctimp2 lsscdiscussionconclus  involv confirm probabl timp2 induc fibrosi ssc timp2 dssc lssc equal\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.819\tosteoporosi osteopathi mastocytosi osteoporosi osteosclerosi lytic mastocytosi sm miner bmd biochem turnov tryptas sm seventeen femal male median 33 2064 mastocytosi ultrasound qu calcaneu bmd sm bmd lumbar spine l1l4 femor neck distal radiu dual xray absorptiometri dxa tryptas biochem turnov lumbar spine l1l4 femor neck distal radiu calcaneu stiff tscore reflect osteopenia tscore osteoporosi tscore dxa lesion tryptas pyridinolin 001 spearman dxa calcan qu sm osteosclerosi osteoclast pyridinolin help sclerot deminer mastocytosisbon miner densitypyridinolinebon turnoverosteopenia introductionmateri methodspatientsbon miner measurementslaboratori measurementsradiograph indexstatist analysisresultspati demograph characteristicsbon miner densitybon turnov markersradiolog findingsdiscuss mastocytosi abnorm mast mc organ mcderiv mediat disrupt infiltr mc mastocytosi mastocytosi marrow patholog organ tryptas mastocytosi categori cutan mastocytosi cm indol mastocytosi ism marrow mastocytosi smolder mastocytosi ssm mastocytosi sm clonal hematolog nonmclineag aggress mastocytosi asm mast leukemia mcl mast sarcoma mc extracutan mastocytoma skelet manifest osteoporosi osteosclerosi lytic sm reflect infiltr mc substanc secret dual xray absorptiometri dxa sm miner bmd spine l1l4 femor neck dxa inappropri ass sm osteosclerosi osteopenia sm purpos bmd sm mastocytosi correl bmd inform consent vari sm radiolog sm consist concurr osteosclerot osteolyt 45 trabecular cortic turnov mc trabecular cortic acceler remodel remark expans peritrabecular fibrosi osteoidosi osteoblast osteoclast extens osteoclast resorb surfac excess mc acceler remodel heterogen mediat granuleassoci mediat histamin heparin neutral protea lipidderiv mediat lipoxygenas cyclooxygenas leukotrien prostaglandin d2 releas mc histamin mediat store modul osteoclast therebi mc osteoclast resorpt osteoclast large osteolys orand osteoporosi caus patholog fractur defin radiograph roentgenographi magnet reson scan densitometri employ skelet dxa instrument measur bmd dxa unabl trabecular microstructur relat mechan dxa miner osteolyt sclerot trabecular pelvi thoracolumbar spine trabecular distal radiu statist bmd dxa adequ aggress mastocytosi osteosclerot concurr bmd occurr osteopenia calcan qu osteoporosi predict fractur portabl inexpens ultrasound paramet typic osteoporot consensu identifi osteoporosi osteosclerosi osteoporosi mastocytosi calcan qu seem dxa estim mastocytosi radiographi osteosclerot osteolyt radiograph fractur radiographi patholog fractur mastocytosi biochem turnov pyridinolin bap hyperthyroid osteoclast osteoblast johansson alp mastocytosi osteoporosi bap alp hepat bap osteocalcin pyridinolin deoxypyridinolin turnov skelet bap pyridinolin mild skelet bap statist pyridinolin 001 kushnirsukhov tryptas mastocytosi confirm done kushnirsukhov mastocytosi tryptas wellestablish diseaserel suspect mastocytosi tryptas likelihood multiorgan tryptas sm correl burden neoplast mc tryptas urin pyridinolin elev pyridinolin tryptas activ metalloproteinas mmp mmp degrad collagen pyridinolin crosslink carboxytermin telopeptid collagen specul osteolyt tryptas pyridinolin insuffici osteosclerosi sm remodel way radiographi bmd dxa calcan qu osteopenia osteosclerot plain radiographi serial bmd osteosclerot sm pyridinolin turnov mastocytosi pyridinolin tryptas\n",
            "\t-4.207\tunusu spontan bleed intens unit mastocytosi 39year old anaphylactoid shock diffus bleed prolong partial thromboplastin emerg room aggress mastocytosi suspect rais tryptas mastocyt infiltr marrow favor support antihistamin imatinib mesyl  backgroundcas presentationconclusionabbreviationscompet interestsauthor contributionscons mastocytosi heterogen excess mast organ marrow mast degranul heparin mediat releas mast spontan bleed rare mastocytosi mastocytosi abnorm mast organ follow benign indol invalid lifethreaten hypotens syncop flush urticaria bronchospasm peptic ulcer diarrhea malabsorpt osteoporosi weigh fatigu aggress mastocytosi enlarg spleen lymph node eosinophilia mastocytosi demonstr mast infiltr marrow special stain cytometri tryptas mastocytosi tryptas exceed ngml depend mast burden organ clinic mediat histamin leukotrien tryptas heparin kinet clot fibrinogenolyt anticoagul tryptas heparin bleed mastocytosi heparinlik anticoagul emerg room mastocytosi avoid trigger heat cold alcohol aspirin nsaid symptomat h1 h2 antihistamin proton pump antileukotrien anticholinerg glucocortico d epinephrin hypotens aggress mastocytosi interferon alpha cladribin imatinib mesyl imatinib d816v ckit abbrevi\n",
            "\t-4.840\t264 basophilmedi anaphylaxi trigger drugactiv complement mastocyt immunoglobulin complement anaphylaxi ige igg socal nonimmun anaphylaxi tryptas complement circul cic anaphylaxi woman infus concentr iron 46 yearsold woman admit depart mix anemia iron cobalamin deficiencyrel start biliopancreat deriv heavi ago start hgb 7gdl ev hydroxicobalamin iron infus plan gttm infus concentr 05 mgml iron discomfort sweat drop bp 6030 tryptas complement cic anaphylaxi start im epinephrin inhal o2 steroid betaagonist ev electrolyt solut vital continu shock resolut gain hour tryptas mcgml nrnormal c3 c4 c3 65 mgdl nr 75 165 c4 mgdl nr 55 search cic igg iga igm gttm 025 mgml iron infus toler exclud ige sensit anaphylaxi mastocyt ige infus hyperosmol hyperconcentr complement anaphylaxi mediat mastocyt basophil anaphylotoxin conclud druginduc complement consequ basophil nonimmun anaphylaxi    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.462\tcircul metalloproteinase4 timp4 sclerosi arteri metalloproteinas mmp excess timp dysregul turnov sclerosi ssc crosssect 106 ssc timp4 preferenti search correl simultan echocardiographi arteri systol pasp myocardi timp4 mmp9 rais ssc subgroup pasp mmhg 69 timp4 compar irrespect diffus fibrosi pasp suggest timp4 03 independ sclerosi fibrosi cardiopulmonari vasculaturespecif timp4 ssc  introduction2 methods21 population22 circul timp4 mmp9 bnp molecules23 analysis3 results31 circul mmp9 timp4 fibrosi ssc32 arteri ssc timp4 levels4 discussion5  herein timp4 perhap mmp stiffen cardiopulmonari vasculatur ssc abnorm deserv timp4 candid ssc pilot pool prospect timp4 highrisk ssc cardiopulmonari perhap biomark warrant\n",
            "\t0.457\tunusu spontan bleed intens unit mastocytosi 39year old anaphylactoid shock diffus bleed prolong partial thromboplastin emerg room aggress mastocytosi suspect rais tryptas mastocyt infiltr marrow favor support antihistamin imatinib mesyl  backgroundcas presentationconclusionabbreviationscompet interestsauthor contributionscons mastocytosi heterogen excess mast organ marrow mast degranul heparin mediat releas mast spontan bleed rare mastocytosi mastocytosi abnorm mast organ follow benign indol invalid lifethreaten hypotens syncop flush urticaria bronchospasm peptic ulcer diarrhea malabsorpt osteoporosi weigh fatigu aggress mastocytosi enlarg spleen lymph node eosinophilia mastocytosi demonstr mast infiltr marrow special stain cytometri tryptas mastocytosi tryptas exceed ngml depend mast burden organ clinic mediat histamin leukotrien tryptas heparin kinet clot fibrinogenolyt anticoagul tryptas heparin bleed mastocytosi heparinlik anticoagul emerg room mastocytosi avoid trigger heat cold alcohol aspirin nsaid symptomat h1 h2 antihistamin proton pump antileukotrien anticholinerg glucocortico d epinephrin hypotens aggress mastocytosi interferon alpha cladribin imatinib mesyl imatinib d816v ckit abbrevi\n",
            "\t0.442\tmetalloproteinas sclerosi abnorm timp2 sclerosi ssc explor 42 ssc equal ct chest ecg echocardiographi timp2 elisa timp2 005 ct dssc timp2 dssc 013 timp2 diastol 80 lssc 133 014 involv point probabl timp2 dssc lssc equal  backgroundmateri methodspatientsdoppl echocardiographyhighresolut comput tomographystatist analysisresultstimp2 dssctimp2 lsscdiscussionconclus  involv confirm probabl timp2 induc fibrosi ssc timp2 dssc lssc equal\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.819\tosteoporosi osteopathi mastocytosi osteoporosi osteosclerosi lytic mastocytosi sm miner bmd biochem turnov tryptas sm seventeen femal male median 33 2064 mastocytosi ultrasound qu calcaneu bmd sm bmd lumbar spine l1l4 femor neck distal radiu dual xray absorptiometri dxa tryptas biochem turnov lumbar spine l1l4 femor neck distal radiu calcaneu stiff tscore reflect osteopenia tscore osteoporosi tscore dxa lesion tryptas pyridinolin 001 spearman dxa calcan qu sm osteosclerosi osteoclast pyridinolin help sclerot deminer mastocytosisbon miner densitypyridinolinebon turnoverosteopenia introductionmateri methodspatientsbon miner measurementslaboratori measurementsradiograph indexstatist analysisresultspati demograph characteristicsbon miner densitybon turnov markersradiolog findingsdiscuss mastocytosi abnorm mast mc organ mcderiv mediat disrupt infiltr mc mastocytosi mastocytosi marrow patholog organ tryptas mastocytosi categori cutan mastocytosi cm indol mastocytosi ism marrow mastocytosi smolder mastocytosi ssm mastocytosi sm clonal hematolog nonmclineag aggress mastocytosi asm mast leukemia mcl mast sarcoma mc extracutan mastocytoma skelet manifest osteoporosi osteosclerosi lytic sm reflect infiltr mc substanc secret dual xray absorptiometri dxa sm miner bmd spine l1l4 femor neck dxa inappropri ass sm osteosclerosi osteopenia sm purpos bmd sm mastocytosi correl bmd inform consent vari sm radiolog sm consist concurr osteosclerot osteolyt 45 trabecular cortic turnov mc trabecular cortic acceler remodel remark expans peritrabecular fibrosi osteoidosi osteoblast osteoclast extens osteoclast resorb surfac excess mc acceler remodel heterogen mediat granuleassoci mediat histamin heparin neutral protea lipidderiv mediat lipoxygenas cyclooxygenas leukotrien prostaglandin d2 releas mc histamin mediat store modul osteoclast therebi mc osteoclast resorpt osteoclast large osteolys orand osteoporosi caus patholog fractur defin radiograph roentgenographi magnet reson scan densitometri employ skelet dxa instrument measur bmd dxa unabl trabecular microstructur relat mechan dxa miner osteolyt sclerot trabecular pelvi thoracolumbar spine trabecular distal radiu statist bmd dxa adequ aggress mastocytosi osteosclerot concurr bmd occurr osteopenia calcan qu osteoporosi predict fractur portabl inexpens ultrasound paramet typic osteoporot consensu identifi osteoporosi osteosclerosi osteoporosi mastocytosi calcan qu seem dxa estim mastocytosi radiographi osteosclerot osteolyt radiograph fractur radiographi patholog fractur mastocytosi biochem turnov pyridinolin bap hyperthyroid osteoclast osteoblast johansson alp mastocytosi osteoporosi bap alp hepat bap osteocalcin pyridinolin deoxypyridinolin turnov skelet bap pyridinolin mild skelet bap statist pyridinolin 001 kushnirsukhov tryptas mastocytosi confirm done kushnirsukhov mastocytosi tryptas wellestablish diseaserel suspect mastocytosi tryptas likelihood multiorgan tryptas sm correl burden neoplast mc tryptas urin pyridinolin elev pyridinolin tryptas activ metalloproteinas mmp mmp degrad collagen pyridinolin crosslink carboxytermin telopeptid collagen specul osteolyt tryptas pyridinolin insuffici osteosclerosi sm remodel way radiographi bmd dxa calcan qu osteopenia osteosclerot plain radiographi serial bmd osteosclerot sm pyridinolin turnov mastocytosi pyridinolin tryptas\n",
            "\t-4.207\tunusu spontan bleed intens unit mastocytosi 39year old anaphylactoid shock diffus bleed prolong partial thromboplastin emerg room aggress mastocytosi suspect rais tryptas mastocyt infiltr marrow favor support antihistamin imatinib mesyl  backgroundcas presentationconclusionabbreviationscompet interestsauthor contributionscons mastocytosi heterogen excess mast organ marrow mast degranul heparin mediat releas mast spontan bleed rare mastocytosi mastocytosi abnorm mast organ follow benign indol invalid lifethreaten hypotens syncop flush urticaria bronchospasm peptic ulcer diarrhea malabsorpt osteoporosi weigh fatigu aggress mastocytosi enlarg spleen lymph node eosinophilia mastocytosi demonstr mast infiltr marrow special stain cytometri tryptas mastocytosi tryptas exceed ngml depend mast burden organ clinic mediat histamin leukotrien tryptas heparin kinet clot fibrinogenolyt anticoagul tryptas heparin bleed mastocytosi heparinlik anticoagul emerg room mastocytosi avoid trigger heat cold alcohol aspirin nsaid symptomat h1 h2 antihistamin proton pump antileukotrien anticholinerg glucocortico d epinephrin hypotens aggress mastocytosi interferon alpha cladribin imatinib mesyl imatinib d816v ckit abbrevi\n",
            "\t-4.840\t264 basophilmedi anaphylaxi trigger drugactiv complement mastocyt immunoglobulin complement anaphylaxi ige igg socal nonimmun anaphylaxi tryptas complement circul cic anaphylaxi woman infus concentr iron 46 yearsold woman admit depart mix anemia iron cobalamin deficiencyrel start biliopancreat deriv heavi ago start hgb 7gdl ev hydroxicobalamin iron infus plan gttm infus concentr 05 mgml iron discomfort sweat drop bp 6030 tryptas complement cic anaphylaxi start im epinephrin inhal o2 steroid betaagonist ev electrolyt solut vital continu shock resolut gain hour tryptas mcgml nrnormal c3 c4 c3 65 mgdl nr 75 165 c4 mgdl nr 55 search cic igg iga igm gttm 025 mgml iron infus toler exclud ige sensit anaphylaxi mastocyt ige infus hyperosmol hyperconcentr complement anaphylaxi mediat mastocyt basophil anaphylotoxin conclud druginduc complement consequ basophil nonimmun anaphylaxi    \n",
            "systemic mastocytosis,Serum tryptase,steroid None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.472\trais latent collagenas activ angiogenesi esaf activ grow intracrani tumour stimul angiogenesi esaf potent mitogen display angiogen differ virtu activ latent metalloproteinas quantifi diseas esaf biopsi intracrani tumour vari close rose compar encount pineal gland richest esaf matur mammal tumour benign contain esaf neoplasm classifi malign 0025 mitot histochem stain esaf agre esaf    \n",
            "\t0.460\tsilent killer atrial thyroid rthle rthle hcc variant follicular tendenc metastas intracavitari metastas thyroid hcc extrem 57yearold thyroid hcc thyroidectomi dyspnea hypoxia hypotens comput tomographi angiogram extens embol 6cm atrial lowerextrem deep vein thrombosi thrombectomi cardiopulmonari bypass intraop mediastinum extend unresect effac atrial wall core biopsi metastat poorli differenti hcc thyroid origin eventu die massiv embol unexplain dyspnea metastas regardless anticoagul prophylaxi deep vein thrombosi limb intracavitari metastas provid prompt improv  introductioncas presentationdiscussionconclusionsstat ethicsdisclosur statement rthle hcc variant follicular refer follicular oxyphil account differenti thyroid ageadjust annual thyroid usa million behav aggress fashion welldifferenti thyroid tendenc metastas intracardiac metastas atrial metastas intracardiac metastas atrium massiv embol pe intracavitari metastas thyroid hcc extrem unexplain dyspnea metastas regardless anticoagul prophylaxi dvt limb intracavitari metastas provid prompt improv statement ethic\n",
            "\t0.460\tsilent killer atrial thyroid rthle rthle hcc variant follicular tendenc metastas intracavitari metastas thyroid hcc extrem 57yearold thyroid hcc thyroidectomi dyspnea hypoxia hypotens comput tomographi angiogram extens embol 6cm atrial lowerextrem deep vein thrombosi thrombectomi cardiopulmonari bypass intraop mediastinum extend unresect effac atrial wall core biopsi metastat poorli differenti hcc thyroid origin eventu die massiv embol unexplain dyspnea metastas regardless anticoagul prophylaxi deep vein thrombosi limb intracavitari metastas provid prompt improv  introductioncas presentationdiscussionconclusionsstat ethicsdisclosur statement rthle hcc variant follicular refer follicular oxyphil account differenti thyroid ageadjust annual thyroid usa million behav aggress fashion welldifferenti thyroid tendenc metastas intracardiac metastas atrial metastas intracardiac metastas atrium massiv embol pe intracavitari metastas thyroid hcc extrem unexplain dyspnea metastas regardless anticoagul prophylaxi dvt limb intracavitari metastas provid prompt improv statement ethic\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.831\tasymptomat radioiodineavid metastas hemithyroidectomi adenomat goiter 65yearold hemithyroidectomi adenomat goiter chest xray lesion computer tomographi ct thyroglobulin tg complet thyroidectomi patholog thyroid malign radioiodineavid posttherapi planar scintigraphi photon emiss comput tomographyct ultrasonographyguid biopsi nodul thyroid follicular metastat differenti thyroid suspect asymptomat incident rais tg thyroid  introductioncas reportdiscuss papillari follicular carcinoma thyroid gland refer differenti thyroid dtc slowli progress 10year 8095 distant metastas minor occurr distant metastas kidney uncommon asymptomat radioiodineavid metastas present hemithyroidectomi adenomat goiter 131 iwhol scintigraphi wb 131 photon emiss comput tomographycomput tomographi 131 ispectct distant metastas dtc latent dtc distant metastas lymph node involv thyroid malign 4559 metastas kidney thyroid constitut 2527 metastas dtc 45 elderli set multifoc metastas patholog malign surgic resect thyroid specimen malign follicular thyroid escap hemithyroidectomi specimen metastas dtc asymptomat apart cough asymptomat metastas metastas dtc occasion decad remov thyroid malign undetect radioiodin done iodin avid throughout planar scintigraphi spectct scan lesion local help precis local abnorm radioiodin hilar node nodul kidney spine metastas poorli iodineavid radioiodin radioiodineavid residu thyroid metastas extrem uncommon metastas thyroid carcinoma metastas discov autopsi median interv dtc 65 actual metastas thyroid mode median diseasespecif metastas 167 underw excis metastas 34 005 metastat organ amen radioiodin steroid cover symptomat cough iodin regular conclud metastat dtc suspect asymptomat incident rais tg thyroid\n",
            "\t-0.968\tfalseposit radioiodin i131 foreign granuloma gluteal adipos purpos wholebodi scan radioact i131 screen residu metastat thyroid wholebodi scan fals radioiodin i131 uptak atyp local 54 yearold woman underw thyroidectomi papillari thyroid appear upper posterolater gluteal posttherapi i131 scan colour doppler ultrasonographi magnet reson histopatholog excis lesion lesion foreign granuloma unexpect posttherapi i131 scan modal avoid unnecessari uncertain situat histopatholog thyroid cancerfals radioiodin uptakeposttherapi i131 scancolour doppler ultrasonographymagnet reson introductioncas reportdiscussionconclus near thyroidectomi radioact i131 rai administ modal select papillari thyroid rai residu metastat thyroid wholebodi scan wb falseposit rai uptak atyp local normal vari proport uptak sometim confus modal histopatholog achiev accur interpret atyp local rai foreign granulom subcutan interest awar kind abnorm radioiodin i131 foreign granuloma adipos recommend avoid unnecessari suspici fals rai uptak exist\n",
            "\t-3.178\tsign metastas papillari thyroid tyrosinekinas diagnos metastas papillari thyroid uncommon rise improv nevertheless fourth date scenario choic notabl largest approv tyrosinekinas thyroid 73yearold ladi dedifferenti papillari thyroid ongo sorafenib dyspnea cardiotox comprehens echocardiographi comput tomographi pet magnet reson appear metastas recov basal start secondlin sunitinib welltoler metastas magnet reson gold sorafenib mainstay firstlin metastat thyroid achiev toler sunitinib safe secondlin option cardiotox promis present tyrosinekinas metastat thyroid encourag deserv  introductioncas reportdiscussiondisclosur statement metastas thyroid entiti histor rang improv thyroid advanc diagnos contribut nevertheless comprehens thyroid histolog subtyp prone metastas anaplast thyroid follicular thyroid rthle date metastas papillari thyroid fourth metastas histor except event occur reason whose rout spread involv scarc metastas indol unspecif attribut challeng avail imagingbas today owe fact mention final diagnos autopsi longev mri contribut metastas slightli distinguish metastas origin uncommon malign melanoma malign germ neoplasm malign thymoma intermedi metastas greatest stomach ovari colon rectum metastas classifi categori thyroid rise actual ninth 90 welldifferenti thyroid wdtc origin follicular encompass papillari follicular thyroid ptc ftc ptc curabl multimod combin radioact iodin tshsuppress hormon nevertheless ptc relaps recurr dedifferenti impli aggress fast metastat iodin radiotherapi situat nodal recurr resect whose patholog pdtc papillari pdtc welldefin entiti turin expert meet wdtc anaplast thyroid carcinoma outlin pdtc aris novo wdtc appear alter transloc mitogenesi carcinogenesi thyroid carcinoma preced unoppos mitogenactiv ret ra braf phosphatidylinositol3kinas pdtc present alter ra braf 45 mutual exclus tp53 tyrosinekinas epiderm vascularendotheli vegfr illustr alter regard histolog subtyp thyroid impos emphas therapi support multikinas tyrosinekinas sorafenib sunitinib vandetanib block vegfr ret braf instead classic cytotox sorafenib firstlin metastat prove approv octob doubleblind random 417 thyroid iodinerefractori sorafenib median diseasefre 1058 58 handfoot diarrhea consid sorafenib mainstay firstlin metastat thyroid excel toler notabl wors enrol spite persist hospit worsen dyspnea episod congest chief dyspnea think concomit trigger congest episod demand consider dyspnea aggress pdtc radiotherapi tyrosinekinas cardiotox sorafenib radiationrel pneumon radiationassoci constrict pericard involv lung malign pericardi effus rule radiationrel unlik neither chronolog pneumon end radiolog cardiotox rule preliminari ecg abnorm echocardiographi ventricular eject fraction final suspici echocardiographi exist metastas pericardium atrium inconclus achiev confirm request mri gold morpholog complet petct scan optim undifferenti thyroid radioiodin mri pericardium atrium abnorm petct petct hypermetabol focus lung thorac vertebra comprehens cover 130 54 metastas thyroid present elect metastas radic favour radiotherapi sarcoma goal date cardiolog lifethreaten contrari fact mention experienc cardiolog just adjust symptomat requir locoregion maneuv secondlin option sunitinib antivegfr plateletderiv multikinas success iodinerefractori thyroid secondlin achiev partial stabil owe prove cardiotox decid start sunitinib stabil present tyrosinekinas metastat thyroid encourag stabil cardiotox spite metastas confirm prospect investig establish optim set disclosur statement\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.472\trais latent collagenas activ angiogenesi esaf activ grow intracrani tumour stimul angiogenesi esaf potent mitogen display angiogen differ virtu activ latent metalloproteinas quantifi diseas esaf biopsi intracrani tumour vari close rose compar encount pineal gland richest esaf matur mammal tumour benign contain esaf neoplasm classifi malign 0025 mitot histochem stain esaf agre esaf    \n",
            "\t0.460\tsilent killer atrial thyroid rthle rthle hcc variant follicular tendenc metastas intracavitari metastas thyroid hcc extrem 57yearold thyroid hcc thyroidectomi dyspnea hypoxia hypotens comput tomographi angiogram extens embol 6cm atrial lowerextrem deep vein thrombosi thrombectomi cardiopulmonari bypass intraop mediastinum extend unresect effac atrial wall core biopsi metastat poorli differenti hcc thyroid origin eventu die massiv embol unexplain dyspnea metastas regardless anticoagul prophylaxi deep vein thrombosi limb intracavitari metastas provid prompt improv  introductioncas presentationdiscussionconclusionsstat ethicsdisclosur statement rthle hcc variant follicular refer follicular oxyphil account differenti thyroid ageadjust annual thyroid usa million behav aggress fashion welldifferenti thyroid tendenc metastas intracardiac metastas atrial metastas intracardiac metastas atrium massiv embol pe intracavitari metastas thyroid hcc extrem unexplain dyspnea metastas regardless anticoagul prophylaxi dvt limb intracavitari metastas provid prompt improv statement ethic\n",
            "\t0.460\tsilent killer atrial thyroid rthle rthle hcc variant follicular tendenc metastas intracavitari metastas thyroid hcc extrem 57yearold thyroid hcc thyroidectomi dyspnea hypoxia hypotens comput tomographi angiogram extens embol 6cm atrial lowerextrem deep vein thrombosi thrombectomi cardiopulmonari bypass intraop mediastinum extend unresect effac atrial wall core biopsi metastat poorli differenti hcc thyroid origin eventu die massiv embol unexplain dyspnea metastas regardless anticoagul prophylaxi deep vein thrombosi limb intracavitari metastas provid prompt improv  introductioncas presentationdiscussionconclusionsstat ethicsdisclosur statement rthle hcc variant follicular refer follicular oxyphil account differenti thyroid ageadjust annual thyroid usa million behav aggress fashion welldifferenti thyroid tendenc metastas intracardiac metastas atrial metastas intracardiac metastas atrium massiv embol pe intracavitari metastas thyroid hcc extrem unexplain dyspnea metastas regardless anticoagul prophylaxi dvt limb intracavitari metastas provid prompt improv statement ethic\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.831\tasymptomat radioiodineavid metastas hemithyroidectomi adenomat goiter 65yearold hemithyroidectomi adenomat goiter chest xray lesion computer tomographi ct thyroglobulin tg complet thyroidectomi patholog thyroid malign radioiodineavid posttherapi planar scintigraphi photon emiss comput tomographyct ultrasonographyguid biopsi nodul thyroid follicular metastat differenti thyroid suspect asymptomat incident rais tg thyroid  introductioncas reportdiscuss papillari follicular carcinoma thyroid gland refer differenti thyroid dtc slowli progress 10year 8095 distant metastas minor occurr distant metastas kidney uncommon asymptomat radioiodineavid metastas present hemithyroidectomi adenomat goiter 131 iwhol scintigraphi wb 131 photon emiss comput tomographycomput tomographi 131 ispectct distant metastas dtc latent dtc distant metastas lymph node involv thyroid malign 4559 metastas kidney thyroid constitut 2527 metastas dtc 45 elderli set multifoc metastas patholog malign surgic resect thyroid specimen malign follicular thyroid escap hemithyroidectomi specimen metastas dtc asymptomat apart cough asymptomat metastas metastas dtc occasion decad remov thyroid malign undetect radioiodin done iodin avid throughout planar scintigraphi spectct scan lesion local help precis local abnorm radioiodin hilar node nodul kidney spine metastas poorli iodineavid radioiodin radioiodineavid residu thyroid metastas extrem uncommon metastas thyroid carcinoma metastas discov autopsi median interv dtc 65 actual metastas thyroid mode median diseasespecif metastas 167 underw excis metastas 34 005 metastat organ amen radioiodin steroid cover symptomat cough iodin regular conclud metastat dtc suspect asymptomat incident rais tg thyroid\n",
            "\t-0.968\tfalseposit radioiodin i131 foreign granuloma gluteal adipos purpos wholebodi scan radioact i131 screen residu metastat thyroid wholebodi scan fals radioiodin i131 uptak atyp local 54 yearold woman underw thyroidectomi papillari thyroid appear upper posterolater gluteal posttherapi i131 scan colour doppler ultrasonographi magnet reson histopatholog excis lesion lesion foreign granuloma unexpect posttherapi i131 scan modal avoid unnecessari uncertain situat histopatholog thyroid cancerfals radioiodin uptakeposttherapi i131 scancolour doppler ultrasonographymagnet reson introductioncas reportdiscussionconclus near thyroidectomi radioact i131 rai administ modal select papillari thyroid rai residu metastat thyroid wholebodi scan wb falseposit rai uptak atyp local normal vari proport uptak sometim confus modal histopatholog achiev accur interpret atyp local rai foreign granulom subcutan interest awar kind abnorm radioiodin i131 foreign granuloma adipos recommend avoid unnecessari suspici fals rai uptak exist\n",
            "\t-3.178\tsign metastas papillari thyroid tyrosinekinas diagnos metastas papillari thyroid uncommon rise improv nevertheless fourth date scenario choic notabl largest approv tyrosinekinas thyroid 73yearold ladi dedifferenti papillari thyroid ongo sorafenib dyspnea cardiotox comprehens echocardiographi comput tomographi pet magnet reson appear metastas recov basal start secondlin sunitinib welltoler metastas magnet reson gold sorafenib mainstay firstlin metastat thyroid achiev toler sunitinib safe secondlin option cardiotox promis present tyrosinekinas metastat thyroid encourag deserv  introductioncas reportdiscussiondisclosur statement metastas thyroid entiti histor rang improv thyroid advanc diagnos contribut nevertheless comprehens thyroid histolog subtyp prone metastas anaplast thyroid follicular thyroid rthle date metastas papillari thyroid fourth metastas histor except event occur reason whose rout spread involv scarc metastas indol unspecif attribut challeng avail imagingbas today owe fact mention final diagnos autopsi longev mri contribut metastas slightli distinguish metastas origin uncommon malign melanoma malign germ neoplasm malign thymoma intermedi metastas greatest stomach ovari colon rectum metastas classifi categori thyroid rise actual ninth 90 welldifferenti thyroid wdtc origin follicular encompass papillari follicular thyroid ptc ftc ptc curabl multimod combin radioact iodin tshsuppress hormon nevertheless ptc relaps recurr dedifferenti impli aggress fast metastat iodin radiotherapi situat nodal recurr resect whose patholog pdtc papillari pdtc welldefin entiti turin expert meet wdtc anaplast thyroid carcinoma outlin pdtc aris novo wdtc appear alter transloc mitogenesi carcinogenesi thyroid carcinoma preced unoppos mitogenactiv ret ra braf phosphatidylinositol3kinas pdtc present alter ra braf 45 mutual exclus tp53 tyrosinekinas epiderm vascularendotheli vegfr illustr alter regard histolog subtyp thyroid impos emphas therapi support multikinas tyrosinekinas sorafenib sunitinib vandetanib block vegfr ret braf instead classic cytotox sorafenib firstlin metastat prove approv octob doubleblind random 417 thyroid iodinerefractori sorafenib median diseasefre 1058 58 handfoot diarrhea consid sorafenib mainstay firstlin metastat thyroid excel toler notabl wors enrol spite persist hospit worsen dyspnea episod congest chief dyspnea think concomit trigger congest episod demand consider dyspnea aggress pdtc radiotherapi tyrosinekinas cardiotox sorafenib radiationrel pneumon radiationassoci constrict pericard involv lung malign pericardi effus rule radiationrel unlik neither chronolog pneumon end radiolog cardiotox rule preliminari ecg abnorm echocardiographi ventricular eject fraction final suspici echocardiographi exist metastas pericardium atrium inconclus achiev confirm request mri gold morpholog complet petct scan optim undifferenti thyroid radioiodin mri pericardium atrium abnorm petct petct hypermetabol focus lung thorac vertebra comprehens cover 130 54 metastas thyroid present elect metastas radic favour radiotherapi sarcoma goal date cardiolog lifethreaten contrari fact mention experienc cardiolog just adjust symptomat requir locoregion maneuv secondlin option sunitinib antivegfr plateletderiv multikinas success iodinerefractori thyroid secondlin achiev partial stabil owe prove cardiotox decid start sunitinib stabil present tyrosinekinas metastat thyroid encourag stabil cardiotox spite metastas confirm prospect investig establish optim set disclosur statement\n",
            "metastatic papillary thyroid cancer,RAI None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.497\tmarfan fatal marfan herit connect affect organ seriou complic marfan progress aortic root dilat aortic dissect ruptur aortic regurgit threaten 34yearold caucasian marfan chest consequ strenuou effort examin aortic root enlarg aortic intramur hematoma endedup fatal recogn marfan prevent action undertaken avoid seriou consequ  introductioncas presentationdiscussionconclusionabbreviationsconsentcompet interestsauthor contribut marfan herit connect musculoskelet ocular seriou complic marfan present progress aortic root dilat aortic dissect ruptur aortic regurgit categori era success prevent therapi prevent includ regular aorta aortic enlarg beta blocker prophylact aortic aorta reach threaten dissect ruptur seriou aortic regurgit 34yearold marfan aortic root enlarg aortic intramur hematoma end fatal recogn marfan recogn prevent action undertaken avoid lifethreaten consequ abbrevi\n",
            "\t0.404\tcystic fibrosisa recurr bronchiol infanc korean infant draw occurr cystic fibrosi cf korean infant awar infant recurr bronchiol manifest cough wheez dyspnea cf clinic suspect demonstr sweat chlorid 97 meql 99 meql delay manifest cf cough diarrhea thrive cf underdiagnos korean uncommon facil iontophoresi sweat lack    \n",
            "\t0.404\tcystic fibrosisa recurr bronchiol infanc korean infant draw occurr cystic fibrosi cf korean infant awar infant recurr bronchiol manifest cough wheez dyspnea cf clinic suspect demonstr sweat chlorid 97 meql 99 meql delay manifest cf cough diarrhea thrive cf underdiagnos korean uncommon facil iontophoresi sweat lack    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.827\tmarfan fatal marfan herit connect affect organ seriou complic marfan progress aortic root dilat aortic dissect ruptur aortic regurgit threaten 34yearold caucasian marfan chest consequ strenuou effort examin aortic root enlarg aortic intramur hematoma endedup fatal recogn marfan prevent action undertaken avoid seriou consequ  introductioncas presentationdiscussionconclusionabbreviationsconsentcompet interestsauthor contribut marfan herit connect musculoskelet ocular seriou complic marfan present progress aortic root dilat aortic dissect ruptur aortic regurgit categori era success prevent therapi prevent includ regular aorta aortic enlarg beta blocker prophylact aortic aorta reach threaten dissect ruptur seriou aortic regurgit 34yearold marfan aortic root enlarg aortic intramur hematoma end fatal recogn marfan recogn prevent action undertaken avoid lifethreaten consequ abbrevi\n",
            "\t-1.631\tthrombolysi marfan   introductioncas reportdiscussiondeclarationcompet interestsfundingeth approvalguarantorcontributorshipacknowledg marfan autosom domin inherit connect pleiotrop manifest classic triad ocular skelet characterist thin tall statur pectu carinatum excavatum scoliosi joint hypermobl arachnodactyli pe planu arch palat ectopia lenti 9800 weak vessel aorta progress dilat aortic root aortic regurgit dissect ruptur threaten featur marfan neurovascular marfan mostli ischaem marfan intracrani aneurysm autopsi 1997 autopsi marfan thrombolysi ischaem thrombolyt ischaem marfan marfan thrombolysi ischaem thrombolysi complic haemorrhag infarct transient deterior neurolog recoveri consid infarct malform haemorrhag widespread haemorrhag transform bleed abnorm vessel unlik haemorrhag marfanrel connect cardioembol ventricular prosthet valv haemorrhag withhold thrombolysi marfan rule aortic dissect marfan thrombolysi pathophysiolog predisposit intracrani aneurysm convinc intracrani aneurysm marfan autopsi take asymptomat haemorrhag symptomat fatal subarachnoid haemorrhag judg cerebr ischaem neurovascular marfan retrospect 513 marfan cerebrovascular 83 ischaem transient ischaem attack cerebr infarct spinal cord infarct haemorrhag subdur haematoma spinal subarachnoid haemorrhag 396 consider stroke embol 77 prosthet valv atrial fibril marfan cerebr ischaem haemorrhag complic thrombolysi recoveri thrombolysi marfan declar\n",
            "\t-8.954\tcystic fibrosisa recurr bronchiol infanc korean infant draw occurr cystic fibrosi cf korean infant awar infant recurr bronchiol manifest cough wheez dyspnea cf clinic suspect demonstr sweat chlorid 97 meql 99 meql delay manifest cf cough diarrhea thrive cf underdiagnos korean uncommon facil iontophoresi sweat lack    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.497\tmarfan fatal marfan herit connect affect organ seriou complic marfan progress aortic root dilat aortic dissect ruptur aortic regurgit threaten 34yearold caucasian marfan chest consequ strenuou effort examin aortic root enlarg aortic intramur hematoma endedup fatal recogn marfan prevent action undertaken avoid seriou consequ  introductioncas presentationdiscussionconclusionabbreviationsconsentcompet interestsauthor contribut marfan herit connect musculoskelet ocular seriou complic marfan present progress aortic root dilat aortic dissect ruptur aortic regurgit categori era success prevent therapi prevent includ regular aorta aortic enlarg beta blocker prophylact aortic aorta reach threaten dissect ruptur seriou aortic regurgit 34yearold marfan aortic root enlarg aortic intramur hematoma end fatal recogn marfan recogn prevent action undertaken avoid lifethreaten consequ abbrevi\n",
            "\t0.404\tcystic fibrosisa recurr bronchiol infanc korean infant draw occurr cystic fibrosi cf korean infant awar infant recurr bronchiol manifest cough wheez dyspnea cf clinic suspect demonstr sweat chlorid 97 meql 99 meql delay manifest cf cough diarrhea thrive cf underdiagnos korean uncommon facil iontophoresi sweat lack    \n",
            "\t0.404\tcystic fibrosisa recurr bronchiol infanc korean infant draw occurr cystic fibrosi cf korean infant awar infant recurr bronchiol manifest cough wheez dyspnea cf clinic suspect demonstr sweat chlorid 97 meql 99 meql delay manifest cf cough diarrhea thrive cf underdiagnos korean uncommon facil iontophoresi sweat lack    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.827\tmarfan fatal marfan herit connect affect organ seriou complic marfan progress aortic root dilat aortic dissect ruptur aortic regurgit threaten 34yearold caucasian marfan chest consequ strenuou effort examin aortic root enlarg aortic intramur hematoma endedup fatal recogn marfan prevent action undertaken avoid seriou consequ  introductioncas presentationdiscussionconclusionabbreviationsconsentcompet interestsauthor contribut marfan herit connect musculoskelet ocular seriou complic marfan present progress aortic root dilat aortic dissect ruptur aortic regurgit categori era success prevent therapi prevent includ regular aorta aortic enlarg beta blocker prophylact aortic aorta reach threaten dissect ruptur seriou aortic regurgit 34yearold marfan aortic root enlarg aortic intramur hematoma end fatal recogn marfan recogn prevent action undertaken avoid lifethreaten consequ abbrevi\n",
            "\t-1.631\tthrombolysi marfan   introductioncas reportdiscussiondeclarationcompet interestsfundingeth approvalguarantorcontributorshipacknowledg marfan autosom domin inherit connect pleiotrop manifest classic triad ocular skelet characterist thin tall statur pectu carinatum excavatum scoliosi joint hypermobl arachnodactyli pe planu arch palat ectopia lenti 9800 weak vessel aorta progress dilat aortic root aortic regurgit dissect ruptur threaten featur marfan neurovascular marfan mostli ischaem marfan intracrani aneurysm autopsi 1997 autopsi marfan thrombolysi ischaem thrombolyt ischaem marfan marfan thrombolysi ischaem thrombolysi complic haemorrhag infarct transient deterior neurolog recoveri consid infarct malform haemorrhag widespread haemorrhag transform bleed abnorm vessel unlik haemorrhag marfanrel connect cardioembol ventricular prosthet valv haemorrhag withhold thrombolysi marfan rule aortic dissect marfan thrombolysi pathophysiolog predisposit intracrani aneurysm convinc intracrani aneurysm marfan autopsi take asymptomat haemorrhag symptomat fatal subarachnoid haemorrhag judg cerebr ischaem neurovascular marfan retrospect 513 marfan cerebrovascular 83 ischaem transient ischaem attack cerebr infarct spinal cord infarct haemorrhag subdur haematoma spinal subarachnoid haemorrhag 396 consider stroke embol 77 prosthet valv atrial fibril marfan cerebr ischaem haemorrhag complic thrombolysi recoveri thrombolysi marfan declar\n",
            "\t-8.954\tcystic fibrosisa recurr bronchiol infanc korean infant draw occurr cystic fibrosi cf korean infant awar infant recurr bronchiol manifest cough wheez dyspnea cf clinic suspect demonstr sweat chlorid 97 meql 99 meql delay manifest cf cough diarrhea thrive cf underdiagnos korean uncommon facil iontophoresi sweat lack    \n",
            "Marfan's syndrome None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.500\tctguid celiac plexu block intract abdomin intract abdomin inoper intraabdomin malign ineffect pharmacolog investig recommend neurolysi celiac ganglion author describ celiac plexu neurolysi ctguidanc rout anterior posterior transaort rout twentyeight rang 36 82 inoper recur intraabdomin malign intract upper abdomin back author absolut alcohol anterior n18 posterior n6 transaort n4 rate analog gaug success mild hypotens transient diarrhea twentyon 75 relief 61 relief ctguid celiac plexu block alcohol safe intraabdomin malign    \n",
            "\t0.472\tmonoclon cellassoci carbohydr determin react antigen cad sda ct antigen determin t200 glycoprotein murin cytotox clone helper clone nonactiv lymphocyt determin recogn mab ct1 ct2 thymocyt development fashion fetal thymu ontogeni subset lyt2 intraepitheli lymphocyt intestin mucosa biosynthesi ct determin compos carbohydr antict mab react carbohydr determin nonreduc terminu oligosaccharid configur galnac beta 14sa alpha 23galactos ct determin ctl clone antigen cad sda variant ctl noncad erythrocyt sda glycoprotein lack galnac residu bind ct mab sialic ct neuraminidas mild period abrog ct carbohydr termin galnac tn antigen recogn ct defin galnac sialic carbohydr antigen discret subset lymphocyt reagent cad sda antigen    \n",
            "\t0.472\tmonoclon cellassoci carbohydr determin react antigen cad sda ct antigen determin t200 glycoprotein murin cytotox clone helper clone nonactiv lymphocyt determin recogn mab ct1 ct2 thymocyt development fashion fetal thymu ontogeni subset lyt2 intraepitheli lymphocyt intestin mucosa biosynthesi ct determin compos carbohydr antict mab react carbohydr determin nonreduc terminu oligosaccharid configur galnac beta 14sa alpha 23galactos ct determin ctl clone antigen cad sda variant ctl noncad erythrocyt sda glycoprotein lack galnac residu bind ct mab sialic ct neuraminidas mild period abrog ct carbohydr termin galnac tn antigen recogn ct defin galnac sialic carbohydr antigen discret subset lymphocyt reagent cad sda antigen    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.007\tvancomycin resist enterococci client northwest ethiopia crosssect enterococci multidrug resist organ immunocompromis lack epidemiolog vancomycin resist enterococci vre ethiopia aim vre antibiot fecal immunodefici client cross section carri 226 113 113 client juli 12013 septemb 302013 univers gondar teach sociodemograph interview guid pretest structur questionnair enterococci stool bacteriolog kari bauer disk diffus enterococci enter spss version packag colon enterococci 889 201226 55 vre vre client 878 331 nineti percent enterococci 181201 resist antibiot enterococci recov stool resist amoxicillin amoxicillincalvulin client 005 antibiot statist vre colon sociodemograph malnutrit leucopenia thromobocytopenia anaemia antiretrovir count drink alcohol vre 005 vre emerg vre antibiot vre colon ration antibiot detail phenotyp genotyp vancomycinresistantenterococccihiv backgroundmethodsstudi periodstudi populationsampl sampl techniquedata collectionstool processingantimicrobi testingqu controldata analysiseth considerationresultssociodemograph clientspreval vre clientsantimicrobi enterococcciassoci vrediscussionlimit studyconclusioncompet interestsauthor contributionsprepubl enterococci inhabit gastrointestin tract enterococc enterococcu faecali faecium enterococci urinari tract intraabdomin pelvic wound bacteraemia endocard neonat sepsi rare mening antibiot hospit vancomycin unit intensivecar unit comorbid urinari cathet colon vancomycin enterococci vre critic ill immunosuppress person intra abdomin cardiothorac indwel urinari venou cathet hivposit receiv antibiot frequent contact healthcar vre enterococcu pathogen occurr highlevel antimicrobi ampicillin vancomycin emerg vre alarm infecti option enterococci staphylococcu aureu pressur vre expans resist vre europ asia australia south america africa enough epidemiolog vre ethiopia aim vre antibiot fecal client univers gondar teach vre client attend univers gondar 55 antibiot colon respect 55 vre emerg vre ration antibiot detail phenotyp genotyp compet interest\n",
            "\t-3.084\tvancomycin multiplex vancomycinresist enterococci rectal swab vancomycinresist enterococci vre rectal specimen recommend limit spread antimicrobi highrisk vancomycin multiplex tandem ausdiagnost australia multiplex realtim detect vana vanb twohundredandeleven rectal swab hematolog oncolog unit submit vre surveil vana vanb vancomycin multiplex tandem enterococci biochem bd phoenix autom microbiolog bd usa vancomycin enterococci etest biomerieux franc vancomycin multiplex tandem 840 988 predict ppv 913 predict npv 976 fail 85 specimen remain 193 specimen 129 vana vanb vana vre vanb specimen vre vancomycin multiplex tandem laborsav option vre surveil rectal swab owe specimen vanb interpret vancomycin resistanceenterococcu faeciumpcr introductionmethods1 specimens2 method3 vancomycin multiplex tandem assayresultsdiscuss emerg glycopeptid antibiot vancomycin teicoplanin enterococci soon becom seriou issu outbreak vancomycinresist enterococcu vre turkey 1998 healthcar cost vancomycin enterococci acquisit vana vanb primarili enterococcu faecium asymptomat intestin colon vre reservoir dissemin colon vre colon vre outbreak culturebas typic vre 2472 hr isol vre colon hr spread vre allow implement barrier precaut nucleic amplif vre quit regimen extract enrich involv select enrich broth recov solid medium vancomycin multiplex tandem kit ausdiagnost alexandria australia rectal swab vre surveil aim kit vre colon vre colon reliabl vre commerci phenotyp genotyp vre genotyp cepheid genexpert vana vanb bd geneohm vanr commerci detect vana specimen compar appar falseposit vanb specimen vanb explain commens fecal flora carri vanb vanb involv vancomycin multiplex tandem surveil vre falseposit vanb vanb specimen vanb genotyp never date vanb 80 225 specimen set confirm prevent unnecessari precaut isol 85 211 rectal swab contain vre highlight disadvantag stool origin dietari polysaccharid chlorophyl herb veget bile salt urea glycolipid hemoglobin heparin autom nucleic extract consist throughput prove insuffici remov protocol remov heat chloroform extract carbon dilut falseneg 129 specimen vre display vana unexpect consid describ isol vanb faecium turkey outbreak hematolog oncolog unit pediatr antibiot select vre antibiot document antibiot vancomycin multiplex tandem kit excel npv ppv vana kit rapidli carri vancomycinresist acquir vana vanb healthcar profession hr admiss polici cross vana rapidli vre vanb vancomycin multiplex tandem rectal swab reliabl option give accur vana vre surveil\n",
            "\t-4.180\tprekallikrein defici present recurr cerebrovascular accid woman hyperlipidemia present recurr episod clinic cerebrovascular accid cva mri suggest ischemia vascul anatom neurolog rheumat cardioembol arteriosclerot etiolog extens workup incident prolong partial thromboplastin aptt prothrombin pt prekallikrein defici cva prothrombot rule manifest prekallikrein defici thrombot  presentation2 discussion3 conclusionsupplementari 32yearold african american woman neurolog clinic episod cerebrovascular accid cva cva episod extens magnet reson mri echocardiogram bubbl ct angiographi carotid doppler ultrasound holter implement aspirin statin episod sudden leftsid weak dysarthria last hour episod selflimit resolut afterward unclear mri order flair diffusionweight dwi surround frontal horn later ventricl suggest ischem etiolog vascul admit workup seek definit verapamil dyslipidemia simvastatin take aspirin 81 mg episod cva transderm contracept bleed thrombot past deni prolong bleed dental menometrorrhagia loss past deni alcohol tobacco abus illicit abus noncontributori admiss normotens afebril sign bleed thrombosi neurolog focal deficit count comprehens panel limit coagul prolong aptt 994 sec pt sec anticoagul mix order aptt correct 301 sec mix coagul defici exclud intrins viii ix xi xii von willebrand vwf fibrinogen lupu anticoagul platelet abnorm aptt shorten prolong incub deficit contact intrins coagul suspect prekallikrein defici prekallikrein pk order clot amidolyt pk undetect final prekallikrein defici rule concomit prothrombot order antithrombin beta microglobulin anticardiolipin lupu anticoagul cd55cd59 cytometri leyden jak2 prothrombin 202010 unremark homocystein sickl screen rule vascul rheumatoid panel order antinuclear antissa antissb antismith antirnp antiscleroderma70 antiribosom antidoublestrand antineutrophil cytoplasm rheumatoid complement c3 c4 12lead electrocardiogram sinu rhythm arrhythmia magnet reson carotid vertebrobasilar angiogram arteri defect atherosclerot candid thrombolysi anticoagul event complet aforement workup discharg home prekallikrein defici recommend continu close surveil neurolog hematolog continu aspirin dyslipidemia woman hyperlipidemia present recurr episod clinic cerebrovascular accid cva mri suggest ischemia vascul dyslipidemia anatom neurolog rheumat cardioembol arteriosclerot etiolog extens workup incident prolong partial thromboplastin aptt prothrombin pt prekallikrein defici unclear pk defici prothrombot rariti underreport prospect cva prothrombot rule manifest prekallikrein defici thrombot infrequ pk encount pathophysiolog formid\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.500\tctguid celiac plexu block intract abdomin intract abdomin inoper intraabdomin malign ineffect pharmacolog investig recommend neurolysi celiac ganglion author describ celiac plexu neurolysi ctguidanc rout anterior posterior transaort rout twentyeight rang 36 82 inoper recur intraabdomin malign intract upper abdomin back author absolut alcohol anterior n18 posterior n6 transaort n4 rate analog gaug success mild hypotens transient diarrhea twentyon 75 relief 61 relief ctguid celiac plexu block alcohol safe intraabdomin malign    \n",
            "\t0.472\tmonoclon cellassoci carbohydr determin react antigen cad sda ct antigen determin t200 glycoprotein murin cytotox clone helper clone nonactiv lymphocyt determin recogn mab ct1 ct2 thymocyt development fashion fetal thymu ontogeni subset lyt2 intraepitheli lymphocyt intestin mucosa biosynthesi ct determin compos carbohydr antict mab react carbohydr determin nonreduc terminu oligosaccharid configur galnac beta 14sa alpha 23galactos ct determin ctl clone antigen cad sda variant ctl noncad erythrocyt sda glycoprotein lack galnac residu bind ct mab sialic ct neuraminidas mild period abrog ct carbohydr termin galnac tn antigen recogn ct defin galnac sialic carbohydr antigen discret subset lymphocyt reagent cad sda antigen    \n",
            "\t0.472\tmonoclon cellassoci carbohydr determin react antigen cad sda ct antigen determin t200 glycoprotein murin cytotox clone helper clone nonactiv lymphocyt determin recogn mab ct1 ct2 thymocyt development fashion fetal thymu ontogeni subset lyt2 intraepitheli lymphocyt intestin mucosa biosynthesi ct determin compos carbohydr antict mab react carbohydr determin nonreduc terminu oligosaccharid configur galnac beta 14sa alpha 23galactos ct determin ctl clone antigen cad sda variant ctl noncad erythrocyt sda glycoprotein lack galnac residu bind ct mab sialic ct neuraminidas mild period abrog ct carbohydr termin galnac tn antigen recogn ct defin galnac sialic carbohydr antigen discret subset lymphocyt reagent cad sda antigen    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.007\tvancomycin resist enterococci client northwest ethiopia crosssect enterococci multidrug resist organ immunocompromis lack epidemiolog vancomycin resist enterococci vre ethiopia aim vre antibiot fecal immunodefici client cross section carri 226 113 113 client juli 12013 septemb 302013 univers gondar teach sociodemograph interview guid pretest structur questionnair enterococci stool bacteriolog kari bauer disk diffus enterococci enter spss version packag colon enterococci 889 201226 55 vre vre client 878 331 nineti percent enterococci 181201 resist antibiot enterococci recov stool resist amoxicillin amoxicillincalvulin client 005 antibiot statist vre colon sociodemograph malnutrit leucopenia thromobocytopenia anaemia antiretrovir count drink alcohol vre 005 vre emerg vre antibiot vre colon ration antibiot detail phenotyp genotyp vancomycinresistantenterococccihiv backgroundmethodsstudi periodstudi populationsampl sampl techniquedata collectionstool processingantimicrobi testingqu controldata analysiseth considerationresultssociodemograph clientspreval vre clientsantimicrobi enterococcciassoci vrediscussionlimit studyconclusioncompet interestsauthor contributionsprepubl enterococci inhabit gastrointestin tract enterococc enterococcu faecali faecium enterococci urinari tract intraabdomin pelvic wound bacteraemia endocard neonat sepsi rare mening antibiot hospit vancomycin unit intensivecar unit comorbid urinari cathet colon vancomycin enterococci vre critic ill immunosuppress person intra abdomin cardiothorac indwel urinari venou cathet hivposit receiv antibiot frequent contact healthcar vre enterococcu pathogen occurr highlevel antimicrobi ampicillin vancomycin emerg vre alarm infecti option enterococci staphylococcu aureu pressur vre expans resist vre europ asia australia south america africa enough epidemiolog vre ethiopia aim vre antibiot fecal client univers gondar teach vre client attend univers gondar 55 antibiot colon respect 55 vre emerg vre ration antibiot detail phenotyp genotyp compet interest\n",
            "\t-3.084\tvancomycin multiplex vancomycinresist enterococci rectal swab vancomycinresist enterococci vre rectal specimen recommend limit spread antimicrobi highrisk vancomycin multiplex tandem ausdiagnost australia multiplex realtim detect vana vanb twohundredandeleven rectal swab hematolog oncolog unit submit vre surveil vana vanb vancomycin multiplex tandem enterococci biochem bd phoenix autom microbiolog bd usa vancomycin enterococci etest biomerieux franc vancomycin multiplex tandem 840 988 predict ppv 913 predict npv 976 fail 85 specimen remain 193 specimen 129 vana vanb vana vre vanb specimen vre vancomycin multiplex tandem laborsav option vre surveil rectal swab owe specimen vanb interpret vancomycin resistanceenterococcu faeciumpcr introductionmethods1 specimens2 method3 vancomycin multiplex tandem assayresultsdiscuss emerg glycopeptid antibiot vancomycin teicoplanin enterococci soon becom seriou issu outbreak vancomycinresist enterococcu vre turkey 1998 healthcar cost vancomycin enterococci acquisit vana vanb primarili enterococcu faecium asymptomat intestin colon vre reservoir dissemin colon vre colon vre outbreak culturebas typic vre 2472 hr isol vre colon hr spread vre allow implement barrier precaut nucleic amplif vre quit regimen extract enrich involv select enrich broth recov solid medium vancomycin multiplex tandem kit ausdiagnost alexandria australia rectal swab vre surveil aim kit vre colon vre colon reliabl vre commerci phenotyp genotyp vre genotyp cepheid genexpert vana vanb bd geneohm vanr commerci detect vana specimen compar appar falseposit vanb specimen vanb explain commens fecal flora carri vanb vanb involv vancomycin multiplex tandem surveil vre falseposit vanb vanb specimen vanb genotyp never date vanb 80 225 specimen set confirm prevent unnecessari precaut isol 85 211 rectal swab contain vre highlight disadvantag stool origin dietari polysaccharid chlorophyl herb veget bile salt urea glycolipid hemoglobin heparin autom nucleic extract consist throughput prove insuffici remov protocol remov heat chloroform extract carbon dilut falseneg 129 specimen vre display vana unexpect consid describ isol vanb faecium turkey outbreak hematolog oncolog unit pediatr antibiot select vre antibiot document antibiot vancomycin multiplex tandem kit excel npv ppv vana kit rapidli carri vancomycinresist acquir vana vanb healthcar profession hr admiss polici cross vana rapidli vre vanb vancomycin multiplex tandem rectal swab reliabl option give accur vana vre surveil\n",
            "\t-4.180\tprekallikrein defici present recurr cerebrovascular accid woman hyperlipidemia present recurr episod clinic cerebrovascular accid cva mri suggest ischemia vascul anatom neurolog rheumat cardioembol arteriosclerot etiolog extens workup incident prolong partial thromboplastin aptt prothrombin pt prekallikrein defici cva prothrombot rule manifest prekallikrein defici thrombot  presentation2 discussion3 conclusionsupplementari 32yearold african american woman neurolog clinic episod cerebrovascular accid cva cva episod extens magnet reson mri echocardiogram bubbl ct angiographi carotid doppler ultrasound holter implement aspirin statin episod sudden leftsid weak dysarthria last hour episod selflimit resolut afterward unclear mri order flair diffusionweight dwi surround frontal horn later ventricl suggest ischem etiolog vascul admit workup seek definit verapamil dyslipidemia simvastatin take aspirin 81 mg episod cva transderm contracept bleed thrombot past deni prolong bleed dental menometrorrhagia loss past deni alcohol tobacco abus illicit abus noncontributori admiss normotens afebril sign bleed thrombosi neurolog focal deficit count comprehens panel limit coagul prolong aptt 994 sec pt sec anticoagul mix order aptt correct 301 sec mix coagul defici exclud intrins viii ix xi xii von willebrand vwf fibrinogen lupu anticoagul platelet abnorm aptt shorten prolong incub deficit contact intrins coagul suspect prekallikrein defici prekallikrein pk order clot amidolyt pk undetect final prekallikrein defici rule concomit prothrombot order antithrombin beta microglobulin anticardiolipin lupu anticoagul cd55cd59 cytometri leyden jak2 prothrombin 202010 unremark homocystein sickl screen rule vascul rheumatoid panel order antinuclear antissa antissb antismith antirnp antiscleroderma70 antiribosom antidoublestrand antineutrophil cytoplasm rheumatoid complement c3 c4 12lead electrocardiogram sinu rhythm arrhythmia magnet reson carotid vertebrobasilar angiogram arteri defect atherosclerot candid thrombolysi anticoagul event complet aforement workup discharg home prekallikrein defici recommend continu close surveil neurolog hematolog continu aspirin dyslipidemia woman hyperlipidemia present recurr episod clinic cerebrovascular accid cva mri suggest ischemia vascul dyslipidemia anatom neurolog rheumat cardioembol arteriosclerot etiolog extens workup incident prolong partial thromboplastin aptt prothrombin pt prekallikrein defici unclear pk defici prothrombot rariti underreport prospect cva prothrombot rule manifest prekallikrein defici thrombot infrequ pk encount pathophysiolog formid\n",
            "CVA,anti-dsDNA Ab,vanc None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.610\tlimit copd model    obstruct copd cigarett smoke copd characterist airway morpholog infiltr mediat copd cigarett smoke c airway c oxid releas recruit smokeinduc c oxidantsfre radic 4700 huge oxid c form endogen imbal oxid antioxid copd contribut fail translat man fail mind consid c copd mucu bronchial tract aspect copd patholog copd copd restrict mimick characterist copd born mind ass util precis conclus drawn agre copd advanc copd date mimic copd inhal noxiou tracheal instil tissuedegrad emphysemalik genemodifi copdlik mammal paus penh consciou indic airflow obstruct ideal invas gold airwaytissu remodel consid complex copd speciesspecif readout research awar copd histopatholog attempt copd airflow limit mucu hypersecret cough exacerb pharmacolog corticosteroid diminish adrenerg bronchodil benefit accru fundament copd copd unexpect idea promis gain atp tlr inflammasom copd cohort copd phenotyp \n",
            "\t0.610\tlimit copd model    obstruct copd cigarett smoke copd characterist airway morpholog infiltr mediat copd cigarett smoke c airway c oxid releas recruit smokeinduc c oxidantsfre radic 4700 huge oxid c form endogen imbal oxid antioxid copd contribut fail translat man fail mind consid c copd mucu bronchial tract aspect copd patholog copd copd restrict mimick characterist copd born mind ass util precis conclus drawn agre copd advanc copd date mimic copd inhal noxiou tracheal instil tissuedegrad emphysemalik genemodifi copdlik mammal paus penh consciou indic airflow obstruct ideal invas gold airwaytissu remodel consid complex copd speciesspecif readout research awar copd histopatholog attempt copd airflow limit mucu hypersecret cough exacerb pharmacolog corticosteroid diminish adrenerg bronchodil benefit accru fundament copd copd unexpect idea promis gain atp tlr inflammasom copd cohort copd phenotyp \n",
            "\t0.568\tcopd obstruct copd precis moder copd pressur vast copd mild moder copd morbid accur radiograph indic echocardiographi principl noninvas technic copd catheter accur pressur angiogenesi copd vasodil select vasodil inhal nitric oxid phosphodiesteras promis copd routin copdpulmonari introductionprevalencediagnost testingphys examinationchest imagingelectrocardiogramechocardiographyhistopathologypathophysiologypathogenesishypoxiadisturb functionair trappingpolycythemiatox cigarett smokegeneticspathobiologyendotheli dysfunctiongrowth factorsinflammationmanagementsmok cessationsupplement oxygensystem vasodilatorstheophyllinefutur targetssummarycas obstruct copd burden worldwid morbid murray lopez 1997 hurd manifest progress airflow limit hyperinfl air trap hypoxemia hypercapnea elev pressur clinic copd breathless cough sputum exacerb impair portend airflow limit ventilatori hypercapnea burrow earl 1969 weitzenblum 1981 anthonisen 1986 correl neg arteri copd morbid hospit copd exacerb burrow 1972 weitzenblum 1984 kessler barbera copd increasingli recogn contribut manifest morbid copd stimul contribut copd epidemiolog copd manifest pathophysiolog \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.540\ttelemonitor copd   introduction2 methods21 subjects22 measures23 subject change24 analysis25 analysis3 results31 participants32 activity33 behavior34 relat copd day35 awar change4 discussion5 implic  moder copd asymptomat goal copd awar readi start design telemedicin copd copd correspond amount copd employ employ subgroup unemploy expect importantli unemploy copd unemploy employ employ worker employ workforc unemploy work ill job emphas copd socioeconom consequ physic demand job unemploy restrict anymor job plan fun visit therebi employ unemploy temporarili afternoon perform morn relaps afternoon afternoon employ copd inspect copd trend underpin profession advic effici hecht copd ltot sharp afternoon activityonli recoveri afterward even telemedicin balanc distribut improv wellb copd unemploy unemploy part employ differentfromoth morn afternoon even correspond fatigu intens smartphon retrospect analogu seem distinct object subject object copd awar readi awar motiv otherwis unlik run transtheoret subject bpaq copd awar object subject bpaq copd 049 bit 066 back 027 word seem fairli awar object subject part mainten mean regard regularli physic extend think fine mainten seem awar fine situat intent consid focus lifestyl motiv valid measur wireless bluetooth connect sensor smartphon drain batteri devic mean devic run hour oper besid charg sensor experienc charg sensor lengthi consequ hour exclud advanc wireless sensor technolog mobil devic overcom issu telemedicin 6minut walk telemedicin telemedicin consequ implic\n",
            "\t0.540\ttelemonitor copd   introduction2 methods21 subjects22 measures23 subject change24 analysis25 analysis3 results31 participants32 activity33 behavior34 relat copd day35 awar change4 discussion5 implic  moder copd asymptomat goal copd awar readi start design telemedicin copd copd correspond amount copd employ employ subgroup unemploy expect importantli unemploy copd unemploy employ employ worker employ workforc unemploy work ill job emphas copd socioeconom consequ physic demand job unemploy restrict anymor job plan fun visit therebi employ unemploy temporarili afternoon perform morn relaps afternoon afternoon employ copd inspect copd trend underpin profession advic effici hecht copd ltot sharp afternoon activityonli recoveri afterward even telemedicin balanc distribut improv wellb copd unemploy unemploy part employ differentfromoth morn afternoon even correspond fatigu intens smartphon retrospect analogu seem distinct object subject object copd awar readi awar motiv otherwis unlik run transtheoret subject bpaq copd awar object subject bpaq copd 049 bit 066 back 027 word seem fairli awar object subject part mainten mean regard regularli physic extend think fine mainten seem awar fine situat intent consid focus lifestyl motiv valid measur wireless bluetooth connect sensor smartphon drain batteri devic mean devic run hour oper besid charg sensor experienc charg sensor lengthi consequ hour exclud advanc wireless sensor technolog mobil devic overcom issu telemedicin 6minut walk telemedicin telemedicin consequ implic\n",
            "\t-1.161\tcopd copd advers affect exacerb unfortun copd meet term term revers arteri normal discoveri rational consid vasodil posse antiprolif statin  introduction2 prevlenc copd3 signific copd4 pathophysiolog copd41 vasoconstriction42 remodeling43 dysfunction44 inflammation45 destruct bed46 polycythemia47 factors48 hyperinflation5 ventricular copd6 copd61 disproportion ph7 copd71 features72 cpet73 chest xray74 ecg75 echo76 bnp77 exhal nitric oxide78 mri79 chest ct scan710 catheterization8 copd9 copd10 oxygen11 nonspecif vasodilators12 vasodilators121 inhal nitric oxide122 inhal iloprost123 lesson learnt inhal vasodilators124 sildenafil125 bosentan126 lesson learnt vasodil tabl statins14 diuretics15 phlebotomy16 bloodless phlebotomi lvrs18 transplant copd vari 91 depend definit mpap hg copd forc expiratori fev1 measur arteri echocardiographi catheter copd rest steadyst rais arteri pap twice rest copd live climb stair walk transient copd satur fall rem sleep pap rise hg exacerb copd pap rise hg return recoveri pathophysiolog copd copd prompt search osa pe attribut copd copd advers affect exacerb unfortun copd meet ltot ltot revers pap normal discoveri rational consid vasodil posse antiprolif statin vasodil statin copd promis mild mpap hg warrant success vasodil depend hyperinfl success moder mpap hg hyperinfl play ictlc copd mpap 45 hg concomit ipah warrant vasodil worthwhil tri copd mpap hg hyperinfl avoid mild hyperinfl play ictlc pharmacotherapi mpap hg ictlc\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.610\tlimit copd model    obstruct copd cigarett smoke copd characterist airway morpholog infiltr mediat copd cigarett smoke c airway c oxid releas recruit smokeinduc c oxidantsfre radic 4700 huge oxid c form endogen imbal oxid antioxid copd contribut fail translat man fail mind consid c copd mucu bronchial tract aspect copd patholog copd copd restrict mimick characterist copd born mind ass util precis conclus drawn agre copd advanc copd date mimic copd inhal noxiou tracheal instil tissuedegrad emphysemalik genemodifi copdlik mammal paus penh consciou indic airflow obstruct ideal invas gold airwaytissu remodel consid complex copd speciesspecif readout research awar copd histopatholog attempt copd airflow limit mucu hypersecret cough exacerb pharmacolog corticosteroid diminish adrenerg bronchodil benefit accru fundament copd copd unexpect idea promis gain atp tlr inflammasom copd cohort copd phenotyp \n",
            "\t0.610\tlimit copd model    obstruct copd cigarett smoke copd characterist airway morpholog infiltr mediat copd cigarett smoke c airway c oxid releas recruit smokeinduc c oxidantsfre radic 4700 huge oxid c form endogen imbal oxid antioxid copd contribut fail translat man fail mind consid c copd mucu bronchial tract aspect copd patholog copd copd restrict mimick characterist copd born mind ass util precis conclus drawn agre copd advanc copd date mimic copd inhal noxiou tracheal instil tissuedegrad emphysemalik genemodifi copdlik mammal paus penh consciou indic airflow obstruct ideal invas gold airwaytissu remodel consid complex copd speciesspecif readout research awar copd histopatholog attempt copd airflow limit mucu hypersecret cough exacerb pharmacolog corticosteroid diminish adrenerg bronchodil benefit accru fundament copd copd unexpect idea promis gain atp tlr inflammasom copd cohort copd phenotyp \n",
            "\t0.568\tcopd obstruct copd precis moder copd pressur vast copd mild moder copd morbid accur radiograph indic echocardiographi principl noninvas technic copd catheter accur pressur angiogenesi copd vasodil select vasodil inhal nitric oxid phosphodiesteras promis copd routin copdpulmonari introductionprevalencediagnost testingphys examinationchest imagingelectrocardiogramechocardiographyhistopathologypathophysiologypathogenesishypoxiadisturb functionair trappingpolycythemiatox cigarett smokegeneticspathobiologyendotheli dysfunctiongrowth factorsinflammationmanagementsmok cessationsupplement oxygensystem vasodilatorstheophyllinefutur targetssummarycas obstruct copd burden worldwid morbid murray lopez 1997 hurd manifest progress airflow limit hyperinfl air trap hypoxemia hypercapnea elev pressur clinic copd breathless cough sputum exacerb impair portend airflow limit ventilatori hypercapnea burrow earl 1969 weitzenblum 1981 anthonisen 1986 correl neg arteri copd morbid hospit copd exacerb burrow 1972 weitzenblum 1984 kessler barbera copd increasingli recogn contribut manifest morbid copd stimul contribut copd epidemiolog copd manifest pathophysiolog \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.540\ttelemonitor copd   introduction2 methods21 subjects22 measures23 subject change24 analysis25 analysis3 results31 participants32 activity33 behavior34 relat copd day35 awar change4 discussion5 implic  moder copd asymptomat goal copd awar readi start design telemedicin copd copd correspond amount copd employ employ subgroup unemploy expect importantli unemploy copd unemploy employ employ worker employ workforc unemploy work ill job emphas copd socioeconom consequ physic demand job unemploy restrict anymor job plan fun visit therebi employ unemploy temporarili afternoon perform morn relaps afternoon afternoon employ copd inspect copd trend underpin profession advic effici hecht copd ltot sharp afternoon activityonli recoveri afterward even telemedicin balanc distribut improv wellb copd unemploy unemploy part employ differentfromoth morn afternoon even correspond fatigu intens smartphon retrospect analogu seem distinct object subject object copd awar readi awar motiv otherwis unlik run transtheoret subject bpaq copd awar object subject bpaq copd 049 bit 066 back 027 word seem fairli awar object subject part mainten mean regard regularli physic extend think fine mainten seem awar fine situat intent consid focus lifestyl motiv valid measur wireless bluetooth connect sensor smartphon drain batteri devic mean devic run hour oper besid charg sensor experienc charg sensor lengthi consequ hour exclud advanc wireless sensor technolog mobil devic overcom issu telemedicin 6minut walk telemedicin telemedicin consequ implic\n",
            "\t0.540\ttelemonitor copd   introduction2 methods21 subjects22 measures23 subject change24 analysis25 analysis3 results31 participants32 activity33 behavior34 relat copd day35 awar change4 discussion5 implic  moder copd asymptomat goal copd awar readi start design telemedicin copd copd correspond amount copd employ employ subgroup unemploy expect importantli unemploy copd unemploy employ employ worker employ workforc unemploy work ill job emphas copd socioeconom consequ physic demand job unemploy restrict anymor job plan fun visit therebi employ unemploy temporarili afternoon perform morn relaps afternoon afternoon employ copd inspect copd trend underpin profession advic effici hecht copd ltot sharp afternoon activityonli recoveri afterward even telemedicin balanc distribut improv wellb copd unemploy unemploy part employ differentfromoth morn afternoon even correspond fatigu intens smartphon retrospect analogu seem distinct object subject object copd awar readi awar motiv otherwis unlik run transtheoret subject bpaq copd awar object subject bpaq copd 049 bit 066 back 027 word seem fairli awar object subject part mainten mean regard regularli physic extend think fine mainten seem awar fine situat intent consid focus lifestyl motiv valid measur wireless bluetooth connect sensor smartphon drain batteri devic mean devic run hour oper besid charg sensor experienc charg sensor lengthi consequ hour exclud advanc wireless sensor technolog mobil devic overcom issu telemedicin 6minut walk telemedicin telemedicin consequ implic\n",
            "\t-1.161\tcopd copd advers affect exacerb unfortun copd meet term term revers arteri normal discoveri rational consid vasodil posse antiprolif statin  introduction2 prevlenc copd3 signific copd4 pathophysiolog copd41 vasoconstriction42 remodeling43 dysfunction44 inflammation45 destruct bed46 polycythemia47 factors48 hyperinflation5 ventricular copd6 copd61 disproportion ph7 copd71 features72 cpet73 chest xray74 ecg75 echo76 bnp77 exhal nitric oxide78 mri79 chest ct scan710 catheterization8 copd9 copd10 oxygen11 nonspecif vasodilators12 vasodilators121 inhal nitric oxide122 inhal iloprost123 lesson learnt inhal vasodilators124 sildenafil125 bosentan126 lesson learnt vasodil tabl statins14 diuretics15 phlebotomy16 bloodless phlebotomi lvrs18 transplant copd vari 91 depend definit mpap hg copd forc expiratori fev1 measur arteri echocardiographi catheter copd rest steadyst rais arteri pap twice rest copd live climb stair walk transient copd satur fall rem sleep pap rise hg exacerb copd pap rise hg return recoveri pathophysiolog copd copd prompt search osa pe attribut copd copd advers affect exacerb unfortun copd meet ltot ltot revers pap normal discoveri rational consid vasodil posse antiprolif statin vasodil statin copd promis mild mpap hg warrant success vasodil depend hyperinfl success moder mpap hg hyperinfl play ictlc copd mpap 45 hg concomit ipah warrant vasodil worthwhil tri copd mpap hg hyperinfl avoid mild hyperinfl play ictlc pharmacotherapi mpap hg ictlc\n",
            "COPD,O2 None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.419\tzoledron prevent decreas miner undergo androgen blockad zoledron za miner bmd receiv androgen blockad cab firstlin androgen depriv receiv cab candid fortytwo randomli assign receiv za bmd boneturnov crosslink ntelopeptid collagen ntx ctelopeptid collagen ictp bonespecif alkalin phosphatas bap period za maintain bmd tscore differ p0009 invers tscore za za prevent ictp bap ntx suppress tscore za prevent bmd undergo cab bmd  introductionpati methodsstudi participantsstudi designstudi pointssafeti assessmentstatist analysisresultspati characteristicsbmdboneturnov markersadvers eventsdiscussionconclus androgen depriv adt option pca adt pca ahmadi daneshmand adt miner bmd surrog fractur skelet fractur predictor pca oefelein guidelin comprehens european urolog recommend regular bmd pca undergo adt nccn guidelin oncologytm eau guidelin receiv adt actual undergo bmd morgan nadler random zoledron za bmd pca receiv adt smith ryan michaelson isra satoh casey kapoor kachnic lang androgen blockad cab prolong pca gonadotropinreleas hormon agonist gnrh monotherapi akaza adapt cab firstlin adt cab boneturnov castrat yamada za bmd cab adt infus za bmd pca receiv cab firstlin adt za safe toler infus za prevent bmd 1year receiv cab great bmd\n",
            "\t0.383\tcharacter zno nanowir cdo composit nanostructur zno nanowir cdo composit nanostructur fabric twostep involv ammonia solut thermal evapor zno nanowir nw grown si substrat aqueou ammonia solut cdo deposit zno nw thermal evapor cadmium chlorid powder morpholog synthes composit scan electron microscopi xray diffract electron microscopi optic absorb spectrum zno nw cdo composit absorb 550 nm photoluminesc spectrum composit cdorel emiss peak band gap modif zno cdo photocurr zno nw cdo composit photocurr bare zno nw zinc oxidecadmium oxidenanowirescompositesopt absorb introductionexperimentresult discussionconclus zinc oxid zno optoelectron band gap 337 ev highexciton mev semiconductor znse mev gan mev zno nanostructur extens past decad interest optic electr nanostructur uv photodetector sensor photocatalyst solar transistor emiss devic piezoelectr devic zno nanostructur zno nanowir attract welldevelop employ fabric zno nanowir gasphas metalorgan vapor deposit mocvd evapor pulsedlas deposit solutionphas bath deposit cbd electrochem deposit hydrotherm solutionphas appeal temperatur potenti scale capabl produc highdens array zno nanowir array transpar electrod solar devic vertic align electr photoelectr devic zno absorb portion solar spectrum visibl band gap widen useabl wavelength znobas photodevic narrow band gap alloy composit zno principl coupl zno narrow band gap band gap extend absorpt visiblelight electronhol pair separ irradi consequ achiev znobas photodevic heterostructur zno metal semiconductor attract optic photocatalyt cdo vi semiconductor attract consider optoelectron devic electr conduct dope carrier optic transmitt visibl solar spectrum alloy cdo cubic narrow band gap ev band gap zno redshift blue green spectral wang uv nearbandedg emiss redshift 407 nm 304 ev 386 nm 321 ev cd quasialign zncdo nanorod heterostructur zno nanostructur cdo character zno nanowir cdo composit twostep involv solut thermal evapor synthes zno nw cdo composit optic absorb visibl synthes zno nw cdo composit twostep involv ammonia solut thermal evapor sem tem cdo deposit tip zno nanowir xrd composit diffract peak correspond cubic cdo apart hexagon zno zno nw cdo composit optic absorpt extend 550 nm visibl pl band gap modif composit visiblelight absorpt capabl composit enhanc photoelectrochem photocatalyt systemat progress explor\n",
            "\t0.379\tcorrect sequenti conform rearrang flaviviru fusion    chao lh klein schmidt ag pe jm harrison sc 2014 sequenti conform rearrang flaviviru fusion elif e04389 doi 107554elife04389 decemb 2014 notic error unit 6b revis 6b unit constant read ret m read ret matlab script code updat avoid ambigu apolog confus articl correct accordingli \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.023\tzc3hc1 rs11556924 polymorph carotid intimamedia thick rheumatoid arthriti rheumatoid arthriti ra polygen acceler atherosclerosi cv metaanalysi zc3hc1 rs11556924 polymorph coronari arteri cad nonrheumat caucasian polymorph subclin atherosclerosi carotid intimamedia thick cimt ra 502 ra northern spain zc3hc1 rs11556924 polymorph genotyp taqman singlenucleotid polymorph snp genotyp c3128306210 7900ht realtim polymeras cimt carotid ultrasonographi technolog ra carri tt genotyp cimt homozyg cc genotyp deviat sd 076 018 sd 071 016 003 adjust tradit cv 004 evidenc confer zc3hc1 rs11556924 polymorph tradit cv zc3hc1 rs11556924 polymorph subclin atherosclerosi ra  introductionmethodspati protocolgenotypingcarotid ultrasonographi examinationstatist analysisresultsdiscussionconclusionabbreviationscompet interestauthor contributionsauthor rheumatoid arthriti ra cv cv acceler atherosclerosi adequ stratif cv special relev ra besid tradit cv highlight implic polymorph acceler atherosclerosi ra cv prematur ra forward highcv ra cv subclin atherosclerosi ra tradit cv valid noninvas subclin atherosclerosi ra offer opportun relat surrog atherosclerosi carotid intimamedia thick cimt carotid ultrasonographi afford subclin atherosclerosi metaanalysi encompass cimt ra abnorm cimt 090 predict cv ra metaanalysi genomewid coronari arteri cad nonrheumat caucasian locus harbor polymorph patholog cad locus respect variant rs11556924 7q322 encod nonsynonym r363h zc3hc1 zinc finger c3hctype cad nonrheumat caucasian take consider aim zc3hc1 rs11556924 polymorph cv subclin atherosclerosi manifest cimt ra zc3hc1 rs11556924 polymorph subclin atherosclerosi ra abbrevi\n",
            "\t-3.023\tzc3hc1 rs11556924 polymorph carotid intimamedia thick rheumatoid arthriti rheumatoid arthriti ra polygen acceler atherosclerosi cv metaanalysi zc3hc1 rs11556924 polymorph coronari arteri cad nonrheumat caucasian polymorph subclin atherosclerosi carotid intimamedia thick cimt ra 502 ra northern spain zc3hc1 rs11556924 polymorph genotyp taqman singlenucleotid polymorph snp genotyp c3128306210 7900ht realtim polymeras cimt carotid ultrasonographi technolog ra carri tt genotyp cimt homozyg cc genotyp deviat sd 076 018 sd 071 016 003 adjust tradit cv 004 evidenc confer zc3hc1 rs11556924 polymorph tradit cv zc3hc1 rs11556924 polymorph subclin atherosclerosi ra  introductionmethodspati protocolgenotypingcarotid ultrasonographi examinationstatist analysisresultsdiscussionconclusionabbreviationscompet interestauthor contributionsauthor rheumatoid arthriti ra cv cv acceler atherosclerosi adequ stratif cv special relev ra besid tradit cv highlight implic polymorph acceler atherosclerosi ra cv prematur ra forward highcv ra cv subclin atherosclerosi ra tradit cv valid noninvas subclin atherosclerosi ra offer opportun relat surrog atherosclerosi carotid intimamedia thick cimt carotid ultrasonographi afford subclin atherosclerosi metaanalysi encompass cimt ra abnorm cimt 090 predict cv ra metaanalysi genomewid coronari arteri cad nonrheumat caucasian locus harbor polymorph patholog cad locus respect variant rs11556924 7q322 encod nonsynonym r363h zc3hc1 zinc finger c3hctype cad nonrheumat caucasian take consider aim zc3hc1 rs11556924 polymorph cv subclin atherosclerosi manifest cimt ra zc3hc1 rs11556924 polymorph subclin atherosclerosi ra abbrevi\n",
            "\t-4.142\tzinc finger c3hctype zc3hc1 rs11556924 variant finnish tamrisk genomewid zinc finger c3hctype zc3hc1 polymorph coronari arteri cad proprotein convertas subtilisinkexin pcsk9 cad lowdens lipoprotein ldl finnish 50yearold 325 hypertens 444 nonhypertens tamper genotyp zc3hc1 rs11556924 pcsk9 rs11206510 polymorph competit allel subpopul age 45 zc3hc1 rs11556924 genotyp cc tallel carrier 0013 pcsk9 rs11206510 genotyp ttgenotyp cholesterol 0044 ldl 0029 callel zc3hc1 rs11556924 50yearold pcsk9 rs11206510 confirm cholesterol  introductionmethodsparticipantsdna genotypingstatist analysisresultsdiscuss genomewid gwa gwa coronari arteri cad disturb contribut atherogenesi lowdens lipoprotein ldl largest gwa cad cardiogram wellknown stand encod ldl proprotein convertas subtilisinkexin pcsk9 ldl atherosclerosi locus atherosclerosi zinc finger c3hctype zc3hc1 rs11556924 polymorph zc3hc1 call partner alk zc3hc1 mammalian e3 ligas regul mitot entri carcinogenesi constitut oncogen gwa cad address zc3hc1 rs11556924 carotid intimamedia thick cimt cad epidemiolog atherosclerosi tend diminish want pcsk9 rs11206510 zc3hc1 rs11556924 finnish 50yearold analyz cohort tamper tamrisk variant zc3hc1 rs11556924 7q322 encod nonsynonym substitut r363h zc3hc1 zc3hc1 rs11556924 callel cad european accord genotyp cc welldocu tamrisk finland 48 64yearold systol read 140 hg europ heredit contrari percent behind explain candidategen gwa variat zc3hc1 zc3hc1 monitor time mitot entri carcinogenesi oncogen pezmej rheumatoid arthriti carri zc3hc1 rs11556924 ttgenotyp cimt homozyg ccgenotyp cimt subclin atherosclerosi zc3hc1 run atherosclerosi somewhat ccgenotyp schunkert callel cad promot arteri stiff smooth vsmc hypertrophi vsmc polyploidi extens vsmc polyploidi phenomenon hypertens zc3hc1 contributor mitot theoret reentri sought phenotyp variat pcsk9 protea cholesterol control ldl ldlr consequ ldl pcsk9 acceler hepat ldlr inactiv pcsk9 theoret ldl pcsk9 lossoffunct ldl cholesterol variat cad accordingli african american lossoffunct pcsk9 mgdl ldlc 90 coronari middl ldl cholesterol replic snp rs11206510 minor callel ldl cholesterol italian replic ttgenotyp cad restrict resid citi finland pose broadli appli restrict pool finnish caucasian extrapol zc3hc1 rs11556924 polymorph tamrisk confirm pcsk9 snp rs11206510 cholesterol\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.419\tzoledron prevent decreas miner undergo androgen blockad zoledron za miner bmd receiv androgen blockad cab firstlin androgen depriv receiv cab candid fortytwo randomli assign receiv za bmd boneturnov crosslink ntelopeptid collagen ntx ctelopeptid collagen ictp bonespecif alkalin phosphatas bap period za maintain bmd tscore differ p0009 invers tscore za za prevent ictp bap ntx suppress tscore za prevent bmd undergo cab bmd  introductionpati methodsstudi participantsstudi designstudi pointssafeti assessmentstatist analysisresultspati characteristicsbmdboneturnov markersadvers eventsdiscussionconclus androgen depriv adt option pca adt pca ahmadi daneshmand adt miner bmd surrog fractur skelet fractur predictor pca oefelein guidelin comprehens european urolog recommend regular bmd pca undergo adt nccn guidelin oncologytm eau guidelin receiv adt actual undergo bmd morgan nadler random zoledron za bmd pca receiv adt smith ryan michaelson isra satoh casey kapoor kachnic lang androgen blockad cab prolong pca gonadotropinreleas hormon agonist gnrh monotherapi akaza adapt cab firstlin adt cab boneturnov castrat yamada za bmd cab adt infus za bmd pca receiv cab firstlin adt za safe toler infus za prevent bmd 1year receiv cab great bmd\n",
            "\t0.383\tcharacter zno nanowir cdo composit nanostructur zno nanowir cdo composit nanostructur fabric twostep involv ammonia solut thermal evapor zno nanowir nw grown si substrat aqueou ammonia solut cdo deposit zno nw thermal evapor cadmium chlorid powder morpholog synthes composit scan electron microscopi xray diffract electron microscopi optic absorb spectrum zno nw cdo composit absorb 550 nm photoluminesc spectrum composit cdorel emiss peak band gap modif zno cdo photocurr zno nw cdo composit photocurr bare zno nw zinc oxidecadmium oxidenanowirescompositesopt absorb introductionexperimentresult discussionconclus zinc oxid zno optoelectron band gap 337 ev highexciton mev semiconductor znse mev gan mev zno nanostructur extens past decad interest optic electr nanostructur uv photodetector sensor photocatalyst solar transistor emiss devic piezoelectr devic zno nanostructur zno nanowir attract welldevelop employ fabric zno nanowir gasphas metalorgan vapor deposit mocvd evapor pulsedlas deposit solutionphas bath deposit cbd electrochem deposit hydrotherm solutionphas appeal temperatur potenti scale capabl produc highdens array zno nanowir array transpar electrod solar devic vertic align electr photoelectr devic zno absorb portion solar spectrum visibl band gap widen useabl wavelength znobas photodevic narrow band gap alloy composit zno principl coupl zno narrow band gap band gap extend absorpt visiblelight electronhol pair separ irradi consequ achiev znobas photodevic heterostructur zno metal semiconductor attract optic photocatalyt cdo vi semiconductor attract consider optoelectron devic electr conduct dope carrier optic transmitt visibl solar spectrum alloy cdo cubic narrow band gap ev band gap zno redshift blue green spectral wang uv nearbandedg emiss redshift 407 nm 304 ev 386 nm 321 ev cd quasialign zncdo nanorod heterostructur zno nanostructur cdo character zno nanowir cdo composit twostep involv solut thermal evapor synthes zno nw cdo composit optic absorb visibl synthes zno nw cdo composit twostep involv ammonia solut thermal evapor sem tem cdo deposit tip zno nanowir xrd composit diffract peak correspond cubic cdo apart hexagon zno zno nw cdo composit optic absorpt extend 550 nm visibl pl band gap modif composit visiblelight absorpt capabl composit enhanc photoelectrochem photocatalyt systemat progress explor\n",
            "\t0.379\tcorrect sequenti conform rearrang flaviviru fusion    chao lh klein schmidt ag pe jm harrison sc 2014 sequenti conform rearrang flaviviru fusion elif e04389 doi 107554elife04389 decemb 2014 notic error unit 6b revis 6b unit constant read ret m read ret matlab script code updat avoid ambigu apolog confus articl correct accordingli \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.023\tzc3hc1 rs11556924 polymorph carotid intimamedia thick rheumatoid arthriti rheumatoid arthriti ra polygen acceler atherosclerosi cv metaanalysi zc3hc1 rs11556924 polymorph coronari arteri cad nonrheumat caucasian polymorph subclin atherosclerosi carotid intimamedia thick cimt ra 502 ra northern spain zc3hc1 rs11556924 polymorph genotyp taqman singlenucleotid polymorph snp genotyp c3128306210 7900ht realtim polymeras cimt carotid ultrasonographi technolog ra carri tt genotyp cimt homozyg cc genotyp deviat sd 076 018 sd 071 016 003 adjust tradit cv 004 evidenc confer zc3hc1 rs11556924 polymorph tradit cv zc3hc1 rs11556924 polymorph subclin atherosclerosi ra  introductionmethodspati protocolgenotypingcarotid ultrasonographi examinationstatist analysisresultsdiscussionconclusionabbreviationscompet interestauthor contributionsauthor rheumatoid arthriti ra cv cv acceler atherosclerosi adequ stratif cv special relev ra besid tradit cv highlight implic polymorph acceler atherosclerosi ra cv prematur ra forward highcv ra cv subclin atherosclerosi ra tradit cv valid noninvas subclin atherosclerosi ra offer opportun relat surrog atherosclerosi carotid intimamedia thick cimt carotid ultrasonographi afford subclin atherosclerosi metaanalysi encompass cimt ra abnorm cimt 090 predict cv ra metaanalysi genomewid coronari arteri cad nonrheumat caucasian locus harbor polymorph patholog cad locus respect variant rs11556924 7q322 encod nonsynonym r363h zc3hc1 zinc finger c3hctype cad nonrheumat caucasian take consider aim zc3hc1 rs11556924 polymorph cv subclin atherosclerosi manifest cimt ra zc3hc1 rs11556924 polymorph subclin atherosclerosi ra abbrevi\n",
            "\t-3.023\tzc3hc1 rs11556924 polymorph carotid intimamedia thick rheumatoid arthriti rheumatoid arthriti ra polygen acceler atherosclerosi cv metaanalysi zc3hc1 rs11556924 polymorph coronari arteri cad nonrheumat caucasian polymorph subclin atherosclerosi carotid intimamedia thick cimt ra 502 ra northern spain zc3hc1 rs11556924 polymorph genotyp taqman singlenucleotid polymorph snp genotyp c3128306210 7900ht realtim polymeras cimt carotid ultrasonographi technolog ra carri tt genotyp cimt homozyg cc genotyp deviat sd 076 018 sd 071 016 003 adjust tradit cv 004 evidenc confer zc3hc1 rs11556924 polymorph tradit cv zc3hc1 rs11556924 polymorph subclin atherosclerosi ra  introductionmethodspati protocolgenotypingcarotid ultrasonographi examinationstatist analysisresultsdiscussionconclusionabbreviationscompet interestauthor contributionsauthor rheumatoid arthriti ra cv cv acceler atherosclerosi adequ stratif cv special relev ra besid tradit cv highlight implic polymorph acceler atherosclerosi ra cv prematur ra forward highcv ra cv subclin atherosclerosi ra tradit cv valid noninvas subclin atherosclerosi ra offer opportun relat surrog atherosclerosi carotid intimamedia thick cimt carotid ultrasonographi afford subclin atherosclerosi metaanalysi encompass cimt ra abnorm cimt 090 predict cv ra metaanalysi genomewid coronari arteri cad nonrheumat caucasian locus harbor polymorph patholog cad locus respect variant rs11556924 7q322 encod nonsynonym r363h zc3hc1 zinc finger c3hctype cad nonrheumat caucasian take consider aim zc3hc1 rs11556924 polymorph cv subclin atherosclerosi manifest cimt ra zc3hc1 rs11556924 polymorph subclin atherosclerosi ra abbrevi\n",
            "\t-4.142\tzinc finger c3hctype zc3hc1 rs11556924 variant finnish tamrisk genomewid zinc finger c3hctype zc3hc1 polymorph coronari arteri cad proprotein convertas subtilisinkexin pcsk9 cad lowdens lipoprotein ldl finnish 50yearold 325 hypertens 444 nonhypertens tamper genotyp zc3hc1 rs11556924 pcsk9 rs11206510 polymorph competit allel subpopul age 45 zc3hc1 rs11556924 genotyp cc tallel carrier 0013 pcsk9 rs11206510 genotyp ttgenotyp cholesterol 0044 ldl 0029 callel zc3hc1 rs11556924 50yearold pcsk9 rs11206510 confirm cholesterol  introductionmethodsparticipantsdna genotypingstatist analysisresultsdiscuss genomewid gwa gwa coronari arteri cad disturb contribut atherogenesi lowdens lipoprotein ldl largest gwa cad cardiogram wellknown stand encod ldl proprotein convertas subtilisinkexin pcsk9 ldl atherosclerosi locus atherosclerosi zinc finger c3hctype zc3hc1 rs11556924 polymorph zc3hc1 call partner alk zc3hc1 mammalian e3 ligas regul mitot entri carcinogenesi constitut oncogen gwa cad address zc3hc1 rs11556924 carotid intimamedia thick cimt cad epidemiolog atherosclerosi tend diminish want pcsk9 rs11206510 zc3hc1 rs11556924 finnish 50yearold analyz cohort tamper tamrisk variant zc3hc1 rs11556924 7q322 encod nonsynonym substitut r363h zc3hc1 zc3hc1 rs11556924 callel cad european accord genotyp cc welldocu tamrisk finland 48 64yearold systol read 140 hg europ heredit contrari percent behind explain candidategen gwa variat zc3hc1 zc3hc1 monitor time mitot entri carcinogenesi oncogen pezmej rheumatoid arthriti carri zc3hc1 rs11556924 ttgenotyp cimt homozyg ccgenotyp cimt subclin atherosclerosi zc3hc1 run atherosclerosi somewhat ccgenotyp schunkert callel cad promot arteri stiff smooth vsmc hypertrophi vsmc polyploidi extens vsmc polyploidi phenomenon hypertens zc3hc1 contributor mitot theoret reentri sought phenotyp variat pcsk9 protea cholesterol control ldl ldlr consequ ldl pcsk9 acceler hepat ldlr inactiv pcsk9 theoret ldl pcsk9 lossoffunct ldl cholesterol variat cad accordingli african american lossoffunct pcsk9 mgdl ldlc 90 coronari middl ldl cholesterol replic snp rs11206510 minor callel ldl cholesterol italian replic ttgenotyp cad restrict resid citi finland pose broadli appli restrict pool finnish caucasian extrapol zc3hc1 rs11556924 polymorph tamrisk confirm pcsk9 snp rs11206510 cholesterol\n",
            "CAD,Zosyn None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.474\tmodel oxygen reoxygen implic oxygen microenviron theoret determin oxygen simul power characteris microscop accur model oxygen take tumour make characteris oxygen aim discus model oxygen reoxygen implic  introduction2 origin hypoxia3 intravascular transport4 models5 model parameters6 model hypoxia7 oxygen model oxygen microenviron hypoxia oxygen restrain necrosi angiogenesi aggress quantif oxygen topic oncolog consequ measur oxygen employ polarograph fluoresc radionuclid magnet reson qualit correl invas sampl resolut signific perspect theoret determin oxygen simul practic characteris microscop aim discus model oxygen reoxygen implic \n",
            "\t0.439\thighflow nasal cannula oxygen volum co remov critic ill hypoxem preliminari   introductionmethodsresultsconclus highflow nasal cannula hfnc increasingli hypoxem nonintub clinic hfnc decreas dyspnea improv comfort improv oxygen enhanc clearanc upper airway secret preliminari aim measur hfnc ga exchang volum inspiratori effort hypoxem nonintub critic ill nonintub hypoxem critic ill hfnc improv oxygen endexpiratori aerat hfnc reduc inspiratori effort minut ventil maintain arteri co tension\n",
            "\t0.421\t14cmisonidazol hypox v79 spheroid metabolisminduc 14clabel misonidazol miso hypox v79 multicel spheroid quantit autoradiographi hypoxia determin maxim hypox bound miso rapidli necrot centr spheroid rapidli oxygen chronic hypox edg necrot centr spheroid maxim hypox n2 radiosensit chronic hypox consequ intermedi oxygen bind miso consider hypox tumour explain simplest o2 diffus invok o2 diffus gradient spheroid    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.587\toxygen hypoxia scarc noninvas decad oxygen leveldepend magnet reson boldmri detect deoxyhemoglobin hypox power oxygen noninvas overview boldmri ckd cortic medullari oxygen furosemid blocker reninangiotensin alter sodium underlin sodium handl oxygen boldmri convincingli oxygen chronic ckd chronic clarifi discrep unravel oxygen ckd  introduction2 determin oxygenation3 oxygen boldmri4 oxygen hypertension5 oxygen disease6 antihypertens oxygenation7 conclus perspect burden affect billion worldwid coronari cerebrovascular accid tightli entangl ckd abnorm persist glomerular filtrat gfr mlmin173 irrespect ckd hypertens ckd account endstag esrd ckd cluster obes share lowgrad sodium retent reninangiotensin kidney culprit transplant follow kidney extrem remov kidney transplant cure resist hypoxia cortic medullari hypoxia document translat cautious hamper noninvas allow oxygen focus determin oxygen actual point hypoxia ckd boldmri open excit oxygen noninvas oxygen furosemid dietari sodium sodium handl determin oxygen convincingli oxygen ckd boldmri enough simpli oxygen assumpt oxygen vari oxygen alway hold kidney profound arterioven shunt nonetheless valid excel shortterm oxygen suboptim simul adapt decad whatev truth boldmri radiolog function noninvas merit full clinician certainli unravel oxygen ckd\n",
            "\t0.969\t14cmisonidazol hypox v79 spheroid metabolisminduc 14clabel misonidazol miso hypox v79 multicel spheroid quantit autoradiographi hypoxia determin maxim hypox bound miso rapidli necrot centr spheroid rapidli oxygen chronic hypox edg necrot centr spheroid maxim hypox n2 radiosensit chronic hypox consequ intermedi oxygen bind miso consider hypox tumour explain simplest o2 diffus invok o2 diffus gradient spheroid    \n",
            "\t-1.760\tanaemia anaesthet implic anaemia haemoglobin hb gmdl qualit defici hb red circul o2 carri compensatori output co pao diphosphoglycer rightward shift dissoci curv odc viscos erythropoietin get degre maintain oxygen offset decreas arteri parturi concomit ongo loss get decompens seriou consequ angina hypoxemia anaemia preoper aim ass anaemia concept accept hb vari compens threat bleed ongo loss anaesthet consider minim interf optim partial arteri anaesthesia region anaesthesia employ judici adequaci perfus oxygen vital organ hypoxia hyperventil hypothermia acidosi shift odc avoid co avert aggress anaemiaanaesthet considerationscompensatori mechanismspregn introductiondefinit anaemiaclassif anaemiaphysiolog haematolog pertin anaemiapathophysiolog anaemiaanaesthet considerationspreop assessmentminim accept hb preoper transfusionchoic anaesthesiaspeci situationssickl diseasethalassaemiaconclus estim 6575 anaemia pregnant india nearli half death anaemia south asian 80 contribut india anaesthet implic anaemia compensatori optim oxygen maintain fine balanc compensatori adequ oxygen parturi region anaesthesia judici ass adequaci perfus oxygen magnitud ongo loss deleteri hypoxemia threat loss periop anticip adequ\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.474\tmodel oxygen reoxygen implic oxygen microenviron theoret determin oxygen simul power characteris microscop accur model oxygen take tumour make characteris oxygen aim discus model oxygen reoxygen implic  introduction2 origin hypoxia3 intravascular transport4 models5 model parameters6 model hypoxia7 oxygen model oxygen microenviron hypoxia oxygen restrain necrosi angiogenesi aggress quantif oxygen topic oncolog consequ measur oxygen employ polarograph fluoresc radionuclid magnet reson qualit correl invas sampl resolut signific perspect theoret determin oxygen simul practic characteris microscop aim discus model oxygen reoxygen implic \n",
            "\t0.439\thighflow nasal cannula oxygen volum co remov critic ill hypoxem preliminari   introductionmethodsresultsconclus highflow nasal cannula hfnc increasingli hypoxem nonintub clinic hfnc decreas dyspnea improv comfort improv oxygen enhanc clearanc upper airway secret preliminari aim measur hfnc ga exchang volum inspiratori effort hypoxem nonintub critic ill nonintub hypoxem critic ill hfnc improv oxygen endexpiratori aerat hfnc reduc inspiratori effort minut ventil maintain arteri co tension\n",
            "\t0.421\t14cmisonidazol hypox v79 spheroid metabolisminduc 14clabel misonidazol miso hypox v79 multicel spheroid quantit autoradiographi hypoxia determin maxim hypox bound miso rapidli necrot centr spheroid rapidli oxygen chronic hypox edg necrot centr spheroid maxim hypox n2 radiosensit chronic hypox consequ intermedi oxygen bind miso consider hypox tumour explain simplest o2 diffus invok o2 diffus gradient spheroid    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.587\toxygen hypoxia scarc noninvas decad oxygen leveldepend magnet reson boldmri detect deoxyhemoglobin hypox power oxygen noninvas overview boldmri ckd cortic medullari oxygen furosemid blocker reninangiotensin alter sodium underlin sodium handl oxygen boldmri convincingli oxygen chronic ckd chronic clarifi discrep unravel oxygen ckd  introduction2 determin oxygenation3 oxygen boldmri4 oxygen hypertension5 oxygen disease6 antihypertens oxygenation7 conclus perspect burden affect billion worldwid coronari cerebrovascular accid tightli entangl ckd abnorm persist glomerular filtrat gfr mlmin173 irrespect ckd hypertens ckd account endstag esrd ckd cluster obes share lowgrad sodium retent reninangiotensin kidney culprit transplant follow kidney extrem remov kidney transplant cure resist hypoxia cortic medullari hypoxia document translat cautious hamper noninvas allow oxygen focus determin oxygen actual point hypoxia ckd boldmri open excit oxygen noninvas oxygen furosemid dietari sodium sodium handl determin oxygen convincingli oxygen ckd boldmri enough simpli oxygen assumpt oxygen vari oxygen alway hold kidney profound arterioven shunt nonetheless valid excel shortterm oxygen suboptim simul adapt decad whatev truth boldmri radiolog function noninvas merit full clinician certainli unravel oxygen ckd\n",
            "\t0.969\t14cmisonidazol hypox v79 spheroid metabolisminduc 14clabel misonidazol miso hypox v79 multicel spheroid quantit autoradiographi hypoxia determin maxim hypox bound miso rapidli necrot centr spheroid rapidli oxygen chronic hypox edg necrot centr spheroid maxim hypox n2 radiosensit chronic hypox consequ intermedi oxygen bind miso consider hypox tumour explain simplest o2 diffus invok o2 diffus gradient spheroid    \n",
            "\t-1.760\tanaemia anaesthet implic anaemia haemoglobin hb gmdl qualit defici hb red circul o2 carri compensatori output co pao diphosphoglycer rightward shift dissoci curv odc viscos erythropoietin get degre maintain oxygen offset decreas arteri parturi concomit ongo loss get decompens seriou consequ angina hypoxemia anaemia preoper aim ass anaemia concept accept hb vari compens threat bleed ongo loss anaesthet consider minim interf optim partial arteri anaesthesia region anaesthesia employ judici adequaci perfus oxygen vital organ hypoxia hyperventil hypothermia acidosi shift odc avoid co avert aggress anaemiaanaesthet considerationscompensatori mechanismspregn introductiondefinit anaemiaclassif anaemiaphysiolog haematolog pertin anaemiapathophysiolog anaemiaanaesthet considerationspreop assessmentminim accept hb preoper transfusionchoic anaesthesiaspeci situationssickl diseasethalassaemiaconclus estim 6575 anaemia pregnant india nearli half death anaemia south asian 80 contribut india anaesthet implic anaemia compensatori optim oxygen maintain fine balanc compensatori adequ oxygen parturi region anaesthesia judici ass adequaci perfus oxygen magnitud ongo loss deleteri hypoxemia threat loss periop anticip adequ\n",
            "chronic hypoxemia,oxygen None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.458\tvalid ass reliabl held statstripxpress lactat meter lactat amniot fluid lactat amniot fluid ass woman labour experienc labour dystocia reliabl amniot fluid lactat bedsid clinic held statstripxpreass lactat meter nova biomed analys abx pentra 400 horiba lactat triplic quantiti thaw amniot fluid spike lactat substrat 62 mmoll ldh12 kit roch sui yield predetermin lactat triplic deme regress linear agreement bland altman plot pair agreement blandaltman plot held meter lab instrument mmoll sd mmoll limit agreement 69 mmoll 49 mmoll deme regress coeffici slope agreement 091 sd 021 amniot fluid lactat statstripxpress held meter reliabl measur lactat amniot fluid  rational backgroundstudi methodseth consentvalid amniot fluid lactat measurementfindingsvalid lactat pro accur amniot fluid lactatediscussionconclus  valid establish proof principl statstripxpress meter commerci product measur lactat reliabl lactat amniot fluid\n",
            "\t0.448\tmyeliti angiostrongylu cantonensi    32yearold man juli headach paresthesia upper limb weak admiss eaten inadequ cook pomacea canaliculata white count 6700mm mild eosinophilia 78 523mm lumbar punctur open 220 160 eosinophil cerebrospin fluid csf cultur circul antigen cag angiostrongylu cantonensi doubl sandwich enzymelink immunosorb elisa 864 crossreact serum parasit help spinal magnet reson mri lesion intens cervic spinal cord sagitt transvers t2weight t2wi figur admiss lesion cervic spinal cord hyperintens sagitt t2wi lesion cervic spinal cord hyperintens transvers t2wi present examin angiostrongyliasi albendazol dexamethason headach paresthesia resolv spinalcord complet resolv 1month figur abnorm sagitt t2wi complet disappear abnorm sagitt t2wi complet disappear \n",
            "\t0.439\tdevelopment venou anomali asymmetr basal ganglion calcif development venou anomali dva lesion formerli venou angioma dva drain parenchyma parenchym abnorm surround dva unilater putamen caudat calcif drainag territori dva deep venou drainag dva superfici deep venou drainag basal ganglion calcif emphas dva unilater basal ganglion calcif  introduction2 presentation21 1an 85yearold longstand tension headach underw mri postcontrast axial t1weight mri reveal dva putamen focal narrow collector vein drainag superfici vein arrow axial gradientrecal echo t2 bilater globu pallidi unilater putamen caudat ct axial gradientrecal echo t2 correspond calcification22 2an 81yearold man dementia basal ganglion hyperdens ct suspici hematoma maximum intens project magnet reson venographi dva lentiform nucleu collector vein development venou anomali drain intern cerebr vein susceptibilityweight reveal bilater lentiform nucleu appar domin comput tomographi demonstr susceptibilityweight correspond calcification3 discus development venou anomali dva lesion formerli venou angioma dva drain parenchyma parenchym abnorm surround dva unilater putamen caudat calcif drainag territori dva deep venou drainag unilater putamen caudat calcif superfici drain dva asymmetr lentiform nucleu calcif accompani deep drain dva calcif dva regardless drainag emphas dva unilater basal ganglion calcif dva malform occur discov incident contrastenhanc mri consid dva embryolog venou drainag radial orient dilat vein drain parenchyma typic liken caput medusa collector vein drain superfici deep venou dva asymptomat headach seizur focal neurolog deficit claim dva parenchym surround dva locoregion atrophi white matter cavern malform cm dystroph calcif surround third dva 125 subjac fluidattenu invers recoveri flair abnorm dehkharghani unilater caudat putamen calcif dva drainag territori believ venou abnorm outflow stenosi collector vein venou dva venou frank stenosi collector vein progress thicken hyalin wall dva vessel complianc venou venou bring ischemia edema microhemorrhag gliosi dystroph calcif atrophi cm repeat microhemorrhag surround dva unilater caudat putamen calcif dva deep venou drainag occurr dystroph calcif drainag territori dva drain deep venou drain superfici venou explain venou former deep venou drainag hemorrhag arterioven malform intranid contrari drainag superfici venou narrow collector vein drainag superfici venou note reliabl angiographi 3d t1weigt post imag nevertheless postul narrow collector vein venou venou congest parenchym dystroph calcif repres unilater putamen caudat calcif territori dva drain superfici venou calcif regardless drainag dva concept venou caus parenchym surround dva bilater punctat basal ganglion calcif involv globu pallidi symmetr 03 frequent elderli abnorm calciumphosph balanc ischem toxic reason bilater calcif corpu striatum unilater corpu striatum calcif includ unilater neoplasm calcif irregular basal ganglion calcif coars circumscrib regular infecti neoplast ct choic calcif notic mri scan routin gre swi dva incident routin mri scan swi agent expect increasingli unilater asymmetr domin corpu striatum calcif notic routin gre swi imag becom know calcif dva unilater caudat putamen calcif drainag territori dva rare postul venou outflow restrict collector vein parenchym dystroph calcif calcif recogn mri routin gre swi great awar entiti avoid unnecessari workup reliev anxieti\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.855\ttypeb lactic acidosi progress myeloma 64yearold ladi immunoglobul lambda myeloma typeb lactic acidosi la multiorgan associ myeloma end immin highlight discus typeb la progress emphas intens support myeloma  pyruvatenadhh lactatenadcas reportdiscuss lactic 051 mmoll lactic accumul util lactic acidosi lactat mmoll ma physiolog lactic acidosi classifi categori typea la typeb la typea la perfus oxygen lactat hypovolemia sepsi cardiopulmonari arrest diminish util lactat thiamin defici typeb la perfus oxygen hepat mellitu malign toxin inborn error lactat link typeb la malign leukemia lymphoma describ myeloma typeb la highlight prognost background la myeloma neoplasm abnorm creatinin hypercalcemia anion gap highdens lipoprotein cholesterol bilirubin erythrocyt sediment acidosi acidosi attribut insuffici proxim distal tubular acidosi typea la glycolyt characterist hallmark malign glycolyt lactic occurr la hematolog solid malign occurr la malign overproduct lactat glycolyt necrosi thiamin defici malign favor glycolysi abund suppli aerob glycolysi warburg malign overexpress hexokinas lactic predispos la myeloma categori look denomin relaps immunoglobulin subtyp cytogenet variabl say la surrog shorter lactic 12hour rise lactat mmoll multisystem organ summari typeb la evid relapsedrefractori myeloma carri lactic acidosi reflect burden warrant consid typeb la malign anion gap acidosi hemodynam delay burden possibl la modal care bicarbon infus hemodialysi thiamin replac mechan ventil wait\n",
            "\t-5.946\tconstruct recombin eukaryot plasmid calcitonin nih3t3   introduction2 methods21 construct recombin pmd 18tighct vector22 construct recombin pcdna30ighct eukaryot vector23 transfect nih3t3 express lines24 hct rtpcr25 hct nih3t3 cells251 immunohistochemistry252 western blotting253 radioimmunoassay26 hct osteoclasts27 analysis3 results31 recombin plasmid pmd 18tighct32 pcdna30igkhct33 hct nih3t3 cells34 hct nih3t3 supernatants35 secret hct osteoclasts4 discus calcitonin 32residu hormon special cparafollicular thyroid gland mammal ultimobranchi gland reptil fish nucleotid translat calcitonin calcitonin regul calcium phosphoru decreas calcium inhibit resorpt calcitonin synthes analog postmenopaus osteoporosi paget spinal stenosi pancreat ulcer elderli osteoporosi threat morbid deterior microarchitectur osteoporosi brittl fractur calcitonin safe osteoporosi antalg calcitonin extract gill salmon pig thyroid gland heterolog resourc expens heterolog calcitonin weak antigen antibodyrel 70 extragastrointestin dursun transient persist nausea experienc diarrhea vomit inject recommend nasal calcitonin reach squamou metaplasia nasal mucou greatli restrict engin calcitonin hct object solut overcom drawback calcitonin purpos construct recombin eukaryot plasmid pcdna30ig hct calcitonin murin ig leader recombin plasmid transfer murin fibroblast nih3t3 recombin hct nih3t3 osteoporosi deterior microarchitectur strength fractur calcitonin reagent osteoporosi antalg believ sct inhibit resorpt reliev nasal calcitonin osteoporosi otherwis calcitonin sharp osteoporosi heterolog calcitonin extract bioactiv calcitonin engin hct calcitonin object optim resolut overcom hct secret synthes cytoplasm nucleotid hct132 lack greatli limit ad murin ig leader hct hct secret supernat synthes cytoplasm cleav avoid influenc hct synthet code ig hct creat ligat oligonucleotid complementari base primer templat amplifi 34 56 34 56 primer templat amplifi primer templat amplifi integr synthes consecut pcr electrophoresi pcdna30ig hct digest hind xba object ig hct success clone ligat eukaryot vector 210 bp fragment correspond ig hct cdna amplifi rtpcr pcdna30igkhcttransfect nih3t3 hct pcdna30ig hcttransfect nih3t3 immunohistolog western blot radioimmunoassay fragment success integr nih3t3 success calcitonin inhibit resorpt osteoclast calcitonin osteoclast primarili osteoclast cocultur supernat pcdna30igkhcttransfect nih3t3 becam crumpl cocultur nontransfect pcdna30transfect nih3t3 profound bioactiv alter morpholog osteoclast peptid posttransl amid terminu great posttransl modif recombin hct eukaryot modif amid calcitonin coupl express amid hctgli nih3t3 obtain amid bioactiv hct microencapsul encapsul implant biocompat select polym insul implant recipi electrolyt metabolit get microencapsul transplant propos secret hct encapsul alginatepolylysinealgin membran microcapsul transplant constantli secret bioactiv hct perioid osteoporosi success construct recombin eukaryot plasmid ig hct hct effect nih3t3 secret supernat murin ig leader secret hct inhibit morpholog primarili osteoclast usag recombin hct osteoporosi\n",
            "\t-6.182\tpamidron postren transplant metaanalysi random pamidron bmd transplant vari consider pamidron graft comprehens search pubm cochran regist embas independ random pamidron evalu transplant cochran handbook systemat review 502 lumbar spine femor neck bmd creatinin calcium intact parathyroid hormon ipth fix random random evalu 281 hundr fortyfour pamidron 137 pamidron lumbar spine standard smd 2462 1625 3299 pamidron femor neck bmd smd 353 184 890 creatinin calcium ipth pamidron creatinin smd 3101 533 089 calcium smd 218 08 516 ipth smd 006 019 031 heterogen calcium ipth creatinin metaanalysi benefici pamidron bmd alter graft transplant heterogen preclud creatinin pamidron  introductionmethodsliteratur searchstudi selectionstudi qualitydata extractionstatist analysisresultsliteratur searchflow diagraminclud trialsdescript metaanalysisquantit analysisforest plot lumbar spine femor neck bmd changeforest plot creatinin calcium ipthbon fractur effectsgraft immunosuppressiondiscussionsupport transplant option endstag esrd bmd pretransplant immunosuppress hyperparathyroid adynam transplant reject smerud 05 femur ultradist radiu bmd lost success transplant pamidron bisphosphon bp prevent treat posttranspl osteodystrophi pamidron reduc reabsorpt turnov bmd maintain improv reduc fractur compar pamidron tradit vitamin calcium pamidron effect protect posttranspl pamidron transplant vari consider pamidron graft posttranspl recipi complet lee pamidron attenu postren transplant metaanalys topic nitrogencontain bp alendron pamidron preferenti skeleton suppress resorpt paget metastat osteolyt hypercalcemia malign glucocorticoidinduc osteoporosi recipi transplant continu undergo persist posttranspl osteoporosi guidelin transplant recommend vitamin calcium supplement contraind bp posttranspl pamidroant transplant preemptiv prophylaxi posttranspl osteoporosi metaanalysi bp mention recommend guidelin metaanalysi pamidron lumbar spine femor neck heterogen pamidron cancel cortic cortic osteoclast seem unaffect bp possibl account bmd lumbar spine femor neck boyc parathyroid hormon 34 plu risedron superior hpth 34 plu 25oh prevent osteoporosi cortic envelop ipth pamidron appar protect pamidron femor neck pamidron transplant calcium ipth pamidron bp alendron detriment slight creatinin heterogen characterist homogen creatinin pamidron dosag durat contribut heterogen articl pool creatini interpret caution creatin pamidron remain optim bmd predict easi administ withdraw infus pamidron welltoler longlast alendron gastrointestin sudden withdraw none seriou pamidron pamidron sometim fever flulik start socal postdos transient predominantli intraven pamidron proinflammatori jaw osteonecrosi atyp femor fractur pamidron remain transplant recipi torregrosa dose pamidron mg iv transplant turnov regimen administ regimen turnov ipth osteocalcin oc procollagen propeptid pinp termin crosslink telopeptid collagen sctx bonespecif alkalin phosphatas bsap monitor remodel reabsorpt torregrosa pinp ctx pamidron remodel pinp ctx fall initi pamidron recov start continu slight pamidron except ipth observ ipth pamidron biomark turnov remodel ctx urin pinp oc indic valid metaanalysi roschger cancel cortic strengthen bp alendron pamidron fouryear pamidron femor neck oneyear ariticl introduc bia multicent random term action pamidron metaanalysi pamidron administ toler seriou benefici transplant confirm conclus monitor turnov\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.458\tvalid ass reliabl held statstripxpress lactat meter lactat amniot fluid lactat amniot fluid ass woman labour experienc labour dystocia reliabl amniot fluid lactat bedsid clinic held statstripxpreass lactat meter nova biomed analys abx pentra 400 horiba lactat triplic quantiti thaw amniot fluid spike lactat substrat 62 mmoll ldh12 kit roch sui yield predetermin lactat triplic deme regress linear agreement bland altman plot pair agreement blandaltman plot held meter lab instrument mmoll sd mmoll limit agreement 69 mmoll 49 mmoll deme regress coeffici slope agreement 091 sd 021 amniot fluid lactat statstripxpress held meter reliabl measur lactat amniot fluid  rational backgroundstudi methodseth consentvalid amniot fluid lactat measurementfindingsvalid lactat pro accur amniot fluid lactatediscussionconclus  valid establish proof principl statstripxpress meter commerci product measur lactat reliabl lactat amniot fluid\n",
            "\t0.448\tmyeliti angiostrongylu cantonensi    32yearold man juli headach paresthesia upper limb weak admiss eaten inadequ cook pomacea canaliculata white count 6700mm mild eosinophilia 78 523mm lumbar punctur open 220 160 eosinophil cerebrospin fluid csf cultur circul antigen cag angiostrongylu cantonensi doubl sandwich enzymelink immunosorb elisa 864 crossreact serum parasit help spinal magnet reson mri lesion intens cervic spinal cord sagitt transvers t2weight t2wi figur admiss lesion cervic spinal cord hyperintens sagitt t2wi lesion cervic spinal cord hyperintens transvers t2wi present examin angiostrongyliasi albendazol dexamethason headach paresthesia resolv spinalcord complet resolv 1month figur abnorm sagitt t2wi complet disappear abnorm sagitt t2wi complet disappear \n",
            "\t0.439\tdevelopment venou anomali asymmetr basal ganglion calcif development venou anomali dva lesion formerli venou angioma dva drain parenchyma parenchym abnorm surround dva unilater putamen caudat calcif drainag territori dva deep venou drainag dva superfici deep venou drainag basal ganglion calcif emphas dva unilater basal ganglion calcif  introduction2 presentation21 1an 85yearold longstand tension headach underw mri postcontrast axial t1weight mri reveal dva putamen focal narrow collector vein drainag superfici vein arrow axial gradientrecal echo t2 bilater globu pallidi unilater putamen caudat ct axial gradientrecal echo t2 correspond calcification22 2an 81yearold man dementia basal ganglion hyperdens ct suspici hematoma maximum intens project magnet reson venographi dva lentiform nucleu collector vein development venou anomali drain intern cerebr vein susceptibilityweight reveal bilater lentiform nucleu appar domin comput tomographi demonstr susceptibilityweight correspond calcification3 discus development venou anomali dva lesion formerli venou angioma dva drain parenchyma parenchym abnorm surround dva unilater putamen caudat calcif drainag territori dva deep venou drainag unilater putamen caudat calcif superfici drain dva asymmetr lentiform nucleu calcif accompani deep drain dva calcif dva regardless drainag emphas dva unilater basal ganglion calcif dva malform occur discov incident contrastenhanc mri consid dva embryolog venou drainag radial orient dilat vein drain parenchyma typic liken caput medusa collector vein drain superfici deep venou dva asymptomat headach seizur focal neurolog deficit claim dva parenchym surround dva locoregion atrophi white matter cavern malform cm dystroph calcif surround third dva 125 subjac fluidattenu invers recoveri flair abnorm dehkharghani unilater caudat putamen calcif dva drainag territori believ venou abnorm outflow stenosi collector vein venou dva venou frank stenosi collector vein progress thicken hyalin wall dva vessel complianc venou venou bring ischemia edema microhemorrhag gliosi dystroph calcif atrophi cm repeat microhemorrhag surround dva unilater caudat putamen calcif dva deep venou drainag occurr dystroph calcif drainag territori dva drain deep venou drain superfici venou explain venou former deep venou drainag hemorrhag arterioven malform intranid contrari drainag superfici venou narrow collector vein drainag superfici venou note reliabl angiographi 3d t1weigt post imag nevertheless postul narrow collector vein venou venou congest parenchym dystroph calcif repres unilater putamen caudat calcif territori dva drain superfici venou calcif regardless drainag dva concept venou caus parenchym surround dva bilater punctat basal ganglion calcif involv globu pallidi symmetr 03 frequent elderli abnorm calciumphosph balanc ischem toxic reason bilater calcif corpu striatum unilater corpu striatum calcif includ unilater neoplasm calcif irregular basal ganglion calcif coars circumscrib regular infecti neoplast ct choic calcif notic mri scan routin gre swi dva incident routin mri scan swi agent expect increasingli unilater asymmetr domin corpu striatum calcif notic routin gre swi imag becom know calcif dva unilater caudat putamen calcif drainag territori dva rare postul venou outflow restrict collector vein parenchym dystroph calcif calcif recogn mri routin gre swi great awar entiti avoid unnecessari workup reliev anxieti\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.855\ttypeb lactic acidosi progress myeloma 64yearold ladi immunoglobul lambda myeloma typeb lactic acidosi la multiorgan associ myeloma end immin highlight discus typeb la progress emphas intens support myeloma  pyruvatenadhh lactatenadcas reportdiscuss lactic 051 mmoll lactic accumul util lactic acidosi lactat mmoll ma physiolog lactic acidosi classifi categori typea la typeb la typea la perfus oxygen lactat hypovolemia sepsi cardiopulmonari arrest diminish util lactat thiamin defici typeb la perfus oxygen hepat mellitu malign toxin inborn error lactat link typeb la malign leukemia lymphoma describ myeloma typeb la highlight prognost background la myeloma neoplasm abnorm creatinin hypercalcemia anion gap highdens lipoprotein cholesterol bilirubin erythrocyt sediment acidosi acidosi attribut insuffici proxim distal tubular acidosi typea la glycolyt characterist hallmark malign glycolyt lactic occurr la hematolog solid malign occurr la malign overproduct lactat glycolyt necrosi thiamin defici malign favor glycolysi abund suppli aerob glycolysi warburg malign overexpress hexokinas lactic predispos la myeloma categori look denomin relaps immunoglobulin subtyp cytogenet variabl say la surrog shorter lactic 12hour rise lactat mmoll multisystem organ summari typeb la evid relapsedrefractori myeloma carri lactic acidosi reflect burden warrant consid typeb la malign anion gap acidosi hemodynam delay burden possibl la modal care bicarbon infus hemodialysi thiamin replac mechan ventil wait\n",
            "\t-5.946\tconstruct recombin eukaryot plasmid calcitonin nih3t3   introduction2 methods21 construct recombin pmd 18tighct vector22 construct recombin pcdna30ighct eukaryot vector23 transfect nih3t3 express lines24 hct rtpcr25 hct nih3t3 cells251 immunohistochemistry252 western blotting253 radioimmunoassay26 hct osteoclasts27 analysis3 results31 recombin plasmid pmd 18tighct32 pcdna30igkhct33 hct nih3t3 cells34 hct nih3t3 supernatants35 secret hct osteoclasts4 discus calcitonin 32residu hormon special cparafollicular thyroid gland mammal ultimobranchi gland reptil fish nucleotid translat calcitonin calcitonin regul calcium phosphoru decreas calcium inhibit resorpt calcitonin synthes analog postmenopaus osteoporosi paget spinal stenosi pancreat ulcer elderli osteoporosi threat morbid deterior microarchitectur osteoporosi brittl fractur calcitonin safe osteoporosi antalg calcitonin extract gill salmon pig thyroid gland heterolog resourc expens heterolog calcitonin weak antigen antibodyrel 70 extragastrointestin dursun transient persist nausea experienc diarrhea vomit inject recommend nasal calcitonin reach squamou metaplasia nasal mucou greatli restrict engin calcitonin hct object solut overcom drawback calcitonin purpos construct recombin eukaryot plasmid pcdna30ig hct calcitonin murin ig leader recombin plasmid transfer murin fibroblast nih3t3 recombin hct nih3t3 osteoporosi deterior microarchitectur strength fractur calcitonin reagent osteoporosi antalg believ sct inhibit resorpt reliev nasal calcitonin osteoporosi otherwis calcitonin sharp osteoporosi heterolog calcitonin extract bioactiv calcitonin engin hct calcitonin object optim resolut overcom hct secret synthes cytoplasm nucleotid hct132 lack greatli limit ad murin ig leader hct hct secret supernat synthes cytoplasm cleav avoid influenc hct synthet code ig hct creat ligat oligonucleotid complementari base primer templat amplifi 34 56 34 56 primer templat amplifi primer templat amplifi integr synthes consecut pcr electrophoresi pcdna30ig hct digest hind xba object ig hct success clone ligat eukaryot vector 210 bp fragment correspond ig hct cdna amplifi rtpcr pcdna30igkhcttransfect nih3t3 hct pcdna30ig hcttransfect nih3t3 immunohistolog western blot radioimmunoassay fragment success integr nih3t3 success calcitonin inhibit resorpt osteoclast calcitonin osteoclast primarili osteoclast cocultur supernat pcdna30igkhcttransfect nih3t3 becam crumpl cocultur nontransfect pcdna30transfect nih3t3 profound bioactiv alter morpholog osteoclast peptid posttransl amid terminu great posttransl modif recombin hct eukaryot modif amid calcitonin coupl express amid hctgli nih3t3 obtain amid bioactiv hct microencapsul encapsul implant biocompat select polym insul implant recipi electrolyt metabolit get microencapsul transplant propos secret hct encapsul alginatepolylysinealgin membran microcapsul transplant constantli secret bioactiv hct perioid osteoporosi success construct recombin eukaryot plasmid ig hct hct effect nih3t3 secret supernat murin ig leader secret hct inhibit morpholog primarili osteoclast usag recombin hct osteoporosi\n",
            "\t-6.182\tpamidron postren transplant metaanalysi random pamidron bmd transplant vari consider pamidron graft comprehens search pubm cochran regist embas independ random pamidron evalu transplant cochran handbook systemat review 502 lumbar spine femor neck bmd creatinin calcium intact parathyroid hormon ipth fix random random evalu 281 hundr fortyfour pamidron 137 pamidron lumbar spine standard smd 2462 1625 3299 pamidron femor neck bmd smd 353 184 890 creatinin calcium ipth pamidron creatinin smd 3101 533 089 calcium smd 218 08 516 ipth smd 006 019 031 heterogen calcium ipth creatinin metaanalysi benefici pamidron bmd alter graft transplant heterogen preclud creatinin pamidron  introductionmethodsliteratur searchstudi selectionstudi qualitydata extractionstatist analysisresultsliteratur searchflow diagraminclud trialsdescript metaanalysisquantit analysisforest plot lumbar spine femor neck bmd changeforest plot creatinin calcium ipthbon fractur effectsgraft immunosuppressiondiscussionsupport transplant option endstag esrd bmd pretransplant immunosuppress hyperparathyroid adynam transplant reject smerud 05 femur ultradist radiu bmd lost success transplant pamidron bisphosphon bp prevent treat posttranspl osteodystrophi pamidron reduc reabsorpt turnov bmd maintain improv reduc fractur compar pamidron tradit vitamin calcium pamidron effect protect posttranspl pamidron transplant vari consider pamidron graft posttranspl recipi complet lee pamidron attenu postren transplant metaanalys topic nitrogencontain bp alendron pamidron preferenti skeleton suppress resorpt paget metastat osteolyt hypercalcemia malign glucocorticoidinduc osteoporosi recipi transplant continu undergo persist posttranspl osteoporosi guidelin transplant recommend vitamin calcium supplement contraind bp posttranspl pamidroant transplant preemptiv prophylaxi posttranspl osteoporosi metaanalysi bp mention recommend guidelin metaanalysi pamidron lumbar spine femor neck heterogen pamidron cancel cortic cortic osteoclast seem unaffect bp possibl account bmd lumbar spine femor neck boyc parathyroid hormon 34 plu risedron superior hpth 34 plu 25oh prevent osteoporosi cortic envelop ipth pamidron appar protect pamidron femor neck pamidron transplant calcium ipth pamidron bp alendron detriment slight creatinin heterogen characterist homogen creatinin pamidron dosag durat contribut heterogen articl pool creatini interpret caution creatin pamidron remain optim bmd predict easi administ withdraw infus pamidron welltoler longlast alendron gastrointestin sudden withdraw none seriou pamidron pamidron sometim fever flulik start socal postdos transient predominantli intraven pamidron proinflammatori jaw osteonecrosi atyp femor fractur pamidron remain transplant recipi torregrosa dose pamidron mg iv transplant turnov regimen administ regimen turnov ipth osteocalcin oc procollagen propeptid pinp termin crosslink telopeptid collagen sctx bonespecif alkalin phosphatas bsap monitor remodel reabsorpt torregrosa pinp ctx pamidron remodel pinp ctx fall initi pamidron recov start continu slight pamidron except ipth observ ipth pamidron biomark turnov remodel ctx urin pinp oc indic valid metaanalysi roschger cancel cortic strengthen bp alendron pamidron fouryear pamidron femor neck oneyear ariticl introduc bia multicent random term action pamidron metaanalysi pamidron administ toler seriou benefici transplant confirm conclus monitor turnov\n",
            "multiple myeloma,calcitonin,pamidronate None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.403\tp009 persist headach botulinum toxin   backgroundcas reportdiscussionconclus persist headach ndph headach unremit headach abrupt lack typic suggest migrain aura tensiontyp headach selflimit refractori stimulu perform valid botulinum toxin refractori headach ndph written inform consent public\n",
            "\t0.378\tlowdos bisphenol ex heart myocyt femalespecif proarrhythm bisphenol bp increasingli substitut bisphenol bpa bpafre consum good thermal paper bp toxic bp poorli understood sought elucid sexspecif bp heart bp heart electrophysiolog confoc fluoresc immunoblot administ perfus excis heart myocyt heart acut bp catecholamineinduc ventricular arrhythmia markedli bpsexpos heart arrhythmogenictrigg ventricular myocyt myocyt handl spontan sarcoplasm reticulum bp action invert ushap bp myocyt handl estrogen handl ryanodin phospholamban proarrhythm bp heart bp organ myocyt lowdos bp proarrhythm heart organ remark bpa bioactiv bp bpa analog bpa altern consum gao ma chen wang h 2015 lowdos bisphenol ex heart myocyt femalespecif proarrhythm environ perspect 123571 578 httpdxdoiorg101289ehp1408679  introductionmateri methodsresultsdiscussionconclus bisphenol chemic hydroxyphenyl function liao kannan bisphenol manufactur industri bisphenol bpa member polycarbon plastic epoxi resin exampl bpabas contain babi bottl beverag line thermal receipt pipe broad bpa detect bpa urin 90 vandenberg 2012a ye bpa estrogen endocrinedisrupt edc bpa reproduct cv diamantikandaraki melzer zoeller bpa step consum european union ban bpa babi bottl european commiss franc issu ban manufactur sale packag bpa start 2015 legifrancegouvfr bisphenol bp 44 sulfonyldiphenol ca 80091 compos phenol sulfonyl bpa bp increasingli substitut bpa bpafre consum bp thermal paper receipt envelop airlin board pas liao 2012b heat sunlight resist bpa bp leach can contain vi bp widespread 315 urin seven asian 84yearold femal male bp 81 urinari 065 ngml nm liao 2012a bpa bp estrogen grignard hashimoto bpa extens bp bisphenol bp bisphenol bpa epidemiolog bpa cv cv lang melzer bpa cv lakind lowdos bpa rapidli promot arrhythmogenictrigg ventricular myocyt rodent yan ischem bpa arrhythmia heart yan bpa cv bp entir lowdos bp rodent heart myocyt arrhythmogen bp lowdos bp proarrhythm heart involv alter myocyt handl action bp point bpa chemic bp structur bpa substitut share endocrinedisrupt bpa\n",
            "\t0.368\tdefin link biomark postop atrial fibril  editorialsarrhythmia rhythm disordersarrhythmia mechanismsatri fibrillationatri fibril arrhythmia fundingdisclosur support nih hl084583 hl083422 hl114383mohler american mohler william jacquelyn well fund murphi lubber ohio univers scientist support univers fellowship \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.640\tbisphosphon bisphosphon bp synthet analogu pyrophosph inhibit resorpt disrupt resorpt includ postmenopaus osteoporosi glucocorticoidinduc osteoporosi paget malignancyrel bp pharmacokinet pharmacodynam describ pharmacolog mode bp focus controversi surround discus pyrophosphatebon resorptionpostmenopaus osteoporosisglucocorticoidinduc osteoporosispaget’ bonemalignancyrel pharmacokinet bisphosphon bpsstructurepharmacologymod actionclin use bpsbp postmenopaus osteoporosi pmobp glucocorticoid gcinduc osteoporosisbp paget pdbbp oncologyadvers bpsconclus  agre benefici bp fractur osteoporosi pdb oncolog mbd greatli outweigh uncertainti exist optimum situat bp risk bp extrem\n",
            "\t-1.331\tlowdos bisphenol ex heart myocyt femalespecif proarrhythm bisphenol bp increasingli substitut bisphenol bpa bpafre consum good thermal paper bp toxic bp poorli understood sought elucid sexspecif bp heart bp heart electrophysiolog confoc fluoresc immunoblot administ perfus excis heart myocyt heart acut bp catecholamineinduc ventricular arrhythmia markedli bpsexpos heart arrhythmogenictrigg ventricular myocyt myocyt handl spontan sarcoplasm reticulum bp action invert ushap bp myocyt handl estrogen handl ryanodin phospholamban proarrhythm bp heart bp organ myocyt lowdos bp proarrhythm heart organ remark bpa bioactiv bp bpa analog bpa altern consum gao ma chen wang h 2015 lowdos bisphenol ex heart myocyt femalespecif proarrhythm environ perspect 123571 578 httpdxdoiorg101289ehp1408679  introductionmateri methodsresultsdiscussionconclus bisphenol chemic hydroxyphenyl function liao kannan bisphenol manufactur industri bisphenol bpa member polycarbon plastic epoxi resin exampl bpabas contain babi bottl beverag line thermal receipt pipe broad bpa detect bpa urin 90 vandenberg 2012a ye bpa estrogen endocrinedisrupt edc bpa reproduct cv diamantikandaraki melzer zoeller bpa step consum european union ban bpa babi bottl european commiss franc issu ban manufactur sale packag bpa start 2015 legifrancegouvfr bisphenol bp 44 sulfonyldiphenol ca 80091 compos phenol sulfonyl bpa bp increasingli substitut bpa bpafre consum bp thermal paper receipt envelop airlin board pas liao 2012b heat sunlight resist bpa bp leach can contain vi bp widespread 315 urin seven asian 84yearold femal male bp 81 urinari 065 ngml nm liao 2012a bpa bp estrogen grignard hashimoto bpa extens bp bisphenol bp bisphenol bpa epidemiolog bpa cv cv lang melzer bpa cv lakind lowdos bpa rapidli promot arrhythmogenictrigg ventricular myocyt rodent yan ischem bpa arrhythmia heart yan bpa cv bp entir lowdos bp rodent heart myocyt arrhythmogen bp lowdos bp proarrhythm heart involv alter myocyt handl action bp point bpa chemic bp structur bpa substitut share endocrinedisrupt bpa\n",
            "\t-1.832\tbisphenol postmenopaus osteoporosi bishphenol bpa repres endocrin disruptor xenoestrogen object bpa analyz relationship bpa miner bmd biochem postmenopaus osteoporosi 51 enrol measur bpa bmd bpa pearson kruskalw bpa immunosorb elisa bpa bpa 144 052 ngml statist bpa signific bpa clarifi bpa scale bisphenol abon markersbon miner densityosteoporosi introductionsubject methods1 subjects2 methods3 analysisresultsdiscussionconclus bisphenol bpa repres endocrin disruptor interrupt hormon million ton bpa annual manufactur epoxi resin contain packag food beverag polycarbon plastic bpa continu path dust etc measur bpa 9395 urin bpa inappropri estrogen besid pancreat beta interrupt thyroid hormon acceler endocrin semen abnorm brought constantli osteoporosi skelet postmenopaus elderli fractur microstructur deterior date estrogen defici osteoporosi occurr consid estrogen defici osteoporosi occurr xenoestrogen occurr osteoporosi today investig bpa xenoestrogen util suzuki tartrateresist phosphatas trap alkalin phosphatas alp biochem inject bpa experi goldfish scale seidlov wuttk boneform boneresorb bpa inject miner bmd investig bpa osteoporosi today object bpa measur bpa osteoporosi analyz relationship bmd biochem emerg endocrin disruptor bpa xenoestrogen bpa correl bpa bmd biochem investig warrant\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.403\tp009 persist headach botulinum toxin   backgroundcas reportdiscussionconclus persist headach ndph headach unremit headach abrupt lack typic suggest migrain aura tensiontyp headach selflimit refractori stimulu perform valid botulinum toxin refractori headach ndph written inform consent public\n",
            "\t0.378\tlowdos bisphenol ex heart myocyt femalespecif proarrhythm bisphenol bp increasingli substitut bisphenol bpa bpafre consum good thermal paper bp toxic bp poorli understood sought elucid sexspecif bp heart bp heart electrophysiolog confoc fluoresc immunoblot administ perfus excis heart myocyt heart acut bp catecholamineinduc ventricular arrhythmia markedli bpsexpos heart arrhythmogenictrigg ventricular myocyt myocyt handl spontan sarcoplasm reticulum bp action invert ushap bp myocyt handl estrogen handl ryanodin phospholamban proarrhythm bp heart bp organ myocyt lowdos bp proarrhythm heart organ remark bpa bioactiv bp bpa analog bpa altern consum gao ma chen wang h 2015 lowdos bisphenol ex heart myocyt femalespecif proarrhythm environ perspect 123571 578 httpdxdoiorg101289ehp1408679  introductionmateri methodsresultsdiscussionconclus bisphenol chemic hydroxyphenyl function liao kannan bisphenol manufactur industri bisphenol bpa member polycarbon plastic epoxi resin exampl bpabas contain babi bottl beverag line thermal receipt pipe broad bpa detect bpa urin 90 vandenberg 2012a ye bpa estrogen endocrinedisrupt edc bpa reproduct cv diamantikandaraki melzer zoeller bpa step consum european union ban bpa babi bottl european commiss franc issu ban manufactur sale packag bpa start 2015 legifrancegouvfr bisphenol bp 44 sulfonyldiphenol ca 80091 compos phenol sulfonyl bpa bp increasingli substitut bpa bpafre consum bp thermal paper receipt envelop airlin board pas liao 2012b heat sunlight resist bpa bp leach can contain vi bp widespread 315 urin seven asian 84yearold femal male bp 81 urinari 065 ngml nm liao 2012a bpa bp estrogen grignard hashimoto bpa extens bp bisphenol bp bisphenol bpa epidemiolog bpa cv cv lang melzer bpa cv lakind lowdos bpa rapidli promot arrhythmogenictrigg ventricular myocyt rodent yan ischem bpa arrhythmia heart yan bpa cv bp entir lowdos bp rodent heart myocyt arrhythmogen bp lowdos bp proarrhythm heart involv alter myocyt handl action bp point bpa chemic bp structur bpa substitut share endocrinedisrupt bpa\n",
            "\t0.368\tdefin link biomark postop atrial fibril  editorialsarrhythmia rhythm disordersarrhythmia mechanismsatri fibrillationatri fibril arrhythmia fundingdisclosur support nih hl084583 hl083422 hl114383mohler american mohler william jacquelyn well fund murphi lubber ohio univers scientist support univers fellowship \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.640\tbisphosphon bisphosphon bp synthet analogu pyrophosph inhibit resorpt disrupt resorpt includ postmenopaus osteoporosi glucocorticoidinduc osteoporosi paget malignancyrel bp pharmacokinet pharmacodynam describ pharmacolog mode bp focus controversi surround discus pyrophosphatebon resorptionpostmenopaus osteoporosisglucocorticoidinduc osteoporosispaget’ bonemalignancyrel pharmacokinet bisphosphon bpsstructurepharmacologymod actionclin use bpsbp postmenopaus osteoporosi pmobp glucocorticoid gcinduc osteoporosisbp paget pdbbp oncologyadvers bpsconclus  agre benefici bp fractur osteoporosi pdb oncolog mbd greatli outweigh uncertainti exist optimum situat bp risk bp extrem\n",
            "\t-1.331\tlowdos bisphenol ex heart myocyt femalespecif proarrhythm bisphenol bp increasingli substitut bisphenol bpa bpafre consum good thermal paper bp toxic bp poorli understood sought elucid sexspecif bp heart bp heart electrophysiolog confoc fluoresc immunoblot administ perfus excis heart myocyt heart acut bp catecholamineinduc ventricular arrhythmia markedli bpsexpos heart arrhythmogenictrigg ventricular myocyt myocyt handl spontan sarcoplasm reticulum bp action invert ushap bp myocyt handl estrogen handl ryanodin phospholamban proarrhythm bp heart bp organ myocyt lowdos bp proarrhythm heart organ remark bpa bioactiv bp bpa analog bpa altern consum gao ma chen wang h 2015 lowdos bisphenol ex heart myocyt femalespecif proarrhythm environ perspect 123571 578 httpdxdoiorg101289ehp1408679  introductionmateri methodsresultsdiscussionconclus bisphenol chemic hydroxyphenyl function liao kannan bisphenol manufactur industri bisphenol bpa member polycarbon plastic epoxi resin exampl bpabas contain babi bottl beverag line thermal receipt pipe broad bpa detect bpa urin 90 vandenberg 2012a ye bpa estrogen endocrinedisrupt edc bpa reproduct cv diamantikandaraki melzer zoeller bpa step consum european union ban bpa babi bottl european commiss franc issu ban manufactur sale packag bpa start 2015 legifrancegouvfr bisphenol bp 44 sulfonyldiphenol ca 80091 compos phenol sulfonyl bpa bp increasingli substitut bpa bpafre consum bp thermal paper receipt envelop airlin board pas liao 2012b heat sunlight resist bpa bp leach can contain vi bp widespread 315 urin seven asian 84yearold femal male bp 81 urinari 065 ngml nm liao 2012a bpa bp estrogen grignard hashimoto bpa extens bp bisphenol bp bisphenol bpa epidemiolog bpa cv cv lang melzer bpa cv lakind lowdos bpa rapidli promot arrhythmogenictrigg ventricular myocyt rodent yan ischem bpa arrhythmia heart yan bpa cv bp entir lowdos bp rodent heart myocyt arrhythmogen bp lowdos bp proarrhythm heart involv alter myocyt handl action bp point bpa chemic bp structur bpa substitut share endocrinedisrupt bpa\n",
            "\t-1.832\tbisphenol postmenopaus osteoporosi bishphenol bpa repres endocrin disruptor xenoestrogen object bpa analyz relationship bpa miner bmd biochem postmenopaus osteoporosi 51 enrol measur bpa bmd bpa pearson kruskalw bpa immunosorb elisa bpa bpa 144 052 ngml statist bpa signific bpa clarifi bpa scale bisphenol abon markersbon miner densityosteoporosi introductionsubject methods1 subjects2 methods3 analysisresultsdiscussionconclus bisphenol bpa repres endocrin disruptor interrupt hormon million ton bpa annual manufactur epoxi resin contain packag food beverag polycarbon plastic bpa continu path dust etc measur bpa 9395 urin bpa inappropri estrogen besid pancreat beta interrupt thyroid hormon acceler endocrin semen abnorm brought constantli osteoporosi skelet postmenopaus elderli fractur microstructur deterior date estrogen defici osteoporosi occurr consid estrogen defici osteoporosi occurr xenoestrogen occurr osteoporosi today investig bpa xenoestrogen util suzuki tartrateresist phosphatas trap alkalin phosphatas alp biochem inject bpa experi goldfish scale seidlov wuttk boneform boneresorb bpa inject miner bmd investig bpa osteoporosi today object bpa measur bpa osteoporosi analyz relationship bmd biochem emerg endocrin disruptor bpa xenoestrogen bpa correl bpa bmd biochem investig warrant\n",
            "BPH None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t1.708\tcomputeraid cad    cad place prompt alert reader reader decid initi commerci cad prompt 94 984 microcalcif 89 mass prompt miss prompt 52 77 evalu cad extrapol assum reader respond appropri everi correct prompt initi recal real reader rang fals prompt uk reader dismiss 1000 fals prompt everi true prompt decis make discrimin investig miss reader dismiss true prompt cad read recal offset reimburs cad read uk cad technolog improv shortli benefici uk unproven \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\t0.537\tobstruct catheterdiagnos coronari arteri    sir comorbid regard obstruct copd coronari arteri cad exist share name cigarett copd cad comorbid affect cad socioeconom cad hypercholesterolemia copd affect next copd project epidemiolog copd hardli relat estim copd catheterdiagnos cad likelihood copd cad comorbid sudan developingworld countri crosssect consecut catheterdiagnos cad recruit center khartoum sudan sudan centr elshaab teach 6month start august ethic approv administr ethic committe sudan centr gave inform consent take interview basic demograph spirometri electron spiromet spida micromed england maneuv explain subject read record height nearest centimet record nearest kilogram calcul black diagnos guidelin initi obstruct copd assign person fev1 80 59 catheterdiagnos cad 59 spirometri fev1 80 copd demograph cad copd comorbid cad comorbid cad copd comorbid 73 64 smoker 38 cad seventythre percent copd cad singlevessel 66 cad multiplevessel demograph spirometrydiagnos copd copd cad characterist copd cad cad 29 72 sd 46 43 73 59 41 smoker 64 38 singlevessel 73 34 multiplevessel 66 cad concomit copd cad copd comorbid exist regard explain recruit cad catheter developingworld countri epidemiologyrel cad copd nevertheless record enough warrant copd catheterproven cad epidemiolog bear brunt worldwid cad consequ project cad copd comorbid cad enorm burden disabl expenditur developingworld budget exhaust load treat prevent endem singlevessel cad copd comorbid cad explan bia concomit copd cad cad recruit cathet symptomat catheter largerscal concomit copd affect singlevessel cad percentag smoker cad cad copd comorbid fall figur record epidemiolog survey believ explan cultur denial femal support epidemiolog commun questionnair conclud cultur religi inhibit prevent smoker provid accur habit consid actual smoker nevertheless percentag smoker cad copd comorbid cad comorbid indict cad copd comorbid explan consid firstli passiv ischem copd rule contribut passiv caus copd cad secondli nonsmokingrel copd cad etiolog copd asthma unlik sudan countri catheterproven cad concomit copd enorm burden expenditur budget strain cost combat endem project cad get wors record warrant routin cad copd largerscal trend defin epidemiolog copd precis \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t2.189\tcomput aid cad overview comput aid cad technolog observ oversight fals interpret imag prospect cad assist overview briefli describ metric defin cad  introductionbackgroundclin implement cadhow cad stand improvementactu experiencesummari comput radiologist acquisit ct mri comput radiographi storag pac report ri imag comput approv aid radiologist detect abnorm radiolog exam term comput aid assist refer cad overview term computeraid refer softwar identifi suspici imag bring radiologist fals read radiologist review activ cad softwar reevalu cadmark concern issu final cad fda ce approv film digit mammographi exam chest ct chest radiograph concept comput aid call cad refer softwar radiograph estim likelihood featur repres benign malign technolog approv \n",
            "\t1.708\tcomputeraid cad    cad place prompt alert reader reader decid initi commerci cad prompt 94 984 microcalcif 89 mass prompt miss prompt 52 77 evalu cad extrapol assum reader respond appropri everi correct prompt initi recal real reader rang fals prompt uk reader dismiss 1000 fals prompt everi true prompt decis make discrimin investig miss reader dismiss true prompt cad read recal offset reimburs cad read uk cad technolog improv shortli benefici uk unproven \n",
            "CAD None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.463\tflavon acet faa recombin interleukin2 til2 malign melanoma nitric oxid undergo flavone8acet faa 48 m2 recombin interleukin2 rhil2 618 iu m2 metastat melanoma analys nitrat indic oxid larginin nitric oxid pretreat nitrat 53 microm volunt microm maximum nitrat 190 29 microm 49 655 microm compar faa initi infus rhil2 infus faa maximum nitrat underw remiss partial 368 143 microm 005 progress hypotens doselimit hypotens rise nitrat faa rhil2 nitric oxid mediat cytotox agent    \n",
            "\t0.445\tinhibitori colchicin amylas parotid gland local golgi colchicin inhibit amylas parotid gland delay inabl reach parotid gland empti secretori granul isoproterenol replenish granul inhibit colchicin colchicin concomitantli alter golgi cisterna surround cluster microvesicl incub parotid gland colchicin prolong durat fail alter store amylas stimul isoproterenol inhibit novo synthes colchicinesbind firmli bound fraction homogen microtubular assemblydisassembl microtubul exist parotid gland percent tubulin polymer microtubul parotid gland oppos percent colchicin primarili inhibit secretori away golgi hormonestimul store amylas    \n",
            "\t0.429\tcharacter interleukin il2r killer il2 p64 il2r gamma il2r beta intermediateaffin il2r interleukin il2 killer nk exhibit affin depend subunit lowaffin 55kda alpha intermediateaffin 7075kd beta highaffin bimolecular alpha beta subunit il2 nk il2 document discrep beta intermediateaffin il2 postul intermediateaffin beta limit nk intermedi affin monoclon recogn beta interfer bind il establish 64 kd beta intermediateaffin il molecul term il2r gamma coprecipit beta chain prepar incub il2 undetect immunoprecipit prepar il2 gamma postil2 nk intermedi affin il2 detect gamma 1012 beta chain contrast equal beta gamma yt beta il2 gamma beta immunoprecipit roughli beta intermediateaffin 64kd gamma regul affin il2 beta subunit defin il2 insight wherebi lymphocyt respons il2    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-6.464\trecommend intern clinician endocrinopathi thalassemia adolesc hormon thalassemia    dear sir statement guidelin endocrin thalassemia hormon defici ghd straightforward retard ghd challeng ghd wellb depress mood feel isol alter diminish adipos ghd sign subtl nonspecif univers provoc cumbersom expens ghd gh replac insulinlik factor1 igf1 avoid perform gh diseas norm agecorrel rang intern clinician endocrinopathi thalassemia adolesc iceta promot collect igf1 italian thalassemia tm igf1 ethylenediaminetetraacet chemiluminesc immunometr nichol institut diagnost san juan separ igf1 liaison autoanalyz diasorin spa saluggia itali ngml intra interassay coeffici variat inhous pool 48 71 120 58 48 male 62 52 femal 260 532 femal 208 512 male 644 2248 334 kgm percentil igf1 tm 118 0249 percentil insulinlik factor1 femal male thalassemia iceta conclud recommend gh statur height deviat prolong iron overload osteoporosi igfi deviat igf1 childhoodonset ghd pituitari iron deposit atrophi suggest ghd tm igfi th percentil consider cutoff gh kindest regard thank iceta \n",
            "\t-7.529\thormon sclerosi   introduction2 methods21 subjects22 immunometr assays23 analysis3 results4 discussion5 conclus sclerosi m demyelin nervou unpredict plethora affect heterogen m autorepar remyelin larg m unclear adequaci differ larg remyelin neuroendocrin unrespons insuffici possibl repar focus attract great deal hormon igfi recognis myelin nervou cn unfortun equivoc heterogen larg methodolog bioavail vari phase permiss contrari inadequ microenviron remyelin put confound neurohormon glucocorticoid gh igfi na ve m phase name hc neurolog ond gh cumul disabl igfi notwithstand bias cerebrospin fluid noteworthi correl bias confound sound gh igfi biomark prognost biomark encourag dissect gh igfi m\n",
            "\t-7.855\tneuropilin1 mediat pdgf smooth signal p130 ca nrp1 neuropilin1 coreceptor vegf increasingli implic signal nrp1 vsmc smooth poorli understood aim nrp1 migratori hcasmc coronari arteri smooth pdgf plateletderiv signal nrp1 haosmc aortic smooth hcasmc modifi vsmc c chondroitin sulfaterich olink glycosyl ser 612 hcasmc pdgfbb pdgfaa inhibit nrp1 sirna interf adenovir nrp1 lack adnrp1 nrp1 coimmunoprecipit pdgfr pdgf immunofluoresc stain nrp1 pdgfr coloc vsmc nrp1 sirna inhibit pdgfinduc pdgfr nrp1specif sirna adnrp1 remov c glycan chondroitinas inhibit pdgfbb aa tyrosin adapt p130 ca ca crkassoci substrat signal p130 ca knockdown inhibit hcasmc chemotaxi p130 ca pdgf inhibit chondroitinas adenovir nonglycosylat nrp1s612a inhibit chemotaxi p130 ca nrp1 nrp1 glycosyl mediat pdgfinduc vsmc possibl act coreceptor pdgfr select mobil p130 ca tyrosin  introductionmateri methodsmaterialscel culturecel treatmentsimmunoprecipitationwestern blottingflow cytometryimmunofluoresc stainingtransfect sirnasmutagenesi adenovirusespdgfr assaymigr assaysurfac biotin label affin selectionstatist analysisresultsexpress neuropilinsneuropilin glycosyl vsmc cellsvsmc neuropilin nglycosylatedrol nrp1 hcasmc migrationnrp1 pdgfinduc vsmc chemotaxisoverexpress nrp1 lack cytosol inhibit vsmc chemotaxispdgfr nrp1 associ hcasmcsnrp1 associ pdgfr hcasmcsrol nrp1 pdgfbb chemotact signal p130 ca nrp1 knockdown inhibit pdgfr activationpdgfstimul p130 ca nrp1pdgfbbinduc vsmc chemotaxi p130 ca nrp1 olink glycosyl pdgfinduc vsmc chemotaxisdiscussiononlin datasupplementari nrp1 neuropilin1 transmembran coreceptor pathfind nrp1 sema3a semaphorin 3a member axon guidanc vegf factora 165 vegf angiogen heparinbind plgf2 placent isoform vegfb vegf nrp2 nrp1 44 ident exhibit nervou nrp1 indic nrp1 vegfdepend nrp1 coreceptor vegf form vegf tyrosin vegfr2 vegf 2kdr insert domaincontain vegfr2 signal angiogenesi nrp1 vsmc smooth nrp upregul fgf2 fibroblast pdgf plateletderiv factorbb vsmc nrp1 coimmunoprecipit pdgfbb nrp1 pdgfregul vsmc poorli nrp1 regul pdgf action nrp1 vsmc vsmc nrp1 haosmc aortic smooth hcasmc coronari arteri smooth usual fulllength 130 kda highmolecularmass modifi olink glycosyl importantli nrp1 decreas migratori pdgfbb adenovir nrp1 lack ctermin inhibit pdgfbbinduc nrp1depend signal nrp1 associ pdgfr pdgf hcasmc nrp1 reduc pdgfbb signal p130 ca ca crkassoci substrat adaptor nrp1 invas u87mg glioma pdgfinduc inhibit nonglycosylat nrp1s612a nrp1 nrp1 olink glycosyl vsmc chemotact pdgfbb nrp1 optim pdgf signal p130 ca nrp vsmc vsmc nrp1 regul vsmc poorli understood nrp1 vsmc potent vsmc chemoattract pdgfaa pdgfbb chemotact pdgf signal vsmc p130 ca nrp1 pdgfbbinduc hcasmc support nrp1 sirna nrp1 nrp1 knockdown nrp1 lack cytoplasm nrp1 inhibit hcasmc pdgfaa pdgfbb nrp1 cytoplasm mediat nrp1 construct lack inhibit migratori pdgfbb nrp1 optim signal downstream pdgfr note adnrp1 mark inhibitori pdgfinduc hcasmc nrp1 sirna basal unstimul nrp1 sirna nrp1 exert dominantneg possibl nrp1 cytoplasm partner transduc chemotact sequestr inact pdgf pdgfr possibl chemotact signal nrp1 cytosol domainbind molecul synectin synectin knockdown pdgfbbinduc reach signific interact nrp1 cytoplasm pdgfbb chemotact signal pdgfbb coimmunoprecipit nrp1 convinc pdgfbb bind nrp1 coimmunoprecipit radiolabel pdgfbb paenrp1 pdgfbb bind nrp1 affin preclud nrp1 pdgfbbinduc involv nrp1 pdgfr nrp1 coimmunoprecipit pdgfr hcasmc unabl pdgfr nrp1 preferenti pdgfr pdgfr ligand pdgfbb pdgfaa homodim pdgfab heterodim pdgfbb pdgfaa pdgfr nrp1 optim chemotact signal nrp1 sirnamedi knockdown mark pdgfr pdgfaa modest pdgfbbinduc pdgfr nrp1 knockdown pdgfr pdgfr modest pdgfr nrp1 knockdown think unlik wholli constitut nrp1 pdgfr partli nrp1 pdgf vsmc nrp1 knockdown pdgfaainduc pdgfr pdgfbb unclear pdgfbbinduc pdgfr reflect pdgfbb pdgfr heterodim pdgfr homodim heterodim nrp1 deplet pdgfbb pdgfaa pdgfr differenti heparin note select nrp1 antagonist peptid block vegf nrp1 partial reduc vegfr2 nrp1 vegfr2 pdgfbb stimul p130 ca tyrosin partial inhibit nrp1 knockdown nrp1 pdgfaa stimul p130 ca tyrosin nrp1 knockdown nrp1 sirna pdgfbbstimul signal erk akt p130 ca adapt phosphoryl tyrosin implic associ implic p130 ca mediat pdgfbbdepend chemotact signal p130 ca knockdown inhibit pdgfbb pdgfbb p130 ca tyrosin nrp1depend u87mg glioblastoma unawar pdgfbb p130 ca tyrosin vsmc pdgfbb tyrosin ca member hef1 enhanc filament p130 ca glioblastoma nrp1 select optim pdgfr chemotact signal tyrosin p130 ca unclear exactli nrp1 p130 ca warrant nrp1 vsmc highmolecularmass olink glycosyl enzymat remov csgag vsmc pdgfinduc p130 ca tyrosin nrp1s612a nonmodifi olink glycosyl inhibit pdgfinduc chondroitinas nonselect remov csgag moieti signal possibl attribut nrp1 deglycosyl nrp1s612a reflect dominantneg util overexpress nonmodifi nrp1 pdgf endogen modifi nrp1 nrp1s612a inhibit p130 ca conclud nrp1 csgag modif nrp1 pdgf signal nrp1 csgag particip cellassoci hitherto unrecogn nrp1 pdgf signal hcasmc p130 ca pdgf signal mediat hcasmc ball nrp1 associ pdgfr mediat pdgf signal mesenchym nrp1depend mobil p130 ca tyrosin chemotact vsmc pdgf implic pathophysiolog vsmc atherosclerot lesion restenosi balloon angioplasti instanc neointim thicken contribut vasculoprolif patholog nrp1 neointim vsmc onlin\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.463\tflavon acet faa recombin interleukin2 til2 malign melanoma nitric oxid undergo flavone8acet faa 48 m2 recombin interleukin2 rhil2 618 iu m2 metastat melanoma analys nitrat indic oxid larginin nitric oxid pretreat nitrat 53 microm volunt microm maximum nitrat 190 29 microm 49 655 microm compar faa initi infus rhil2 infus faa maximum nitrat underw remiss partial 368 143 microm 005 progress hypotens doselimit hypotens rise nitrat faa rhil2 nitric oxid mediat cytotox agent    \n",
            "\t0.445\tinhibitori colchicin amylas parotid gland local golgi colchicin inhibit amylas parotid gland delay inabl reach parotid gland empti secretori granul isoproterenol replenish granul inhibit colchicin colchicin concomitantli alter golgi cisterna surround cluster microvesicl incub parotid gland colchicin prolong durat fail alter store amylas stimul isoproterenol inhibit novo synthes colchicinesbind firmli bound fraction homogen microtubular assemblydisassembl microtubul exist parotid gland percent tubulin polymer microtubul parotid gland oppos percent colchicin primarili inhibit secretori away golgi hormonestimul store amylas    \n",
            "\t0.429\tcharacter interleukin il2r killer il2 p64 il2r gamma il2r beta intermediateaffin il2r interleukin il2 killer nk exhibit affin depend subunit lowaffin 55kda alpha intermediateaffin 7075kd beta highaffin bimolecular alpha beta subunit il2 nk il2 document discrep beta intermediateaffin il2 postul intermediateaffin beta limit nk intermedi affin monoclon recogn beta interfer bind il establish 64 kd beta intermediateaffin il molecul term il2r gamma coprecipit beta chain prepar incub il2 undetect immunoprecipit prepar il2 gamma postil2 nk intermedi affin il2 detect gamma 1012 beta chain contrast equal beta gamma yt beta il2 gamma beta immunoprecipit roughli beta intermediateaffin 64kd gamma regul affin il2 beta subunit defin il2 insight wherebi lymphocyt respons il2    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-6.464\trecommend intern clinician endocrinopathi thalassemia adolesc hormon thalassemia    dear sir statement guidelin endocrin thalassemia hormon defici ghd straightforward retard ghd challeng ghd wellb depress mood feel isol alter diminish adipos ghd sign subtl nonspecif univers provoc cumbersom expens ghd gh replac insulinlik factor1 igf1 avoid perform gh diseas norm agecorrel rang intern clinician endocrinopathi thalassemia adolesc iceta promot collect igf1 italian thalassemia tm igf1 ethylenediaminetetraacet chemiluminesc immunometr nichol institut diagnost san juan separ igf1 liaison autoanalyz diasorin spa saluggia itali ngml intra interassay coeffici variat inhous pool 48 71 120 58 48 male 62 52 femal 260 532 femal 208 512 male 644 2248 334 kgm percentil igf1 tm 118 0249 percentil insulinlik factor1 femal male thalassemia iceta conclud recommend gh statur height deviat prolong iron overload osteoporosi igfi deviat igf1 childhoodonset ghd pituitari iron deposit atrophi suggest ghd tm igfi th percentil consider cutoff gh kindest regard thank iceta \n",
            "\t-7.529\thormon sclerosi   introduction2 methods21 subjects22 immunometr assays23 analysis3 results4 discussion5 conclus sclerosi m demyelin nervou unpredict plethora affect heterogen m autorepar remyelin larg m unclear adequaci differ larg remyelin neuroendocrin unrespons insuffici possibl repar focus attract great deal hormon igfi recognis myelin nervou cn unfortun equivoc heterogen larg methodolog bioavail vari phase permiss contrari inadequ microenviron remyelin put confound neurohormon glucocorticoid gh igfi na ve m phase name hc neurolog ond gh cumul disabl igfi notwithstand bias cerebrospin fluid noteworthi correl bias confound sound gh igfi biomark prognost biomark encourag dissect gh igfi m\n",
            "\t-7.855\tneuropilin1 mediat pdgf smooth signal p130 ca nrp1 neuropilin1 coreceptor vegf increasingli implic signal nrp1 vsmc smooth poorli understood aim nrp1 migratori hcasmc coronari arteri smooth pdgf plateletderiv signal nrp1 haosmc aortic smooth hcasmc modifi vsmc c chondroitin sulfaterich olink glycosyl ser 612 hcasmc pdgfbb pdgfaa inhibit nrp1 sirna interf adenovir nrp1 lack adnrp1 nrp1 coimmunoprecipit pdgfr pdgf immunofluoresc stain nrp1 pdgfr coloc vsmc nrp1 sirna inhibit pdgfinduc pdgfr nrp1specif sirna adnrp1 remov c glycan chondroitinas inhibit pdgfbb aa tyrosin adapt p130 ca ca crkassoci substrat signal p130 ca knockdown inhibit hcasmc chemotaxi p130 ca pdgf inhibit chondroitinas adenovir nonglycosylat nrp1s612a inhibit chemotaxi p130 ca nrp1 nrp1 glycosyl mediat pdgfinduc vsmc possibl act coreceptor pdgfr select mobil p130 ca tyrosin  introductionmateri methodsmaterialscel culturecel treatmentsimmunoprecipitationwestern blottingflow cytometryimmunofluoresc stainingtransfect sirnasmutagenesi adenovirusespdgfr assaymigr assaysurfac biotin label affin selectionstatist analysisresultsexpress neuropilinsneuropilin glycosyl vsmc cellsvsmc neuropilin nglycosylatedrol nrp1 hcasmc migrationnrp1 pdgfinduc vsmc chemotaxisoverexpress nrp1 lack cytosol inhibit vsmc chemotaxispdgfr nrp1 associ hcasmcsnrp1 associ pdgfr hcasmcsrol nrp1 pdgfbb chemotact signal p130 ca nrp1 knockdown inhibit pdgfr activationpdgfstimul p130 ca nrp1pdgfbbinduc vsmc chemotaxi p130 ca nrp1 olink glycosyl pdgfinduc vsmc chemotaxisdiscussiononlin datasupplementari nrp1 neuropilin1 transmembran coreceptor pathfind nrp1 sema3a semaphorin 3a member axon guidanc vegf factora 165 vegf angiogen heparinbind plgf2 placent isoform vegfb vegf nrp2 nrp1 44 ident exhibit nervou nrp1 indic nrp1 vegfdepend nrp1 coreceptor vegf form vegf tyrosin vegfr2 vegf 2kdr insert domaincontain vegfr2 signal angiogenesi nrp1 vsmc smooth nrp upregul fgf2 fibroblast pdgf plateletderiv factorbb vsmc nrp1 coimmunoprecipit pdgfbb nrp1 pdgfregul vsmc poorli nrp1 regul pdgf action nrp1 vsmc vsmc nrp1 haosmc aortic smooth hcasmc coronari arteri smooth usual fulllength 130 kda highmolecularmass modifi olink glycosyl importantli nrp1 decreas migratori pdgfbb adenovir nrp1 lack ctermin inhibit pdgfbbinduc nrp1depend signal nrp1 associ pdgfr pdgf hcasmc nrp1 reduc pdgfbb signal p130 ca ca crkassoci substrat adaptor nrp1 invas u87mg glioma pdgfinduc inhibit nonglycosylat nrp1s612a nrp1 nrp1 olink glycosyl vsmc chemotact pdgfbb nrp1 optim pdgf signal p130 ca nrp vsmc vsmc nrp1 regul vsmc poorli understood nrp1 vsmc potent vsmc chemoattract pdgfaa pdgfbb chemotact pdgf signal vsmc p130 ca nrp1 pdgfbbinduc hcasmc support nrp1 sirna nrp1 nrp1 knockdown nrp1 lack cytoplasm nrp1 inhibit hcasmc pdgfaa pdgfbb nrp1 cytoplasm mediat nrp1 construct lack inhibit migratori pdgfbb nrp1 optim signal downstream pdgfr note adnrp1 mark inhibitori pdgfinduc hcasmc nrp1 sirna basal unstimul nrp1 sirna nrp1 exert dominantneg possibl nrp1 cytoplasm partner transduc chemotact sequestr inact pdgf pdgfr possibl chemotact signal nrp1 cytosol domainbind molecul synectin synectin knockdown pdgfbbinduc reach signific interact nrp1 cytoplasm pdgfbb chemotact signal pdgfbb coimmunoprecipit nrp1 convinc pdgfbb bind nrp1 coimmunoprecipit radiolabel pdgfbb paenrp1 pdgfbb bind nrp1 affin preclud nrp1 pdgfbbinduc involv nrp1 pdgfr nrp1 coimmunoprecipit pdgfr hcasmc unabl pdgfr nrp1 preferenti pdgfr pdgfr ligand pdgfbb pdgfaa homodim pdgfab heterodim pdgfbb pdgfaa pdgfr nrp1 optim chemotact signal nrp1 sirnamedi knockdown mark pdgfr pdgfaa modest pdgfbbinduc pdgfr nrp1 knockdown pdgfr pdgfr modest pdgfr nrp1 knockdown think unlik wholli constitut nrp1 pdgfr partli nrp1 pdgf vsmc nrp1 knockdown pdgfaainduc pdgfr pdgfbb unclear pdgfbbinduc pdgfr reflect pdgfbb pdgfr heterodim pdgfr homodim heterodim nrp1 deplet pdgfbb pdgfaa pdgfr differenti heparin note select nrp1 antagonist peptid block vegf nrp1 partial reduc vegfr2 nrp1 vegfr2 pdgfbb stimul p130 ca tyrosin partial inhibit nrp1 knockdown nrp1 pdgfaa stimul p130 ca tyrosin nrp1 knockdown nrp1 sirna pdgfbbstimul signal erk akt p130 ca adapt phosphoryl tyrosin implic associ implic p130 ca mediat pdgfbbdepend chemotact signal p130 ca knockdown inhibit pdgfbb pdgfbb p130 ca tyrosin nrp1depend u87mg glioblastoma unawar pdgfbb p130 ca tyrosin vsmc pdgfbb tyrosin ca member hef1 enhanc filament p130 ca glioblastoma nrp1 select optim pdgfr chemotact signal tyrosin p130 ca unclear exactli nrp1 p130 ca warrant nrp1 vsmc highmolecularmass olink glycosyl enzymat remov csgag vsmc pdgfinduc p130 ca tyrosin nrp1s612a nonmodifi olink glycosyl inhibit pdgfinduc chondroitinas nonselect remov csgag moieti signal possibl attribut nrp1 deglycosyl nrp1s612a reflect dominantneg util overexpress nonmodifi nrp1 pdgf endogen modifi nrp1 nrp1s612a inhibit p130 ca conclud nrp1 csgag modif nrp1 pdgf signal nrp1 csgag particip cellassoci hitherto unrecogn nrp1 pdgf signal hcasmc p130 ca pdgf signal mediat hcasmc ball nrp1 associ pdgfr mediat pdgf signal mesenchym nrp1depend mobil p130 ca tyrosin chemotact vsmc pdgf implic pathophysiolog vsmc atherosclerot lesion restenosi balloon angioplasti instanc neointim thicken contribut vasculoprolif patholog nrp1 neointim vsmc onlin\n",
            "acne,IGF-1,testosterone None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.544\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "\t0.523\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t0.523\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.158\tcalciphylaxi alcohol cirrhosi   reportdisclosur 38yearold woman alcohol cirrhosi admit recurr extrem rash alcohol abus abdomin fatigu violac rash abdomen proxim extrem biopsi vessel calcif outer wall calciphylaxi sodium thiosulf mg intraven weekli serial wound debrid resolut rash recurr pain violac rash deni alcohol receiv albumin infus transfus bmi kgm heal graft note thigh surround tender punctat erythema calcium phosphoru parathyroid hormon creatinin abdomin ct cirrhosi start sodium thiosulf wound respond recurr date pain violac rash extrem calciphylaxi calciphylaxi lifethreaten cutan ischem necrosi calcif exclus endstag cirrhosi calciphylaxi unclear defici corticosteroid albumin transfus calciumphosphoru product clinic calciphylaxi present tender violac mottl progress blacken eschar nonheal ulcer fatcontain trunk genit medial thigh calciphylaxi 52 mostli superimpos sepsi lower calciumphosphoru product antiinflammatori aggress wound sodium thiosulf emerg calciphylaxi act calcium decreas reactiv notabl exhibit calciphylaxi pose calciphylaxi prompt cirrhot present rash \n",
            "\t-1.158\tcalciphylaxi alcohol cirrhosi   reportdisclosur 38yearold woman alcohol cirrhosi admit recurr extrem rash alcohol abus abdomin fatigu violac rash abdomen proxim extrem biopsi vessel calcif outer wall calciphylaxi sodium thiosulf mg intraven weekli serial wound debrid resolut rash recurr pain violac rash deni alcohol receiv albumin infus transfus bmi kgm heal graft note thigh surround tender punctat erythema calcium phosphoru parathyroid hormon creatinin abdomin ct cirrhosi start sodium thiosulf wound respond recurr date pain violac rash extrem calciphylaxi calciphylaxi lifethreaten cutan ischem necrosi calcif exclus endstag cirrhosi calciphylaxi unclear defici corticosteroid albumin transfus calciumphosphoru product clinic calciphylaxi present tender violac mottl progress blacken eschar nonheal ulcer fatcontain trunk genit medial thigh calciphylaxi 52 mostli superimpos sepsi lower calciumphosphoru product antiinflammatori aggress wound sodium thiosulf emerg calciphylaxi act calcium decreas reactiv notabl exhibit calciphylaxi pose calciphylaxi prompt cirrhot present rash \n",
            "\t-4.965\tpolymorph alcohol adh1b aldh2 alcohol colorect colorect crc worldwid epidemiolog crc alcohol metabol acetaldehyd alcohol dehydrogenas oxid acet aldehyd dehydrogenas consequ alcohol analyz snp adh1b aldh2 crc alcohol crc snp adh1b aldh2 alcohol genotyp 1694 crc 1851 match epidemiolog colorect clinicopatholog lifestyl dietari habit logist regress alcohol crc epidemiolog colorect mecc 147 95ci 118181 snp rs1229984 adh1b crc recess 175 aa genotyp 95ci 121252 pvalu 00025 path equat model adh1b polymorph colorect carcinogenesi indirect alcohol polymorph alcohol colorect carcinogenesi ethanol acetaldehyd oxid  introductionmethodspatientslifestyl informationsnp genotypingstatist methodsresultsbaselin populationdistribut particip categori alcohol consumptionalcohol crc riskalcohol snp crc riskassoci polymorph alcohol colorect onlyalcohol snp alcohol consumptionassoci polymorph alcohol alcohol onlypath snp alcohol ethnic crcpolymorph alcohol adh1b aldh2 alcohol colorect path equat model semdiscussionconclusionsupport colorect crc worldwid million half million death everi crc benign adenomat polyp bowel crc veget fruit dietari process meat nonsteroid antiinflammatori hormon replac statin protect lifestyl tobacco alcohol inconclus alcohol modest risk crc differ subtyp anatom alcohol influenc crc understood carcinogen chemic ethanol alcohol beverag nitrosamin solvent facilit absorpt carcinogen ethanol carcinogen genotox acetaldehyd metabolit ethanol carcinogen ethanol carcinogen drink alcohol beverag causal caviti pharynx larynx iarc group1 controversi alcohol colorect acetaldehyd cytotox mutagen carcinogen metabolit ethanol enhanc aberr acetaldehyd bind adduct reactiv ro error oncogen suppressor epigenet alter alcohol metabolit select acetyl histon acetaldehyd ethanol ingest depend ethanol consum allel code ethanolmetabol ethanol metabol acetaldehyd alcohol dehydrogenas adh oxid acet acetaldehyd dehydrogenas aldh file s1 nucleotid polymorph snp adh1b aldh2 encod alcohol variat oxid acetaldehyd polymorph alcohol crc snp alcohol adh1b aldh2 crc alcohol crc populationbas casecontrol israel epidemiolog colorect mecc polymorph rs1229984 adh1b colorect carcinogenesi fail polymorph rs886205 aldh2 valid character adh1b aldh2 polymorph insight contribut crc\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.544\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "\t0.523\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t0.523\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.158\tcalciphylaxi alcohol cirrhosi   reportdisclosur 38yearold woman alcohol cirrhosi admit recurr extrem rash alcohol abus abdomin fatigu violac rash abdomen proxim extrem biopsi vessel calcif outer wall calciphylaxi sodium thiosulf mg intraven weekli serial wound debrid resolut rash recurr pain violac rash deni alcohol receiv albumin infus transfus bmi kgm heal graft note thigh surround tender punctat erythema calcium phosphoru parathyroid hormon creatinin abdomin ct cirrhosi start sodium thiosulf wound respond recurr date pain violac rash extrem calciphylaxi calciphylaxi lifethreaten cutan ischem necrosi calcif exclus endstag cirrhosi calciphylaxi unclear defici corticosteroid albumin transfus calciumphosphoru product clinic calciphylaxi present tender violac mottl progress blacken eschar nonheal ulcer fatcontain trunk genit medial thigh calciphylaxi 52 mostli superimpos sepsi lower calciumphosphoru product antiinflammatori aggress wound sodium thiosulf emerg calciphylaxi act calcium decreas reactiv notabl exhibit calciphylaxi pose calciphylaxi prompt cirrhot present rash \n",
            "\t-1.158\tcalciphylaxi alcohol cirrhosi   reportdisclosur 38yearold woman alcohol cirrhosi admit recurr extrem rash alcohol abus abdomin fatigu violac rash abdomen proxim extrem biopsi vessel calcif outer wall calciphylaxi sodium thiosulf mg intraven weekli serial wound debrid resolut rash recurr pain violac rash deni alcohol receiv albumin infus transfus bmi kgm heal graft note thigh surround tender punctat erythema calcium phosphoru parathyroid hormon creatinin abdomin ct cirrhosi start sodium thiosulf wound respond recurr date pain violac rash extrem calciphylaxi calciphylaxi lifethreaten cutan ischem necrosi calcif exclus endstag cirrhosi calciphylaxi unclear defici corticosteroid albumin transfus calciumphosphoru product clinic calciphylaxi present tender violac mottl progress blacken eschar nonheal ulcer fatcontain trunk genit medial thigh calciphylaxi 52 mostli superimpos sepsi lower calciumphosphoru product antiinflammatori aggress wound sodium thiosulf emerg calciphylaxi act calcium decreas reactiv notabl exhibit calciphylaxi pose calciphylaxi prompt cirrhot present rash \n",
            "\t-4.965\tpolymorph alcohol adh1b aldh2 alcohol colorect colorect crc worldwid epidemiolog crc alcohol metabol acetaldehyd alcohol dehydrogenas oxid acet aldehyd dehydrogenas consequ alcohol analyz snp adh1b aldh2 crc alcohol crc snp adh1b aldh2 alcohol genotyp 1694 crc 1851 match epidemiolog colorect clinicopatholog lifestyl dietari habit logist regress alcohol crc epidemiolog colorect mecc 147 95ci 118181 snp rs1229984 adh1b crc recess 175 aa genotyp 95ci 121252 pvalu 00025 path equat model adh1b polymorph colorect carcinogenesi indirect alcohol polymorph alcohol colorect carcinogenesi ethanol acetaldehyd oxid  introductionmethodspatientslifestyl informationsnp genotypingstatist methodsresultsbaselin populationdistribut particip categori alcohol consumptionalcohol crc riskalcohol snp crc riskassoci polymorph alcohol colorect onlyalcohol snp alcohol consumptionassoci polymorph alcohol alcohol onlypath snp alcohol ethnic crcpolymorph alcohol adh1b aldh2 alcohol colorect path equat model semdiscussionconclusionsupport colorect crc worldwid million half million death everi crc benign adenomat polyp bowel crc veget fruit dietari process meat nonsteroid antiinflammatori hormon replac statin protect lifestyl tobacco alcohol inconclus alcohol modest risk crc differ subtyp anatom alcohol influenc crc understood carcinogen chemic ethanol alcohol beverag nitrosamin solvent facilit absorpt carcinogen ethanol carcinogen genotox acetaldehyd metabolit ethanol carcinogen ethanol carcinogen drink alcohol beverag causal caviti pharynx larynx iarc group1 controversi alcohol colorect acetaldehyd cytotox mutagen carcinogen metabolit ethanol enhanc aberr acetaldehyd bind adduct reactiv ro error oncogen suppressor epigenet alter alcohol metabolit select acetyl histon acetaldehyd ethanol ingest depend ethanol consum allel code ethanolmetabol ethanol metabol acetaldehyd alcohol dehydrogenas adh oxid acet acetaldehyd dehydrogenas aldh file s1 nucleotid polymorph snp adh1b aldh2 encod alcohol variat oxid acetaldehyd polymorph alcohol crc snp alcohol adh1b aldh2 crc alcohol crc populationbas casecontrol israel epidemiolog colorect mecc polymorph rs1229984 adh1b colorect carcinogenesi fail polymorph rs886205 aldh2 valid character adh1b aldh2 polymorph insight contribut crc\n",
            "abdominal pain,CRP,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.414\tcrohn present abdomen abdomen admit intestin obstruct exploratori laparotomi diseas resect segment crohn histopatholog crohn kept present abdomen vagu abdomin complaint crohn diseaseobstructionstricturegangren bowel introductioncas onecas twodiscussionconclus crohn cd gi tract uncommon india come entiti sparingli sign cd overlap abdomin tuberculosi ulcer coliti irrit bowel etc involv git accur armamentarium conserv present intestin obstruct perfor abscess fistula format encourt intestin obstruct requir cd histopatholog rariti curio entiti report cd mimic abdomin kept back mind abdomen intestin patholog\n",
            "\t0.384\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t0.384\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.504\tgastrointestin manifest henochsch nlein purpura intestin lesion henochsch nlein purpura abdomen old boy sudden colicki abdomin purpura pain joint swell manifest abdomin distens hematemesi hematochezia hematuria exploratori laparotomi mark bowel distens edema patchi dark reddish discolor jejunum ileum patchi transmur hemorrhag necrosi characterist leukocytoclast vascul hemorrhag vascul henochsch nlein purpura    \n",
            "\t-3.491\tirrit bowel dysmenorrhea 10year   introduction2 methods21 setting22 questionnaire23 dysmenorrhea24 ibs25 transit final survey26 data27 analysis28 ethics3 results31 demograph individuals32 dysmenorrhea pain menstruation33 dysmenorrhea irrit bowel syndrome34 dysmenorrhea gastrointestin disorders35 dysmenorrhea 1996 menopaus ib abdomin severity36 transit 1996 surveys37 birth dysmenorrhea4 discus irrit bowel ib bowel abdomin discomfort defec bowel habit disord defec bloat sensat incomplet evacu strain constip urgenc diarrhea western seek healthcar irrit bowel ib possibl explain involv gender gonad hormon reactiv sociocultur bowel ib gender complic ration menwomen ib constip nausea bloat extraintestin psycholog ib genderrel gastrointestin somat appar person ib promin postmenopaus abdomin disrupt ib impact ib gender occurr ib cultur psychosoci healthcar issu instead pure physiolog dysmenorrhea 90 dysmenorrhea complaint menstruationassoci spasmod abdomen dysmenorrhea dyspareunia pelvic irrit bowel complaint reproduct consist demograph discomfort period interfer live special monthli pain problemat disabl interfer live inconveni dysmenorrhea enough worsen equal bear populationbas studi ib minor ib seek selfmed note ib nonpati great ib healthcar ib constip hormon ib gastrointestin men menopaus declin ovarian hormon estrogen progesteron withdraw indirectli object connect ib dysmenorrhea 10year object ib menopaus birth dysmenorrhea object connect gastrointestin fgid dyspepsia fd heartburn frequent abdomin fap dysmenorrhea make follow dysmenorrhea tenyear observ fgid dysmenorrhea everi menstruat dysmenorrhea dysmenorrhea ib rome man man rome dysmenorrhea tenyear ib rome man dysmenorrhea rome metaanalysi gastrointestin pre postmenopaus conclud insuffici menopaus ib ib menopaus ib gastrointestin men menopaus declin ovarian hormon estrogen progesteron withdraw indirectli gastrointestin burden postmenopaus mostli disappear dysmenorrhea gastrointestin concurr uterin cramp men nondysmenorrh gastrointestin tend phase ib immedi men fgid dysmenorrh great dysmenorrhea fgid ib abdomin menopaus abdomin disrupt ib transit substanti dysmenorrhea dysmenorrhea remain asymptomat dysmenorrhea fgid dysmenorrh dysmenorrhea menstrual bowel metaanalysi menstrual loo stool bloat abdomin stool bowel habit strength homogen randomli registri iceland repres nation minor ib seek populationbas studi ib iceland 300 thousand inhabit repres countri interview organ 10year postal went make organ unlik contracept lack endometriosi gynaecolog address 67 1996 69 dropout bia exclud respond nonrespond dropout bia\n",
            "\t-3.862\ttrajectori adolesc prospect trajectori describ trajectori adolesc prospect trajectori adolesc 1336 latent carri selfreport back headach stomach facial everi forti percent adolesc pain trajectori persist headach pain trajectori persist back stomach pain trajectori facial pain trajectori report persist trajectori pain trajectori somat satisfact femal trajectori differ bmi agreement trajectori membership moder summari report pain trajectori adolesc persist minor experienc  introductionmethodsstudi sampledata proceduresmeasuresstatist analysisresultsresponsetrajectoriesback trajectoriesfaci trajectoriesheadach trajectoriesstomach trajectoriesclust 3year timeoverlap sitesdiscussionconflict statement ach pain age back rang 45 adolesc elderli throughout adulthood similarli headach rang 51 childrenadolesc 46 42 elderli temporomandibular 44 adolesc stomach adolesc complaint figur illustr episod simpli experienc adulthood tendenc experienc childhood adolesc persist adolesc younger clue throughout live latent modelbas cluster facilit typolog trajectori parallel rise epidemiolog emphasis trajectori model trajectori advantag simpler defin point trajectori recurr fluctuat pain tradit epidemiolog trajectori subgroup cluster back adolesc regular headach neck upper back adolesc trajectori recurr headach stomach ach back ach everi anxietydepress predictor trajectori conclud narrow sampl window frequent studi trajectori adolesc detail predictor elucid begin identifi trajectori ascertain similar trajectori overlap trajectori membership argu epidemiolog similar symptombas unclear person get person get predictor tendenc adolesc trajectori back headach stomach facial overlap trajectori membership uncov adolesc trajectori back facial headach stomach trajectori cluster solut optim facial headach stomach half adolesc probabl frequent throughout 3year trajectori 44 pain trajectori headach back stomach pain trajectori headach quarter classifi pain trajectori facial figur mirror facial headach abdomin back add occurr highlight substanti adolesc fair probabl age persist trajectori depend persist trajectori predominantli somat start satisfi repres substanti adolesc never trajectori probabl incid adolesc trajectori give detail reliabl lcga alloc cluster probabl cluster describ clusterspecif fluctuat simpli point miss fluctuat misclassifi shortterm flareup throughout repres alloc trajectori abnorm enabl age probabl back tendenc back combin pain give represent true burden studi overlap trajectori membership chanc modest minor frequent interest consist cluster except facial persist persist cluster somat cluster somat predict persist disabl contribut debat manifest separ tendenc adolesc persist throughout adulthood experienc pain limb adolesc wish trajectori uniqu present populationbas use cluster trajectori notabl facial cluster mask cluster precis estim cluster back cluster facial cluster probabl experienc rise fall interest conduct separ subgroup male femal insuffici carri race ethnic seattl metropolitan miss point lcga advantag alloc cluster probabl belong miss minimis probabl belong alloc cluster place cluster certainti good fit decid ideal cluster lcga cluster fit cluster occasion miss point origin miss point noninclud tend psycholog scale experienc predictor adolesc particip parent child past bia poorer psycholog trajectori overestim pain trajectori size cluster imagin substanti trajectori trajectori fill gap rais question trajectori adolesc elucid adolesc rais question fit throughout lifecours pain trajectori begin lifelong tendenc verifi frequent adolesc repres begin indic tendenc add symptombas separ manifest consist trajectori similar subject cluster trajectori unclear adolesc back facial add throughout cluster adolesc trajectori back facial headach stomach probabl throughout wors psycholog regardless pain trajectori clinic aim modifi persist similar trajectori cluster implic questionnair standardis valuabl frequent adolesc conflict statement\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.414\tcrohn present abdomen abdomen admit intestin obstruct exploratori laparotomi diseas resect segment crohn histopatholog crohn kept present abdomen vagu abdomin complaint crohn diseaseobstructionstricturegangren bowel introductioncas onecas twodiscussionconclus crohn cd gi tract uncommon india come entiti sparingli sign cd overlap abdomin tuberculosi ulcer coliti irrit bowel etc involv git accur armamentarium conserv present intestin obstruct perfor abscess fistula format encourt intestin obstruct requir cd histopatholog rariti curio entiti report cd mimic abdomin kept back mind abdomen intestin patholog\n",
            "\t0.384\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t0.384\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.504\tgastrointestin manifest henochsch nlein purpura intestin lesion henochsch nlein purpura abdomen old boy sudden colicki abdomin purpura pain joint swell manifest abdomin distens hematemesi hematochezia hematuria exploratori laparotomi mark bowel distens edema patchi dark reddish discolor jejunum ileum patchi transmur hemorrhag necrosi characterist leukocytoclast vascul hemorrhag vascul henochsch nlein purpura    \n",
            "\t-3.491\tirrit bowel dysmenorrhea 10year   introduction2 methods21 setting22 questionnaire23 dysmenorrhea24 ibs25 transit final survey26 data27 analysis28 ethics3 results31 demograph individuals32 dysmenorrhea pain menstruation33 dysmenorrhea irrit bowel syndrome34 dysmenorrhea gastrointestin disorders35 dysmenorrhea 1996 menopaus ib abdomin severity36 transit 1996 surveys37 birth dysmenorrhea4 discus irrit bowel ib bowel abdomin discomfort defec bowel habit disord defec bloat sensat incomplet evacu strain constip urgenc diarrhea western seek healthcar irrit bowel ib possibl explain involv gender gonad hormon reactiv sociocultur bowel ib gender complic ration menwomen ib constip nausea bloat extraintestin psycholog ib genderrel gastrointestin somat appar person ib promin postmenopaus abdomin disrupt ib impact ib gender occurr ib cultur psychosoci healthcar issu instead pure physiolog dysmenorrhea 90 dysmenorrhea complaint menstruationassoci spasmod abdomen dysmenorrhea dyspareunia pelvic irrit bowel complaint reproduct consist demograph discomfort period interfer live special monthli pain problemat disabl interfer live inconveni dysmenorrhea enough worsen equal bear populationbas studi ib minor ib seek selfmed note ib nonpati great ib healthcar ib constip hormon ib gastrointestin men menopaus declin ovarian hormon estrogen progesteron withdraw indirectli object connect ib dysmenorrhea 10year object ib menopaus birth dysmenorrhea object connect gastrointestin fgid dyspepsia fd heartburn frequent abdomin fap dysmenorrhea make follow dysmenorrhea tenyear observ fgid dysmenorrhea everi menstruat dysmenorrhea dysmenorrhea ib rome man man rome dysmenorrhea tenyear ib rome man dysmenorrhea rome metaanalysi gastrointestin pre postmenopaus conclud insuffici menopaus ib ib menopaus ib gastrointestin men menopaus declin ovarian hormon estrogen progesteron withdraw indirectli gastrointestin burden postmenopaus mostli disappear dysmenorrhea gastrointestin concurr uterin cramp men nondysmenorrh gastrointestin tend phase ib immedi men fgid dysmenorrh great dysmenorrhea fgid ib abdomin menopaus abdomin disrupt ib transit substanti dysmenorrhea dysmenorrhea remain asymptomat dysmenorrhea fgid dysmenorrh dysmenorrhea menstrual bowel metaanalysi menstrual loo stool bloat abdomin stool bowel habit strength homogen randomli registri iceland repres nation minor ib seek populationbas studi ib iceland 300 thousand inhabit repres countri interview organ 10year postal went make organ unlik contracept lack endometriosi gynaecolog address 67 1996 69 dropout bia exclud respond nonrespond dropout bia\n",
            "\t-3.862\ttrajectori adolesc prospect trajectori describ trajectori adolesc prospect trajectori adolesc 1336 latent carri selfreport back headach stomach facial everi forti percent adolesc pain trajectori persist headach pain trajectori persist back stomach pain trajectori facial pain trajectori report persist trajectori pain trajectori somat satisfact femal trajectori differ bmi agreement trajectori membership moder summari report pain trajectori adolesc persist minor experienc  introductionmethodsstudi sampledata proceduresmeasuresstatist analysisresultsresponsetrajectoriesback trajectoriesfaci trajectoriesheadach trajectoriesstomach trajectoriesclust 3year timeoverlap sitesdiscussionconflict statement ach pain age back rang 45 adolesc elderli throughout adulthood similarli headach rang 51 childrenadolesc 46 42 elderli temporomandibular 44 adolesc stomach adolesc complaint figur illustr episod simpli experienc adulthood tendenc experienc childhood adolesc persist adolesc younger clue throughout live latent modelbas cluster facilit typolog trajectori parallel rise epidemiolog emphasis trajectori model trajectori advantag simpler defin point trajectori recurr fluctuat pain tradit epidemiolog trajectori subgroup cluster back adolesc regular headach neck upper back adolesc trajectori recurr headach stomach ach back ach everi anxietydepress predictor trajectori conclud narrow sampl window frequent studi trajectori adolesc detail predictor elucid begin identifi trajectori ascertain similar trajectori overlap trajectori membership argu epidemiolog similar symptombas unclear person get person get predictor tendenc adolesc trajectori back headach stomach facial overlap trajectori membership uncov adolesc trajectori back facial headach stomach trajectori cluster solut optim facial headach stomach half adolesc probabl frequent throughout 3year trajectori 44 pain trajectori headach back stomach pain trajectori headach quarter classifi pain trajectori facial figur mirror facial headach abdomin back add occurr highlight substanti adolesc fair probabl age persist trajectori depend persist trajectori predominantli somat start satisfi repres substanti adolesc never trajectori probabl incid adolesc trajectori give detail reliabl lcga alloc cluster probabl cluster describ clusterspecif fluctuat simpli point miss fluctuat misclassifi shortterm flareup throughout repres alloc trajectori abnorm enabl age probabl back tendenc back combin pain give represent true burden studi overlap trajectori membership chanc modest minor frequent interest consist cluster except facial persist persist cluster somat cluster somat predict persist disabl contribut debat manifest separ tendenc adolesc persist throughout adulthood experienc pain limb adolesc wish trajectori uniqu present populationbas use cluster trajectori notabl facial cluster mask cluster precis estim cluster back cluster facial cluster probabl experienc rise fall interest conduct separ subgroup male femal insuffici carri race ethnic seattl metropolitan miss point lcga advantag alloc cluster probabl belong miss minimis probabl belong alloc cluster place cluster certainti good fit decid ideal cluster lcga cluster fit cluster occasion miss point origin miss point noninclud tend psycholog scale experienc predictor adolesc particip parent child past bia poorer psycholog trajectori overestim pain trajectori size cluster imagin substanti trajectori trajectori fill gap rais question trajectori adolesc elucid adolesc rais question fit throughout lifecours pain trajectori begin lifelong tendenc verifi frequent adolesc repres begin indic tendenc add symptombas separ manifest consist trajectori similar subject cluster trajectori unclear adolesc back facial add throughout cluster adolesc trajectori back facial headach stomach probabl throughout wors psycholog regardless pain trajectori clinic aim modifi persist similar trajectori cluster implic questionnair standardis valuabl frequent adolesc conflict statement\n",
            "abdominal pain None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.514\trhiniti sinus ocular 2039 intranas steroid cough upper airway couth   backgroundmethodsresultsconclus upper airway cough uac rhinosinus cough rhinosinus cough object observ cough uac intranas steroid benefici cough uac rhinosinus pn\n",
            "\t0.497\tdyspnea wheez adenosin inject eosinophil bronchiti 58yearold nonsmok refer cough workup cough eosinophil bronchiti workup eosinophil bronchiti bronchial biopsi discus eosinophil bronchiti differenti asthma dyspnea flush wheez adenosin spite methacholin indirect stimulu airway hyperrespons mast eosinophil bronchiti  introduction2 report3 discussion4 eosinophil bronchiti uncommon cough entiti refer 33 nonsmok refer cough eosinophil bronchiti origin gibson 1989 subsequ recogn cough 58yearold cough eosinophil bronchiti complic dyspnea flush wheez adenosin sestamibi eosinophil bronchiti cough referr center share similar asthma eosinophil airway il4 il5 inhal corticosteroid eosinophil bronchiti differ asthma present airway respons airway hyperrespons adenosin eosinophil bronchiti present cough\n",
            "\t0.497\tdyspnea wheez adenosin inject eosinophil bronchiti 58yearold nonsmok refer cough workup cough eosinophil bronchiti workup eosinophil bronchiti bronchial biopsi discus eosinophil bronchiti differenti asthma dyspnea flush wheez adenosin spite methacholin indirect stimulu airway hyperrespons mast eosinophil bronchiti  introduction2 report3 discussion4 eosinophil bronchiti uncommon cough entiti refer 33 nonsmok refer cough eosinophil bronchiti origin gibson 1989 subsequ recogn cough 58yearold cough eosinophil bronchiti complic dyspnea flush wheez adenosin sestamibi eosinophil bronchiti cough referr center share similar asthma eosinophil airway il4 il5 inhal corticosteroid eosinophil bronchiti differ asthma present airway respons airway hyperrespons adenosin eosinophil bronchiti present cough\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t3.234\tcorticosteroid cough servic societ cost present protocol randomis tract lrti manag intern costli antibiot improv uncompl lrti contribut antimicrobi lrti exacerb asthma corticosteroid effect osac steroid cough prednisolon mg moder bad wors cough postrandomis entri lrti present osac twoarm multicentr placebocontrol randomis superior 436 dropout recruit practition surgeri england resolut moder bad wors cough postrandomis antibiot burden particip satisfact intent consult ill parallel econom costeffect osac costeffect corticosteroid lrti establish option substanti chosen enabl decid inhal corticosteroid grow investig ill steroid undesir isrctn57309858 31 januari onlin version articl doi101186s1306301505695 author user  backgroundepidemiolog cost tract infectionrational effect corticosteroid tract infectionrational designresearch questionsprimari questionsecondari questionsmethodsdesigneligibilityinclus criteriaexclus criteriaintervent blindingtreat alloc conceal emerg unblindingoutcomeshow ascertainedprimari measuressecondari measuressampl calculationtri medicinesrecruit sitesresearch ethic governancescreen elig routin consultationtri entri recruit interviewparticip followupdata managementanalysisanalysi outcomesanalysi outcomessubgroup analyseseconom analysisdiscussiontri  describ placebocontrol randomis multicentr superior establish effect corticosteroid entir indic commonest manag lrti recruit 326 436 nonasthmat present cough tract elig consent randomis receiv 5day mg prednisolon match placebo ask diari depend ill telephon weekli cough resolv maximum recruit\n",
            "\t2.451\tcapabl hyperton salin cough provoc predict inhal corticosteroid cough prospect openlabel cough respond inhal corticosteroid predict respond defin capabl hyperton salin cough provoc predict respons inhal corticosteroid cough salin monitor heal cough corticosteroid fortythre cough recruit spirometri ambulatori peak nitric oxid histamin airway salin respond salin repeat nitric oxid visit inhal budesonid 400 ug twice twelv leicest cough questionnair twelv seventyseven leicest cough questionnair symptomat neither magnitud speed salin histamin strongest predict maxim leicest cough questionnair 508 376 640 point histamin 278 155 401 point histamin 0006 nitric oxid leicest cough questionnair 002 cough salin gradual budesonid respond nonrespond nitric oxid rapidli respond salin predict respons inhal corticosteroid cough util monitor regist clinicaltrialsgov databas kuh5801112 clinicaltrialsgov identifi nct00859274 coughinh corticosteroidscough provoc testsairway hyperresponsivenessnitr oxid backgroundmethodssubjectsstudi designleicest cough questionnair definit responseshyperton salin cough provoc teststatist analysisresultsth resultsth budesonid treatmentbaselin predictor budesonid treatmentchang salin cdr budesonid lcq scorediscussionconclusionsabbreviationscompet interestsauthor contribut cough guidelin cough defin direct probabl recommend cough corticosteroidsensit airway object asthma inhal corticosteroid ic cough recommend unsuccess capabl ic valuabl sputum eosinophilia exhal nitric oxid predict twoweek ic cough retrospect predict monthslong ic prospect fail confirm neither methacholin adenosin predict fourweek inhal fluticason 200 ug abovement prospect critic predetermin valid defin cough provoc hyperton aerosol cough provoc tradit cough capsaicin citric capabl stimul sensori cough transient vanilloid subfamili member cough hyperton aerosol involv cough hyperton aerosol asthma ic attenu cough asthma cough hyperton salin correl leicest cough questionnair junip asthma questionnair respons hyperton salin cough provoc regard valid asthmaassoci cough hypothes predict respons ic cough secondli hypothes respons hyperton salin reflect heal cough plan hypothes confirm cough benefit ic respons ic hyperton salin cough provoc nonselect cough respons histamin airway strongest predict featur ic salin monitor antiinflammatori cough pathophysiolog phenomenon complementari heal cough abbrevi\n",
            "\t1.648\tcough asthma cough complaint seek cough variant asthma cva asthma present sole cough cva cough importantli cva unless adequ progress classic asthma cva share pathophysiolog classic asthma atopi airway hyperrespons eosinophil airway airway remodel inhal corticosteroid cva cough classic asthma airway remodel airflow obstruct  introductioncough asthmamucu hypersecret asthma coughcough variant asthmaatop featuresphysiolog featurespatholog featuresdiagnosistreat prognosisdisord cvaconclus cough complaint seek guidelin cough cough last cough asthma airway narrow excess airway hyperrespons ahr eosinophil airway classic asthma airflow obstruct typic wheez dyspnea cough variant asthma origin glauser 1972 subsequ renam corrao cough variant asthma cva cough sole present cva commonest cough worldwid importantli cough wors articl discus subtyp asthma eosinophil airway cva nonasthmat eosinophil bronchiti naeb origin term eosinophil bronchiti asthma atop cough cva cough cva present persist cough inhal corticosteroid cva inhal corticosteroid cough cva wheez airway remodel airflow obstruct\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.514\trhiniti sinus ocular 2039 intranas steroid cough upper airway couth   backgroundmethodsresultsconclus upper airway cough uac rhinosinus cough rhinosinus cough object observ cough uac intranas steroid benefici cough uac rhinosinus pn\n",
            "\t0.497\tdyspnea wheez adenosin inject eosinophil bronchiti 58yearold nonsmok refer cough workup cough eosinophil bronchiti workup eosinophil bronchiti bronchial biopsi discus eosinophil bronchiti differenti asthma dyspnea flush wheez adenosin spite methacholin indirect stimulu airway hyperrespons mast eosinophil bronchiti  introduction2 report3 discussion4 eosinophil bronchiti uncommon cough entiti refer 33 nonsmok refer cough eosinophil bronchiti origin gibson 1989 subsequ recogn cough 58yearold cough eosinophil bronchiti complic dyspnea flush wheez adenosin sestamibi eosinophil bronchiti cough referr center share similar asthma eosinophil airway il4 il5 inhal corticosteroid eosinophil bronchiti differ asthma present airway respons airway hyperrespons adenosin eosinophil bronchiti present cough\n",
            "\t0.497\tdyspnea wheez adenosin inject eosinophil bronchiti 58yearold nonsmok refer cough workup cough eosinophil bronchiti workup eosinophil bronchiti bronchial biopsi discus eosinophil bronchiti differenti asthma dyspnea flush wheez adenosin spite methacholin indirect stimulu airway hyperrespons mast eosinophil bronchiti  introduction2 report3 discussion4 eosinophil bronchiti uncommon cough entiti refer 33 nonsmok refer cough eosinophil bronchiti origin gibson 1989 subsequ recogn cough 58yearold cough eosinophil bronchiti complic dyspnea flush wheez adenosin sestamibi eosinophil bronchiti cough referr center share similar asthma eosinophil airway il4 il5 inhal corticosteroid eosinophil bronchiti differ asthma present airway respons airway hyperrespons adenosin eosinophil bronchiti present cough\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t3.234\tcorticosteroid cough servic societ cost present protocol randomis tract lrti manag intern costli antibiot improv uncompl lrti contribut antimicrobi lrti exacerb asthma corticosteroid effect osac steroid cough prednisolon mg moder bad wors cough postrandomis entri lrti present osac twoarm multicentr placebocontrol randomis superior 436 dropout recruit practition surgeri england resolut moder bad wors cough postrandomis antibiot burden particip satisfact intent consult ill parallel econom costeffect osac costeffect corticosteroid lrti establish option substanti chosen enabl decid inhal corticosteroid grow investig ill steroid undesir isrctn57309858 31 januari onlin version articl doi101186s1306301505695 author user  backgroundepidemiolog cost tract infectionrational effect corticosteroid tract infectionrational designresearch questionsprimari questionsecondari questionsmethodsdesigneligibilityinclus criteriaexclus criteriaintervent blindingtreat alloc conceal emerg unblindingoutcomeshow ascertainedprimari measuressecondari measuressampl calculationtri medicinesrecruit sitesresearch ethic governancescreen elig routin consultationtri entri recruit interviewparticip followupdata managementanalysisanalysi outcomesanalysi outcomessubgroup analyseseconom analysisdiscussiontri  describ placebocontrol randomis multicentr superior establish effect corticosteroid entir indic commonest manag lrti recruit 326 436 nonasthmat present cough tract elig consent randomis receiv 5day mg prednisolon match placebo ask diari depend ill telephon weekli cough resolv maximum recruit\n",
            "\t2.451\tcapabl hyperton salin cough provoc predict inhal corticosteroid cough prospect openlabel cough respond inhal corticosteroid predict respond defin capabl hyperton salin cough provoc predict respons inhal corticosteroid cough salin monitor heal cough corticosteroid fortythre cough recruit spirometri ambulatori peak nitric oxid histamin airway salin respond salin repeat nitric oxid visit inhal budesonid 400 ug twice twelv leicest cough questionnair twelv seventyseven leicest cough questionnair symptomat neither magnitud speed salin histamin strongest predict maxim leicest cough questionnair 508 376 640 point histamin 278 155 401 point histamin 0006 nitric oxid leicest cough questionnair 002 cough salin gradual budesonid respond nonrespond nitric oxid rapidli respond salin predict respons inhal corticosteroid cough util monitor regist clinicaltrialsgov databas kuh5801112 clinicaltrialsgov identifi nct00859274 coughinh corticosteroidscough provoc testsairway hyperresponsivenessnitr oxid backgroundmethodssubjectsstudi designleicest cough questionnair definit responseshyperton salin cough provoc teststatist analysisresultsth resultsth budesonid treatmentbaselin predictor budesonid treatmentchang salin cdr budesonid lcq scorediscussionconclusionsabbreviationscompet interestsauthor contribut cough guidelin cough defin direct probabl recommend cough corticosteroidsensit airway object asthma inhal corticosteroid ic cough recommend unsuccess capabl ic valuabl sputum eosinophilia exhal nitric oxid predict twoweek ic cough retrospect predict monthslong ic prospect fail confirm neither methacholin adenosin predict fourweek inhal fluticason 200 ug abovement prospect critic predetermin valid defin cough provoc hyperton aerosol cough provoc tradit cough capsaicin citric capabl stimul sensori cough transient vanilloid subfamili member cough hyperton aerosol involv cough hyperton aerosol asthma ic attenu cough asthma cough hyperton salin correl leicest cough questionnair junip asthma questionnair respons hyperton salin cough provoc regard valid asthmaassoci cough hypothes predict respons ic cough secondli hypothes respons hyperton salin reflect heal cough plan hypothes confirm cough benefit ic respons ic hyperton salin cough provoc nonselect cough respons histamin airway strongest predict featur ic salin monitor antiinflammatori cough pathophysiolog phenomenon complementari heal cough abbrevi\n",
            "\t1.648\tcough asthma cough complaint seek cough variant asthma cva asthma present sole cough cva cough importantli cva unless adequ progress classic asthma cva share pathophysiolog classic asthma atopi airway hyperrespons eosinophil airway airway remodel inhal corticosteroid cva cough classic asthma airway remodel airflow obstruct  introductioncough asthmamucu hypersecret asthma coughcough variant asthmaatop featuresphysiolog featurespatholog featuresdiagnosistreat prognosisdisord cvaconclus cough complaint seek guidelin cough cough last cough asthma airway narrow excess airway hyperrespons ahr eosinophil airway classic asthma airflow obstruct typic wheez dyspnea cough variant asthma origin glauser 1972 subsequ renam corrao cough variant asthma cva cough sole present cva commonest cough worldwid importantli cough wors articl discus subtyp asthma eosinophil airway cva nonasthmat eosinophil bronchiti naeb origin term eosinophil bronchiti asthma atop cough cva cough cva present persist cough inhal corticosteroid cva inhal corticosteroid cough cva wheez airway remodel airflow obstruct\n",
            "cough,corticosteroids None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.474\tlabelfre antiglucopeptid sclerosi   detailsglucopeptid immobil immobil bufferglucopeptid immobilizationmonitor glucopeptid antigenantibodi protocol optimizationcalibr curv purifi antibodiesspr serum challeng sclerosi setup immunodiagnost gold magnet reson cerebrospin fluid plasmon reson spr success biomolecular cognat antigen antiglucopeptid sclerosi herein enabl labelfre serum glucopeptid term csf114glc profil sclerosi serum enzymelink immunosorb elisa sprbase biosensor evidenc view independ \n",
            "\t0.452\tvitamin antagonist atrial fibril venou thromboembol systemat aid trialist systemat review standardis report atrial fibril af venou thromboembol vte attempt recommend report employ systemat search bibliograph databas june af vte evalu doseadjust vitamin antagonist vka report report sd subgroup standardis extract independ extract disagr resolv separ investig 148 57 meanstudy213 136 spent intern normalis ttr 79 accompani abovebelow 52 af vte 63 37 p0004 mean236 153 0001 observ randomis 76 33 0001 mean258 163 0001 59 p005 mean223 148 p002 ttr utilis vka half lack consist trend report vka horizon af observ  strength studyintroductionmethodsresultsdiscussionconclusionssupplementari materialauthor manuscriptreview comment systemat n148 add exist provid updat consist vitamin antagonist vka report fitzmauric vka indic atrial fibril af vte unlik review systemat vka report report af vte randomis observ explor vka concomitantli vka consist combin trend report vka horizon af observ systemat consider research perform\n",
            "\t0.452\tvitamin antagonist atrial fibril venou thromboembol systemat aid trialist systemat review standardis report atrial fibril af venou thromboembol vte attempt recommend report employ systemat search bibliograph databas june af vte evalu doseadjust vitamin antagonist vka report report sd subgroup standardis extract independ extract disagr resolv separ investig 148 57 meanstudy213 136 spent intern normalis ttr 79 accompani abovebelow 52 af vte 63 37 p0004 mean236 153 0001 observ randomis 76 33 0001 mean258 163 0001 59 p005 mean223 148 p002 ttr utilis vka half lack consist trend report vka horizon af observ  strength studyintroductionmethodsresultsdiscussionconclusionssupplementari materialauthor manuscriptreview comment systemat n148 add exist provid updat consist vitamin antagonist vka report fitzmauric vka indic atrial fibril af vte unlik review systemat vka report report af vte randomis observ explor vka concomitantli vka consist combin trend report vka horizon af observ systemat consider research perform\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-6.620\tdexamethason pul sclerosi viabl proposit kashmir sclerosi multisystem autoimmun intraven dexamethason pul 1998 wasto benefici dexamethason pul sclerosi vi vi fortyseven sclerosi look submit investig score done 6month interv furst organ indic of47 sclerosi 45 femal male acrosclerosi sclerosi contractur moder proteinuria restrict dysphagia valvular seena of13 dexamethason pul tuberculosi score raynaud phenomenon dysphagia restrict benefici dexamethason pul seem mere cosmet  introductionmateri methodsresultsdiscuss sclerosi multisystem autoimmun affect predominantli lung gut kidney fulfil label sclerosi subcommitte scleroderma american rheumatolog criterion sclerosi proxim digit face limb neck trunk minor sclerodactyli digit pit scar bilater zone basal fibrosi option vasodil immunosuppress antifibrot steroid intraven dexamethason pul dp recommend depart dermatolog std leprosi smh teach govern colleg srinagar benefici dexamethason pul sclerosi vi vi ideal sclerosi conjectur univers agreement choic start goal steroid pul immunemedi pemphigu bullou pemphigoid lupu erythmatosu rheumatoid arthriti pyoderma gangrenosum pai dp sclerosi unfortun benefici steroid pul sclerosi masood preliminari dp sclerosi commun depart sclerosi dexamethason mg dextros intraven daysmonth 1218 pul complet raynaud phenomenon mark 610 moder 310 mild 110 digit ulcer respond markedli 89 sclerosi markedli 310 moder 610 mildli 110 visual palpat pre posttreat biopsi breathless dysphagia symptomat tubercular cervic lymphadenopathi abnorm gain peptic modif dexamethason mg extend till maxim till pul furst organ indic score pretreat local cutan sclerosi crest predominantli manag symptomat threaten continu gangren requir amput pul variant sclerosi anemia dp the10 crf malign ht dp tuberculosi genitor urinari tuberculosi benefici dp sclerosi seem mere cosmet weigh therein dp discard center revis organspecif schedul adopt includ calcium channel blocker lowdos aspirin pentoxyphyllin losartan fluoxetin raynaud phenomenon ace pah crisi methotrex indur cyclophosphamid interstiti antifibrot dpenicillamin colchicin indur\n",
            "\t-7.474\tabh antigen benign malign preserv antigen malign epithelium aboh 45 carcinoma benign breast indirect immunoperoxidas histochem monoclon ab tumour lost isoantigen tumour express antigen tumour antigen histolog invas metastas carcinoma antigen lymph node fail antigen malign appear correl delet glycosyl transferas consist isoantigen benign vari seven lack abh antigen histolog substanc    \n",
            "\t-7.669\tvitamin male femal sunni rich countri vitamin vit sunni vit qatar retrospect januari novemb vi ngml demograph profil male femal vit 547 144 ngml vitamin 56 femal 48 44 male 496 sever vit ngml 231 46 46 femal male vitamin mellitu 38 p0001 dyslipidemia 41 29 p0007 myocardi infarct 55 p0001 angiograph document coronari arteri cad 53 p0001 multivari logist regress vit predictor cad 10795 102111 80 1673982 support widespread vit sunni vit mi male cad vit regardless gender  introductionmethodsstatist analysisresultslow vitamin ngmldiscussionconclus insuffici vitamin vit ngml 75 nmoll worldwid sun vit vit sunni sunshin middl eastern vit sun cultur practic 25ohd near nmoll lebanes saudi emirati iranian femal elderli lebanes 37 male 56 femal vit nmoll similarli intern femal osteoporosi vit note middl east adolesc girl 70 iran 80 saudi arabia 25ohd nmoll insuffici vit affect male femal femal male elderli european adolesc lebanon yearli age zealand gender epidemiolog vit vit cvd never explor preval vit explor vit sex qatar substanti widespread vit sunni htn cad vit regardless gender vit hypertens vit suffici lower hypertens vit mi male random vit cv\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.474\tlabelfre antiglucopeptid sclerosi   detailsglucopeptid immobil immobil bufferglucopeptid immobilizationmonitor glucopeptid antigenantibodi protocol optimizationcalibr curv purifi antibodiesspr serum challeng sclerosi setup immunodiagnost gold magnet reson cerebrospin fluid plasmon reson spr success biomolecular cognat antigen antiglucopeptid sclerosi herein enabl labelfre serum glucopeptid term csf114glc profil sclerosi serum enzymelink immunosorb elisa sprbase biosensor evidenc view independ \n",
            "\t0.452\tvitamin antagonist atrial fibril venou thromboembol systemat aid trialist systemat review standardis report atrial fibril af venou thromboembol vte attempt recommend report employ systemat search bibliograph databas june af vte evalu doseadjust vitamin antagonist vka report report sd subgroup standardis extract independ extract disagr resolv separ investig 148 57 meanstudy213 136 spent intern normalis ttr 79 accompani abovebelow 52 af vte 63 37 p0004 mean236 153 0001 observ randomis 76 33 0001 mean258 163 0001 59 p005 mean223 148 p002 ttr utilis vka half lack consist trend report vka horizon af observ  strength studyintroductionmethodsresultsdiscussionconclusionssupplementari materialauthor manuscriptreview comment systemat n148 add exist provid updat consist vitamin antagonist vka report fitzmauric vka indic atrial fibril af vte unlik review systemat vka report report af vte randomis observ explor vka concomitantli vka consist combin trend report vka horizon af observ systemat consider research perform\n",
            "\t0.452\tvitamin antagonist atrial fibril venou thromboembol systemat aid trialist systemat review standardis report atrial fibril af venou thromboembol vte attempt recommend report employ systemat search bibliograph databas june af vte evalu doseadjust vitamin antagonist vka report report sd subgroup standardis extract independ extract disagr resolv separ investig 148 57 meanstudy213 136 spent intern normalis ttr 79 accompani abovebelow 52 af vte 63 37 p0004 mean236 153 0001 observ randomis 76 33 0001 mean258 163 0001 59 p005 mean223 148 p002 ttr utilis vka half lack consist trend report vka horizon af observ  strength studyintroductionmethodsresultsdiscussionconclusionssupplementari materialauthor manuscriptreview comment systemat n148 add exist provid updat consist vitamin antagonist vka report fitzmauric vka indic atrial fibril af vte unlik review systemat vka report report af vte randomis observ explor vka concomitantli vka consist combin trend report vka horizon af observ systemat consider research perform\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-6.620\tdexamethason pul sclerosi viabl proposit kashmir sclerosi multisystem autoimmun intraven dexamethason pul 1998 wasto benefici dexamethason pul sclerosi vi vi fortyseven sclerosi look submit investig score done 6month interv furst organ indic of47 sclerosi 45 femal male acrosclerosi sclerosi contractur moder proteinuria restrict dysphagia valvular seena of13 dexamethason pul tuberculosi score raynaud phenomenon dysphagia restrict benefici dexamethason pul seem mere cosmet  introductionmateri methodsresultsdiscuss sclerosi multisystem autoimmun affect predominantli lung gut kidney fulfil label sclerosi subcommitte scleroderma american rheumatolog criterion sclerosi proxim digit face limb neck trunk minor sclerodactyli digit pit scar bilater zone basal fibrosi option vasodil immunosuppress antifibrot steroid intraven dexamethason pul dp recommend depart dermatolog std leprosi smh teach govern colleg srinagar benefici dexamethason pul sclerosi vi vi ideal sclerosi conjectur univers agreement choic start goal steroid pul immunemedi pemphigu bullou pemphigoid lupu erythmatosu rheumatoid arthriti pyoderma gangrenosum pai dp sclerosi unfortun benefici steroid pul sclerosi masood preliminari dp sclerosi commun depart sclerosi dexamethason mg dextros intraven daysmonth 1218 pul complet raynaud phenomenon mark 610 moder 310 mild 110 digit ulcer respond markedli 89 sclerosi markedli 310 moder 610 mildli 110 visual palpat pre posttreat biopsi breathless dysphagia symptomat tubercular cervic lymphadenopathi abnorm gain peptic modif dexamethason mg extend till maxim till pul furst organ indic score pretreat local cutan sclerosi crest predominantli manag symptomat threaten continu gangren requir amput pul variant sclerosi anemia dp the10 crf malign ht dp tuberculosi genitor urinari tuberculosi benefici dp sclerosi seem mere cosmet weigh therein dp discard center revis organspecif schedul adopt includ calcium channel blocker lowdos aspirin pentoxyphyllin losartan fluoxetin raynaud phenomenon ace pah crisi methotrex indur cyclophosphamid interstiti antifibrot dpenicillamin colchicin indur\n",
            "\t-7.474\tabh antigen benign malign preserv antigen malign epithelium aboh 45 carcinoma benign breast indirect immunoperoxidas histochem monoclon ab tumour lost isoantigen tumour express antigen tumour antigen histolog invas metastas carcinoma antigen lymph node fail antigen malign appear correl delet glycosyl transferas consist isoantigen benign vari seven lack abh antigen histolog substanc    \n",
            "\t-7.669\tvitamin male femal sunni rich countri vitamin vit sunni vit qatar retrospect januari novemb vi ngml demograph profil male femal vit 547 144 ngml vitamin 56 femal 48 44 male 496 sever vit ngml 231 46 46 femal male vitamin mellitu 38 p0001 dyslipidemia 41 29 p0007 myocardi infarct 55 p0001 angiograph document coronari arteri cad 53 p0001 multivari logist regress vit predictor cad 10795 102111 80 1673982 support widespread vit sunni vit mi male cad vit regardless gender  introductionmethodsstatist analysisresultslow vitamin ngmldiscussionconclus insuffici vitamin vit ngml 75 nmoll worldwid sun vit vit sunni sunshin middl eastern vit sun cultur practic 25ohd near nmoll lebanes saudi emirati iranian femal elderli lebanes 37 male 56 femal vit nmoll similarli intern femal osteoporosi vit note middl east adolesc girl 70 iran 80 saudi arabia 25ohd nmoll insuffici vit affect male femal femal male elderli european adolesc lebanon yearli age zealand gender epidemiolog vit vit cvd never explor preval vit explor vit sex qatar substanti widespread vit sunni htn cad vit regardless gender vit hypertens vit suffici lower hypertens vit mi male random vit cv\n",
            "Prostate-specific antigen,Vit D None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.464\tcoexist benign phyllod invas ductal breast describ coexist benign phyllod cm invas ductal cm synchron 66yearold underw bilater mastectomi situat refer occurr ductal lobular situ malign phyllod ipsilater intralesion breastphyllod tumorcarcinoma backgroundcas presentationdiscussionconclusionsconsentcompet interestauthor contribut phyllod biphas neoplasm compos stromal correspond fibroepitheli concomit malign neoplasm phyllod malign ductal lobular situ invas situat insid lesion near fibroepitheli neoplasm depend fibroepitheli lesion intrins excis lesion margin adequ benign phyllod phyllod mastectomi recommend locat lymph node determin term occur synchron coexist benign phyllod invas document phyllod invas ductal synchron coexist benign phyllod invas ductal breast phyllod carcinoma synchron separ breast coexist benign phyllod synchron invas ductal separ breast consent\n",
            "\t0.450\tverapamil hepatocarcinogenesi nnitrosomorpholin spraguedawley verapamil hepatocarcinogenesi nnitrosomorpholin nnm spraguedawley drink nnm ip inject verapamil vehicl everi start experi preneoplast neoplast stain gammaglutamyl transpeptidas ggt placent glutathionestransferas gstp histochem week prolong verapamil ggtposit gstpposit percentag parenchyma hepatocellular carcinoma verapamil verapamil label indic preneoplast adjac verapamil inhibit hepatocarcinogenesi inhibitori neoplast surround hepatocyt    \n",
            "\t0.437\tintraduct dci liposom doxorubicin preoper rural california    thirti ductal carcinomainsitu dci minim invas biopsi recruit irb approv neoadjuv pegyl liposom doxorubicin doxil deliv duct histolog preprocedur mri mammographi consent core biopsi demonstr dci duct cannul ductogram document perfor dye diseas duct mg cc doxil instil duct hour hour continu staff period contact verifi just mammogram mri cbc repeat oper ductoscopi duct pathologist india ink gel instil immedi remov duct histolog thirti random receiv salin instead doxil blind fashion date consent technic difficulti ductogram remain sustain perfor duct full correct duct smaller adjac duct welltoler doxil episod last hour respond antiinflammatori histolog lumpectomi verifi squamou metaplasia necrosi sponsor susan love foundat dslrf fund california cbcrp take place economicallychalleng medicallyunderserv highlevel origin pride valid ideal cbcrp dslrf clinician substanti maintain visibl summari feasibl set concept ductal confin duct correctli orific duct inspect mammogram welltoler mammograph appear document \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.955\tductal lobular nurs ductal lobular carcinoma invas wellestablish differenti histolog subtyp prospect hormon nonhormon exposur histolog subtyp 4655 ductal 659 lobular postmenopaus nurs multivari cox proport hazard regress stratifi histolog subtyp ductal lobular subtyp calcul heterogen likelihood compar separ estim subtyp estim subtyp menarch heterogen het 003 birth het 0001 postmenopaus hormon het 0001 lobular nullipar pariti menopaus menopaus alcohol bmi bmi person benign vari subtyp het 008 restrict estrogen receptorposit progesteron receptorposit heterogen suggest etiolog epidemiolog continu take modifi histolog  introductionmateri methodsstudi populationexposur dataidentif casesexclusionsstatist analysisresultsreproduct hormon exposuresnonreproduct exposure pr statusdiscussionconclusionsabbreviationscompet interestsauthor contribut epidemiolog reproduct lifestyl anthropometr exposur predict differenti histolog subtyp invas 75 ductal carcinoma lobular remaind mix histolog patholog ductal lobular etiolog implic respect lobular ductal estrogen erposit progesteron prposit postmenopaus hormon pmh histolog stronger lobular carcinoma besid pmh histolog wellestablish vari histolog formal subtyp pr retrospect prospect invas ductal lobular postmenopaus nurs nh summari reproduct hormon nonreproduct differenti postmenopaus histolog subtyp complement grow etiolog heterogen ductal lobular continu stratifi histolog abbrevi\n",
            "\t-3.071\ter81 hyperplasia er81 er81 carcinogenesi er81 carcinogenesi er81 idc dci adh hut immunohistochem stain er81 257 935 hut 412 717 adh 545 1222 dci 630 5181 idc dci adh hut er81 1420 70 idc er81 dci posit er81 adh er81 hut signific nbt hut 05 hut adh 05 clinicalpatholog er81 her2 amplif neg pr er81 er81 carcinogenesi  introduction2 methods21 materials22 immunohistochem staining23 immunohistochem staining24 fluoresc situ hybrid fish25 analysis3 results4 discus carcinogenesi undergo transit epithelium invas idc hyperplasia usual hut atyp ductal hyperplasia adh situ dci annual dci untreat dci idc origin biopsi unclear idc er81 etsrel 81 call et variant etv1 member et dnabind note ewe ew transloc onto er81 result ewser81 fusion exert oncogen dysregul er81 dispar ewe sarcoma carcinoma causal tumorigenesi note er81 dramat her2neu tyrosin protooncoprotein er81 murin overexpress her2neu er81 tumorigenesi gain insight er81 tumorigenesi attempt er81 invas ductal situ atyp ductal hyperplasia hyperplasia atypia multistep carcinogenesi epithelium hyperplasia atypia hyperplasia atypia ductal situ invas carri deom hyperplast alveolar nodul han murin mammari transplant clear mammari pad half carcinoma happen biopsi harbour malign infiltr sidebysid situ benign prolifer occasion morpholog transit continu invas karpa 645 biopsi 226 malign 419 benign atyp hyperplasia 62 malign biopsi benign biopsi similarli kern brook atyp ductal hyperplasia adh cancerbear breast foot stewart papillari hyperplasia atypia cancer breast ryan coadi hyperplasia cancer breast histopatholog convinc prolif invas adh invas transform hyperplasia molecularli er81 downstream her2 neu tyrosin protooncoprotein her2 note er81 dramat her2neu er81 her2 upregul her2 exist feedforward loop upregul her2neu er81 murin overexpress her2neu er81 tumorigenesi shin er81 downregul suppress her2 mdamb231 prove exist er81 physiolog transgen overexpress er81 mammari er81 prime malign instanc her2neu er81 carcinogenesi step examin er81 idc dci adh hut repres weak stain yield maximum ir er81 ir er81 257 935 hut 412 717 adh 545 1222 pure dci 630 5181 idc er81 hut er81 moder stain er81 lesion impli er81 examin er81 adjac hyperplas repres er81 70 1420 idc er81 dci posit er81 adh er81 hut signific nbt hut 05 hut adh 05 signific adh dci 05 dci idc 05 confirm er81 involv carcinogenesi er81 clinicalpatholog her2 amplif pr er81 her2 amplif neg pr er81 age menopaus size nodal histolog her2 amplif er81 her2 amplif know er81 possibl er81 transcript compet er81 induc her2 ra raf map her2 er81 synerg carcinogenesi conclus er81 er81 carcinogenesi\n",
            "\t-3.214\tbreastfeed immunohistochem ki67 p53 bcl2 infiltr lobular invas lobular invas ductal american societi 180000 invas person analyz breastfeed infiltr lobular relat clinicopatholog hormon tissuebas 80 ilc 46 breastfe axillari lymph node distant histolog grade hg estrogen progesteron pr androgen ar ki67 p53 bcl2 ilc nonlact 0009 lymph node 0051 distant 0060 prolif ki67 0053 breastfeed regardless histolog subtyp lactat ilc defin subgroup axillari lymph node distant ki67  introductionmateri methodspatientsmethodsresultsrelationship breastfeed clinicopatholog infiltr lobular ilcrelationship breastfeed hormon tissuebas infiltr lobular ilcdiscuss invas infiltr lobular ilc start milkproduc gland lobul invas ductal begin milkcarri duct spread beyond american societi 180000 invas ilc spread metastas part invas invas lobular carcinoma ilc harder mammogram invas ductal typic doesnt lump instead feel thicken full surround lactat attribut reduct rang 43 64 know hormonedepend invas situ adenocarcinoma subtyp lactat lactat basal carcinomastripl extend lumin pathophysiolog lactat anovul mammari milk carcinogen excret lactat recurr prognost lymph node histolog grade hormon ajcc stage determin histolog grade hormon behav unexpect vari prognost predict effort phenomenon ki67 p53 bcl2 analyz breastfeed lobular relat clinicopatholog hormon tissuebas worldwid malign invas ductal lobular constitut largest tumour compris 95of risk incorpor ass woman breastfeed reduc mix lactat clinicopatholog ilc lactat axillari lymph node distant metastas reflect poorer hypothes protect lactat lactat promot mammari suscept carcinogen render suscept carcinogen lactat decreas woman lifetim cycl hormon suppress ovul lactat protect rodent statist ki67 breastfeed immunohistochem ki67 ki67 know radiotherapi conserv axillari lymph node prognost 87 adjuv highlight prognost ki67 restrict erposit histolog grade ki67 easili reproduc complement histolog grade prognost adjuv robust costeffect subdivid grade carcinoma provid prognost plan therapi acquir great classif consid guidelin ki67 patholog preliminari consider lactat ilc defin subgroup axillari lymph node distant ki67\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.464\tcoexist benign phyllod invas ductal breast describ coexist benign phyllod cm invas ductal cm synchron 66yearold underw bilater mastectomi situat refer occurr ductal lobular situ malign phyllod ipsilater intralesion breastphyllod tumorcarcinoma backgroundcas presentationdiscussionconclusionsconsentcompet interestauthor contribut phyllod biphas neoplasm compos stromal correspond fibroepitheli concomit malign neoplasm phyllod malign ductal lobular situ invas situat insid lesion near fibroepitheli neoplasm depend fibroepitheli lesion intrins excis lesion margin adequ benign phyllod phyllod mastectomi recommend locat lymph node determin term occur synchron coexist benign phyllod invas document phyllod invas ductal synchron coexist benign phyllod invas ductal breast phyllod carcinoma synchron separ breast coexist benign phyllod synchron invas ductal separ breast consent\n",
            "\t0.450\tverapamil hepatocarcinogenesi nnitrosomorpholin spraguedawley verapamil hepatocarcinogenesi nnitrosomorpholin nnm spraguedawley drink nnm ip inject verapamil vehicl everi start experi preneoplast neoplast stain gammaglutamyl transpeptidas ggt placent glutathionestransferas gstp histochem week prolong verapamil ggtposit gstpposit percentag parenchyma hepatocellular carcinoma verapamil verapamil label indic preneoplast adjac verapamil inhibit hepatocarcinogenesi inhibitori neoplast surround hepatocyt    \n",
            "\t0.437\tintraduct dci liposom doxorubicin preoper rural california    thirti ductal carcinomainsitu dci minim invas biopsi recruit irb approv neoadjuv pegyl liposom doxorubicin doxil deliv duct histolog preprocedur mri mammographi consent core biopsi demonstr dci duct cannul ductogram document perfor dye diseas duct mg cc doxil instil duct hour hour continu staff period contact verifi just mammogram mri cbc repeat oper ductoscopi duct pathologist india ink gel instil immedi remov duct histolog thirti random receiv salin instead doxil blind fashion date consent technic difficulti ductogram remain sustain perfor duct full correct duct smaller adjac duct welltoler doxil episod last hour respond antiinflammatori histolog lumpectomi verifi squamou metaplasia necrosi sponsor susan love foundat dslrf fund california cbcrp take place economicallychalleng medicallyunderserv highlevel origin pride valid ideal cbcrp dslrf clinician substanti maintain visibl summari feasibl set concept ductal confin duct correctli orific duct inspect mammogram welltoler mammograph appear document \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.955\tductal lobular nurs ductal lobular carcinoma invas wellestablish differenti histolog subtyp prospect hormon nonhormon exposur histolog subtyp 4655 ductal 659 lobular postmenopaus nurs multivari cox proport hazard regress stratifi histolog subtyp ductal lobular subtyp calcul heterogen likelihood compar separ estim subtyp estim subtyp menarch heterogen het 003 birth het 0001 postmenopaus hormon het 0001 lobular nullipar pariti menopaus menopaus alcohol bmi bmi person benign vari subtyp het 008 restrict estrogen receptorposit progesteron receptorposit heterogen suggest etiolog epidemiolog continu take modifi histolog  introductionmateri methodsstudi populationexposur dataidentif casesexclusionsstatist analysisresultsreproduct hormon exposuresnonreproduct exposure pr statusdiscussionconclusionsabbreviationscompet interestsauthor contribut epidemiolog reproduct lifestyl anthropometr exposur predict differenti histolog subtyp invas 75 ductal carcinoma lobular remaind mix histolog patholog ductal lobular etiolog implic respect lobular ductal estrogen erposit progesteron prposit postmenopaus hormon pmh histolog stronger lobular carcinoma besid pmh histolog wellestablish vari histolog formal subtyp pr retrospect prospect invas ductal lobular postmenopaus nurs nh summari reproduct hormon nonreproduct differenti postmenopaus histolog subtyp complement grow etiolog heterogen ductal lobular continu stratifi histolog abbrevi\n",
            "\t-3.071\ter81 hyperplasia er81 er81 carcinogenesi er81 carcinogenesi er81 idc dci adh hut immunohistochem stain er81 257 935 hut 412 717 adh 545 1222 dci 630 5181 idc dci adh hut er81 1420 70 idc er81 dci posit er81 adh er81 hut signific nbt hut 05 hut adh 05 clinicalpatholog er81 her2 amplif neg pr er81 er81 carcinogenesi  introduction2 methods21 materials22 immunohistochem staining23 immunohistochem staining24 fluoresc situ hybrid fish25 analysis3 results4 discus carcinogenesi undergo transit epithelium invas idc hyperplasia usual hut atyp ductal hyperplasia adh situ dci annual dci untreat dci idc origin biopsi unclear idc er81 etsrel 81 call et variant etv1 member et dnabind note ewe ew transloc onto er81 result ewser81 fusion exert oncogen dysregul er81 dispar ewe sarcoma carcinoma causal tumorigenesi note er81 dramat her2neu tyrosin protooncoprotein er81 murin overexpress her2neu er81 tumorigenesi gain insight er81 tumorigenesi attempt er81 invas ductal situ atyp ductal hyperplasia hyperplasia atypia multistep carcinogenesi epithelium hyperplasia atypia hyperplasia atypia ductal situ invas carri deom hyperplast alveolar nodul han murin mammari transplant clear mammari pad half carcinoma happen biopsi harbour malign infiltr sidebysid situ benign prolifer occasion morpholog transit continu invas karpa 645 biopsi 226 malign 419 benign atyp hyperplasia 62 malign biopsi benign biopsi similarli kern brook atyp ductal hyperplasia adh cancerbear breast foot stewart papillari hyperplasia atypia cancer breast ryan coadi hyperplasia cancer breast histopatholog convinc prolif invas adh invas transform hyperplasia molecularli er81 downstream her2 neu tyrosin protooncoprotein her2 note er81 dramat her2neu er81 her2 upregul her2 exist feedforward loop upregul her2neu er81 murin overexpress her2neu er81 tumorigenesi shin er81 downregul suppress her2 mdamb231 prove exist er81 physiolog transgen overexpress er81 mammari er81 prime malign instanc her2neu er81 carcinogenesi step examin er81 idc dci adh hut repres weak stain yield maximum ir er81 ir er81 257 935 hut 412 717 adh 545 1222 pure dci 630 5181 idc er81 hut er81 moder stain er81 lesion impli er81 examin er81 adjac hyperplas repres er81 70 1420 idc er81 dci posit er81 adh er81 hut signific nbt hut 05 hut adh 05 signific adh dci 05 dci idc 05 confirm er81 involv carcinogenesi er81 clinicalpatholog her2 amplif pr er81 her2 amplif neg pr er81 age menopaus size nodal histolog her2 amplif er81 her2 amplif know er81 possibl er81 transcript compet er81 induc her2 ra raf map her2 er81 synerg carcinogenesi conclus er81 er81 carcinogenesi\n",
            "\t-3.214\tbreastfeed immunohistochem ki67 p53 bcl2 infiltr lobular invas lobular invas ductal american societi 180000 invas person analyz breastfeed infiltr lobular relat clinicopatholog hormon tissuebas 80 ilc 46 breastfe axillari lymph node distant histolog grade hg estrogen progesteron pr androgen ar ki67 p53 bcl2 ilc nonlact 0009 lymph node 0051 distant 0060 prolif ki67 0053 breastfeed regardless histolog subtyp lactat ilc defin subgroup axillari lymph node distant ki67  introductionmateri methodspatientsmethodsresultsrelationship breastfeed clinicopatholog infiltr lobular ilcrelationship breastfeed hormon tissuebas infiltr lobular ilcdiscuss invas infiltr lobular ilc start milkproduc gland lobul invas ductal begin milkcarri duct spread beyond american societi 180000 invas ilc spread metastas part invas invas lobular carcinoma ilc harder mammogram invas ductal typic doesnt lump instead feel thicken full surround lactat attribut reduct rang 43 64 know hormonedepend invas situ adenocarcinoma subtyp lactat lactat basal carcinomastripl extend lumin pathophysiolog lactat anovul mammari milk carcinogen excret lactat recurr prognost lymph node histolog grade hormon ajcc stage determin histolog grade hormon behav unexpect vari prognost predict effort phenomenon ki67 p53 bcl2 analyz breastfeed lobular relat clinicopatholog hormon tissuebas worldwid malign invas ductal lobular constitut largest tumour compris 95of risk incorpor ass woman breastfeed reduc mix lactat clinicopatholog ilc lactat axillari lymph node distant metastas reflect poorer hypothes protect lactat lactat promot mammari suscept carcinogen render suscept carcinogen lactat decreas woman lifetim cycl hormon suppress ovul lactat protect rodent statist ki67 breastfeed immunohistochem ki67 ki67 know radiotherapi conserv axillari lymph node prognost 87 adjuv highlight prognost ki67 restrict erposit histolog grade ki67 easili reproduc complement histolog grade prognost adjuv robust costeffect subdivid grade carcinoma provid prognost plan therapi acquir great classif consid guidelin ki67 patholog preliminari consider lactat ilc defin subgroup axillari lymph node distant ki67\n",
            "ductal breast carcinoma,HER2,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.546\talcohol alcohol immun explor alcohol simian immunodefici siv siv alcoholconsum oppos defens nutrit balanc consequ proinflammatori consum alcohol acceler siv possibl alcohol aod abus dependenceaod effectsdiseas factordiseas complicationimmun systemhuman immunodefici hivhiv infectionacquir defici syndromeantiretrovir therapysimian immunodefici virusanim modelsrhesu macaqu alcohol transmissionbehavior effectsphysiolog effectsalcohol pathogenesisviru entri replicationalcohol systemeffect alcohol exposureeffect alcohol exposurealcohol arv treatmentalcohol compliancealcohol metabolismeffect alcohol coinfectionsoth alcohol arv drugseffect alcohol systemanim studi alcohol infectionnhp pathogen siv infectionresearch applicationssiv pathogenesisimmun responsesadvantagesresearch siv alcohol modelalcohol progressionalcohol replicationalcohol tcell subsetssiv alcohol weightperspectivesalcohol intestin inflammationalcohol state alcohol review \n",
            "\t0.546\talcohol alcohol immun explor alcohol simian immunodefici siv siv alcoholconsum oppos defens nutrit balanc consequ proinflammatori consum alcohol acceler siv possibl alcohol aod abus dependenceaod effectsdiseas factordiseas complicationimmun systemhuman immunodefici hivhiv infectionacquir defici syndromeantiretrovir therapysimian immunodefici virusanim modelsrhesu macaqu alcohol transmissionbehavior effectsphysiolog effectsalcohol pathogenesisviru entri replicationalcohol systemeffect alcohol exposureeffect alcohol exposurealcohol arv treatmentalcohol compliancealcohol metabolismeffect alcohol coinfectionsoth alcohol arv drugseffect alcohol systemanim studi alcohol infectionnhp pathogen siv infectionresearch applicationssiv pathogenesisimmun responsesadvantagesresearch siv alcohol modelalcohol progressionalcohol replicationalcohol tcell subsetssiv alcohol weightperspectivesalcohol intestin inflammationalcohol state alcohol review \n",
            "\t0.531\talcohol wellknown pneumonia alcohol abus recogn fourfold distress percent translat ten thousand excess death alcoholmedi compar scar cirrhosi alcoholrel shed basic alcohol abus predispos pneumonia util treat uniqu vulner alcohol date alcohol abus larg unrecogn research parallel effort pneumonia genom proteom involv organ infanc alcohol repres suit alcohol abusealcohol disorderpneumoniaacut distress ardsacut injuryglutathionealveolar cellalveolar macrophageimmun functioncmcsf alcohol abus pneumoniaepidemiolog alcohol abus pneumoniapotenti alcohol abus pneumoniaalcohol abus injuryepidemiolog alcohol abus injurypotenti alcohol abus injuryglutathion depletionglutathion injuryposs factorsrol angiotensin tgf injurypotenti strategiessystem biolog alcohol alcohol abus recogn pneumonia section epidemiolog alcohol abus pneumonia alcohol abus pneumonia \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.231\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "\t-4.925\talcohol alcohol independ stand reason addit alcohol exacerb therebi affect alcohol mucos gastrointestin tract genit tract lung  alcohol interact hivalcohol mucos systemth gastrointestin mucos systempathogenesi alcohol infectionan conduct studiesreferencesmicrobi transloc alcohol hivmicrobi flora innat mucos immun alcohol abuseintestin turnov infectionalcohol genit tractalcohol lungalcohol wast diseasereferencesalcoholhiv hematopoiet systemalcohol adapt infectionconclus alcohol alcohol immunosuppress activ innat adapt molina szabo intox dose alcohol immunosuppress pneumonia szabo zhang hivposit alcohol activ caus alcohol distress wast alcohol mix bagbi 1998 hahn basgasra colleagu 1993 administ alcohol uninfect mononuclear alcohol cook colleagu 1997 lymphocyt subset aud acceler fong colleagu 1994 user heavili abus alcohol rapidli progress aid shortli seroconvers said alcohol count hivposit mix pol colleagu 1996 count hivposit alcohol receiv art stop drink alcohol count art conen crosssect 325 alcohol statist correl count take take art wu baum colleagu frequent alcohol user art declin count count load likewis likelihood declin count art samet colleagu count art heavi alcohol art count french carrieri 2014 art alcohol gram count abstain categor moder alcohol consum count abstain investig alcohol proxi healthier behavior encompass thing alcohol load antiretrovir vari wu load art consum alcohol samet consum alcohol adher art viremia baum load turn infecti unprotect uninfect partner becom drink kalichman epidemiolog art fail alcohol abus coat 1990 kaslow 1989 face methodolog obstacl difficulti obtain accur alcohol control confound variat demograph ethnic comorbid influenc research gotten methodolog issu creat simian immunodefici siv rhesu macaqu monkey textbox conduct alcohol logic tandem addit begun alcohol exacerb badli strain clearest connect alcohol gastrointestin tract alcohol mucos line intestin barrier leakag turn strengthen grip alcohol mucos synergist intestin genit tract environ mucos worsen risk done clarifi alcohol elucid\n",
            "\t-4.925\talcohol alcohol independ stand reason addit alcohol exacerb therebi affect alcohol mucos gastrointestin tract genit tract lung  alcohol interact hivalcohol mucos systemth gastrointestin mucos systempathogenesi alcohol infectionan conduct studiesreferencesmicrobi transloc alcohol hivmicrobi flora innat mucos immun alcohol abuseintestin turnov infectionalcohol genit tractalcohol lungalcohol wast diseasereferencesalcoholhiv hematopoiet systemalcohol adapt infectionconclus alcohol alcohol immunosuppress activ innat adapt molina szabo intox dose alcohol immunosuppress pneumonia szabo zhang hivposit alcohol activ caus alcohol distress wast alcohol mix bagbi 1998 hahn basgasra colleagu 1993 administ alcohol uninfect mononuclear alcohol cook colleagu 1997 lymphocyt subset aud acceler fong colleagu 1994 user heavili abus alcohol rapidli progress aid shortli seroconvers said alcohol count hivposit mix pol colleagu 1996 count hivposit alcohol receiv art stop drink alcohol count art conen crosssect 325 alcohol statist correl count take take art wu baum colleagu frequent alcohol user art declin count count load likewis likelihood declin count art samet colleagu count art heavi alcohol art count french carrieri 2014 art alcohol gram count abstain categor moder alcohol consum count abstain investig alcohol proxi healthier behavior encompass thing alcohol load antiretrovir vari wu load art consum alcohol samet consum alcohol adher art viremia baum load turn infecti unprotect uninfect partner becom drink kalichman epidemiolog art fail alcohol abus coat 1990 kaslow 1989 face methodolog obstacl difficulti obtain accur alcohol control confound variat demograph ethnic comorbid influenc research gotten methodolog issu creat simian immunodefici siv rhesu macaqu monkey textbox conduct alcohol logic tandem addit begun alcohol exacerb badli strain clearest connect alcohol gastrointestin tract alcohol mucos line intestin barrier leakag turn strengthen grip alcohol mucos synergist intestin genit tract environ mucos worsen risk done clarifi alcohol elucid\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.546\talcohol alcohol immun explor alcohol simian immunodefici siv siv alcoholconsum oppos defens nutrit balanc consequ proinflammatori consum alcohol acceler siv possibl alcohol aod abus dependenceaod effectsdiseas factordiseas complicationimmun systemhuman immunodefici hivhiv infectionacquir defici syndromeantiretrovir therapysimian immunodefici virusanim modelsrhesu macaqu alcohol transmissionbehavior effectsphysiolog effectsalcohol pathogenesisviru entri replicationalcohol systemeffect alcohol exposureeffect alcohol exposurealcohol arv treatmentalcohol compliancealcohol metabolismeffect alcohol coinfectionsoth alcohol arv drugseffect alcohol systemanim studi alcohol infectionnhp pathogen siv infectionresearch applicationssiv pathogenesisimmun responsesadvantagesresearch siv alcohol modelalcohol progressionalcohol replicationalcohol tcell subsetssiv alcohol weightperspectivesalcohol intestin inflammationalcohol state alcohol review \n",
            "\t0.546\talcohol alcohol immun explor alcohol simian immunodefici siv siv alcoholconsum oppos defens nutrit balanc consequ proinflammatori consum alcohol acceler siv possibl alcohol aod abus dependenceaod effectsdiseas factordiseas complicationimmun systemhuman immunodefici hivhiv infectionacquir defici syndromeantiretrovir therapysimian immunodefici virusanim modelsrhesu macaqu alcohol transmissionbehavior effectsphysiolog effectsalcohol pathogenesisviru entri replicationalcohol systemeffect alcohol exposureeffect alcohol exposurealcohol arv treatmentalcohol compliancealcohol metabolismeffect alcohol coinfectionsoth alcohol arv drugseffect alcohol systemanim studi alcohol infectionnhp pathogen siv infectionresearch applicationssiv pathogenesisimmun responsesadvantagesresearch siv alcohol modelalcohol progressionalcohol replicationalcohol tcell subsetssiv alcohol weightperspectivesalcohol intestin inflammationalcohol state alcohol review \n",
            "\t0.531\talcohol wellknown pneumonia alcohol abus recogn fourfold distress percent translat ten thousand excess death alcoholmedi compar scar cirrhosi alcoholrel shed basic alcohol abus predispos pneumonia util treat uniqu vulner alcohol date alcohol abus larg unrecogn research parallel effort pneumonia genom proteom involv organ infanc alcohol repres suit alcohol abusealcohol disorderpneumoniaacut distress ardsacut injuryglutathionealveolar cellalveolar macrophageimmun functioncmcsf alcohol abus pneumoniaepidemiolog alcohol abus pneumoniapotenti alcohol abus pneumoniaalcohol abus injuryepidemiolog alcohol abus injurypotenti alcohol abus injuryglutathion depletionglutathion injuryposs factorsrol angiotensin tgf injurypotenti strategiessystem biolog alcohol alcohol abus recogn pneumonia section epidemiolog alcohol abus pneumonia alcohol abus pneumonia \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.231\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "\t-4.925\talcohol alcohol independ stand reason addit alcohol exacerb therebi affect alcohol mucos gastrointestin tract genit tract lung  alcohol interact hivalcohol mucos systemth gastrointestin mucos systempathogenesi alcohol infectionan conduct studiesreferencesmicrobi transloc alcohol hivmicrobi flora innat mucos immun alcohol abuseintestin turnov infectionalcohol genit tractalcohol lungalcohol wast diseasereferencesalcoholhiv hematopoiet systemalcohol adapt infectionconclus alcohol alcohol immunosuppress activ innat adapt molina szabo intox dose alcohol immunosuppress pneumonia szabo zhang hivposit alcohol activ caus alcohol distress wast alcohol mix bagbi 1998 hahn basgasra colleagu 1993 administ alcohol uninfect mononuclear alcohol cook colleagu 1997 lymphocyt subset aud acceler fong colleagu 1994 user heavili abus alcohol rapidli progress aid shortli seroconvers said alcohol count hivposit mix pol colleagu 1996 count hivposit alcohol receiv art stop drink alcohol count art conen crosssect 325 alcohol statist correl count take take art wu baum colleagu frequent alcohol user art declin count count load likewis likelihood declin count art samet colleagu count art heavi alcohol art count french carrieri 2014 art alcohol gram count abstain categor moder alcohol consum count abstain investig alcohol proxi healthier behavior encompass thing alcohol load antiretrovir vari wu load art consum alcohol samet consum alcohol adher art viremia baum load turn infecti unprotect uninfect partner becom drink kalichman epidemiolog art fail alcohol abus coat 1990 kaslow 1989 face methodolog obstacl difficulti obtain accur alcohol control confound variat demograph ethnic comorbid influenc research gotten methodolog issu creat simian immunodefici siv rhesu macaqu monkey textbox conduct alcohol logic tandem addit begun alcohol exacerb badli strain clearest connect alcohol gastrointestin tract alcohol mucos line intestin barrier leakag turn strengthen grip alcohol mucos synergist intestin genit tract environ mucos worsen risk done clarifi alcohol elucid\n",
            "\t-4.925\talcohol alcohol independ stand reason addit alcohol exacerb therebi affect alcohol mucos gastrointestin tract genit tract lung  alcohol interact hivalcohol mucos systemth gastrointestin mucos systempathogenesi alcohol infectionan conduct studiesreferencesmicrobi transloc alcohol hivmicrobi flora innat mucos immun alcohol abuseintestin turnov infectionalcohol genit tractalcohol lungalcohol wast diseasereferencesalcoholhiv hematopoiet systemalcohol adapt infectionconclus alcohol alcohol immunosuppress activ innat adapt molina szabo intox dose alcohol immunosuppress pneumonia szabo zhang hivposit alcohol activ caus alcohol distress wast alcohol mix bagbi 1998 hahn basgasra colleagu 1993 administ alcohol uninfect mononuclear alcohol cook colleagu 1997 lymphocyt subset aud acceler fong colleagu 1994 user heavili abus alcohol rapidli progress aid shortli seroconvers said alcohol count hivposit mix pol colleagu 1996 count hivposit alcohol receiv art stop drink alcohol count art conen crosssect 325 alcohol statist correl count take take art wu baum colleagu frequent alcohol user art declin count count load likewis likelihood declin count art samet colleagu count art heavi alcohol art count french carrieri 2014 art alcohol gram count abstain categor moder alcohol consum count abstain investig alcohol proxi healthier behavior encompass thing alcohol load antiretrovir vari wu load art consum alcohol samet consum alcohol adher art viremia baum load turn infecti unprotect uninfect partner becom drink kalichman epidemiolog art fail alcohol abus coat 1990 kaslow 1989 face methodolog obstacl difficulti obtain accur alcohol control confound variat demograph ethnic comorbid influenc research gotten methodolog issu creat simian immunodefici siv rhesu macaqu monkey textbox conduct alcohol logic tandem addit begun alcohol exacerb badli strain clearest connect alcohol gastrointestin tract alcohol mucos line intestin barrier leakag turn strengthen grip alcohol mucos synergist intestin genit tract environ mucos worsen risk done clarifi alcohol elucid\n",
            "abdominal pain,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.539\thepat substanc user enrol communitybas hepat hcv frequent bloodborn epidemiolog hcv complet understood minor hcv substanc abus femal institut alcohol abus alcohol niaaa institut abus nida fund street recruit month interview substanc sexual behavior implement share practic tattoo pierc transfus share person hygien equip tweezer toothbrush razor urin hcv ab sexual transmit std 782 predominantli african american 162 hcv ab 0001 inject 0001 lifetim crack cocain 0004 tattoo 001 hcv ab posit hcv ab posit sexual behavior hcv ab predominantli african american substanc abus hcv ab posit awar hcv serostatu intraven idu hcv ab posit tattoo lifetim crack rout hcv  backgroundmethodssampl descriptionlaboratori testingstatist analysesresultsbaselin characteristicssubst sexual behaviourmultivari analysessubgroup analysesdiscussionconclusionscompet interestsauthor contribut hepat hcv frequent bloodborn caus morbid 4500 inhospit death hcv nutrit nhane hcv ab million person chronic hcv hcv endstag subsequ transplant hcv indic transplant transplant hcv hcv origin document nona nonb caus transfus hepat hcv spread parenter intraven idu introduct univers 1990 transfus hcv hcv vari depend race epidemiolog hcv african american reason hcv femal male regardless race hcv femal extens set coinfect vertic hcv inject predomin rout idu hcv rang 6090 carri morbid burden sexual hcv hepat sexual hcv vertic 67 viremia rout idu tattoo pierc share prepar equip share person hygien item hcv noninject user intranas cocain share drugus equip hcv virolog confirm hcv nasal secret support epidemiolog comprehens hcv underrepres hcv substanc abus predominantli african american femal epidemiolog eprg washington univers school highlight born reach understudi underreport epidemiolog inject contribut hcv ab posit predominantli african american substanc abus reveal awar hcv ab awar hcv ab implic perspect hcv counsel overcom barrier ensur referr comprehens incorpor address substanc idu hcv ab posit tattoo lifetim crack inject rout hcv largescal prospect compet interest\n",
            "\t0.507\thepat cascad call address ongo barrier aim hepat hcv cascad hivinfect reason refer initi hcv complet hcv stage retrospect hivinfect univers california san diego ucsd screen hcv logist regress referr hcv electron record review ascertain reason initi hcv 4725 hivinfect ucsd owen clinic 4534 96 screen hcv 748 reactiv hcv 542 hcv engag predictor nonreferr hcv odd 508 confid interv 324 697 000001 predictor unstabl hous 226 aid 183 detect load 198 nonwhit 167 reason initi defer hcv ongo barrier hcv hivinfect half hcv refer hcv improv hcv benefit realiz unless deal barrier implement  introductionmethodspati hcv carestudi designstudi definitionsstatist analysisresultsdemograph count load refer nonref hepat considerationcommon provid decis referr hivinfect hepat considerationpredictor nonb refer hcv consider 562 unadjust adjust analysesth depict hepat cascad hivinfect attend univers california san diego owen clinic januari 31 decemb 2012discussionsupport person live immunodefici coinfect hepat hcv guidelin recommend hcv person establish diver clinic 85 hivinfect person hcv 3month enrol hcv hivinfect person advanc hcv hcv europ hcv liverrel morbid contribut cost urgent hcv hivinfect person advent act antivir hcv opportun cure hcv coinfect person influenc hcv referr disposit hcv establish reason nonreferr hcv initi hcv hivinfect refer hcv narrow gap hcv nonreferr hcv consider character reason start hcv complet hcv stage describ hcv cascad hcv owen clinic univers california san diego ucsd conclusions1 hivinfect screen hcv half hivinfect hcv coinfect refer hcv reason initi hcv ongo barrier compromis engag reflect extant dispar nonwhit engag unstabl hous uncontrol hivinfect refer hcv idu refer hcv msm idu want refer stigma hcv msm iud creat opportun awar provid rise hcv hivinfect msm idu coinfect ongo hcv refer hcv interferon contraind hcv referr neither unwilling receiv hcv interferonbas detail clinic note highlight interferon regimen cure immedi barrier referr address never receiv hcv unexpect ongo substanc abus neuropsychiatr predictor hcv referr ascertain bia explan refer hcv engag reliabl selfreport ongo alcohol abus uncertain similarli systemat evalu document alcohol abus neuropsychiatr electron record refer hcv noniniti hcv attribut alcohol abus neuropsychiatr engag refer hcv realworld challeng success hcv accomplish 4188 start attain sustain interferonfre therapi efficaci shorter approv emphasi place implement integr multidisciplinari hcv alcohol substanc stigma discrimin coinfect retain initi hcv cur insur incom influenc referr hcv hcv coinfect clinic oper clinic insur coverag allow univers hcv argu definit engag gold miss visit gap visit constanc comprehens descript engag chose hrsa hivaid bureau retent align updat guidelin highlight concept adher restrict reason initi hcv finish hcv stage critic 53 303 refer hcv never hcv appoint return hcv appoint 33 rule unmeasur travel distanc clinic hcv literaci neg impact hcv initi limit balanc strength complet hcv stage underw detail character logist barrier hcv initi generaliz fund geograph percentag coinfect ultim hcv sustain mirror cohort europ improv hcv benefit realiz unless deal barrier address\n",
            "\t0.503\tcoronavirus simultan stool nasopharyng swab hospit gastroenter coronavirus hcov wellknown gastrointestin unclear object signific hcov etiolog gastroenter stool nasopharyng np swab 260 hospit 160 157 otherwis admit elect hcov real rtpcr regist clinicaltrialsgov reg nct00987519 hcov frequent 23260 88 4151 odd 33 confid interv 001 hcovposit asymptomat sampl recal gastrointestin hcov np stool 22256 86 6260 00004 56 hcov stool np swab probabl hcov stool 153 0006 stool np 33 001 hcov stool np hcov hcov np swab compound occurr stool stool hcov minor caus gastrointestin ill old coronavirusvir gastroenteritisrespiratori backgroundresultspatientsdetect hcov stool np swab agecontrol groupdiscussionconclusionsmethodsstudi designlaboratori methodsstatist analysisabbreviationscompet interestsauthor contribut  hcov frequent demonstr probabl hcov stool causal hcov interpret hcov np swab stool stool half sign rti hcov play minor gastrointestin ill\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.008\traloxifen inhibit hepat postmenopaus hepat exhibit interferon premenopaus osteoporosi typic complic postmenopaus osteoporot reagent vitamin d3 exhibit antihepat hcv osteoporot reagent raloxifen exhibit antihcv raloxifen inhibit hcv genotyp 1b genotyp 2a raloxifen antihcv link biolog osteoporosi hcv  introductionmateri methodsreag antibodiescel hcv rnasrl assaywst1 assaywestern blot analysishcv infectionresultsraloxifen inhibit hcv replicationraloxifen antihcv raloxifen antagon antihcv statinraloxifen inhibit genotyp 2a hcvdiscuss hepat hcv belong flavivirida singlestrand 96 kb hcv encod polyprotein precursor 3000 cleav protea core envelop e1 e2 p7 nonstructur ns2 ns3 ns4a ns4b ns5a ns5b virolog antivir reagent hcv replicon infecti hcv genotyp 2a hcv jfh1 hepatomaderiv huh7 hcv reproduc genomelength hcv report huh7deriv or6 or6 genotyp 1b hcvo renilla luciferas rl replic robustli hcv jfh1 report hcv hepat ch seriou cirrhosi hepatocellular hcv worldwid elimin hcv antivir reagent prevent fatal pegylatedinterferon pegifn ribavirin rbv ch sustain virolog svr remain protea telaprevir svr 70 pegifnrbv pegifnrbv depend gender ifnrbv postmenopaus ch exhibit premenopaus estrogen dyslipidemia osteoporosi typic postmenopaus statin dyslipidemia reagent inhibit hcv vitamin d3 osteoporot reagent exhibit antihcv estradiol inhibit infecti hcv hepat estrogen raloxifen tamoxifen synthet select estrogen modul serm osteoporosi set serm estrogen er serm exhibit agonist action antagonist action raloxifen tamoxifen antagonist agonist tamoxifen raloxifen exhibit agonist uteru tamoxifen inhibit hcv tamoxifen agonist uterin raloxifen belong antiosteoporot reagent offer advantag uterin decid raloxifen exhibit antihcv raloxifen osteoporot reagent inhibit genotyp 1b hcv inhibit genotyp 2a hcv jfh1 raloxifen addit antihcv raloxifen exhibit antagonist statin pegifnrbv svr ch telaprevir pegifnrbv pegifnrbv complic anemia pegifnrbv telaprevir ad consid pegifnrbvbas postmenopaus addon postmenopaus candid improv svr reagent compens estrogen dyslipidemia osteoporosi postmenopaus attribut estrogen statin clinic reagent dyslipidemia inhibit hcv raloxifen exhibit antihcv genotyp 1b hcv genotyp 2a hcv raloxifen inhibit genotyp 2a hcv genotyp 1b hcv raloxifen reagent antihcv hcv clarifi vitamin d3 osteoporot reagent inhibit hcv vitamin d3 ch statin inhibit hcv suppress geranylgeranyl pyrophosph ggpp osteoporot reagent bisphosphon posse antihcv inhibit biosynthesi ggpp mevalon inhibit farnesyl pyrophosph synthetas hcv osteoporosi raloxifen tamoxifen serm osteoporosi tamoxifen estrogen receptorposit inhibit hcv tamoxifen antihcv raloxifen inhibit hcv clarifi multipotenti raloxifen uterin raloxifen tamoxifen advantag raloxifen ch precis hcv reach microarray or6 hayashida potent estrogen estradiol inhibit infecti hcv huh75 select agonist inhibit infecti hcv select agonist watashi interferencemedi knockdown hcv antihcv raloxifen seem attribut huh7deriv or6 express huh7 1982 okayama univers distribut worldwid bensadoun background il28b genotyp huh7 differ laboratori consequ polyploid hepatoma gpr30 or6 microarray gpr30 antihcv or6 clarifi issu raloxifen inhibit hcv genotyp 1b genotyp 2a raloxifen addit antihcv antagonist statin raloxifen yield reagent vitamin d3 antihcv field osteoporosi hcv\n",
            "\t-2.300\tcytomegaloviru strictli inhibit sirna ul54 ul97 ul122123 transcript cytomegaloviru hcmv sequela immunocompromis host antivir therapi seriou set problemat make interf rna sirna hcmv transcript ul54 polymeras ul97 ul122123 immediateearli cultur sirna hcmv design western blot plaqu continu embryon 293t hcmv nonspecif scrambl sisc sirna transfect plasmid express transcript mrc5 fibroblast hcmvsirna sisc hcmv ad169 pfucel hcmv immediateearli ie1p72 ie2p86 pp65 earlyl pul97 true mcp progeni round concord siul54b siul97a siul122b display potent inhibitori 927 996 937 plasmid 659 581 648 hcmv 972 962 943 00001 progeni analys sirna inhibitori round hcmv multipl 0001 pfucel siul54b siul97a siul122b 800 596 845 hcmv 529 492 583 985 914 991 00001 progeni dpi sirna therapi hcmv transcript ul54 ul97 ul122123 antivir sirna ul97 load  introductionresultsdiffer hcmv sirna display vari efficaci inhibit plasmidderiv transcript targetssirna inhibit plasmidderiv hcmv expressionsirna silenc plasmidderiv hcmv correl inhibit hcmv progeni round replicationsirna inhibit hcmv round hcmv multipl infectionsirna inhibit hcmv progeni round hcmv multipl infectionhcmv sirna ul54 ul97 ul122123 transcript inhibit hcmv progeni round replicationsirna hcmv progeni round multipl infectionsirna progeni multipl round hcmv concord hcmv expressionsirna hcmv round multipl infectionsirna hcmv dissemin round multipl infectionsirna hcmv dissemin round multipl infectiondiscussionmethodscel prepar stockssirna antisens sequencessirna assayssirna transfect infectionvir curveswestern blot analysisimmunofluorescencestatist cytomegaloviru hcmv ubiquit caus seriou sequela immunocompromis fetu introduct rubella immunis hcmv infecti congenit malform licens vaccin routin hcmvinduc take compromis seroposit reactiv transplant recipi fetu antivir hcmv ganciclovir valganciclovir foscarnet cidofovir fomivirsen toxic unsuit set immunocompromis emerg resist mutant subset period press treat hcmv development letermovir aicuri wuppert germani terminas present undergo promis final approv put address detail synthet interf sirna patholog neurolog effect sirna hcmv immunodefici virus1 hepat hepat polioviru papillomaviru influenza develop sirna technolog immunostimulatori offtarget efficaci sirna nanoparticl vehicl sirna promis treat hcmv permiss hcmv undergo tempor sequenti initi immediateearli transcrib polymeras requir hcmv immediateearli ie1p72 ie2p86 altern splice precursor transcript ul122123 auxiliari immediateearli transactiv hcmv immediateearli antivir fomivirisen 21nucleotid antisens act translat hcmv immediateearli secondlin hcmv retin hcmv encod polymeras pul54 hcmv pul97 nonessenti hcmv pul54 pul97 antivir hcmv former princip antivir primarili encod assembl egress enabl reactiv public sirna antihcmv efficaci ul54 ul97 ul122123 transcript date hcmv transcript ident analys inhibitori efficaci sirna hcmv transcript ul54 ul97 ul122123 measur hcmv immediateearli ie1p72 ie2p86 pp65 earlyl pul97 true mcp progeni round hcmv mrc5 fibroblast fibroblast hcmv sirna ul54 ul97 ul122123 inhibitori hcmv multiround cycl utilis sirna hcmv transcript ul54 ul97 ul122123 efficaci inhibit plasmid construct concord efficaci inhibit hcmv immediateearli ie1p72 ie2p86 pp65 earlyl pul97 true mcp progeni mrc5 fibroblast transfect hcmv sirna hcmv moi pfucel sirna inhibitori efficaci round sirna inhibit hcmv progeni 72 hpi siul54b 972 00001 siul97a 962 00001 siul122b 943 00001 siul122a 890 00001 siul97b 442 1000 siul54a 239 1000 concord efficaci sirna inhibit transcript 293t cellplasmid hcmv progeni round sirna hcmv transcript knockdown nonspecif offtarget sequenceindepend sirna put offtarget never rule complet obvious unaffect housekeep actin morpholog microscop inspect render unlik sirna efficaci inhibit hcmv round mrc5 transfect sirna siul54b siul97a siul122b moi 0001 pfucel sirna hcmv transcript ul122123 greatest inhibitori progeni 991 00001 siul54b 985 00001 siul97a 957 00001 western blot immunofluoresc hcmv converg plaqu siul54b siul122b block hcmv ie1p72 ie2p86 pp65 pul97 gb mcp siul97a sirna siul97a potent antihcmv moi pfucel round display moi 0001 pfucel round unclear siul97 multiplicitydepend attribut pul97 cyclin cdk ortholog cdkoverlap moi pfucel hcmv arrest effici simultan therebi cdk pul97 crucial hcmv moi moi 0001 pfucel arrest pronounc cdk supplement sirnamedi defici pul97 modest antivir antivir antihcmv antivir maribavir ul97 influenc cdk potenti antivir maribavir siul97a inhibit hcmv ie1p72 round hcmv bigley hcmv pul97 regul hcmv immediateearli phosphorylationmedi disrupt histon deacetylas immediateearli investig efficaci sirna hcmv transcript ul54 ul122123 inhibit hcmv siul97 shin siul97 siul54 inhibit hcmv ul83 ie2p86 pul83 infecti progeni make comparison sirna present analys sirna ul97 transcript siul97a display potent antihcmv compar sirna hcmv transcript ul54 ul122123 multipl siul97a lose substanti antivir multipl pul97 multifunct posse crucial hcmv review marschal pul97 valid ongo development maribavir viropharma moder ul97direct sirna multipl possibl reflect limit ul97direct sirna inhibitori efficaci sirna siul54b siul122b hcmv transcript ul54 ul122123 limit attribut transfect effici fibroblast cultur transfect 293t transient synthet sirna oppos continu sirna vector shrna residu knockdown iv hcmv countermeasur rnai review exist hcmv sirna virusencod suppressor sirna minimis transcript sirna transcript sirna virusencod sirna suppressor genom incorpor nucleotid incorpor nucleotid risk feasibl sirna escap readili hcmv intrahost variabl compar possibl select sweep immunemedi emphasis sirna hcmv transcript inhibit hcmv differ efficaci sirna transcript antivir differ multipl round sirna therapeut inhibit hcmv nonessenti hcmv transcript ul54 ul97 ul122123 reproduc antivir\n",
            "\t-2.456\tlymphocyt mirror hcv adipogenesi deregul hepat spectrum rang mild hepat endstag cirrhosi hepatocellular intrigu aspect hcv close connect play hcv hcv hepatotrop infect mononuclear pbmc goal compar adipogenesi lymphocyt hcv pbmc reflect alter occur hcvrelat steatosi adipogenesi array pbmc hcv hbv donor hd modul hcv hbvliver lymphoid pbmc reflect adipogenesi deregul adipogenesi transform upregul hcv posit virolog hepat hcv contrari hbv display complet pbmc hcv seem hcvrelat deregul biomark hcvrelat  introductionexperiment procedurespati recruit collectionvir load qualit hepat virushbv load hbeag hbsag detectioncel construct reagentsrepl assaysimmunofluorescencesampl analysishuman adipogenesi arraywestern blot analysisstatist analysisresultspati characteristicsbiochem hcv donor hdsbiochem hbv patientsvirolog hcv hbvthe adipogenesi hcv patientshcv affect liver pbmc hcv patientsth deregul adipogenesi hcvinfectionhcv hbv adipogenesi profileposs biomark hcvdepend damagehcv upregul addict transformationderegul hcv infectionin hcv upregul metabolismhcv upregul close virolog biochem steatosi fibrosi virolog biochem steatosisdiscussionsupport hepat hcv affect 170 million world grade speed cofactor gender host background alcohol coinfect hcv infect hepatocyt mononuclear pbmc hcv abnorm hypobetalipoproteinaemia steatosi steatosi throughout fibrosi histolog hcv deregul affect antivir therapi circul hcv particl chronic heterogen particl attribut apolipoproteinbeta apob triglycerid rich lipoprotein trl hybrid lipoprotein lipoviroparticl lvp lvp contain envelop glycoprotein e1 e2 capsid hcvrna infect particl infect particl lipid hcv entri partli lipoprotein ldlr matur particl apolipoprotein lipoprotein vldl hcv affect aspect lipoprotein hcvrelat deregul hepat hormon lipas lipe lipoprotein lipas lpl leptin accordingli exhibit abnorm ldl resistin retn adiponectin adipoq adipogenin adig novo beta oxid alpha lxr alpha sterol element srebp1c fatti synthas fasn acetyl coa carboxylas beta acacb hcv fatti fabp4 modul adipocyt ask pbmc mirror adipogen deregul occur hcv adipogenesi lymphocyt hcv vital homeostasi systemat deregul persist hcv pbmc reflect adipogenesi deregul hcv modul hcvrelat hcv lymphoid highlight pbmc surrog hcv steatot hepat hcv hepatotrop infect strictli hcv pbmc adipogenesi rt profil array 84 adipogenesi modul pbmc emphas compart match hcv 70 similarli deregul hcv pbmc hcvrelat deregul caus hormon lipas lipe lipoprotein lipas lpl leptin modul novo beta oxid lxr alpha srebp1c fasn acacb hcvrelat adipogen deregul support adipogen hbv liver pbmc deepli hcv accordingli j6jfh1 hcv display adipogenesi pbmc modul realli mimic hepatocyt artifact lymphocyt infiltr hcv interest overexpress adipogenin adig upregul hcv opposit respect hbv adig adipogenesi upregul kr ppellik klf hcv noteworthi klf adipogenesi klf3 regul adipogenesi erythropoiesi klf15 hbv klf15 hbv klf implic adipogenesi hepatocarcinogenesi modul appreci upregul transform adipsin complement cfd 7like tcf7l2 twist1 adipsin serin protea secret adipocyt bloodstream regul complement adipogen transform hepatocyt adipsin differ hcv respect hbv tcf7l2 wntbeta catenin hcvrelat hcc repres invas metastat posit modul adipogenesi hcv modul hbv lastli posit modul adipogenesi hcv twist1 epithelialmesenchym transit emt hcvrelat neoplast transform noteworthi deregul hcv display intrigu virolog vl abt hepat alt ast steatosi fibrosi hcv pbmc reflect adipogenesi pbmc real valid hcvrelat pathogenet deregul explor therapeut overcom hcvrelat transform\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.539\thepat substanc user enrol communitybas hepat hcv frequent bloodborn epidemiolog hcv complet understood minor hcv substanc abus femal institut alcohol abus alcohol niaaa institut abus nida fund street recruit month interview substanc sexual behavior implement share practic tattoo pierc transfus share person hygien equip tweezer toothbrush razor urin hcv ab sexual transmit std 782 predominantli african american 162 hcv ab 0001 inject 0001 lifetim crack cocain 0004 tattoo 001 hcv ab posit hcv ab posit sexual behavior hcv ab predominantli african american substanc abus hcv ab posit awar hcv serostatu intraven idu hcv ab posit tattoo lifetim crack rout hcv  backgroundmethodssampl descriptionlaboratori testingstatist analysesresultsbaselin characteristicssubst sexual behaviourmultivari analysessubgroup analysesdiscussionconclusionscompet interestsauthor contribut hepat hcv frequent bloodborn caus morbid 4500 inhospit death hcv nutrit nhane hcv ab million person chronic hcv hcv endstag subsequ transplant hcv indic transplant transplant hcv hcv origin document nona nonb caus transfus hepat hcv spread parenter intraven idu introduct univers 1990 transfus hcv hcv vari depend race epidemiolog hcv african american reason hcv femal male regardless race hcv femal extens set coinfect vertic hcv inject predomin rout idu hcv rang 6090 carri morbid burden sexual hcv hepat sexual hcv vertic 67 viremia rout idu tattoo pierc share prepar equip share person hygien item hcv noninject user intranas cocain share drugus equip hcv virolog confirm hcv nasal secret support epidemiolog comprehens hcv underrepres hcv substanc abus predominantli african american femal epidemiolog eprg washington univers school highlight born reach understudi underreport epidemiolog inject contribut hcv ab posit predominantli african american substanc abus reveal awar hcv ab awar hcv ab implic perspect hcv counsel overcom barrier ensur referr comprehens incorpor address substanc idu hcv ab posit tattoo lifetim crack inject rout hcv largescal prospect compet interest\n",
            "\t0.507\thepat cascad call address ongo barrier aim hepat hcv cascad hivinfect reason refer initi hcv complet hcv stage retrospect hivinfect univers california san diego ucsd screen hcv logist regress referr hcv electron record review ascertain reason initi hcv 4725 hivinfect ucsd owen clinic 4534 96 screen hcv 748 reactiv hcv 542 hcv engag predictor nonreferr hcv odd 508 confid interv 324 697 000001 predictor unstabl hous 226 aid 183 detect load 198 nonwhit 167 reason initi defer hcv ongo barrier hcv hivinfect half hcv refer hcv improv hcv benefit realiz unless deal barrier implement  introductionmethodspati hcv carestudi designstudi definitionsstatist analysisresultsdemograph count load refer nonref hepat considerationcommon provid decis referr hivinfect hepat considerationpredictor nonb refer hcv consider 562 unadjust adjust analysesth depict hepat cascad hivinfect attend univers california san diego owen clinic januari 31 decemb 2012discussionsupport person live immunodefici coinfect hepat hcv guidelin recommend hcv person establish diver clinic 85 hivinfect person hcv 3month enrol hcv hivinfect person advanc hcv hcv europ hcv liverrel morbid contribut cost urgent hcv hivinfect person advent act antivir hcv opportun cure hcv coinfect person influenc hcv referr disposit hcv establish reason nonreferr hcv initi hcv hivinfect refer hcv narrow gap hcv nonreferr hcv consider character reason start hcv complet hcv stage describ hcv cascad hcv owen clinic univers california san diego ucsd conclusions1 hivinfect screen hcv half hivinfect hcv coinfect refer hcv reason initi hcv ongo barrier compromis engag reflect extant dispar nonwhit engag unstabl hous uncontrol hivinfect refer hcv idu refer hcv msm idu want refer stigma hcv msm iud creat opportun awar provid rise hcv hivinfect msm idu coinfect ongo hcv refer hcv interferon contraind hcv referr neither unwilling receiv hcv interferonbas detail clinic note highlight interferon regimen cure immedi barrier referr address never receiv hcv unexpect ongo substanc abus neuropsychiatr predictor hcv referr ascertain bia explan refer hcv engag reliabl selfreport ongo alcohol abus uncertain similarli systemat evalu document alcohol abus neuropsychiatr electron record refer hcv noniniti hcv attribut alcohol abus neuropsychiatr engag refer hcv realworld challeng success hcv accomplish 4188 start attain sustain interferonfre therapi efficaci shorter approv emphasi place implement integr multidisciplinari hcv alcohol substanc stigma discrimin coinfect retain initi hcv cur insur incom influenc referr hcv hcv coinfect clinic oper clinic insur coverag allow univers hcv argu definit engag gold miss visit gap visit constanc comprehens descript engag chose hrsa hivaid bureau retent align updat guidelin highlight concept adher restrict reason initi hcv finish hcv stage critic 53 303 refer hcv never hcv appoint return hcv appoint 33 rule unmeasur travel distanc clinic hcv literaci neg impact hcv initi limit balanc strength complet hcv stage underw detail character logist barrier hcv initi generaliz fund geograph percentag coinfect ultim hcv sustain mirror cohort europ improv hcv benefit realiz unless deal barrier address\n",
            "\t0.503\tcoronavirus simultan stool nasopharyng swab hospit gastroenter coronavirus hcov wellknown gastrointestin unclear object signific hcov etiolog gastroenter stool nasopharyng np swab 260 hospit 160 157 otherwis admit elect hcov real rtpcr regist clinicaltrialsgov reg nct00987519 hcov frequent 23260 88 4151 odd 33 confid interv 001 hcovposit asymptomat sampl recal gastrointestin hcov np stool 22256 86 6260 00004 56 hcov stool np swab probabl hcov stool 153 0006 stool np 33 001 hcov stool np hcov hcov np swab compound occurr stool stool hcov minor caus gastrointestin ill old coronavirusvir gastroenteritisrespiratori backgroundresultspatientsdetect hcov stool np swab agecontrol groupdiscussionconclusionsmethodsstudi designlaboratori methodsstatist analysisabbreviationscompet interestsauthor contribut  hcov frequent demonstr probabl hcov stool causal hcov interpret hcov np swab stool stool half sign rti hcov play minor gastrointestin ill\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.008\traloxifen inhibit hepat postmenopaus hepat exhibit interferon premenopaus osteoporosi typic complic postmenopaus osteoporot reagent vitamin d3 exhibit antihepat hcv osteoporot reagent raloxifen exhibit antihcv raloxifen inhibit hcv genotyp 1b genotyp 2a raloxifen antihcv link biolog osteoporosi hcv  introductionmateri methodsreag antibodiescel hcv rnasrl assaywst1 assaywestern blot analysishcv infectionresultsraloxifen inhibit hcv replicationraloxifen antihcv raloxifen antagon antihcv statinraloxifen inhibit genotyp 2a hcvdiscuss hepat hcv belong flavivirida singlestrand 96 kb hcv encod polyprotein precursor 3000 cleav protea core envelop e1 e2 p7 nonstructur ns2 ns3 ns4a ns4b ns5a ns5b virolog antivir reagent hcv replicon infecti hcv genotyp 2a hcv jfh1 hepatomaderiv huh7 hcv reproduc genomelength hcv report huh7deriv or6 or6 genotyp 1b hcvo renilla luciferas rl replic robustli hcv jfh1 report hcv hepat ch seriou cirrhosi hepatocellular hcv worldwid elimin hcv antivir reagent prevent fatal pegylatedinterferon pegifn ribavirin rbv ch sustain virolog svr remain protea telaprevir svr 70 pegifnrbv pegifnrbv depend gender ifnrbv postmenopaus ch exhibit premenopaus estrogen dyslipidemia osteoporosi typic postmenopaus statin dyslipidemia reagent inhibit hcv vitamin d3 osteoporot reagent exhibit antihcv estradiol inhibit infecti hcv hepat estrogen raloxifen tamoxifen synthet select estrogen modul serm osteoporosi set serm estrogen er serm exhibit agonist action antagonist action raloxifen tamoxifen antagonist agonist tamoxifen raloxifen exhibit agonist uteru tamoxifen inhibit hcv tamoxifen agonist uterin raloxifen belong antiosteoporot reagent offer advantag uterin decid raloxifen exhibit antihcv raloxifen osteoporot reagent inhibit genotyp 1b hcv inhibit genotyp 2a hcv jfh1 raloxifen addit antihcv raloxifen exhibit antagonist statin pegifnrbv svr ch telaprevir pegifnrbv pegifnrbv complic anemia pegifnrbv telaprevir ad consid pegifnrbvbas postmenopaus addon postmenopaus candid improv svr reagent compens estrogen dyslipidemia osteoporosi postmenopaus attribut estrogen statin clinic reagent dyslipidemia inhibit hcv raloxifen exhibit antihcv genotyp 1b hcv genotyp 2a hcv raloxifen inhibit genotyp 2a hcv genotyp 1b hcv raloxifen reagent antihcv hcv clarifi vitamin d3 osteoporot reagent inhibit hcv vitamin d3 ch statin inhibit hcv suppress geranylgeranyl pyrophosph ggpp osteoporot reagent bisphosphon posse antihcv inhibit biosynthesi ggpp mevalon inhibit farnesyl pyrophosph synthetas hcv osteoporosi raloxifen tamoxifen serm osteoporosi tamoxifen estrogen receptorposit inhibit hcv tamoxifen antihcv raloxifen inhibit hcv clarifi multipotenti raloxifen uterin raloxifen tamoxifen advantag raloxifen ch precis hcv reach microarray or6 hayashida potent estrogen estradiol inhibit infecti hcv huh75 select agonist inhibit infecti hcv select agonist watashi interferencemedi knockdown hcv antihcv raloxifen seem attribut huh7deriv or6 express huh7 1982 okayama univers distribut worldwid bensadoun background il28b genotyp huh7 differ laboratori consequ polyploid hepatoma gpr30 or6 microarray gpr30 antihcv or6 clarifi issu raloxifen inhibit hcv genotyp 1b genotyp 2a raloxifen addit antihcv antagonist statin raloxifen yield reagent vitamin d3 antihcv field osteoporosi hcv\n",
            "\t-2.300\tcytomegaloviru strictli inhibit sirna ul54 ul97 ul122123 transcript cytomegaloviru hcmv sequela immunocompromis host antivir therapi seriou set problemat make interf rna sirna hcmv transcript ul54 polymeras ul97 ul122123 immediateearli cultur sirna hcmv design western blot plaqu continu embryon 293t hcmv nonspecif scrambl sisc sirna transfect plasmid express transcript mrc5 fibroblast hcmvsirna sisc hcmv ad169 pfucel hcmv immediateearli ie1p72 ie2p86 pp65 earlyl pul97 true mcp progeni round concord siul54b siul97a siul122b display potent inhibitori 927 996 937 plasmid 659 581 648 hcmv 972 962 943 00001 progeni analys sirna inhibitori round hcmv multipl 0001 pfucel siul54b siul97a siul122b 800 596 845 hcmv 529 492 583 985 914 991 00001 progeni dpi sirna therapi hcmv transcript ul54 ul97 ul122123 antivir sirna ul97 load  introductionresultsdiffer hcmv sirna display vari efficaci inhibit plasmidderiv transcript targetssirna inhibit plasmidderiv hcmv expressionsirna silenc plasmidderiv hcmv correl inhibit hcmv progeni round replicationsirna inhibit hcmv round hcmv multipl infectionsirna inhibit hcmv progeni round hcmv multipl infectionhcmv sirna ul54 ul97 ul122123 transcript inhibit hcmv progeni round replicationsirna hcmv progeni round multipl infectionsirna progeni multipl round hcmv concord hcmv expressionsirna hcmv round multipl infectionsirna hcmv dissemin round multipl infectionsirna hcmv dissemin round multipl infectiondiscussionmethodscel prepar stockssirna antisens sequencessirna assayssirna transfect infectionvir curveswestern blot analysisimmunofluorescencestatist cytomegaloviru hcmv ubiquit caus seriou sequela immunocompromis fetu introduct rubella immunis hcmv infecti congenit malform licens vaccin routin hcmvinduc take compromis seroposit reactiv transplant recipi fetu antivir hcmv ganciclovir valganciclovir foscarnet cidofovir fomivirsen toxic unsuit set immunocompromis emerg resist mutant subset period press treat hcmv development letermovir aicuri wuppert germani terminas present undergo promis final approv put address detail synthet interf sirna patholog neurolog effect sirna hcmv immunodefici virus1 hepat hepat polioviru papillomaviru influenza develop sirna technolog immunostimulatori offtarget efficaci sirna nanoparticl vehicl sirna promis treat hcmv permiss hcmv undergo tempor sequenti initi immediateearli transcrib polymeras requir hcmv immediateearli ie1p72 ie2p86 altern splice precursor transcript ul122123 auxiliari immediateearli transactiv hcmv immediateearli antivir fomivirisen 21nucleotid antisens act translat hcmv immediateearli secondlin hcmv retin hcmv encod polymeras pul54 hcmv pul97 nonessenti hcmv pul54 pul97 antivir hcmv former princip antivir primarili encod assembl egress enabl reactiv public sirna antihcmv efficaci ul54 ul97 ul122123 transcript date hcmv transcript ident analys inhibitori efficaci sirna hcmv transcript ul54 ul97 ul122123 measur hcmv immediateearli ie1p72 ie2p86 pp65 earlyl pul97 true mcp progeni round hcmv mrc5 fibroblast fibroblast hcmv sirna ul54 ul97 ul122123 inhibitori hcmv multiround cycl utilis sirna hcmv transcript ul54 ul97 ul122123 efficaci inhibit plasmid construct concord efficaci inhibit hcmv immediateearli ie1p72 ie2p86 pp65 earlyl pul97 true mcp progeni mrc5 fibroblast transfect hcmv sirna hcmv moi pfucel sirna inhibitori efficaci round sirna inhibit hcmv progeni 72 hpi siul54b 972 00001 siul97a 962 00001 siul122b 943 00001 siul122a 890 00001 siul97b 442 1000 siul54a 239 1000 concord efficaci sirna inhibit transcript 293t cellplasmid hcmv progeni round sirna hcmv transcript knockdown nonspecif offtarget sequenceindepend sirna put offtarget never rule complet obvious unaffect housekeep actin morpholog microscop inspect render unlik sirna efficaci inhibit hcmv round mrc5 transfect sirna siul54b siul97a siul122b moi 0001 pfucel sirna hcmv transcript ul122123 greatest inhibitori progeni 991 00001 siul54b 985 00001 siul97a 957 00001 western blot immunofluoresc hcmv converg plaqu siul54b siul122b block hcmv ie1p72 ie2p86 pp65 pul97 gb mcp siul97a sirna siul97a potent antihcmv moi pfucel round display moi 0001 pfucel round unclear siul97 multiplicitydepend attribut pul97 cyclin cdk ortholog cdkoverlap moi pfucel hcmv arrest effici simultan therebi cdk pul97 crucial hcmv moi moi 0001 pfucel arrest pronounc cdk supplement sirnamedi defici pul97 modest antivir antivir antihcmv antivir maribavir ul97 influenc cdk potenti antivir maribavir siul97a inhibit hcmv ie1p72 round hcmv bigley hcmv pul97 regul hcmv immediateearli phosphorylationmedi disrupt histon deacetylas immediateearli investig efficaci sirna hcmv transcript ul54 ul122123 inhibit hcmv siul97 shin siul97 siul54 inhibit hcmv ul83 ie2p86 pul83 infecti progeni make comparison sirna present analys sirna ul97 transcript siul97a display potent antihcmv compar sirna hcmv transcript ul54 ul122123 multipl siul97a lose substanti antivir multipl pul97 multifunct posse crucial hcmv review marschal pul97 valid ongo development maribavir viropharma moder ul97direct sirna multipl possibl reflect limit ul97direct sirna inhibitori efficaci sirna siul54b siul122b hcmv transcript ul54 ul122123 limit attribut transfect effici fibroblast cultur transfect 293t transient synthet sirna oppos continu sirna vector shrna residu knockdown iv hcmv countermeasur rnai review exist hcmv sirna virusencod suppressor sirna minimis transcript sirna transcript sirna virusencod sirna suppressor genom incorpor nucleotid incorpor nucleotid risk feasibl sirna escap readili hcmv intrahost variabl compar possibl select sweep immunemedi emphasis sirna hcmv transcript inhibit hcmv differ efficaci sirna transcript antivir differ multipl round sirna therapeut inhibit hcmv nonessenti hcmv transcript ul54 ul97 ul122123 reproduc antivir\n",
            "\t-2.456\tlymphocyt mirror hcv adipogenesi deregul hepat spectrum rang mild hepat endstag cirrhosi hepatocellular intrigu aspect hcv close connect play hcv hcv hepatotrop infect mononuclear pbmc goal compar adipogenesi lymphocyt hcv pbmc reflect alter occur hcvrelat steatosi adipogenesi array pbmc hcv hbv donor hd modul hcv hbvliver lymphoid pbmc reflect adipogenesi deregul adipogenesi transform upregul hcv posit virolog hepat hcv contrari hbv display complet pbmc hcv seem hcvrelat deregul biomark hcvrelat  introductionexperiment procedurespati recruit collectionvir load qualit hepat virushbv load hbeag hbsag detectioncel construct reagentsrepl assaysimmunofluorescencesampl analysishuman adipogenesi arraywestern blot analysisstatist analysisresultspati characteristicsbiochem hcv donor hdsbiochem hbv patientsvirolog hcv hbvthe adipogenesi hcv patientshcv affect liver pbmc hcv patientsth deregul adipogenesi hcvinfectionhcv hbv adipogenesi profileposs biomark hcvdepend damagehcv upregul addict transformationderegul hcv infectionin hcv upregul metabolismhcv upregul close virolog biochem steatosi fibrosi virolog biochem steatosisdiscussionsupport hepat hcv affect 170 million world grade speed cofactor gender host background alcohol coinfect hcv infect hepatocyt mononuclear pbmc hcv abnorm hypobetalipoproteinaemia steatosi steatosi throughout fibrosi histolog hcv deregul affect antivir therapi circul hcv particl chronic heterogen particl attribut apolipoproteinbeta apob triglycerid rich lipoprotein trl hybrid lipoprotein lipoviroparticl lvp lvp contain envelop glycoprotein e1 e2 capsid hcvrna infect particl infect particl lipid hcv entri partli lipoprotein ldlr matur particl apolipoprotein lipoprotein vldl hcv affect aspect lipoprotein hcvrelat deregul hepat hormon lipas lipe lipoprotein lipas lpl leptin accordingli exhibit abnorm ldl resistin retn adiponectin adipoq adipogenin adig novo beta oxid alpha lxr alpha sterol element srebp1c fatti synthas fasn acetyl coa carboxylas beta acacb hcv fatti fabp4 modul adipocyt ask pbmc mirror adipogen deregul occur hcv adipogenesi lymphocyt hcv vital homeostasi systemat deregul persist hcv pbmc reflect adipogenesi deregul hcv modul hcvrelat hcv lymphoid highlight pbmc surrog hcv steatot hepat hcv hepatotrop infect strictli hcv pbmc adipogenesi rt profil array 84 adipogenesi modul pbmc emphas compart match hcv 70 similarli deregul hcv pbmc hcvrelat deregul caus hormon lipas lipe lipoprotein lipas lpl leptin modul novo beta oxid lxr alpha srebp1c fasn acacb hcvrelat adipogen deregul support adipogen hbv liver pbmc deepli hcv accordingli j6jfh1 hcv display adipogenesi pbmc modul realli mimic hepatocyt artifact lymphocyt infiltr hcv interest overexpress adipogenin adig upregul hcv opposit respect hbv adig adipogenesi upregul kr ppellik klf hcv noteworthi klf adipogenesi klf3 regul adipogenesi erythropoiesi klf15 hbv klf15 hbv klf implic adipogenesi hepatocarcinogenesi modul appreci upregul transform adipsin complement cfd 7like tcf7l2 twist1 adipsin serin protea secret adipocyt bloodstream regul complement adipogen transform hepatocyt adipsin differ hcv respect hbv tcf7l2 wntbeta catenin hcvrelat hcc repres invas metastat posit modul adipogenesi hcv modul hbv lastli posit modul adipogenesi hcv twist1 epithelialmesenchym transit emt hcvrelat neoplast transform noteworthi deregul hcv display intrigu virolog vl abt hepat alt ast steatosi fibrosi hcv pbmc reflect adipogenesi pbmc real valid hcvrelat pathogenet deregul explor therapeut overcom hcvrelat transform\n",
            "HCV infection,IFN,RBV None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.468\tshortterm intrasubject exhal volatil organ voc copd classif exhal volatil organ voc noninvas breath voc breath assum wholli repres person motiv variabl breath profil breath minut interv 118 obstruct copd 63 ga chromatographi spectroscopi gcm voc differ copd differ isopren bulk voc machin breath establish differ discrimin copd aggreg set offer discrimin breath gave classif separ 665 683 classifi correctli depend breath repetit combin breath set gave discrimin 734 classifi correctli copd set sampl variabl shortterm exert breath reliabl optim discrimin copdexh volatil organ vocvariationmachin introduction2 section21 subjects22 breath sampl procedure23 normalization24 intra subject variabl voc levels25 classif copd machin methods3 discussion31 breath 332 classif copd machin methods33 discussion331 isoprene332 vocs333 breath repetit discrimin copd states334 implications335 improv techniques4 conclus  voc vari sequenti breath voc differ copd differ isopren bulk voc breath gave classif separ 665 683 classifi correctli depend breath repetit aggreg breath set gave notic discrimin breath classif improv 734 classifi reliabl standard sampl minutebyminut variabl voc shortterm exert breath repres offer optim discriminatori\n",
            "\t0.468\tshortterm intrasubject exhal volatil organ voc copd classif exhal volatil organ voc noninvas breath voc breath assum wholli repres person motiv variabl breath profil breath minut interv 118 obstruct copd 63 ga chromatographi spectroscopi gcm voc differ copd differ isopren bulk voc machin breath establish differ discrimin copd aggreg set offer discrimin breath gave classif separ 665 683 classifi correctli depend breath repetit combin breath set gave discrimin 734 classifi correctli copd set sampl variabl shortterm exert breath reliabl optim discrimin copdexh volatil organ vocvariationmachin introduction2 section21 subjects22 breath sampl procedure23 normalization24 intra subject variabl voc levels25 classif copd machin methods3 discussion31 breath 332 classif copd machin methods33 discussion331 isoprene332 vocs333 breath repetit discrimin copd states334 implications335 improv techniques4 conclus  voc vari sequenti breath voc differ copd differ isopren bulk voc breath gave classif separ 665 683 classifi correctli depend breath repetit aggreg breath set gave notic discrimin breath classif improv 734 classifi reliabl standard sampl minutebyminut variabl voc shortterm exert breath repres offer optim discriminatori\n",
            "\t0.458\twoman dyspnea hemoptysi 55yearold emerg depart cough fever dyspnea bloodstreak sputum chest radiograph order pneumonia discharg home antibiot return afebril worsen dyspnea gross hemoptysi murmur never echocardiographi comput tomographi chest echocardiographi atrial myxoma video transfer underw excis  discus discus 005 overwhelm myxoma atrium atrium ventricl myxoma histolog present benign myxoma triad consist obstruct short breath malais embol reveal murmur plop mimic mitral stenosi evalu etiolog present echocardiographi chest comput tomographi ct magnet reson mri angiographi echocardiographi advantag shape locat mobil dynam fashion sensit nearli transthorac transesophag mri ct lesser reliabl determin origin 96 10year \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.508\tfever short breath   questionsanswersdiscuss radiolog miliari tubercl fundu complic pneumomediastinum mediastin emphysema air mediastinum ga origin mediastin airway esophagu neck fascial plane abdomin caviti iv interstiti commonest air mediastin space sudden alveolar caus ruptur ruptur escap air perivascular peribronchi interstitium air reach hilum mediastin space air track upward fascial plane reach neck sheath aorta reach abdomen air ruptur mediastin pleura pneumothorax pneumomediastinum clinic chest dyspnea reveal subcutan emphysema neck anterior chest wall crunch sound synchron sound heard auscult chest hamman sign sign pneumomediastinum radiolog pneumomediastinum radioluc streak air outlin mediastin displac mediastin pleura uncontrol hematogen dissemin mycobacterium tuberculosi miliari tuberculosi occurr pneumomediastinum subcutan emphysema excess cough miliari tuberculosi alveolar ruptur sudden intraalveolar concomit airway narrow forc air interstiti thenc adventitia hilum pneumomediastinum subcutan emphysema pneumothorax occur complic miliari tuberculosi describ occurr pneumothorax miliari tuberculosi entiti\n",
            "\t-3.796\tshort breath bilater infiltr eosinophil clinic challeng diagnos come classif eosinophil eosinophil infiltr actual eosinophil 54yearold woman asthma short breath eosinophilia broad includ infecti churg strauss hematolog hypereosinophil challeng inher present chang landscap label evolv abnorm  reportdiscuss 54yearold caucasian woman emerg depart 3week product cough short breath malais visit ear nasal full sinus 10day levofloxacin triamcinolon nasal spray short breath exert fever chill rigour intermitt night sweat reevalu present clarithromycin 500 mg twice communityacquir pneumonia progress came emerg depart resid husband child director homeless shelter inspect shelter weekli tuberculin deni lifelong nonsmok consum alcohol beverag week deni sick contact allergi travel allerg rhiniti recurr sinus asthma asthma inhal steroid fluticason shortact agonist salbutamol salmeterol leukotrien antagonist montelukast began take montelukast present corticosteroid asthma exacerb separ occas preced present present asthma clarithromycin triamcinolon nasal spray anaphylact allergi lactos appear thin moder distress rest febril 38 pul 104 beatsmin 13977 hg 34 breathsmin satur 92 room air auscult chest breath sound throughout field crackl heard predominantli upper lobe precordium sound grade iivi systol eject murmur heard base rash rest bloodwork hemoglobin 146 138 175 gl white count 293 45 167 57 eosinophil 378 neutrophil 62 lymphocyt monocyt basophil arteri ga 749 735 745 partial carbon dioxid co 45 hg partial 57 80 hg bicarbon mmoll lactic dehydrogenas 357 iul reactiv 136 mgl rheumatolog wegen granulomatosi goodpastur rheumatoid antinuclear titer antineutrophil cytoplasm antiglomerular basement immunoglobulin titer asid ige 1280 iul chest radiograph bilater infiltr spare radiographi pneumonia tuberculosi warrant consider occup insidi ill asthma infiltr place churg strauss box broadspectrum empir ceftriaxon clarithromycin initi montelukast discontinu montelukast churg strauss vascul asthma antibiot remain febril 39 tachycard 110 beatsminut tachypn breathsmin maintain satur 90 cultur sputum urin stool yield stain sputum specimen acidfast bacillus enzymelink immunosorb elisa urin legionella comput tomographi chest mild mediastin lymphadenopathi paratrach lymph node measur cm diamet bilater pleural effus extens airspac scatter consolid lobe confluent consolid upper lobe embolu cavit locul pleural irregular complain short breath retrostern chest heavi rest troponin 094 gl creatin phosphokinas cpk 290 160 iul cpk mb fraction electrocardiogram anterior st segment elev mild pr segment ischemia pericard echocardiogram ventricular eject fraction anterior wall hypokinesi trace pericardi effus valvular abnorm echocardiographi conjunct screen antineutrophil cytoplasm eosinophil count myocardi churg strauss hypereosinophil consent bronchoscopi discret bronchial lavag fluid contain 92 eosinophil lymphocyt neutrophil 70 80 histiocyt malign gram acidfast stain transbronchi biopsi defer coagul bonemarrow aspir biopsi marrow exhibit 45 55 eosinophil hyperplasia erythropoiesi granulopoiesi atypia granuloma lymphoid aggreg metastat suspicion churg strauss comput tomographi scan parana sinus minor mucos thicken floor maxillari sinus eosinophilia multisystem emerg depart asthma antibiot work diagnos churg strauss hypereosinophil antibiot discontinu mg prednisolon cough fever short breath resolv next white count white return repeat chest radiogram bilater opac repeat electrocardiogram ischemia discharg home instruct slowli taper prednisolon mg presumpt discharg churg strauss echocardiogram outpati resolut wall motion abnorm cytogenet hypereosinophil f1p1l1pdgfralpha note cytogenet hypereosinophil vari cytogenet predict success imatinib 80 remiss interleukin5 sometim subgroup hypereosinophilia clonal antiinterleukin5 benefici discharg recurr eosinophil count hydroxyurea eosinophil count prednisolon taper mgday magnet reson mildli dilat ventricl eject fraction systol repeat chest radiographi abdomin ultrasound unremark film eosinophilia chest radiograph anteriorposterior view comput tomogram chest carina marrow biospsi eosinophilia box american colleg rheumatolog 1990 classif churg strauss sign communityacquir pneumonia pneumonia clue expand occup nonresolv rais tuberculosi diagnos churg strauss druginduc asthma leukotrien antagonist eosinophilia rais suspicion hematolog hypereosinophil box hypereosinophil churg strauss hypereosinophil syndrom eosinophil challeng classif eosinophil eosinophil infiltr classif actual eosinophil eosinophilia simplifi classif hing question eosinophilia intrins eosinophil extrins outsid eosinophil lineag intrins eosinophil hematolog affect pluripot multipot extrins eosinophil trigger cytokin eosinophil precursor intrins eosinophil chromosom abnorm involv tyrosin fibroblast plateletderiv abnorm involv plateletderiv manifest clonal involv pluripot cytogenet f1p1l1pdgfralpha commerci basic reversetranscriptas polymeras recogn abnorm transcript karyotyp interstiti delet 3colour fluoresc situhybrid util cytogenet myelocyt leukemia cml cml philadelphia fusion product bcrabl1 tyrosin unregul clonal myeloid cml bcrabl1 allow discoveri success molecul imatinib mesyl remiss cml extrins eosinophil numer subdivid tcellmedi tumourcellmedi eosinophil tcellmedi eosinophilia allerg bronchial asthma autoimmun churg strauss interleukin5 mediat eosinophil eosinophil worsen organ implic remodel cytogenet elimin eosinophil push clinician consid diagnos idiopath hypereosinophil patholog eosinophilia neither clonal document endorgan absolut eosinophil count definit cytogenet marrow histolog display abnorm mast monocytosi trilineag myeloprolifer dysplasia hypereosinophil includ highdos steroid firstlin hydroxyurea ad remiss classic push toward churg strauss promin spectrum organ organfocus classif ill seem consid idiopath hypereosinophil tradit categor flux learn aid clinician make clinician reli patholog abnorm spark revolut diagnos dyscrasia discoveri philadelphia dramat chang involv neoplast transform jak2 myeloprolif histor classifi oper myeloid lymphoid morpholog blast delin decad classif genet immunolog increasingli train recogn syndrom patholog realiti dyscrasia asymptomat film cytogenet becom mainstay confirm pretest probabl epigenet hered examin background epigenet modifi deleteri epigenet modif coval modif nucleosom histon underli reclassif dyscrasia unlik epigenet definit revers offer excit hope modifi carri label idiopath hypereosinophil unless develop necessit continu treat immunosuppress await deeper true intrins extrins trigger box hypereosinophil epidemiolog churg strauss hypereosinophil\n",
            "\t-4.563\tcor pulmonal atrial 0002 025 intracardiac manifest embol hepatocellular hcc uncommon autopsi 32yearold asian man refer short breath last month unproduct cough manual labor alcohol clinic embol echocardiogram atrium magnet reson atrium extend inferior vena cava portal hepat antigenposit hepat underw excis patholog hcc embolus lung kind highlight 6monthli hepat hcc  reportdiscussionconclusionsdisclosur statement 32yearold asian man manual labor insidi breathless exert lowgrad intermitt fever fever occur even rigor chill take paracetamol 500 mg practition gave temporari relief back regularli take glibenclamid mg twice habitu alcohol consum 200 ml countrymad liquor cigarett product cough scanti whitish sputum hospit past kg month admiss experienc cardiospecif past emerg servic cor pulmonal consciou dyspneic tachycardia 140min tachypnea 26min jugular venou pul cm sternal angl exhibit grade club icteru lymphadenopathi enlarg cm costal margin spleen tip palpabl s1 s2 loud loud p2 ventricular s3 exhibit murmur bilater basal crepit wheez electrocardiogram chest xray move ward routin investig emerg echocardiogram occupi atrium attach interatri septum transesophag echocardiogram cm atrium extens inferior vena cava ivc attach interatri septum tricuspid valv suggest abdomin ultrasound mild hepatomegali coars echo textur portal vein diamet suggest portal promin hepat vein ivc atrium doppler venou limb esophagogastroduodenoscopi grade esophag varic routin investig urinalysi bilirubin mgdl 06 mgdl glutam oxaloacet transaminaseglutamicpyruv transaminas 23890 iu alkalin phosphatas 197 iu 140 89 gdl albumin 39 gdl prothrombin 132 intern normal alphafetoprotein 67751 ngdl 72 carcinoembryon 644 ngdl 34 hepat antihepat core hepat weil widal brucella agglutin titer immunodefici magnet reson thorax fill atrium 2a magnet reson thorax abdomen atrium extend ivc middl hepat vein irregular fill defect superior vein suggest embolu cirrhot 2b emerg excis atrial specimen sent histopatholog resect neoplasm trabecular perivascular hepatocyt moder eosinophil cytoplasm vesicular nucleus promin nucleolus section atrium malign atrium embolus confirm atrial hepatocellular hcc immedi postop sudden worsen succumb hcc atrium embol alcohol cirrhosi portal hepat clinic silent view camouflag hcc prefer perform alphafetoprotein abdomin ultrasound everi concurr cirrhosi hepat echocardiograph soon angina pectori embol rhythm disturb murmur becom audibl adequ surveil mandatori consid dismal ineffect surveil implement practition disclosur statement\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.468\tshortterm intrasubject exhal volatil organ voc copd classif exhal volatil organ voc noninvas breath voc breath assum wholli repres person motiv variabl breath profil breath minut interv 118 obstruct copd 63 ga chromatographi spectroscopi gcm voc differ copd differ isopren bulk voc machin breath establish differ discrimin copd aggreg set offer discrimin breath gave classif separ 665 683 classifi correctli depend breath repetit combin breath set gave discrimin 734 classifi correctli copd set sampl variabl shortterm exert breath reliabl optim discrimin copdexh volatil organ vocvariationmachin introduction2 section21 subjects22 breath sampl procedure23 normalization24 intra subject variabl voc levels25 classif copd machin methods3 discussion31 breath 332 classif copd machin methods33 discussion331 isoprene332 vocs333 breath repetit discrimin copd states334 implications335 improv techniques4 conclus  voc vari sequenti breath voc differ copd differ isopren bulk voc breath gave classif separ 665 683 classifi correctli depend breath repetit aggreg breath set gave notic discrimin breath classif improv 734 classifi reliabl standard sampl minutebyminut variabl voc shortterm exert breath repres offer optim discriminatori\n",
            "\t0.468\tshortterm intrasubject exhal volatil organ voc copd classif exhal volatil organ voc noninvas breath voc breath assum wholli repres person motiv variabl breath profil breath minut interv 118 obstruct copd 63 ga chromatographi spectroscopi gcm voc differ copd differ isopren bulk voc machin breath establish differ discrimin copd aggreg set offer discrimin breath gave classif separ 665 683 classifi correctli depend breath repetit combin breath set gave discrimin 734 classifi correctli copd set sampl variabl shortterm exert breath reliabl optim discrimin copdexh volatil organ vocvariationmachin introduction2 section21 subjects22 breath sampl procedure23 normalization24 intra subject variabl voc levels25 classif copd machin methods3 discussion31 breath 332 classif copd machin methods33 discussion331 isoprene332 vocs333 breath repetit discrimin copd states334 implications335 improv techniques4 conclus  voc vari sequenti breath voc differ copd differ isopren bulk voc breath gave classif separ 665 683 classifi correctli depend breath repetit aggreg breath set gave notic discrimin breath classif improv 734 classifi reliabl standard sampl minutebyminut variabl voc shortterm exert breath repres offer optim discriminatori\n",
            "\t0.458\twoman dyspnea hemoptysi 55yearold emerg depart cough fever dyspnea bloodstreak sputum chest radiograph order pneumonia discharg home antibiot return afebril worsen dyspnea gross hemoptysi murmur never echocardiographi comput tomographi chest echocardiographi atrial myxoma video transfer underw excis  discus discus 005 overwhelm myxoma atrium atrium ventricl myxoma histolog present benign myxoma triad consist obstruct short breath malais embol reveal murmur plop mimic mitral stenosi evalu etiolog present echocardiographi chest comput tomographi ct magnet reson mri angiographi echocardiographi advantag shape locat mobil dynam fashion sensit nearli transthorac transesophag mri ct lesser reliabl determin origin 96 10year \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.508\tfever short breath   questionsanswersdiscuss radiolog miliari tubercl fundu complic pneumomediastinum mediastin emphysema air mediastinum ga origin mediastin airway esophagu neck fascial plane abdomin caviti iv interstiti commonest air mediastin space sudden alveolar caus ruptur ruptur escap air perivascular peribronchi interstitium air reach hilum mediastin space air track upward fascial plane reach neck sheath aorta reach abdomen air ruptur mediastin pleura pneumothorax pneumomediastinum clinic chest dyspnea reveal subcutan emphysema neck anterior chest wall crunch sound synchron sound heard auscult chest hamman sign sign pneumomediastinum radiolog pneumomediastinum radioluc streak air outlin mediastin displac mediastin pleura uncontrol hematogen dissemin mycobacterium tuberculosi miliari tuberculosi occurr pneumomediastinum subcutan emphysema excess cough miliari tuberculosi alveolar ruptur sudden intraalveolar concomit airway narrow forc air interstiti thenc adventitia hilum pneumomediastinum subcutan emphysema pneumothorax occur complic miliari tuberculosi describ occurr pneumothorax miliari tuberculosi entiti\n",
            "\t-3.796\tshort breath bilater infiltr eosinophil clinic challeng diagnos come classif eosinophil eosinophil infiltr actual eosinophil 54yearold woman asthma short breath eosinophilia broad includ infecti churg strauss hematolog hypereosinophil challeng inher present chang landscap label evolv abnorm  reportdiscuss 54yearold caucasian woman emerg depart 3week product cough short breath malais visit ear nasal full sinus 10day levofloxacin triamcinolon nasal spray short breath exert fever chill rigour intermitt night sweat reevalu present clarithromycin 500 mg twice communityacquir pneumonia progress came emerg depart resid husband child director homeless shelter inspect shelter weekli tuberculin deni lifelong nonsmok consum alcohol beverag week deni sick contact allergi travel allerg rhiniti recurr sinus asthma asthma inhal steroid fluticason shortact agonist salbutamol salmeterol leukotrien antagonist montelukast began take montelukast present corticosteroid asthma exacerb separ occas preced present present asthma clarithromycin triamcinolon nasal spray anaphylact allergi lactos appear thin moder distress rest febril 38 pul 104 beatsmin 13977 hg 34 breathsmin satur 92 room air auscult chest breath sound throughout field crackl heard predominantli upper lobe precordium sound grade iivi systol eject murmur heard base rash rest bloodwork hemoglobin 146 138 175 gl white count 293 45 167 57 eosinophil 378 neutrophil 62 lymphocyt monocyt basophil arteri ga 749 735 745 partial carbon dioxid co 45 hg partial 57 80 hg bicarbon mmoll lactic dehydrogenas 357 iul reactiv 136 mgl rheumatolog wegen granulomatosi goodpastur rheumatoid antinuclear titer antineutrophil cytoplasm antiglomerular basement immunoglobulin titer asid ige 1280 iul chest radiograph bilater infiltr spare radiographi pneumonia tuberculosi warrant consider occup insidi ill asthma infiltr place churg strauss box broadspectrum empir ceftriaxon clarithromycin initi montelukast discontinu montelukast churg strauss vascul asthma antibiot remain febril 39 tachycard 110 beatsminut tachypn breathsmin maintain satur 90 cultur sputum urin stool yield stain sputum specimen acidfast bacillus enzymelink immunosorb elisa urin legionella comput tomographi chest mild mediastin lymphadenopathi paratrach lymph node measur cm diamet bilater pleural effus extens airspac scatter consolid lobe confluent consolid upper lobe embolu cavit locul pleural irregular complain short breath retrostern chest heavi rest troponin 094 gl creatin phosphokinas cpk 290 160 iul cpk mb fraction electrocardiogram anterior st segment elev mild pr segment ischemia pericard echocardiogram ventricular eject fraction anterior wall hypokinesi trace pericardi effus valvular abnorm echocardiographi conjunct screen antineutrophil cytoplasm eosinophil count myocardi churg strauss hypereosinophil consent bronchoscopi discret bronchial lavag fluid contain 92 eosinophil lymphocyt neutrophil 70 80 histiocyt malign gram acidfast stain transbronchi biopsi defer coagul bonemarrow aspir biopsi marrow exhibit 45 55 eosinophil hyperplasia erythropoiesi granulopoiesi atypia granuloma lymphoid aggreg metastat suspicion churg strauss comput tomographi scan parana sinus minor mucos thicken floor maxillari sinus eosinophilia multisystem emerg depart asthma antibiot work diagnos churg strauss hypereosinophil antibiot discontinu mg prednisolon cough fever short breath resolv next white count white return repeat chest radiogram bilater opac repeat electrocardiogram ischemia discharg home instruct slowli taper prednisolon mg presumpt discharg churg strauss echocardiogram outpati resolut wall motion abnorm cytogenet hypereosinophil f1p1l1pdgfralpha note cytogenet hypereosinophil vari cytogenet predict success imatinib 80 remiss interleukin5 sometim subgroup hypereosinophilia clonal antiinterleukin5 benefici discharg recurr eosinophil count hydroxyurea eosinophil count prednisolon taper mgday magnet reson mildli dilat ventricl eject fraction systol repeat chest radiographi abdomin ultrasound unremark film eosinophilia chest radiograph anteriorposterior view comput tomogram chest carina marrow biospsi eosinophilia box american colleg rheumatolog 1990 classif churg strauss sign communityacquir pneumonia pneumonia clue expand occup nonresolv rais tuberculosi diagnos churg strauss druginduc asthma leukotrien antagonist eosinophilia rais suspicion hematolog hypereosinophil box hypereosinophil churg strauss hypereosinophil syndrom eosinophil challeng classif eosinophil eosinophil infiltr classif actual eosinophil eosinophilia simplifi classif hing question eosinophilia intrins eosinophil extrins outsid eosinophil lineag intrins eosinophil hematolog affect pluripot multipot extrins eosinophil trigger cytokin eosinophil precursor intrins eosinophil chromosom abnorm involv tyrosin fibroblast plateletderiv abnorm involv plateletderiv manifest clonal involv pluripot cytogenet f1p1l1pdgfralpha commerci basic reversetranscriptas polymeras recogn abnorm transcript karyotyp interstiti delet 3colour fluoresc situhybrid util cytogenet myelocyt leukemia cml cml philadelphia fusion product bcrabl1 tyrosin unregul clonal myeloid cml bcrabl1 allow discoveri success molecul imatinib mesyl remiss cml extrins eosinophil numer subdivid tcellmedi tumourcellmedi eosinophil tcellmedi eosinophilia allerg bronchial asthma autoimmun churg strauss interleukin5 mediat eosinophil eosinophil worsen organ implic remodel cytogenet elimin eosinophil push clinician consid diagnos idiopath hypereosinophil patholog eosinophilia neither clonal document endorgan absolut eosinophil count definit cytogenet marrow histolog display abnorm mast monocytosi trilineag myeloprolifer dysplasia hypereosinophil includ highdos steroid firstlin hydroxyurea ad remiss classic push toward churg strauss promin spectrum organ organfocus classif ill seem consid idiopath hypereosinophil tradit categor flux learn aid clinician make clinician reli patholog abnorm spark revolut diagnos dyscrasia discoveri philadelphia dramat chang involv neoplast transform jak2 myeloprolif histor classifi oper myeloid lymphoid morpholog blast delin decad classif genet immunolog increasingli train recogn syndrom patholog realiti dyscrasia asymptomat film cytogenet becom mainstay confirm pretest probabl epigenet hered examin background epigenet modifi deleteri epigenet modif coval modif nucleosom histon underli reclassif dyscrasia unlik epigenet definit revers offer excit hope modifi carri label idiopath hypereosinophil unless develop necessit continu treat immunosuppress await deeper true intrins extrins trigger box hypereosinophil epidemiolog churg strauss hypereosinophil\n",
            "\t-4.563\tcor pulmonal atrial 0002 025 intracardiac manifest embol hepatocellular hcc uncommon autopsi 32yearold asian man refer short breath last month unproduct cough manual labor alcohol clinic embol echocardiogram atrium magnet reson atrium extend inferior vena cava portal hepat antigenposit hepat underw excis patholog hcc embolus lung kind highlight 6monthli hepat hcc  reportdiscussionconclusionsdisclosur statement 32yearold asian man manual labor insidi breathless exert lowgrad intermitt fever fever occur even rigor chill take paracetamol 500 mg practition gave temporari relief back regularli take glibenclamid mg twice habitu alcohol consum 200 ml countrymad liquor cigarett product cough scanti whitish sputum hospit past kg month admiss experienc cardiospecif past emerg servic cor pulmonal consciou dyspneic tachycardia 140min tachypnea 26min jugular venou pul cm sternal angl exhibit grade club icteru lymphadenopathi enlarg cm costal margin spleen tip palpabl s1 s2 loud loud p2 ventricular s3 exhibit murmur bilater basal crepit wheez electrocardiogram chest xray move ward routin investig emerg echocardiogram occupi atrium attach interatri septum transesophag echocardiogram cm atrium extens inferior vena cava ivc attach interatri septum tricuspid valv suggest abdomin ultrasound mild hepatomegali coars echo textur portal vein diamet suggest portal promin hepat vein ivc atrium doppler venou limb esophagogastroduodenoscopi grade esophag varic routin investig urinalysi bilirubin mgdl 06 mgdl glutam oxaloacet transaminaseglutamicpyruv transaminas 23890 iu alkalin phosphatas 197 iu 140 89 gdl albumin 39 gdl prothrombin 132 intern normal alphafetoprotein 67751 ngdl 72 carcinoembryon 644 ngdl 34 hepat antihepat core hepat weil widal brucella agglutin titer immunodefici magnet reson thorax fill atrium 2a magnet reson thorax abdomen atrium extend ivc middl hepat vein irregular fill defect superior vein suggest embolu cirrhot 2b emerg excis atrial specimen sent histopatholog resect neoplasm trabecular perivascular hepatocyt moder eosinophil cytoplasm vesicular nucleus promin nucleolus section atrium malign atrium embolus confirm atrial hepatocellular hcc immedi postop sudden worsen succumb hcc atrium embol alcohol cirrhosi portal hepat clinic silent view camouflag hcc prefer perform alphafetoprotein abdomin ultrasound everi concurr cirrhosi hepat echocardiograph soon angina pectori embol rhythm disturb murmur becom audibl adequ surveil mandatori consid dismal ineffect surveil implement practition disclosur statement\n",
            "shortness of breath,HTN,Vit D3 None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.494\tlongstand insulinoma insulinoma pancreat endocrin benign solitari nonspecif difficulti local arab pancreat longstand insulinoma episod hypoglycem biochem morpholog workup local pancreat insulinoma done insulinoma success remov enucl insulinoma practition suspect easili endocrin supervis fast accur preoper local safest  backgroundcas present 1case present 2discussionconclusioncons pancreat endocrin insulinoma million person slightli insulinoma present benign solitari cm diamet sporad insulinoma endocrin neoplasia nonspecif insulinoma misdiagnos hypoglycemia sign inappropri biochem confirm hyperinsulin preoper local pancrea remov cur continu choic manuscript pancreat insulinoma discus local uncommon insulinoma neuroendocrin benign lifethreaten caus hypoglycem accid biochem easi preoper local prove insulinoma intraop experienc surgeon resect choic extrem success laparoscop increasingli blind pancreat resect recommend option reserv unresect metastat consent\n",
            "\t0.478\tlowdown sugar high    shortliv sugar high give quick boost elosta page 2409 leav last bad impress vessel diabet hg overexpress nf histon modif nf set7 attack trigger atherosclerot plaqu arteri extend period arteri persist reduc explan phenomenon shortliv sugar high insulintr diabet trigger histon modif longlast sugar high persist sugar creat reactiv methylglyox activ histon methyl set7 brief sugar peak set7 bound nf therebi nf switch recruit attach plaqueform monocyt vessel wall aorta persist return prevent block methylglyox aim temporari rise sugar inject adjust time regimen avoid spike hb \n",
            "\t0.478\tlowdown sugar high    shortliv sugar high give quick boost elosta page 2409 leav last bad impress vessel diabet hg overexpress nf histon modif nf set7 attack trigger atherosclerot plaqu arteri extend period arteri persist reduc explan phenomenon shortliv sugar high insulintr diabet trigger histon modif longlast sugar high persist sugar creat reactiv methylglyox activ histon methyl set7 brief sugar peak set7 bound nf therebi nf switch recruit attach plaqueform monocyt vessel wall aorta persist return prevent block methylglyox aim temporari rise sugar inject adjust time regimen avoid spike hb \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.759\tglucosedepend insulinotrop polypeptid depend glucosedepend insulinotrop polypeptid gip glucagon sem age bmi kgm hba 1c 55 01 salin dose gip administ intraven random doubl blind 90 min insulininduc hypoglycemia euglycemia hyperglycemia hypoglycemia gip infus glucagon min salin 76 pmoll min 0008 peak glucagon reach min euglycemia gip infus elicit glucagon 62 pmoll 90 min 0005 hyperglycemia compar suppress glucagon 461 81 371 pmoll 90 min 026 gip salin infus hyperglycemia gip doubl 00001 gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip bifunct stabil diverg glucosedepend pancreat glucoregulatori hormon  methodsstudi protocolsubjectsdesign studypeptidesblood specimensanalyt proceduresstatist calculationsresultsglucosegipinsulin isrglucagondiscuss  action gip pancreat hormon glycem gip invert glucosedepend glucagon gip exhibit glucagonotrop fast hypoglycem exert hormon gip glucagon hyperglycemia robustli potenti glucoseinduc controversi exist glucagonotrop gip hyperglycem clamp glucagon glucagon earliest accord reexamin origin vilsb ll shortdur gip infus min glycem mmoll actual gave rise glucagon salin stepwis mmoll mmoll glucagon increasingli suppress nonsignific glucagon gip salin origin public collect glycem threshold 55 mmoll exist gip exert glucagonotrop action illustr bifunct glucosedepend gip pg interv mmoll bear resembl perfus pancrea pederson brown ago glucagon cpeptid relat glucagon dark blue curv squar cpeptid blue curv circl pg mmoll stimul gip broken fill symbol basal full symbol sem 005 pair glucagonotrop insulinotrop gip seem constitut preserv rodent alik relev dual hormon regul gip elucid gip physiolog interest respect note gip stimul depend ingest postprandi circumst alway alongsid coincretin glucagonlik glp1 glucosedepend insulinotrop hormon glp1 gip wellestablish suppress glucagon seemingli capabl hypoglycemia discern gip robustli rodent canin gip obes highfat diet relev gip elus 29 nervou reli hypothes gip glucagonotrop buffer reactiv hypoglycemia meal buffer compat gip anabol hormon adipos 29 regard pancreat islet hormon interest gip euglycemia glucagon concurr hyperinsulinem hypoglycemia glucagon min gip concomit presum pancreat intraislet wellknown paracrin amylin aminobutyr zinc ion etc director glucagon refer intraislet 31 domin gip glucagon presum pancreat secret neighbor euglycemia hypoglycemia demonstr suppress glucagon gip infus hyperglycemia depend concurr rise drawn cpeptid intraven arginin paracrin intraislet prevail glycemia glucagon consequ parallel glucagon euglycem slight lower pg probabl consequ nonhepat circumst certainli exclud buffer glucagon hepat excurs toward hypoglycemia pg complet superimpos gip salin nonphysiolog hyperinsulinemia inher clamp stimul glucagon min modifi downwardslop pg curv hyperinsulinem clamp glucagon concomit gip infus pg 55 mmoll maxim glucagon reach lowest pg gip salin maxim glucagon hypoglycemia autonom nervou clinic sweat glucagonotrop gip pathophysiolog consequ excess glucagon weigh postprandi fast determin hyperglycemia evid hyperglucagonemia sole explain intriguingli insulinotrop gip sever defici glucagonotrop gip ad mismatch insulintoglucagon maxim glucagon gip salin euglycemia amount pmoll relev insuffici oppos support pmoll fast glucagon 33 notion gip infus supraphysiolog dose worsen postprandi hyperglycemia 34 antagon glucagonsuppress glp1 36 gip glucagon hypoglycemia dipeptidyl peptidase4 vildagliptin 37 gip safeguard hypoglycemia pathophysiolog implic explor glucosedepend glucagonotrop gip gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip pancreat islet regul diverg pancreat glucoregulatori hormon glucagon\n",
            "\t-5.380\tinsulin basal realworld set asia basal fine asia multin prospect observ insulinna ve mellitu t2dm asia uncontrol a1c hypoglycem basal initi basal initi concomit dose adjust individu choic decis initi discret reflect reallif 2679 asian enrol sd 93 65 681 127 kg a1c 98 basal nph glargin detemir a1c 77 337 reach a1c fast fbg 117 36 72 mmoll 368 reach fbg 61 mmoll margin 018 023 ukg 022 024 ukg month hypoglycemia initi delay asian hyperglycemia initi basal safe asian t2dm realworld set differ western asiainsulintyp mellitu introductionmethodsobject registryregistri designpatientsstudi assessmentsprimari endpointsstatist analysisresultspati characteristicsglycem controlbodi weighthypoglycemia adrstreat satisfactiondiscuss mellitu t2dm worldwid asian 40year 1960 approxim decad t2dm china tripl 1996 estim 97 repeat asian contin fivefold t2dm past india indonesia korea thailand epidem asia bmi asian percentag abdomin western equival bmi tendenc asian t2dm younger diabetesassoci western make minim burden diabetesassoci morbid tight glycem cornerston european asian intern feder idf western pacif prefer a1c 65 asian t2dm american adaeuropean assocaiton easd consensu statement a1c recommend initi meet a1c recommend basal ad soon plu metformin a1c 70 random prompt basal a1c maxim dose metformin sulfonylurea clinic improv glycem intensif lifestyl proven benefit exist guidelin initi util glycem suboptim hong kong registri 7549 chine t2dm a1c 77 603 a1c 70 receiv hypoglycem oha inadequ glycem oha a1c t2dm 237 759 inadequ intensif diabcar intern mellitu idmp registri util asia chang markedli past evolv guidelin advoc initi intensif reach a1c goal 65 object basal fine asia detail realworld insulin t2dm asia toler basal regimen prospect observ registrybas initi basal asian longstand t2dm fail oha clinic improv glycem reveal benefit recommend intern guidelin initi asia delay hyperglycemia compris poorli t2dm a1c 98 93 65 oha 87 63 insulin onethird a1c confirm intensif initi delay asian irrespect intern region guidelin asian credit registri 3031 start northern america europ asia t2dm a1c initi basal statist clinic a1c 98 77 onethird reach adaeasd consensu a1c basal 022 024 ukg achiev a1c western treattotarget north american t2dm a1c dose 048 ukg 472 iu glargin 042 ukg 418 iu nph meanwhil european a1c 096 bedtim glargin 084 nph dose reach 39 37 iu endpoint dose reflect bmi asian western t2dm bmi 261 kgm kgm european kgm treatto north american populationbas 3071 asian 129 116 nonhispan white asian t2dm nonasian nevertheless onethird basal glargin reach a1c 70 titrat reflect cautiou titrat asia asian conserv titrat goal compar western owe perceiv hypoglycemia asian leaner western counterpart hypoglycemia tempt specul aggress titrat recommend idf western pacif achiev 70 a1c note observ registrybas advantag disadvantag random advantag registri largerscal monitor reallif reflect registri random receiv modal insulin countri conclus compar nph glargin detemir asian drawn observ mark insulin 2196 637 75 glargin nph detemir reflect avail awar insulin detemir china vietnam familiar detemir nph glargin detemir option twicedaili dose twicedaili achiev optim suboptim titrat agent vari receiv insulin longest receiv detemir influenc variat a1c receiv insulin reflect unadjust adjust a1c fbg a1c respond readili a1c closer note threshold a1c registri candid a1c achiev goal ad accordingli incomplet crosssect t2dm reflect heterogen nevertheless unaccept a1c candid modif intensif fine asia variat a1c reli accur report a1c initi countryspecif prescrib procedur question reflect realworld consid registri underus glycem suboptim t2dm asia fine asia basal initi repres option t2dm suboptim basal therapi discret treat confirm realworld set random initi basal welltoler option asian t2dm fail meet oha asian possibl bmi compar western aggress titrat enabl achiev limit burden asian\n",
            "\t-5.615\ttype2 intensif insuffici glycaem prospect diaregi antidiabet monotherapi unabl suffici type2 intensifi determin predictor occurr comorbid improv diaregi prospect 3810 type2 diabet treat aim intensifi optimis antidiabet insuffici intensif origin select prescrib aim monitor comorbid burden type2 multivari adjust predictor comorbid 3058 complet substanti comorbid neuropathi intensif dpp4 glp1 analogu achiev reduct hba1c fast postprandi 75 die experienc nonfat macrovascular 119 experienc microvascular 43 predictor macromicrovascular complicationsheart failuredeath 136 110 168 173 139 216 278 210 368 determin comorbid intens glucoselow improv constitut predictor receiv  backgroundmethodspatientsphysiciansdocumentationglucos hypoglycaemia comorbiditystatist analysisresultspati characteristicspharmacotherapi controladvers event burden type2 followupmultivari adjust predictor comorbid eventsdiscussionconclus monotherapi antidiabet metformin choic type2 diabet dietari restrict manag achiev adequ escal discret consult option administ prescrib antidiabet oad inject glp1 analogu altern recommend hba1c safe ad decis consid goal econom diminish util predefin goal algorithm instead favour meet regard european easd partnership american ada european societi cardiolog esc guidelin patientcentr type2 diabet guidelin prescript algorithm owe evidencebas infer ultim compar realworld diaregi prospect treat aim intensifi optimis antidiabet insuffici antidiabet enrol intensif origin select prescrib background monitor comorbid burden type2 multivari adjust predictor comorbid antidiabet monotherapi unabl suffici type2 intensifi determin predictor occurr improv hf predictor receiv intens antidiabet regimen decreas\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.494\tlongstand insulinoma insulinoma pancreat endocrin benign solitari nonspecif difficulti local arab pancreat longstand insulinoma episod hypoglycem biochem morpholog workup local pancreat insulinoma done insulinoma success remov enucl insulinoma practition suspect easili endocrin supervis fast accur preoper local safest  backgroundcas present 1case present 2discussionconclusioncons pancreat endocrin insulinoma million person slightli insulinoma present benign solitari cm diamet sporad insulinoma endocrin neoplasia nonspecif insulinoma misdiagnos hypoglycemia sign inappropri biochem confirm hyperinsulin preoper local pancrea remov cur continu choic manuscript pancreat insulinoma discus local uncommon insulinoma neuroendocrin benign lifethreaten caus hypoglycem accid biochem easi preoper local prove insulinoma intraop experienc surgeon resect choic extrem success laparoscop increasingli blind pancreat resect recommend option reserv unresect metastat consent\n",
            "\t0.478\tlowdown sugar high    shortliv sugar high give quick boost elosta page 2409 leav last bad impress vessel diabet hg overexpress nf histon modif nf set7 attack trigger atherosclerot plaqu arteri extend period arteri persist reduc explan phenomenon shortliv sugar high insulintr diabet trigger histon modif longlast sugar high persist sugar creat reactiv methylglyox activ histon methyl set7 brief sugar peak set7 bound nf therebi nf switch recruit attach plaqueform monocyt vessel wall aorta persist return prevent block methylglyox aim temporari rise sugar inject adjust time regimen avoid spike hb \n",
            "\t0.478\tlowdown sugar high    shortliv sugar high give quick boost elosta page 2409 leav last bad impress vessel diabet hg overexpress nf histon modif nf set7 attack trigger atherosclerot plaqu arteri extend period arteri persist reduc explan phenomenon shortliv sugar high insulintr diabet trigger histon modif longlast sugar high persist sugar creat reactiv methylglyox activ histon methyl set7 brief sugar peak set7 bound nf therebi nf switch recruit attach plaqueform monocyt vessel wall aorta persist return prevent block methylglyox aim temporari rise sugar inject adjust time regimen avoid spike hb \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.759\tglucosedepend insulinotrop polypeptid depend glucosedepend insulinotrop polypeptid gip glucagon sem age bmi kgm hba 1c 55 01 salin dose gip administ intraven random doubl blind 90 min insulininduc hypoglycemia euglycemia hyperglycemia hypoglycemia gip infus glucagon min salin 76 pmoll min 0008 peak glucagon reach min euglycemia gip infus elicit glucagon 62 pmoll 90 min 0005 hyperglycemia compar suppress glucagon 461 81 371 pmoll 90 min 026 gip salin infus hyperglycemia gip doubl 00001 gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip bifunct stabil diverg glucosedepend pancreat glucoregulatori hormon  methodsstudi protocolsubjectsdesign studypeptidesblood specimensanalyt proceduresstatist calculationsresultsglucosegipinsulin isrglucagondiscuss  action gip pancreat hormon glycem gip invert glucosedepend glucagon gip exhibit glucagonotrop fast hypoglycem exert hormon gip glucagon hyperglycemia robustli potenti glucoseinduc controversi exist glucagonotrop gip hyperglycem clamp glucagon glucagon earliest accord reexamin origin vilsb ll shortdur gip infus min glycem mmoll actual gave rise glucagon salin stepwis mmoll mmoll glucagon increasingli suppress nonsignific glucagon gip salin origin public collect glycem threshold 55 mmoll exist gip exert glucagonotrop action illustr bifunct glucosedepend gip pg interv mmoll bear resembl perfus pancrea pederson brown ago glucagon cpeptid relat glucagon dark blue curv squar cpeptid blue curv circl pg mmoll stimul gip broken fill symbol basal full symbol sem 005 pair glucagonotrop insulinotrop gip seem constitut preserv rodent alik relev dual hormon regul gip elucid gip physiolog interest respect note gip stimul depend ingest postprandi circumst alway alongsid coincretin glucagonlik glp1 glucosedepend insulinotrop hormon glp1 gip wellestablish suppress glucagon seemingli capabl hypoglycemia discern gip robustli rodent canin gip obes highfat diet relev gip elus 29 nervou reli hypothes gip glucagonotrop buffer reactiv hypoglycemia meal buffer compat gip anabol hormon adipos 29 regard pancreat islet hormon interest gip euglycemia glucagon concurr hyperinsulinem hypoglycemia glucagon min gip concomit presum pancreat intraislet wellknown paracrin amylin aminobutyr zinc ion etc director glucagon refer intraislet 31 domin gip glucagon presum pancreat secret neighbor euglycemia hypoglycemia demonstr suppress glucagon gip infus hyperglycemia depend concurr rise drawn cpeptid intraven arginin paracrin intraislet prevail glycemia glucagon consequ parallel glucagon euglycem slight lower pg probabl consequ nonhepat circumst certainli exclud buffer glucagon hepat excurs toward hypoglycemia pg complet superimpos gip salin nonphysiolog hyperinsulinemia inher clamp stimul glucagon min modifi downwardslop pg curv hyperinsulinem clamp glucagon concomit gip infus pg 55 mmoll maxim glucagon reach lowest pg gip salin maxim glucagon hypoglycemia autonom nervou clinic sweat glucagonotrop gip pathophysiolog consequ excess glucagon weigh postprandi fast determin hyperglycemia evid hyperglucagonemia sole explain intriguingli insulinotrop gip sever defici glucagonotrop gip ad mismatch insulintoglucagon maxim glucagon gip salin euglycemia amount pmoll relev insuffici oppos support pmoll fast glucagon 33 notion gip infus supraphysiolog dose worsen postprandi hyperglycemia 34 antagon glucagonsuppress glp1 36 gip glucagon hypoglycemia dipeptidyl peptidase4 vildagliptin 37 gip safeguard hypoglycemia pathophysiolog implic explor glucosedepend glucagonotrop gip gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip pancreat islet regul diverg pancreat glucoregulatori hormon glucagon\n",
            "\t-5.380\tinsulin basal realworld set asia basal fine asia multin prospect observ insulinna ve mellitu t2dm asia uncontrol a1c hypoglycem basal initi basal initi concomit dose adjust individu choic decis initi discret reflect reallif 2679 asian enrol sd 93 65 681 127 kg a1c 98 basal nph glargin detemir a1c 77 337 reach a1c fast fbg 117 36 72 mmoll 368 reach fbg 61 mmoll margin 018 023 ukg 022 024 ukg month hypoglycemia initi delay asian hyperglycemia initi basal safe asian t2dm realworld set differ western asiainsulintyp mellitu introductionmethodsobject registryregistri designpatientsstudi assessmentsprimari endpointsstatist analysisresultspati characteristicsglycem controlbodi weighthypoglycemia adrstreat satisfactiondiscuss mellitu t2dm worldwid asian 40year 1960 approxim decad t2dm china tripl 1996 estim 97 repeat asian contin fivefold t2dm past india indonesia korea thailand epidem asia bmi asian percentag abdomin western equival bmi tendenc asian t2dm younger diabetesassoci western make minim burden diabetesassoci morbid tight glycem cornerston european asian intern feder idf western pacif prefer a1c 65 asian t2dm american adaeuropean assocaiton easd consensu statement a1c recommend initi meet a1c recommend basal ad soon plu metformin a1c 70 random prompt basal a1c maxim dose metformin sulfonylurea clinic improv glycem intensif lifestyl proven benefit exist guidelin initi util glycem suboptim hong kong registri 7549 chine t2dm a1c 77 603 a1c 70 receiv hypoglycem oha inadequ glycem oha a1c t2dm 237 759 inadequ intensif diabcar intern mellitu idmp registri util asia chang markedli past evolv guidelin advoc initi intensif reach a1c goal 65 object basal fine asia detail realworld insulin t2dm asia toler basal regimen prospect observ registrybas initi basal asian longstand t2dm fail oha clinic improv glycem reveal benefit recommend intern guidelin initi asia delay hyperglycemia compris poorli t2dm a1c 98 93 65 oha 87 63 insulin onethird a1c confirm intensif initi delay asian irrespect intern region guidelin asian credit registri 3031 start northern america europ asia t2dm a1c initi basal statist clinic a1c 98 77 onethird reach adaeasd consensu a1c basal 022 024 ukg achiev a1c western treattotarget north american t2dm a1c dose 048 ukg 472 iu glargin 042 ukg 418 iu nph meanwhil european a1c 096 bedtim glargin 084 nph dose reach 39 37 iu endpoint dose reflect bmi asian western t2dm bmi 261 kgm kgm european kgm treatto north american populationbas 3071 asian 129 116 nonhispan white asian t2dm nonasian nevertheless onethird basal glargin reach a1c 70 titrat reflect cautiou titrat asia asian conserv titrat goal compar western owe perceiv hypoglycemia asian leaner western counterpart hypoglycemia tempt specul aggress titrat recommend idf western pacif achiev 70 a1c note observ registrybas advantag disadvantag random advantag registri largerscal monitor reallif reflect registri random receiv modal insulin countri conclus compar nph glargin detemir asian drawn observ mark insulin 2196 637 75 glargin nph detemir reflect avail awar insulin detemir china vietnam familiar detemir nph glargin detemir option twicedaili dose twicedaili achiev optim suboptim titrat agent vari receiv insulin longest receiv detemir influenc variat a1c receiv insulin reflect unadjust adjust a1c fbg a1c respond readili a1c closer note threshold a1c registri candid a1c achiev goal ad accordingli incomplet crosssect t2dm reflect heterogen nevertheless unaccept a1c candid modif intensif fine asia variat a1c reli accur report a1c initi countryspecif prescrib procedur question reflect realworld consid registri underus glycem suboptim t2dm asia fine asia basal initi repres option t2dm suboptim basal therapi discret treat confirm realworld set random initi basal welltoler option asian t2dm fail meet oha asian possibl bmi compar western aggress titrat enabl achiev limit burden asian\n",
            "\t-5.615\ttype2 intensif insuffici glycaem prospect diaregi antidiabet monotherapi unabl suffici type2 intensifi determin predictor occurr comorbid improv diaregi prospect 3810 type2 diabet treat aim intensifi optimis antidiabet insuffici intensif origin select prescrib aim monitor comorbid burden type2 multivari adjust predictor comorbid 3058 complet substanti comorbid neuropathi intensif dpp4 glp1 analogu achiev reduct hba1c fast postprandi 75 die experienc nonfat macrovascular 119 experienc microvascular 43 predictor macromicrovascular complicationsheart failuredeath 136 110 168 173 139 216 278 210 368 determin comorbid intens glucoselow improv constitut predictor receiv  backgroundmethodspatientsphysiciansdocumentationglucos hypoglycaemia comorbiditystatist analysisresultspati characteristicspharmacotherapi controladvers event burden type2 followupmultivari adjust predictor comorbid eventsdiscussionconclus monotherapi antidiabet metformin choic type2 diabet dietari restrict manag achiev adequ escal discret consult option administ prescrib antidiabet oad inject glp1 analogu altern recommend hba1c safe ad decis consid goal econom diminish util predefin goal algorithm instead favour meet regard european easd partnership american ada european societi cardiolog esc guidelin patientcentr type2 diabet guidelin prescript algorithm owe evidencebas infer ultim compar realworld diaregi prospect treat aim intensifi optimis antidiabet insuffici antidiabet enrol intensif origin select prescrib background monitor comorbid burden type2 multivari adjust predictor comorbid antidiabet monotherapi unabl suffici type2 intensifi determin predictor occurr improv hf predictor receiv intens antidiabet regimen decreas\n",
            "type 1 diabetes,insulin,glucose None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.463\tlevosimendan shock   levosimendan intraven levosimendan act predominantli calcium sensit atpsensit channel katpchannel open bind calciumdepend troponin stabil calciuminduc conform enhanc calcium myofila advantag calcium sensit dobutamin calcium overload act demand handl calcium methodresultsconclus fifteen cardiogen septic mix cardiogenicsept shock administ load gkgmin levosimendan continu infus 01 gkgmin hour septic shock cardiogen shock mix septic cardiogen shock apach 213 64 arteri pressur monitor close arteri cathet intraven noradrenalin administ maintain arteri 65 mmhg echocardiograph ventricular eject fraction lvef simpson btype natriuret biosit triag hour levosimendan infus levosimendan shock prove feasibl hold promis catecholamin inotrop\n",
            "\t0.457\tt3 toxicosi complic metastat thyroid follicular thyroid trap unwari thyroxin suppress   comment 63 old man t3toxicosi thyroidectomi abl radioiodin follicular thyroid ftc asymptomat t4 184 pmoll tsh 001 mul take levothyroxin t4 200 gd suppress thyroxin uncontrol atrial fibril congest thyrotoxicosi excess levothyroxin t4 147 pmoll t3toxicosi suspect t3 vari 105238 nmoll iodineavid hepat metastas visual 123 scan neck thyroxin withdrawn 3700 mbq 131 comment thyrotoxicosi thyroid rare follicular neoplasia boni metastat biochem t3toxicosi thyrotoxicosi euthyroid ftc hyperthyroid impli bulk iodin concentr await biochem 131 guard \n",
            "\t0.457\tt3 toxicosi complic metastat thyroid follicular thyroid trap unwari thyroxin suppress   comment 63 old man t3toxicosi thyroidectomi abl radioiodin follicular thyroid ftc asymptomat t4 184 pmoll tsh 001 mul take levothyroxin t4 200 gd suppress thyroxin uncontrol atrial fibril congest thyrotoxicosi excess levothyroxin t4 147 pmoll t3toxicosi suspect t3 vari 105238 nmoll iodineavid hepat metastas visual 123 scan neck thyroxin withdrawn 3700 mbq 131 comment thyrotoxicosi thyroid rare follicular neoplasia boni metastat biochem t3toxicosi thyrotoxicosi euthyroid ftc hyperthyroid impli bulk iodin concentr await biochem 131 guard \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.238\tlevothyroxin thyroid stimul hormon hypothyroid miner bmd abnorm hypothyroid scarc conclus thyroid hormon bmd mix sever osteoporosi hypothyroid crosssect descript 150 age total hypothyroid enrol divid consist hypothyroid hypothyroid levothyroxin thyroid stimul hormon tsh densitometri bmd tscore osteoporosi tscore lumbar vertebra l2l4 femor neck dual xray absorptiometri spss regress mann whitney kruskal walli varianc signific 005 tsh 0001 tscore lumbar spine l2l4 001 linear regress tsh bmd categori remov tsh 001 hypothyroid thyroid hormon reduc tsh proper osteoporosi levothyroxineosteoporosisprimari hypothyroid introductionmethodsresultsdiscussionauthor contribut thyroid 1891 von recklinghausen explain hyperthyroid fractur hypothyroid affect hyperthyroid osteoporosi thyroid hormon thyroid stimul hormon tsh abnorm physiolog controversi osteoporosi imbal harvest remov replac old organ definit tscore deviat miner bmd osteoporosi tscore bmd tscore osteopenia tscore plu fractur sever establish osteoporosi uncontrol hyperthyroid regener balanc resorpt intestin absorpt calcium phosphoru grow tsh bmd turnov hyperthyroid vertebr nonvertebr fractur 45 32fold tsh 01 iul likewis euthyroid tsh lowest tertil vertebr fractur thyroid hormon tsh turnov tsh hypothyroid unclear decreas caus congenit hypothyroid slow halt thyroid hormon improv bmd thyroidectomi tsh inhibit levothyroxin hormon bmd bmd abnorm hypothyroid scarc conclus thyroid hormon bmd mix fractur tsh suppress tsh tsh suppress tsh fractur unsuppress tsh untreat hypothyroid thick cortic hypothyroid know tsh osteoporosi osteopenia hypothyroid osteoporosi disabl actual treatabl thyroid hyperthyroid osteoporosi hyperthyroid osteoporot hypothyroid osteoporosi question subject purpos untreat hypothyroid osteoporosi evid tsh osteoporosi linear regress osteoporosi weak tsh pedro thyroxin vestergaard mosekild 11776 hyperthyroid 4473 hypothyroid fractur hyperthyroid fractur fractur hyperthyroid reduc fractur fractur hypothyroid conclud fractur hyperthyroid hypothyroid hypothyroid fractur hypothyroid bmd levothyroxin replac simultan hypothyroid grimn femor neck postmenopaus tsh 597 tsh tsh hypothyroid bmd spine pelvic congenit hypothyroid subclin hypothyroid qualiti ultrasound tsh calcul osteo sonoassess hypothyroid affect thyroid hormon homeostasi bmd osteoporosi thyroid osteoporosi hypothyroid thyroid hormon tsh spine hypothyroid hypothyroid thyroid hormon reduc tsh proper osteoporosi contribut\n",
            "\t-0.394\tweekli intramuscular inject levothyroxin myxoedema practic solut old crisi 82yearold hypothyroid admit floor unkempt confus bradycard hypotherm bare arous biochemistri thyroid stimul hormon tsh mul thyroxin ft pmoll support myxoedema coma resuscit commenc liothyronin levothyroxin hydrocortison becam appar hide spit levothyroxin levothyroxin elixir prompt sought advic intern expert intramuscular levothyroxin recommend manag onward intramuscular levothyroxin 200 mcg week subsequ 500 mcg thyroid normal continu progress discharg rehabilit intramuscular levothyroxin stop subsequ restart levothyroxin plan ongo close thyroid highlight intramuscular levothyroxin hypothyroid aris complianc levothyroxin absorpt  introduction2 report3 clinician myxoedema coma endocrin emerg 70 uncommon nowaday widespread thyroid threshold initi levothyroxin levothyroxin 215 persist tsh mul widespread complianc malabsorpt myxoedema coma winter complianc hypothyroid judici levothyroxin liothyronin hydrocortison support mainstay favour interest myxoedema coma success manag intramuscular levothyroxin complianc levothyroxin demonstr intramuscular levothyroxin myxoedema coma \n",
            "\t-0.409\tlevothyroxin benign thyroid nodul suppress levothyroxin thyroid nodul realli accept purpos levothyroxin benign thyroid nodul forti benign nodul randomli divid 50gday levothyroxin take sonographi dimens nodul tsh regist irct 201103185692 n3 levothyroxin 4157 941 4445 109 p0386 tsh longitudin transvers dimens 005 tsh 165 052 067 muil p0001 longitudin transvers dimens 111 190 115 144 090 149 102 cm p074 p07 219 132 197 157 095 126 07 p035 01 suppress levothyroxin alter benign nodul  methodsresultsdiscuss thyroid nodul patholog endocrinologist deal consider accident discov perform radiolog carotid sonographi neck ct scan pet scan definit thyroid nodul 02 palpabl thyroid nodul frequent palpabl nodul cm way thyroid nodul nodul remov radioact conserv levothyroxin mere thyroid nodul expens accompani prefer medicin consensu suppress levothyroxin thyroid nodul tsh thyroid divis t4 contribut tsh feedback consequ eventu hypertrophi hyperplasia thyrocyt purpos levothyroxin inhibit tsh thyrotoxicosi unwant levothyroxin maintain tsh 0105 miul mention nodul cm colloid goiter colloid nodular suppress levothyroxin thyroid nodul random thyroid nodul refer depart endocrinolog babol univers scienc palpabl thyroid nodul enter benign fnab ensur exist nodul sonographi 1860 old t4 tsh euthyroid exclus thyroid neoplast neck hot nodul none seriou hepat none pregnant none suppress levothyroxin thyroidassoci inform inform consent randomli divid n20 levothyroxin gday iran hormon compani levothyroxin coordin tsh suppress bring tsh 05mu1 n20 tsh commerci kit 0545 muil thyroid sonographi suppress longitudin transvers dimens sonographi suppress longitudin transvers dimens nodul partial 2050 longitudin transvers dimens nodul spss version deviat pair 005 meaning forti 34 femal male 4305 1017 particip levothyroxin gday gender tsh longitudin transvers dimens nodul tsh 158 106 muil 052 067 muil levothyroxin femal male demonstr tsh p0001 tsh 118 muil 132 098 p0442 dimens thyroid nodul likewis nodul display remark dimens longitudin transvers dimens thyroid nodul partial seven levothyroxin levothyroxin base n20 pvalu sd levothyroxin sd 0386 4445 109 4157 941 yr 0390 165 118 200 165 tsh 0523 219 132 194 114 longitudin dimens cm 0662 157 095 144 090 transvers dimens cm compar dimens nodul pvalu dimens cm 0735 0657 190 115 149 102 111 144 090 longitudin transvers levothyroxin n20 0354 0109 197 140 126 070 219 132 157 095 longitudin transvers n20 discus levothyroxin benign thyroid nodul nodul placebo percent nodul contradict levothyroxin thyroid nodul purpos levothyroxin thyroid nodul tsh believ tsh thyroid tsh thyroid follicl medium thyroxin inhibit thyroid tsh success 052 067 muil levothyroxin papini suppress levothyroxin 51 thyroid nodul contribut 45 tsh reach 006 006 muil drugtreat lima 1997 54 oneyear levothyroxin none nodul suppress brought tsh 01muil drugtreat zelmanovitz 45 thyroid nodul conclud suppress levothyroxin nodul nodul larijani 62 doubl blind levothyroxin placebo percent nodul tsh 017 02 muil random doubl blind wemeau 123 thyroid nodul percent nodul follow levothyroxin placebo tsh reach 073 08 mui levothyroxin tsai exhibit receiv levothyroxin thyroid nodul reach tsh 008 002 muil thyroglobulin suppress demonstr suppress levothyroxin alter benign thyroid nodul levothyroxin benign thyroid nodul nodul placebo percent nodul contradict levothyroxin thyroid nodul purpos levothyroxin thyroid nodul tsh believ tsh thyroid tsh thyroid follicl medium thyroxin inhibit thyroid tsh success 052 067 muil levothyroxin papini suppress levothyroxin 51 thyroid nodul contribut 45 tsh reach 006 006 muil drugtreat lima 1997 54 oneyear levothyroxin none nodul suppress brought tsh 01muil drugtreat zelmanovitz 45 thyroid nodul conclud suppress levothyroxin nodul nodul larijani 62 doubl blind levothyroxin placebo percent nodul tsh 017 02 muil random doubl blind wemeau 123 thyroid nodul percent nodul follow levothyroxin placebo tsh reach 073 08 mui levothyroxin tsai exhibit receiv levothyroxin thyroid nodul reach tsh 008 002 muil thyroglobulin suppress demonstr suppress levothyroxin alter benign thyroid nodul\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.463\tlevosimendan shock   levosimendan intraven levosimendan act predominantli calcium sensit atpsensit channel katpchannel open bind calciumdepend troponin stabil calciuminduc conform enhanc calcium myofila advantag calcium sensit dobutamin calcium overload act demand handl calcium methodresultsconclus fifteen cardiogen septic mix cardiogenicsept shock administ load gkgmin levosimendan continu infus 01 gkgmin hour septic shock cardiogen shock mix septic cardiogen shock apach 213 64 arteri pressur monitor close arteri cathet intraven noradrenalin administ maintain arteri 65 mmhg echocardiograph ventricular eject fraction lvef simpson btype natriuret biosit triag hour levosimendan infus levosimendan shock prove feasibl hold promis catecholamin inotrop\n",
            "\t0.457\tt3 toxicosi complic metastat thyroid follicular thyroid trap unwari thyroxin suppress   comment 63 old man t3toxicosi thyroidectomi abl radioiodin follicular thyroid ftc asymptomat t4 184 pmoll tsh 001 mul take levothyroxin t4 200 gd suppress thyroxin uncontrol atrial fibril congest thyrotoxicosi excess levothyroxin t4 147 pmoll t3toxicosi suspect t3 vari 105238 nmoll iodineavid hepat metastas visual 123 scan neck thyroxin withdrawn 3700 mbq 131 comment thyrotoxicosi thyroid rare follicular neoplasia boni metastat biochem t3toxicosi thyrotoxicosi euthyroid ftc hyperthyroid impli bulk iodin concentr await biochem 131 guard \n",
            "\t0.457\tt3 toxicosi complic metastat thyroid follicular thyroid trap unwari thyroxin suppress   comment 63 old man t3toxicosi thyroidectomi abl radioiodin follicular thyroid ftc asymptomat t4 184 pmoll tsh 001 mul take levothyroxin t4 200 gd suppress thyroxin uncontrol atrial fibril congest thyrotoxicosi excess levothyroxin t4 147 pmoll t3toxicosi suspect t3 vari 105238 nmoll iodineavid hepat metastas visual 123 scan neck thyroxin withdrawn 3700 mbq 131 comment thyrotoxicosi thyroid rare follicular neoplasia boni metastat biochem t3toxicosi thyrotoxicosi euthyroid ftc hyperthyroid impli bulk iodin concentr await biochem 131 guard \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.238\tlevothyroxin thyroid stimul hormon hypothyroid miner bmd abnorm hypothyroid scarc conclus thyroid hormon bmd mix sever osteoporosi hypothyroid crosssect descript 150 age total hypothyroid enrol divid consist hypothyroid hypothyroid levothyroxin thyroid stimul hormon tsh densitometri bmd tscore osteoporosi tscore lumbar vertebra l2l4 femor neck dual xray absorptiometri spss regress mann whitney kruskal walli varianc signific 005 tsh 0001 tscore lumbar spine l2l4 001 linear regress tsh bmd categori remov tsh 001 hypothyroid thyroid hormon reduc tsh proper osteoporosi levothyroxineosteoporosisprimari hypothyroid introductionmethodsresultsdiscussionauthor contribut thyroid 1891 von recklinghausen explain hyperthyroid fractur hypothyroid affect hyperthyroid osteoporosi thyroid hormon thyroid stimul hormon tsh abnorm physiolog controversi osteoporosi imbal harvest remov replac old organ definit tscore deviat miner bmd osteoporosi tscore bmd tscore osteopenia tscore plu fractur sever establish osteoporosi uncontrol hyperthyroid regener balanc resorpt intestin absorpt calcium phosphoru grow tsh bmd turnov hyperthyroid vertebr nonvertebr fractur 45 32fold tsh 01 iul likewis euthyroid tsh lowest tertil vertebr fractur thyroid hormon tsh turnov tsh hypothyroid unclear decreas caus congenit hypothyroid slow halt thyroid hormon improv bmd thyroidectomi tsh inhibit levothyroxin hormon bmd bmd abnorm hypothyroid scarc conclus thyroid hormon bmd mix fractur tsh suppress tsh tsh suppress tsh fractur unsuppress tsh untreat hypothyroid thick cortic hypothyroid know tsh osteoporosi osteopenia hypothyroid osteoporosi disabl actual treatabl thyroid hyperthyroid osteoporosi hyperthyroid osteoporot hypothyroid osteoporosi question subject purpos untreat hypothyroid osteoporosi evid tsh osteoporosi linear regress osteoporosi weak tsh pedro thyroxin vestergaard mosekild 11776 hyperthyroid 4473 hypothyroid fractur hyperthyroid fractur fractur hyperthyroid reduc fractur fractur hypothyroid conclud fractur hyperthyroid hypothyroid hypothyroid fractur hypothyroid bmd levothyroxin replac simultan hypothyroid grimn femor neck postmenopaus tsh 597 tsh tsh hypothyroid bmd spine pelvic congenit hypothyroid subclin hypothyroid qualiti ultrasound tsh calcul osteo sonoassess hypothyroid affect thyroid hormon homeostasi bmd osteoporosi thyroid osteoporosi hypothyroid thyroid hormon tsh spine hypothyroid hypothyroid thyroid hormon reduc tsh proper osteoporosi contribut\n",
            "\t-0.394\tweekli intramuscular inject levothyroxin myxoedema practic solut old crisi 82yearold hypothyroid admit floor unkempt confus bradycard hypotherm bare arous biochemistri thyroid stimul hormon tsh mul thyroxin ft pmoll support myxoedema coma resuscit commenc liothyronin levothyroxin hydrocortison becam appar hide spit levothyroxin levothyroxin elixir prompt sought advic intern expert intramuscular levothyroxin recommend manag onward intramuscular levothyroxin 200 mcg week subsequ 500 mcg thyroid normal continu progress discharg rehabilit intramuscular levothyroxin stop subsequ restart levothyroxin plan ongo close thyroid highlight intramuscular levothyroxin hypothyroid aris complianc levothyroxin absorpt  introduction2 report3 clinician myxoedema coma endocrin emerg 70 uncommon nowaday widespread thyroid threshold initi levothyroxin levothyroxin 215 persist tsh mul widespread complianc malabsorpt myxoedema coma winter complianc hypothyroid judici levothyroxin liothyronin hydrocortison support mainstay favour interest myxoedema coma success manag intramuscular levothyroxin complianc levothyroxin demonstr intramuscular levothyroxin myxoedema coma \n",
            "\t-0.409\tlevothyroxin benign thyroid nodul suppress levothyroxin thyroid nodul realli accept purpos levothyroxin benign thyroid nodul forti benign nodul randomli divid 50gday levothyroxin take sonographi dimens nodul tsh regist irct 201103185692 n3 levothyroxin 4157 941 4445 109 p0386 tsh longitudin transvers dimens 005 tsh 165 052 067 muil p0001 longitudin transvers dimens 111 190 115 144 090 149 102 cm p074 p07 219 132 197 157 095 126 07 p035 01 suppress levothyroxin alter benign nodul  methodsresultsdiscuss thyroid nodul patholog endocrinologist deal consider accident discov perform radiolog carotid sonographi neck ct scan pet scan definit thyroid nodul 02 palpabl thyroid nodul frequent palpabl nodul cm way thyroid nodul nodul remov radioact conserv levothyroxin mere thyroid nodul expens accompani prefer medicin consensu suppress levothyroxin thyroid nodul tsh thyroid divis t4 contribut tsh feedback consequ eventu hypertrophi hyperplasia thyrocyt purpos levothyroxin inhibit tsh thyrotoxicosi unwant levothyroxin maintain tsh 0105 miul mention nodul cm colloid goiter colloid nodular suppress levothyroxin thyroid nodul random thyroid nodul refer depart endocrinolog babol univers scienc palpabl thyroid nodul enter benign fnab ensur exist nodul sonographi 1860 old t4 tsh euthyroid exclus thyroid neoplast neck hot nodul none seriou hepat none pregnant none suppress levothyroxin thyroidassoci inform inform consent randomli divid n20 levothyroxin gday iran hormon compani levothyroxin coordin tsh suppress bring tsh 05mu1 n20 tsh commerci kit 0545 muil thyroid sonographi suppress longitudin transvers dimens sonographi suppress longitudin transvers dimens nodul partial 2050 longitudin transvers dimens nodul spss version deviat pair 005 meaning forti 34 femal male 4305 1017 particip levothyroxin gday gender tsh longitudin transvers dimens nodul tsh 158 106 muil 052 067 muil levothyroxin femal male demonstr tsh p0001 tsh 118 muil 132 098 p0442 dimens thyroid nodul likewis nodul display remark dimens longitudin transvers dimens thyroid nodul partial seven levothyroxin levothyroxin base n20 pvalu sd levothyroxin sd 0386 4445 109 4157 941 yr 0390 165 118 200 165 tsh 0523 219 132 194 114 longitudin dimens cm 0662 157 095 144 090 transvers dimens cm compar dimens nodul pvalu dimens cm 0735 0657 190 115 149 102 111 144 090 longitudin transvers levothyroxin n20 0354 0109 197 140 126 070 219 132 157 095 longitudin transvers n20 discus levothyroxin benign thyroid nodul nodul placebo percent nodul contradict levothyroxin thyroid nodul purpos levothyroxin thyroid nodul tsh believ tsh thyroid tsh thyroid follicl medium thyroxin inhibit thyroid tsh success 052 067 muil levothyroxin papini suppress levothyroxin 51 thyroid nodul contribut 45 tsh reach 006 006 muil drugtreat lima 1997 54 oneyear levothyroxin none nodul suppress brought tsh 01muil drugtreat zelmanovitz 45 thyroid nodul conclud suppress levothyroxin nodul nodul larijani 62 doubl blind levothyroxin placebo percent nodul tsh 017 02 muil random doubl blind wemeau 123 thyroid nodul percent nodul follow levothyroxin placebo tsh reach 073 08 mui levothyroxin tsai exhibit receiv levothyroxin thyroid nodul reach tsh 008 002 muil thyroglobulin suppress demonstr suppress levothyroxin alter benign thyroid nodul levothyroxin benign thyroid nodul nodul placebo percent nodul contradict levothyroxin thyroid nodul purpos levothyroxin thyroid nodul tsh believ tsh thyroid tsh thyroid follicl medium thyroxin inhibit thyroid tsh success 052 067 muil levothyroxin papini suppress levothyroxin 51 thyroid nodul contribut 45 tsh reach 006 006 muil drugtreat lima 1997 54 oneyear levothyroxin none nodul suppress brought tsh 01muil drugtreat zelmanovitz 45 thyroid nodul conclud suppress levothyroxin nodul nodul larijani 62 doubl blind levothyroxin placebo percent nodul tsh 017 02 muil random doubl blind wemeau 123 thyroid nodul percent nodul follow levothyroxin placebo tsh reach 073 08 mui levothyroxin tsai exhibit receiv levothyroxin thyroid nodul reach tsh 008 002 muil thyroglobulin suppress demonstr suppress levothyroxin alter benign thyroid nodul\n",
            "hirsutism,TSH,Levothyroxine None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.478\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t0.477\tfetal alcohol spectrum damag prenat alcohol continu drink creat fetal alcohol spectrum fasd identifi articl describ spectrum therapeut pharmacolog nutrit environmentalbehavior alcoholinduc protect alcohol teratogen enhanc nervou plastic alcohol alcohol ceas insight gain date offer candid attenu deficit fasd fetal alcohol spectrum disordersprenat alcohol exposurepregnancyteratogen effectstreatmenttreat modelsexperiment treatmentsinterventionsnutrit interventionspharmacolog interventionsenvironment alcohol methyl aspart antagonistsserotonin agonistsantagon alcohol l1 adhes moleculesneurotroph factorsantioxidantsnutrit factorstreat fasdnutrit supplementationpharmacolog interventionsenvironment interventionsconclus alcohol disrupt numer indirect investig attempt alcoholinduc block discus born fasd lifetim behavior ideal interven alcohol prevent alcohol alway seek mitig development alcoholrel deficit insight gain date offer candid attenu deficit prenat alcohol translat arena pose challeng difficulti administ prenat period concern continu refin viabl nutrit behavior manipul readili translat continu drink alcohol continu pursu attenu alcohol fasd\n",
            "\t0.473\tpylorus cytokin profil balanc alcohol ingest amount ingest alcohol alcohol helicobact pylorus sought cytokin balanc pylorus alcohol 142 divid 59 alcohol ingest pylorus 53 alcohol ingest pylorus caga interleukin il10 eselectin malondialdehyd mda superoxid dismutas sod enzymelink immunosorb elisa age pylorus caga drink alcohol match compar compar bmi bmi statist f3921 005 bmi 0001 001 bmi statist 005 caga comparison 005 il10 eselectin il10 005 eselectin 005 il10 001 eselectin differ 005 il10 eselectin il10 0001 eselectin 005 differ 005 mda sod slightli 005 believ pylorus cytokin profil alcohol ingest chronic ingest alcohol exert adjust pylorus alcohol balanc  introductionmateri methodssubject selectionexperiment setup reagentsspecimen processingstatist analysisresultscomparison bmi caga bmi kgm caga ngl deviationcomparison il10 eselectin ngl deviationcomparison mda sod mda ngl sod uml deviationdiscuss helicobact pylorus pylorus recogn carcinogen intern agenc numer pylorus alcohol abus gastrointestin tract extradigest pylorus be worldwid infect world pathogen colon epithelium stomach circumst lifelong research paid pylorus research pro antiinflammatori peptic ulcer adenocarcinoma pylorus excess alcohol modest alcohol drink drink equival ethanol nonetheless manifest obscur alcohol mucos disrupt mucos homeostasi drink habit cytokin polymorph cytokin balanc hepat manifest alcohol pylorus alcohol ingest occurr cerebrovascular mellitu therebi pose threat reactionrel interleukin il10 eselectin balanc malondialdehyd mda superoxid dismutas sod mediat reaction adhes name neoplasm suspect event etiolog china pylorus alcohol numer pylorus alcohol coexist pylorus alcohol peroxid controversi aim alcohol ingest pylorus peroxid measur antiinflammatori antioxid pylorus colon stomach mucos unabl draw pylorus pylorus stimul upregul eselectin il8 il6 compar pylorirel concentr mucosa pathogen mucosa il10 il10 similarli pylorus cytokin il1 il1 il6 il8 convers il10 messeng pylorus hp gastriti 001 il10 pylorus upregul eselectin local mucosa defici il10 endogen il10 inhibit protect pylorus cagaposit pylorus caga pylorus trigger csx cag pathogen island cagpai pylorus bile duct pathogen cagaposit pylorus demonstr caga crucial dendrit toler modul il10 il18 cagaposit predispos digest ulcer virul pylorus stimul cagencod mononuclear duoden ulcerpromot a1 pylorus meanwhil alcohol cytokin alter alcohol alter il6 dysregul cytokin il10 il12 moder drinker exhibit icam1 eselectin abstain etiolog bmi predictor hscrp 0001 consid bmi antiinflammatori alcohol ingest pylorus chronic ingest alcohol overweight exert modulatori deduc chronic ingest alcoholrel cytokin profil chronic ingest alcohol se quantiti calori chronic ingest alcohol overweight pylorus chronic ingest alcohol pylorus ingest ethanol elucid bmi erad pylorus erad pylorus bmi bmi eselectin antiinflammatori reflect il10 pylorus alcohol ingest alcohol pylorus alcohol ingest pylorus bmi caga comparison alcohol pylorus alcohol pylorus pylorus cytokin profil alcohol ingest accord pylorus chronic ingest alcohol put pylorus ingest ethanol pylorus iv alcohol dehydrogenas pylorus ingest ethanol correl bmi amount ethanol attenu pylorus seem opinion pylorus caga conduct pylorus caga cytokin profil pylorus alcoholinduc pylorus ethanol definit chang balanc pylorus alcohol ingest pyloriinfect reactiv ro pylorus pylorus pylorus mda close mda nitric oxid histopatholog genotyp pylorus pylorus inhabit peroxid gastriti pylorus pylorus caga antioxid pylorus sod caga margin caga ethanol peroxid radic acetaldehyd induc injur mitochondrion ethanol oxid pathogen event alcoholinduc bing ethanol endogen peroxid peroxid sod pylorus alcohol balanc conclus pylorus pylorus caga alcoholinduc confirm alcohol ingest pylorus elev bmi cytokin eselectin il10 tnfa pylorus pro antiinflammatori alcohol pylorus caga obviou alcohol ingest pylorus partli bmi cytokin pylorus caga balanc exact subject bias disproportion predomin comorbid steatosi steatohepat influenc conclus prospect observ complet random fourth amount alcohol pylorus wellcharacter\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.154\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t-3.188\talcohol promot mammari vegfdepend angiogenesi alcohol recogn alcohol promot exist mammari unclear vegf alcohol promot xenograft mammari threedimension 3d tumorendotheli cocultur xenograft e0771 implant mammari pad c57bl6 alcohol drink 3d cocultur e0771 mdamb231 cocultur svec410ee2 umbil vein alcohol angiogenesi acceler appear alcohol vegf block vegf su5416 inhibit angiogenesi 3d tumorendotheli cocultur inject su5416 inhibit alcoholpromot mammari alcohol mammari stimul vegfdepend angiogenesi alcoholbreast cancerangiogenesisendotheli introductionmateri methodsmaterialscel cultureanim alcohol exposuremous xenograft modelimmunohistochemistri ihc microvessel amvdthreedimension 3d cocultur systemin alcohol exposureimmunoblottingvegf enzymelink immunosorb elisastatist analysisresultsethanol vegf angiogenesisethanol promot angiogenesissu5416 inhibit ethanolpromot xenograft modeldiscuss malign femal worldwid cancerrel usa reproductivehormon lifestyl epidemiolog alcohol dosedepend alcohol enhanc exist promot unclear angiogenesi vegf stimul vasculogenesi angiogenesi vegf angiogenesi promot stabil vegf adjac alcohol promot angiogenesi monocyt chemotact protein1 mcp1 mcp1 partial alcohol block mcp1 partial revers alcohol angiogenesi mammari alcoholinduc promot consid vegf angiogenesi hypothes vegf alcohol promot angiogenesi mammari util address alcohol promot unclear vegf implic angiogenesi alcohol angiogenesi acceler alcohol upregul vegf block vegf inhibit alcoholstimul angiogenesi 3d tumorendotheli cocultur block vegf inhibit alcoholacceler mammari vegfdepend angiogenesi alcoholmedi promot epidemiolog alcohol promot malign alcohol moder drink dark enhanc mammari c57bl6 alcohol enhanc angiogenesi alcoholstimul angiogenesi unclear alcohol alcohol promot tumorendotheli enhanc angiogenesi 3d cocultur tumorendotheli alcohol stimul mcp1 mammari angiogenesi block mcp1 partial revers alcohol angiogenesi hypothes mediat alcoholstimul angiogenesi vegf potent effector patholog angiogenesi prove occurr microenviron vegf stromal platelet vegf regul angiogenesi highaffin tyrosin kina vegfr1 flt1 vegfr2kdr flk1 vegf vegfr tube upregul permeabl 29 vegf indirect leukocyt migrat induc mcp1 il8 31 su5416 tyrosin vegfr2 block cellstimul angiogenesi elimin alcoholmedi promot angiogenesi su5416 inhibit alcoholstimul mammari confirm vegf alcohol promot mammari vegf alcoholmedi promot typespecif moder alcohol vegf angiogenesi xenograft melanoma alcohol promot mammari vegf elucid wherebi alcohol regul vegf\n",
            "\t-4.100\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.478\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t0.477\tfetal alcohol spectrum damag prenat alcohol continu drink creat fetal alcohol spectrum fasd identifi articl describ spectrum therapeut pharmacolog nutrit environmentalbehavior alcoholinduc protect alcohol teratogen enhanc nervou plastic alcohol alcohol ceas insight gain date offer candid attenu deficit fasd fetal alcohol spectrum disordersprenat alcohol exposurepregnancyteratogen effectstreatmenttreat modelsexperiment treatmentsinterventionsnutrit interventionspharmacolog interventionsenvironment alcohol methyl aspart antagonistsserotonin agonistsantagon alcohol l1 adhes moleculesneurotroph factorsantioxidantsnutrit factorstreat fasdnutrit supplementationpharmacolog interventionsenvironment interventionsconclus alcohol disrupt numer indirect investig attempt alcoholinduc block discus born fasd lifetim behavior ideal interven alcohol prevent alcohol alway seek mitig development alcoholrel deficit insight gain date offer candid attenu deficit prenat alcohol translat arena pose challeng difficulti administ prenat period concern continu refin viabl nutrit behavior manipul readili translat continu drink alcohol continu pursu attenu alcohol fasd\n",
            "\t0.473\tpylorus cytokin profil balanc alcohol ingest amount ingest alcohol alcohol helicobact pylorus sought cytokin balanc pylorus alcohol 142 divid 59 alcohol ingest pylorus 53 alcohol ingest pylorus caga interleukin il10 eselectin malondialdehyd mda superoxid dismutas sod enzymelink immunosorb elisa age pylorus caga drink alcohol match compar compar bmi bmi statist f3921 005 bmi 0001 001 bmi statist 005 caga comparison 005 il10 eselectin il10 005 eselectin 005 il10 001 eselectin differ 005 il10 eselectin il10 0001 eselectin 005 differ 005 mda sod slightli 005 believ pylorus cytokin profil alcohol ingest chronic ingest alcohol exert adjust pylorus alcohol balanc  introductionmateri methodssubject selectionexperiment setup reagentsspecimen processingstatist analysisresultscomparison bmi caga bmi kgm caga ngl deviationcomparison il10 eselectin ngl deviationcomparison mda sod mda ngl sod uml deviationdiscuss helicobact pylorus pylorus recogn carcinogen intern agenc numer pylorus alcohol abus gastrointestin tract extradigest pylorus be worldwid infect world pathogen colon epithelium stomach circumst lifelong research paid pylorus research pro antiinflammatori peptic ulcer adenocarcinoma pylorus excess alcohol modest alcohol drink drink equival ethanol nonetheless manifest obscur alcohol mucos disrupt mucos homeostasi drink habit cytokin polymorph cytokin balanc hepat manifest alcohol pylorus alcohol ingest occurr cerebrovascular mellitu therebi pose threat reactionrel interleukin il10 eselectin balanc malondialdehyd mda superoxid dismutas sod mediat reaction adhes name neoplasm suspect event etiolog china pylorus alcohol numer pylorus alcohol coexist pylorus alcohol peroxid controversi aim alcohol ingest pylorus peroxid measur antiinflammatori antioxid pylorus colon stomach mucos unabl draw pylorus pylorus stimul upregul eselectin il8 il6 compar pylorirel concentr mucosa pathogen mucosa il10 il10 similarli pylorus cytokin il1 il1 il6 il8 convers il10 messeng pylorus hp gastriti 001 il10 pylorus upregul eselectin local mucosa defici il10 endogen il10 inhibit protect pylorus cagaposit pylorus caga pylorus trigger csx cag pathogen island cagpai pylorus bile duct pathogen cagaposit pylorus demonstr caga crucial dendrit toler modul il10 il18 cagaposit predispos digest ulcer virul pylorus stimul cagencod mononuclear duoden ulcerpromot a1 pylorus meanwhil alcohol cytokin alter alcohol alter il6 dysregul cytokin il10 il12 moder drinker exhibit icam1 eselectin abstain etiolog bmi predictor hscrp 0001 consid bmi antiinflammatori alcohol ingest pylorus chronic ingest alcohol overweight exert modulatori deduc chronic ingest alcoholrel cytokin profil chronic ingest alcohol se quantiti calori chronic ingest alcohol overweight pylorus chronic ingest alcohol pylorus ingest ethanol elucid bmi erad pylorus erad pylorus bmi bmi eselectin antiinflammatori reflect il10 pylorus alcohol ingest alcohol pylorus alcohol ingest pylorus bmi caga comparison alcohol pylorus alcohol pylorus pylorus cytokin profil alcohol ingest accord pylorus chronic ingest alcohol put pylorus ingest ethanol pylorus iv alcohol dehydrogenas pylorus ingest ethanol correl bmi amount ethanol attenu pylorus seem opinion pylorus caga conduct pylorus caga cytokin profil pylorus alcoholinduc pylorus ethanol definit chang balanc pylorus alcohol ingest pyloriinfect reactiv ro pylorus pylorus pylorus mda close mda nitric oxid histopatholog genotyp pylorus pylorus inhabit peroxid gastriti pylorus pylorus caga antioxid pylorus sod caga margin caga ethanol peroxid radic acetaldehyd induc injur mitochondrion ethanol oxid pathogen event alcoholinduc bing ethanol endogen peroxid peroxid sod pylorus alcohol balanc conclus pylorus pylorus caga alcoholinduc confirm alcohol ingest pylorus elev bmi cytokin eselectin il10 tnfa pylorus pro antiinflammatori alcohol pylorus caga obviou alcohol ingest pylorus partli bmi cytokin pylorus caga balanc exact subject bias disproportion predomin comorbid steatosi steatohepat influenc conclus prospect observ complet random fourth amount alcohol pylorus wellcharacter\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.154\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t-3.188\talcohol promot mammari vegfdepend angiogenesi alcohol recogn alcohol promot exist mammari unclear vegf alcohol promot xenograft mammari threedimension 3d tumorendotheli cocultur xenograft e0771 implant mammari pad c57bl6 alcohol drink 3d cocultur e0771 mdamb231 cocultur svec410ee2 umbil vein alcohol angiogenesi acceler appear alcohol vegf block vegf su5416 inhibit angiogenesi 3d tumorendotheli cocultur inject su5416 inhibit alcoholpromot mammari alcohol mammari stimul vegfdepend angiogenesi alcoholbreast cancerangiogenesisendotheli introductionmateri methodsmaterialscel cultureanim alcohol exposuremous xenograft modelimmunohistochemistri ihc microvessel amvdthreedimension 3d cocultur systemin alcohol exposureimmunoblottingvegf enzymelink immunosorb elisastatist analysisresultsethanol vegf angiogenesisethanol promot angiogenesissu5416 inhibit ethanolpromot xenograft modeldiscuss malign femal worldwid cancerrel usa reproductivehormon lifestyl epidemiolog alcohol dosedepend alcohol enhanc exist promot unclear angiogenesi vegf stimul vasculogenesi angiogenesi vegf angiogenesi promot stabil vegf adjac alcohol promot angiogenesi monocyt chemotact protein1 mcp1 mcp1 partial alcohol block mcp1 partial revers alcohol angiogenesi mammari alcoholinduc promot consid vegf angiogenesi hypothes vegf alcohol promot angiogenesi mammari util address alcohol promot unclear vegf implic angiogenesi alcohol angiogenesi acceler alcohol upregul vegf block vegf inhibit alcoholstimul angiogenesi 3d tumorendotheli cocultur block vegf inhibit alcoholacceler mammari vegfdepend angiogenesi alcoholmedi promot epidemiolog alcohol promot malign alcohol moder drink dark enhanc mammari c57bl6 alcohol enhanc angiogenesi alcoholstimul angiogenesi unclear alcohol alcohol promot tumorendotheli enhanc angiogenesi 3d cocultur tumorendotheli alcohol stimul mcp1 mammari angiogenesi block mcp1 partial revers alcohol angiogenesi hypothes mediat alcoholstimul angiogenesi vegf potent effector patholog angiogenesi prove occurr microenviron vegf stromal platelet vegf regul angiogenesi highaffin tyrosin kina vegfr1 flt1 vegfr2kdr flk1 vegf vegfr tube upregul permeabl 29 vegf indirect leukocyt migrat induc mcp1 il8 31 su5416 tyrosin vegfr2 block cellstimul angiogenesi elimin alcoholmedi promot angiogenesi su5416 inhibit alcoholstimul mammari confirm vegf alcohol promot mammari vegf alcoholmedi promot typespecif moder alcohol vegf angiogenesi xenograft melanoma alcohol promot mammari vegf elucid wherebi alcohol regul vegf\n",
            "\t-4.100\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "cervical cancer,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.373\tcreatin heart genet creatin creatin cardiomyocyt accumul creatin creatin transport crt fail myocardi creatin gain insight crt sever myocardi creatin creatin heart creatinefre guanidinoacet methyl transferas knock gamt overexpress myocardi crt crtoe cradiolabel creatin crt real rtpcr creatin hplc heart gamt 7fold max creatin 14fold crt cr crt complet prevent fed creatin supplement creatin subject feedback creatin crtoe 27fold consider creatin crt myocardi creatin 067 00001 endogen crt correl myocardi creatin 001 096 creatin massiv upregul magnitud upregul subject feedback crt predominantli alter  introductionmethodsmicecreatin perfus heartmrna measurementswestern blottingbiochem measurementscalcul crt revers potentialstatist analysisresultscreatin uptakecrt levelssgk1 levelscreatin levelsfre creatin transportdiscuss demand myocardium creatin atp synthes mitochondrion react creatin creatin ck adp phosphocreatin atp consum revers take place replenish atp maintain adp creatin origin dietari biosynthesi predominantli kidney cardiomyocyt synthes creatin accumul gradient na creatin cotransport crt creatin lost cardiomyocyt spontan nonenzymat convers creatinin permeabl diffus possibl efflux creatin creatin tightli creatin supplement creatin downregul creatin myocardi creatin unchang myocardi creatin cr coronari ligat myocardi creatin explain myocardi creatin crt crt crt downregul upregul creatin analogu guanidinoproprion gpa act competit crt creatin regul crt upregul glucocorticoid sgk1 xenopu oocyt express crt crt genet manipul myocardi creatin guanidinoacet methyl transferas knock gamt unabl synthes creatin fed creatinefre entir creatinefre instead accumul creatin precursor guanidinoacet ga phosphoryl ck instead creatin partial take creatin ck veloc order magnitud ga substrat overexpress crt crtoe myocardi creatin creatin creatin extrem creatin forc creatin insight creatin hypothes creatin trigger upregul creatin myocardi crt creatin quantifi crt upregul creatin heart gamt crt overexpress crt heart sgk1 candid crt regul heart gamt creatinefre gamt heart creatin massiv 7fold wt crt 14fold feed creatin supplement essenti abolish heart creatin crt creatin endogen crt creatin crt crt domin crt patho intra creatin alter crt creatin creatin feed creatin kinet unalt myocardi creatin creatin heart wt fed creatin supplement similarli creatin deplet feed creatin analogu gpa creatin g8 myoblast creatin creatin creatin creatin wherebi creatin alter crt poorli understood crt interpret caution anticrt cross react pyruv dehydrogenas crt take place sandov crt compat housekeep crt heart creatinefre gamt revers creatin feed suscept chang crt heart 7fold creatin consid extrem stimulu zero creatin alter minor crt endogen crt downregul creatin heart crtoe crt feed wt creatin supplement crt heart crt heart crtoe heart creatinefre gamt creatin gamt heart crt primarili subject posttranscript posttranscript crt modif crt put pkc close transmembran dopamin transport downregul transloc dopamin transport sarcolemma pool conceiv regul exist crt xenopu oocyt express crt coexpress sgk1 creatin sgk1 stimul crt unalt sgk1 gamt sgk1 upregul creatin heart exclud sgk1 gamt heart undetect methodolog heart overexpress crt creatin creatin crt myc interest note ventricular rv creatin crtoe heart ventricular lv creatin transgen crt myc mlc2v normal ventricl ventricular transgen mlc2v mlc2v rv explain creatin ventricl myocardium rv lv creatin rv creatin lv creatin heart creatin rv crtoe lv actual creatin rv discrep attribut heart lv creatin heart greatest ventricular creatin discrep creatin lv creatin never wt altogeth creatin exce start determin myocardi creatin crt ever oper revers creatin calcul revers creatin becom thermodynam revers heart creatin revers plateau revers creatin thermodynam unpublish consciou ecg crtoe calcul qt interv reflect take theoret revers creatin take place substanti fraction heart creatin crt revers theori hypothes heart lv transgen crt revers creatin systol act creatin dissoci lv creatin creatin heart creatin ventricl creatin gamt accumul creatin precursor guanidinoacet capabl phosphoryl creatin substrat impli gamt heart phosphoryl creatin rapidli convert instant transport keep creatin facilit creatin experi limit exclud myocardium crt residu ccreatin unlik confound min washout heart coronari effluent min washout regardless residu absolut worst underestim creatinefre heart gamt creatin transsarcolemm creatin gradient revers experi passiv diffus creatin heart creatin heart impli gradient rapidli disappear experi unlik substanti ccreatin creatin heart gamt enorm creatin creatin smaller 7fold creatin heart fed gpa heart creatin max creatin 63 remov creatin crt upregul creatin revers creatin fail worthwhil unravel signal creatin pharmacolog manipul restor myocardi creatin fail\n",
            "\t0.366\tdrink drink liter meal man twentytwo nitrogen equilibrium ingest uniform product aggreg pound excret urinari nitrogen excess nitrogen urea ammonia creatin excret creatinin coincid appear creatin urin creatinin output believ copiou drink stimul catabol appear creatin partial muscular disintegr creatin profound enough yield nitrogen output creatin excret nitrogen output ammonia interpret output juic excret fece fecal nitrogen excret fecal nitrogen magnitud secur lower excret nonbacteri nitrogen quantiti excret percentag nitrogen appear nitrogen creatinin coeffici econom util constitu reach experi drink meal attend desir undesir    \n",
            "\t0.365\timmunomodulatori bilirubin bilirubin endogen product heme mammal bilirubin cytotox wast product excret bilirubin posse bilirubin protect autoimmun rheumatoid arthriti sclerosi lupu erythematosu autoimmun close leukocyt antigen hla hypothes bilirubin bind antigen peptidebind groov hla exert immunosuppress action theoret dock bilirubin hla undertaken silico bilirubin bind antigen peptidebind groov hla autoimmun affin bound bilirubin block antigen peptid suppress autoimmun discoveri autoimmun  introduction2 method3 discussion4 conclus bilirubin product heme mammal bilirubin cytotox wast product benefici bilirubin decad physiolog bilirubin antioxid bilirubin bilirubin besid antioxid document bilirubin posse immunomodulatori bilirubin effect suppress autoimmun liu colleagu bilirubin posse power immunomodulatori suppress autoimmun encephalomyel eae fischman colleagu bilirubin protect rheumatoid arthriti ra nutrit peng colleagu bilirubin sclerosi m tek colleagu bilirubin lupu erythematosu sle plausibl immunomodulatori bilirubin antioxid liu colleagu potent immunosuppress bilirubin attribut antioxid bilirubin broad suppress reactiv consid background wellknown fact autoimmun close leukocyt antigen hla hypothes bilirubin interact hla hinder antigen peptid trigger crystal hla threedimension suppress autoimmun bilirubin diseaseassoci hla bilirubin bilirubin hla explor theoret dock simul reason undertaken dock simul bilirubin hla bilirubin posse immunomodulatori bilirubin hla autoimmun immunomodulatori theoret dock simul turn correct certainli autoimmun adequ pharmacotherapi lack\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.324\tvitamin lcarnitin separ intradialyt dialysi hypotens cramp treat vitamin lcarnitin supplement intradialyt prospect hemodialysi intradialyt hypotens cramp nausea vomit headach 45 period begin receiv vitamin 200 iud receiv lcarnitin 500 mgd intradialyt record cramp vitamin lcarnitin cramp effect hypotens vitamin vitamin lcarnitin compar intradialyt vitamin lcarnitin effect intradialyt recommend hemodialysi  background2 objectives3 methods31 population32 design33 analyses4 resultsintradialyt protocol discus crf seriou crf slow progress declin hemodialysi lifesav crf intradialyt hypotens chest back cramp nausea vomit headach pruritu fatigu intradialyt hypotens complic nausea vomit dizzi cramp intradialyt hypotens prematur discontinu hemodialysi underdialysi risk preval complic cramp interfer amongst vitamin lcarnitin supplement beneficiari one vitamin reduc vitamin supplement vitamin recommend choic hd cramp lcarnitin quaternari amin fatti cytoplasm oxid carnitin pivot mark carnitin endstag esrd hemodialysi regular carnitin supplement hemodialysi intradialyt cramp hypotens asthenia weak cardiomyopathi dialysisrel cramp intradialyt hypotens question hemodialysi replac therapi lifesav hemodialysi accompani preval cramp hypotens nausea vomit headach pruritu effort vitamin lcarnitin supplement respect beneficiari lcarnitin ration hemodialysi situat balanc amelior evalu vitamin lcarnitin separ vitamin lcarnitin 29 vitamin lcarnitin intradialyt cramp preval intradialyt complic tri introduc palli cramp protocol vitamin cramp lcarnitin supplement elhennawi zaib cramp attack vitamin supplement lcarnitin reliev cramp khajedehi colleagu receiv vitamin vitamin vitamin cramp khajedehi colleagu indic vitamin ahmad hypotens receiv lcarnitin metaanalysi lynch colleagu confirm benefici lcarnitin supplement dialysisrel intradialyt hypotens evalu vitamin supplement intradialyt hypotens vitamin emodifi dialyz hypotens 31 beneficiari vitamin lcarnitin intradialyt hypotens hypotens vitamin lcarnitin neither nausea vomit pruritu begin lcarnitin supplement bioavail dose probabl toxic metabolit 33 34 recommend lcarnitin 10003000 mgd unlik 500 mgd lcarnitin intradialyt lcarnitin administ debskaslizien colleagu 36 lcarnitin dose 500 mgd carnitin subsequ indic effect lcarnitin supplement vitamin probabl lcarnitin recommend intradialyt vitamin lcarnitin supplement compar improv intradialyt vitamin lcarnitin effect intradialyt recommend hemodialysi\n",
            "\t-2.678\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t-2.678\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.373\tcreatin heart genet creatin creatin cardiomyocyt accumul creatin creatin transport crt fail myocardi creatin gain insight crt sever myocardi creatin creatin heart creatinefre guanidinoacet methyl transferas knock gamt overexpress myocardi crt crtoe cradiolabel creatin crt real rtpcr creatin hplc heart gamt 7fold max creatin 14fold crt cr crt complet prevent fed creatin supplement creatin subject feedback creatin crtoe 27fold consider creatin crt myocardi creatin 067 00001 endogen crt correl myocardi creatin 001 096 creatin massiv upregul magnitud upregul subject feedback crt predominantli alter  introductionmethodsmicecreatin perfus heartmrna measurementswestern blottingbiochem measurementscalcul crt revers potentialstatist analysisresultscreatin uptakecrt levelssgk1 levelscreatin levelsfre creatin transportdiscuss demand myocardium creatin atp synthes mitochondrion react creatin creatin ck adp phosphocreatin atp consum revers take place replenish atp maintain adp creatin origin dietari biosynthesi predominantli kidney cardiomyocyt synthes creatin accumul gradient na creatin cotransport crt creatin lost cardiomyocyt spontan nonenzymat convers creatinin permeabl diffus possibl efflux creatin creatin tightli creatin supplement creatin downregul creatin myocardi creatin unchang myocardi creatin cr coronari ligat myocardi creatin explain myocardi creatin crt crt crt downregul upregul creatin analogu guanidinoproprion gpa act competit crt creatin regul crt upregul glucocorticoid sgk1 xenopu oocyt express crt crt genet manipul myocardi creatin guanidinoacet methyl transferas knock gamt unabl synthes creatin fed creatinefre entir creatinefre instead accumul creatin precursor guanidinoacet ga phosphoryl ck instead creatin partial take creatin ck veloc order magnitud ga substrat overexpress crt crtoe myocardi creatin creatin creatin extrem creatin forc creatin insight creatin hypothes creatin trigger upregul creatin myocardi crt creatin quantifi crt upregul creatin heart gamt crt overexpress crt heart sgk1 candid crt regul heart gamt creatinefre gamt heart creatin massiv 7fold wt crt 14fold feed creatin supplement essenti abolish heart creatin crt creatin endogen crt creatin crt crt domin crt patho intra creatin alter crt creatin creatin feed creatin kinet unalt myocardi creatin creatin heart wt fed creatin supplement similarli creatin deplet feed creatin analogu gpa creatin g8 myoblast creatin creatin creatin creatin wherebi creatin alter crt poorli understood crt interpret caution anticrt cross react pyruv dehydrogenas crt take place sandov crt compat housekeep crt heart creatinefre gamt revers creatin feed suscept chang crt heart 7fold creatin consid extrem stimulu zero creatin alter minor crt endogen crt downregul creatin heart crtoe crt feed wt creatin supplement crt heart crt heart crtoe heart creatinefre gamt creatin gamt heart crt primarili subject posttranscript posttranscript crt modif crt put pkc close transmembran dopamin transport downregul transloc dopamin transport sarcolemma pool conceiv regul exist crt xenopu oocyt express crt coexpress sgk1 creatin sgk1 stimul crt unalt sgk1 gamt sgk1 upregul creatin heart exclud sgk1 gamt heart undetect methodolog heart overexpress crt creatin creatin crt myc interest note ventricular rv creatin crtoe heart ventricular lv creatin transgen crt myc mlc2v normal ventricl ventricular transgen mlc2v mlc2v rv explain creatin ventricl myocardium rv lv creatin rv creatin lv creatin heart creatin rv crtoe lv actual creatin rv discrep attribut heart lv creatin heart greatest ventricular creatin discrep creatin lv creatin never wt altogeth creatin exce start determin myocardi creatin crt ever oper revers creatin calcul revers creatin becom thermodynam revers heart creatin revers plateau revers creatin thermodynam unpublish consciou ecg crtoe calcul qt interv reflect take theoret revers creatin take place substanti fraction heart creatin crt revers theori hypothes heart lv transgen crt revers creatin systol act creatin dissoci lv creatin creatin heart creatin ventricl creatin gamt accumul creatin precursor guanidinoacet capabl phosphoryl creatin substrat impli gamt heart phosphoryl creatin rapidli convert instant transport keep creatin facilit creatin experi limit exclud myocardium crt residu ccreatin unlik confound min washout heart coronari effluent min washout regardless residu absolut worst underestim creatinefre heart gamt creatin transsarcolemm creatin gradient revers experi passiv diffus creatin heart creatin heart impli gradient rapidli disappear experi unlik substanti ccreatin creatin heart gamt enorm creatin creatin smaller 7fold creatin heart fed gpa heart creatin max creatin 63 remov creatin crt upregul creatin revers creatin fail worthwhil unravel signal creatin pharmacolog manipul restor myocardi creatin fail\n",
            "\t0.366\tdrink drink liter meal man twentytwo nitrogen equilibrium ingest uniform product aggreg pound excret urinari nitrogen excess nitrogen urea ammonia creatin excret creatinin coincid appear creatin urin creatinin output believ copiou drink stimul catabol appear creatin partial muscular disintegr creatin profound enough yield nitrogen output creatin excret nitrogen output ammonia interpret output juic excret fece fecal nitrogen excret fecal nitrogen magnitud secur lower excret nonbacteri nitrogen quantiti excret percentag nitrogen appear nitrogen creatinin coeffici econom util constitu reach experi drink meal attend desir undesir    \n",
            "\t0.365\timmunomodulatori bilirubin bilirubin endogen product heme mammal bilirubin cytotox wast product excret bilirubin posse bilirubin protect autoimmun rheumatoid arthriti sclerosi lupu erythematosu autoimmun close leukocyt antigen hla hypothes bilirubin bind antigen peptidebind groov hla exert immunosuppress action theoret dock bilirubin hla undertaken silico bilirubin bind antigen peptidebind groov hla autoimmun affin bound bilirubin block antigen peptid suppress autoimmun discoveri autoimmun  introduction2 method3 discussion4 conclus bilirubin product heme mammal bilirubin cytotox wast product benefici bilirubin decad physiolog bilirubin antioxid bilirubin bilirubin besid antioxid document bilirubin posse immunomodulatori bilirubin effect suppress autoimmun liu colleagu bilirubin posse power immunomodulatori suppress autoimmun encephalomyel eae fischman colleagu bilirubin protect rheumatoid arthriti ra nutrit peng colleagu bilirubin sclerosi m tek colleagu bilirubin lupu erythematosu sle plausibl immunomodulatori bilirubin antioxid liu colleagu potent immunosuppress bilirubin attribut antioxid bilirubin broad suppress reactiv consid background wellknown fact autoimmun close leukocyt antigen hla hypothes bilirubin interact hla hinder antigen peptid trigger crystal hla threedimension suppress autoimmun bilirubin diseaseassoci hla bilirubin bilirubin hla explor theoret dock simul reason undertaken dock simul bilirubin hla bilirubin posse immunomodulatori bilirubin hla autoimmun immunomodulatori theoret dock simul turn correct certainli autoimmun adequ pharmacotherapi lack\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.324\tvitamin lcarnitin separ intradialyt dialysi hypotens cramp treat vitamin lcarnitin supplement intradialyt prospect hemodialysi intradialyt hypotens cramp nausea vomit headach 45 period begin receiv vitamin 200 iud receiv lcarnitin 500 mgd intradialyt record cramp vitamin lcarnitin cramp effect hypotens vitamin vitamin lcarnitin compar intradialyt vitamin lcarnitin effect intradialyt recommend hemodialysi  background2 objectives3 methods31 population32 design33 analyses4 resultsintradialyt protocol discus crf seriou crf slow progress declin hemodialysi lifesav crf intradialyt hypotens chest back cramp nausea vomit headach pruritu fatigu intradialyt hypotens complic nausea vomit dizzi cramp intradialyt hypotens prematur discontinu hemodialysi underdialysi risk preval complic cramp interfer amongst vitamin lcarnitin supplement beneficiari one vitamin reduc vitamin supplement vitamin recommend choic hd cramp lcarnitin quaternari amin fatti cytoplasm oxid carnitin pivot mark carnitin endstag esrd hemodialysi regular carnitin supplement hemodialysi intradialyt cramp hypotens asthenia weak cardiomyopathi dialysisrel cramp intradialyt hypotens question hemodialysi replac therapi lifesav hemodialysi accompani preval cramp hypotens nausea vomit headach pruritu effort vitamin lcarnitin supplement respect beneficiari lcarnitin ration hemodialysi situat balanc amelior evalu vitamin lcarnitin separ vitamin lcarnitin 29 vitamin lcarnitin intradialyt cramp preval intradialyt complic tri introduc palli cramp protocol vitamin cramp lcarnitin supplement elhennawi zaib cramp attack vitamin supplement lcarnitin reliev cramp khajedehi colleagu receiv vitamin vitamin vitamin cramp khajedehi colleagu indic vitamin ahmad hypotens receiv lcarnitin metaanalysi lynch colleagu confirm benefici lcarnitin supplement dialysisrel intradialyt hypotens evalu vitamin supplement intradialyt hypotens vitamin emodifi dialyz hypotens 31 beneficiari vitamin lcarnitin intradialyt hypotens hypotens vitamin lcarnitin neither nausea vomit pruritu begin lcarnitin supplement bioavail dose probabl toxic metabolit 33 34 recommend lcarnitin 10003000 mgd unlik 500 mgd lcarnitin intradialyt lcarnitin administ debskaslizien colleagu 36 lcarnitin dose 500 mgd carnitin subsequ indic effect lcarnitin supplement vitamin probabl lcarnitin recommend intradialyt vitamin lcarnitin supplement compar improv intradialyt vitamin lcarnitin effect intradialyt recommend hemodialysi\n",
            "\t-2.678\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t-2.678\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "vomiting,Hemoglobin,Creatinine None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.358\tallergen avoid infant sensit metaanalysi uncertainti allergen avoid manag prevent allergi purpos effect allergen avoid allerg sensit newborn allergi onlin search articl januari 1980 decemb pubm cochran regist articl involv random rct allergen avoid allergen newborn rr eczema asthma rhiniti wheez cough employ sensit standard smd forc expiratori fev1 peak expiratori pefr jadad rct metaanalysi allergen avoid newborn allerg eczema 021 rhiniti 03 cough 01 asthma wheez highrisk infant asthma 003 wheez 00004 sensit allergen fev1 03 pefr morn 053 pefr even 02 pefr 029 allergen avoid alway success prevent allerg rigor methodolog confirm metaanalysisallergen avoidanceallergen newbornsprevi sensit patientsallerg introductionmateri methodssearch strategyinclus criteriaexclus criteriaoutcom measuresdata extractiontri assessmentstatist analysisresultsstudi descriptionsdata qualityeffect interventionssensit analysisdiscuss allerg epidem proport decad allerg allergen avoid pharmacotherapi allergenspecif immunotherapi sit allergen contribut hypersensit allergi societi advoc allergen avoid allergi allerg anamnesi ige clinician recommend avoid contact allergen allergen avoid allerg allergi note ineffect allergen allergi bed cover imperm hous dust mite decreas allergen amelior asthma extend delay introduct food allerg reaction actual allergi infant stringent allergen avoid alway practic allergi desensit supervis mayb feasibl option allergen avoid allerg uncertainti controversi allergen avoid manag prevent allergi allergen avoid reliabl continu recommend clinician allerg random rct allergen avoid allergi believ allergen avoid reduc ofor preventsallerg reaction allergen argument effect avoid date allergen avoid allevi prevent allergi review guidelin acknowledg allergen ineffect recommend rct broader mesh allergen avoid allergen allergen abat allergen inclus allergen avoidancerel allergen interfer allergi reliabl credibl metaanalysi rct retriev search elig word allergen avoid classifi allergen avoid dietari antigen allergen pertain avoid indoor allergen remov pet air filtrat vacuum cleaner allergenimperm mattress pillow cover cockroach extermin mold home sensit allergen restrict diet recruit rct dietari avoid appli newborn mother pregnant lactat mother strict dietari regimen hydrolyz formula instead milkbreastfeed record allergen cat dander mite count collect allergen home workplac decreas allergen sampl alway correspond allergen bronchial respons consid allergen allergen avoid allergen protect moderatetosever asthma allergen month asthmat recur review allergen avoid fals allergen interfer allevi 29 rct sensit metaanalysi grade moder support reliabl nevertheless incomplet random blind inadequ alloc conceal pose bia rct allergen avoid achiev statist allerg eczema cough rhiniti highrisk infant eczema rhiniti cough metaanalysi practic allergen avoid eczema rhiniti cough highrisk infant asthma wheez worth note dietari avoid fetal nutrit restrict food egg milk nut nutrient sensit enrol asthmat sensit hous mite fev1 pefr morn even evalu asthma 31 asthma ongo airway elimin allergen asthmat asthmat allergen mite mention mitesensit asthmat crossreact allergen allergen complic achiev allergen 33 consid unwil eat food allergi rct allergen problemat crosssensit invalid attempt avoid allergen pollensensit allerg ingest plantderiv 34 36 inhal pollen 37 phylogenet relationship organ crosssensit allergen homolog antigen allergen avoid prevent allerg strict allergen avoid alway suitabl difficulti implement learn avoid crossreact crosscontamin allergen product label facilit allergen list ingredi let unlabel allergen restrict avoid 38 avoid airborn allergen morri ling 39 adequ allergen avoid airborn allergen noncompli indoor allergen reliabl hous clean outdoor pollen mold imposs avoid complet asthmat referenc fev1 pefr morn even allergen avoid rational practic allergen avoid assumpt danger unpleas allerg reaction avoid acceler recoveri allerg assumpt agre hygien 39 childhood infecti symbiot microorgan parasit allerg suppress expand noninfecti foodallerg elimin dysregul th1 th2 allergen 41 peanut infanc avoid peanut allergi demonstr allergen avoid aim allerg sensit alway success suitabl diver view allergen avoid perspect allerg rigor methodolog\n",
            "\t0.321\terratum vol april    articl sodium packag food censu divis recommend incorrectli state sentenc articl read equiv salesweight categori meet fda sodium limit food label claim 600 mg sodiumserv meal 480 mgserv food calcul correct recommend receiv label claim 600 mg sodium serv meal 480 mg sodium serv food correct websit august 2015 onlin httpwwwcdcgovpcdissues2015140500htm regret confus inconveni error \n",
            "\t0.294\tnutrit spoon    soy food rich isoflavon genistein daidzein antioxid bind estrogen soy intrigu hint confer protect asian male male former eat soy latter offer intrigu confus ever nori kurahashi colleagu japan center 1995 japan centerbas prospect analyz 43509 japanes age 45 74 answer question lifestyl ate 147 food 307 74 220 local gland undetermin kurahashi dosedepend lower local soy food miso soup ate bowl miso soup twice ate bowl local rose genistein daidzein soy food march epidemiolog biomark richard hoffman associ professor univers mexico point kurahashi adjust tri isoflavon say confound produc spuriou isoflavon confound isoflavon weakli estrogen inhibit testosteron limit estrogen lose free testosteron make aggress appar protect local kurahashi say isoflavon delay latent japanes isoflavon latent local isoflavon chemoprevent kurahashi colleagu follow full decad conduct nest archiv hope solv puzzl \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.756\tallergi emerg therapi igemedi allergi concern worldwid manifest igemedi allergi urticaria angioedema pruritu difficulti breath laryng oedema vomit diarrhoea hypotens minut hour offend food ingest care support possibl challeng allergi focus avoid allergen prompt emerg reaction epinephrin autoinjector reaction optim time introduc allergen child possibl allergi therapi difficulti allergen avoid fatal reaction allergen therapi sublingu epicutan immunotherapi allergen nonspecif therapi chine herbal formula fahf2 omalizumab promis therapi mainstream anaphylaxisavoidancediagnosisfood allergyskin prick testtestingtreat introductionworld experiencediagnosismanagementprevent treatmentconclus allergi aris reproduc allergi concern affect worldwid estim allergi true establish selfreport metaanalysi rona selfreport allergi vari cent milk 02 cent egg cent peanut fish cent shellfish cent cent peanut milk egg shrimp take ige childhood nonhispan black raceethn australian proven allergi month old cent peanut 89 cent egg 08 cent sesam allergi asia figur western percept allergi preval continu fatal foodinduc anaphylaxi standard allergi demand reaction exist focus sole immunoglobulin ige allergi hallmark manifest igemedi allergi urticaria angioedema pruritu difficulti breath laryng oedema vomit diarrhoea hypotens cutan sign reaction cent age rash rule anaphylaxi typic minut hour ingest allergen reproduc ingest constel involv organ anaphylaxi fatal promptli goal highlight evolv therapeut igemedi allergi allergi concern worldwid fatal reaction cur place proper avoid offend allergen prompt reaction mainstay allergi delay introduct allergen food elucid optim time allergen introduct headway allergi option allergen nonspecif therapi promis readi optim dose\n",
            "\t-3.326\tallergen avoid infant sensit metaanalysi uncertainti allergen avoid manag prevent allergi purpos effect allergen avoid allerg sensit newborn allergi onlin search articl januari 1980 decemb pubm cochran regist articl involv random rct allergen avoid allergen newborn rr eczema asthma rhiniti wheez cough employ sensit standard smd forc expiratori fev1 peak expiratori pefr jadad rct metaanalysi allergen avoid newborn allerg eczema 021 rhiniti 03 cough 01 asthma wheez highrisk infant asthma 003 wheez 00004 sensit allergen fev1 03 pefr morn 053 pefr even 02 pefr 029 allergen avoid alway success prevent allerg rigor methodolog confirm metaanalysisallergen avoidanceallergen newbornsprevi sensit patientsallerg introductionmateri methodssearch strategyinclus criteriaexclus criteriaoutcom measuresdata extractiontri assessmentstatist analysisresultsstudi descriptionsdata qualityeffect interventionssensit analysisdiscuss allerg epidem proport decad allerg allergen avoid pharmacotherapi allergenspecif immunotherapi sit allergen contribut hypersensit allergi societi advoc allergen avoid allergi allerg anamnesi ige clinician recommend avoid contact allergen allergen avoid allerg allergi note ineffect allergen allergi bed cover imperm hous dust mite decreas allergen amelior asthma extend delay introduct food allerg reaction actual allergi infant stringent allergen avoid alway practic allergi desensit supervis mayb feasibl option allergen avoid allerg uncertainti controversi allergen avoid manag prevent allergi allergen avoid reliabl continu recommend clinician allerg random rct allergen avoid allergi believ allergen avoid reduc ofor preventsallerg reaction allergen argument effect avoid date allergen avoid allevi prevent allergi review guidelin acknowledg allergen ineffect recommend rct broader mesh allergen avoid allergen allergen abat allergen inclus allergen avoidancerel allergen interfer allergi reliabl credibl metaanalysi rct retriev search elig word allergen avoid classifi allergen avoid dietari antigen allergen pertain avoid indoor allergen remov pet air filtrat vacuum cleaner allergenimperm mattress pillow cover cockroach extermin mold home sensit allergen restrict diet recruit rct dietari avoid appli newborn mother pregnant lactat mother strict dietari regimen hydrolyz formula instead milkbreastfeed record allergen cat dander mite count collect allergen home workplac decreas allergen sampl alway correspond allergen bronchial respons consid allergen allergen avoid allergen protect moderatetosever asthma allergen month asthmat recur review allergen avoid fals allergen interfer allevi 29 rct sensit metaanalysi grade moder support reliabl nevertheless incomplet random blind inadequ alloc conceal pose bia rct allergen avoid achiev statist allerg eczema cough rhiniti highrisk infant eczema rhiniti cough metaanalysi practic allergen avoid eczema rhiniti cough highrisk infant asthma wheez worth note dietari avoid fetal nutrit restrict food egg milk nut nutrient sensit enrol asthmat sensit hous mite fev1 pefr morn even evalu asthma 31 asthma ongo airway elimin allergen asthmat asthmat allergen mite mention mitesensit asthmat crossreact allergen allergen complic achiev allergen 33 consid unwil eat food allergi rct allergen problemat crosssensit invalid attempt avoid allergen pollensensit allerg ingest plantderiv 34 36 inhal pollen 37 phylogenet relationship organ crosssensit allergen homolog antigen allergen avoid prevent allerg strict allergen avoid alway suitabl difficulti implement learn avoid crossreact crosscontamin allergen product label facilit allergen list ingredi let unlabel allergen restrict avoid 38 avoid airborn allergen morri ling 39 adequ allergen avoid airborn allergen noncompli indoor allergen reliabl hous clean outdoor pollen mold imposs avoid complet asthmat referenc fev1 pefr morn even allergen avoid rational practic allergen avoid assumpt danger unpleas allerg reaction avoid acceler recoveri allerg assumpt agre hygien 39 childhood infecti symbiot microorgan parasit allerg suppress expand noninfecti foodallerg elimin dysregul th1 th2 allergen 41 peanut infanc avoid peanut allergi demonstr allergen avoid aim allerg sensit alway success suitabl diver view allergen avoid perspect allerg rigor methodolog\n",
            "\t-4.078\tanaphylaxi fooddepend exerciseinduc anaphylaxi fdeian intens allergi allergen fdeian allergen predispos fdeian urticaria allerg reaction fdeian dermatolog ige typic prescreen decad detect prevent fdeian stimul mediat igedepend mast fdeian threshold exceed mast fdeian food fdeian wheat egg chicken shrimp shellfish nut fruit veget aspirin occurr allergi food intens frequent provok attack intens frequent view pathophysiolog fdeian immunolog detail fdeian definit etiolog cholinerg urticaria uc exerciseinduc anaphylaxi eia foodexerciseanaphylaxisfdeian introductionth discoursecuconvent eiavari eia fdeiandiagnosi pathophysiolog fdeianconclus anaphylaxi seriou hypersensit allerg involv tract gastrointestin gi tract spontan accompani sign dyspnea angioedema hypotens anaphylaxi bioactiv mediat basophil mast anaphylaxi 0008 005 lifetim 005 anaphylaxi underestim occurr dramat scientif western anaphylaxi anaphylaxi fooddepend exerciseinduc anaphylaxi fdeian inclus caus fdeian aris allergen highintens regimen word fedian sign hour ingest allergen fdeian subtyp exerciseinduc anaphylaxi eia anaphylaxi exert allerg reaction fdeian urticaria disturb dyspnea cough wheez angioedema gi manifest hypotens eia moment 90 min cessat fdeian ingest allergen preced minut hour fdeian ingest allergen soon complet allergen stellato exercis consum shellfish allerg reaction omega5 gliadin gluten allergen wheatdepend fdeian appar crustacean wheat food fdeian fdeian accur infrequ phenomenon fdeian surmis allerg anaphylaxi initi lowgrad allergi food help absorpt allergen gi tract degranul mast histamin eia ige allergi isotyp switch dermatolog foodspecif ige enough igemedi hyperreact fdeian overlook lifethreaten fdeian fdeian clinic anaphylaxi exercis hour eat allergen precis unclear fdeian anaphylaxi allergen food manifest soon exercis exercis predispos fdeian run tenni basketbal soccer swim brisk walk numer food fruit shrimp shellfish chicken wheat nut egg veget allergen fdeian eia exert cu distinguish eia occurr fdeian eat caus exercis avoid vigor caus reliabl prevent fdeian eia cu fdeian diagnos urgent\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.358\tallergen avoid infant sensit metaanalysi uncertainti allergen avoid manag prevent allergi purpos effect allergen avoid allerg sensit newborn allergi onlin search articl januari 1980 decemb pubm cochran regist articl involv random rct allergen avoid allergen newborn rr eczema asthma rhiniti wheez cough employ sensit standard smd forc expiratori fev1 peak expiratori pefr jadad rct metaanalysi allergen avoid newborn allerg eczema 021 rhiniti 03 cough 01 asthma wheez highrisk infant asthma 003 wheez 00004 sensit allergen fev1 03 pefr morn 053 pefr even 02 pefr 029 allergen avoid alway success prevent allerg rigor methodolog confirm metaanalysisallergen avoidanceallergen newbornsprevi sensit patientsallerg introductionmateri methodssearch strategyinclus criteriaexclus criteriaoutcom measuresdata extractiontri assessmentstatist analysisresultsstudi descriptionsdata qualityeffect interventionssensit analysisdiscuss allerg epidem proport decad allerg allergen avoid pharmacotherapi allergenspecif immunotherapi sit allergen contribut hypersensit allergi societi advoc allergen avoid allergi allerg anamnesi ige clinician recommend avoid contact allergen allergen avoid allerg allergi note ineffect allergen allergi bed cover imperm hous dust mite decreas allergen amelior asthma extend delay introduct food allerg reaction actual allergi infant stringent allergen avoid alway practic allergi desensit supervis mayb feasibl option allergen avoid allerg uncertainti controversi allergen avoid manag prevent allergi allergen avoid reliabl continu recommend clinician allerg random rct allergen avoid allergi believ allergen avoid reduc ofor preventsallerg reaction allergen argument effect avoid date allergen avoid allevi prevent allergi review guidelin acknowledg allergen ineffect recommend rct broader mesh allergen avoid allergen allergen abat allergen inclus allergen avoidancerel allergen interfer allergi reliabl credibl metaanalysi rct retriev search elig word allergen avoid classifi allergen avoid dietari antigen allergen pertain avoid indoor allergen remov pet air filtrat vacuum cleaner allergenimperm mattress pillow cover cockroach extermin mold home sensit allergen restrict diet recruit rct dietari avoid appli newborn mother pregnant lactat mother strict dietari regimen hydrolyz formula instead milkbreastfeed record allergen cat dander mite count collect allergen home workplac decreas allergen sampl alway correspond allergen bronchial respons consid allergen allergen avoid allergen protect moderatetosever asthma allergen month asthmat recur review allergen avoid fals allergen interfer allevi 29 rct sensit metaanalysi grade moder support reliabl nevertheless incomplet random blind inadequ alloc conceal pose bia rct allergen avoid achiev statist allerg eczema cough rhiniti highrisk infant eczema rhiniti cough metaanalysi practic allergen avoid eczema rhiniti cough highrisk infant asthma wheez worth note dietari avoid fetal nutrit restrict food egg milk nut nutrient sensit enrol asthmat sensit hous mite fev1 pefr morn even evalu asthma 31 asthma ongo airway elimin allergen asthmat asthmat allergen mite mention mitesensit asthmat crossreact allergen allergen complic achiev allergen 33 consid unwil eat food allergi rct allergen problemat crosssensit invalid attempt avoid allergen pollensensit allerg ingest plantderiv 34 36 inhal pollen 37 phylogenet relationship organ crosssensit allergen homolog antigen allergen avoid prevent allerg strict allergen avoid alway suitabl difficulti implement learn avoid crossreact crosscontamin allergen product label facilit allergen list ingredi let unlabel allergen restrict avoid 38 avoid airborn allergen morri ling 39 adequ allergen avoid airborn allergen noncompli indoor allergen reliabl hous clean outdoor pollen mold imposs avoid complet asthmat referenc fev1 pefr morn even allergen avoid rational practic allergen avoid assumpt danger unpleas allerg reaction avoid acceler recoveri allerg assumpt agre hygien 39 childhood infecti symbiot microorgan parasit allerg suppress expand noninfecti foodallerg elimin dysregul th1 th2 allergen 41 peanut infanc avoid peanut allergi demonstr allergen avoid aim allerg sensit alway success suitabl diver view allergen avoid perspect allerg rigor methodolog\n",
            "\t0.321\terratum vol april    articl sodium packag food censu divis recommend incorrectli state sentenc articl read equiv salesweight categori meet fda sodium limit food label claim 600 mg sodiumserv meal 480 mgserv food calcul correct recommend receiv label claim 600 mg sodium serv meal 480 mg sodium serv food correct websit august 2015 onlin httpwwwcdcgovpcdissues2015140500htm regret confus inconveni error \n",
            "\t0.294\tnutrit spoon    soy food rich isoflavon genistein daidzein antioxid bind estrogen soy intrigu hint confer protect asian male male former eat soy latter offer intrigu confus ever nori kurahashi colleagu japan center 1995 japan centerbas prospect analyz 43509 japanes age 45 74 answer question lifestyl ate 147 food 307 74 220 local gland undetermin kurahashi dosedepend lower local soy food miso soup ate bowl miso soup twice ate bowl local rose genistein daidzein soy food march epidemiolog biomark richard hoffman associ professor univers mexico point kurahashi adjust tri isoflavon say confound produc spuriou isoflavon confound isoflavon weakli estrogen inhibit testosteron limit estrogen lose free testosteron make aggress appar protect local kurahashi say isoflavon delay latent japanes isoflavon latent local isoflavon chemoprevent kurahashi colleagu follow full decad conduct nest archiv hope solv puzzl \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.756\tallergi emerg therapi igemedi allergi concern worldwid manifest igemedi allergi urticaria angioedema pruritu difficulti breath laryng oedema vomit diarrhoea hypotens minut hour offend food ingest care support possibl challeng allergi focus avoid allergen prompt emerg reaction epinephrin autoinjector reaction optim time introduc allergen child possibl allergi therapi difficulti allergen avoid fatal reaction allergen therapi sublingu epicutan immunotherapi allergen nonspecif therapi chine herbal formula fahf2 omalizumab promis therapi mainstream anaphylaxisavoidancediagnosisfood allergyskin prick testtestingtreat introductionworld experiencediagnosismanagementprevent treatmentconclus allergi aris reproduc allergi concern affect worldwid estim allergi true establish selfreport metaanalysi rona selfreport allergi vari cent milk 02 cent egg cent peanut fish cent shellfish cent cent peanut milk egg shrimp take ige childhood nonhispan black raceethn australian proven allergi month old cent peanut 89 cent egg 08 cent sesam allergi asia figur western percept allergi preval continu fatal foodinduc anaphylaxi standard allergi demand reaction exist focus sole immunoglobulin ige allergi hallmark manifest igemedi allergi urticaria angioedema pruritu difficulti breath laryng oedema vomit diarrhoea hypotens cutan sign reaction cent age rash rule anaphylaxi typic minut hour ingest allergen reproduc ingest constel involv organ anaphylaxi fatal promptli goal highlight evolv therapeut igemedi allergi allergi concern worldwid fatal reaction cur place proper avoid offend allergen prompt reaction mainstay allergi delay introduct allergen food elucid optim time allergen introduct headway allergi option allergen nonspecif therapi promis readi optim dose\n",
            "\t-3.326\tallergen avoid infant sensit metaanalysi uncertainti allergen avoid manag prevent allergi purpos effect allergen avoid allerg sensit newborn allergi onlin search articl januari 1980 decemb pubm cochran regist articl involv random rct allergen avoid allergen newborn rr eczema asthma rhiniti wheez cough employ sensit standard smd forc expiratori fev1 peak expiratori pefr jadad rct metaanalysi allergen avoid newborn allerg eczema 021 rhiniti 03 cough 01 asthma wheez highrisk infant asthma 003 wheez 00004 sensit allergen fev1 03 pefr morn 053 pefr even 02 pefr 029 allergen avoid alway success prevent allerg rigor methodolog confirm metaanalysisallergen avoidanceallergen newbornsprevi sensit patientsallerg introductionmateri methodssearch strategyinclus criteriaexclus criteriaoutcom measuresdata extractiontri assessmentstatist analysisresultsstudi descriptionsdata qualityeffect interventionssensit analysisdiscuss allerg epidem proport decad allerg allergen avoid pharmacotherapi allergenspecif immunotherapi sit allergen contribut hypersensit allergi societi advoc allergen avoid allergi allerg anamnesi ige clinician recommend avoid contact allergen allergen avoid allerg allergi note ineffect allergen allergi bed cover imperm hous dust mite decreas allergen amelior asthma extend delay introduct food allerg reaction actual allergi infant stringent allergen avoid alway practic allergi desensit supervis mayb feasibl option allergen avoid allerg uncertainti controversi allergen avoid manag prevent allergi allergen avoid reliabl continu recommend clinician allerg random rct allergen avoid allergi believ allergen avoid reduc ofor preventsallerg reaction allergen argument effect avoid date allergen avoid allevi prevent allergi review guidelin acknowledg allergen ineffect recommend rct broader mesh allergen avoid allergen allergen abat allergen inclus allergen avoidancerel allergen interfer allergi reliabl credibl metaanalysi rct retriev search elig word allergen avoid classifi allergen avoid dietari antigen allergen pertain avoid indoor allergen remov pet air filtrat vacuum cleaner allergenimperm mattress pillow cover cockroach extermin mold home sensit allergen restrict diet recruit rct dietari avoid appli newborn mother pregnant lactat mother strict dietari regimen hydrolyz formula instead milkbreastfeed record allergen cat dander mite count collect allergen home workplac decreas allergen sampl alway correspond allergen bronchial respons consid allergen allergen avoid allergen protect moderatetosever asthma allergen month asthmat recur review allergen avoid fals allergen interfer allevi 29 rct sensit metaanalysi grade moder support reliabl nevertheless incomplet random blind inadequ alloc conceal pose bia rct allergen avoid achiev statist allerg eczema cough rhiniti highrisk infant eczema rhiniti cough metaanalysi practic allergen avoid eczema rhiniti cough highrisk infant asthma wheez worth note dietari avoid fetal nutrit restrict food egg milk nut nutrient sensit enrol asthmat sensit hous mite fev1 pefr morn even evalu asthma 31 asthma ongo airway elimin allergen asthmat asthmat allergen mite mention mitesensit asthmat crossreact allergen allergen complic achiev allergen 33 consid unwil eat food allergi rct allergen problemat crosssensit invalid attempt avoid allergen pollensensit allerg ingest plantderiv 34 36 inhal pollen 37 phylogenet relationship organ crosssensit allergen homolog antigen allergen avoid prevent allerg strict allergen avoid alway suitabl difficulti implement learn avoid crossreact crosscontamin allergen product label facilit allergen list ingredi let unlabel allergen restrict avoid 38 avoid airborn allergen morri ling 39 adequ allergen avoid airborn allergen noncompli indoor allergen reliabl hous clean outdoor pollen mold imposs avoid complet asthmat referenc fev1 pefr morn even allergen avoid rational practic allergen avoid assumpt danger unpleas allerg reaction avoid acceler recoveri allerg assumpt agre hygien 39 childhood infecti symbiot microorgan parasit allerg suppress expand noninfecti foodallerg elimin dysregul th1 th2 allergen 41 peanut infanc avoid peanut allergi demonstr allergen avoid aim allerg sensit alway success suitabl diver view allergen avoid perspect allerg rigor methodolog\n",
            "\t-4.078\tanaphylaxi fooddepend exerciseinduc anaphylaxi fdeian intens allergi allergen fdeian allergen predispos fdeian urticaria allerg reaction fdeian dermatolog ige typic prescreen decad detect prevent fdeian stimul mediat igedepend mast fdeian threshold exceed mast fdeian food fdeian wheat egg chicken shrimp shellfish nut fruit veget aspirin occurr allergi food intens frequent provok attack intens frequent view pathophysiolog fdeian immunolog detail fdeian definit etiolog cholinerg urticaria uc exerciseinduc anaphylaxi eia foodexerciseanaphylaxisfdeian introductionth discoursecuconvent eiavari eia fdeiandiagnosi pathophysiolog fdeianconclus anaphylaxi seriou hypersensit allerg involv tract gastrointestin gi tract spontan accompani sign dyspnea angioedema hypotens anaphylaxi bioactiv mediat basophil mast anaphylaxi 0008 005 lifetim 005 anaphylaxi underestim occurr dramat scientif western anaphylaxi anaphylaxi fooddepend exerciseinduc anaphylaxi fdeian inclus caus fdeian aris allergen highintens regimen word fedian sign hour ingest allergen fdeian subtyp exerciseinduc anaphylaxi eia anaphylaxi exert allerg reaction fdeian urticaria disturb dyspnea cough wheez angioedema gi manifest hypotens eia moment 90 min cessat fdeian ingest allergen preced minut hour fdeian ingest allergen soon complet allergen stellato exercis consum shellfish allerg reaction omega5 gliadin gluten allergen wheatdepend fdeian appar crustacean wheat food fdeian fdeian accur infrequ phenomenon fdeian surmis allerg anaphylaxi initi lowgrad allergi food help absorpt allergen gi tract degranul mast histamin eia ige allergi isotyp switch dermatolog foodspecif ige enough igemedi hyperreact fdeian overlook lifethreaten fdeian fdeian clinic anaphylaxi exercis hour eat allergen precis unclear fdeian anaphylaxi allergen food manifest soon exercis exercis predispos fdeian run tenni basketbal soccer swim brisk walk numer food fruit shrimp shellfish chicken wheat nut egg veget allergen fdeian eia exert cu distinguish eia occurr fdeian eat caus exercis avoid vigor caus reliabl prevent fdeian eia cu fdeian diagnos urgent\n",
            "allergies to any food or drugs None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.424\talcohol dysfunct attitud femal alcohol addict aim alcohol alcohol dysfunct attitud 120 alcohol addict karolinska stockholm sweden twice 2year checklist90 alcohol inventori dysfunct attitud da latent curv alcohol dysfunct attitud alcohol alcohol drink stronger dysfunct attitud da subscal magnitud relat complianc dysfunct attitud stronger alcohol incorpor predictor alcohol alcohol addict dysfunct attitud indirectli incorpor alcohol dysfunct attitud complianc  introductionchang alcohol depressionar dysfunct attitud alcohol consumptionresearch hypothesesmateri methodsparticipantsinterventionmeasuresanalysesresultssepar lgc analysespredict alcohol consumptiondiscussionlevel alcohol consumptiondysfunct attitud alcohol indirectli directlytreat compliancelimit studyconclusionsfund alcohol manifest way alcohol harm drink relaps alcohol drink alcohol covari crosssect longitudin epidemiolog burn dixit crum hayn ramsey alway burn dysfunct attitud interact therebi alcohol relat dysfunct attitud mostli analys alcohol addict exclud oei 1995 haver gjestad explor relat dysfunct attitud alcohol curv comorbid alcohol describ pictur confirm expand alcohol inclus dysfunct attitud moder relat alcohol degre depend dysfunct attitud item da subscal alcohol lastli complianc mediat alcohol implic comorbid alcohol addict fund\n",
            "\t0.410\talcohol depend implic   disclosur alcohol worldwid 36 age 65 rehm morbid consequ suffer categor alcohol complic subject debat organis intern classif icd alcohol depend separ characteris cluster behaviour phenomenon desir drink alcohol difficulti control toler consum amount get withdraw stop alcohol harm alcohol organis 1997 distinct reflect american psychiatr manual dsm iv dsm updat diagnos alcohol depend alcohol abus merg alcohol concern phenomenon spectrum institut alcohol abus alcohol 2015 systemat metaanalysi laram colleagu alcohol depend broad diagnos icd dsm iv laram 2015 systemat alcohol alcohol roereck rehm laram alcohol depend alcohol abus continuum roereck rehm alcohol standardis ratio digest cirrhosi roereck rehm 2014 unintent injuri suicid substanti causespecif alcohol depend similar alcohol alcohol depend allcaus substanti alcohol depend laram consid differ alcohol depend continu drink heavili abstin alcohol lowest abstin drink justifi drink valid alongsid abstin add actual decreas drink save live alcohol heavi alcohol revers never interven laram alcohol decreas alcohol substanti reduc ill roereck alcohol morbid gap alcohol kohn alcohol receiv kohn drummond reason multifactori diver stigma schomeru profession fund kohn laram substanti alcohol depend emphasis harm disclosur author declar conflict \n",
            "\t0.410\talcohol depend implic   disclosur alcohol worldwid 36 age 65 rehm morbid consequ suffer categor alcohol complic subject debat organis intern classif icd alcohol depend separ characteris cluster behaviour phenomenon desir drink alcohol difficulti control toler consum amount get withdraw stop alcohol harm alcohol organis 1997 distinct reflect american psychiatr manual dsm iv dsm updat diagnos alcohol depend alcohol abus merg alcohol concern phenomenon spectrum institut alcohol abus alcohol 2015 systemat metaanalysi laram colleagu alcohol depend broad diagnos icd dsm iv laram 2015 systemat alcohol alcohol roereck rehm laram alcohol depend alcohol abus continuum roereck rehm alcohol standardis ratio digest cirrhosi roereck rehm 2014 unintent injuri suicid substanti causespecif alcohol depend similar alcohol alcohol depend allcaus substanti alcohol depend laram consid differ alcohol depend continu drink heavili abstin alcohol lowest abstin drink justifi drink valid alongsid abstin add actual decreas drink save live alcohol heavi alcohol revers never interven laram alcohol decreas alcohol substanti reduc ill roereck alcohol morbid gap alcohol kohn alcohol receiv kohn drummond reason multifactori diver stigma schomeru profession fund kohn laram substanti alcohol depend emphasis harm disclosur author declar conflict \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.969\tsuicid violenc impuls alcohol alcohol depend aggressionimpuls suicid suicid consist consecut admit addict suicid violenc impuls violenc childhood karolinska interperson violenc kiv hc suicid ideat suicid violenc suicid ideat score selfreport impuls barratt impuls bi trauma violent coupl impuls suicid longitudin ass trait identifi suicid  methodsparticipantscolumbiasuicid rate cssrsthe karolinska interperson violenc kivsbarratt impuls bisstatist analysisresultsparticipantsexperi violenc hcexperi violenc suicid ideationexperi violenc suicid behaviorexperi violenc suicid attemptviol analysesimpuls suicid patientsdiscussionaddit  suicid ideat suicid violenc suicid ideat selfrat impuls collect trauma trait aggress impuls contribut suicid corrobor violenceaggress suicid jokinen violenc kiv subscal victim violenc childhood violenc adulthood complet suicid suicid attempt suicid suicid score subscal predict complet suicid violenc increment suicid suicid ideat violenc statist doserespons violenc suicid collect valuabl receiv outpati addict suicid behavior util kiv suicid complet alway commun suicid thought sometim suicid 41 ass violenc accur suicid otherwis lowrisk tradit suicid ass violenc childhood suicid subscal differenti hc childhood maltreat emot sexual abus 42 43 interpret childhood trauma suicid childhood advers mediat psychopatholog 42 suicid attempt 44 196 huang 45 childhood trauma psychiatr suicid attempt childhood trauma act suicid illustr ass trauma childhood perform suicid ass kiv feasibl purpos neurobiolog correl vast serotonerg neurotransmiss violenc suicid 46 47 kiv subscal measur violenc childhood serotonin metabolit 5hydroxyindoleacet 5hiaa cerebrospin fluid csf suicid attempt 48 emot neglect serotonerg neurotransmiss neuroendocrin 49 neurobiolog correl suicid childhood trauma serotonerg neurotransmiss combin suicid ass pathophysiolog suicid selfrat impuls suicid ideat suicid suicid attempt plausibl explan discrep varianc selfrat impuls 44 89 62 suicid insuffici secondli selfrat impuls construct heterogen suicid substanti behavior impuls selfrat accur distinguish impuls suicid attempt 31 kiv subscal selfrat impuls construct separ possibl constitut suicid rule confound otherwis suicid suicid gender alcohol 90 hered suicid drive suicid ideat fulfil dsmiv violenc suicid respect past psychiatr suicid ideat past depress episod schwandt childhood trauma influenc depend 280 neurotic retrospect 17337 dube 44 childhood abus suicid attempt partial selfreport violenc suicid depend depress address consist crosssect emphas interpret caution replic actual suicid suicid attempt secondli clinic person antisoci person violenc 51 impuls alcohol 52 confound suicid attempt person impuls borderlin person anti person psychiatr person unmeasur person thirdli hc match done yield ident origin mismatch bia lastli hc kiv administ semistructur interview train clinician complet kiv rate selfreport possibl bia substanc converg correl interview selfreport childhood trauma 53 discrep kiv constitut bia summari suicid violenc suicid hc suicid ideat selfrat impuls employ prospect violenc impuls predict attempt complet suicid substanc\n",
            "\t-5.409\talcohol depend rural korea excess drink alcohol depend rural south korea repres nest casecontrol 1998 alcohol depend ad villag korea alcohol 290 ad n1058 145 alcohol alcohol depend ad alcohol depend questionnair n59 excess drink depend n86 145 nondrink match alcohol revisit villag complet person interview multivari logist regress morbid alcohol depend nondrink importantli excess drink depend morbid investig attend alcohol depend alcohol alcoholismalcohol drinkingmortalitymorbiditykorea introductionmateri methods1998 surveyfollowup surveymeasurementsalcohol dependenceexcess drinkinghealth outcomessmokingdemograph characteristicsstatist analysisresultsdescript resultsalcohol mortalityalcohol problemsdiscuss consequ alcohol depend substanti unambigu foremost contribut advers accid suicid alcohol depend shorten expect yr alcohol depend fatti hepat cirrhosi pancreat gastriti ulcer fractur neuropathi alcoholrel classifi cluster neuropsychiatr gastrointestin perinat toxic accid selfinflict injuri violent death numer alcohol abus date larg morbid trend access certif avail morbid conduct resourc unlik registr death routin registr disabl alcohol depend employ alcohol continu instead binomi alcohol depend excess alcohol euroamerican canada britain sweden norway asian attempt fill gap alcohol drink popular republ korea korea psychiatr epidemiolog korea psychiatr alcohol depend substanti korea alcohol drink korea decad 1986 statist 41 korea yr drinker substanti 68 drinker 08 1995 onemonth alcohol drink 631 yr 83 446 drink risen caput alcohol korea 1996 131 pure alcohol 1995 death korea attribut alcohol certif epidemiolog link alcohol depend excess alcohol alcohol screen excess drink alcohol depend nondrink compris abstain drinker 6yr exacerb alcohol morbid object alcohol depend excess drink morbid rural socioeconom se korea multivari substanti alcohol depend control varianc 6yr morbid alcohol depend nondrink excess drink moder alcohol depend appear smoker morbid alcohol depend nonsmok stop regard excess drink inconsist alcohol inconsist alcohol depend excess drink tend reli alcohol categor alcohol abus depend bing drink etc drink gain heavi drink occas drink meal beverag graduat gf prefer quantiti qf alcohol drink research cage questionnair drink dsmiv alcohol depend classifi alcohol depend excess drink correspond beverag consequ controversi prospect wine drinker consum beer liquor 29 se rural korean farmer beverag drinker farmer soju drinker soju consum afford alcohol beverag korea regard beverag breakfast se insomnia etc morbid note concentr methodolog challeng ass impact alcohol depend morbid stipul respond selfreport employ binari classifi neither distinguish exclud linear moder appear protect congest 31 arteri definit omiss influenc unexpect moder alcohol depend hypothes confid gener rural korea applic korea alcohol drink korea younger reader remind alcohol comparison person alcohol nondrink moder alcohol consider lost attrit younger nonalcohol alcohol attrit influenc attrit younger distinguish lost morbid 290 alcohol alcohol tabl attrit alcohol bias respect tabl alway challeng model predictor reason examin entir option place cart front hors ideal predictor restrict predictor consequ alcohol abus regardless behavior modif yr motiv issu subject debat view unlik alter omiss diver selfreport quit regularli epidemiolog survey selfreport vulner bia subject vulner inabl captur yr valid morbid flaw unmarri partial valid interpret morbid alcohol depend excess drink morbid way add alcohol abus flaw inclus morbid enhanc noxiou excess alcohol abus alcohol depend rural korea alcohol depend excess drink se multifold investig alcohol alcohol depend alcohol drink emphas conduct prospect incorpor empir discrimin alcohol depend excess drink depend offer alcoholrel death\n",
            "\t-5.409\talcohol depend rural korea excess drink alcohol depend rural south korea repres nest casecontrol 1998 alcohol depend ad villag korea alcohol 290 ad n1058 145 alcohol alcohol depend ad alcohol depend questionnair n59 excess drink depend n86 145 nondrink match alcohol revisit villag complet person interview multivari logist regress morbid alcohol depend nondrink importantli excess drink depend morbid investig attend alcohol depend alcohol alcoholismalcohol drinkingmortalitymorbiditykorea introductionmateri methods1998 surveyfollowup surveymeasurementsalcohol dependenceexcess drinkinghealth outcomessmokingdemograph characteristicsstatist analysisresultsdescript resultsalcohol mortalityalcohol problemsdiscuss consequ alcohol depend substanti unambigu foremost contribut advers accid suicid alcohol depend shorten expect yr alcohol depend fatti hepat cirrhosi pancreat gastriti ulcer fractur neuropathi alcoholrel classifi cluster neuropsychiatr gastrointestin perinat toxic accid selfinflict injuri violent death numer alcohol abus date larg morbid trend access certif avail morbid conduct resourc unlik registr death routin registr disabl alcohol depend employ alcohol continu instead binomi alcohol depend excess alcohol euroamerican canada britain sweden norway asian attempt fill gap alcohol drink popular republ korea korea psychiatr epidemiolog korea psychiatr alcohol depend substanti korea alcohol drink korea decad 1986 statist 41 korea yr drinker substanti 68 drinker 08 1995 onemonth alcohol drink 631 yr 83 446 drink risen caput alcohol korea 1996 131 pure alcohol 1995 death korea attribut alcohol certif epidemiolog link alcohol depend excess alcohol alcohol screen excess drink alcohol depend nondrink compris abstain drinker 6yr exacerb alcohol morbid object alcohol depend excess drink morbid rural socioeconom se korea multivari substanti alcohol depend control varianc 6yr morbid alcohol depend nondrink excess drink moder alcohol depend appear smoker morbid alcohol depend nonsmok stop regard excess drink inconsist alcohol inconsist alcohol depend excess drink tend reli alcohol categor alcohol abus depend bing drink etc drink gain heavi drink occas drink meal beverag graduat gf prefer quantiti qf alcohol drink research cage questionnair drink dsmiv alcohol depend classifi alcohol depend excess drink correspond beverag consequ controversi prospect wine drinker consum beer liquor 29 se rural korean farmer beverag drinker farmer soju drinker soju consum afford alcohol beverag korea regard beverag breakfast se insomnia etc morbid note concentr methodolog challeng ass impact alcohol depend morbid stipul respond selfreport employ binari classifi neither distinguish exclud linear moder appear protect congest 31 arteri definit omiss influenc unexpect moder alcohol depend hypothes confid gener rural korea applic korea alcohol drink korea younger reader remind alcohol comparison person alcohol nondrink moder alcohol consider lost attrit younger nonalcohol alcohol attrit influenc attrit younger distinguish lost morbid 290 alcohol alcohol tabl attrit alcohol bias respect tabl alway challeng model predictor reason examin entir option place cart front hors ideal predictor restrict predictor consequ alcohol abus regardless behavior modif yr motiv issu subject debat view unlik alter omiss diver selfreport quit regularli epidemiolog survey selfreport vulner bia subject vulner inabl captur yr valid morbid flaw unmarri partial valid interpret morbid alcohol depend excess drink morbid way add alcohol abus flaw inclus morbid enhanc noxiou excess alcohol abus alcohol depend rural korea alcohol depend excess drink se multifold investig alcohol alcohol depend alcohol drink emphas conduct prospect incorpor empir discrimin alcohol depend excess drink depend offer alcoholrel death\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.424\talcohol dysfunct attitud femal alcohol addict aim alcohol alcohol dysfunct attitud 120 alcohol addict karolinska stockholm sweden twice 2year checklist90 alcohol inventori dysfunct attitud da latent curv alcohol dysfunct attitud alcohol alcohol drink stronger dysfunct attitud da subscal magnitud relat complianc dysfunct attitud stronger alcohol incorpor predictor alcohol alcohol addict dysfunct attitud indirectli incorpor alcohol dysfunct attitud complianc  introductionchang alcohol depressionar dysfunct attitud alcohol consumptionresearch hypothesesmateri methodsparticipantsinterventionmeasuresanalysesresultssepar lgc analysespredict alcohol consumptiondiscussionlevel alcohol consumptiondysfunct attitud alcohol indirectli directlytreat compliancelimit studyconclusionsfund alcohol manifest way alcohol harm drink relaps alcohol drink alcohol covari crosssect longitudin epidemiolog burn dixit crum hayn ramsey alway burn dysfunct attitud interact therebi alcohol relat dysfunct attitud mostli analys alcohol addict exclud oei 1995 haver gjestad explor relat dysfunct attitud alcohol curv comorbid alcohol describ pictur confirm expand alcohol inclus dysfunct attitud moder relat alcohol degre depend dysfunct attitud item da subscal alcohol lastli complianc mediat alcohol implic comorbid alcohol addict fund\n",
            "\t0.410\talcohol depend implic   disclosur alcohol worldwid 36 age 65 rehm morbid consequ suffer categor alcohol complic subject debat organis intern classif icd alcohol depend separ characteris cluster behaviour phenomenon desir drink alcohol difficulti control toler consum amount get withdraw stop alcohol harm alcohol organis 1997 distinct reflect american psychiatr manual dsm iv dsm updat diagnos alcohol depend alcohol abus merg alcohol concern phenomenon spectrum institut alcohol abus alcohol 2015 systemat metaanalysi laram colleagu alcohol depend broad diagnos icd dsm iv laram 2015 systemat alcohol alcohol roereck rehm laram alcohol depend alcohol abus continuum roereck rehm alcohol standardis ratio digest cirrhosi roereck rehm 2014 unintent injuri suicid substanti causespecif alcohol depend similar alcohol alcohol depend allcaus substanti alcohol depend laram consid differ alcohol depend continu drink heavili abstin alcohol lowest abstin drink justifi drink valid alongsid abstin add actual decreas drink save live alcohol heavi alcohol revers never interven laram alcohol decreas alcohol substanti reduc ill roereck alcohol morbid gap alcohol kohn alcohol receiv kohn drummond reason multifactori diver stigma schomeru profession fund kohn laram substanti alcohol depend emphasis harm disclosur author declar conflict \n",
            "\t0.410\talcohol depend implic   disclosur alcohol worldwid 36 age 65 rehm morbid consequ suffer categor alcohol complic subject debat organis intern classif icd alcohol depend separ characteris cluster behaviour phenomenon desir drink alcohol difficulti control toler consum amount get withdraw stop alcohol harm alcohol organis 1997 distinct reflect american psychiatr manual dsm iv dsm updat diagnos alcohol depend alcohol abus merg alcohol concern phenomenon spectrum institut alcohol abus alcohol 2015 systemat metaanalysi laram colleagu alcohol depend broad diagnos icd dsm iv laram 2015 systemat alcohol alcohol roereck rehm laram alcohol depend alcohol abus continuum roereck rehm alcohol standardis ratio digest cirrhosi roereck rehm 2014 unintent injuri suicid substanti causespecif alcohol depend similar alcohol alcohol depend allcaus substanti alcohol depend laram consid differ alcohol depend continu drink heavili abstin alcohol lowest abstin drink justifi drink valid alongsid abstin add actual decreas drink save live alcohol heavi alcohol revers never interven laram alcohol decreas alcohol substanti reduc ill roereck alcohol morbid gap alcohol kohn alcohol receiv kohn drummond reason multifactori diver stigma schomeru profession fund kohn laram substanti alcohol depend emphasis harm disclosur author declar conflict \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.969\tsuicid violenc impuls alcohol alcohol depend aggressionimpuls suicid suicid consist consecut admit addict suicid violenc impuls violenc childhood karolinska interperson violenc kiv hc suicid ideat suicid violenc suicid ideat score selfreport impuls barratt impuls bi trauma violent coupl impuls suicid longitudin ass trait identifi suicid  methodsparticipantscolumbiasuicid rate cssrsthe karolinska interperson violenc kivsbarratt impuls bisstatist analysisresultsparticipantsexperi violenc hcexperi violenc suicid ideationexperi violenc suicid behaviorexperi violenc suicid attemptviol analysesimpuls suicid patientsdiscussionaddit  suicid ideat suicid violenc suicid ideat selfrat impuls collect trauma trait aggress impuls contribut suicid corrobor violenceaggress suicid jokinen violenc kiv subscal victim violenc childhood violenc adulthood complet suicid suicid attempt suicid suicid score subscal predict complet suicid violenc increment suicid suicid ideat violenc statist doserespons violenc suicid collect valuabl receiv outpati addict suicid behavior util kiv suicid complet alway commun suicid thought sometim suicid 41 ass violenc accur suicid otherwis lowrisk tradit suicid ass violenc childhood suicid subscal differenti hc childhood maltreat emot sexual abus 42 43 interpret childhood trauma suicid childhood advers mediat psychopatholog 42 suicid attempt 44 196 huang 45 childhood trauma psychiatr suicid attempt childhood trauma act suicid illustr ass trauma childhood perform suicid ass kiv feasibl purpos neurobiolog correl vast serotonerg neurotransmiss violenc suicid 46 47 kiv subscal measur violenc childhood serotonin metabolit 5hydroxyindoleacet 5hiaa cerebrospin fluid csf suicid attempt 48 emot neglect serotonerg neurotransmiss neuroendocrin 49 neurobiolog correl suicid childhood trauma serotonerg neurotransmiss combin suicid ass pathophysiolog suicid selfrat impuls suicid ideat suicid suicid attempt plausibl explan discrep varianc selfrat impuls 44 89 62 suicid insuffici secondli selfrat impuls construct heterogen suicid substanti behavior impuls selfrat accur distinguish impuls suicid attempt 31 kiv subscal selfrat impuls construct separ possibl constitut suicid rule confound otherwis suicid suicid gender alcohol 90 hered suicid drive suicid ideat fulfil dsmiv violenc suicid respect past psychiatr suicid ideat past depress episod schwandt childhood trauma influenc depend 280 neurotic retrospect 17337 dube 44 childhood abus suicid attempt partial selfreport violenc suicid depend depress address consist crosssect emphas interpret caution replic actual suicid suicid attempt secondli clinic person antisoci person violenc 51 impuls alcohol 52 confound suicid attempt person impuls borderlin person anti person psychiatr person unmeasur person thirdli hc match done yield ident origin mismatch bia lastli hc kiv administ semistructur interview train clinician complet kiv rate selfreport possibl bia substanc converg correl interview selfreport childhood trauma 53 discrep kiv constitut bia summari suicid violenc suicid hc suicid ideat selfrat impuls employ prospect violenc impuls predict attempt complet suicid substanc\n",
            "\t-5.409\talcohol depend rural korea excess drink alcohol depend rural south korea repres nest casecontrol 1998 alcohol depend ad villag korea alcohol 290 ad n1058 145 alcohol alcohol depend ad alcohol depend questionnair n59 excess drink depend n86 145 nondrink match alcohol revisit villag complet person interview multivari logist regress morbid alcohol depend nondrink importantli excess drink depend morbid investig attend alcohol depend alcohol alcoholismalcohol drinkingmortalitymorbiditykorea introductionmateri methods1998 surveyfollowup surveymeasurementsalcohol dependenceexcess drinkinghealth outcomessmokingdemograph characteristicsstatist analysisresultsdescript resultsalcohol mortalityalcohol problemsdiscuss consequ alcohol depend substanti unambigu foremost contribut advers accid suicid alcohol depend shorten expect yr alcohol depend fatti hepat cirrhosi pancreat gastriti ulcer fractur neuropathi alcoholrel classifi cluster neuropsychiatr gastrointestin perinat toxic accid selfinflict injuri violent death numer alcohol abus date larg morbid trend access certif avail morbid conduct resourc unlik registr death routin registr disabl alcohol depend employ alcohol continu instead binomi alcohol depend excess alcohol euroamerican canada britain sweden norway asian attempt fill gap alcohol drink popular republ korea korea psychiatr epidemiolog korea psychiatr alcohol depend substanti korea alcohol drink korea decad 1986 statist 41 korea yr drinker substanti 68 drinker 08 1995 onemonth alcohol drink 631 yr 83 446 drink risen caput alcohol korea 1996 131 pure alcohol 1995 death korea attribut alcohol certif epidemiolog link alcohol depend excess alcohol alcohol screen excess drink alcohol depend nondrink compris abstain drinker 6yr exacerb alcohol morbid object alcohol depend excess drink morbid rural socioeconom se korea multivari substanti alcohol depend control varianc 6yr morbid alcohol depend nondrink excess drink moder alcohol depend appear smoker morbid alcohol depend nonsmok stop regard excess drink inconsist alcohol inconsist alcohol depend excess drink tend reli alcohol categor alcohol abus depend bing drink etc drink gain heavi drink occas drink meal beverag graduat gf prefer quantiti qf alcohol drink research cage questionnair drink dsmiv alcohol depend classifi alcohol depend excess drink correspond beverag consequ controversi prospect wine drinker consum beer liquor 29 se rural korean farmer beverag drinker farmer soju drinker soju consum afford alcohol beverag korea regard beverag breakfast se insomnia etc morbid note concentr methodolog challeng ass impact alcohol depend morbid stipul respond selfreport employ binari classifi neither distinguish exclud linear moder appear protect congest 31 arteri definit omiss influenc unexpect moder alcohol depend hypothes confid gener rural korea applic korea alcohol drink korea younger reader remind alcohol comparison person alcohol nondrink moder alcohol consider lost attrit younger nonalcohol alcohol attrit influenc attrit younger distinguish lost morbid 290 alcohol alcohol tabl attrit alcohol bias respect tabl alway challeng model predictor reason examin entir option place cart front hors ideal predictor restrict predictor consequ alcohol abus regardless behavior modif yr motiv issu subject debat view unlik alter omiss diver selfreport quit regularli epidemiolog survey selfreport vulner bia subject vulner inabl captur yr valid morbid flaw unmarri partial valid interpret morbid alcohol depend excess drink morbid way add alcohol abus flaw inclus morbid enhanc noxiou excess alcohol abus alcohol depend rural korea alcohol depend excess drink se multifold investig alcohol alcohol depend alcohol drink emphas conduct prospect incorpor empir discrimin alcohol depend excess drink depend offer alcoholrel death\n",
            "\t-5.409\talcohol depend rural korea excess drink alcohol depend rural south korea repres nest casecontrol 1998 alcohol depend ad villag korea alcohol 290 ad n1058 145 alcohol alcohol depend ad alcohol depend questionnair n59 excess drink depend n86 145 nondrink match alcohol revisit villag complet person interview multivari logist regress morbid alcohol depend nondrink importantli excess drink depend morbid investig attend alcohol depend alcohol alcoholismalcohol drinkingmortalitymorbiditykorea introductionmateri methods1998 surveyfollowup surveymeasurementsalcohol dependenceexcess drinkinghealth outcomessmokingdemograph characteristicsstatist analysisresultsdescript resultsalcohol mortalityalcohol problemsdiscuss consequ alcohol depend substanti unambigu foremost contribut advers accid suicid alcohol depend shorten expect yr alcohol depend fatti hepat cirrhosi pancreat gastriti ulcer fractur neuropathi alcoholrel classifi cluster neuropsychiatr gastrointestin perinat toxic accid selfinflict injuri violent death numer alcohol abus date larg morbid trend access certif avail morbid conduct resourc unlik registr death routin registr disabl alcohol depend employ alcohol continu instead binomi alcohol depend excess alcohol euroamerican canada britain sweden norway asian attempt fill gap alcohol drink popular republ korea korea psychiatr epidemiolog korea psychiatr alcohol depend substanti korea alcohol drink korea decad 1986 statist 41 korea yr drinker substanti 68 drinker 08 1995 onemonth alcohol drink 631 yr 83 446 drink risen caput alcohol korea 1996 131 pure alcohol 1995 death korea attribut alcohol certif epidemiolog link alcohol depend excess alcohol alcohol screen excess drink alcohol depend nondrink compris abstain drinker 6yr exacerb alcohol morbid object alcohol depend excess drink morbid rural socioeconom se korea multivari substanti alcohol depend control varianc 6yr morbid alcohol depend nondrink excess drink moder alcohol depend appear smoker morbid alcohol depend nonsmok stop regard excess drink inconsist alcohol inconsist alcohol depend excess drink tend reli alcohol categor alcohol abus depend bing drink etc drink gain heavi drink occas drink meal beverag graduat gf prefer quantiti qf alcohol drink research cage questionnair drink dsmiv alcohol depend classifi alcohol depend excess drink correspond beverag consequ controversi prospect wine drinker consum beer liquor 29 se rural korean farmer beverag drinker farmer soju drinker soju consum afford alcohol beverag korea regard beverag breakfast se insomnia etc morbid note concentr methodolog challeng ass impact alcohol depend morbid stipul respond selfreport employ binari classifi neither distinguish exclud linear moder appear protect congest 31 arteri definit omiss influenc unexpect moder alcohol depend hypothes confid gener rural korea applic korea alcohol drink korea younger reader remind alcohol comparison person alcohol nondrink moder alcohol consider lost attrit younger nonalcohol alcohol attrit influenc attrit younger distinguish lost morbid 290 alcohol alcohol tabl attrit alcohol bias respect tabl alway challeng model predictor reason examin entir option place cart front hors ideal predictor restrict predictor consequ alcohol abus regardless behavior modif yr motiv issu subject debat view unlik alter omiss diver selfreport quit regularli epidemiolog survey selfreport vulner bia subject vulner inabl captur yr valid morbid flaw unmarri partial valid interpret morbid alcohol depend excess drink morbid way add alcohol abus flaw inclus morbid enhanc noxiou excess alcohol abus alcohol depend rural korea alcohol depend excess drink se multifold investig alcohol alcohol depend alcohol drink emphas conduct prospect incorpor empir discrimin alcohol depend excess drink depend offer alcoholrel death\n",
            "worthlessness,Vit D,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.393\tletter editor   dear editor dear editor congratul articl entitl optim nausea vomit comprehens frequent complic letter arriv public think research clarif seemingli minor avoid confus point metoclopramid section statement subcutan metoclopramid nvp hg support observ continu subcutan metoclopramid distinct receiv 267 4432 unfavor comparison recommend expens altern explor subject extrem prudent perhap continu subcutan metoclopramid accident suggest reassur excess sleepi impli diclectin tire continu subcutan metoclopramid wast resourc reckless \n",
            "\t0.361\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t0.361\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.018\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t2.018\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t1.775\tintract nausea vomit present manifest neuromyel optica    neuromyel optica nmo demyelin nervou recurr optic neuriti longitudin extens transvers myeliti letm simultan isol intract nausea hiccough present nmo misdiagnosi unnecessari investig initi 29yearold woman 6week recurr nausea vomit giddi headach true vertigo initi gastroenterologist upper gastrointestin tract endoscopi twice antiemet symptomat start recurr episod vomit giddi diplopia sway side walk weak limb pain paresthesia upper limb neurolog bilater papil optic atrophi bilater horizont gazeevok nystagmu neuron facial palsi spastic asymmetr pyramid weak upper limb exagger reflex bilater extensor plantar spinothalam sensori c7 cerebellar sign csf cellsmm lymphocyt 68 mgdl mri longitudin extend transvers myeliti segment cervicomedullari hyperintens periventricular pericallos nmoigg methyl prednisolon gmday initi subsequ exchang view former exchang axial flair imag posterior fossa demonstr hyperintens dorsal medullari postrema arrow axial t1w contrastenhanc imag depict enhanc dorsal medulla sagitt t2 cervic spine depict patchi hyperintens dorsal pon medulla cervicomedullari junction segment cervic spinal cord sagitt t1 imag correspond heterogen moder enhanc correspond nausea vomit nonspecif giddi headach prompt consider correctli intracrani lesion subject unnecessari investig delay vomit humor postrema circumventricular organ situat floor fourth ventricl special ependym rich aquaporin4 bloodborn stimul toxin peptid lesion stimul postrema nucleu tractu solitariu vomit dorsal medulla implic present sustain vomit hiccup 1420 care neurolog spontan vomit gastrointestin investig nmo treatabl nausea vomit gastroenterologist initi optic neuriti myeliti \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.393\tletter editor   dear editor dear editor congratul articl entitl optim nausea vomit comprehens frequent complic letter arriv public think research clarif seemingli minor avoid confus point metoclopramid section statement subcutan metoclopramid nvp hg support observ continu subcutan metoclopramid distinct receiv 267 4432 unfavor comparison recommend expens altern explor subject extrem prudent perhap continu subcutan metoclopramid accident suggest reassur excess sleepi impli diclectin tire continu subcutan metoclopramid wast resourc reckless \n",
            "\t0.361\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\t0.361\tinfarct    58yearold leftsid abdomin constant ach nausea vomit bowel movement even deni fever chill appetit dysuria irregular rhythm leftsid midabdomin tender deep palpat rebound guard mild costovertebralangl tender ekg atrial fibril urinalysi comput tomographi abdomen pelvi comput tomographi abdomen pelvi comput tomographi imag enhanc infarct anticoagul intraven heparin maintain discharg infarct typic affect abdomin hematuria fever nausea vomit oliguria atrial fibril hematuria urinalysi leukocytosi creatinin markedli ldh includ diverticular aortic aneurysm gynecolog append angiographi gold ct abdomen infarct doppler ultrasound date contrastenhanc ultrasonographi preclud \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.018\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t2.018\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t1.775\tintract nausea vomit present manifest neuromyel optica    neuromyel optica nmo demyelin nervou recurr optic neuriti longitudin extens transvers myeliti letm simultan isol intract nausea hiccough present nmo misdiagnosi unnecessari investig initi 29yearold woman 6week recurr nausea vomit giddi headach true vertigo initi gastroenterologist upper gastrointestin tract endoscopi twice antiemet symptomat start recurr episod vomit giddi diplopia sway side walk weak limb pain paresthesia upper limb neurolog bilater papil optic atrophi bilater horizont gazeevok nystagmu neuron facial palsi spastic asymmetr pyramid weak upper limb exagger reflex bilater extensor plantar spinothalam sensori c7 cerebellar sign csf cellsmm lymphocyt 68 mgdl mri longitudin extend transvers myeliti segment cervicomedullari hyperintens periventricular pericallos nmoigg methyl prednisolon gmday initi subsequ exchang view former exchang axial flair imag posterior fossa demonstr hyperintens dorsal medullari postrema arrow axial t1w contrastenhanc imag depict enhanc dorsal medulla sagitt t2 cervic spine depict patchi hyperintens dorsal pon medulla cervicomedullari junction segment cervic spinal cord sagitt t1 imag correspond heterogen moder enhanc correspond nausea vomit nonspecif giddi headach prompt consider correctli intracrani lesion subject unnecessari investig delay vomit humor postrema circumventricular organ situat floor fourth ventricl special ependym rich aquaporin4 bloodborn stimul toxin peptid lesion stimul postrema nucleu tractu solitariu vomit dorsal medulla implic present sustain vomit hiccup 1420 care neurolog spontan vomit gastrointestin investig nmo treatabl nausea vomit gastroenterologist initi optic neuriti myeliti \n",
            "nausea None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.576\tlipas revers cholesterol mellitu aimsintroduct lipas el lipoprotein hdl el proatherogen el cholesterol efflux arteri stiff el assay elisa 172 175 cholesterol efflux arteri stiff measur pul wave veloc pwv carotid femor arteri reactiv crp el 277 166 ngml 240 113 005 cholesterol efflux scaveng 151 167 31 001 el cholesterol efflux 016 0025 trend linear regress hdl el waist circumfer determin cholesterol efflux determin cholesterol efflux hdl crp pwv 001 el pwv conclus el cholesterol efflux hdl subclin invest doi 101111j2040 1124201000016x    \n",
            "\t0.571\tcompar antioxid lipoprotein hyperglycemia etiolog atherosclerosi modif lipoprotein ldl atherosclerosi compar antioxid aop ldl carri 80 80 separ match bmi glycosyl hemoglobin ldl precipit heparin citrat precipit aop ldl xanthin xanthin oxidas aop 005 ldl prone oxid antioxid potentialdiabet mellituslow lipoprotein ntroduct ateri ethod esult iscuss onclus mellitu macrovascular microvascular hyperglycemia etiolog atherosclerosi alter oxidizablitiy lipoprotein contributori mellitu convers lipoprotein ldl oxid ldl event initi acceler atherosclerot lesion fatti streak coronari chd equal prove postmenopaus chd ldl oxid know oxldl macrovascular ldl gener peroxid measur antioxid aop aim compar aop ldl diabet compar gender \n",
            "\t0.569\tmbl    circul mannosebind lectin mbl attack page 117 diabet cholesterol indic mbl bind sugar broad microorgan promot clearanc mbl infecti link goe toward settl controversi examin mbl myocardi infarct senior author helgi valdimarsson point stratifi link mbl attack diabet cholesterol measur mbl reliabl mbl genotyp mbl virtual unchang decad genotyp vari unpublish mbl protect myocardi infarct help oxid cholesterol build arteri cholesterol abund mbl news \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.235\timplic epidem lipidlow nonhdl cholesterol replac ldl cholesterol diabet overlap event coronari classifi coronari equival lipoprotein ldl cholesterol frequent apolipoprotein triglycerid nonhigh lipoprotein hdl cholesterol ldl cholesterol nonhdl cholesterol repres recommend atp hypertriglyceridemia articl overview nonhdl cholesterol superior ldl cholesterol predict present nonhdl cholesterol pandem adopt nonhdl cholesterol conceiv intensif ldl cholesterol obesitycoronari arteri diseasenonhdl cholesterolldl cholesterolmetabol syndromediabet ldl cholesterol therapydiabet atherogen dyslipidemia eventsth obesitycholesterol resistancenonhdlc correl ldlc apobnonhdlc correl ldlc den ldl particlesnonhdlc superior ldlc predictionperspect epidemiolog coronari arteri cad highlight lipoprotein cholesterol ldlc prevent newonset cad recurr ischem stamler 1986 1984b 1984a rossouw 1990 wong 1991 wilson 1998 loglinear ldlc cad hold true ldlc grundi surprisingli ldlc cholesterol ncep panel atp cholesterolreduc success ncep atp recommend success ldlc goal atp atpiii acknowledg triglycerid tg 200 mgdl remnant atherogen lipoprotein greatli heighten ldlc substanti lipoprotein cholesterol vldlc atp vldlc account calcul ldlc panel tg 150 mgdl vldlc mgdl vldlc arguabl make contribut atherogen cholesterol pool 1979 tg 200 mgdl non lipoprotein cholesterol nonhdlc mgdl ldlc atp nonhdlc simpli calcul panel cholesterol tc minu hdlc account ldlc vldlc idlc chylomicron remnant lipoprotein nonhdlc apolipoprotein apob accur cholesterol atherogen particl atp nonhdlc ldlc 094 tg 150 mgdl nonhdlc becom displac upward weaken abat 1993 hypertriglyceridemia affect american 37 diabet shepherd nonhdlc ldlc reliabl sizeabl pischon nonhdlc superior predictor cad regardless tg 5794 person framingham nonhdlc superior predictor cad ldlc vldlc predict cad adjust ldlc tg 200 mgdl tg 200 mgdl liu vldlc poorli 008 ldlc advantag nonhdlc incorpor ldlc vldlc triglyceriderich lipoprotein account ldlc angiograph cad hard point phillip 1993 mack 1996 sack nonhdlc invers hdlc gordon 1989 srinivasan arguabl press hypertriglyceridemia propos nonhdlc \n",
            "\t0.235\timplic epidem lipidlow nonhdl cholesterol replac ldl cholesterol diabet overlap event coronari classifi coronari equival lipoprotein ldl cholesterol frequent apolipoprotein triglycerid nonhigh lipoprotein hdl cholesterol ldl cholesterol nonhdl cholesterol repres recommend atp hypertriglyceridemia articl overview nonhdl cholesterol superior ldl cholesterol predict present nonhdl cholesterol pandem adopt nonhdl cholesterol conceiv intensif ldl cholesterol obesitycoronari arteri diseasenonhdl cholesterolldl cholesterolmetabol syndromediabet ldl cholesterol therapydiabet atherogen dyslipidemia eventsth obesitycholesterol resistancenonhdlc correl ldlc apobnonhdlc correl ldlc den ldl particlesnonhdlc superior ldlc predictionperspect epidemiolog coronari arteri cad highlight lipoprotein cholesterol ldlc prevent newonset cad recurr ischem stamler 1986 1984b 1984a rossouw 1990 wong 1991 wilson 1998 loglinear ldlc cad hold true ldlc grundi surprisingli ldlc cholesterol ncep panel atp cholesterolreduc success ncep atp recommend success ldlc goal atp atpiii acknowledg triglycerid tg 200 mgdl remnant atherogen lipoprotein greatli heighten ldlc substanti lipoprotein cholesterol vldlc atp vldlc account calcul ldlc panel tg 150 mgdl vldlc mgdl vldlc arguabl make contribut atherogen cholesterol pool 1979 tg 200 mgdl non lipoprotein cholesterol nonhdlc mgdl ldlc atp nonhdlc simpli calcul panel cholesterol tc minu hdlc account ldlc vldlc idlc chylomicron remnant lipoprotein nonhdlc apolipoprotein apob accur cholesterol atherogen particl atp nonhdlc ldlc 094 tg 150 mgdl nonhdlc becom displac upward weaken abat 1993 hypertriglyceridemia affect american 37 diabet shepherd nonhdlc ldlc reliabl sizeabl pischon nonhdlc superior predictor cad regardless tg 5794 person framingham nonhdlc superior predictor cad ldlc vldlc predict cad adjust ldlc tg 200 mgdl tg 200 mgdl liu vldlc poorli 008 ldlc advantag nonhdlc incorpor ldlc vldlc triglyceriderich lipoprotein account ldlc angiograph cad hard point phillip 1993 mack 1996 sack nonhdlc invers hdlc gordon 1989 srinivasan arguabl press hypertriglyceridemia propos nonhdlc \n",
            "\t0.235\timplic epidem lipidlow nonhdl cholesterol replac ldl cholesterol diabet overlap event coronari classifi coronari equival lipoprotein ldl cholesterol frequent apolipoprotein triglycerid nonhigh lipoprotein hdl cholesterol ldl cholesterol nonhdl cholesterol repres recommend atp hypertriglyceridemia articl overview nonhdl cholesterol superior ldl cholesterol predict present nonhdl cholesterol pandem adopt nonhdl cholesterol conceiv intensif ldl cholesterol obesitycoronari arteri diseasenonhdl cholesterolldl cholesterolmetabol syndromediabet ldl cholesterol therapydiabet atherogen dyslipidemia eventsth obesitycholesterol resistancenonhdlc correl ldlc apobnonhdlc correl ldlc den ldl particlesnonhdlc superior ldlc predictionperspect epidemiolog coronari arteri cad highlight lipoprotein cholesterol ldlc prevent newonset cad recurr ischem stamler 1986 1984b 1984a rossouw 1990 wong 1991 wilson 1998 loglinear ldlc cad hold true ldlc grundi surprisingli ldlc cholesterol ncep panel atp cholesterolreduc success ncep atp recommend success ldlc goal atp atpiii acknowledg triglycerid tg 200 mgdl remnant atherogen lipoprotein greatli heighten ldlc substanti lipoprotein cholesterol vldlc atp vldlc account calcul ldlc panel tg 150 mgdl vldlc mgdl vldlc arguabl make contribut atherogen cholesterol pool 1979 tg 200 mgdl non lipoprotein cholesterol nonhdlc mgdl ldlc atp nonhdlc simpli calcul panel cholesterol tc minu hdlc account ldlc vldlc idlc chylomicron remnant lipoprotein nonhdlc apolipoprotein apob accur cholesterol atherogen particl atp nonhdlc ldlc 094 tg 150 mgdl nonhdlc becom displac upward weaken abat 1993 hypertriglyceridemia affect american 37 diabet shepherd nonhdlc ldlc reliabl sizeabl pischon nonhdlc superior predictor cad regardless tg 5794 person framingham nonhdlc superior predictor cad ldlc vldlc predict cad adjust ldlc tg 200 mgdl tg 200 mgdl liu vldlc poorli 008 ldlc advantag nonhdlc incorpor ldlc vldlc triglyceriderich lipoprotein account ldlc angiograph cad hard point phillip 1993 mack 1996 sack nonhdlc invers hdlc gordon 1989 srinivasan arguabl press hypertriglyceridemia propos nonhdlc \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.576\tlipas revers cholesterol mellitu aimsintroduct lipas el lipoprotein hdl el proatherogen el cholesterol efflux arteri stiff el assay elisa 172 175 cholesterol efflux arteri stiff measur pul wave veloc pwv carotid femor arteri reactiv crp el 277 166 ngml 240 113 005 cholesterol efflux scaveng 151 167 31 001 el cholesterol efflux 016 0025 trend linear regress hdl el waist circumfer determin cholesterol efflux determin cholesterol efflux hdl crp pwv 001 el pwv conclus el cholesterol efflux hdl subclin invest doi 101111j2040 1124201000016x    \n",
            "\t0.571\tcompar antioxid lipoprotein hyperglycemia etiolog atherosclerosi modif lipoprotein ldl atherosclerosi compar antioxid aop ldl carri 80 80 separ match bmi glycosyl hemoglobin ldl precipit heparin citrat precipit aop ldl xanthin xanthin oxidas aop 005 ldl prone oxid antioxid potentialdiabet mellituslow lipoprotein ntroduct ateri ethod esult iscuss onclus mellitu macrovascular microvascular hyperglycemia etiolog atherosclerosi alter oxidizablitiy lipoprotein contributori mellitu convers lipoprotein ldl oxid ldl event initi acceler atherosclerot lesion fatti streak coronari chd equal prove postmenopaus chd ldl oxid know oxldl macrovascular ldl gener peroxid measur antioxid aop aim compar aop ldl diabet compar gender \n",
            "\t0.569\tmbl    circul mannosebind lectin mbl attack page 117 diabet cholesterol indic mbl bind sugar broad microorgan promot clearanc mbl infecti link goe toward settl controversi examin mbl myocardi infarct senior author helgi valdimarsson point stratifi link mbl attack diabet cholesterol measur mbl reliabl mbl genotyp mbl virtual unchang decad genotyp vari unpublish mbl protect myocardi infarct help oxid cholesterol build arteri cholesterol abund mbl news \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.235\timplic epidem lipidlow nonhdl cholesterol replac ldl cholesterol diabet overlap event coronari classifi coronari equival lipoprotein ldl cholesterol frequent apolipoprotein triglycerid nonhigh lipoprotein hdl cholesterol ldl cholesterol nonhdl cholesterol repres recommend atp hypertriglyceridemia articl overview nonhdl cholesterol superior ldl cholesterol predict present nonhdl cholesterol pandem adopt nonhdl cholesterol conceiv intensif ldl cholesterol obesitycoronari arteri diseasenonhdl cholesterolldl cholesterolmetabol syndromediabet ldl cholesterol therapydiabet atherogen dyslipidemia eventsth obesitycholesterol resistancenonhdlc correl ldlc apobnonhdlc correl ldlc den ldl particlesnonhdlc superior ldlc predictionperspect epidemiolog coronari arteri cad highlight lipoprotein cholesterol ldlc prevent newonset cad recurr ischem stamler 1986 1984b 1984a rossouw 1990 wong 1991 wilson 1998 loglinear ldlc cad hold true ldlc grundi surprisingli ldlc cholesterol ncep panel atp cholesterolreduc success ncep atp recommend success ldlc goal atp atpiii acknowledg triglycerid tg 200 mgdl remnant atherogen lipoprotein greatli heighten ldlc substanti lipoprotein cholesterol vldlc atp vldlc account calcul ldlc panel tg 150 mgdl vldlc mgdl vldlc arguabl make contribut atherogen cholesterol pool 1979 tg 200 mgdl non lipoprotein cholesterol nonhdlc mgdl ldlc atp nonhdlc simpli calcul panel cholesterol tc minu hdlc account ldlc vldlc idlc chylomicron remnant lipoprotein nonhdlc apolipoprotein apob accur cholesterol atherogen particl atp nonhdlc ldlc 094 tg 150 mgdl nonhdlc becom displac upward weaken abat 1993 hypertriglyceridemia affect american 37 diabet shepherd nonhdlc ldlc reliabl sizeabl pischon nonhdlc superior predictor cad regardless tg 5794 person framingham nonhdlc superior predictor cad ldlc vldlc predict cad adjust ldlc tg 200 mgdl tg 200 mgdl liu vldlc poorli 008 ldlc advantag nonhdlc incorpor ldlc vldlc triglyceriderich lipoprotein account ldlc angiograph cad hard point phillip 1993 mack 1996 sack nonhdlc invers hdlc gordon 1989 srinivasan arguabl press hypertriglyceridemia propos nonhdlc \n",
            "\t0.235\timplic epidem lipidlow nonhdl cholesterol replac ldl cholesterol diabet overlap event coronari classifi coronari equival lipoprotein ldl cholesterol frequent apolipoprotein triglycerid nonhigh lipoprotein hdl cholesterol ldl cholesterol nonhdl cholesterol repres recommend atp hypertriglyceridemia articl overview nonhdl cholesterol superior ldl cholesterol predict present nonhdl cholesterol pandem adopt nonhdl cholesterol conceiv intensif ldl cholesterol obesitycoronari arteri diseasenonhdl cholesterolldl cholesterolmetabol syndromediabet ldl cholesterol therapydiabet atherogen dyslipidemia eventsth obesitycholesterol resistancenonhdlc correl ldlc apobnonhdlc correl ldlc den ldl particlesnonhdlc superior ldlc predictionperspect epidemiolog coronari arteri cad highlight lipoprotein cholesterol ldlc prevent newonset cad recurr ischem stamler 1986 1984b 1984a rossouw 1990 wong 1991 wilson 1998 loglinear ldlc cad hold true ldlc grundi surprisingli ldlc cholesterol ncep panel atp cholesterolreduc success ncep atp recommend success ldlc goal atp atpiii acknowledg triglycerid tg 200 mgdl remnant atherogen lipoprotein greatli heighten ldlc substanti lipoprotein cholesterol vldlc atp vldlc account calcul ldlc panel tg 150 mgdl vldlc mgdl vldlc arguabl make contribut atherogen cholesterol pool 1979 tg 200 mgdl non lipoprotein cholesterol nonhdlc mgdl ldlc atp nonhdlc simpli calcul panel cholesterol tc minu hdlc account ldlc vldlc idlc chylomicron remnant lipoprotein nonhdlc apolipoprotein apob accur cholesterol atherogen particl atp nonhdlc ldlc 094 tg 150 mgdl nonhdlc becom displac upward weaken abat 1993 hypertriglyceridemia affect american 37 diabet shepherd nonhdlc ldlc reliabl sizeabl pischon nonhdlc superior predictor cad regardless tg 5794 person framingham nonhdlc superior predictor cad ldlc vldlc predict cad adjust ldlc tg 200 mgdl tg 200 mgdl liu vldlc poorli 008 ldlc advantag nonhdlc incorpor ldlc vldlc triglyceriderich lipoprotein account ldlc angiograph cad hard point phillip 1993 mack 1996 sack nonhdlc invers hdlc gordon 1989 srinivasan arguabl press hypertriglyceridemia propos nonhdlc \n",
            "\t0.235\timplic epidem lipidlow nonhdl cholesterol replac ldl cholesterol diabet overlap event coronari classifi coronari equival lipoprotein ldl cholesterol frequent apolipoprotein triglycerid nonhigh lipoprotein hdl cholesterol ldl cholesterol nonhdl cholesterol repres recommend atp hypertriglyceridemia articl overview nonhdl cholesterol superior ldl cholesterol predict present nonhdl cholesterol pandem adopt nonhdl cholesterol conceiv intensif ldl cholesterol obesitycoronari arteri diseasenonhdl cholesterolldl cholesterolmetabol syndromediabet ldl cholesterol therapydiabet atherogen dyslipidemia eventsth obesitycholesterol resistancenonhdlc correl ldlc apobnonhdlc correl ldlc den ldl particlesnonhdlc superior ldlc predictionperspect epidemiolog coronari arteri cad highlight lipoprotein cholesterol ldlc prevent newonset cad recurr ischem stamler 1986 1984b 1984a rossouw 1990 wong 1991 wilson 1998 loglinear ldlc cad hold true ldlc grundi surprisingli ldlc cholesterol ncep panel atp cholesterolreduc success ncep atp recommend success ldlc goal atp atpiii acknowledg triglycerid tg 200 mgdl remnant atherogen lipoprotein greatli heighten ldlc substanti lipoprotein cholesterol vldlc atp vldlc account calcul ldlc panel tg 150 mgdl vldlc mgdl vldlc arguabl make contribut atherogen cholesterol pool 1979 tg 200 mgdl non lipoprotein cholesterol nonhdlc mgdl ldlc atp nonhdlc simpli calcul panel cholesterol tc minu hdlc account ldlc vldlc idlc chylomicron remnant lipoprotein nonhdlc apolipoprotein apob accur cholesterol atherogen particl atp nonhdlc ldlc 094 tg 150 mgdl nonhdlc becom displac upward weaken abat 1993 hypertriglyceridemia affect american 37 diabet shepherd nonhdlc ldlc reliabl sizeabl pischon nonhdlc superior predictor cad regardless tg 5794 person framingham nonhdlc superior predictor cad ldlc vldlc predict cad adjust ldlc tg 200 mgdl tg 200 mgdl liu vldlc poorli 008 ldlc advantag nonhdlc incorpor ldlc vldlc triglyceriderich lipoprotein account ldlc angiograph cad hard point phillip 1993 mack 1996 sack nonhdlc invers hdlc gordon 1989 srinivasan arguabl press hypertriglyceridemia propos nonhdlc \n",
            "obese,LDL,Cholesterol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.574\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t0.566\talcohol   introductionth evidencenurs studymetaanalysi nutrit casecontrol studiesmetaanalysi studiespool prospect studiescollabor hormon cancerpubl responseeuropean code cancerintern agenc monographbreast burden attribut alcohol consumptionkey studiesmillion ukwomen 1992 2004nation institut healthaarp 1995 2003summaryconclusiondo moder alcohol cancerdo alcohol consumptioni alcohol cancerwhat stop alcohol riski alcohol knownabbreviationscompet interest alcohol man centuri link alcohol drink review convinc epidemiolog alcohol beverag caviti pharynx larynx squamou oesophagu risk tend ethanol drunk threshold evid alcohol drink sole cirrhosi impli moder drink colorect casecontrol linearli alcohol consum beverag alcohol come fore past look monitor throughout text drink glass beer glass wine spirit contain ethanol question aris consid alcohol moder alcohol\n",
            "\t0.556\tfirstlin alcoholrel univers belaru   backgroundmateri methodsresultsconclus alcohol biosociopsychofacet psycholog dysfunct subsequ alcoholus alcohol alcoholrel fail recogn psychobehavior psycholog dysfunct alcohol mayb subsequ alcohol staci coauthor note motiv person behavior alcohol etc consequ percept start alcohol regularli misus consequ alcohol expect motiv proxim alcohol theori alcohol societi selfeffect motiv theori alcohol alcohol user mostli motiv prefer mostli alcohol misus alcohol solitari drink alcohol belaru unravel psychobehavior alcoholus firstlin alcohol belaru alcohol belaru firstlin alcohol drink bad mood wage get drunk sweet qualiti alcohol firstlin psychobehavior alcohol psycholog dysfunct subsequ alcoholus alcohol alcoholrel firstlin psychobehavior alcohol proxim alcohol\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.696\talcohol alcohol alcoholdepend screen alcohol depend preval heterogen etiolog famili tendenc regard alcohol evalu alcohol evalu cut annoy guilti eyeopen cage alcohol audit manual disordersfourth edit dsmiv recruit 487 eight hospit korea cage audit dsmiv histori drink initi uncontrol drink drink cage annoy alcohol spontan compuls alcoholseek frequenc psycholog depend guilt alcohol drink item cage audit meet harm drink clinician consid alcohol correct plan alcohol disordersfamili historycut annoy guilti eyeopen testalcohol testdiagnost manual disorderfourth edit introductionmethodssubjectsresearch tools1 questionnair drink history2 cut annoy guilti eyeopen cage test3 alcohol auditstatist analysisresultspati characteristicscag item relat alcohol disorderaudit item relat alcohol disorderdsmiv relat alcohol disorderdiscuss korean ministri welfar lifetim alcohol alcohol depend abus 134 korean make preval 207 alcohol excess drink damag econom loss trillion krw 139 billion usd korea alcohol drink issu prevent treat alcoholrel emerg vital intens alcohol decreas tri address healthcar center educ institut korea recommend distribut selfreport instrument korea screen alcohol cut annoy guilti eyeopen cage alcohol audit michigan alcohol manual fourth edit dsmiv alcohol alcohol presum varianc account alcohol antisoci problemat alcohol alcohol relat item question differ unansw purpos compar item cage audit dsmiv alcohol alcohol purpos alcohol cage audit endors dsmiv alcoholdepend annoy item cage cage alcohol drink annoy blame drink defens involv project turn denial defens insight drink render comment drink annoy critic feel alcoholrel issu yield convers interfer nonverb skill express emot rapidli respond reaction rais emot face abus alcohol adulthood interpret alcohol creation atmospher indic harm norm emot alcohol phenomenon viciou alcohol perpetu annoy item alcohol alcohol audit item inquir item address harm drink audit harm drink hazard drink conclud alcohol chronic audit accur distinguish harm drink alcohol 5197 7896 set includ question take answer shorter summar audit item servic easi brief version audit auditc includ item auditpc audit item audit3 audit item audit5 audit item set abbrevi version audit consist question hazard alcohol hazard drinker harm alcohol user depend subscal audit likelihood meet brief version audit alcohol overlook neglect harm drink dsmiv item toler alcoholdepend drink drink intend devot drink give occup recreat infer watch drink home accustom drink excess drink difficulti gener hospit reliabl recruit set selfreport subject difficulti experienc respond question unrealist posit questionnair underreport minim deni insight defens denial project heterogen research tri subtyp subtyp subtyp provid individu alcohol cage audit subtyp individu alcohol cage audit dsmiv annoy harm drink toler recreat alcohol drink item cage audit endors impli depend harm drink diagnos treat alcohol clinician consid alcohol diagnos facilit\n",
            "\t-0.696\talcohol alcohol alcoholdepend screen alcohol depend preval heterogen etiolog famili tendenc regard alcohol evalu alcohol evalu cut annoy guilti eyeopen cage alcohol audit manual disordersfourth edit dsmiv recruit 487 eight hospit korea cage audit dsmiv histori drink initi uncontrol drink drink cage annoy alcohol spontan compuls alcoholseek frequenc psycholog depend guilt alcohol drink item cage audit meet harm drink clinician consid alcohol correct plan alcohol disordersfamili historycut annoy guilti eyeopen testalcohol testdiagnost manual disorderfourth edit introductionmethodssubjectsresearch tools1 questionnair drink history2 cut annoy guilti eyeopen cage test3 alcohol auditstatist analysisresultspati characteristicscag item relat alcohol disorderaudit item relat alcohol disorderdsmiv relat alcohol disorderdiscuss korean ministri welfar lifetim alcohol alcohol depend abus 134 korean make preval 207 alcohol excess drink damag econom loss trillion krw 139 billion usd korea alcohol drink issu prevent treat alcoholrel emerg vital intens alcohol decreas tri address healthcar center educ institut korea recommend distribut selfreport instrument korea screen alcohol cut annoy guilti eyeopen cage alcohol audit michigan alcohol manual fourth edit dsmiv alcohol alcohol presum varianc account alcohol antisoci problemat alcohol alcohol relat item question differ unansw purpos compar item cage audit dsmiv alcohol alcohol purpos alcohol cage audit endors dsmiv alcoholdepend annoy item cage cage alcohol drink annoy blame drink defens involv project turn denial defens insight drink render comment drink annoy critic feel alcoholrel issu yield convers interfer nonverb skill express emot rapidli respond reaction rais emot face abus alcohol adulthood interpret alcohol creation atmospher indic harm norm emot alcohol phenomenon viciou alcohol perpetu annoy item alcohol alcohol audit item inquir item address harm drink audit harm drink hazard drink conclud alcohol chronic audit accur distinguish harm drink alcohol 5197 7896 set includ question take answer shorter summar audit item servic easi brief version audit auditc includ item auditpc audit item audit3 audit item audit5 audit item set abbrevi version audit consist question hazard alcohol hazard drinker harm alcohol user depend subscal audit likelihood meet brief version audit alcohol overlook neglect harm drink dsmiv item toler alcoholdepend drink drink intend devot drink give occup recreat infer watch drink home accustom drink excess drink difficulti gener hospit reliabl recruit set selfreport subject difficulti experienc respond question unrealist posit questionnair underreport minim deni insight defens denial project heterogen research tri subtyp subtyp subtyp provid individu alcohol cage audit subtyp individu alcohol cage audit dsmiv annoy harm drink toler recreat alcohol drink item cage audit endors impli depend harm drink diagnos treat alcohol clinician consid alcohol diagnos facilit\n",
            "\t-1.283\talcohol alcohol independ stand reason addit alcohol exacerb therebi affect alcohol mucos gastrointestin tract genit tract lung  alcohol interact hivalcohol mucos systemth gastrointestin mucos systempathogenesi alcohol infectionan conduct studiesreferencesmicrobi transloc alcohol hivmicrobi flora innat mucos immun alcohol abuseintestin turnov infectionalcohol genit tractalcohol lungalcohol wast diseasereferencesalcoholhiv hematopoiet systemalcohol adapt infectionconclus alcohol alcohol immunosuppress activ innat adapt molina szabo intox dose alcohol immunosuppress pneumonia szabo zhang hivposit alcohol activ caus alcohol distress wast alcohol mix bagbi 1998 hahn basgasra colleagu 1993 administ alcohol uninfect mononuclear alcohol cook colleagu 1997 lymphocyt subset aud acceler fong colleagu 1994 user heavili abus alcohol rapidli progress aid shortli seroconvers said alcohol count hivposit mix pol colleagu 1996 count hivposit alcohol receiv art stop drink alcohol count art conen crosssect 325 alcohol statist correl count take take art wu baum colleagu frequent alcohol user art declin count count load likewis likelihood declin count art samet colleagu count art heavi alcohol art count french carrieri 2014 art alcohol gram count abstain categor moder alcohol consum count abstain investig alcohol proxi healthier behavior encompass thing alcohol load antiretrovir vari wu load art consum alcohol samet consum alcohol adher art viremia baum load turn infecti unprotect uninfect partner becom drink kalichman epidemiolog art fail alcohol abus coat 1990 kaslow 1989 face methodolog obstacl difficulti obtain accur alcohol control confound variat demograph ethnic comorbid influenc research gotten methodolog issu creat simian immunodefici siv rhesu macaqu monkey textbox conduct alcohol logic tandem addit begun alcohol exacerb badli strain clearest connect alcohol gastrointestin tract alcohol mucos line intestin barrier leakag turn strengthen grip alcohol mucos synergist intestin genit tract environ mucos worsen risk done clarifi alcohol elucid\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.574\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t0.566\talcohol   introductionth evidencenurs studymetaanalysi nutrit casecontrol studiesmetaanalysi studiespool prospect studiescollabor hormon cancerpubl responseeuropean code cancerintern agenc monographbreast burden attribut alcohol consumptionkey studiesmillion ukwomen 1992 2004nation institut healthaarp 1995 2003summaryconclusiondo moder alcohol cancerdo alcohol consumptioni alcohol cancerwhat stop alcohol riski alcohol knownabbreviationscompet interest alcohol man centuri link alcohol drink review convinc epidemiolog alcohol beverag caviti pharynx larynx squamou oesophagu risk tend ethanol drunk threshold evid alcohol drink sole cirrhosi impli moder drink colorect casecontrol linearli alcohol consum beverag alcohol come fore past look monitor throughout text drink glass beer glass wine spirit contain ethanol question aris consid alcohol moder alcohol\n",
            "\t0.556\tfirstlin alcoholrel univers belaru   backgroundmateri methodsresultsconclus alcohol biosociopsychofacet psycholog dysfunct subsequ alcoholus alcohol alcoholrel fail recogn psychobehavior psycholog dysfunct alcohol mayb subsequ alcohol staci coauthor note motiv person behavior alcohol etc consequ percept start alcohol regularli misus consequ alcohol expect motiv proxim alcohol theori alcohol societi selfeffect motiv theori alcohol alcohol user mostli motiv prefer mostli alcohol misus alcohol solitari drink alcohol belaru unravel psychobehavior alcoholus firstlin alcohol belaru alcohol belaru firstlin alcohol drink bad mood wage get drunk sweet qualiti alcohol firstlin psychobehavior alcohol psycholog dysfunct subsequ alcoholus alcohol alcoholrel firstlin psychobehavior alcohol proxim alcohol\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.696\talcohol alcohol alcoholdepend screen alcohol depend preval heterogen etiolog famili tendenc regard alcohol evalu alcohol evalu cut annoy guilti eyeopen cage alcohol audit manual disordersfourth edit dsmiv recruit 487 eight hospit korea cage audit dsmiv histori drink initi uncontrol drink drink cage annoy alcohol spontan compuls alcoholseek frequenc psycholog depend guilt alcohol drink item cage audit meet harm drink clinician consid alcohol correct plan alcohol disordersfamili historycut annoy guilti eyeopen testalcohol testdiagnost manual disorderfourth edit introductionmethodssubjectsresearch tools1 questionnair drink history2 cut annoy guilti eyeopen cage test3 alcohol auditstatist analysisresultspati characteristicscag item relat alcohol disorderaudit item relat alcohol disorderdsmiv relat alcohol disorderdiscuss korean ministri welfar lifetim alcohol alcohol depend abus 134 korean make preval 207 alcohol excess drink damag econom loss trillion krw 139 billion usd korea alcohol drink issu prevent treat alcoholrel emerg vital intens alcohol decreas tri address healthcar center educ institut korea recommend distribut selfreport instrument korea screen alcohol cut annoy guilti eyeopen cage alcohol audit michigan alcohol manual fourth edit dsmiv alcohol alcohol presum varianc account alcohol antisoci problemat alcohol alcohol relat item question differ unansw purpos compar item cage audit dsmiv alcohol alcohol purpos alcohol cage audit endors dsmiv alcoholdepend annoy item cage cage alcohol drink annoy blame drink defens involv project turn denial defens insight drink render comment drink annoy critic feel alcoholrel issu yield convers interfer nonverb skill express emot rapidli respond reaction rais emot face abus alcohol adulthood interpret alcohol creation atmospher indic harm norm emot alcohol phenomenon viciou alcohol perpetu annoy item alcohol alcohol audit item inquir item address harm drink audit harm drink hazard drink conclud alcohol chronic audit accur distinguish harm drink alcohol 5197 7896 set includ question take answer shorter summar audit item servic easi brief version audit auditc includ item auditpc audit item audit3 audit item audit5 audit item set abbrevi version audit consist question hazard alcohol hazard drinker harm alcohol user depend subscal audit likelihood meet brief version audit alcohol overlook neglect harm drink dsmiv item toler alcoholdepend drink drink intend devot drink give occup recreat infer watch drink home accustom drink excess drink difficulti gener hospit reliabl recruit set selfreport subject difficulti experienc respond question unrealist posit questionnair underreport minim deni insight defens denial project heterogen research tri subtyp subtyp subtyp provid individu alcohol cage audit subtyp individu alcohol cage audit dsmiv annoy harm drink toler recreat alcohol drink item cage audit endors impli depend harm drink diagnos treat alcohol clinician consid alcohol diagnos facilit\n",
            "\t-0.696\talcohol alcohol alcoholdepend screen alcohol depend preval heterogen etiolog famili tendenc regard alcohol evalu alcohol evalu cut annoy guilti eyeopen cage alcohol audit manual disordersfourth edit dsmiv recruit 487 eight hospit korea cage audit dsmiv histori drink initi uncontrol drink drink cage annoy alcohol spontan compuls alcoholseek frequenc psycholog depend guilt alcohol drink item cage audit meet harm drink clinician consid alcohol correct plan alcohol disordersfamili historycut annoy guilti eyeopen testalcohol testdiagnost manual disorderfourth edit introductionmethodssubjectsresearch tools1 questionnair drink history2 cut annoy guilti eyeopen cage test3 alcohol auditstatist analysisresultspati characteristicscag item relat alcohol disorderaudit item relat alcohol disorderdsmiv relat alcohol disorderdiscuss korean ministri welfar lifetim alcohol alcohol depend abus 134 korean make preval 207 alcohol excess drink damag econom loss trillion krw 139 billion usd korea alcohol drink issu prevent treat alcoholrel emerg vital intens alcohol decreas tri address healthcar center educ institut korea recommend distribut selfreport instrument korea screen alcohol cut annoy guilti eyeopen cage alcohol audit michigan alcohol manual fourth edit dsmiv alcohol alcohol presum varianc account alcohol antisoci problemat alcohol alcohol relat item question differ unansw purpos compar item cage audit dsmiv alcohol alcohol purpos alcohol cage audit endors dsmiv alcoholdepend annoy item cage cage alcohol drink annoy blame drink defens involv project turn denial defens insight drink render comment drink annoy critic feel alcoholrel issu yield convers interfer nonverb skill express emot rapidli respond reaction rais emot face abus alcohol adulthood interpret alcohol creation atmospher indic harm norm emot alcohol phenomenon viciou alcohol perpetu annoy item alcohol alcohol audit item inquir item address harm drink audit harm drink hazard drink conclud alcohol chronic audit accur distinguish harm drink alcohol 5197 7896 set includ question take answer shorter summar audit item servic easi brief version audit auditc includ item auditpc audit item audit3 audit item audit5 audit item set abbrevi version audit consist question hazard alcohol hazard drinker harm alcohol user depend subscal audit likelihood meet brief version audit alcohol overlook neglect harm drink dsmiv item toler alcoholdepend drink drink intend devot drink give occup recreat infer watch drink home accustom drink excess drink difficulti gener hospit reliabl recruit set selfreport subject difficulti experienc respond question unrealist posit questionnair underreport minim deni insight defens denial project heterogen research tri subtyp subtyp subtyp provid individu alcohol cage audit subtyp individu alcohol cage audit dsmiv annoy harm drink toler recreat alcohol drink item cage audit endors impli depend harm drink diagnos treat alcohol clinician consid alcohol diagnos facilit\n",
            "\t-1.283\talcohol alcohol independ stand reason addit alcohol exacerb therebi affect alcohol mucos gastrointestin tract genit tract lung  alcohol interact hivalcohol mucos systemth gastrointestin mucos systempathogenesi alcohol infectionan conduct studiesreferencesmicrobi transloc alcohol hivmicrobi flora innat mucos immun alcohol abuseintestin turnov infectionalcohol genit tractalcohol lungalcohol wast diseasereferencesalcoholhiv hematopoiet systemalcohol adapt infectionconclus alcohol alcohol immunosuppress activ innat adapt molina szabo intox dose alcohol immunosuppress pneumonia szabo zhang hivposit alcohol activ caus alcohol distress wast alcohol mix bagbi 1998 hahn basgasra colleagu 1993 administ alcohol uninfect mononuclear alcohol cook colleagu 1997 lymphocyt subset aud acceler fong colleagu 1994 user heavili abus alcohol rapidli progress aid shortli seroconvers said alcohol count hivposit mix pol colleagu 1996 count hivposit alcohol receiv art stop drink alcohol count art conen crosssect 325 alcohol statist correl count take take art wu baum colleagu frequent alcohol user art declin count count load likewis likelihood declin count art samet colleagu count art heavi alcohol art count french carrieri 2014 art alcohol gram count abstain categor moder alcohol consum count abstain investig alcohol proxi healthier behavior encompass thing alcohol load antiretrovir vari wu load art consum alcohol samet consum alcohol adher art viremia baum load turn infecti unprotect uninfect partner becom drink kalichman epidemiolog art fail alcohol abus coat 1990 kaslow 1989 face methodolog obstacl difficulti obtain accur alcohol control confound variat demograph ethnic comorbid influenc research gotten methodolog issu creat simian immunodefici siv rhesu macaqu monkey textbox conduct alcohol logic tandem addit begun alcohol exacerb badli strain clearest connect alcohol gastrointestin tract alcohol mucos line intestin barrier leakag turn strengthen grip alcohol mucos synergist intestin genit tract environ mucos worsen risk done clarifi alcohol elucid\n",
            "one,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.499\tedema myasthen crisi asymptomat 50yearold ladi came myasthen crisi present myasthenia gravi edema intraven immunoglobulin ischem ecg ventricular echocardiographi diuret dobutamin fluid restrict englishlanguag describ myasthen crisi takotsubo cardiomyopathyrel edema intraven immunoglobulin  introduction2 case3 discussion4 myasthenia gravi mg antibodymedi neurolog affect neuromuscular junction myasthen crisi mechan ventil takotsubo cardiomyopathi profound revers ventricular coronari arteri 50yearold ladi myasthen crisi mc oedema intraven immunoglobulin ivig suggest takotsubo cardiomyopathi tc mc probabl tc precipit immunoglobulin englishlanguag mg tc emot stress subject compound ivig tc care electrocardiograph mg ivig coronari arteri ivig\n",
            "\t0.488\tmyasthenia gravi present myasthenia gravi mg complic myasthen crisi neurolog sign present 68yearold woman mg present illustr consid neuromuscular unexplain myasthenia gravisrespiratori insuffici introductioncas reportdiscuss myasthenia gravi mg autoimmun neuromuscular mg autoantibodi attack acetylcholin plate striat muscl weak wors mg mg neurolog woman mg mg mg autoimmun third extrins ocular abnorm bulbar weak progress limb muscl complic mg myasthen crisi present unusu korea mg manifest ocular bulbar neurolog mg suspect mg initi tri hypoxem definit infiltr edema effus pneumothorax chest xray thromboembol chest ct scan intracardiac shunt congest echocardiographi suspect ventilatori trauma ventilatori rule electrolyt limit neuromuscular guillainbarr myasthenia gravi neuromuscular cerebrospin fluid neurophysiolog myasthenia gravi neuromuscular hypoxia daao2 hypoventil daa o2 mg occasion atelectasi consid neuromuscular myasthenia gravi unless neurolog ocular bulbar unlik mg 6month visit 68yearold woman myasthenia gravi mg manifest consid neuromuscular unexplain\n",
            "\t0.460\ttumorigen antisens ectop synthes alpha subunit chorion gonadotropin clonal chago bronchogen synthes secret amount alpha alpha compar beta beta subunit glycoprotein hormon chorion gonadotropin hcg chago lost characterist anchorageindepend antialphahcg partial revers alphahcg medium chago transfect vector prsvantialpha hcg direct complementari alphahcg transfect alphahcg antisens alphahcg transfect display phenotyp morpholog mitosi anchorageindepend tumorigen nude transfect 8bromocamp alphahcg alphahcg antisens 3hthymidin incorpor restor anchorageindepend cmyc chago unaffect alphahcg ectop alpha subunit hcg transform    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.032\tverapamilassoci cardiogen shock 71yearold man myasthenia gravi myasthenia gravi neuromuscular avail acetylcholin postsynapt membran skelet muscl antiacetylcholin neuromuscular junction autoimmun insult compromis neuromuscular verapamil dosedepend fashion neuromuscular myasthenia gravi 71yearold caucasian man myasthenia gravi cardiogen shock verapamil uncontrol atrial fibril 120 beatsmin atenolol mg start next verapamil sr 240 mg start hour verapamil complain weak dyspnea sign shock 7050 hg 101 beatsmin echocardiogram diffus hypokinesi ventricl eject fraction catheter coronari arteri appear stenosi diffus hypokinesi verapamil stop intraven glucagon calcium chlorid antiacetylcholin antistri hour echocardiogram ventricular return caution administ verapamil myasthenia gravi antiacetylcholin antistri titr  introductioncas presentationdiscussionconclusionabbreviationsconsentcompet interestsauthor contribut myasthenia gravi mg cases100000 neuromuscular weak excess fatig skelet muscl repetit effort slow recoveri defect mg avail acetylcholin postsynapt membran skelet muscl antiacetylcholin achrab neuromuscular junction nmj autoimmun insult compromis neuromuscular nmt verapamil calcium channel blocker lower slow atrioventricular conduct dosedepend fashion nmt mg verapamil constip dizzi nausea mg experienc cardiogen shock verapamil mg cardiogen shock verapamil deleteri nmt caution administ verapamil ccb mg nmt achrab antistri titr abbrevi\n",
            "\t-2.090\tedema myasthen crisi asymptomat 50yearold ladi came myasthen crisi present myasthenia gravi edema intraven immunoglobulin ischem ecg ventricular echocardiographi diuret dobutamin fluid restrict englishlanguag describ myasthen crisi takotsubo cardiomyopathyrel edema intraven immunoglobulin  introduction2 case3 discussion4 myasthenia gravi mg antibodymedi neurolog affect neuromuscular junction myasthen crisi mechan ventil takotsubo cardiomyopathi profound revers ventricular coronari arteri 50yearold ladi myasthen crisi mc oedema intraven immunoglobulin ivig suggest takotsubo cardiomyopathi tc mc probabl tc precipit immunoglobulin englishlanguag mg tc emot stress subject compound ivig tc care electrocardiograph mg ivig coronari arteri ivig\n",
            "\t-2.134\tmyasthenia gravi present myasthenia gravi mg complic myasthen crisi neurolog sign present 68yearold woman mg present illustr consid neuromuscular unexplain myasthenia gravisrespiratori insuffici introductioncas reportdiscuss myasthenia gravi mg autoimmun neuromuscular mg autoantibodi attack acetylcholin plate striat muscl weak wors mg mg neurolog woman mg mg mg autoimmun third extrins ocular abnorm bulbar weak progress limb muscl complic mg myasthen crisi present unusu korea mg manifest ocular bulbar neurolog mg suspect mg initi tri hypoxem definit infiltr edema effus pneumothorax chest xray thromboembol chest ct scan intracardiac shunt congest echocardiographi suspect ventilatori trauma ventilatori rule electrolyt limit neuromuscular guillainbarr myasthenia gravi neuromuscular cerebrospin fluid neurophysiolog myasthenia gravi neuromuscular hypoxia daao2 hypoventil daa o2 mg occasion atelectasi consid neuromuscular myasthenia gravi unless neurolog ocular bulbar unlik mg 6month visit 68yearold woman myasthenia gravi mg manifest consid neuromuscular unexplain\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.499\tedema myasthen crisi asymptomat 50yearold ladi came myasthen crisi present myasthenia gravi edema intraven immunoglobulin ischem ecg ventricular echocardiographi diuret dobutamin fluid restrict englishlanguag describ myasthen crisi takotsubo cardiomyopathyrel edema intraven immunoglobulin  introduction2 case3 discussion4 myasthenia gravi mg antibodymedi neurolog affect neuromuscular junction myasthen crisi mechan ventil takotsubo cardiomyopathi profound revers ventricular coronari arteri 50yearold ladi myasthen crisi mc oedema intraven immunoglobulin ivig suggest takotsubo cardiomyopathi tc mc probabl tc precipit immunoglobulin englishlanguag mg tc emot stress subject compound ivig tc care electrocardiograph mg ivig coronari arteri ivig\n",
            "\t0.488\tmyasthenia gravi present myasthenia gravi mg complic myasthen crisi neurolog sign present 68yearold woman mg present illustr consid neuromuscular unexplain myasthenia gravisrespiratori insuffici introductioncas reportdiscuss myasthenia gravi mg autoimmun neuromuscular mg autoantibodi attack acetylcholin plate striat muscl weak wors mg mg neurolog woman mg mg mg autoimmun third extrins ocular abnorm bulbar weak progress limb muscl complic mg myasthen crisi present unusu korea mg manifest ocular bulbar neurolog mg suspect mg initi tri hypoxem definit infiltr edema effus pneumothorax chest xray thromboembol chest ct scan intracardiac shunt congest echocardiographi suspect ventilatori trauma ventilatori rule electrolyt limit neuromuscular guillainbarr myasthenia gravi neuromuscular cerebrospin fluid neurophysiolog myasthenia gravi neuromuscular hypoxia daao2 hypoventil daa o2 mg occasion atelectasi consid neuromuscular myasthenia gravi unless neurolog ocular bulbar unlik mg 6month visit 68yearold woman myasthenia gravi mg manifest consid neuromuscular unexplain\n",
            "\t0.460\ttumorigen antisens ectop synthes alpha subunit chorion gonadotropin clonal chago bronchogen synthes secret amount alpha alpha compar beta beta subunit glycoprotein hormon chorion gonadotropin hcg chago lost characterist anchorageindepend antialphahcg partial revers alphahcg medium chago transfect vector prsvantialpha hcg direct complementari alphahcg transfect alphahcg antisens alphahcg transfect display phenotyp morpholog mitosi anchorageindepend tumorigen nude transfect 8bromocamp alphahcg alphahcg antisens 3hthymidin incorpor restor anchorageindepend cmyc chago unaffect alphahcg ectop alpha subunit hcg transform    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.032\tverapamilassoci cardiogen shock 71yearold man myasthenia gravi myasthenia gravi neuromuscular avail acetylcholin postsynapt membran skelet muscl antiacetylcholin neuromuscular junction autoimmun insult compromis neuromuscular verapamil dosedepend fashion neuromuscular myasthenia gravi 71yearold caucasian man myasthenia gravi cardiogen shock verapamil uncontrol atrial fibril 120 beatsmin atenolol mg start next verapamil sr 240 mg start hour verapamil complain weak dyspnea sign shock 7050 hg 101 beatsmin echocardiogram diffus hypokinesi ventricl eject fraction catheter coronari arteri appear stenosi diffus hypokinesi verapamil stop intraven glucagon calcium chlorid antiacetylcholin antistri hour echocardiogram ventricular return caution administ verapamil myasthenia gravi antiacetylcholin antistri titr  introductioncas presentationdiscussionconclusionabbreviationsconsentcompet interestsauthor contribut myasthenia gravi mg cases100000 neuromuscular weak excess fatig skelet muscl repetit effort slow recoveri defect mg avail acetylcholin postsynapt membran skelet muscl antiacetylcholin achrab neuromuscular junction nmj autoimmun insult compromis neuromuscular nmt verapamil calcium channel blocker lower slow atrioventricular conduct dosedepend fashion nmt mg verapamil constip dizzi nausea mg experienc cardiogen shock verapamil mg cardiogen shock verapamil deleteri nmt caution administ verapamil ccb mg nmt achrab antistri titr abbrevi\n",
            "\t-2.090\tedema myasthen crisi asymptomat 50yearold ladi came myasthen crisi present myasthenia gravi edema intraven immunoglobulin ischem ecg ventricular echocardiographi diuret dobutamin fluid restrict englishlanguag describ myasthen crisi takotsubo cardiomyopathyrel edema intraven immunoglobulin  introduction2 case3 discussion4 myasthenia gravi mg antibodymedi neurolog affect neuromuscular junction myasthen crisi mechan ventil takotsubo cardiomyopathi profound revers ventricular coronari arteri 50yearold ladi myasthen crisi mc oedema intraven immunoglobulin ivig suggest takotsubo cardiomyopathi tc mc probabl tc precipit immunoglobulin englishlanguag mg tc emot stress subject compound ivig tc care electrocardiograph mg ivig coronari arteri ivig\n",
            "\t-2.134\tmyasthenia gravi present myasthenia gravi mg complic myasthen crisi neurolog sign present 68yearold woman mg present illustr consid neuromuscular unexplain myasthenia gravisrespiratori insuffici introductioncas reportdiscuss myasthenia gravi mg autoimmun neuromuscular mg autoantibodi attack acetylcholin plate striat muscl weak wors mg mg neurolog woman mg mg mg autoimmun third extrins ocular abnorm bulbar weak progress limb muscl complic mg myasthen crisi present unusu korea mg manifest ocular bulbar neurolog mg suspect mg initi tri hypoxem definit infiltr edema effus pneumothorax chest xray thromboembol chest ct scan intracardiac shunt congest echocardiographi suspect ventilatori trauma ventilatori rule electrolyt limit neuromuscular guillainbarr myasthenia gravi neuromuscular cerebrospin fluid neurophysiolog myasthenia gravi neuromuscular hypoxia daao2 hypoventil daa o2 mg occasion atelectasi consid neuromuscular myasthenia gravi unless neurolog ocular bulbar unlik mg 6month visit 68yearold woman myasthenia gravi mg manifest consid neuromuscular unexplain\n",
            "myasthenia gravis, class IIa,anti-AChR antibody,pyridostigmine None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.582\tbilirubin bilirubin predict just    estim cvd make decis establish guidelin recommend routin cvd asymptomat prognost equat reliabl predict fatal cvd circul biomark enabl equat readili intermedi cvd creactiv fibrinogen vitamin routin confirmatori bilirubin cholestasi believ toxic wast metabolit heme catabol newborn bilirubin protect heme degrad heme oxygenas ho produc biliverdin carbon monoxid co ferrou iron fe isoform ho ho1 induc ho2 constitut test hoderiv co ga mediat cytoprotect action vasodilat biliverdin subsequ bilirubin biliverdin reductas bilirubin nonpolar molecul solubil bed albumin bilirubin conjug glucuron uridin diphosph glucuronosyltransferas a1 ugt1a1 watersolubl elimin accumul protect ho1cobilirubin protect bilirubin gilbert gilbert ugt1a1 reduc elimin bilirubin repres benign nonhemolyt unconjug hyperbilirubinemia gilbert bilirubin novotni vitek bilirubin cvd receiv hemodialysi metaanalysi support modest elev unconjug bilirubin gilbert neg cvd numer circul bilirubin bilirubin microangiopathi japanes crosssect lowest quartil bilirubin retinopathi quartil bilirubin urinari albumin excret contrari korean bilirubin nephropathi invers bilirubin coronari arteri cad consist bilirubin atherosclerot cvd circul bilirubin invers coronari arteri calcif metaanalysi protect bilirubin atherosclerosi wherein moll bilirubin 65 cvd male prospect bilirubin protect predict biomark close turfan bilirubin invers cad bilirubin angina consist protect bilirubin antioxid bilirubin potent inhibit peroxid close initi atherosclerosi bilirubin antiinflammatori inhibit cytokin interleukin2 interferon necrosi intercept complement c3 c1qimmunoglobulin igg unconjug bilirubin inhibit nicotinamid adenin dinucleotid phosphat oxidas smooth wellknown antithrombot bilirubin involv bilirubin platelet antioxid inhibit collageninduc platelet aggreg thrombu liu unconjug bilirubin nearli 80 dbdb bilirubin revers ex akt princip bilirubin akt eno nitrit bilirubin issu leem circul bilirubin biochem cad asymptomat obstruct cad stenosi lumen 64channel detector comput tomographi coronari comput tomograph angiographi recommend routin cad care remark bilirubin benefici obstruct cad adjust persist regardless coronari calcium plaqu subtyp except calcifi plaqu bilirubin framingham fr fr asymptomat impli bilirubin clinic util predict complementari conflict bilirubin panel cvd prospect metaanalysi discrep cvd desper reliabl cvd capabl readili identifi highrisk asymptomat consid bilirubin candid miss messag yellow pigment unknowingli progress cvd bilirubin \n",
            "\t0.582\tbilirubin bilirubin predict just    estim cvd make decis establish guidelin recommend routin cvd asymptomat prognost equat reliabl predict fatal cvd circul biomark enabl equat readili intermedi cvd creactiv fibrinogen vitamin routin confirmatori bilirubin cholestasi believ toxic wast metabolit heme catabol newborn bilirubin protect heme degrad heme oxygenas ho produc biliverdin carbon monoxid co ferrou iron fe isoform ho ho1 induc ho2 constitut test hoderiv co ga mediat cytoprotect action vasodilat biliverdin subsequ bilirubin biliverdin reductas bilirubin nonpolar molecul solubil bed albumin bilirubin conjug glucuron uridin diphosph glucuronosyltransferas a1 ugt1a1 watersolubl elimin accumul protect ho1cobilirubin protect bilirubin gilbert gilbert ugt1a1 reduc elimin bilirubin repres benign nonhemolyt unconjug hyperbilirubinemia gilbert bilirubin novotni vitek bilirubin cvd receiv hemodialysi metaanalysi support modest elev unconjug bilirubin gilbert neg cvd numer circul bilirubin bilirubin microangiopathi japanes crosssect lowest quartil bilirubin retinopathi quartil bilirubin urinari albumin excret contrari korean bilirubin nephropathi invers bilirubin coronari arteri cad consist bilirubin atherosclerot cvd circul bilirubin invers coronari arteri calcif metaanalysi protect bilirubin atherosclerosi wherein moll bilirubin 65 cvd male prospect bilirubin protect predict biomark close turfan bilirubin invers cad bilirubin angina consist protect bilirubin antioxid bilirubin potent inhibit peroxid close initi atherosclerosi bilirubin antiinflammatori inhibit cytokin interleukin2 interferon necrosi intercept complement c3 c1qimmunoglobulin igg unconjug bilirubin inhibit nicotinamid adenin dinucleotid phosphat oxidas smooth wellknown antithrombot bilirubin involv bilirubin platelet antioxid inhibit collageninduc platelet aggreg thrombu liu unconjug bilirubin nearli 80 dbdb bilirubin revers ex akt princip bilirubin akt eno nitrit bilirubin issu leem circul bilirubin biochem cad asymptomat obstruct cad stenosi lumen 64channel detector comput tomographi coronari comput tomograph angiographi recommend routin cad care remark bilirubin benefici obstruct cad adjust persist regardless coronari calcium plaqu subtyp except calcifi plaqu bilirubin framingham fr fr asymptomat impli bilirubin clinic util predict complementari conflict bilirubin panel cvd prospect metaanalysi discrep cvd desper reliabl cvd capabl readili identifi highrisk asymptomat consid bilirubin candid miss messag yellow pigment unknowingli progress cvd bilirubin \n",
            "\t0.582\tbilirubin bilirubin predict just    estim cvd make decis establish guidelin recommend routin cvd asymptomat prognost equat reliabl predict fatal cvd circul biomark enabl equat readili intermedi cvd creactiv fibrinogen vitamin routin confirmatori bilirubin cholestasi believ toxic wast metabolit heme catabol newborn bilirubin protect heme degrad heme oxygenas ho produc biliverdin carbon monoxid co ferrou iron fe isoform ho ho1 induc ho2 constitut test hoderiv co ga mediat cytoprotect action vasodilat biliverdin subsequ bilirubin biliverdin reductas bilirubin nonpolar molecul solubil bed albumin bilirubin conjug glucuron uridin diphosph glucuronosyltransferas a1 ugt1a1 watersolubl elimin accumul protect ho1cobilirubin protect bilirubin gilbert gilbert ugt1a1 reduc elimin bilirubin repres benign nonhemolyt unconjug hyperbilirubinemia gilbert bilirubin novotni vitek bilirubin cvd receiv hemodialysi metaanalysi support modest elev unconjug bilirubin gilbert neg cvd numer circul bilirubin bilirubin microangiopathi japanes crosssect lowest quartil bilirubin retinopathi quartil bilirubin urinari albumin excret contrari korean bilirubin nephropathi invers bilirubin coronari arteri cad consist bilirubin atherosclerot cvd circul bilirubin invers coronari arteri calcif metaanalysi protect bilirubin atherosclerosi wherein moll bilirubin 65 cvd male prospect bilirubin protect predict biomark close turfan bilirubin invers cad bilirubin angina consist protect bilirubin antioxid bilirubin potent inhibit peroxid close initi atherosclerosi bilirubin antiinflammatori inhibit cytokin interleukin2 interferon necrosi intercept complement c3 c1qimmunoglobulin igg unconjug bilirubin inhibit nicotinamid adenin dinucleotid phosphat oxidas smooth wellknown antithrombot bilirubin involv bilirubin platelet antioxid inhibit collageninduc platelet aggreg thrombu liu unconjug bilirubin nearli 80 dbdb bilirubin revers ex akt princip bilirubin akt eno nitrit bilirubin issu leem circul bilirubin biochem cad asymptomat obstruct cad stenosi lumen 64channel detector comput tomographi coronari comput tomograph angiographi recommend routin cad care remark bilirubin benefici obstruct cad adjust persist regardless coronari calcium plaqu subtyp except calcifi plaqu bilirubin framingham fr fr asymptomat impli bilirubin clinic util predict complementari conflict bilirubin panel cvd prospect metaanalysi discrep cvd desper reliabl cvd capabl readili identifi highrisk asymptomat consid bilirubin candid miss messag yellow pigment unknowingli progress cvd bilirubin \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.376\tneonat jaundic    neonat jaundic unconjug bilirubin temporari delay ugt1a1 conjug bilirubin excret uncontrol hyperbilirubinemia perman neurolog muro bilirubin neurotox gener bear null ugt1 investig bilirubin neurotox background research bilirubin strainspecif therebi underscor modifi modul bilirubin expo phototherapi convert unconjug bilirubin watersolubl postnat window bilirubin establish ugt1 null versatil bilirubin neurotox hyperbilirubinemia page 1057 \n",
            "\t0.965\tcoexist gilbert hereditari spherocytosi child present extrem jaundic gilbert inherit bilirubin glucuronid intermitt episod jaundic hepatocellular hemolysi hereditari spherocytosi inherit hemolyt anemia spheric osmot fragil erythrocyt select trap spleen degre anemia jaundic splenomegali hereditari spherocytosi mildtomoder elev bilirubin hyperbilirubinemia hemolysi suspicion gilbert thalassemia 12yearold boy extrem jaundic nausea hereditari spherocytosi osmot fragil gilbert gilbert diseasehereditari spherocytosisjaundic introductioncas reportdiscuss gilbert g hereditari bilirubin uridin diphosphateglucuronyl transferas 1a1 ugt1a1 unconjug hyperbilirubinemia hemolysi hereditari spherocytosi h inherit hemolyt anemia red defect prematur destruct 75 h autosom domin inherit degre anemia jaundic splenomegali vari asymptomat hemolyt anemia coinherit g spherocytosi thalassemia cystic fibrosi bilirubin tendenc gallston coexist g h child extrem jaundic g hereditari bilirubin g male femal possibl owe bilirubin male puberti endogen steroid hormon bilirubin bilirubin g ugt1a1 ugt1a1 ugt1a1 ugt1a1 unconjug hyperbilirubinemia elong ta repeat 7taa ugt1a128 g caucasian maruo linkag g 7taa ugt1a128 t3279g ugt1a160 missens 211g g asian korea g homozyg 77taa compound heterozygos t3279g g211a heterozygos t3279g 7taa g211a g fluctuat indirect bilirubin fast dehydr menstruat overexert experienc jaundic typic asymptomat bilirubin mgdl set bilirubin mgdl h inherit hemolyt deform defect ankyrin band spectrin 42 spherocyt vulner splenic sequestr destruct anemia jaundic splenomegali anemia absent mild moder wellcompens hemolyt anemia cholelithiasi hemolyt episod aplast crise splenectomi choic moder splenectomi hb transfus reticulocytosi fall bilirubin likelihood gallston red shorten guidelin h mild h anemia mild reticulocytosi jaundic hb gdl reticulocyt count bilirubin mgdl h mark reticulocytosi anemia hyperbilirubinemia hb gdl reticulocyt count bilirubin mgdl mild h hb extrem bilirubin discrep unconjug hyperbilirubinemia inherit defici hepat glucuronosyltransferas g 37 h 12000 person calcul coexist 1535 million birth korea simultan h g bilirubin abnorm bilirubin mgdl bilirubin cholelithiasi del giudic h coinherit g 5fold tendenc gallston h gallston splenectomi h moder h gall bladder remov concomitantli symptomat gallston splenectomi cholecystectomi coexist g h coexist g h 12yearold boy coexist g h inappropri bilirubin h\n",
            "\t0.770\tjaundiceassoci    spontan vagin 32weekgest babi immedi distress apgar min min gener oedema bilater pleural effus prenat unremark nonimmun hydrop fetali mechan ventil surfact prostaglandin support initi escherichia coli sepsi fourth week jaundic bilirubin 342 mgdl 01 conjug bilirubin 241 mgdl 03 sgot 231 ul 37 sgpt 86 ul albumin 29 gdl urea nitrogen 184 mgdl creatinin mgdl anur episod ensu babi die autopsi lymphangiectasia hydrop fetali kidney green formalin fixat numer pigment cast exclus distal tubul collect duct proxim tubul cast brown red greenishyellow discolor hall stain highlight bile pigment green convert bilirubin biliverdin bile cast inset support jaundiceassoci occasion calcium oxal crystal note distal nephron segment green ting convers bilirubin biliverdin formalin fixat accentu green discolour dark red yellowishgreen intratubular cast distal nephron segment consist bile hall stain inset 400 400 jaundic histor term cholem nephrosi understood tubular bile salt bilirubin recov jaundic manag extens intratubular bile cast jaundic intratubular bilirubin bile salt impair tubular nephron obstruct conflict statement none declar \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.582\tbilirubin bilirubin predict just    estim cvd make decis establish guidelin recommend routin cvd asymptomat prognost equat reliabl predict fatal cvd circul biomark enabl equat readili intermedi cvd creactiv fibrinogen vitamin routin confirmatori bilirubin cholestasi believ toxic wast metabolit heme catabol newborn bilirubin protect heme degrad heme oxygenas ho produc biliverdin carbon monoxid co ferrou iron fe isoform ho ho1 induc ho2 constitut test hoderiv co ga mediat cytoprotect action vasodilat biliverdin subsequ bilirubin biliverdin reductas bilirubin nonpolar molecul solubil bed albumin bilirubin conjug glucuron uridin diphosph glucuronosyltransferas a1 ugt1a1 watersolubl elimin accumul protect ho1cobilirubin protect bilirubin gilbert gilbert ugt1a1 reduc elimin bilirubin repres benign nonhemolyt unconjug hyperbilirubinemia gilbert bilirubin novotni vitek bilirubin cvd receiv hemodialysi metaanalysi support modest elev unconjug bilirubin gilbert neg cvd numer circul bilirubin bilirubin microangiopathi japanes crosssect lowest quartil bilirubin retinopathi quartil bilirubin urinari albumin excret contrari korean bilirubin nephropathi invers bilirubin coronari arteri cad consist bilirubin atherosclerot cvd circul bilirubin invers coronari arteri calcif metaanalysi protect bilirubin atherosclerosi wherein moll bilirubin 65 cvd male prospect bilirubin protect predict biomark close turfan bilirubin invers cad bilirubin angina consist protect bilirubin antioxid bilirubin potent inhibit peroxid close initi atherosclerosi bilirubin antiinflammatori inhibit cytokin interleukin2 interferon necrosi intercept complement c3 c1qimmunoglobulin igg unconjug bilirubin inhibit nicotinamid adenin dinucleotid phosphat oxidas smooth wellknown antithrombot bilirubin involv bilirubin platelet antioxid inhibit collageninduc platelet aggreg thrombu liu unconjug bilirubin nearli 80 dbdb bilirubin revers ex akt princip bilirubin akt eno nitrit bilirubin issu leem circul bilirubin biochem cad asymptomat obstruct cad stenosi lumen 64channel detector comput tomographi coronari comput tomograph angiographi recommend routin cad care remark bilirubin benefici obstruct cad adjust persist regardless coronari calcium plaqu subtyp except calcifi plaqu bilirubin framingham fr fr asymptomat impli bilirubin clinic util predict complementari conflict bilirubin panel cvd prospect metaanalysi discrep cvd desper reliabl cvd capabl readili identifi highrisk asymptomat consid bilirubin candid miss messag yellow pigment unknowingli progress cvd bilirubin \n",
            "\t0.582\tbilirubin bilirubin predict just    estim cvd make decis establish guidelin recommend routin cvd asymptomat prognost equat reliabl predict fatal cvd circul biomark enabl equat readili intermedi cvd creactiv fibrinogen vitamin routin confirmatori bilirubin cholestasi believ toxic wast metabolit heme catabol newborn bilirubin protect heme degrad heme oxygenas ho produc biliverdin carbon monoxid co ferrou iron fe isoform ho ho1 induc ho2 constitut test hoderiv co ga mediat cytoprotect action vasodilat biliverdin subsequ bilirubin biliverdin reductas bilirubin nonpolar molecul solubil bed albumin bilirubin conjug glucuron uridin diphosph glucuronosyltransferas a1 ugt1a1 watersolubl elimin accumul protect ho1cobilirubin protect bilirubin gilbert gilbert ugt1a1 reduc elimin bilirubin repres benign nonhemolyt unconjug hyperbilirubinemia gilbert bilirubin novotni vitek bilirubin cvd receiv hemodialysi metaanalysi support modest elev unconjug bilirubin gilbert neg cvd numer circul bilirubin bilirubin microangiopathi japanes crosssect lowest quartil bilirubin retinopathi quartil bilirubin urinari albumin excret contrari korean bilirubin nephropathi invers bilirubin coronari arteri cad consist bilirubin atherosclerot cvd circul bilirubin invers coronari arteri calcif metaanalysi protect bilirubin atherosclerosi wherein moll bilirubin 65 cvd male prospect bilirubin protect predict biomark close turfan bilirubin invers cad bilirubin angina consist protect bilirubin antioxid bilirubin potent inhibit peroxid close initi atherosclerosi bilirubin antiinflammatori inhibit cytokin interleukin2 interferon necrosi intercept complement c3 c1qimmunoglobulin igg unconjug bilirubin inhibit nicotinamid adenin dinucleotid phosphat oxidas smooth wellknown antithrombot bilirubin involv bilirubin platelet antioxid inhibit collageninduc platelet aggreg thrombu liu unconjug bilirubin nearli 80 dbdb bilirubin revers ex akt princip bilirubin akt eno nitrit bilirubin issu leem circul bilirubin biochem cad asymptomat obstruct cad stenosi lumen 64channel detector comput tomographi coronari comput tomograph angiographi recommend routin cad care remark bilirubin benefici obstruct cad adjust persist regardless coronari calcium plaqu subtyp except calcifi plaqu bilirubin framingham fr fr asymptomat impli bilirubin clinic util predict complementari conflict bilirubin panel cvd prospect metaanalysi discrep cvd desper reliabl cvd capabl readili identifi highrisk asymptomat consid bilirubin candid miss messag yellow pigment unknowingli progress cvd bilirubin \n",
            "\t0.582\tbilirubin bilirubin predict just    estim cvd make decis establish guidelin recommend routin cvd asymptomat prognost equat reliabl predict fatal cvd circul biomark enabl equat readili intermedi cvd creactiv fibrinogen vitamin routin confirmatori bilirubin cholestasi believ toxic wast metabolit heme catabol newborn bilirubin protect heme degrad heme oxygenas ho produc biliverdin carbon monoxid co ferrou iron fe isoform ho ho1 induc ho2 constitut test hoderiv co ga mediat cytoprotect action vasodilat biliverdin subsequ bilirubin biliverdin reductas bilirubin nonpolar molecul solubil bed albumin bilirubin conjug glucuron uridin diphosph glucuronosyltransferas a1 ugt1a1 watersolubl elimin accumul protect ho1cobilirubin protect bilirubin gilbert gilbert ugt1a1 reduc elimin bilirubin repres benign nonhemolyt unconjug hyperbilirubinemia gilbert bilirubin novotni vitek bilirubin cvd receiv hemodialysi metaanalysi support modest elev unconjug bilirubin gilbert neg cvd numer circul bilirubin bilirubin microangiopathi japanes crosssect lowest quartil bilirubin retinopathi quartil bilirubin urinari albumin excret contrari korean bilirubin nephropathi invers bilirubin coronari arteri cad consist bilirubin atherosclerot cvd circul bilirubin invers coronari arteri calcif metaanalysi protect bilirubin atherosclerosi wherein moll bilirubin 65 cvd male prospect bilirubin protect predict biomark close turfan bilirubin invers cad bilirubin angina consist protect bilirubin antioxid bilirubin potent inhibit peroxid close initi atherosclerosi bilirubin antiinflammatori inhibit cytokin interleukin2 interferon necrosi intercept complement c3 c1qimmunoglobulin igg unconjug bilirubin inhibit nicotinamid adenin dinucleotid phosphat oxidas smooth wellknown antithrombot bilirubin involv bilirubin platelet antioxid inhibit collageninduc platelet aggreg thrombu liu unconjug bilirubin nearli 80 dbdb bilirubin revers ex akt princip bilirubin akt eno nitrit bilirubin issu leem circul bilirubin biochem cad asymptomat obstruct cad stenosi lumen 64channel detector comput tomographi coronari comput tomograph angiographi recommend routin cad care remark bilirubin benefici obstruct cad adjust persist regardless coronari calcium plaqu subtyp except calcifi plaqu bilirubin framingham fr fr asymptomat impli bilirubin clinic util predict complementari conflict bilirubin panel cvd prospect metaanalysi discrep cvd desper reliabl cvd capabl readili identifi highrisk asymptomat consid bilirubin candid miss messag yellow pigment unknowingli progress cvd bilirubin \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.376\tneonat jaundic    neonat jaundic unconjug bilirubin temporari delay ugt1a1 conjug bilirubin excret uncontrol hyperbilirubinemia perman neurolog muro bilirubin neurotox gener bear null ugt1 investig bilirubin neurotox background research bilirubin strainspecif therebi underscor modifi modul bilirubin expo phototherapi convert unconjug bilirubin watersolubl postnat window bilirubin establish ugt1 null versatil bilirubin neurotox hyperbilirubinemia page 1057 \n",
            "\t0.965\tcoexist gilbert hereditari spherocytosi child present extrem jaundic gilbert inherit bilirubin glucuronid intermitt episod jaundic hepatocellular hemolysi hereditari spherocytosi inherit hemolyt anemia spheric osmot fragil erythrocyt select trap spleen degre anemia jaundic splenomegali hereditari spherocytosi mildtomoder elev bilirubin hyperbilirubinemia hemolysi suspicion gilbert thalassemia 12yearold boy extrem jaundic nausea hereditari spherocytosi osmot fragil gilbert gilbert diseasehereditari spherocytosisjaundic introductioncas reportdiscuss gilbert g hereditari bilirubin uridin diphosphateglucuronyl transferas 1a1 ugt1a1 unconjug hyperbilirubinemia hemolysi hereditari spherocytosi h inherit hemolyt anemia red defect prematur destruct 75 h autosom domin inherit degre anemia jaundic splenomegali vari asymptomat hemolyt anemia coinherit g spherocytosi thalassemia cystic fibrosi bilirubin tendenc gallston coexist g h child extrem jaundic g hereditari bilirubin g male femal possibl owe bilirubin male puberti endogen steroid hormon bilirubin bilirubin g ugt1a1 ugt1a1 ugt1a1 ugt1a1 unconjug hyperbilirubinemia elong ta repeat 7taa ugt1a128 g caucasian maruo linkag g 7taa ugt1a128 t3279g ugt1a160 missens 211g g asian korea g homozyg 77taa compound heterozygos t3279g g211a heterozygos t3279g 7taa g211a g fluctuat indirect bilirubin fast dehydr menstruat overexert experienc jaundic typic asymptomat bilirubin mgdl set bilirubin mgdl h inherit hemolyt deform defect ankyrin band spectrin 42 spherocyt vulner splenic sequestr destruct anemia jaundic splenomegali anemia absent mild moder wellcompens hemolyt anemia cholelithiasi hemolyt episod aplast crise splenectomi choic moder splenectomi hb transfus reticulocytosi fall bilirubin likelihood gallston red shorten guidelin h mild h anemia mild reticulocytosi jaundic hb gdl reticulocyt count bilirubin mgdl h mark reticulocytosi anemia hyperbilirubinemia hb gdl reticulocyt count bilirubin mgdl mild h hb extrem bilirubin discrep unconjug hyperbilirubinemia inherit defici hepat glucuronosyltransferas g 37 h 12000 person calcul coexist 1535 million birth korea simultan h g bilirubin abnorm bilirubin mgdl bilirubin cholelithiasi del giudic h coinherit g 5fold tendenc gallston h gallston splenectomi h moder h gall bladder remov concomitantli symptomat gallston splenectomi cholecystectomi coexist g h coexist g h 12yearold boy coexist g h inappropri bilirubin h\n",
            "\t0.770\tjaundiceassoci    spontan vagin 32weekgest babi immedi distress apgar min min gener oedema bilater pleural effus prenat unremark nonimmun hydrop fetali mechan ventil surfact prostaglandin support initi escherichia coli sepsi fourth week jaundic bilirubin 342 mgdl 01 conjug bilirubin 241 mgdl 03 sgot 231 ul 37 sgpt 86 ul albumin 29 gdl urea nitrogen 184 mgdl creatinin mgdl anur episod ensu babi die autopsi lymphangiectasia hydrop fetali kidney green formalin fixat numer pigment cast exclus distal tubul collect duct proxim tubul cast brown red greenishyellow discolor hall stain highlight bile pigment green convert bilirubin biliverdin bile cast inset support jaundiceassoci occasion calcium oxal crystal note distal nephron segment green ting convers bilirubin biliverdin formalin fixat accentu green discolour dark red yellowishgreen intratubular cast distal nephron segment consist bile hall stain inset 400 400 jaundic histor term cholem nephrosi understood tubular bile salt bilirubin recov jaundic manag extens intratubular bile cast jaundic intratubular bilirubin bile salt impair tubular nephron obstruct conflict statement none declar \n",
            "jaundice,AST,bilirubin None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.464\tdual alpha beta revisit    worldwid progress dialysi transplant combat block pkc pkc compris serinethreonin kina ubiquit particip pkc divid classic atyp isoform biochem isoform diabet pkc upregul retina glomerulus pkc isoform isoform glomerulus preclin benefici select pkc ruboxistaurin eye diseasestreat ruboxistaurin albuminuria glomerular filtrat retin circul administ oral db db ruboxistaurin amelior albuminuria mesangi expans transform tgf fibronectin iv collagen subsequ transgen ren pkc ruboxistaurin amelior albuminuria tgf continu hyperglycemia term ruboxistaurin retinopathi preclin term eye disappoint modest albuminuria ruboxistaurin pkc warrant research implic pkc implic pkc albuminuria streptozotocin stz kang pkc isoform pkc isoform pkc knockout haller pkc transform tgf hypertrophi expans pkc perlecan vegf nephrin albuminuria similarli king pkc knockout carri glomerular hypertrophi modest albuminuria delet pkc isoform inhibit stz albuminuria complet prevent exclus pkc knockout pharmacolog pkc cgp41252 agent util classic pkc amelior albuminuria fail hypertrophi stz 129sv db db interpret implic cgp41252 broad pkc oppos pkc agent inhibit pkc isoform pkc delet pkc glomerulosclerosi tubulointerstiti fibrosi protect continu complic repres global urgent intensifi renin angiotensin albuminuria preserv slow declin diabet highlight isoform pkc pkc pkc isoform discoveri pkc isoform hyperglycemia dyslipidemia pkc protect precis pkc ctgf connect nf kappa enhanc tgf transform vegf imag \n",
            "\t0.464\tdual alpha beta revisit    worldwid progress dialysi transplant combat block pkc pkc compris serinethreonin kina ubiquit particip pkc divid classic atyp isoform biochem isoform diabet pkc upregul retina glomerulus pkc isoform isoform glomerulus preclin benefici select pkc ruboxistaurin eye diseasestreat ruboxistaurin albuminuria glomerular filtrat retin circul administ oral db db ruboxistaurin amelior albuminuria mesangi expans transform tgf fibronectin iv collagen subsequ transgen ren pkc ruboxistaurin amelior albuminuria tgf continu hyperglycemia term ruboxistaurin retinopathi preclin term eye disappoint modest albuminuria ruboxistaurin pkc warrant research implic pkc implic pkc albuminuria streptozotocin stz kang pkc isoform pkc isoform pkc knockout haller pkc transform tgf hypertrophi expans pkc perlecan vegf nephrin albuminuria similarli king pkc knockout carri glomerular hypertrophi modest albuminuria delet pkc isoform inhibit stz albuminuria complet prevent exclus pkc knockout pharmacolog pkc cgp41252 agent util classic pkc amelior albuminuria fail hypertrophi stz 129sv db db interpret implic cgp41252 broad pkc oppos pkc agent inhibit pkc isoform pkc delet pkc glomerulosclerosi tubulointerstiti fibrosi protect continu complic repres global urgent intensifi renin angiotensin albuminuria preserv slow declin diabet highlight isoform pkc pkc pkc isoform discoveri pkc isoform hyperglycemia dyslipidemia pkc protect precis pkc ctgf connect nf kappa enhanc tgf transform vegf imag \n",
            "\t0.463\tpolymorph aldosteron synthas cytochrom p450 11b2 mineralocorticoid coronari arteri taiwan aldosteron synthas cytochrom p450 11b2 cyp11b2 mineralocorticoid mr coronari arteri cad nucleotid polymorph snp cyp11b2 cyp11b2 t344c mr mr c3514g mr c4582a cad taiwanes hundr nine unrel elect coronari angiographi recruit chung shan univers enrol noninvas cyp11b2 t344c mr c3514g mr c4582a polymeras reactionrestrict fragment polymorph cyp11b2 cc cad genotyp distribut mr c3514g mr c4582a cad multivari cyp11b2 t344c cad taiwanes conclus cyp11b2 cc cad mellitu impli cyp11b2 cc cad taiwanes  introductionmateri methodssubjectsblood extractionselect cyp11b2 t344c mr c3514g mr c4582a polymorphismspolymeras reactionrestrict fragment polymorph pcrrflpstatist analysisresultsdiscuss coronari morbid worldwid affect million coronari multifactori nonconvent gender hyperlipidemia mellitu dm nonconvent welldefin reninangiotensinaldosteron raa affect circulatori homeostasi regul adren gland regul fluid sodium balanc raa maintain kidney sodium balanc vessel abnorm raa array atherosclerot coronari arteri cad plaqu ruptur myocardi infarct aldosteron pathogen renin cleav angiotensinogen synthes secret angiotensin circul angiotensin hydrolyz angiotensin angiotensinconvert primarili endothelium angiotensin initi vasoconstrictor stimul aldosteron adren gland aldosteron ventricular remodel aldosteron perivascular fibrosi ventricular caus modifi facilit adapt remodel aldosteron act mineralocorticoid mr aldosteron larg final biosynthesi aldosteron synthas encod aldosteron synthas cytochrom p450 11b2 cyp11b2 aldosteron mr extraren larg detriment set cyp11b2 implic snp hypothes cyp11b2 nucleotid polymorph snp cyp11b2 t344c mr snp mr c3514g mr c4582a cad cyp11b2 t344c mr c4582a mr c3514g cad taiwan aim correl cyp11b2 t344c mr c4582a mr c3514g cad taiwanes dm cad subgroup stratif gender dm cad framingham highnorm systol 130139 mmhg diastol 8589 mmhg 2fold dm ethnicallymatch dm multivari dm cad taiwanes defin nonconvent polymorph cad taiwanes genotyp distribut cyp11b2 t344c mr c3514g mr c4582a snp cad stratifi gender remain insignific subgroup cyp11b2 cc cad allel genotyp distribut mr c3514g mr c4582a snp cad nucleotid polymorph transit 344 cyp11b2 allel bind steroidogen allel aldosteron cyp11b2 polymorph 344c allel myocardi infarct angiotensin blocker cc genotyp predict antihypertens 344 genotyp aldosteron inconsist report 344t allel metaanalysi 344t polymorph yp11b2 cad caucasian asian stratif gender mishra cyp11b2 cad ventricular indian 29 stratifi gender mr c3514g mr c4582a snp cad enough mr ligand mr bind cortisol aldosteron nearli equal affin hudson mr canon element glucocorticoid mode lever arm conform mineralocorticoid glucocorticoid 31 glucocorticoid activ mr basal glucocorticoid inactiv cortisol corticosteron hydroxysteroid dehydrogenas aldosteron activ mr aldosteron limit glucocorticoid polymorph mr cortisol aldosteronemedi mr kidney 33 complic mr cad sia mr normotens hypertens echocardiograph 34 framingham varianc aldosteron primarili nongenet polymorph cyp11b2 aldosteron synthas coronari catheter taiwan cc allel femal cad lvm lvedd cc allel cad aldosteron bress takai pojoga cyp11b2 344cc genotyp overrepres extrem elev aldosteron dilat cardiomyopathi 36 37 cyp11b2 344cc genotyp aldosteron snp lvm eventfre african american 36 38 cyp11b2 cc predispos taiwanes cad regardless cad cyp11b2 cc exacerb ventricl lvm lvedd taiwanes lvm lvedd cad multivari cyp11b2 cc exhibit cad dm impli cyp11b2 cc cad taiwanes nevertheless cyp11b2 t344c polymorph 39 jia 344c allel idiopath hyperaldosteron 41 warrant elucid cyp11b2 cc cad cyp11b2 cad noncad snp cyp11b2 t344c carri homozygot cc cyp11b2 atherosclerosi worth candid cyp11b2 t344c mr c3514g mr c4582a effector cad genotyp distribut cyp11b2 t344c mr c3514g mr c4582a snp cad stratifi gender multivari cyp11b2 t344c exhibit cad taiwanes\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.525\talkalin phosphatas 181 thai hospit alkalin phosphatas alp bone lesser amount intestin placenta kidney leukocyt alp done alp thai hospit record inpati alp 1000 iul king chulalongkorn memori thailand januari decemb exclud involv malign pediatr younger old hivseroposit 181 hospit elig record 96 male 85 femal 494 161 alp rang 1001 3067 iul divid alp hospit obstruct biliari infiltr sepsi accord nonetheless cholangiocarcionoma tropic set mark elev alp  backgroundmateri methodsresultsdiscussionconclusioncompet interestsprepubl alkalin phosphatas alp ec 3131 compris catalyz hydrolysi phosphat ester alkalin gener organ radic inorgan phosphat isoenzym bone lesser amount intestin placenta kidney leukocyt alp extrahepat bile obstruct intrahepat cholestasi infiltr hepat mention unfortun elev alp non insuffici definit markedli alp hyperalkalinephosphatasemia predominantli malign biliari obstruct biliari cirrhosi scleros cholang hepat lymphoma sarcoidosi sepsi malign obstruct hyperalkalinephosphatasemia diffus benign hyperalkalinephosphatasemia markedli alp thai hospit record alp equal 1000 iul oneyear thai tertiari alp hospit etiolog obstruct biliari infiltr sepsi accord interest set cholangiocarcinoma ofhyperalkalinephosphatasemia tropic etiolog mark elev alp thai hospit compet interest\n",
            "\t-8.625\tmlc phosphatas mapk signal rest vasoconstrict nitric oxid vasodilat myosin mlc phosphatas abnorm nitric oxid mediat vasodilat guanyl cyclas cgmp cgmpdepend pkgi pkgi activ smooth relax mlc phosphatas mlc phosphatas holoenzym consist subunit kd subunit 38kd catalyt subunit myosin subunit mypt1 splice 31 bp exon gener mypt1 isoform differ coohterminu leucin zipper lz pkgimedi mlc phosphatas lz mypt1 congest lz mypt1 cgmpmediat smooth relax beyond afterload angiotensin convert ace benefici maintain lz mypt1 isoform therebi conserv cgmpmediat vasodilat differenti regul mitogen mapk signal ace reduc circul angiotensin limit downstream mapk signal possibl prevent alter preserv mypt1nitr oxidesmooth musclevasoconstrictionvasodilatationangiotensin failureregul smooth contractilityca sensitizationca desensitizationmypt1 isoform cgmpcgmp mypt1 phosphorylationvascular cgmp signallingcaptopril mypt1 hfcaptopril expressionconclus congest chf complain dyspnea exert orthopnea extrem edema date advanc chf cure transplant regimen aim prolong abnorm contractil document chf subject intens review chf tone nitric oxid vasodilat vasculatur compensatori impair heart gener output meet demand exacerb vasculatur contractil smooth abnorm subject neuroendocrin renin angiotensin ra implic contribut abnorm vasoconstrict chf angiotensin ang modul endothelium regul remodel cultur smooth smc ang activ nicotinamid adenin dinucleotid nadnadh oxidas superoxid nitric oxid catabol avail reactiv superoxid anion hydrogen peroxid stimul hypertrophi hyperplasia smc nitric oxid bioavail tone endotheliumdepend andindepend vasorelax chf complic abnorm vasculatur rest vasoconstrict nitric oxid vasodilat nitric oxid vasodilat attribut nitric oxid defect smooth evid lz mypt1 isoform lz mypt1 produc nitric oxid vasodilat nitric oxid blunt flowmedi vasodilat rest vasoconstrict p38 mapk p4244 mapk signal activ homeobox ace captopril alter preserv lz cgmpmediat vasodilat mapk signal alter maintain lz mypt1 nonetheless mapk signal chf pleomorph mapk trigger smc hypertrophi ang modul augment tone ration block mapk cascad revers\n",
            "\t-9.233\tnitric oxid distanc organ bilater ischemiareperfus larginin ngnitrolarginin methyl ester ischemiareperfus rir act larginin endogen nitric oxid precursor ngnitrolarginin methyl ester lname rir fiftyeight wistar randomli assign shamoper salin mlkg ip ischemia isch salin mlkg ip isch lname lname mgkg ip isch larginin larginin 300 mgkg ip clamp pedicl 45 min 24h reperfus subject patholog investig urea nitrogen bun creatinin cr ktd isch isch lname sham larginin 005 bun cr ktd isch isch lname sham larginin malondialdehyd alkalin phosphatas larginin precursor rir improv larginineliverngnitrolarginin methyl esterratren ischemia introductionmateri methodsanimalsexperiment protocolmeasurementssup oxid dismutas assayglutathion assayassess factorshistopatholog proceduresstatist analysisresultseffect ngnitrolarginin methyl ester larginin urea nitrogen creatinin bw scoreeffect ngnitrolarginin methyl ester larginin nitrit malondialdehyd glutathion super oxid dismutaseeffect ngnitrolarginin methyl ester larginin alanin aminotransferas aspart aminotransferas alkalin phosphatasediscussionconclusionfinanci sponsorshipconflict ischemiareperfus rir partial nephrectomi transplant revascular arteri supraren aortic aneurysm pathophysiolog rir deplet reserv biochem patholog injuri reactiv ro superoxid anion hydrogen peroxid o2 hydroxyl radic oh macromolecul rir glomerular filtrat gfr antioxid glutathion gsh glutathion reductas superoxid dismutas sod catalas disturb nitric oxid ischemiareperfus ir affect remot organ lung imbal oxid antioxid radic easili pas membran relax smooth muscl dilat improv arteri isoform synthas no name no eno induc no ino neuron no nno isoform eno vas rectum inner medullari collect duct glomerulus ino smooth tubular monocyt neutrophil nno macula densa particip tubuloglomerular feedback medullari perfus larginin non kidney act substrat no ngnitrolarginin methyl ester lname larginin no inhibit antagonist larginin atanasova discov lname worsen ischemia isch klahr larginin protect gfr alter antioxid rir pretreat precursor blocker mention iri affect remot organ lung intestin ro circul distal big gland numer glycogen storag decomposit red hormon detoxif produc bile larginin lname rir accordingli larginin lname biomark conclud larginin protect histolog rir larginin opposit financi sponsorship\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.464\tdual alpha beta revisit    worldwid progress dialysi transplant combat block pkc pkc compris serinethreonin kina ubiquit particip pkc divid classic atyp isoform biochem isoform diabet pkc upregul retina glomerulus pkc isoform isoform glomerulus preclin benefici select pkc ruboxistaurin eye diseasestreat ruboxistaurin albuminuria glomerular filtrat retin circul administ oral db db ruboxistaurin amelior albuminuria mesangi expans transform tgf fibronectin iv collagen subsequ transgen ren pkc ruboxistaurin amelior albuminuria tgf continu hyperglycemia term ruboxistaurin retinopathi preclin term eye disappoint modest albuminuria ruboxistaurin pkc warrant research implic pkc implic pkc albuminuria streptozotocin stz kang pkc isoform pkc isoform pkc knockout haller pkc transform tgf hypertrophi expans pkc perlecan vegf nephrin albuminuria similarli king pkc knockout carri glomerular hypertrophi modest albuminuria delet pkc isoform inhibit stz albuminuria complet prevent exclus pkc knockout pharmacolog pkc cgp41252 agent util classic pkc amelior albuminuria fail hypertrophi stz 129sv db db interpret implic cgp41252 broad pkc oppos pkc agent inhibit pkc isoform pkc delet pkc glomerulosclerosi tubulointerstiti fibrosi protect continu complic repres global urgent intensifi renin angiotensin albuminuria preserv slow declin diabet highlight isoform pkc pkc pkc isoform discoveri pkc isoform hyperglycemia dyslipidemia pkc protect precis pkc ctgf connect nf kappa enhanc tgf transform vegf imag \n",
            "\t0.464\tdual alpha beta revisit    worldwid progress dialysi transplant combat block pkc pkc compris serinethreonin kina ubiquit particip pkc divid classic atyp isoform biochem isoform diabet pkc upregul retina glomerulus pkc isoform isoform glomerulus preclin benefici select pkc ruboxistaurin eye diseasestreat ruboxistaurin albuminuria glomerular filtrat retin circul administ oral db db ruboxistaurin amelior albuminuria mesangi expans transform tgf fibronectin iv collagen subsequ transgen ren pkc ruboxistaurin amelior albuminuria tgf continu hyperglycemia term ruboxistaurin retinopathi preclin term eye disappoint modest albuminuria ruboxistaurin pkc warrant research implic pkc implic pkc albuminuria streptozotocin stz kang pkc isoform pkc isoform pkc knockout haller pkc transform tgf hypertrophi expans pkc perlecan vegf nephrin albuminuria similarli king pkc knockout carri glomerular hypertrophi modest albuminuria delet pkc isoform inhibit stz albuminuria complet prevent exclus pkc knockout pharmacolog pkc cgp41252 agent util classic pkc amelior albuminuria fail hypertrophi stz 129sv db db interpret implic cgp41252 broad pkc oppos pkc agent inhibit pkc isoform pkc delet pkc glomerulosclerosi tubulointerstiti fibrosi protect continu complic repres global urgent intensifi renin angiotensin albuminuria preserv slow declin diabet highlight isoform pkc pkc pkc isoform discoveri pkc isoform hyperglycemia dyslipidemia pkc protect precis pkc ctgf connect nf kappa enhanc tgf transform vegf imag \n",
            "\t0.463\tpolymorph aldosteron synthas cytochrom p450 11b2 mineralocorticoid coronari arteri taiwan aldosteron synthas cytochrom p450 11b2 cyp11b2 mineralocorticoid mr coronari arteri cad nucleotid polymorph snp cyp11b2 cyp11b2 t344c mr mr c3514g mr c4582a cad taiwanes hundr nine unrel elect coronari angiographi recruit chung shan univers enrol noninvas cyp11b2 t344c mr c3514g mr c4582a polymeras reactionrestrict fragment polymorph cyp11b2 cc cad genotyp distribut mr c3514g mr c4582a cad multivari cyp11b2 t344c cad taiwanes conclus cyp11b2 cc cad mellitu impli cyp11b2 cc cad taiwanes  introductionmateri methodssubjectsblood extractionselect cyp11b2 t344c mr c3514g mr c4582a polymorphismspolymeras reactionrestrict fragment polymorph pcrrflpstatist analysisresultsdiscuss coronari morbid worldwid affect million coronari multifactori nonconvent gender hyperlipidemia mellitu dm nonconvent welldefin reninangiotensinaldosteron raa affect circulatori homeostasi regul adren gland regul fluid sodium balanc raa maintain kidney sodium balanc vessel abnorm raa array atherosclerot coronari arteri cad plaqu ruptur myocardi infarct aldosteron pathogen renin cleav angiotensinogen synthes secret angiotensin circul angiotensin hydrolyz angiotensin angiotensinconvert primarili endothelium angiotensin initi vasoconstrictor stimul aldosteron adren gland aldosteron ventricular remodel aldosteron perivascular fibrosi ventricular caus modifi facilit adapt remodel aldosteron act mineralocorticoid mr aldosteron larg final biosynthesi aldosteron synthas encod aldosteron synthas cytochrom p450 11b2 cyp11b2 aldosteron mr extraren larg detriment set cyp11b2 implic snp hypothes cyp11b2 nucleotid polymorph snp cyp11b2 t344c mr snp mr c3514g mr c4582a cad cyp11b2 t344c mr c4582a mr c3514g cad taiwan aim correl cyp11b2 t344c mr c4582a mr c3514g cad taiwanes dm cad subgroup stratif gender dm cad framingham highnorm systol 130139 mmhg diastol 8589 mmhg 2fold dm ethnicallymatch dm multivari dm cad taiwanes defin nonconvent polymorph cad taiwanes genotyp distribut cyp11b2 t344c mr c3514g mr c4582a snp cad stratifi gender remain insignific subgroup cyp11b2 cc cad allel genotyp distribut mr c3514g mr c4582a snp cad nucleotid polymorph transit 344 cyp11b2 allel bind steroidogen allel aldosteron cyp11b2 polymorph 344c allel myocardi infarct angiotensin blocker cc genotyp predict antihypertens 344 genotyp aldosteron inconsist report 344t allel metaanalysi 344t polymorph yp11b2 cad caucasian asian stratif gender mishra cyp11b2 cad ventricular indian 29 stratifi gender mr c3514g mr c4582a snp cad enough mr ligand mr bind cortisol aldosteron nearli equal affin hudson mr canon element glucocorticoid mode lever arm conform mineralocorticoid glucocorticoid 31 glucocorticoid activ mr basal glucocorticoid inactiv cortisol corticosteron hydroxysteroid dehydrogenas aldosteron activ mr aldosteron limit glucocorticoid polymorph mr cortisol aldosteronemedi mr kidney 33 complic mr cad sia mr normotens hypertens echocardiograph 34 framingham varianc aldosteron primarili nongenet polymorph cyp11b2 aldosteron synthas coronari catheter taiwan cc allel femal cad lvm lvedd cc allel cad aldosteron bress takai pojoga cyp11b2 344cc genotyp overrepres extrem elev aldosteron dilat cardiomyopathi 36 37 cyp11b2 344cc genotyp aldosteron snp lvm eventfre african american 36 38 cyp11b2 cc predispos taiwanes cad regardless cad cyp11b2 cc exacerb ventricl lvm lvedd taiwanes lvm lvedd cad multivari cyp11b2 cc exhibit cad dm impli cyp11b2 cc cad taiwanes nevertheless cyp11b2 t344c polymorph 39 jia 344c allel idiopath hyperaldosteron 41 warrant elucid cyp11b2 cc cad cyp11b2 cad noncad snp cyp11b2 t344c carri homozygot cc cyp11b2 atherosclerosi worth candid cyp11b2 t344c mr c3514g mr c4582a effector cad genotyp distribut cyp11b2 t344c mr c3514g mr c4582a snp cad stratifi gender multivari cyp11b2 t344c exhibit cad taiwanes\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.525\talkalin phosphatas 181 thai hospit alkalin phosphatas alp bone lesser amount intestin placenta kidney leukocyt alp done alp thai hospit record inpati alp 1000 iul king chulalongkorn memori thailand januari decemb exclud involv malign pediatr younger old hivseroposit 181 hospit elig record 96 male 85 femal 494 161 alp rang 1001 3067 iul divid alp hospit obstruct biliari infiltr sepsi accord nonetheless cholangiocarcionoma tropic set mark elev alp  backgroundmateri methodsresultsdiscussionconclusioncompet interestsprepubl alkalin phosphatas alp ec 3131 compris catalyz hydrolysi phosphat ester alkalin gener organ radic inorgan phosphat isoenzym bone lesser amount intestin placenta kidney leukocyt alp extrahepat bile obstruct intrahepat cholestasi infiltr hepat mention unfortun elev alp non insuffici definit markedli alp hyperalkalinephosphatasemia predominantli malign biliari obstruct biliari cirrhosi scleros cholang hepat lymphoma sarcoidosi sepsi malign obstruct hyperalkalinephosphatasemia diffus benign hyperalkalinephosphatasemia markedli alp thai hospit record alp equal 1000 iul oneyear thai tertiari alp hospit etiolog obstruct biliari infiltr sepsi accord interest set cholangiocarcinoma ofhyperalkalinephosphatasemia tropic etiolog mark elev alp thai hospit compet interest\n",
            "\t-8.625\tmlc phosphatas mapk signal rest vasoconstrict nitric oxid vasodilat myosin mlc phosphatas abnorm nitric oxid mediat vasodilat guanyl cyclas cgmp cgmpdepend pkgi pkgi activ smooth relax mlc phosphatas mlc phosphatas holoenzym consist subunit kd subunit 38kd catalyt subunit myosin subunit mypt1 splice 31 bp exon gener mypt1 isoform differ coohterminu leucin zipper lz pkgimedi mlc phosphatas lz mypt1 congest lz mypt1 cgmpmediat smooth relax beyond afterload angiotensin convert ace benefici maintain lz mypt1 isoform therebi conserv cgmpmediat vasodilat differenti regul mitogen mapk signal ace reduc circul angiotensin limit downstream mapk signal possibl prevent alter preserv mypt1nitr oxidesmooth musclevasoconstrictionvasodilatationangiotensin failureregul smooth contractilityca sensitizationca desensitizationmypt1 isoform cgmpcgmp mypt1 phosphorylationvascular cgmp signallingcaptopril mypt1 hfcaptopril expressionconclus congest chf complain dyspnea exert orthopnea extrem edema date advanc chf cure transplant regimen aim prolong abnorm contractil document chf subject intens review chf tone nitric oxid vasodilat vasculatur compensatori impair heart gener output meet demand exacerb vasculatur contractil smooth abnorm subject neuroendocrin renin angiotensin ra implic contribut abnorm vasoconstrict chf angiotensin ang modul endothelium regul remodel cultur smooth smc ang activ nicotinamid adenin dinucleotid nadnadh oxidas superoxid nitric oxid catabol avail reactiv superoxid anion hydrogen peroxid stimul hypertrophi hyperplasia smc nitric oxid bioavail tone endotheliumdepend andindepend vasorelax chf complic abnorm vasculatur rest vasoconstrict nitric oxid vasodilat nitric oxid vasodilat attribut nitric oxid defect smooth evid lz mypt1 isoform lz mypt1 produc nitric oxid vasodilat nitric oxid blunt flowmedi vasodilat rest vasoconstrict p38 mapk p4244 mapk signal activ homeobox ace captopril alter preserv lz cgmpmediat vasodilat mapk signal alter maintain lz mypt1 nonetheless mapk signal chf pleomorph mapk trigger smc hypertrophi ang modul augment tone ration block mapk cascad revers\n",
            "\t-9.233\tnitric oxid distanc organ bilater ischemiareperfus larginin ngnitrolarginin methyl ester ischemiareperfus rir act larginin endogen nitric oxid precursor ngnitrolarginin methyl ester lname rir fiftyeight wistar randomli assign shamoper salin mlkg ip ischemia isch salin mlkg ip isch lname lname mgkg ip isch larginin larginin 300 mgkg ip clamp pedicl 45 min 24h reperfus subject patholog investig urea nitrogen bun creatinin cr ktd isch isch lname sham larginin 005 bun cr ktd isch isch lname sham larginin malondialdehyd alkalin phosphatas larginin precursor rir improv larginineliverngnitrolarginin methyl esterratren ischemia introductionmateri methodsanimalsexperiment protocolmeasurementssup oxid dismutas assayglutathion assayassess factorshistopatholog proceduresstatist analysisresultseffect ngnitrolarginin methyl ester larginin urea nitrogen creatinin bw scoreeffect ngnitrolarginin methyl ester larginin nitrit malondialdehyd glutathion super oxid dismutaseeffect ngnitrolarginin methyl ester larginin alanin aminotransferas aspart aminotransferas alkalin phosphatasediscussionconclusionfinanci sponsorshipconflict ischemiareperfus rir partial nephrectomi transplant revascular arteri supraren aortic aneurysm pathophysiolog rir deplet reserv biochem patholog injuri reactiv ro superoxid anion hydrogen peroxid o2 hydroxyl radic oh macromolecul rir glomerular filtrat gfr antioxid glutathion gsh glutathion reductas superoxid dismutas sod catalas disturb nitric oxid ischemiareperfus ir affect remot organ lung imbal oxid antioxid radic easili pas membran relax smooth muscl dilat improv arteri isoform synthas no name no eno induc no ino neuron no nno isoform eno vas rectum inner medullari collect duct glomerulus ino smooth tubular monocyt neutrophil nno macula densa particip tubuloglomerular feedback medullari perfus larginin non kidney act substrat no ngnitrolarginin methyl ester lname larginin no inhibit antagonist larginin atanasova discov lname worsen ischemia isch klahr larginin protect gfr alter antioxid rir pretreat precursor blocker mention iri affect remot organ lung intestin ro circul distal big gland numer glycogen storag decomposit red hormon detoxif produc bile larginin lname rir accordingli larginin lname biomark conclud larginin protect histolog rir larginin opposit financi sponsorship\n",
            "headaches,serum alkaline phosphatase,pyridinoline None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.427\tamyotroph later sclerosi frontotempor dementia basic regen amyotroph later sclerosi al frontotempor dementia ftd spectrum trigger gener somat transfect exogen pluripot open avenu phenotyp relat never regen tailor cultur discus pluripot ipsc al ftd discus ipsc bank alsftd spectrum  introduction2 lesson models21 embryon cells22 pluripot cells3 ipsc bank31 premis comprehens bank32 ipsc bank reveal pathogen alsftd33 banks34 challeng ipsc technology4 direct  \n",
            "\t0.424\themorrhag bullou henoch schonlein purpura paediatrician   backgroundpatientsconclus hemorrag bullou notic hsp unusu cutan manifest paediatr childhood hsp occurr hemorrhag bulla typic paediatr toxic epiderm necrolisi erythema multiform pemphigu bullou impetigo dermat herpetiformi staphylococc scald bullou cutan\n",
            "\t0.420\torthostat intraven levodopa intraven levodopa multitud predict pharmacokinet parkinson pd levodopa precursor dopamin intraven dopamin tone decarboxylas intend block pul orthostat record intraven levodopa placebo carbidopa tic ticfre levodopa statist clinic pul add iv levodopa adequ dopa decarboxylas  introductionmethodssubjectsmedicationsmeasurementsstatist analysisresultsbaselin subjectsorthostat vital sign levodopa infusionvit sign levodopa placebo infusionsselfreport effectsdiscussionsupplement informationdata vital sign subject characteristicsinform consent document levodopa parkinson pd intraven rout birkmay hornykiewicz 1961 birkmay hornykiewicz 1998 hornykiewicz prefer clinic ea intraven iv levodopa infus favor circumst chase engber mouradian 1994 abramski goldschmidt 1974 horai mizuno iv rout advantag purpos black black black 2015 levodopa approv pd parkinsonian formul give approv rout purpos investig ind chang rout risk decreas accept risk cfr 3122biii httpwwwaccessdatafdagovscriptscdrhcfdocscfcfrcfrsearchcfmfr3122 assum hold iv levodopa numer brief infus singledos iv bolus iv levodopa toler levodopa abraham 2015 siddiqi 2015 deliber attempt hallucin give highdos iv levodopa hallucin goetz 1998 hemodynam iv levodopa past quantit decarboxylas abraham 2015 siddiqi 2015 doubleblind randomalloc crossov orthostat pul iv levodopa adequ carbidopa pretreat comprehens iv levodopa produc biolog meaning parkinson meaning orthostat vital sign adequ dopa decarboxylas review elsewher abraham 2015 summar advent decarboxylas dose iv levodopa moorthi 1972 gave 200 mg levodopa iv min age 77 slight aortic arteri pressur output systol diastol aortic arteri slight arteri signific placebo note recov min infus subject conclud intraven levodopa safe pd moorthi 1972 bruno brigida 1965 baldymoulini 1977 monitor pul bp frequent interv iv infus mgkg 140 mg min 125 mg min simpli arteri bp baldymoulini 1977 184 infus bruno brigida 1965 nonneurolog levodopa prevent amelior carbidopa decarboxylas whose purpos levodopa convert dopamin circul barbeau roy 1976 cotzia papavasili gellen 1969 decarboxylas revolution pd 45 ago papavasili 1972 autonom gastrointestin levodopa doserel nausea dizzi orthostat hypotens smaller dose decarboxylas mg carbidopa autonom intraven levodopa irwin 1992 levodopa mg benserazid noack 2014 rout leovodopa carbidopa 200 mg enough adequ absorpt levodopa effect prevent autonom posit favor younger parkinson hypotens levodopa pdi pd whitsett goldberg 1972 caln 1970 nard 1995 haapaniemi bouhaddi wolf hypotens levodopa pd suppress dose pdi mehagnoulschipp similarli carbidopa dose levodopa cerebr hershey 1998 pd dose carbidopa similarli bp iv levodopa black black unpublish ascrib dose carbidopa sedat levodopa pd dyskinesia hallucin confus gambl paraphilia disinhibit emerg substanti minor dopamimet black friedman synthet dopamin agonist weintraub poletti unawar intraven levodopa levodopa elucid intraven levodopa reaffirm meaning orthostat vital sign carbidopa schedul add compar levodopa allevi concern intraven levodopa supplement\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.638\tpharmacolog parkinson    past levodopa ld pharmacolog treat idiopath parkinson pd neurodegen nervou ld pharmacolog inact precursor convert enzymat neurotransmitt dopamin declin substantia nigra patholog pd smooth last amount ld get wors treatmentrel aris fluctuat slowli emerg ld gradual replac smooth frequent dose abnorm involuntari movement dyskinesia wearingoff hour organ psychosi confus hallucin progress independ character complic pharmacolog pd antiparkinson ld pharmacolog agent relief pd dopamin agonist greatli encourag indic pd younger delay fluctuat dyskinesia princip dopamin agonist ergolin bromocriptin lisurid pergolid cabergolin nonergolin ropirinolo pramipexol apomorphin pharmacolog compar dopamin administ subcutan pd apomorphin quickli revers period fluctuat continu infus portabl micropump bolu inject mao comt metabol dopamin nervou mao comt prolong halflif ld repres selegilin mao tolcapon entacapon comt italian guidelin pd monotherapi recommend dopamin agonist ld age 70 monotherapi recommend dopamin agonist ld \n",
            "\t-0.955\tmembran nephropathi levodopacarbidopa    sir membran nephropathi mn nephrot 75 mn aetiolog agent mn mn typic develop soon offend agent classic offend gold penicillamin nonsteroid antiinflammatori captopril thorough literari search levodopacarbidopa mn 45yearold regular follow parkinson pd past levodopacarbidopa 110 mg twice gradual worsen swell foot face oliguria frothi urin present 12080 mmhg investig investig biopsi glomerulus glomerulus capillari loop stiff round patent thick basement silver methanamin stain spike tubul unremark immunofluoresc diffus granular deposit immunoglobulin igg iga trace igm trace c3 capillari loop suggest mn antiphospholipasea 2receptor pla2r done enzymelink immunosorb suspect levodopacarbidopa mn stop ropinirol 05 mg half bid start next swell foot face disappear proteinuria declin 414 mgday albumin 67 gdl 39 gdl anti phospholipasea2receptor 70 idiopath mn antipla2r mn lupu erythematosu hepat mn malign mn sarcoidosi mn antipla2r idiopath mn exclud mn await welldesign prospect underway relat levodopacarbidopa proteinuria consequ stoppag anti pla2r point levodopacarbidopa mn spontan remiss mn \n",
            "\t-1.274\tparkinson lowdos haloperidol dopamin   introduction2 object study3 methods31 ethics32 methods33 inclusionexclus criteria34 evaluation35 treatment36 data4 results41 parkinson sign symptoms42 subgroup analysis43 freez signs44 safety5 discus levodopa mainstay parkinson levodopa desir way enhanc levodopa delay progress enhanc dopaminerg dopamin d2 dopamin agonist dose dopamin antagonist d2 highaffin dopamin d2high striatal d2high consist behaviour alttoa spontan exploratori d2 highaffin spontan exploratori onemonth postnat divid lowcurios lowcurios highaffin d2 averag 225 d2 highcurios d2high 438 d2high exploratori administ haloperidol ip equival 04 approv indic psychosi success highaffin d2 twice untreat exhibit heighten locomot explor groom demonstr dose stop d2 highaffin correl dia lowdos haloperidol dopaminergiclik addon microgram haloperidol appear enhanc levodopa addon lowdos haloperidol haloperidol stop synerg haloperidol levodopa surpris haloperidol dopamin supersensit note haloperidol invert ushap dose haloperidol caus dopamin supersensit dose haloperidol elicit opposit exacerb parkinsonian sign extend addon give addon haloperidol month enhanc levodopa testretest haloperidol haloperidol potenti levodopa reinstat haloperidoladdon continu gener extend parkinson potenti levodopa lowdos haloperidol depend concomit levodopa aspect extend freez surpris unexpect week withdraw elev dopamin d2high haloperidol note elev haloperidolinduc elev d2high d2 d2high matter d2 somewhat appar enhanc levodopa lowdos haloperidol principl delay progress ldopa dose treat parkinson diseas\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.427\tamyotroph later sclerosi frontotempor dementia basic regen amyotroph later sclerosi al frontotempor dementia ftd spectrum trigger gener somat transfect exogen pluripot open avenu phenotyp relat never regen tailor cultur discus pluripot ipsc al ftd discus ipsc bank alsftd spectrum  introduction2 lesson models21 embryon cells22 pluripot cells3 ipsc bank31 premis comprehens bank32 ipsc bank reveal pathogen alsftd33 banks34 challeng ipsc technology4 direct  \n",
            "\t0.424\themorrhag bullou henoch schonlein purpura paediatrician   backgroundpatientsconclus hemorrag bullou notic hsp unusu cutan manifest paediatr childhood hsp occurr hemorrhag bulla typic paediatr toxic epiderm necrolisi erythema multiform pemphigu bullou impetigo dermat herpetiformi staphylococc scald bullou cutan\n",
            "\t0.420\torthostat intraven levodopa intraven levodopa multitud predict pharmacokinet parkinson pd levodopa precursor dopamin intraven dopamin tone decarboxylas intend block pul orthostat record intraven levodopa placebo carbidopa tic ticfre levodopa statist clinic pul add iv levodopa adequ dopa decarboxylas  introductionmethodssubjectsmedicationsmeasurementsstatist analysisresultsbaselin subjectsorthostat vital sign levodopa infusionvit sign levodopa placebo infusionsselfreport effectsdiscussionsupplement informationdata vital sign subject characteristicsinform consent document levodopa parkinson pd intraven rout birkmay hornykiewicz 1961 birkmay hornykiewicz 1998 hornykiewicz prefer clinic ea intraven iv levodopa infus favor circumst chase engber mouradian 1994 abramski goldschmidt 1974 horai mizuno iv rout advantag purpos black black black 2015 levodopa approv pd parkinsonian formul give approv rout purpos investig ind chang rout risk decreas accept risk cfr 3122biii httpwwwaccessdatafdagovscriptscdrhcfdocscfcfrcfrsearchcfmfr3122 assum hold iv levodopa numer brief infus singledos iv bolus iv levodopa toler levodopa abraham 2015 siddiqi 2015 deliber attempt hallucin give highdos iv levodopa hallucin goetz 1998 hemodynam iv levodopa past quantit decarboxylas abraham 2015 siddiqi 2015 doubleblind randomalloc crossov orthostat pul iv levodopa adequ carbidopa pretreat comprehens iv levodopa produc biolog meaning parkinson meaning orthostat vital sign adequ dopa decarboxylas review elsewher abraham 2015 summar advent decarboxylas dose iv levodopa moorthi 1972 gave 200 mg levodopa iv min age 77 slight aortic arteri pressur output systol diastol aortic arteri slight arteri signific placebo note recov min infus subject conclud intraven levodopa safe pd moorthi 1972 bruno brigida 1965 baldymoulini 1977 monitor pul bp frequent interv iv infus mgkg 140 mg min 125 mg min simpli arteri bp baldymoulini 1977 184 infus bruno brigida 1965 nonneurolog levodopa prevent amelior carbidopa decarboxylas whose purpos levodopa convert dopamin circul barbeau roy 1976 cotzia papavasili gellen 1969 decarboxylas revolution pd 45 ago papavasili 1972 autonom gastrointestin levodopa doserel nausea dizzi orthostat hypotens smaller dose decarboxylas mg carbidopa autonom intraven levodopa irwin 1992 levodopa mg benserazid noack 2014 rout leovodopa carbidopa 200 mg enough adequ absorpt levodopa effect prevent autonom posit favor younger parkinson hypotens levodopa pdi pd whitsett goldberg 1972 caln 1970 nard 1995 haapaniemi bouhaddi wolf hypotens levodopa pd suppress dose pdi mehagnoulschipp similarli carbidopa dose levodopa cerebr hershey 1998 pd dose carbidopa similarli bp iv levodopa black black unpublish ascrib dose carbidopa sedat levodopa pd dyskinesia hallucin confus gambl paraphilia disinhibit emerg substanti minor dopamimet black friedman synthet dopamin agonist weintraub poletti unawar intraven levodopa levodopa elucid intraven levodopa reaffirm meaning orthostat vital sign carbidopa schedul add compar levodopa allevi concern intraven levodopa supplement\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.638\tpharmacolog parkinson    past levodopa ld pharmacolog treat idiopath parkinson pd neurodegen nervou ld pharmacolog inact precursor convert enzymat neurotransmitt dopamin declin substantia nigra patholog pd smooth last amount ld get wors treatmentrel aris fluctuat slowli emerg ld gradual replac smooth frequent dose abnorm involuntari movement dyskinesia wearingoff hour organ psychosi confus hallucin progress independ character complic pharmacolog pd antiparkinson ld pharmacolog agent relief pd dopamin agonist greatli encourag indic pd younger delay fluctuat dyskinesia princip dopamin agonist ergolin bromocriptin lisurid pergolid cabergolin nonergolin ropirinolo pramipexol apomorphin pharmacolog compar dopamin administ subcutan pd apomorphin quickli revers period fluctuat continu infus portabl micropump bolu inject mao comt metabol dopamin nervou mao comt prolong halflif ld repres selegilin mao tolcapon entacapon comt italian guidelin pd monotherapi recommend dopamin agonist ld age 70 monotherapi recommend dopamin agonist ld \n",
            "\t-0.955\tmembran nephropathi levodopacarbidopa    sir membran nephropathi mn nephrot 75 mn aetiolog agent mn mn typic develop soon offend agent classic offend gold penicillamin nonsteroid antiinflammatori captopril thorough literari search levodopacarbidopa mn 45yearold regular follow parkinson pd past levodopacarbidopa 110 mg twice gradual worsen swell foot face oliguria frothi urin present 12080 mmhg investig investig biopsi glomerulus glomerulus capillari loop stiff round patent thick basement silver methanamin stain spike tubul unremark immunofluoresc diffus granular deposit immunoglobulin igg iga trace igm trace c3 capillari loop suggest mn antiphospholipasea 2receptor pla2r done enzymelink immunosorb suspect levodopacarbidopa mn stop ropinirol 05 mg half bid start next swell foot face disappear proteinuria declin 414 mgday albumin 67 gdl 39 gdl anti phospholipasea2receptor 70 idiopath mn antipla2r mn lupu erythematosu hepat mn malign mn sarcoidosi mn antipla2r idiopath mn exclud mn await welldesign prospect underway relat levodopacarbidopa proteinuria consequ stoppag anti pla2r point levodopacarbidopa mn spontan remiss mn \n",
            "\t-1.274\tparkinson lowdos haloperidol dopamin   introduction2 object study3 methods31 ethics32 methods33 inclusionexclus criteria34 evaluation35 treatment36 data4 results41 parkinson sign symptoms42 subgroup analysis43 freez signs44 safety5 discus levodopa mainstay parkinson levodopa desir way enhanc levodopa delay progress enhanc dopaminerg dopamin d2 dopamin agonist dose dopamin antagonist d2 highaffin dopamin d2high striatal d2high consist behaviour alttoa spontan exploratori d2 highaffin spontan exploratori onemonth postnat divid lowcurios lowcurios highaffin d2 averag 225 d2 highcurios d2high 438 d2high exploratori administ haloperidol ip equival 04 approv indic psychosi success highaffin d2 twice untreat exhibit heighten locomot explor groom demonstr dose stop d2 highaffin correl dia lowdos haloperidol dopaminergiclik addon microgram haloperidol appear enhanc levodopa addon lowdos haloperidol haloperidol stop synerg haloperidol levodopa surpris haloperidol dopamin supersensit note haloperidol invert ushap dose haloperidol caus dopamin supersensit dose haloperidol elicit opposit exacerb parkinsonian sign extend addon give addon haloperidol month enhanc levodopa testretest haloperidol haloperidol potenti levodopa reinstat haloperidoladdon continu gener extend parkinson potenti levodopa lowdos haloperidol depend concomit levodopa aspect extend freez surpris unexpect week withdraw elev dopamin d2high haloperidol note elev haloperidolinduc elev d2high d2 d2high matter d2 somewhat appar enhanc levodopa lowdos haloperidol principl delay progress ldopa dose treat parkinson diseas\n",
            "Parkinson's disease,Levodop None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.494\tissu   overview alcohol revisitedstress alcohol epidemiolog evidencealcohol militarychildhood trauma posttraumat alcohol dependenceanxieti alcohol comorbid considerationshow alcohol relapseneur integr relev alcohol abuseeffect alcohol depend withdraw respons alcohol consumptionclin stressor alcohol relationshipsstress hpa axi glucocorticoid alcohol dependencegenet determin respondingstress epigenet alcoholismresili meet addict psychobiolog considerationstreat alcohol depend antagonist drink alcohol reliev creat sen doubleedg sword link alcohol drink alcohol ongo ultim alcohol anthenelli reaction vari makeup gender articl anthenelli review introduc articl issu pp 386 390 \n",
            "\t0.480\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t0.472\talcohol friend foe alcohol abus 79000 death stem organ everi manifest alcohol abus defect contractil dilat cardiomyopathi lowoutput alcohol phenomenon elus signific mediat alcohol alcohol alcohol alcohol pairf nonalcohol heart dissect section stain cresyl violet immunohistochem caspase3 put cardiomyocyt alcohol contract relax alcohol display mark thin ventricular wall caspase3 contractil alcohol contractil protect alcohol cardiomyocyteapoptosisalcoholcontractilitycardiomyopathi introduction2 results3 discussion4 methods41 histology42 immunohistochemistry43 imag analysis44 prepar cardiomyocytes45 contract relaxation46 analysis5 conclus alcohol abus disabl issu plagu societi prevent 79000 casualti everi epidemiolog alcohol 303 experienc alcohol live excess alcohol 2235 billion healthcar expenditur contributor healthcar expens excess alcohol asymptomat alcohol cardiomyopathi acm progress ventricular wall thick output accompani electrocardiogram ecg abnorm contributor occurr delet fragment shrinkag proteolyt cleavag protea caspas apoptot alcohol render prone undergo assum reactiv ro mediat transduct cardiomyocyt caspas lethal cardiomyopathi transgen moder alcohol activ pi3kakt therebi cardioprotect antiapoptot alcohol elus yuan note explan pi3kakt inhibit caspase9 negat apoptot pi3kakt crucial mediat benefici detriment dose alcohol myocardi determin morbid limit cardiomyocyt implic therapeut aim alcohol caspase3 contractil heart alcohol avert maintain myofila architectur integr ventricular wall contractil convers alcohol detriment initi thin ventricular wall\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.772\thostmicrobiom alcohol alcohol morbid liverrel worldwid intestin overgrowth dysbiosi ethanol ingest alcohol alcohol lumen enter alter therebi disturb intestin homeostasi disrupt mucos barrier transloc microbi induc hepat discus alcohol intestin microbiom transloc ecolog balanc alcohol microbiom reveal alcohol injurymicrobiotapermeabilitymetabol introductionalcoholinduc gut microfloramicrobi transloc alcohol diseaseeffect alcohol intestin microfloraconclus alcohol beverag consum creat worldwid alcohol elucid alcohol alcohol gutliv axi gutderiv pathogen pamp lipopolysaccharid lp endotoxin transloc intestin lumen hepat steatosi fibrosi leaki gut barrier facilit microbi transloc intestin overgrowth dysbiosi promin microbiom alcohol intestin mucos barrier becom leaki transloc alcohol intestin microbiom alcohol summar exactli gut microflora barrier disturb intestin homeostasi warrant detail ethanol intestin microbiom alcohol insight alcohol reveal alcohol\n",
            "\t-3.951\talcoholinduc endoplasm reticulum organ injuri alcohol readili distribut throughout stream cross membran virtual insid excess alcohol numer patholog endoplasm reticulum unfoldedmisfold accumul contribut alcohol organ pancrea trigger alcohol indirectli alcohol includ toxic acetaldehyd homocystein perturb calcium iron homeostasi alter sadenosylmethionin sadenosylhomocystein abnorm epigenet modif interrupt trigger anticip benefit alcohol  introduction2 unfold upr3 alcohol organ injuries31 liver32 pancreas33 brain34 heart4 alcoholinduc stress41 acetaldehyd adduct stress42 homocystein stress43 samsah epigenet alter stress44 disrupt iron homeostasi stress45 synergist alcohol environments5 conclud remark alcohol social accept addict alcohol abus depend domest violenc product place traffic accidentrel injuri organ excess alcohol prevent 38 death worldwid alcoholrel alcoholinduc injuri alcohol readili distribut throughout stream cross membran virtual organ alcohol enter oxid toxic acetaldehyd catalyz cytosol alcohol dehydrogenas adh acetaldehyd convert acetaldehyd dehydrogenas aldh acet primarili alcohol oxid acetaldehyd cytochrom p450iie1 cyp2e1 gener hydrogen peroxid alcoholrel ill indirectli toxic alcohol metabolit alcohol injuri organ gastrointestin tract pancrea review alcoholinduc ald organ ald includ spectrum rang steatosi steatohepat fibrosi cirrhosi ald complet understood cofactor ald malfunct cyp2e1 endotoxin innat adapt immun hypoxia methionin epigenet modif cofactor malnutrit hcvhiv alcoholinduc perturb homeostasi endoplasm reticulum evolv contribut fatti review comprehens review alcohol accumul beyond purpos highlight phenomenolog alcoholinduc select organ discus caus alcohol \n",
            "\t-5.013\tpueraria radix extract endotoxin gutderiv endotoxin alcohol kudzu pueraria lobata earliest medicin treat alcohol abus tradit chine millennium alcohol pueraria radix extract rpe alcohol kupffer kc necrosi alpha gutderiv endotoxin macrophag rpe allevi patholog lipid deposit alanin aminotransferas alt aspart aminotransferas ast hepat gammaglutamyl transpeptidas ggt meanwhil rpe inhibit kc hepat downregul endotoxin lipopolysaccharid lbp cd14 tolllik tlr tlr4 alcohol rpe inhibit endotoxin cd14 tlr4 lp raw2647 summari rpe mitig deposit alcohol endotoxin  introduction2 prepar pre22 rpe23 treatments24 treatment25 ldh raw264726 histolog examination27 alt ast assay28 hepat ggt assay29 hepat tg assay210 endotoxin portal vein211 immunohistochem hepat cd68212 elisa213 determin cd68 endotoxin western blot214 analysis3 results31 liquid diet liverbodi ratio32 rpe live alcohol intake33 rpe hepat deposition34 endotoxin portal vein hepat concentration35 rpe kupffer endotoxin liver36 ldh raw2647 supernat cultur rpe37 rpe raw2647 supernat lp 38 rpe endotoxin lp discussion5 alcohol abus issu worldwid cover death western eastern 1980 morbid alcohol ald abruptli seriou trend china ald encompass spectrum rang steatosi hepat cirrhosi alcohol fatti fatti drop disappear abstin steatosi hepatocyt continu ingest alcohol steatohepat neutrophil infiltr hepatocyt degener balloon oncot necrosi rare recov hepat histolog ethanol withdraw alcohol steatohepat trigger patholog progress fibrosi cirrhosi ratelimit ald block revers earlyphas histopatholog steatosi steatohepat ald besid alcohol oxid endotoxin toxic lipopolysaccharid lp gut gramneg classic alcohol intestin permeabl alcohol endotoxin releas circul transport lp lpsbind lbp bind cd14 hepat kupffer kc cd14lbplp interact tolllik tlr4 trigger cascad kc activ nf promot preinflammatori necrosi alpha gut permeabl oxid perpetu progress kudzu pueraria lobata earliest medicin treat alcohol abus tradit chine millennium antidipsotrop isoflavon radix pueraria puerarin daidzin daidzein suppress ethanol rodent abolish alcohol withdraw antioxid cuzn sod catalas mitig hepat oxid ethanoltr investig radix pueraria extract rpe antialcohol comprehens rpe alcohol endotoxin gutderiv endotoxin rpe mitig deposit alcohol endotoxin\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.494\tissu   overview alcohol revisitedstress alcohol epidemiolog evidencealcohol militarychildhood trauma posttraumat alcohol dependenceanxieti alcohol comorbid considerationshow alcohol relapseneur integr relev alcohol abuseeffect alcohol depend withdraw respons alcohol consumptionclin stressor alcohol relationshipsstress hpa axi glucocorticoid alcohol dependencegenet determin respondingstress epigenet alcoholismresili meet addict psychobiolog considerationstreat alcohol depend antagonist drink alcohol reliev creat sen doubleedg sword link alcohol drink alcohol ongo ultim alcohol anthenelli reaction vari makeup gender articl anthenelli review introduc articl issu pp 386 390 \n",
            "\t0.480\talcohol invas alcohol consist epidemiolog relat alcohol alcohol 3146 invas swedish mammographi alcohol questionnair cox proport hazard calcul hazard ratio hr confid interv ci 1987 385 cancerspecif death 860 death alcohol cancerspecif consum correspond 075 drink alcohol adjust hr cancerspecif 136 082 226p trend 047 nondrink invers alcohol nonbreast death consum 34 99 alcohol 33 nondrink 050 090p trend 004 alcohol drink neg cancerspecif half drink alcoholbreast cancersurviv methodsstudi populationdietari assessmentoutcom assessmentstatist analysisresultsdiscuss  populationbas prospect swedish alcohol cancerspecif moder alcohol occurr smithwarn 1998 aicr dorgan singletari gapstur dumitrescu shield alcohol antier hormon replac recurr ewertz 1991 keneman examin alcohol consist unfavor endpoint holm allcaus endpoint seven ewertz 1991 zhang 1995 holm sax mceligot franceschi kwan invers alcohol barnett rede beasley flatt endpoint cancerspecif recurr rohan 1993 goodwin alcohol hebert 1998 green mcdonald beasley kwan alcohol cancerspecif suggest consum correspond 075 drinkday hr136 082 226 suzuki cancerspecif strongest moder drinker consum half drink moder alcohol reduc heavier drink fuch 1995 prediagnosi postdiagnosi dietari subset complet ffq postdiagnosi 92 remain adjac categori alcohol error dietari selfadminist ffq alcohol portion 1987 ffq ffq valid record 09 alcohol wolk unpublish 1992 error attenu true limit alcohol alcohol cancerspecif alcohol smc prospect cohort consist rang 55 126 smithwarn 1998 pr menopaus grade lymph node 77 strength prospect populationbas death 860 385 death allow cancerspecif differ hormon alcohol drink neg cancerspecif invers nonbreast fundamerican institut recommend alcohol drink consum alcohol drink aicr alcohol specificmort wider alcohol\n",
            "\t0.472\talcohol friend foe alcohol abus 79000 death stem organ everi manifest alcohol abus defect contractil dilat cardiomyopathi lowoutput alcohol phenomenon elus signific mediat alcohol alcohol alcohol alcohol pairf nonalcohol heart dissect section stain cresyl violet immunohistochem caspase3 put cardiomyocyt alcohol contract relax alcohol display mark thin ventricular wall caspase3 contractil alcohol contractil protect alcohol cardiomyocyteapoptosisalcoholcontractilitycardiomyopathi introduction2 results3 discussion4 methods41 histology42 immunohistochemistry43 imag analysis44 prepar cardiomyocytes45 contract relaxation46 analysis5 conclus alcohol abus disabl issu plagu societi prevent 79000 casualti everi epidemiolog alcohol 303 experienc alcohol live excess alcohol 2235 billion healthcar expenditur contributor healthcar expens excess alcohol asymptomat alcohol cardiomyopathi acm progress ventricular wall thick output accompani electrocardiogram ecg abnorm contributor occurr delet fragment shrinkag proteolyt cleavag protea caspas apoptot alcohol render prone undergo assum reactiv ro mediat transduct cardiomyocyt caspas lethal cardiomyopathi transgen moder alcohol activ pi3kakt therebi cardioprotect antiapoptot alcohol elus yuan note explan pi3kakt inhibit caspase9 negat apoptot pi3kakt crucial mediat benefici detriment dose alcohol myocardi determin morbid limit cardiomyocyt implic therapeut aim alcohol caspase3 contractil heart alcohol avert maintain myofila architectur integr ventricular wall contractil convers alcohol detriment initi thin ventricular wall\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.772\thostmicrobiom alcohol alcohol morbid liverrel worldwid intestin overgrowth dysbiosi ethanol ingest alcohol alcohol lumen enter alter therebi disturb intestin homeostasi disrupt mucos barrier transloc microbi induc hepat discus alcohol intestin microbiom transloc ecolog balanc alcohol microbiom reveal alcohol injurymicrobiotapermeabilitymetabol introductionalcoholinduc gut microfloramicrobi transloc alcohol diseaseeffect alcohol intestin microfloraconclus alcohol beverag consum creat worldwid alcohol elucid alcohol alcohol gutliv axi gutderiv pathogen pamp lipopolysaccharid lp endotoxin transloc intestin lumen hepat steatosi fibrosi leaki gut barrier facilit microbi transloc intestin overgrowth dysbiosi promin microbiom alcohol intestin mucos barrier becom leaki transloc alcohol intestin microbiom alcohol summar exactli gut microflora barrier disturb intestin homeostasi warrant detail ethanol intestin microbiom alcohol insight alcohol reveal alcohol\n",
            "\t-3.951\talcoholinduc endoplasm reticulum organ injuri alcohol readili distribut throughout stream cross membran virtual insid excess alcohol numer patholog endoplasm reticulum unfoldedmisfold accumul contribut alcohol organ pancrea trigger alcohol indirectli alcohol includ toxic acetaldehyd homocystein perturb calcium iron homeostasi alter sadenosylmethionin sadenosylhomocystein abnorm epigenet modif interrupt trigger anticip benefit alcohol  introduction2 unfold upr3 alcohol organ injuries31 liver32 pancreas33 brain34 heart4 alcoholinduc stress41 acetaldehyd adduct stress42 homocystein stress43 samsah epigenet alter stress44 disrupt iron homeostasi stress45 synergist alcohol environments5 conclud remark alcohol social accept addict alcohol abus depend domest violenc product place traffic accidentrel injuri organ excess alcohol prevent 38 death worldwid alcoholrel alcoholinduc injuri alcohol readili distribut throughout stream cross membran virtual organ alcohol enter oxid toxic acetaldehyd catalyz cytosol alcohol dehydrogenas adh acetaldehyd convert acetaldehyd dehydrogenas aldh acet primarili alcohol oxid acetaldehyd cytochrom p450iie1 cyp2e1 gener hydrogen peroxid alcoholrel ill indirectli toxic alcohol metabolit alcohol injuri organ gastrointestin tract pancrea review alcoholinduc ald organ ald includ spectrum rang steatosi steatohepat fibrosi cirrhosi ald complet understood cofactor ald malfunct cyp2e1 endotoxin innat adapt immun hypoxia methionin epigenet modif cofactor malnutrit hcvhiv alcoholinduc perturb homeostasi endoplasm reticulum evolv contribut fatti review comprehens review alcohol accumul beyond purpos highlight phenomenolog alcoholinduc select organ discus caus alcohol \n",
            "\t-5.013\tpueraria radix extract endotoxin gutderiv endotoxin alcohol kudzu pueraria lobata earliest medicin treat alcohol abus tradit chine millennium alcohol pueraria radix extract rpe alcohol kupffer kc necrosi alpha gutderiv endotoxin macrophag rpe allevi patholog lipid deposit alanin aminotransferas alt aspart aminotransferas ast hepat gammaglutamyl transpeptidas ggt meanwhil rpe inhibit kc hepat downregul endotoxin lipopolysaccharid lbp cd14 tolllik tlr tlr4 alcohol rpe inhibit endotoxin cd14 tlr4 lp raw2647 summari rpe mitig deposit alcohol endotoxin  introduction2 prepar pre22 rpe23 treatments24 treatment25 ldh raw264726 histolog examination27 alt ast assay28 hepat ggt assay29 hepat tg assay210 endotoxin portal vein211 immunohistochem hepat cd68212 elisa213 determin cd68 endotoxin western blot214 analysis3 results31 liquid diet liverbodi ratio32 rpe live alcohol intake33 rpe hepat deposition34 endotoxin portal vein hepat concentration35 rpe kupffer endotoxin liver36 ldh raw2647 supernat cultur rpe37 rpe raw2647 supernat lp 38 rpe endotoxin lp discussion5 alcohol abus issu worldwid cover death western eastern 1980 morbid alcohol ald abruptli seriou trend china ald encompass spectrum rang steatosi hepat cirrhosi alcohol fatti fatti drop disappear abstin steatosi hepatocyt continu ingest alcohol steatohepat neutrophil infiltr hepatocyt degener balloon oncot necrosi rare recov hepat histolog ethanol withdraw alcohol steatohepat trigger patholog progress fibrosi cirrhosi ratelimit ald block revers earlyphas histopatholog steatosi steatohepat ald besid alcohol oxid endotoxin toxic lipopolysaccharid lp gut gramneg classic alcohol intestin permeabl alcohol endotoxin releas circul transport lp lpsbind lbp bind cd14 hepat kupffer kc cd14lbplp interact tolllik tlr4 trigger cascad kc activ nf promot preinflammatori necrosi alpha gut permeabl oxid perpetu progress kudzu pueraria lobata earliest medicin treat alcohol abus tradit chine millennium antidipsotrop isoflavon radix pueraria puerarin daidzin daidzein suppress ethanol rodent abolish alcohol withdraw antioxid cuzn sod catalas mitig hepat oxid ethanoltr investig radix pueraria extract rpe antialcohol comprehens rpe alcohol endotoxin gutderiv endotoxin rpe mitig deposit alcohol endotoxin\n",
            "OB,liver transaminase,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.555\ttoxin ab isol clostridium difficil clostridium perfringen dog mina gerai brazil object difficil ab toxin isol perfringen difficil diarrheic nondiarrh dog brazil stool 57 dog appar diarrheic difficil ab toxin elisa perfringen difficil multiplex difficil ab toxin 368 762 diarrheic dog 238 nondiarrh dog twelv difficil 211 ten nontoxigen nondiarrh binari toxin cdtb nondiarrh dog perfringen 702 45 diarrheic 55 belong nondiarrh classifi perfringen cpe diarrhea ten cpb2 ab toxin nondiarrh dog occurr subclin dog carriag toxin elucid epidemiolog difficil perfringen dog difficil zoonot agent binari toxin difficil dog brazil nosocomi diarrheasmal animalscolitisenteritiscanin introductionmateri methodsresult discus clostridium difficil sporeform anaerob gramposit bacillu recogn pathogen implic enter hors foal piglet rabbit silva 2013a dog difficil diarrhea difficil outbreak dog veterinari wee armstrong clooten doubt difficil agent caus diarrhea dog difficil toxin toxin enterotoxin toxin cytotoxin voth ballard difficil toxin immunoassay elisa delm binari toxin call difficil transferas cdt virul stubb cdt consist unlink chain encod separ design cdta cdtb schwan toxin adher colon bacterium date binari toxin dog perfringen anaerob sporeform gramposit bacillu outbreak diarrhea be broiler chicken pig dog hors rudmann songer uzal silva eriksen waggett silva 2013b perfringen classifi toxigen toxin alpha beta epsilon iota toxin perfringen toxin enterotoxin canin enter bowel diarrhea kruth 1989 sasaki wee beta2 toxin diarrhea pig hors herholz songer uzal silva 2013c isol toxin distribut occurr diarrhea elucid epidemiolog difficil perfringen arroyo barbut object difficil ab toxin isol perfringen difficil stool diarrheic nondiarrh dog difficil ab toxin 368 762 diarrheic dog 238 nondiarrh dog 005 toxin ab diarrhea corrobor ab toxin diarrhea dog wee mark clooten mark 38 5130 posit 80 belong diarrheic dog wee 155 22142 posit mark interest note nondiarrh ab toxin corrobor wee mark clooten occurr subclin dog carriag ab toxin histolog examin intestin nondiarrh dog toxin piglet occurr subclin ab toxin intestin microscop difficil yaeger toxin dog diarrhea difficil diarrheacaus agent dog twelv difficil diarrheic dog ten nondiarrh dog isol influenc dog 316 dog 39 684 dog diarrheic noteworthi account account nondiarrh strubl 1994 colon difficil proportion dog corrobor statement youngest age ten variant wee difficil 2142 dog stool mark strubl 1994 recov difficil 131 17130 184 28152 dog 706 toxigen variant corrobor strubl 1994 wee mark clooten date dog visit hospit lefebvr nontoxigen corrobor alvarezperez clooten colon nontoxigen reduc diarrhea difficil dog trend piglet buggi 1983 kyne silva nontoxigen competit exclus atrisk songer binari toxin nondiarrh binari toxin stool dog brazil persson cdt 973 domest binari toxin hors arroyo piglet norman silva relev pathogen cdt difficil cdt potent cytotoxin gon alv prepar toxin altern cdt synergi toxin depolymer cytoskeleton complementari note descript cdtb brazil isol toxinotyp frequenc practic cluster arroyo geograph preval genotyp difficil geograph avbersek carrier difficil vari asymptomat depend keel songer cdt highlight difficil dog difficil readytoeat retail meat salad ribotyp difficil bakri rodriguezpalacio songer note toxigen ribotyp dog 90 recogn difficil arroyo rais difficil fecal contamin dog zoonot confirm percentag isol ab toxin simultan corrobor dog strubl 1994 mark difficulti isol toxin ab fecal bacterium veget difficil persist aerob sporul viabl fece buggi 1983 grow ccfa antibiot select medium songer uzal perfringen 702 45 belong diarrheic dog 55 belong nondiarrh dog mark wee perfringen 78 80 dog stool wee mark isol diarrheic nondiarrh classifi perfringen cpe encod enterotoxin 375 171 appar nine 409 diarrheic dog corrobor frequent perfringen dog sasaki mark siqueira 005 cpe diarrhea mark ten cpb2 domest pig hors perfringen cpb2 diarrhea typhlocol herholz songer uzal silva 2013c elucid beta2 toxin perfringen diarrhea dog next minimum inhibitori antibiot clinic difficil perfringen pcrribotyp elucid epidemiolog difficil dog add difficil zoonot agent perfringen difficil dog brazil\n",
            "\t0.554\tid unit interpret clostridium difficil interpret clostridium difficil challeng laboratori combin unit demonstr basic principl strength weak illustr clostridium difficilelaboratori  68yearold woman clindamycin routin dental next wateri diarrhea clostridium difficil follow toxin pend interpret confus tri interpret antibioticassoci clostridium difficil rest assur microbiolog laboratori util optim ensur turnaround avoid delay unit concept difficil prototyp diarrheal ill difficil easi simpli pick perform detect stool colon depend adher colon mucosa pathogen difficil releas toxin toxin toxin cytotox colon indirect destruct activ difficil equip produc toxin toxin pathogen toxigen difficil live harmlessli colon produc toxin balanc antibiot immunosuppress microbiom mediat toxigen organ activ produc toxin balanc asymptomat carrier toxigen difficil toxin rise healthcar set prospect admit colon toxigen difficil facil difficil actual toxigen toxin toxin answer depend send summar summari difficil comment elisa distinguish toxigen nontoxigen elisa toxin easi perform toxigen distinguish asymptomat carriag expens elisa cytotoxin slow 2448hr gold facil enzymelink immunosorb elisa glutam dehydrogenas gdh difficil organ use gdh preserv difficil excel 90 turnaround 45 minut inexpens toxin gdh distinguish toxigen nontoxigen polymeras toxigen difficil organ polymeras use primer amplifi copi clostridium difficil amplifi toxigen difficil tcdb encod toxin tcdc encod toxin clostridium difficil toxin carri toxigen difficil sound ideal dont just expens difficil elisa costeffect distinguish toxigen nontoxigen toxin pick asymptomat carrier difficil adequ antibiot challeng interpret difficil past elisa toxin toxin use difficil toxin toxin nearli perfect excel confirm quickli 45 minut inexpens pitfal toxin 75 fals neg cytotoxin neutral toxin cytopath gold specimen prepar centrifug liquid stool harvest supernat inocul dilut onto monolay foreskin monitor interv cytotox disrupt difficil antitoxin ad monitor cytotox cytotox abrog antitoxin difficil simul clinic toxic histor prefer laboratori downsid take clinician wait 48 hour weekend delay workflow perform interpret intens reli technician introduc element user variabl cheaper faster cytotoxin fallen favor complic confus contradictori situat modal valid cytotox gold actual care difficil loo poorli form stool diarrhea pitfal laboratori combin optim ensur deliv clinician time typic algorithm combin elisa gdh elisa toxin depict toxin elisa interpret power inexpens concord get bit complic toxin indetermin explan indetermin nontoxigen difficil toxin true asymptomat carrier toxigen difficil toxin true toxigen difficil toxin fals util tie breaker certainti toxigen difficil final interpret recal distinguish asymptomat carriag distinct difficil serv remind interpret suspect identifi asymptomat carriag help ask dig old cytotoxin scratch head tempt abandon altogeth enlist cliff ador 2yearold beagl train sniff toxigen difficil unfortun effect run pitfal distinguish difficil asymptomat colon enough endors mythic pet 4leg difficil scalabl costeffect \n",
            "\t0.551\ttoxin clostridium difficil quorum clostridium difficil cdi dramat antibiot hospitalassoci diarrhea worldwid difficil multidrugresist pathogen flourish colon gut microbiota antibiot consequ produc toxin enorm pose pathogen toxin remain larg difficil toxin accessori regul quorumsign 1000da thiolacton stool cdi difficil toxin offer excit avenu difficil quorumsignalingbas nonantibiot therapi combat lifethreaten emerg pathogen  introductionresultsth difficil stationaryphas supernat toxin productionth ti stimul toxin hypervirul difficil strainsth purifi ti difficil toxin genesrol accessori regul agr ti signalmedi regulationth ti cdi stoolsdiscussiona paradigm difficil toxin pathogenesismateri methodsbacteri conditionssampl storag stockstoxin cdifftox assayii enzymelink immunosorb assayiii difficil quorumsign bioassaydialysi stationaryphas supernat fluidpurif difficil toxininduc stationaryphas supernat fluideffect purifi toxininduc hypervirul difficil tcda tcdb tcdc transcriptionrandom mutagenesismultipl align agrd genesdetect ti cdi stoolssupplementari clostridium difficil cdi annual 48 billion dollar hamper antibiot virul infect recurr preserv colon microbiota morbid cdiassoci past make difficil emerg pathogen cdi antibiot antimicrobi ineffect recurr cdi urgent nonantibiot cdi preserv colon microbiota standalon therapi adjunct therapi augment option pathogen difficil posse 196kb pathogen locu compos tcdr tcdb tcde tcda tcdc s1 supplement locu toxin encod tcda tcdb toxin difficil toxin regul encod pathogen locu tcdr tcdc tcda tcdb promot tcdr encod posit act sigma toxin promot tcdc encod regul toxin tcdc includ emerg epidem nap1027 delet frameshift tcdc toxin neither delet entir tcdc restor tcdc frameshift alter toxin difficil toxin involv discov virul pathogen quorum cellcel commun wherebi coordin consequ quorumsign enabl har energet expens potenti quorum accumul quorum sen monitor molecul coordin modul advantag act synchroni 31 difficil toxin predominantli thiolacton quorumsign tcdc profound implic toxin colon block newli quorumsign nonantibiot cdi paradigm difficil toxin\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t3.629\ttoxin clostridium difficil quorum clostridium difficil cdi dramat antibiot hospitalassoci diarrhea worldwid difficil multidrugresist pathogen flourish colon gut microbiota antibiot consequ produc toxin enorm pose pathogen toxin remain larg difficil toxin accessori regul quorumsign 1000da thiolacton stool cdi difficil toxin offer excit avenu difficil quorumsignalingbas nonantibiot therapi combat lifethreaten emerg pathogen  introductionresultsth difficil stationaryphas supernat toxin productionth ti stimul toxin hypervirul difficil strainsth purifi ti difficil toxin genesrol accessori regul agr ti signalmedi regulationth ti cdi stoolsdiscussiona paradigm difficil toxin pathogenesismateri methodsbacteri conditionssampl storag stockstoxin cdifftox assayii enzymelink immunosorb assayiii difficil quorumsign bioassaydialysi stationaryphas supernat fluidpurif difficil toxininduc stationaryphas supernat fluideffect purifi toxininduc hypervirul difficil tcda tcdb tcdc transcriptionrandom mutagenesismultipl align agrd genesdetect ti cdi stoolssupplementari clostridium difficil cdi annual 48 billion dollar hamper antibiot virul infect recurr preserv colon microbiota morbid cdiassoci past make difficil emerg pathogen cdi antibiot antimicrobi ineffect recurr cdi urgent nonantibiot cdi preserv colon microbiota standalon therapi adjunct therapi augment option pathogen difficil posse 196kb pathogen locu compos tcdr tcdb tcde tcda tcdc s1 supplement locu toxin encod tcda tcdb toxin difficil toxin regul encod pathogen locu tcdr tcdc tcda tcdb promot tcdr encod posit act sigma toxin promot tcdc encod regul toxin tcdc includ emerg epidem nap1027 delet frameshift tcdc toxin neither delet entir tcdc restor tcdc frameshift alter toxin difficil toxin involv discov virul pathogen quorum cellcel commun wherebi coordin consequ quorumsign enabl har energet expens potenti quorum accumul quorum sen monitor molecul coordin modul advantag act synchroni 31 difficil toxin predominantli thiolacton quorumsign tcdc profound implic toxin colon block newli quorumsign nonantibiot cdi paradigm difficil toxin\n",
            "\t3.129\tclostridium difficil gastrointestin complaint difficil gastrointestin complaint enteropathogen microb enterotoxin cytotoxin toxin toxin difficil stool doubl sandwich enzymelink immunosorb commerci kit premier toxin gener inc germani microbi isol done 356 576 424 difficil 53 337 946 difficil kit exist difficil toxin microbi antibiot usag support probabl cdifficil gastrointestin complaint diarrhea difficil  introductionpati methodsresultsdiscuss introduct clostridium difficil cdifficil 90 pseudomembran coliti diarrhea antibiot manifest asymptomat colon diarrhea pseudomembran coliti pmc toxic megacolon cdifficil produc toxin toxin enterotoxin toxin cytotoxin colon mucos cdifficil toxin pathogen detect toxin toxin extens initi toxin toxin review toxin toxin possibl virul pathogen decis allow clinician take adequ control nosocomi spread difficil toxin iran laboratori reach definit difficil reliabl toxin gold cytotox toxin util preincub neutral toxin cytotox picogram toxin stool 94100 99 take facil immunosorb elisa toxin stool 1001000 picogram toxin 6694 9298 believ infecti introduct proper control difficil gastrointestin 356 stool refer depart foodborn diarrheal taleghani tehran complaint abdomin flatul tenesmu diarrhea dysenteri stool cultur pathogen fungi cryptosporidium spp parasit modifi acidfast stain enterotoxin cytotoxin toxin toxin difficil stool specimen doubl sandwich enzymelink immunosorb commerci kit premier toxin gener inc germani manufactur instruct 356 576 424 refer depart foodborn diarrheal difficil 53 cdifficil gastrointestin complaint gender gender difficil gastrointestin complaint 63 192 636 205 576 145 96 151 423 53 337 946 356 enter pathogen intestin parasit found nonpathogen parasit ecoli 51 ibottch 356 gi abdomin diarrhea 315 nausea 285 vomit 102 485 356 recruit stool 284 stool 72 2022 diarrheic stool 356 46 antibiot gastrointestin difficil compar noninfect gastrointestin difficil noninfect abdomin 45 diarrhea 45 nausea 52 146 vomit 82 42 385 286 discus difficil organ peopl caus coliti predispos actor antibiot difficil toxin damag fragil line bowel caus loo wateri bowel movement diarrhea organ acquir contamin worker carri hand contamin instrument rapid ea elisa toxin laboratori difficil difficil 53 gastrointestin complaint iran difficil 61 nosocomi diarrhea diarrhea iran 49 turkish diarrhea 46 toxigen difficil take antibiot sampl 964 antibiot iran hospit toxigen cdifficil stool antibiot sampl brazil difficil 55 hospit diarrhea argentina 385 difficil symptomat elisa 99 75 85 cdifficil toxin cdifficil pathogen gastrointestin complaint deni antibiot admiss hospit consequ organ microenviron difficil organ peopl caus coliti predispos actor antibiot difficil toxin damag fragil line bowel caus loo wateri bowel movement diarrhea organ acquir contamin worker carri hand contamin instrument rapid ea elisa toxin laboratori difficil difficil 53 gastrointestin complaint iran difficil 61 nosocomi diarrhea diarrhea iran 49 turkish diarrhea 46 toxigen difficil take antibiot sampl 964 antibiot iran hospit toxigen cdifficil stool antibiot sampl brazil difficil 55 hospit diarrhea argentina 385 difficil symptomat elisa 99 75 85 cdifficil toxin cdifficil pathogen gastrointestin complaint deni antibiot admiss hospit consequ organ microenviron\n",
            "\t2.734\tclostridium difficil nap1027 mexican clostridium difficil nap1ribotyp 027 nap1ribotyp 027 difficil tertiari 106 stool 106 toxin cultur ccfa agar tcda tcdb tcdc cdta cdtb amplifi tcda delet pcrribotyp pulsedfield gel electrophoresi pfge stool genexpert difficil thirtysix toxin difficil toxin genexpert difficil stay 161 toxin antibiot 162 median antibiot 30day crude 84 die death attribut difficil 909 2022 carri tcdb tcda cdta cdtb carri correspond downregul tcdc 18bp delet pfge ribotyp clonal spread difficil institut includ nap1027 difficil ribotyp nap1027 mexico  introductionmateri methodseth statementstudi datadetect infectionanalysi tcda tcdb cdta cdtb analysisprim type difficil tcd tcd intern infram delet tcda delet analysisgenexpert difficil pcrribotypingpulsedfield gel electrophoresi pfgecontrol strainstatist analysisresultsclin patientsdistribut populationcomparison patientsisolatespres cytoleth distend toxin cdt locu difficil testeddiscuss clostridium difficil gramposit anaerob bacterium spore fatal diarrheal princip virul toxin toxin encod tcda tcdb 21kilobas section chromosom pathogen locu paloc tcdc encod regul toxin toxin virul aberr tcdc genotyp toxin toxin binari toxin encod ctda ctdb outsid paloc spore anaerob bacterium distribut environ ingest gut microflora contribut colon spectrum difficil cdi start asymptomat carriag diarrhea progress pseudomembran coliti toxic megacolon epidemiolog difficil chang past decad emerg polymeras ribotyp rt 027north american pul napfield 01 outbreak canada usa europ difficil nap1027 present morbid present financi burden latin america costa rica chile mexico cdi demonstr risk cdi h2 blocker hospit intens unit cephalosporin fluoroquinolon clindamycin mexican nap1027 difficil tertiari difficil nosocomi pathogen diarrheal difficil ribotyp nap1027 mexico cdi immunocard screen 106 probabl cdi 36 immunocard difficil immunocard manufactur immunocard 952 985 predict 99 immunocard miss object perform accur stool specimen cdi predict predict recommend prefer cdi difficil cytotoxigen cytotoxin gold standard bia confirm implement ten acquir difficil die ribotyp nap1027 441 65 81 die 136 die cdi 676 consid 44 36 toxinposit plu cultureposit immunocardneg attribut cdi 68 344 epidemiolog link cdi nap1027 difficil cost stay hospitalacquir difficil extend stay difficil nosocomi infecti agent reservoir healthcar worker cdi antibiot preced stay 161 toxin antibiot 162 median antibiot type difficil mostli type scheme restrict epidem clone bi pfge epidem clone nap1 ribotyp epidem clone ribotyp 027 pfge exhibit discriminatori ribotyp 0843 0688 methodolog clonal ribotyp easier perform pfge labori present ribotyp nap1027 non027 ribotyp nap1027 excess amount toxin tcdc delet ribotyp nap1027 dissemin ward special avoid spread ribotyp summari clonal spread difficil institut includ ribotyp nap1027 clonal spread difficil mayor concern healthcar isol difficil nap1027 ongo surveil polici clorin disinfect isol precaut reinforc confirm emerg difficil mexico surveil dissemin establish bacterium healthcar facil difficil ribotyp nap1027 mexico\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.555\ttoxin ab isol clostridium difficil clostridium perfringen dog mina gerai brazil object difficil ab toxin isol perfringen difficil diarrheic nondiarrh dog brazil stool 57 dog appar diarrheic difficil ab toxin elisa perfringen difficil multiplex difficil ab toxin 368 762 diarrheic dog 238 nondiarrh dog twelv difficil 211 ten nontoxigen nondiarrh binari toxin cdtb nondiarrh dog perfringen 702 45 diarrheic 55 belong nondiarrh classifi perfringen cpe diarrhea ten cpb2 ab toxin nondiarrh dog occurr subclin dog carriag toxin elucid epidemiolog difficil perfringen dog difficil zoonot agent binari toxin difficil dog brazil nosocomi diarrheasmal animalscolitisenteritiscanin introductionmateri methodsresult discus clostridium difficil sporeform anaerob gramposit bacillu recogn pathogen implic enter hors foal piglet rabbit silva 2013a dog difficil diarrhea difficil outbreak dog veterinari wee armstrong clooten doubt difficil agent caus diarrhea dog difficil toxin toxin enterotoxin toxin cytotoxin voth ballard difficil toxin immunoassay elisa delm binari toxin call difficil transferas cdt virul stubb cdt consist unlink chain encod separ design cdta cdtb schwan toxin adher colon bacterium date binari toxin dog perfringen anaerob sporeform gramposit bacillu outbreak diarrhea be broiler chicken pig dog hors rudmann songer uzal silva eriksen waggett silva 2013b perfringen classifi toxigen toxin alpha beta epsilon iota toxin perfringen toxin enterotoxin canin enter bowel diarrhea kruth 1989 sasaki wee beta2 toxin diarrhea pig hors herholz songer uzal silva 2013c isol toxin distribut occurr diarrhea elucid epidemiolog difficil perfringen arroyo barbut object difficil ab toxin isol perfringen difficil stool diarrheic nondiarrh dog difficil ab toxin 368 762 diarrheic dog 238 nondiarrh dog 005 toxin ab diarrhea corrobor ab toxin diarrhea dog wee mark clooten mark 38 5130 posit 80 belong diarrheic dog wee 155 22142 posit mark interest note nondiarrh ab toxin corrobor wee mark clooten occurr subclin dog carriag ab toxin histolog examin intestin nondiarrh dog toxin piglet occurr subclin ab toxin intestin microscop difficil yaeger toxin dog diarrhea difficil diarrheacaus agent dog twelv difficil diarrheic dog ten nondiarrh dog isol influenc dog 316 dog 39 684 dog diarrheic noteworthi account account nondiarrh strubl 1994 colon difficil proportion dog corrobor statement youngest age ten variant wee difficil 2142 dog stool mark strubl 1994 recov difficil 131 17130 184 28152 dog 706 toxigen variant corrobor strubl 1994 wee mark clooten date dog visit hospit lefebvr nontoxigen corrobor alvarezperez clooten colon nontoxigen reduc diarrhea difficil dog trend piglet buggi 1983 kyne silva nontoxigen competit exclus atrisk songer binari toxin nondiarrh binari toxin stool dog brazil persson cdt 973 domest binari toxin hors arroyo piglet norman silva relev pathogen cdt difficil cdt potent cytotoxin gon alv prepar toxin altern cdt synergi toxin depolymer cytoskeleton complementari note descript cdtb brazil isol toxinotyp frequenc practic cluster arroyo geograph preval genotyp difficil geograph avbersek carrier difficil vari asymptomat depend keel songer cdt highlight difficil dog difficil readytoeat retail meat salad ribotyp difficil bakri rodriguezpalacio songer note toxigen ribotyp dog 90 recogn difficil arroyo rais difficil fecal contamin dog zoonot confirm percentag isol ab toxin simultan corrobor dog strubl 1994 mark difficulti isol toxin ab fecal bacterium veget difficil persist aerob sporul viabl fece buggi 1983 grow ccfa antibiot select medium songer uzal perfringen 702 45 belong diarrheic dog 55 belong nondiarrh dog mark wee perfringen 78 80 dog stool wee mark isol diarrheic nondiarrh classifi perfringen cpe encod enterotoxin 375 171 appar nine 409 diarrheic dog corrobor frequent perfringen dog sasaki mark siqueira 005 cpe diarrhea mark ten cpb2 domest pig hors perfringen cpb2 diarrhea typhlocol herholz songer uzal silva 2013c elucid beta2 toxin perfringen diarrhea dog next minimum inhibitori antibiot clinic difficil perfringen pcrribotyp elucid epidemiolog difficil dog add difficil zoonot agent perfringen difficil dog brazil\n",
            "\t0.554\tid unit interpret clostridium difficil interpret clostridium difficil challeng laboratori combin unit demonstr basic principl strength weak illustr clostridium difficilelaboratori  68yearold woman clindamycin routin dental next wateri diarrhea clostridium difficil follow toxin pend interpret confus tri interpret antibioticassoci clostridium difficil rest assur microbiolog laboratori util optim ensur turnaround avoid delay unit concept difficil prototyp diarrheal ill difficil easi simpli pick perform detect stool colon depend adher colon mucosa pathogen difficil releas toxin toxin toxin cytotox colon indirect destruct activ difficil equip produc toxin toxin pathogen toxigen difficil live harmlessli colon produc toxin balanc antibiot immunosuppress microbiom mediat toxigen organ activ produc toxin balanc asymptomat carrier toxigen difficil toxin rise healthcar set prospect admit colon toxigen difficil facil difficil actual toxigen toxin toxin answer depend send summar summari difficil comment elisa distinguish toxigen nontoxigen elisa toxin easi perform toxigen distinguish asymptomat carriag expens elisa cytotoxin slow 2448hr gold facil enzymelink immunosorb elisa glutam dehydrogenas gdh difficil organ use gdh preserv difficil excel 90 turnaround 45 minut inexpens toxin gdh distinguish toxigen nontoxigen polymeras toxigen difficil organ polymeras use primer amplifi copi clostridium difficil amplifi toxigen difficil tcdb encod toxin tcdc encod toxin clostridium difficil toxin carri toxigen difficil sound ideal dont just expens difficil elisa costeffect distinguish toxigen nontoxigen toxin pick asymptomat carrier difficil adequ antibiot challeng interpret difficil past elisa toxin toxin use difficil toxin toxin nearli perfect excel confirm quickli 45 minut inexpens pitfal toxin 75 fals neg cytotoxin neutral toxin cytopath gold specimen prepar centrifug liquid stool harvest supernat inocul dilut onto monolay foreskin monitor interv cytotox disrupt difficil antitoxin ad monitor cytotox cytotox abrog antitoxin difficil simul clinic toxic histor prefer laboratori downsid take clinician wait 48 hour weekend delay workflow perform interpret intens reli technician introduc element user variabl cheaper faster cytotoxin fallen favor complic confus contradictori situat modal valid cytotox gold actual care difficil loo poorli form stool diarrhea pitfal laboratori combin optim ensur deliv clinician time typic algorithm combin elisa gdh elisa toxin depict toxin elisa interpret power inexpens concord get bit complic toxin indetermin explan indetermin nontoxigen difficil toxin true asymptomat carrier toxigen difficil toxin true toxigen difficil toxin fals util tie breaker certainti toxigen difficil final interpret recal distinguish asymptomat carriag distinct difficil serv remind interpret suspect identifi asymptomat carriag help ask dig old cytotoxin scratch head tempt abandon altogeth enlist cliff ador 2yearold beagl train sniff toxigen difficil unfortun effect run pitfal distinguish difficil asymptomat colon enough endors mythic pet 4leg difficil scalabl costeffect \n",
            "\t0.551\ttoxin clostridium difficil quorum clostridium difficil cdi dramat antibiot hospitalassoci diarrhea worldwid difficil multidrugresist pathogen flourish colon gut microbiota antibiot consequ produc toxin enorm pose pathogen toxin remain larg difficil toxin accessori regul quorumsign 1000da thiolacton stool cdi difficil toxin offer excit avenu difficil quorumsignalingbas nonantibiot therapi combat lifethreaten emerg pathogen  introductionresultsth difficil stationaryphas supernat toxin productionth ti stimul toxin hypervirul difficil strainsth purifi ti difficil toxin genesrol accessori regul agr ti signalmedi regulationth ti cdi stoolsdiscussiona paradigm difficil toxin pathogenesismateri methodsbacteri conditionssampl storag stockstoxin cdifftox assayii enzymelink immunosorb assayiii difficil quorumsign bioassaydialysi stationaryphas supernat fluidpurif difficil toxininduc stationaryphas supernat fluideffect purifi toxininduc hypervirul difficil tcda tcdb tcdc transcriptionrandom mutagenesismultipl align agrd genesdetect ti cdi stoolssupplementari clostridium difficil cdi annual 48 billion dollar hamper antibiot virul infect recurr preserv colon microbiota morbid cdiassoci past make difficil emerg pathogen cdi antibiot antimicrobi ineffect recurr cdi urgent nonantibiot cdi preserv colon microbiota standalon therapi adjunct therapi augment option pathogen difficil posse 196kb pathogen locu compos tcdr tcdb tcde tcda tcdc s1 supplement locu toxin encod tcda tcdb toxin difficil toxin regul encod pathogen locu tcdr tcdc tcda tcdb promot tcdr encod posit act sigma toxin promot tcdc encod regul toxin tcdc includ emerg epidem nap1027 delet frameshift tcdc toxin neither delet entir tcdc restor tcdc frameshift alter toxin difficil toxin involv discov virul pathogen quorum cellcel commun wherebi coordin consequ quorumsign enabl har energet expens potenti quorum accumul quorum sen monitor molecul coordin modul advantag act synchroni 31 difficil toxin predominantli thiolacton quorumsign tcdc profound implic toxin colon block newli quorumsign nonantibiot cdi paradigm difficil toxin\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t3.629\ttoxin clostridium difficil quorum clostridium difficil cdi dramat antibiot hospitalassoci diarrhea worldwid difficil multidrugresist pathogen flourish colon gut microbiota antibiot consequ produc toxin enorm pose pathogen toxin remain larg difficil toxin accessori regul quorumsign 1000da thiolacton stool cdi difficil toxin offer excit avenu difficil quorumsignalingbas nonantibiot therapi combat lifethreaten emerg pathogen  introductionresultsth difficil stationaryphas supernat toxin productionth ti stimul toxin hypervirul difficil strainsth purifi ti difficil toxin genesrol accessori regul agr ti signalmedi regulationth ti cdi stoolsdiscussiona paradigm difficil toxin pathogenesismateri methodsbacteri conditionssampl storag stockstoxin cdifftox assayii enzymelink immunosorb assayiii difficil quorumsign bioassaydialysi stationaryphas supernat fluidpurif difficil toxininduc stationaryphas supernat fluideffect purifi toxininduc hypervirul difficil tcda tcdb tcdc transcriptionrandom mutagenesismultipl align agrd genesdetect ti cdi stoolssupplementari clostridium difficil cdi annual 48 billion dollar hamper antibiot virul infect recurr preserv colon microbiota morbid cdiassoci past make difficil emerg pathogen cdi antibiot antimicrobi ineffect recurr cdi urgent nonantibiot cdi preserv colon microbiota standalon therapi adjunct therapi augment option pathogen difficil posse 196kb pathogen locu compos tcdr tcdb tcde tcda tcdc s1 supplement locu toxin encod tcda tcdb toxin difficil toxin regul encod pathogen locu tcdr tcdc tcda tcdb promot tcdr encod posit act sigma toxin promot tcdc encod regul toxin tcdc includ emerg epidem nap1027 delet frameshift tcdc toxin neither delet entir tcdc restor tcdc frameshift alter toxin difficil toxin involv discov virul pathogen quorum cellcel commun wherebi coordin consequ quorumsign enabl har energet expens potenti quorum accumul quorum sen monitor molecul coordin modul advantag act synchroni 31 difficil toxin predominantli thiolacton quorumsign tcdc profound implic toxin colon block newli quorumsign nonantibiot cdi paradigm difficil toxin\n",
            "\t3.129\tclostridium difficil gastrointestin complaint difficil gastrointestin complaint enteropathogen microb enterotoxin cytotoxin toxin toxin difficil stool doubl sandwich enzymelink immunosorb commerci kit premier toxin gener inc germani microbi isol done 356 576 424 difficil 53 337 946 difficil kit exist difficil toxin microbi antibiot usag support probabl cdifficil gastrointestin complaint diarrhea difficil  introductionpati methodsresultsdiscuss introduct clostridium difficil cdifficil 90 pseudomembran coliti diarrhea antibiot manifest asymptomat colon diarrhea pseudomembran coliti pmc toxic megacolon cdifficil produc toxin toxin enterotoxin toxin cytotoxin colon mucos cdifficil toxin pathogen detect toxin toxin extens initi toxin toxin review toxin toxin possibl virul pathogen decis allow clinician take adequ control nosocomi spread difficil toxin iran laboratori reach definit difficil reliabl toxin gold cytotox toxin util preincub neutral toxin cytotox picogram toxin stool 94100 99 take facil immunosorb elisa toxin stool 1001000 picogram toxin 6694 9298 believ infecti introduct proper control difficil gastrointestin 356 stool refer depart foodborn diarrheal taleghani tehran complaint abdomin flatul tenesmu diarrhea dysenteri stool cultur pathogen fungi cryptosporidium spp parasit modifi acidfast stain enterotoxin cytotoxin toxin toxin difficil stool specimen doubl sandwich enzymelink immunosorb commerci kit premier toxin gener inc germani manufactur instruct 356 576 424 refer depart foodborn diarrheal difficil 53 cdifficil gastrointestin complaint gender gender difficil gastrointestin complaint 63 192 636 205 576 145 96 151 423 53 337 946 356 enter pathogen intestin parasit found nonpathogen parasit ecoli 51 ibottch 356 gi abdomin diarrhea 315 nausea 285 vomit 102 485 356 recruit stool 284 stool 72 2022 diarrheic stool 356 46 antibiot gastrointestin difficil compar noninfect gastrointestin difficil noninfect abdomin 45 diarrhea 45 nausea 52 146 vomit 82 42 385 286 discus difficil organ peopl caus coliti predispos actor antibiot difficil toxin damag fragil line bowel caus loo wateri bowel movement diarrhea organ acquir contamin worker carri hand contamin instrument rapid ea elisa toxin laboratori difficil difficil 53 gastrointestin complaint iran difficil 61 nosocomi diarrhea diarrhea iran 49 turkish diarrhea 46 toxigen difficil take antibiot sampl 964 antibiot iran hospit toxigen cdifficil stool antibiot sampl brazil difficil 55 hospit diarrhea argentina 385 difficil symptomat elisa 99 75 85 cdifficil toxin cdifficil pathogen gastrointestin complaint deni antibiot admiss hospit consequ organ microenviron difficil organ peopl caus coliti predispos actor antibiot difficil toxin damag fragil line bowel caus loo wateri bowel movement diarrhea organ acquir contamin worker carri hand contamin instrument rapid ea elisa toxin laboratori difficil difficil 53 gastrointestin complaint iran difficil 61 nosocomi diarrhea diarrhea iran 49 turkish diarrhea 46 toxigen difficil take antibiot sampl 964 antibiot iran hospit toxigen cdifficil stool antibiot sampl brazil difficil 55 hospit diarrhea argentina 385 difficil symptomat elisa 99 75 85 cdifficil toxin cdifficil pathogen gastrointestin complaint deni antibiot admiss hospit consequ organ microenviron\n",
            "\t2.734\tclostridium difficil nap1027 mexican clostridium difficil nap1ribotyp 027 nap1ribotyp 027 difficil tertiari 106 stool 106 toxin cultur ccfa agar tcda tcdb tcdc cdta cdtb amplifi tcda delet pcrribotyp pulsedfield gel electrophoresi pfge stool genexpert difficil thirtysix toxin difficil toxin genexpert difficil stay 161 toxin antibiot 162 median antibiot 30day crude 84 die death attribut difficil 909 2022 carri tcdb tcda cdta cdtb carri correspond downregul tcdc 18bp delet pfge ribotyp clonal spread difficil institut includ nap1027 difficil ribotyp nap1027 mexico  introductionmateri methodseth statementstudi datadetect infectionanalysi tcda tcdb cdta cdtb analysisprim type difficil tcd tcd intern infram delet tcda delet analysisgenexpert difficil pcrribotypingpulsedfield gel electrophoresi pfgecontrol strainstatist analysisresultsclin patientsdistribut populationcomparison patientsisolatespres cytoleth distend toxin cdt locu difficil testeddiscuss clostridium difficil gramposit anaerob bacterium spore fatal diarrheal princip virul toxin toxin encod tcda tcdb 21kilobas section chromosom pathogen locu paloc tcdc encod regul toxin toxin virul aberr tcdc genotyp toxin toxin binari toxin encod ctda ctdb outsid paloc spore anaerob bacterium distribut environ ingest gut microflora contribut colon spectrum difficil cdi start asymptomat carriag diarrhea progress pseudomembran coliti toxic megacolon epidemiolog difficil chang past decad emerg polymeras ribotyp rt 027north american pul napfield 01 outbreak canada usa europ difficil nap1027 present morbid present financi burden latin america costa rica chile mexico cdi demonstr risk cdi h2 blocker hospit intens unit cephalosporin fluoroquinolon clindamycin mexican nap1027 difficil tertiari difficil nosocomi pathogen diarrheal difficil ribotyp nap1027 mexico cdi immunocard screen 106 probabl cdi 36 immunocard difficil immunocard manufactur immunocard 952 985 predict 99 immunocard miss object perform accur stool specimen cdi predict predict recommend prefer cdi difficil cytotoxigen cytotoxin gold standard bia confirm implement ten acquir difficil die ribotyp nap1027 441 65 81 die 136 die cdi 676 consid 44 36 toxinposit plu cultureposit immunocardneg attribut cdi 68 344 epidemiolog link cdi nap1027 difficil cost stay hospitalacquir difficil extend stay difficil nosocomi infecti agent reservoir healthcar worker cdi antibiot preced stay 161 toxin antibiot 162 median antibiot type difficil mostli type scheme restrict epidem clone bi pfge epidem clone nap1 ribotyp epidem clone ribotyp 027 pfge exhibit discriminatori ribotyp 0843 0688 methodolog clonal ribotyp easier perform pfge labori present ribotyp nap1027 non027 ribotyp nap1027 excess amount toxin tcdc delet ribotyp nap1027 dissemin ward special avoid spread ribotyp summari clonal spread difficil institut includ ribotyp nap1027 clonal spread difficil mayor concern healthcar isol difficil nap1027 ongo surveil polici clorin disinfect isol precaut reinforc confirm emerg difficil mexico surveil dissemin establish bacterium healthcar facil difficil ribotyp nap1027 mexico\n",
            "stroke,Clostridium difficile toxin None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.408\tthoracolumbar scoliosi proteu proteu p congenit hamartomat malform spinal deform present scoliosi occur set p explor 17yearold chine scoliosi hemihypertrophi upper extrem exostosi leg joint hip knee ankl toe manifest suggest p underw posterior correct thorac 2lumbar t5 l4 mosssi spinal 3month followup clinic balanc plain radiograph solid spine fusion deform correct scoliosi p progress aggrav correct extens spinal deform adequ interdisciplinari  introductionconsentcas reportdiscussionconclus proteu p patchi segment overgrowth organ connect nevus epiderm nevus lymphat malform craniofaci hyperostosi cohen hayden 1979 dietrich titl diver somat manifest greek god proteu properli confus syndrom klippel trenaunay weber neurofibromatosi mafucci 200 p malform exact embryolog origin p subject discus p result scoliosi p 17yearold girl unusu present scoliosi p p scoliosi challeng scoliosi p etiolog manifest clearer scoliosi p progress aggrav correct extens spinal deform consid recommend\n",
            "\t0.408\tthoracolumbar scoliosi proteu proteu p congenit hamartomat malform spinal deform present scoliosi occur set p explor 17yearold chine scoliosi hemihypertrophi upper extrem exostosi leg joint hip knee ankl toe manifest suggest p underw posterior correct thorac 2lumbar t5 l4 mosssi spinal 3month followup clinic balanc plain radiograph solid spine fusion deform correct scoliosi p progress aggrav correct extens spinal deform adequ interdisciplinari  introductionconsentcas reportdiscussionconclus proteu p patchi segment overgrowth organ connect nevus epiderm nevus lymphat malform craniofaci hyperostosi cohen hayden 1979 dietrich titl diver somat manifest greek god proteu properli confus syndrom klippel trenaunay weber neurofibromatosi mafucci 200 p malform exact embryolog origin p subject discus p result scoliosi p 17yearold girl unusu present scoliosi p p scoliosi challeng scoliosi p etiolog manifest clearer scoliosi p progress aggrav correct extens spinal deform consid recommend\n",
            "\t0.398\tjuvenil sclerosi   introductionobjectivesmethodsresultsconclusiondisclosur introduct sclerosi childhood fibrosi intern organ vasculopathi juvenil sclerosi jssc repres scleroderma conclus diffus cutan subtyp jssc preval pediatr rheumatolog center raynaud phenomenon capillaroscop abnorm univers present intern organ clinic silent disclosur\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.590\tscoliosi internet china popular search onlin consider scoliosi obtain scoliosi internet onlin vari depend china restrict internet outsid border scoliosi onlin recogn score analyz internet china surveybas questionnair distribut 280 respond outpati clinic demograph internet binari logist predictor internet top scoliosi websit search engin review surgeon onlin discern jama benchmark internet scoliosi 878 respond colleg internet home urban resid predictor internet onlin scoliosi discern 279 117 mislead scoliosi outlin scoliosi internet 878 scoliosi outpati clinic search scoliosi internet urban internet home predictor internet search onlin scoliosi confus websit seem contain reliabl  introductionmateri methodseth statementsubjectsanalysi questionnaireinstrument score scoliosisrel websitesflow chart websit search popular search enginesstatisticsresultssubjectsdemograph detail questionnaireanalysi questionnaireresult internet usag respondentsresult question ass search respondentsbinari logist regress internet scoliosi informationinstrument score scoliosisrel websitesdescript websit evaluatedaverag discern jama benchmark descript categorydiscussionconclusionssupport informationquestionnair distribut outpati studydiscern score internet commun search healthrel internet widespread 525 internet user search topic help ill websit consult contain onlin concern incorrect bias perspect make outpati consult challeng poll internet healthrel 86 believ reliabl 64 report internet impact decis internet scoliosi internet onlin commun clinician demand onlin internet usag vari drastic depend primarili background econom respect scoliosi baker correct posse insur predictor internet usag scoliosi ireland wellburn scoliosi internet unregul nason onlin fals interpret misl person consider region diseaserel internet countri internet cultur access websit languag access consider concern scoliosi onlin carri internet countri document onlin scoliosi china internet recogn score object analyz internet china countri 878 scoliosi outpati clinic search scoliosi internet urban internet home potenti predictor internet onlin scoliosi confus websit contain reliabl commerci nonphysician websit benefici healthcar provid govern hospit internet servic provid collabor creat conveni reliabl internet platform\n",
            "\t-2.374\tsyndrom scoliosi syndrom histor scoliosi marfan neurofibromatosi syndrom group etiolog scoliosi syndrom scoliosi periop pauciti collect complic pubm embas databas search encompass undergo correct scoliosi syndrom scoliosi exclus articl collect complic articl categor special discus complic trend note univers nearli wound rett 292 dural tear marfan ehlersdanlo implant praderwilli pseudarthrosi ehlersdanlo syndrom classic group umbrella term syndrom ailment preoper intraop postop set  introductionmethodsresultsmarfan syndromedown syndromerett syndromeneurofibromatosisehlersdanlososteogenesi imperfectapraderwillifriedreich ataxiadiscussioncompl surgic ai conclusioncons scoliosi pediatr tradit classifi idiopath congenit neuromuscular syndrom etiolog syndrom scoliosi recogn scoliosi scoliosi marfan neurofibromatosi rett achondroplasia ehlersdanlo praderwilli friedrich ataxia osteogenesi imperfecta scoliosi usag umbrella term syndrom scoliosi pauciti discus entiti collect complic complic syndrom scoliosi scoliosi neurolog compromis nonidiopath scoliosi neuromuscular transfus idiopath scoliosi note nonidiopath comorbid idiopath syndrom result spinal deform comorbid complic syndrom scoliosi allow articl collect syndrom scoliosi special periop purpos syndrom view categori delin idiopath congenit neuromuscular scoliosi scoliosi syndrom intraop postop anecdot gap specif complic profil ai compar neuromuscular scoliosi issu discus syndrom beyond issu deal handicap syndrom umbrella syndrom scoliosi present ad challeng rehabilit solut minim multidisciplinari integr nurs anesthesia provid rett integr periop overst fluid resuscit transfus protocol detail hope ad detail interdisciplinari predict safer surgeri rariti syndrom establish track provid protocol tailor serv improv spinal abnorm perhap chief articl rang decad constantli evolv technolog anesthet periop dramat acknowledg confound post oper report unabl stratifi consist intermedi complic syndrom scoliosi believ surgeri benefici notabl except paper disappoint reward syndrom scoliosi quantiti pinpoint intraop postop challeng forward consolid consid syndrom scoliosi consent\n",
            "\t-2.453\tscoliosi parkinson scoliosi parkinson pd elderli pd scoliosi direct scoliosi later domin pd dopaminerg pharmacotherapi scoliosi spinal curvatur deviat compris 97 42 55 idiopath pd submit wholespin scanograph scoliosi cobb true scoliosi 97 pd 0006 scoliosi scoliosi 665 92 728 73 sd 0001 pd later scoliosi occurr scoliosi differ novo levodopa ldopatr neither ldopa later pd appear scoliosi parkinson diseasescoliosislevodopa introductionmethodspatientsradiolog analysisresultsdiscuss scoliosi later curvatur spine vertebr rotat asymmetr deform trunk parkinson pd direct scoliosi congruou later sign pd scoliosi close nigrostriat dopamin defici contradictori dopaminerg pharmacotherapi direct scoliosi pd poorli understood divid pd spinal curvatur spinal asymmetri non scoliosi true scoliosi later pd direct scoliosi dopaminerg pharmacotherapi scoliosi pd scoliosi later curvatur spine rotat scoliosi elderli vari rise pd rang 43 90 ashour jankov scoliosi 164 pd 85 retrospect radiolog 97 pd 33 scoliosi deviat hormon biomechan neuromuscular scoliosi pd exact pathophysiolog understood accord frequent dystonia pd scoliosi seven pd counterpart oldag pd scoliosi pd duvoisin marsden consecut unoper pd direct postur deviat later sign parkinson scoliosi analog unilater destruct dopaminerg nigrostriat aris zona compacta substantia nigra nervou scoliosi axial dystonia camptocormia pisa scoliosi bilater ascend dopamin later pd parkinsonian deficit direct scoliosi direct scoliosi later parkinsonian sign dyston postur ldopa scoliosi nigrostriat dopamin defici caus scoliosi degen scoliosi lordosi axial rotat later listhesi spondylolisthesi scoliosi spinal abnorm explan osteoporosi scoliosi lumbar degen scoliosi osteoporosi lumbar scoliosi elderli osteoporosi scoliosi scoliosi elderli osteoporosi 389 36 scoliosi lumbar degen scoliosi osteoporosi mild pd make compar pd limit discern base scoliosi contain elderli mild scoliosi spite scoliosi pd manifest pd updr direct scoliosi convex later pd dyston postur ldopa pdassoci dystonia ldopa pdassoci scoliosi scoliosi pd curvatur scoliosi pd scoliosi scoliosi pd pd domin updr ldopa compar concord nonconcord direct scoliosi later sign parkinson ldopa\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.408\tthoracolumbar scoliosi proteu proteu p congenit hamartomat malform spinal deform present scoliosi occur set p explor 17yearold chine scoliosi hemihypertrophi upper extrem exostosi leg joint hip knee ankl toe manifest suggest p underw posterior correct thorac 2lumbar t5 l4 mosssi spinal 3month followup clinic balanc plain radiograph solid spine fusion deform correct scoliosi p progress aggrav correct extens spinal deform adequ interdisciplinari  introductionconsentcas reportdiscussionconclus proteu p patchi segment overgrowth organ connect nevus epiderm nevus lymphat malform craniofaci hyperostosi cohen hayden 1979 dietrich titl diver somat manifest greek god proteu properli confus syndrom klippel trenaunay weber neurofibromatosi mafucci 200 p malform exact embryolog origin p subject discus p result scoliosi p 17yearold girl unusu present scoliosi p p scoliosi challeng scoliosi p etiolog manifest clearer scoliosi p progress aggrav correct extens spinal deform consid recommend\n",
            "\t0.408\tthoracolumbar scoliosi proteu proteu p congenit hamartomat malform spinal deform present scoliosi occur set p explor 17yearold chine scoliosi hemihypertrophi upper extrem exostosi leg joint hip knee ankl toe manifest suggest p underw posterior correct thorac 2lumbar t5 l4 mosssi spinal 3month followup clinic balanc plain radiograph solid spine fusion deform correct scoliosi p progress aggrav correct extens spinal deform adequ interdisciplinari  introductionconsentcas reportdiscussionconclus proteu p patchi segment overgrowth organ connect nevus epiderm nevus lymphat malform craniofaci hyperostosi cohen hayden 1979 dietrich titl diver somat manifest greek god proteu properli confus syndrom klippel trenaunay weber neurofibromatosi mafucci 200 p malform exact embryolog origin p subject discus p result scoliosi p 17yearold girl unusu present scoliosi p p scoliosi challeng scoliosi p etiolog manifest clearer scoliosi p progress aggrav correct extens spinal deform consid recommend\n",
            "\t0.398\tjuvenil sclerosi   introductionobjectivesmethodsresultsconclusiondisclosur introduct sclerosi childhood fibrosi intern organ vasculopathi juvenil sclerosi jssc repres scleroderma conclus diffus cutan subtyp jssc preval pediatr rheumatolog center raynaud phenomenon capillaroscop abnorm univers present intern organ clinic silent disclosur\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.590\tscoliosi internet china popular search onlin consider scoliosi obtain scoliosi internet onlin vari depend china restrict internet outsid border scoliosi onlin recogn score analyz internet china surveybas questionnair distribut 280 respond outpati clinic demograph internet binari logist predictor internet top scoliosi websit search engin review surgeon onlin discern jama benchmark internet scoliosi 878 respond colleg internet home urban resid predictor internet onlin scoliosi discern 279 117 mislead scoliosi outlin scoliosi internet 878 scoliosi outpati clinic search scoliosi internet urban internet home predictor internet search onlin scoliosi confus websit seem contain reliabl  introductionmateri methodseth statementsubjectsanalysi questionnaireinstrument score scoliosisrel websitesflow chart websit search popular search enginesstatisticsresultssubjectsdemograph detail questionnaireanalysi questionnaireresult internet usag respondentsresult question ass search respondentsbinari logist regress internet scoliosi informationinstrument score scoliosisrel websitesdescript websit evaluatedaverag discern jama benchmark descript categorydiscussionconclusionssupport informationquestionnair distribut outpati studydiscern score internet commun search healthrel internet widespread 525 internet user search topic help ill websit consult contain onlin concern incorrect bias perspect make outpati consult challeng poll internet healthrel 86 believ reliabl 64 report internet impact decis internet scoliosi internet onlin commun clinician demand onlin internet usag vari drastic depend primarili background econom respect scoliosi baker correct posse insur predictor internet usag scoliosi ireland wellburn scoliosi internet unregul nason onlin fals interpret misl person consider region diseaserel internet countri internet cultur access websit languag access consider concern scoliosi onlin carri internet countri document onlin scoliosi china internet recogn score object analyz internet china countri 878 scoliosi outpati clinic search scoliosi internet urban internet home potenti predictor internet onlin scoliosi confus websit contain reliabl commerci nonphysician websit benefici healthcar provid govern hospit internet servic provid collabor creat conveni reliabl internet platform\n",
            "\t-2.374\tsyndrom scoliosi syndrom histor scoliosi marfan neurofibromatosi syndrom group etiolog scoliosi syndrom scoliosi periop pauciti collect complic pubm embas databas search encompass undergo correct scoliosi syndrom scoliosi exclus articl collect complic articl categor special discus complic trend note univers nearli wound rett 292 dural tear marfan ehlersdanlo implant praderwilli pseudarthrosi ehlersdanlo syndrom classic group umbrella term syndrom ailment preoper intraop postop set  introductionmethodsresultsmarfan syndromedown syndromerett syndromeneurofibromatosisehlersdanlososteogenesi imperfectapraderwillifriedreich ataxiadiscussioncompl surgic ai conclusioncons scoliosi pediatr tradit classifi idiopath congenit neuromuscular syndrom etiolog syndrom scoliosi recogn scoliosi scoliosi marfan neurofibromatosi rett achondroplasia ehlersdanlo praderwilli friedrich ataxia osteogenesi imperfecta scoliosi usag umbrella term syndrom scoliosi pauciti discus entiti collect complic complic syndrom scoliosi scoliosi neurolog compromis nonidiopath scoliosi neuromuscular transfus idiopath scoliosi note nonidiopath comorbid idiopath syndrom result spinal deform comorbid complic syndrom scoliosi allow articl collect syndrom scoliosi special periop purpos syndrom view categori delin idiopath congenit neuromuscular scoliosi scoliosi syndrom intraop postop anecdot gap specif complic profil ai compar neuromuscular scoliosi issu discus syndrom beyond issu deal handicap syndrom umbrella syndrom scoliosi present ad challeng rehabilit solut minim multidisciplinari integr nurs anesthesia provid rett integr periop overst fluid resuscit transfus protocol detail hope ad detail interdisciplinari predict safer surgeri rariti syndrom establish track provid protocol tailor serv improv spinal abnorm perhap chief articl rang decad constantli evolv technolog anesthet periop dramat acknowledg confound post oper report unabl stratifi consist intermedi complic syndrom scoliosi believ surgeri benefici notabl except paper disappoint reward syndrom scoliosi quantiti pinpoint intraop postop challeng forward consolid consid syndrom scoliosi consent\n",
            "\t-2.453\tscoliosi parkinson scoliosi parkinson pd elderli pd scoliosi direct scoliosi later domin pd dopaminerg pharmacotherapi scoliosi spinal curvatur deviat compris 97 42 55 idiopath pd submit wholespin scanograph scoliosi cobb true scoliosi 97 pd 0006 scoliosi scoliosi 665 92 728 73 sd 0001 pd later scoliosi occurr scoliosi differ novo levodopa ldopatr neither ldopa later pd appear scoliosi parkinson diseasescoliosislevodopa introductionmethodspatientsradiolog analysisresultsdiscuss scoliosi later curvatur spine vertebr rotat asymmetr deform trunk parkinson pd direct scoliosi congruou later sign pd scoliosi close nigrostriat dopamin defici contradictori dopaminerg pharmacotherapi direct scoliosi pd poorli understood divid pd spinal curvatur spinal asymmetri non scoliosi true scoliosi later pd direct scoliosi dopaminerg pharmacotherapi scoliosi pd scoliosi later curvatur spine rotat scoliosi elderli vari rise pd rang 43 90 ashour jankov scoliosi 164 pd 85 retrospect radiolog 97 pd 33 scoliosi deviat hormon biomechan neuromuscular scoliosi pd exact pathophysiolog understood accord frequent dystonia pd scoliosi seven pd counterpart oldag pd scoliosi pd duvoisin marsden consecut unoper pd direct postur deviat later sign parkinson scoliosi analog unilater destruct dopaminerg nigrostriat aris zona compacta substantia nigra nervou scoliosi axial dystonia camptocormia pisa scoliosi bilater ascend dopamin later pd parkinsonian deficit direct scoliosi direct scoliosi later parkinsonian sign dyston postur ldopa scoliosi nigrostriat dopamin defici caus scoliosi degen scoliosi lordosi axial rotat later listhesi spondylolisthesi scoliosi spinal abnorm explan osteoporosi scoliosi lumbar degen scoliosi osteoporosi lumbar scoliosi elderli osteoporosi scoliosi scoliosi elderli osteoporosi 389 36 scoliosi lumbar degen scoliosi osteoporosi mild pd make compar pd limit discern base scoliosi contain elderli mild scoliosi spite scoliosi pd manifest pd updr direct scoliosi convex later pd dyston postur ldopa pdassoci dystonia ldopa pdassoci scoliosi scoliosi pd curvatur scoliosi pd scoliosi scoliosi pd pd domin updr ldopa compar concord nonconcord direct scoliosi later sign parkinson ldopa\n",
            "scoliosis None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.400\tmobil atrial thrombus hemoglobin sc intracardiac thrombus atrial fibril spontan atrial thrombu hypercoagul sub optim anticoagul  introduction2 report3 discussion4 sickl scd inherit autosom recess haemoglobin hb substitut glutam valin beta haemoglobin vasoocclus haemolyt worth note manifest hypercoagul vessel thrombosi intracardiac thrombu spontan atrial thrombu sickl suboptim anticoagul sickl hypercoagu intracardiac thrombu suspicion tte intracardiac thrombosi immedi save instanc intraven thrombolyt offer safer accept remov thrombu\n",
            "\t0.400\tmobil atrial thrombus hemoglobin sc intracardiac thrombus atrial fibril spontan atrial thrombu hypercoagul sub optim anticoagul  introduction2 report3 discussion4 sickl scd inherit autosom recess haemoglobin hb substitut glutam valin beta haemoglobin vasoocclus haemolyt worth note manifest hypercoagul vessel thrombosi intracardiac thrombu spontan atrial thrombu sickl suboptim anticoagul sickl hypercoagu intracardiac thrombu suspicion tte intracardiac thrombosi immedi save instanc intraven thrombolyt offer safer accept remov thrombu\n",
            "\t0.390\tabdomen oxycodon opioid mainstay moder oxycodon fewer morphin oxycodon morphin constip nausea sedat abdomin rare present abdomen stercor diarrhea 54yearold man squamou extern auditori canal take oxycodon relief oxycodon never complain diarrhea constip dosag oxycodon complain abdomin distens constip administ lax complain diarrhea abdomin visit emerg depart colon obstruct constip selfmed oxycodon dosag 180 mgday abrupt oxycodon stercor diarrhea blockag stool abdomen  introduction2 report3 discussion4 conflict interest opioid success adequ analgesia excess avail opioid opioid morphin oxycodon opioid subtyp differ variat opioid oxycodon morphin distinctli pharmacolog profil constip oxycodon morphin oxycodon success adequ analgesia excess constip inappropri oxycodon develop abdomin emerg watch treat constip take opioid conflict interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.876\tcomment hydroxyurea sickl anemia    sickl scd monogenet beta globin facilit unstabl sickl hemoglobinhb deoxygen aggreg erythrocyt rigid rigid block microvasculatur vasoocclus ischemia organ rigid tend lyse easili releas hemoglobin oxid hemebound iron pathophysiolog scd driven hb vasoocclus hemolysi implic scd unstabl hb spontan autooxid induc superoxid intravascular hemolysi hemoglobin heme facilit hydroxylrad vasoocclus repeat ischemiareperfus cycl throughout xanthin oxidas nicotinamid adenin dinucleotid phosphat nadph oxidas radic arginasecatalyz deplet arginin substrat nitric oxid synthas uncoupl consequ reactiv glycat organ scd doubt promin pathophysiolog scd hydroxyurea hu diseasemodifi approv scd hu fetal hb hb inhibit polymer hb sickl augment hb reduc oxid scd hb reduc pain vasoocclus crise hemolysi vasoocclus hemolysi hu scd hu balanc antioxid instanc hu glutathion peroxidas antioxid sickl erythrocyt glutathion peroxidas peroxid promot therebi hemolysi hu oxid indirect antioxid azid moieti oxid hemoglobin methemoglobin nitrosyl hemoglobin sickl erythrocyt tend hu scd methemoglobin problemat methemoglobin carri inhibit hb polymer hemolysi vasoocclus hu metabol nitric oxid antioxid hu creat difficulti predict net oxid scd edit revista brasileira hematologia hemoterapia torr scd hu topic lightli compar scd transfus chelat scd hu chelat latter peroxid mononuclear scd hu torr thiobarbitur reactiv tbar quantifi peroxid theplasma scd hu scd hu peroxid scd take hu hb peroxid parallel scd appli trolox equival antioxid teac antioxid give impress antioxid influenc instanc bilirubin uric torr scd teac teac scd hu antioxid rise scd adapt hu augment antioxid interpret glutathion scd glutathion tend 100fold erythrocyt scd erythrocyt erythrocyt sickl erythrocyt export oxid glutathion erythrocyt oxid glutathion back glutathion glutathion reductas releas lyse sickl erythrocyt reflect glutathion complex glutathion interpret torr influenc bia scd hu refer confound indic support idea hu attenu scd hb peroxid antioxid hu larg attribut hb hb antioxid hu question \n",
            "\t-4.663\tabdomen oxycodon opioid mainstay moder oxycodon fewer morphin oxycodon morphin constip nausea sedat abdomin rare present abdomen stercor diarrhea 54yearold man squamou extern auditori canal take oxycodon relief oxycodon never complain diarrhea constip dosag oxycodon complain abdomin distens constip administ lax complain diarrhea abdomin visit emerg depart colon obstruct constip selfmed oxycodon dosag 180 mgday abrupt oxycodon stercor diarrhea blockag stool abdomen  introduction2 report3 discussion4 conflict interest opioid success adequ analgesia excess avail opioid opioid morphin oxycodon opioid subtyp differ variat opioid oxycodon morphin distinctli pharmacolog profil constip oxycodon morphin oxycodon success adequ analgesia excess constip inappropri oxycodon develop abdomin emerg watch treat constip take opioid conflict interest\n",
            "\t-5.256\thighdens lipoprotein cholesterol hdlc steadyst sickl search sickl scd biomark establish attempt highdens lipoprotein cholesterol hdlc steadyst scd antiinflammatori antioxid antiaggreg anticoagul profibrinolyt sickl prospect biochem hematolog biomark 152 steadyst infant scd 132 immunochemistri immunoassay electron counter record 152 infant highdens lipoprotein cholesterol hemoglobin 0001 hematocrit 0001 cholesterol 0001 reticulocyt 0046 leukocyt 0015 monocyt 0004 platelet 0005 bilirubin bilirubin 0001 bilirubin 0001 indirect bilirubin 0001 iron 0001 aminotransferas aspart aminotransferas 0004 alanin aminotransferas 0035 lactat dehydrogenas 0001 urea 0030 alpha 1antitrypsin 0001 lowdens lipoprotein cholesterol 0003 triglycerid 0005 hemoglobin 0002 highdens lipoprotein cholesterol abnorm 0025 pneumonia 0033 transfus 0025 lipid cholelithiasi hypothes scd dyslipidem subphenotyp hdlc hypertriglyceridemia vldlc biomark repres toward reliabl warrant scd  backgroundsubject methodssubject controlslaboratori methodsdefinit eventsstatist analysisresultshdlc hemolysi dysfunctionassoci hdlc sickl historydiscussionconclusionsabbreviationscompet interestsauthor contribut sickl scd vari mild multiorgan manifest scd vasoocclus episod voe intravascular sickl capillari vessel research predict sickl vasoocclus phenomenon event particip stress reticulocyt sickl erythrocyt leukocyt platelet endothelium reactiv ro scaveng nitric oxid regul homeostasi scd biomark scd fetal hemoglobin hbf leukocyt count reticulocyt count classic lactat dehydrogenas ldh wellknown intravascular hemolysi biomark scd nitric oxid priapism leg ulcer scd prospect highdens lipoprotein cholesterol hdlc determin cholesterol lowdens lipoprotein cholesterol ldlc lowdens lipoprotein cholesterol vldlc triglycerid steadyst sickl biomark determin subphenotyp hypothes scd dyslipidem subphenotyp hdlc hypertriglyceridemia vldlc biomark repres toward reliabl warrant scd abbrevi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.400\tmobil atrial thrombus hemoglobin sc intracardiac thrombus atrial fibril spontan atrial thrombu hypercoagul sub optim anticoagul  introduction2 report3 discussion4 sickl scd inherit autosom recess haemoglobin hb substitut glutam valin beta haemoglobin vasoocclus haemolyt worth note manifest hypercoagul vessel thrombosi intracardiac thrombu spontan atrial thrombu sickl suboptim anticoagul sickl hypercoagu intracardiac thrombu suspicion tte intracardiac thrombosi immedi save instanc intraven thrombolyt offer safer accept remov thrombu\n",
            "\t0.400\tmobil atrial thrombus hemoglobin sc intracardiac thrombus atrial fibril spontan atrial thrombu hypercoagul sub optim anticoagul  introduction2 report3 discussion4 sickl scd inherit autosom recess haemoglobin hb substitut glutam valin beta haemoglobin vasoocclus haemolyt worth note manifest hypercoagul vessel thrombosi intracardiac thrombu spontan atrial thrombu sickl suboptim anticoagul sickl hypercoagu intracardiac thrombu suspicion tte intracardiac thrombosi immedi save instanc intraven thrombolyt offer safer accept remov thrombu\n",
            "\t0.390\tabdomen oxycodon opioid mainstay moder oxycodon fewer morphin oxycodon morphin constip nausea sedat abdomin rare present abdomen stercor diarrhea 54yearold man squamou extern auditori canal take oxycodon relief oxycodon never complain diarrhea constip dosag oxycodon complain abdomin distens constip administ lax complain diarrhea abdomin visit emerg depart colon obstruct constip selfmed oxycodon dosag 180 mgday abrupt oxycodon stercor diarrhea blockag stool abdomen  introduction2 report3 discussion4 conflict interest opioid success adequ analgesia excess avail opioid opioid morphin oxycodon opioid subtyp differ variat opioid oxycodon morphin distinctli pharmacolog profil constip oxycodon morphin oxycodon success adequ analgesia excess constip inappropri oxycodon develop abdomin emerg watch treat constip take opioid conflict interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.876\tcomment hydroxyurea sickl anemia    sickl scd monogenet beta globin facilit unstabl sickl hemoglobinhb deoxygen aggreg erythrocyt rigid rigid block microvasculatur vasoocclus ischemia organ rigid tend lyse easili releas hemoglobin oxid hemebound iron pathophysiolog scd driven hb vasoocclus hemolysi implic scd unstabl hb spontan autooxid induc superoxid intravascular hemolysi hemoglobin heme facilit hydroxylrad vasoocclus repeat ischemiareperfus cycl throughout xanthin oxidas nicotinamid adenin dinucleotid phosphat nadph oxidas radic arginasecatalyz deplet arginin substrat nitric oxid synthas uncoupl consequ reactiv glycat organ scd doubt promin pathophysiolog scd hydroxyurea hu diseasemodifi approv scd hu fetal hb hb inhibit polymer hb sickl augment hb reduc oxid scd hb reduc pain vasoocclus crise hemolysi vasoocclus hemolysi hu scd hu balanc antioxid instanc hu glutathion peroxidas antioxid sickl erythrocyt glutathion peroxidas peroxid promot therebi hemolysi hu oxid indirect antioxid azid moieti oxid hemoglobin methemoglobin nitrosyl hemoglobin sickl erythrocyt tend hu scd methemoglobin problemat methemoglobin carri inhibit hb polymer hemolysi vasoocclus hu metabol nitric oxid antioxid hu creat difficulti predict net oxid scd edit revista brasileira hematologia hemoterapia torr scd hu topic lightli compar scd transfus chelat scd hu chelat latter peroxid mononuclear scd hu torr thiobarbitur reactiv tbar quantifi peroxid theplasma scd hu scd hu peroxid scd take hu hb peroxid parallel scd appli trolox equival antioxid teac antioxid give impress antioxid influenc instanc bilirubin uric torr scd teac teac scd hu antioxid rise scd adapt hu augment antioxid interpret glutathion scd glutathion tend 100fold erythrocyt scd erythrocyt erythrocyt sickl erythrocyt export oxid glutathion erythrocyt oxid glutathion back glutathion glutathion reductas releas lyse sickl erythrocyt reflect glutathion complex glutathion interpret torr influenc bia scd hu refer confound indic support idea hu attenu scd hb peroxid antioxid hu larg attribut hb hb antioxid hu question \n",
            "\t-4.663\tabdomen oxycodon opioid mainstay moder oxycodon fewer morphin oxycodon morphin constip nausea sedat abdomin rare present abdomen stercor diarrhea 54yearold man squamou extern auditori canal take oxycodon relief oxycodon never complain diarrhea constip dosag oxycodon complain abdomin distens constip administ lax complain diarrhea abdomin visit emerg depart colon obstruct constip selfmed oxycodon dosag 180 mgday abrupt oxycodon stercor diarrhea blockag stool abdomen  introduction2 report3 discussion4 conflict interest opioid success adequ analgesia excess avail opioid opioid morphin oxycodon opioid subtyp differ variat opioid oxycodon morphin distinctli pharmacolog profil constip oxycodon morphin oxycodon success adequ analgesia excess constip inappropri oxycodon develop abdomin emerg watch treat constip take opioid conflict interest\n",
            "\t-5.256\thighdens lipoprotein cholesterol hdlc steadyst sickl search sickl scd biomark establish attempt highdens lipoprotein cholesterol hdlc steadyst scd antiinflammatori antioxid antiaggreg anticoagul profibrinolyt sickl prospect biochem hematolog biomark 152 steadyst infant scd 132 immunochemistri immunoassay electron counter record 152 infant highdens lipoprotein cholesterol hemoglobin 0001 hematocrit 0001 cholesterol 0001 reticulocyt 0046 leukocyt 0015 monocyt 0004 platelet 0005 bilirubin bilirubin 0001 bilirubin 0001 indirect bilirubin 0001 iron 0001 aminotransferas aspart aminotransferas 0004 alanin aminotransferas 0035 lactat dehydrogenas 0001 urea 0030 alpha 1antitrypsin 0001 lowdens lipoprotein cholesterol 0003 triglycerid 0005 hemoglobin 0002 highdens lipoprotein cholesterol abnorm 0025 pneumonia 0033 transfus 0025 lipid cholelithiasi hypothes scd dyslipidem subphenotyp hdlc hypertriglyceridemia vldlc biomark repres toward reliabl warrant scd  backgroundsubject methodssubject controlslaboratori methodsdefinit eventsstatist analysisresultshdlc hemolysi dysfunctionassoci hdlc sickl historydiscussionconclusionsabbreviationscompet interestsauthor contribut sickl scd vari mild multiorgan manifest scd vasoocclus episod voe intravascular sickl capillari vessel research predict sickl vasoocclus phenomenon event particip stress reticulocyt sickl erythrocyt leukocyt platelet endothelium reactiv ro scaveng nitric oxid regul homeostasi scd biomark scd fetal hemoglobin hbf leukocyt count reticulocyt count classic lactat dehydrogenas ldh wellknown intravascular hemolysi biomark scd nitric oxid priapism leg ulcer scd prospect highdens lipoprotein cholesterol hdlc determin cholesterol lowdens lipoprotein cholesterol ldlc lowdens lipoprotein cholesterol vldlc triglycerid steadyst sickl biomark determin subphenotyp hypothes scd dyslipidem subphenotyp hdlc hypertriglyceridemia vldlc biomark repres toward reliabl warrant scd abbrevi\n",
            "Sickle cell disease,Hgb,oxycodone None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.484\toxygen photodynam fluenc o2 photodynam pdt photochem deplet ambient caus hypoxia limit effect fluenc po2 murin rif pdt mg kg1 photofrin fluenc 75 150 mw cm2 median po2 pdt rang 29 52 mmhg minut illumin median po2 fluenc 07 mmhg rapidli complet revers illumin interrupt prolong illumin 2050 cm2 po2 recov mw cm2 fluenc median 74 mmhg remain 150 mw cm2 fluenc median po2 mmhg fluenc pdt 150 mw cm2 median po2 fell 1018 mmhg pdt cm2 mw cm2 00004 median regrowth pdt 150 mw cm2 fluenc pdt perfus uncov fluenc ratedepend vasculatur establish po2 fluenc pdt immedi relev    \n",
            "\t0.416\tcough extrathorac airway respons inhal capsaicin cough cough cough extrathorac airway constrict inhal histamin cough relat extrathorac airway hyperrespons eahr cough capsaicin inhal unclear etiolog entiti cough seventyseven dri cough persist spirometri chest radiographi underw methacholin bronchial provoc capsaicin cough provoc elicit cough flowvolum curv inhal capsaicin cough eahr thirtythre postnas drip extrathorac airway respons cough capsaicin cough cough variant asthma cva bronchial hyperrespons eahr inhal capsaicin remain tent idiopath cough icc eleven icc cough eahr inhal capsaicin cough close extrathorac airway respons capsaicin provoc cough eahr cough inhal capsaicin cough    \n",
            "\t0.399\timmunolog inhal cotton dust byssinosi worker cotton flax soft hemp classic short breath cough chest tight monday return veget dust term cotton dustinduc cdird introduc clinic centuri cdird obscur allerg articl review rais cdird preexist occup mold allergi    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.843\tobject cough lr102 cough problemat subject automat cough episod lr102 cough meter electromyographi audio sensor ten complain cough recruit set ask wear lr102 consecut hour film cough lr102 manual count close 087 cough episod hour 089 cough hour lr102 overestim cough blandaltman plot influenc cough lr102 offer estim cough coughvalid studycough meter introductionmethodspatientscough recordinglr102refer recordingoutcomesvideo recordingread lr102 tracesvideo recordingread lr102 tracesanalysisresultsdiscussionmain findingsstrength limitationsimpl researchsummarycompet interestsauthor contribut cough reason seek preval extens object cough subject object inconsist correl object subject cough monitor object cough qualityoflif questionnair verbal descript vd analogu scale va subject cough cough involv cough object intens expuls effort cough cough perceiv systemat psychometr valid coughspecif qualityoflif scale leicest cough questionnair cough questionnair burden cough questionnair valid vd va correl qualityoflif cough cough qualityof correl vd va object cough vari consider percept cough vd va influenc cough face valid scale regard valid indic cough repercuss cough conclud coughspecif qualityoflif questionnair valid cough develop cough devic promis realist recommend widespread requisit monitor accur cough object accur cough situat cough purpos judg cough suppress cough suppress substanti everi week take cough suppress effect valid lack seriou sideeffect cough suppress nonvalid subject cough scale descript measur cough object cough suppress cough intens time lr102 cough meter logan sinclair electromyographi emg intercost muscl auditori accompani softwar manufactur perform offlin analys regist autom cough episod advantag distinguish cough nearbi autom equip compact leav pursu valid 1994 valid manual trace read cough episod automat cough episod valid purpos valid autom cough episod lr102 manual count episod view video record pilot cough meter approv ethic committe aim predict sign prolong cough \n",
            "\t-3.463\t o2 h2o2 injur potent oxid o2 h2o2 mediat lethal ferric iron o2 reduc ferric ferrou iron latter react h2o2 potent oxid oh equival reactiv turn oh initi peroxid decomposit phospholipid membran oh damag inner deenerg initi similarli viabil repres oh depend coupl kill poli adpribos polymeras    \n",
            "\t-3.774\tcapsaicinsensit cough airway cough hypersensit upper airway cough cough hypersensit upper airway cough uac purpos capsaicinsensit cough laryngopharynx airway cough hypersensit uac 59 uac 33 rhinitissinus cough 39 volunt recruit cough threshold c5 lowest capsaicin cough esposur capsaicin laryngopharng anesthesia lidocain sputum cytolog histamin prostaglandin e2 pge2 calcitoningenerel cgpr sputum elisa uac sputum cytolog mediat repeat success c5 capsaicin uac rhinitissinus 39 098 78 moll 78 39 9375 moll 312 156 625 moll h4012 p0000 laryngopharng anesthesia lidocain dramat c5 capsaicin uac lowest histamin pge2 cgrp sputum cough resolv cetirizin erythromycin cgrp histamin sputum uac obviou pge2 sputum laryng trpv1 cough sensit capsaicinsensit cough airway cough hypersensit uac upper airway cough syndromerhinitissinusitiscough sensitivitylaryngopharyx backgroundmateri methodssubjectsdetect cough capsaicinsputum cytologymeasur mediat supernat sputumproceduresstatist analysisresultscough threshold c5 inhal capsaicin laryngopharng anesthesiacel count mediat sputumdiscussionconclus upper airway cough uac refer postnas drip pnd cough western 52 cough china uac poorli understood mechano chemostimul affer nerv innerv pharynx larynx airway secret eman nose sinus drip elicit cough uac postnas drip event millilit mucu secret nose everi move backward wave epithelium cilium nasopharynx swallow expector throatclear cough elabor bardin secret maxillari sinu seed sinus asthma sinus aspir uac cough hypersensit univers featur cough uac affer limb sensit cough reflex uac exagger cough threshold subthreshold upper airway uac sensori nerv innerv hypopharynx larynx cough hypersensit logic specul issu conflict prospect crosssect capsaicinsensit sensori nerv laryng airway cough hypersensit uac compar rhinitissinus cough volunt laryng trpv1 cough uac sensit capsaicinsensit cough airway cough hypersensit elucid airway cough hypersensit cough upper airway\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.484\toxygen photodynam fluenc o2 photodynam pdt photochem deplet ambient caus hypoxia limit effect fluenc po2 murin rif pdt mg kg1 photofrin fluenc 75 150 mw cm2 median po2 pdt rang 29 52 mmhg minut illumin median po2 fluenc 07 mmhg rapidli complet revers illumin interrupt prolong illumin 2050 cm2 po2 recov mw cm2 fluenc median 74 mmhg remain 150 mw cm2 fluenc median po2 mmhg fluenc pdt 150 mw cm2 median po2 fell 1018 mmhg pdt cm2 mw cm2 00004 median regrowth pdt 150 mw cm2 fluenc pdt perfus uncov fluenc ratedepend vasculatur establish po2 fluenc pdt immedi relev    \n",
            "\t0.416\tcough extrathorac airway respons inhal capsaicin cough cough cough extrathorac airway constrict inhal histamin cough relat extrathorac airway hyperrespons eahr cough capsaicin inhal unclear etiolog entiti cough seventyseven dri cough persist spirometri chest radiographi underw methacholin bronchial provoc capsaicin cough provoc elicit cough flowvolum curv inhal capsaicin cough eahr thirtythre postnas drip extrathorac airway respons cough capsaicin cough cough variant asthma cva bronchial hyperrespons eahr inhal capsaicin remain tent idiopath cough icc eleven icc cough eahr inhal capsaicin cough close extrathorac airway respons capsaicin provoc cough eahr cough inhal capsaicin cough    \n",
            "\t0.399\timmunolog inhal cotton dust byssinosi worker cotton flax soft hemp classic short breath cough chest tight monday return veget dust term cotton dustinduc cdird introduc clinic centuri cdird obscur allerg articl review rais cdird preexist occup mold allergi    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.843\tobject cough lr102 cough problemat subject automat cough episod lr102 cough meter electromyographi audio sensor ten complain cough recruit set ask wear lr102 consecut hour film cough lr102 manual count close 087 cough episod hour 089 cough hour lr102 overestim cough blandaltman plot influenc cough lr102 offer estim cough coughvalid studycough meter introductionmethodspatientscough recordinglr102refer recordingoutcomesvideo recordingread lr102 tracesvideo recordingread lr102 tracesanalysisresultsdiscussionmain findingsstrength limitationsimpl researchsummarycompet interestsauthor contribut cough reason seek preval extens object cough subject object inconsist correl object subject cough monitor object cough qualityoflif questionnair verbal descript vd analogu scale va subject cough cough involv cough object intens expuls effort cough cough perceiv systemat psychometr valid coughspecif qualityoflif scale leicest cough questionnair cough questionnair burden cough questionnair valid vd va correl qualityoflif cough cough qualityof correl vd va object cough vari consider percept cough vd va influenc cough face valid scale regard valid indic cough repercuss cough conclud coughspecif qualityoflif questionnair valid cough develop cough devic promis realist recommend widespread requisit monitor accur cough object accur cough situat cough purpos judg cough suppress cough suppress substanti everi week take cough suppress effect valid lack seriou sideeffect cough suppress nonvalid subject cough scale descript measur cough object cough suppress cough intens time lr102 cough meter logan sinclair electromyographi emg intercost muscl auditori accompani softwar manufactur perform offlin analys regist autom cough episod advantag distinguish cough nearbi autom equip compact leav pursu valid 1994 valid manual trace read cough episod automat cough episod valid purpos valid autom cough episod lr102 manual count episod view video record pilot cough meter approv ethic committe aim predict sign prolong cough \n",
            "\t-3.463\t o2 h2o2 injur potent oxid o2 h2o2 mediat lethal ferric iron o2 reduc ferric ferrou iron latter react h2o2 potent oxid oh equival reactiv turn oh initi peroxid decomposit phospholipid membran oh damag inner deenerg initi similarli viabil repres oh depend coupl kill poli adpribos polymeras    \n",
            "\t-3.774\tcapsaicinsensit cough airway cough hypersensit upper airway cough cough hypersensit upper airway cough uac purpos capsaicinsensit cough laryngopharynx airway cough hypersensit uac 59 uac 33 rhinitissinus cough 39 volunt recruit cough threshold c5 lowest capsaicin cough esposur capsaicin laryngopharng anesthesia lidocain sputum cytolog histamin prostaglandin e2 pge2 calcitoningenerel cgpr sputum elisa uac sputum cytolog mediat repeat success c5 capsaicin uac rhinitissinus 39 098 78 moll 78 39 9375 moll 312 156 625 moll h4012 p0000 laryngopharng anesthesia lidocain dramat c5 capsaicin uac lowest histamin pge2 cgrp sputum cough resolv cetirizin erythromycin cgrp histamin sputum uac obviou pge2 sputum laryng trpv1 cough sensit capsaicinsensit cough airway cough hypersensit uac upper airway cough syndromerhinitissinusitiscough sensitivitylaryngopharyx backgroundmateri methodssubjectsdetect cough capsaicinsputum cytologymeasur mediat supernat sputumproceduresstatist analysisresultscough threshold c5 inhal capsaicin laryngopharng anesthesiacel count mediat sputumdiscussionconclus upper airway cough uac refer postnas drip pnd cough western 52 cough china uac poorli understood mechano chemostimul affer nerv innerv pharynx larynx airway secret eman nose sinus drip elicit cough uac postnas drip event millilit mucu secret nose everi move backward wave epithelium cilium nasopharynx swallow expector throatclear cough elabor bardin secret maxillari sinu seed sinus asthma sinus aspir uac cough hypersensit univers featur cough uac affer limb sensit cough reflex uac exagger cough threshold subthreshold upper airway uac sensori nerv innerv hypopharynx larynx cough hypersensit logic specul issu conflict prospect crosssect capsaicinsensit sensori nerv laryng airway cough hypersensit uac compar rhinitissinus cough volunt laryng trpv1 cough uac sensit capsaicinsensit cough airway cough hypersensit elucid airway cough hypersensit cough upper airway\n",
            "cough,Hgb,O2 None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.459\tfetal alcohol spectrum damag prenat alcohol continu drink creat fetal alcohol spectrum fasd identifi articl describ spectrum therapeut pharmacolog nutrit environmentalbehavior alcoholinduc protect alcohol teratogen enhanc nervou plastic alcohol alcohol ceas insight gain date offer candid attenu deficit fasd fetal alcohol spectrum disordersprenat alcohol exposurepregnancyteratogen effectstreatmenttreat modelsexperiment treatmentsinterventionsnutrit interventionspharmacolog interventionsenvironment alcohol methyl aspart antagonistsserotonin agonistsantagon alcohol l1 adhes moleculesneurotroph factorsantioxidantsnutrit factorstreat fasdnutrit supplementationpharmacolog interventionsenvironment interventionsconclus alcohol disrupt numer indirect investig attempt alcoholinduc block discus born fasd lifetim behavior ideal interven alcohol prevent alcohol alway seek mitig development alcoholrel deficit insight gain date offer candid attenu deficit prenat alcohol translat arena pose challeng difficulti administ prenat period concern continu refin viabl nutrit behavior manipul readili translat continu drink alcohol continu pursu attenu alcohol fasd\n",
            "\t0.447\tendogen retrovirus sclerosi neuropharmacolog grow env endogen retrovirus herv contribut sclerosi m endogen retrovir locu ervwe1 put sclerosi retroviru msrv hervw env offer pharmacolog assist sclerosi  introductionhuman endogen retrovirusesth organis retrovirusesth ervwe1 locusth msassoci retrovirusmsrvhervw pathogenet physiologicalreexamin basicsneuropharmacolog extrapolationsdiagnost predict extrapolationstherapeut extrapol sclerosi m autoimmun patholog involv put adapt recognis self inconclus come mendelian genet meanwhil aetiolog m uncertain innat adapt becom increasingli understood contribut autoimmun extend histocompat xmhc regard adapt immun 421 believ immunoregulatori autoimmun grow endogen retrovirus herv play xmhc continu malfunct know herv contribut se implic embryolog physiolog logic systemat situat herv \n",
            "\t0.446\talcohol clinic alcohol homedwel age 65 crosssect stratifi random 2100 elderli 65 espoo finland 716 communitydwel code anatom atc classif atc ddd alcohol interact ai swedish finnish xreferenc sfinx databas concomit nervou hypoglycaem warfarin alcohol atrisk alcohol user consum drinksweek drink typic drink drink timesweek moder user consum drinkmonth drinksweek minimalnonus drinkmonth 1395 1142 respond respond user 715 626 person alcohol 42 sd atrisk user sd moder user 54 sd 34 minimalnonus 0001 concomit ai widespread atrisk user moder user minimalnonus 422 349 527 ai 0001 atrisk user warfarin hypnoticssed metformin ai risk alcohol  introductionmateri methodsresultsdescript respondentspreval alcohol interactionsdiscussionsummarystrength weaknessespotenti aisclin mean past decad nine take advanc reaction adr ddi epidemiolog declin alcohol drink drink born 1950 heavier drink habit reach old alcohol age 65 74 abstin past decad 82 drank excess guidelin person 65 interact advers alcohol alcohol reason alcohol concomitantli drink alcohol take age suscept alcohol slower clearanc delay resolut 65 80 onder adjust confound moder alcohol agerel absorpt alcohol disulfiramlik reaction exacerb alcohol interfer alcohol warfarin alcohol concomit alcohol warfarin interindividu intraindividu variat intern normal ratio inr alcohol enhanc sed antidepress barbitur benzodiazepin opioid creat fall declin nervou alcohol hypoglycaem hypoglycaemia alcohol potenti metformin lactat rare lactic acidosi alcohol intox epidemiolog investig concomit alcohol present emerg depart admiss repres homedwel concomit alcohol psychotrop 77 alcohol eastern finland ai moder drinker clinic alcohol random homedwel age 65 summari\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.777\theroin addict focal weak 24yearold heroin abus experienc painless stiff elbow joint weak shoulder upper limb muscl inject 46 altern upper extrem spare limb electromyographi emg myopath clinic unaffect muscl magnet reson mri fibrosi inject muscl subcutan muscl anterior posterior compart thigh inject support oedema emg mri congruent abnorm muscl inject distant heroin adulter toxic immunolog  reportdiscuss 24yearold unremark person experienc painless stiff elbow joint weak shoulder upper limb muscl inject heroin 46 upper extrem muscl altern deni inject extrem alcohol neurolog cranial nerv bilater scapular wing compensatori hypermobl scapulo thorac joint wast stiff rhomboid pectorali deltoid bicep tricep muscl strength grade 01 bilater mrc extrem strength 1a bend elbow joint contractur deep reflex weaken sensibl coordin count sediment thyroid b12 hiv12 antinuclear extract complement c3 c4 chest xray refus biopsi test facioscapulohumer becker limbgirdl muscular dystrophi 2a electromyographi emg infraspinatu rhomboid deltoid bicep tricep muscl fibril recruit effort polyphas unit potenti mup approach fibrou needl medial later vastu rectu femori soleu emg spontan rest mup amplitud recruit effort ulnar peron tibial sural conduct magnet reson mri upper limb muscl intens t1weight imag fibrou replac subcutan muscl anterior posterior compart thigh t2weight shorttau invers recoveri imag stir intens keep edema 1c prednison mgkgdaili emg muscl brief polyphas mup recruit spontan wast shoulder proxim limb muscl mri philip 15t akieva midthigh coron axial t1w imag tr 45te7 asymmetr focal hypointens axial t2w tr4600te estir imag tr 80te 6330 thick enlarg muscl edemalik hyperintens signalwhit arrow muscl anterior posterior compart subcutan focal upper limb weak atrophi begin adulthood broad includ limbgirdl dystrophi spinal muscular atrophi polymyos myopath heroin addict repeat intramuscular inject alcohol loui 43 atroph fibrot myopathi affect select shoulder muscl weber exhibit biopsi proven myopathi respons steroid penicillamin biopsi atroph fiber lymphocyt macrophag perivascular endomysi infiltr endomysi fibrosi ongo regeneraton recoveri joint contractur weak mildli ck muscl distant inject clinic unaffect sign upper limb weak stiff ck myopat emg muscl distant inject emg mri congruent abnorm limb distanc circul heroin adulter diffus rhabdomyolysi unrel coma compress intraven self heroin dabbi nervou rhabdomyolysi intraven heroin intranas self plexopathi symmetr distal sensorimotor axon neuropathi notic 336 hour heroin aa toxic appear non compress neuropathi immunolog mielkeibrahim herdmann gupta transvers myeliti rhabdomyolysi na ve smoke heroin hypersensit uncertain heroin abus toxic se immunolog consequ inject heroin substanc ad adulter opioid modul tlymphocyt interleukin il herointr il1 il12 nitric oxid antiinflammatori il4 il10 opiat opioid lymphocyt nervou detail pathogen heroin myotox strike patholog featur eosinophil hypersensit homogen hypercontract myofibril degener fibr heroin myopathi hm equal muscl vulner depend region capillari fiber predomin receiv repeat intraperiton inject pure heroin degen regen abnorm soleu mostli compos fiber anterior tibiali compos fiber pe conclud hm myofibrillar hypercontract hm recov unclear threshold last exposur myotox\n",
            "\t-7.449\tmitogenactiv cro tyrosin t47d alcohol affect alcohol principl carcinogenesi alcoholinduc metastat observ alcohol differenti alcoholexpos t47d gelbas proteom cro tyrosin ros1 autophosphoryl therebi activ mitogen stressactiv msk1 mitogenactiv mapk msk1 turn phosphoryl histon serin h3s10p nucleu h3s10 consequ immediateearli cfo alcohol phosphoryl ros1 activ msk1 erk12 mapk modif histon 1433 recruit canceralcoholreceptor tyrosin kinasemitogenactiv pathwayhiston introductionmateri methodscel cultureproteom analysiswestern blottingrealtim revers transcriptas rtpcrdetermin proliferationchromatin immunoprecipit chip assaystatist analysisresultsidentif upregul ros1 alcoholtr t47d proteom analysiseffect alcohol ros1 mapk pathwayregul immediateearli alcohol mek12 treatmentregul recruit 1433 alcohol exposurediscuss alcohol oropharynx larynx esophag colon rectal alcoholinduc mutagen retino folat estrogen alcohol alcohol carcinogenesi alcohol affect upstream downstream mitogenactiv mapk mapk relay nucleu mapk activ parallel cascad downstream signalregul kina erk12 p38 mapk stressactiv kinasecjun nh2termin sapkjnk erk12 tyrosin kina rtk alcohol relay nucleu erk12 erk12 alcohol mcf7 epigenet histon modif carcinogen alcohol histon modif affect remodel chromatin histon posttransl modif acetyl ubiquitin sumoyl nucleosom remodel histon chaperon histon modifi histon regul condens instanc histon serin h3s10p regul interphas crosstalk modif h3 tail acetyl aid initi mapk uv irradi h3s10p h3 serin h3s28p hepatocyt alcohol acetaldehyd h3s10p h3s28p alcohol h3s10p h3s28p turn regul cfo cjun mkp1 kina phosphoryl histon aurora vrk1 mitogen stressactiv kinase12 msk12 pim1 rsk2 pkbakt ikk msk12 h3 stressactiv erk12 h3 immediateearli cfo cjun mapk alcoholinduc influenc chromatin alcohol proteom profil histon modif relay mapk alcoholtr ros1 alcoholexpos t47d ros1 protooncogen transduct regul mediat celltocel commun 31 ros1 autophosphoryl y2274 y2334 regul transduct mapk substrat irs1 phosphatidylinositol 3kinas pi3k akt stat3 vav3 mapk influenc chromatin therebi regul 33 mapk alcohol 34 36 alcohol ad hepatocellular hepg2 skhep erk12 alcoholinduc inhibit mek12 ad 37 erk12 p38 mapk jnk alcoholexpos hippocamp ht22 p38 mapk reactiv 38 erk12 compar nearbi erk12 erk12 pathophysiolog 65 alcohol mcf7 erk12induc 400 mek1 pd98059 administ alcohol 200 mcf7 hepatocyt hippocamp t47d exhibit erk12 msk1 alcohol ad t47d alcohol ad untreat mek12 u0126treat t47d alcohol u0126 restor u0126treat t47d reason alcoholinduc ros1 influenc mapk msk1 mapk alcoholexpos phosphoryl msk1 act h3 h3s10p h3s10p h3s28p intraperiton inject gkg alcohol cfo cjun mkp1 alcohol acetaldehyd administ separ hepatocyt p38 mapk reach peak min p38 mapk h3s10p h3s28p histon alcohol alcohol close histon alcoholinduc h3s10p regul recruit 1433 upstream cfo 1433 isoform abund phosphospecif bind phosphoryl histon serin 39 link phosphoryl histon 1433 29 phosphoryl h3s10 tpastimul msk1 recruit 1433 mediat recruit swisnf fosjun polymeras induc 29 alcohol 1433 upstream cfo notabl h3s10 recruit 1433 msk1 knockdown 29 msk1 extern alcohol histon remodel t47d alcohol ros1 upregul autophosphoryl ros1 turn activ msk1 erk12 mapk msk1induc h3s10p cfo 1433 recruit influenc alcoholexpos ros1 alcohol mapk alcohol mapk ros1 believ alcohol activ mapk ros1 confirm alcohol detriment\n",
            "\t-7.867\tapelin elev icr lnameinduc apelin endogen ligand apj belong proteincoupl apelin apj smooth apelin exert hypotens nitric oxid synthas eno apelin patholog poorli understood nitrolarginin methyl ester lname potent no administ chronic lnametr exhibit adhes molecule1 plasminogen activ inhibitor1 aorta vasodilat aortic eno withdraw lname apelin apelin nontreat transient elev lnametr apelin vasopressor patholog apelinapjlnameendotheli dysfunctionimpair vasodilatationmicevasopressor introductionmateri methodsgener hypertens miceaorta prepar extractiongen realtim rtpcrmeasur isometr tensionblood intraperiton inject apelinstatist analysisresultshypertens lnametr miceexpress damagerel lname treatmentimpair vasodil lnametr aortahypertens apelin lnametr micediscuss apelin origin bovin stomach endogen ligand apj belong proteincoupl apelin apj smooth apelin hypotens nitric oxid synthas no apj apelindepend hypotens no eno apjdefici hypothes apelin vasodil steadi apelin contract saphen vein endothelium physic remov ex phosphoryl myosin ratelimit event constrict cultur smooth apelin vasopressor vasoconstrict homeostasi apelindepend predispos thrombu nitrolarginin methyl ester lname potent no chronic administ lnametr exhibit dysfunctionrel vasodilat apelin transient elev lnametr hypotens nontreat apelin pathophysiolog apelin releas vasodilatori substanc lower apelin patholog chronic treat lname analog molecul asymmetr dimethyl arginin adma seriou lname adma inhibit suppress enzymat eno accompani lnametr dysfunctionrel vasodil fig lname tie2 2c retain damag wall 2a lname eno 2d eno lname aortic bioavail acceler patholog vasodil 2e patholog apelin provok vasopressor lower nontreat 3a hypertens lname mediat vasoconstrict apelin smooth apj aortic remov 3b apelin pas admadamag barrier permeabl apelin gain smooth constrict apelin affect becom patholog hypothes protect substanc constrict vessel respect detail insight complex apelin\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.459\tfetal alcohol spectrum damag prenat alcohol continu drink creat fetal alcohol spectrum fasd identifi articl describ spectrum therapeut pharmacolog nutrit environmentalbehavior alcoholinduc protect alcohol teratogen enhanc nervou plastic alcohol alcohol ceas insight gain date offer candid attenu deficit fasd fetal alcohol spectrum disordersprenat alcohol exposurepregnancyteratogen effectstreatmenttreat modelsexperiment treatmentsinterventionsnutrit interventionspharmacolog interventionsenvironment alcohol methyl aspart antagonistsserotonin agonistsantagon alcohol l1 adhes moleculesneurotroph factorsantioxidantsnutrit factorstreat fasdnutrit supplementationpharmacolog interventionsenvironment interventionsconclus alcohol disrupt numer indirect investig attempt alcoholinduc block discus born fasd lifetim behavior ideal interven alcohol prevent alcohol alway seek mitig development alcoholrel deficit insight gain date offer candid attenu deficit prenat alcohol translat arena pose challeng difficulti administ prenat period concern continu refin viabl nutrit behavior manipul readili translat continu drink alcohol continu pursu attenu alcohol fasd\n",
            "\t0.447\tendogen retrovirus sclerosi neuropharmacolog grow env endogen retrovirus herv contribut sclerosi m endogen retrovir locu ervwe1 put sclerosi retroviru msrv hervw env offer pharmacolog assist sclerosi  introductionhuman endogen retrovirusesth organis retrovirusesth ervwe1 locusth msassoci retrovirusmsrvhervw pathogenet physiologicalreexamin basicsneuropharmacolog extrapolationsdiagnost predict extrapolationstherapeut extrapol sclerosi m autoimmun patholog involv put adapt recognis self inconclus come mendelian genet meanwhil aetiolog m uncertain innat adapt becom increasingli understood contribut autoimmun extend histocompat xmhc regard adapt immun 421 believ immunoregulatori autoimmun grow endogen retrovirus herv play xmhc continu malfunct know herv contribut se implic embryolog physiolog logic systemat situat herv \n",
            "\t0.446\talcohol clinic alcohol homedwel age 65 crosssect stratifi random 2100 elderli 65 espoo finland 716 communitydwel code anatom atc classif atc ddd alcohol interact ai swedish finnish xreferenc sfinx databas concomit nervou hypoglycaem warfarin alcohol atrisk alcohol user consum drinksweek drink typic drink drink timesweek moder user consum drinkmonth drinksweek minimalnonus drinkmonth 1395 1142 respond respond user 715 626 person alcohol 42 sd atrisk user sd moder user 54 sd 34 minimalnonus 0001 concomit ai widespread atrisk user moder user minimalnonus 422 349 527 ai 0001 atrisk user warfarin hypnoticssed metformin ai risk alcohol  introductionmateri methodsresultsdescript respondentspreval alcohol interactionsdiscussionsummarystrength weaknessespotenti aisclin mean past decad nine take advanc reaction adr ddi epidemiolog declin alcohol drink drink born 1950 heavier drink habit reach old alcohol age 65 74 abstin past decad 82 drank excess guidelin person 65 interact advers alcohol alcohol reason alcohol concomitantli drink alcohol take age suscept alcohol slower clearanc delay resolut 65 80 onder adjust confound moder alcohol agerel absorpt alcohol disulfiramlik reaction exacerb alcohol interfer alcohol warfarin alcohol concomit alcohol warfarin interindividu intraindividu variat intern normal ratio inr alcohol enhanc sed antidepress barbitur benzodiazepin opioid creat fall declin nervou alcohol hypoglycaem hypoglycaemia alcohol potenti metformin lactat rare lactic acidosi alcohol intox epidemiolog investig concomit alcohol present emerg depart admiss repres homedwel concomit alcohol psychotrop 77 alcohol eastern finland ai moder drinker clinic alcohol random homedwel age 65 summari\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.777\theroin addict focal weak 24yearold heroin abus experienc painless stiff elbow joint weak shoulder upper limb muscl inject 46 altern upper extrem spare limb electromyographi emg myopath clinic unaffect muscl magnet reson mri fibrosi inject muscl subcutan muscl anterior posterior compart thigh inject support oedema emg mri congruent abnorm muscl inject distant heroin adulter toxic immunolog  reportdiscuss 24yearold unremark person experienc painless stiff elbow joint weak shoulder upper limb muscl inject heroin 46 upper extrem muscl altern deni inject extrem alcohol neurolog cranial nerv bilater scapular wing compensatori hypermobl scapulo thorac joint wast stiff rhomboid pectorali deltoid bicep tricep muscl strength grade 01 bilater mrc extrem strength 1a bend elbow joint contractur deep reflex weaken sensibl coordin count sediment thyroid b12 hiv12 antinuclear extract complement c3 c4 chest xray refus biopsi test facioscapulohumer becker limbgirdl muscular dystrophi 2a electromyographi emg infraspinatu rhomboid deltoid bicep tricep muscl fibril recruit effort polyphas unit potenti mup approach fibrou needl medial later vastu rectu femori soleu emg spontan rest mup amplitud recruit effort ulnar peron tibial sural conduct magnet reson mri upper limb muscl intens t1weight imag fibrou replac subcutan muscl anterior posterior compart thigh t2weight shorttau invers recoveri imag stir intens keep edema 1c prednison mgkgdaili emg muscl brief polyphas mup recruit spontan wast shoulder proxim limb muscl mri philip 15t akieva midthigh coron axial t1w imag tr 45te7 asymmetr focal hypointens axial t2w tr4600te estir imag tr 80te 6330 thick enlarg muscl edemalik hyperintens signalwhit arrow muscl anterior posterior compart subcutan focal upper limb weak atrophi begin adulthood broad includ limbgirdl dystrophi spinal muscular atrophi polymyos myopath heroin addict repeat intramuscular inject alcohol loui 43 atroph fibrot myopathi affect select shoulder muscl weber exhibit biopsi proven myopathi respons steroid penicillamin biopsi atroph fiber lymphocyt macrophag perivascular endomysi infiltr endomysi fibrosi ongo regeneraton recoveri joint contractur weak mildli ck muscl distant inject clinic unaffect sign upper limb weak stiff ck myopat emg muscl distant inject emg mri congruent abnorm limb distanc circul heroin adulter diffus rhabdomyolysi unrel coma compress intraven self heroin dabbi nervou rhabdomyolysi intraven heroin intranas self plexopathi symmetr distal sensorimotor axon neuropathi notic 336 hour heroin aa toxic appear non compress neuropathi immunolog mielkeibrahim herdmann gupta transvers myeliti rhabdomyolysi na ve smoke heroin hypersensit uncertain heroin abus toxic se immunolog consequ inject heroin substanc ad adulter opioid modul tlymphocyt interleukin il herointr il1 il12 nitric oxid antiinflammatori il4 il10 opiat opioid lymphocyt nervou detail pathogen heroin myotox strike patholog featur eosinophil hypersensit homogen hypercontract myofibril degener fibr heroin myopathi hm equal muscl vulner depend region capillari fiber predomin receiv repeat intraperiton inject pure heroin degen regen abnorm soleu mostli compos fiber anterior tibiali compos fiber pe conclud hm myofibrillar hypercontract hm recov unclear threshold last exposur myotox\n",
            "\t-7.449\tmitogenactiv cro tyrosin t47d alcohol affect alcohol principl carcinogenesi alcoholinduc metastat observ alcohol differenti alcoholexpos t47d gelbas proteom cro tyrosin ros1 autophosphoryl therebi activ mitogen stressactiv msk1 mitogenactiv mapk msk1 turn phosphoryl histon serin h3s10p nucleu h3s10 consequ immediateearli cfo alcohol phosphoryl ros1 activ msk1 erk12 mapk modif histon 1433 recruit canceralcoholreceptor tyrosin kinasemitogenactiv pathwayhiston introductionmateri methodscel cultureproteom analysiswestern blottingrealtim revers transcriptas rtpcrdetermin proliferationchromatin immunoprecipit chip assaystatist analysisresultsidentif upregul ros1 alcoholtr t47d proteom analysiseffect alcohol ros1 mapk pathwayregul immediateearli alcohol mek12 treatmentregul recruit 1433 alcohol exposurediscuss alcohol oropharynx larynx esophag colon rectal alcoholinduc mutagen retino folat estrogen alcohol alcohol carcinogenesi alcohol affect upstream downstream mitogenactiv mapk mapk relay nucleu mapk activ parallel cascad downstream signalregul kina erk12 p38 mapk stressactiv kinasecjun nh2termin sapkjnk erk12 tyrosin kina rtk alcohol relay nucleu erk12 erk12 alcohol mcf7 epigenet histon modif carcinogen alcohol histon modif affect remodel chromatin histon posttransl modif acetyl ubiquitin sumoyl nucleosom remodel histon chaperon histon modifi histon regul condens instanc histon serin h3s10p regul interphas crosstalk modif h3 tail acetyl aid initi mapk uv irradi h3s10p h3 serin h3s28p hepatocyt alcohol acetaldehyd h3s10p h3s28p alcohol h3s10p h3s28p turn regul cfo cjun mkp1 kina phosphoryl histon aurora vrk1 mitogen stressactiv kinase12 msk12 pim1 rsk2 pkbakt ikk msk12 h3 stressactiv erk12 h3 immediateearli cfo cjun mapk alcoholinduc influenc chromatin alcohol proteom profil histon modif relay mapk alcoholtr ros1 alcoholexpos t47d ros1 protooncogen transduct regul mediat celltocel commun 31 ros1 autophosphoryl y2274 y2334 regul transduct mapk substrat irs1 phosphatidylinositol 3kinas pi3k akt stat3 vav3 mapk influenc chromatin therebi regul 33 mapk alcohol 34 36 alcohol ad hepatocellular hepg2 skhep erk12 alcoholinduc inhibit mek12 ad 37 erk12 p38 mapk jnk alcoholexpos hippocamp ht22 p38 mapk reactiv 38 erk12 compar nearbi erk12 erk12 pathophysiolog 65 alcohol mcf7 erk12induc 400 mek1 pd98059 administ alcohol 200 mcf7 hepatocyt hippocamp t47d exhibit erk12 msk1 alcohol ad t47d alcohol ad untreat mek12 u0126treat t47d alcohol u0126 restor u0126treat t47d reason alcoholinduc ros1 influenc mapk msk1 mapk alcoholexpos phosphoryl msk1 act h3 h3s10p h3s10p h3s28p intraperiton inject gkg alcohol cfo cjun mkp1 alcohol acetaldehyd administ separ hepatocyt p38 mapk reach peak min p38 mapk h3s10p h3s28p histon alcohol alcohol close histon alcoholinduc h3s10p regul recruit 1433 upstream cfo 1433 isoform abund phosphospecif bind phosphoryl histon serin 39 link phosphoryl histon 1433 29 phosphoryl h3s10 tpastimul msk1 recruit 1433 mediat recruit swisnf fosjun polymeras induc 29 alcohol 1433 upstream cfo notabl h3s10 recruit 1433 msk1 knockdown 29 msk1 extern alcohol histon remodel t47d alcohol ros1 upregul autophosphoryl ros1 turn activ msk1 erk12 mapk msk1induc h3s10p cfo 1433 recruit influenc alcoholexpos ros1 alcohol mapk alcohol mapk ros1 believ alcohol activ mapk ros1 confirm alcohol detriment\n",
            "\t-7.867\tapelin elev icr lnameinduc apelin endogen ligand apj belong proteincoupl apelin apj smooth apelin exert hypotens nitric oxid synthas eno apelin patholog poorli understood nitrolarginin methyl ester lname potent no administ chronic lnametr exhibit adhes molecule1 plasminogen activ inhibitor1 aorta vasodilat aortic eno withdraw lname apelin apelin nontreat transient elev lnametr apelin vasopressor patholog apelinapjlnameendotheli dysfunctionimpair vasodilatationmicevasopressor introductionmateri methodsgener hypertens miceaorta prepar extractiongen realtim rtpcrmeasur isometr tensionblood intraperiton inject apelinstatist analysisresultshypertens lnametr miceexpress damagerel lname treatmentimpair vasodil lnametr aortahypertens apelin lnametr micediscuss apelin origin bovin stomach endogen ligand apj belong proteincoupl apelin apj smooth apelin hypotens nitric oxid synthas no apj apelindepend hypotens no eno apjdefici hypothes apelin vasodil steadi apelin contract saphen vein endothelium physic remov ex phosphoryl myosin ratelimit event constrict cultur smooth apelin vasopressor vasoconstrict homeostasi apelindepend predispos thrombu nitrolarginin methyl ester lname potent no chronic administ lnametr exhibit dysfunctionrel vasodilat apelin transient elev lnametr hypotens nontreat apelin pathophysiolog apelin releas vasodilatori substanc lower apelin patholog chronic treat lname analog molecul asymmetr dimethyl arginin adma seriou lname adma inhibit suppress enzymat eno accompani lnametr dysfunctionrel vasodil fig lname tie2 2c retain damag wall 2a lname eno 2d eno lname aortic bioavail acceler patholog vasodil 2e patholog apelin provok vasopressor lower nontreat 3a hypertens lname mediat vasoconstrict apelin smooth apj aortic remov 3b apelin pas admadamag barrier permeabl apelin gain smooth constrict apelin affect becom patholog hypothes protect substanc constrict vessel respect detail insight complex apelin\n",
            "left upper and lower extremity weakness,recombinant tissue plasminogen activator,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.356\titch lesson cough itch unpleas sensat elicit desir scratch remov irrit cough reflex irrit purpos remov said irrit airway cough itch anatom smalldiamet sensori fiber cough itch sensori fiber neuropeptid nerv cough itch involv mast mediat releas degranul mast itch cough anatomi itch compar cough highlight itch cough thought perspect field itchcoughskinairwaycfibersafibersmast cellstrpsgpcrsinflamm introductionreviewprimari sensori fiber itch cough pathwaysmyelin fibersitchcoughc fibersitchcoughionotrop itch coughtrpv1itchcoughtrpa1itchcoughinflammatori mediatorssubst pitchcoughbradykininitchcoughmast mediatorshistamineitchcoughserotoninitchcoughproteasesitchcoughgastrinreleas receptoritchcoughconclus directionseth approvalabbreviationscompet interestsauthor contribut  itch start explor expans coupl challeng overcom itch itch pruritogen misfunct itch downstream itch discov itch expand valid extens collabor basic research clinician dermatologist logist compani antipain compani realiz itch industri collabor basic laboratori conduct screen itch blocker compani convinc antichron itch market anatom itch grow obviou sensori importantli cfiber pivot itch percept tie close sensori fiber neurogen involv sp bradykinin mast itch flare wheal easili cough similar itch cough sen irrit cough incorpor movement itch scratch muscl joint scratch receiv itch cough smooth movement incorpor actual cough reflex move irrit blockag airway motil aspect special myelin fiber cough special itch cough reason visit itch quickli detriment realiz similar itch cough idea perhap way appli exist clinic antihistamin itch cough antihistamin real discov histamineindepend progress histamineindepend itch discoveri mrgpr mrgpr encod orphan proteincoupl gpcr consist mrgpr mrgpra3 mrgprc11 subset smalldiamet sensori drg trigemin ganglion mrgprx select drg mrgpr sensori sensat itch mrgpr contribut cough besid drg mrgpra3 mrgprc11 nodosevagu ganglion innerv airway discoveri ligand mrgprx1 mrgprc11 bam822 tussiv mrgpr quickli explor alanin activ mrgprd histamin insensit interest know mrgpr agonist alanin cough mrgpr cough realiz similar itch cough expans repertoir tussiv work direct pruritogen probe expand cough realiz parallel similar itch therapi theori eventu enhanc itch cough million everi ethic approv\n",
            "\t0.320\t    articl foot ankl germanaustrian consensu oper charcot neuroarthropathi perspect charcot forc german foot citat foot ankl 10207 doi 103402dfav2i010207 print error th subsect page incorrect correct percentag mark bold foot compris subgroup pvd pnp pvd pnp cn pnp alway alway notic thousand diabet pnp german insur german situat translat 5000 emerg everi stuck annual thousand diabet cn pnp \n",
            "\t0.320\t    articl foot ankl germanaustrian consensu oper charcot neuroarthropathi perspect charcot forc german foot citat foot ankl 10207 doi 103402dfav2i010207 print error th subsect page incorrect correct percentag mark bold foot compris subgroup pvd pnp pvd pnp cn pnp alway alway notic thousand diabet pnp german insur german situat translat 5000 emerg everi stuck annual thousand diabet cn pnp \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.484\tbrachydactyli featur brachydactyli bd refer shorten hand foot bd bde featur syndrom pseudohypopthyroid php bd bilginturan bd htnb bd retard bdmr bde statur pthlh characterist skelet brachydactyli constant featur phenotyp variabl syndrom misdiagnos brachydactyli discus object syndrom bde focus biochem diagnos establish algorithm recruit endocrinolog pediatr endocrinolog statur algorithm step profession  brachydactyli bd refer limb malform shorten hand foot ad intern nosolog classif skelet genet dysostos brachydactyli distinguish anatom ground classif bell modifi temtami mckusick except a3 bda3 omim112700 bdd omim113200 brachydactyli bde omim113300 syndrom bde encompass shorten metacarpalsmetatars phalang hertzog classifi bde varieti e1 shorten metacarp iv sometim shorten metatars iv metatars e2 shorten metacarp iv metatars shorten distal phalanx thumb e3 combin metacarp phalang held exactli syndrom distal phalanx thumb phalang shorten syndrom bde outlin biochem file s1 establish algorithm accur bde acrodysostosi trichorinhophalang pure brachydactyli peculiar radiolog sometim misdiagnos syndrom bde tri defin distinguish multihormon pthyroid hormon pth thyroid hormon tsh featur classifi syndrom depend multihormon recruit endocrinolog pediatr endocrinolog statur hormon brachydactyli hoxd13 omim113300brachydactyli syndromesbd multihormon resistancepseudohypopthyroidismacrodysostosi multihormon acrdys1 omim101800bd multihormon resistanceshort staturebilginturan bd brachydactyli htnb omim112410bd statur pthlh omim613382aholikebrachydactyli retard bdmr omim600430acrodysostosi multihormon acrdys2 omim614613trichorhinophalang trpsturner tsconclud remarkscompet interestsauthor contributionssupplementari materialaddit file s1 bde occasion entiti heterozyg homeobox d13 hoxd13 2q311 missens nonsens caus bde overlap bde bdd shorten distal phalanx thumb note malform bde syndactyli digit iv synpolydactyli finger iv distal phalang hoxd13 produc synpolydactyli spd omim186000 syndactyli unspecifi limb malform bde hoxd13 variat shorten metacarp sometim iv foot shorten metatars iv sometim metatars broaden hallux littlefing distal phalanx hypoplasiaaplasia later phalang duplic clinodactyli finger iv syndactyli finger iiiiv statur appreci psychomotor development delay file s2 radiograph hand foot non heterozyg hoxd13 omim113300 courtesi aleksand jamsheer shorten widen iv metacarp evid iv distal brachyphalangi mild clynodactyli distal phalanx foot note asymmetr shorten metatars foot iv shorten iv note clynodactyli hallux \n",
            "\t-7.144\tleech bite 42 final leech bite specialti infecti unusu hirudo medicinali medicinali refer leech ancient modern centuri introduc discus leech bite beyond extern hemorrhag 42yearold woman refer emerg room pain itchi foot leg knee leg leech adher onto leg rubor itch leechadh poplit leg posterior erythemat edemat plaquelik shape ecchymot hemorrhag centr articl woman refer emerg depart leech bite region subcutan hematoma cutan reaction medicinali ecchymosi extern bleed keep mind leech bite itchi calv knee foot leech bitecompl leech biteregion subcutan hematomacutan reaction backgroundcas reportdiscussionconclus hirudo medicinali medicinali term leech ancient modern centuri flab reimplant graft surgeon venou congest maintain circul medicinali folk remedi joint vagin rectal nasal extern cutan bleed leech bite region subcutan hematoma cutan reaction region cutan reaction ecchymos leech bite medicinali ecchymosi extern bleed leech leech elicit itchi calv knee foot consid leech bite alert leech bite\n",
            "\t-7.443\torangebrown chromonychia kawasaki    dear editor kawasaki kd middle arteri coronari arteri etiolog unclear classic kd fever last bilater nonpurul conjunctiv inject mucos red swell hand foot rash cervic lymphadenopathi cutan kd typic nail transvers leukonychia onychomadesi pincer nail pal giri kd transvers orangebrown chromonychia incorpor addon kd 5yearold korean girl transvers orangebrown discolor finger toe nail periungu desquam chromonychia ten kd aspirin visit orangebrown discolor distal portion nail conjunctiv hyperemia crack lip strawberri tongu nail discolor orangebrown chromonychia kd transvers orangebrown discolor disappear nail abnorm kd ciastko onychomadesi boy kd start fever pincer nail deform beau kd nail abnorm spontan resolv otherwis lindsley red transvers nailb kd chromonychia local vascul nailb hyperemia thereaft pal amd giri typic transvers orangebrown discolor nail kd 75 29 recogn orangebrown chromonychia start appear fifth eight fever slowli fade away orangebrown chromonychia featur kd differ nail chromonychia antineoplast adriamycin cyclophosphamid vincristin thermal contact element iron angiotensinreceptor blockag nail harden lupu erythematosu hyperbilirubinemia summari orangebrown chromonychia kd kd appear \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.356\titch lesson cough itch unpleas sensat elicit desir scratch remov irrit cough reflex irrit purpos remov said irrit airway cough itch anatom smalldiamet sensori fiber cough itch sensori fiber neuropeptid nerv cough itch involv mast mediat releas degranul mast itch cough anatomi itch compar cough highlight itch cough thought perspect field itchcoughskinairwaycfibersafibersmast cellstrpsgpcrsinflamm introductionreviewprimari sensori fiber itch cough pathwaysmyelin fibersitchcoughc fibersitchcoughionotrop itch coughtrpv1itchcoughtrpa1itchcoughinflammatori mediatorssubst pitchcoughbradykininitchcoughmast mediatorshistamineitchcoughserotoninitchcoughproteasesitchcoughgastrinreleas receptoritchcoughconclus directionseth approvalabbreviationscompet interestsauthor contribut  itch start explor expans coupl challeng overcom itch itch pruritogen misfunct itch downstream itch discov itch expand valid extens collabor basic research clinician dermatologist logist compani antipain compani realiz itch industri collabor basic laboratori conduct screen itch blocker compani convinc antichron itch market anatom itch grow obviou sensori importantli cfiber pivot itch percept tie close sensori fiber neurogen involv sp bradykinin mast itch flare wheal easili cough similar itch cough sen irrit cough incorpor movement itch scratch muscl joint scratch receiv itch cough smooth movement incorpor actual cough reflex move irrit blockag airway motil aspect special myelin fiber cough special itch cough reason visit itch quickli detriment realiz similar itch cough idea perhap way appli exist clinic antihistamin itch cough antihistamin real discov histamineindepend progress histamineindepend itch discoveri mrgpr mrgpr encod orphan proteincoupl gpcr consist mrgpr mrgpra3 mrgprc11 subset smalldiamet sensori drg trigemin ganglion mrgprx select drg mrgpr sensori sensat itch mrgpr contribut cough besid drg mrgpra3 mrgprc11 nodosevagu ganglion innerv airway discoveri ligand mrgprx1 mrgprc11 bam822 tussiv mrgpr quickli explor alanin activ mrgprd histamin insensit interest know mrgpr agonist alanin cough mrgpr cough realiz similar itch cough expans repertoir tussiv work direct pruritogen probe expand cough realiz parallel similar itch therapi theori eventu enhanc itch cough million everi ethic approv\n",
            "\t0.320\t    articl foot ankl germanaustrian consensu oper charcot neuroarthropathi perspect charcot forc german foot citat foot ankl 10207 doi 103402dfav2i010207 print error th subsect page incorrect correct percentag mark bold foot compris subgroup pvd pnp pvd pnp cn pnp alway alway notic thousand diabet pnp german insur german situat translat 5000 emerg everi stuck annual thousand diabet cn pnp \n",
            "\t0.320\t    articl foot ankl germanaustrian consensu oper charcot neuroarthropathi perspect charcot forc german foot citat foot ankl 10207 doi 103402dfav2i010207 print error th subsect page incorrect correct percentag mark bold foot compris subgroup pvd pnp pvd pnp cn pnp alway alway notic thousand diabet pnp german insur german situat translat 5000 emerg everi stuck annual thousand diabet cn pnp \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.484\tbrachydactyli featur brachydactyli bd refer shorten hand foot bd bde featur syndrom pseudohypopthyroid php bd bilginturan bd htnb bd retard bdmr bde statur pthlh characterist skelet brachydactyli constant featur phenotyp variabl syndrom misdiagnos brachydactyli discus object syndrom bde focus biochem diagnos establish algorithm recruit endocrinolog pediatr endocrinolog statur algorithm step profession  brachydactyli bd refer limb malform shorten hand foot ad intern nosolog classif skelet genet dysostos brachydactyli distinguish anatom ground classif bell modifi temtami mckusick except a3 bda3 omim112700 bdd omim113200 brachydactyli bde omim113300 syndrom bde encompass shorten metacarpalsmetatars phalang hertzog classifi bde varieti e1 shorten metacarp iv sometim shorten metatars iv metatars e2 shorten metacarp iv metatars shorten distal phalanx thumb e3 combin metacarp phalang held exactli syndrom distal phalanx thumb phalang shorten syndrom bde outlin biochem file s1 establish algorithm accur bde acrodysostosi trichorinhophalang pure brachydactyli peculiar radiolog sometim misdiagnos syndrom bde tri defin distinguish multihormon pthyroid hormon pth thyroid hormon tsh featur classifi syndrom depend multihormon recruit endocrinolog pediatr endocrinolog statur hormon brachydactyli hoxd13 omim113300brachydactyli syndromesbd multihormon resistancepseudohypopthyroidismacrodysostosi multihormon acrdys1 omim101800bd multihormon resistanceshort staturebilginturan bd brachydactyli htnb omim112410bd statur pthlh omim613382aholikebrachydactyli retard bdmr omim600430acrodysostosi multihormon acrdys2 omim614613trichorhinophalang trpsturner tsconclud remarkscompet interestsauthor contributionssupplementari materialaddit file s1 bde occasion entiti heterozyg homeobox d13 hoxd13 2q311 missens nonsens caus bde overlap bde bdd shorten distal phalanx thumb note malform bde syndactyli digit iv synpolydactyli finger iv distal phalang hoxd13 produc synpolydactyli spd omim186000 syndactyli unspecifi limb malform bde hoxd13 variat shorten metacarp sometim iv foot shorten metatars iv sometim metatars broaden hallux littlefing distal phalanx hypoplasiaaplasia later phalang duplic clinodactyli finger iv syndactyli finger iiiiv statur appreci psychomotor development delay file s2 radiograph hand foot non heterozyg hoxd13 omim113300 courtesi aleksand jamsheer shorten widen iv metacarp evid iv distal brachyphalangi mild clynodactyli distal phalanx foot note asymmetr shorten metatars foot iv shorten iv note clynodactyli hallux \n",
            "\t-7.144\tleech bite 42 final leech bite specialti infecti unusu hirudo medicinali medicinali refer leech ancient modern centuri introduc discus leech bite beyond extern hemorrhag 42yearold woman refer emerg room pain itchi foot leg knee leg leech adher onto leg rubor itch leechadh poplit leg posterior erythemat edemat plaquelik shape ecchymot hemorrhag centr articl woman refer emerg depart leech bite region subcutan hematoma cutan reaction medicinali ecchymosi extern bleed keep mind leech bite itchi calv knee foot leech bitecompl leech biteregion subcutan hematomacutan reaction backgroundcas reportdiscussionconclus hirudo medicinali medicinali term leech ancient modern centuri flab reimplant graft surgeon venou congest maintain circul medicinali folk remedi joint vagin rectal nasal extern cutan bleed leech bite region subcutan hematoma cutan reaction region cutan reaction ecchymos leech bite medicinali ecchymosi extern bleed leech leech elicit itchi calv knee foot consid leech bite alert leech bite\n",
            "\t-7.443\torangebrown chromonychia kawasaki    dear editor kawasaki kd middle arteri coronari arteri etiolog unclear classic kd fever last bilater nonpurul conjunctiv inject mucos red swell hand foot rash cervic lymphadenopathi cutan kd typic nail transvers leukonychia onychomadesi pincer nail pal giri kd transvers orangebrown chromonychia incorpor addon kd 5yearold korean girl transvers orangebrown discolor finger toe nail periungu desquam chromonychia ten kd aspirin visit orangebrown discolor distal portion nail conjunctiv hyperemia crack lip strawberri tongu nail discolor orangebrown chromonychia kd transvers orangebrown discolor disappear nail abnorm kd ciastko onychomadesi boy kd start fever pincer nail deform beau kd nail abnorm spontan resolv otherwis lindsley red transvers nailb kd chromonychia local vascul nailb hyperemia thereaft pal amd giri typic transvers orangebrown discolor nail kd 75 29 recogn orangebrown chromonychia start appear fifth eight fever slowli fade away orangebrown chromonychia featur kd differ nail chromonychia antineoplast adriamycin cyclophosphamid vincristin thermal contact element iron angiotensinreceptor blockag nail harden lupu erythematosu hyperbilirubinemia summari orangebrown chromonychia kd kd appear \n",
            "itchy foot,KOH None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.411\ttoler korean lean elderli toler igt undiagnos postchalleng hyperglycemia iph elderli korean elderli lean fortyon lean age 6588 took hr toler ogtt stratifi toler ngt n20 igt n6 diabet n15 seven iph hba1c fructosamin progress ngt p0006 p0001 ngt insulinogen aucin 053 044 145 018 000 111 p003 306165 19978 pmoll p002 auccpeptid 22159 20634 14951 pmoll p0001 homeostasi homair conclud ngt elderli lean glucoseinduc preserv necessarili korean elderli lean    \n",
            "\t0.411\ttoler korean lean elderli toler igt undiagnos postchalleng hyperglycemia iph elderli korean elderli lean fortyon lean age 6588 took hr toler ogtt stratifi toler ngt n20 igt n6 diabet n15 seven iph hba1c fructosamin progress ngt p0006 p0001 ngt insulinogen aucin 053 044 145 018 000 111 p003 306165 19978 pmoll p002 auccpeptid 22159 20634 14951 pmoll p0001 homeostasi homair conclud ngt elderli lean glucoseinduc preserv necessarili korean elderli lean    \n",
            "\t0.407\testrogen polymorph relat angl glaucoma account gender circul estrogen glaucoma phenotyp trait estrogen nucleotid polymorph snp panel relat angl glaucoma poag account gender 3108 poag 3430 gender glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium genotyp illumina 660wquad platform relat snp panel repres estrogen poag genebas random incorpor pari softwar pari execut permut algorithm signific compar architectur metaanalyz glaugen neighbor set poag subtyp poag intraocular iop mmhg highpressur glaucoma hpg iop mmhg glaucoma npg gender separ jointli estrogen snp poag permut p0006 hpg permut 0001 npg permut p009 relat estrogen snp poag permut 099 genebas catecholomethyltransferas htg permut 0001 npg permut p001 estrogen snp poag  introductionmethodsdescript populationsophthalm participantsgenotyp datagen analysesdefin estrogen random incorpor analysisresultssignific estrogen relat openangl glaucoma poag glaugen neighbor dataset poag subtyp poag intraocular gendergen signific estrogen subdivid intraocular glaucoma diagnosisdiscuss accumul circul estrogen glaucoma reproduct postreproduct estrogen approxim intraocular iop concomit corneal thick estrogen throughout menstrual neuroretin rim confoc scan laser ophthalmoscopi wavelength autom perimetri ocular postmenopaus iop agematch menstruat postmenopaus hormon pmh iop ocular age pmh restor ocular indic premenopaus menopaus angl glaucoma rotterdam nurs nh age 65 enter menopaus 54 angl glaucoma poag nh pmh hightens poag 65 collect estrogen poag ioprel optic neuropathi convers hormon poag date estrogen poag restrict candid estrogen esr2 retin ganglion investig estrogen esr1 esr2 nucleotid polymorph snp poag conflict entir estrogen snp poag genderspecif hypothes estrogen glaucoma exist aggreg estrogen snp poag aris weak glaucomat research aggreg estrogen uterin yield encourag assembl throughput genotyp snp set glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium estrogen snp panel random incorpor pari softwar packag panel poag similarli collect snp compris poag esr2 snp poag differ consider gender pmh poag candid ass estrogen snp candid poag estrogen snp poag genomewid estrogen poag notion modest glaucomat estrogen poag classifi hpg highlight sexual dimorph definit poag latter contribut null relat estrogen poag jointli esr1 code estrogen alpha retina sex 87 incid poag 3616 haplotyp esr1 snp angl glaucoma rotterdam 3108 3430 genotyp 127 esr1 snp collect esr1 snp contribut estrogen poag hpg permut 0001 esr1 modest esr1 permut poag 031 neighbor 2132 026 glaugen 976 reach signific esr1 modestli poag permut p0023 exogen estrogen protect neurodegener glaucoma rais question polymorph esr2 code estrogen retin ganglion alter affin estrogen retin ganglion viabil glaucoma japanes esr2 rs1256031 rs4986938 hpg 212 191 859 hpg 1937 contain genotyp 38 esr2 snp snp ld rs1256031 rs4986938 collect esr2 snp npg permut 0001 hpg permut p010 rs1256031 rs4986938 hpg rotterdam european caucasian esr2 snp angl glaucoma esr2 snp poag permut 099 rs1256031 rs4986938 snp 045 conflict stratif ass set evalu collect relat glaucoma exist estrogen polymorph poag esr1 snp play hpg esr2 snp play npg comt code catecholomethyltransferas catalyz methyl sadenosyl methionin hydroxyl estrogen dopamin epinephrin comt methyl deriv estradiol 2hydroxyestradiol 4hydroxyestradiol perhap estrogen bioavail comt hpg npg comt angl glaucoma saw intern set permut comt hpg 001 neighbor 002 glaugen robust comt differenti cytochrom p450 estrogen code contribut estrogen poag cyp3a4 htg cyp17a1 cypia1 cypia2 npg cyp1b1 snp poag metaanalysi cyp1bi snp poag consist 1953 1341 larg 3108 3430 cyp1b1 aggreg snp poag permut p0098 cytochrom p450 glaucoma intrigu specul estrogen cytochrom p450 alter estrogen angl glaucoma none snp estrogen poag gender strict bonferroni correct impos nonetheless exist genomewid poag underpow biolog meaning snp modest curb fals discoveri purpos hypothesisdriven involv snp subset insight poag compar replic intern neighbor glaugen comt hpg intrigu polymorph estrogenmetabol poag caution warrant replic set estrogen snp poag discret glaucomat largest 6538 ass relat aggreg 903 estrogenmetabol snp relat poag snp poag shed epidemiolog basic scienc implic estrogen poag avenu estrogen poag genderspecif tailor makeup\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.750\testrogen polymorph relat angl glaucoma account gender circul estrogen glaucoma phenotyp trait estrogen nucleotid polymorph snp panel relat angl glaucoma poag account gender 3108 poag 3430 gender glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium genotyp illumina 660wquad platform relat snp panel repres estrogen poag genebas random incorpor pari softwar pari execut permut algorithm signific compar architectur metaanalyz glaugen neighbor set poag subtyp poag intraocular iop mmhg highpressur glaucoma hpg iop mmhg glaucoma npg gender separ jointli estrogen snp poag permut p0006 hpg permut 0001 npg permut p009 relat estrogen snp poag permut 099 genebas catecholomethyltransferas htg permut 0001 npg permut p001 estrogen snp poag  introductionmethodsdescript populationsophthalm participantsgenotyp datagen analysesdefin estrogen random incorpor analysisresultssignific estrogen relat openangl glaucoma poag glaugen neighbor dataset poag subtyp poag intraocular gendergen signific estrogen subdivid intraocular glaucoma diagnosisdiscuss accumul circul estrogen glaucoma reproduct postreproduct estrogen approxim intraocular iop concomit corneal thick estrogen throughout menstrual neuroretin rim confoc scan laser ophthalmoscopi wavelength autom perimetri ocular postmenopaus iop agematch menstruat postmenopaus hormon pmh iop ocular age pmh restor ocular indic premenopaus menopaus angl glaucoma rotterdam nurs nh age 65 enter menopaus 54 angl glaucoma poag nh pmh hightens poag 65 collect estrogen poag ioprel optic neuropathi convers hormon poag date estrogen poag restrict candid estrogen esr2 retin ganglion investig estrogen esr1 esr2 nucleotid polymorph snp poag conflict entir estrogen snp poag genderspecif hypothes estrogen glaucoma exist aggreg estrogen snp poag aris weak glaucomat research aggreg estrogen uterin yield encourag assembl throughput genotyp snp set glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium estrogen snp panel random incorpor pari softwar packag panel poag similarli collect snp compris poag esr2 snp poag differ consider gender pmh poag candid ass estrogen snp candid poag estrogen snp poag genomewid estrogen poag notion modest glaucomat estrogen poag classifi hpg highlight sexual dimorph definit poag latter contribut null relat estrogen poag jointli esr1 code estrogen alpha retina sex 87 incid poag 3616 haplotyp esr1 snp angl glaucoma rotterdam 3108 3430 genotyp 127 esr1 snp collect esr1 snp contribut estrogen poag hpg permut 0001 esr1 modest esr1 permut poag 031 neighbor 2132 026 glaugen 976 reach signific esr1 modestli poag permut p0023 exogen estrogen protect neurodegener glaucoma rais question polymorph esr2 code estrogen retin ganglion alter affin estrogen retin ganglion viabil glaucoma japanes esr2 rs1256031 rs4986938 hpg 212 191 859 hpg 1937 contain genotyp 38 esr2 snp snp ld rs1256031 rs4986938 collect esr2 snp npg permut 0001 hpg permut p010 rs1256031 rs4986938 hpg rotterdam european caucasian esr2 snp angl glaucoma esr2 snp poag permut 099 rs1256031 rs4986938 snp 045 conflict stratif ass set evalu collect relat glaucoma exist estrogen polymorph poag esr1 snp play hpg esr2 snp play npg comt code catecholomethyltransferas catalyz methyl sadenosyl methionin hydroxyl estrogen dopamin epinephrin comt methyl deriv estradiol 2hydroxyestradiol 4hydroxyestradiol perhap estrogen bioavail comt hpg npg comt angl glaucoma saw intern set permut comt hpg 001 neighbor 002 glaugen robust comt differenti cytochrom p450 estrogen code contribut estrogen poag cyp3a4 htg cyp17a1 cypia1 cypia2 npg cyp1b1 snp poag metaanalysi cyp1bi snp poag consist 1953 1341 larg 3108 3430 cyp1b1 aggreg snp poag permut p0098 cytochrom p450 glaucoma intrigu specul estrogen cytochrom p450 alter estrogen angl glaucoma none snp estrogen poag gender strict bonferroni correct impos nonetheless exist genomewid poag underpow biolog meaning snp modest curb fals discoveri purpos hypothesisdriven involv snp subset insight poag compar replic intern neighbor glaugen comt hpg intrigu polymorph estrogenmetabol poag caution warrant replic set estrogen snp poag discret glaucomat largest 6538 ass relat aggreg 903 estrogenmetabol snp relat poag snp poag shed epidemiolog basic scienc implic estrogen poag avenu estrogen poag genderspecif tailor makeup\n",
            "\t-5.463\t3m cul7 distress gh 3m autosom recess cul7 obsl1 ccdc8 characteris dysmorph skelet abnorm gh statur emirati sibl 10yearold boy characterist prenat postnat triangular face philtrum full lip promin heel pval88ala cul7 parent firstdegre cousin nine die birth retard boy sibl reach height 117 cm 671 sd never gh start gh height 94 cm 53 sd 3m statur dysmorph skelet abnorm famili consanguin sibl infanc clue confirm counsel gh benefici improv statur 3m famili sibl statur consanguin help confirm sibl gh improv statur 3m  backgroundcas presentationinvestigationgenet testingtreatmentoutcom followupdiscussionconclusionpati consentauthor contribut statement 3m autosom recess initi miller name 3m characteris dysmorph skelet abnorm prenat postnat retard intellig subtl differenti dwarfism rais underdiagnos resembl silver russel syndrom achiev height descript 3m differenti silver russel classic 3m triangular face point chin philtrum full lip skelet hyperlordosi digit promin heel wing scapula pe planu joint hypermobl disloc classic radiolog typic slender bone foreshorten vertebr bodi defect 3m1 3m2 3m3 cul7 locat 6p211 obsl1 2q35 ccdc8 19q1332 huber cul7 29 famili 3m throughout cul7 3m prenat postnat child dysmorph skelet intrafamili degre compat view gh rhgh enabl counsel recess consent\n",
            "\t-6.162\tgynecomastia anti androgen gynecomastia bothersom take antiandrogen except distress physic mental man age 63 welltreat macroprolactinoma refer gynecomastia appear microsurgeri radiotherapi flutamid lesion suspect except huge enlarg breast mammographi breast mri suppos prostat phosphat rang hormon explor subclin hypogonad testosteron 74 ngml 39 fsh 149 muml 0711 lh 97 muml 0876 test ultrasound radiolog hormon adren explor cortisol 76 ngml 50250 dhea 59 gml 50560 e2402 pgml scan discus etiolog post subclin hypogonad anti androgen flutamid withdraw sign recurr gynecomastia disappear fibrosi agingantiandrogensgynecomastiaprost ntroduct ase eport iscuss gynecomastia present adolesc old imbal estrogen androgen sensibl estrogen antiandrogen antihypertens anticortisol antivirus iatrogen gynecomastia frequent antiandrogen vari hypertrophi mild moder giant huge pain bear physic psycholog \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.411\ttoler korean lean elderli toler igt undiagnos postchalleng hyperglycemia iph elderli korean elderli lean fortyon lean age 6588 took hr toler ogtt stratifi toler ngt n20 igt n6 diabet n15 seven iph hba1c fructosamin progress ngt p0006 p0001 ngt insulinogen aucin 053 044 145 018 000 111 p003 306165 19978 pmoll p002 auccpeptid 22159 20634 14951 pmoll p0001 homeostasi homair conclud ngt elderli lean glucoseinduc preserv necessarili korean elderli lean    \n",
            "\t0.411\ttoler korean lean elderli toler igt undiagnos postchalleng hyperglycemia iph elderli korean elderli lean fortyon lean age 6588 took hr toler ogtt stratifi toler ngt n20 igt n6 diabet n15 seven iph hba1c fructosamin progress ngt p0006 p0001 ngt insulinogen aucin 053 044 145 018 000 111 p003 306165 19978 pmoll p002 auccpeptid 22159 20634 14951 pmoll p0001 homeostasi homair conclud ngt elderli lean glucoseinduc preserv necessarili korean elderli lean    \n",
            "\t0.407\testrogen polymorph relat angl glaucoma account gender circul estrogen glaucoma phenotyp trait estrogen nucleotid polymorph snp panel relat angl glaucoma poag account gender 3108 poag 3430 gender glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium genotyp illumina 660wquad platform relat snp panel repres estrogen poag genebas random incorpor pari softwar pari execut permut algorithm signific compar architectur metaanalyz glaugen neighbor set poag subtyp poag intraocular iop mmhg highpressur glaucoma hpg iop mmhg glaucoma npg gender separ jointli estrogen snp poag permut p0006 hpg permut 0001 npg permut p009 relat estrogen snp poag permut 099 genebas catecholomethyltransferas htg permut 0001 npg permut p001 estrogen snp poag  introductionmethodsdescript populationsophthalm participantsgenotyp datagen analysesdefin estrogen random incorpor analysisresultssignific estrogen relat openangl glaucoma poag glaugen neighbor dataset poag subtyp poag intraocular gendergen signific estrogen subdivid intraocular glaucoma diagnosisdiscuss accumul circul estrogen glaucoma reproduct postreproduct estrogen approxim intraocular iop concomit corneal thick estrogen throughout menstrual neuroretin rim confoc scan laser ophthalmoscopi wavelength autom perimetri ocular postmenopaus iop agematch menstruat postmenopaus hormon pmh iop ocular age pmh restor ocular indic premenopaus menopaus angl glaucoma rotterdam nurs nh age 65 enter menopaus 54 angl glaucoma poag nh pmh hightens poag 65 collect estrogen poag ioprel optic neuropathi convers hormon poag date estrogen poag restrict candid estrogen esr2 retin ganglion investig estrogen esr1 esr2 nucleotid polymorph snp poag conflict entir estrogen snp poag genderspecif hypothes estrogen glaucoma exist aggreg estrogen snp poag aris weak glaucomat research aggreg estrogen uterin yield encourag assembl throughput genotyp snp set glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium estrogen snp panel random incorpor pari softwar packag panel poag similarli collect snp compris poag esr2 snp poag differ consider gender pmh poag candid ass estrogen snp candid poag estrogen snp poag genomewid estrogen poag notion modest glaucomat estrogen poag classifi hpg highlight sexual dimorph definit poag latter contribut null relat estrogen poag jointli esr1 code estrogen alpha retina sex 87 incid poag 3616 haplotyp esr1 snp angl glaucoma rotterdam 3108 3430 genotyp 127 esr1 snp collect esr1 snp contribut estrogen poag hpg permut 0001 esr1 modest esr1 permut poag 031 neighbor 2132 026 glaugen 976 reach signific esr1 modestli poag permut p0023 exogen estrogen protect neurodegener glaucoma rais question polymorph esr2 code estrogen retin ganglion alter affin estrogen retin ganglion viabil glaucoma japanes esr2 rs1256031 rs4986938 hpg 212 191 859 hpg 1937 contain genotyp 38 esr2 snp snp ld rs1256031 rs4986938 collect esr2 snp npg permut 0001 hpg permut p010 rs1256031 rs4986938 hpg rotterdam european caucasian esr2 snp angl glaucoma esr2 snp poag permut 099 rs1256031 rs4986938 snp 045 conflict stratif ass set evalu collect relat glaucoma exist estrogen polymorph poag esr1 snp play hpg esr2 snp play npg comt code catecholomethyltransferas catalyz methyl sadenosyl methionin hydroxyl estrogen dopamin epinephrin comt methyl deriv estradiol 2hydroxyestradiol 4hydroxyestradiol perhap estrogen bioavail comt hpg npg comt angl glaucoma saw intern set permut comt hpg 001 neighbor 002 glaugen robust comt differenti cytochrom p450 estrogen code contribut estrogen poag cyp3a4 htg cyp17a1 cypia1 cypia2 npg cyp1b1 snp poag metaanalysi cyp1bi snp poag consist 1953 1341 larg 3108 3430 cyp1b1 aggreg snp poag permut p0098 cytochrom p450 glaucoma intrigu specul estrogen cytochrom p450 alter estrogen angl glaucoma none snp estrogen poag gender strict bonferroni correct impos nonetheless exist genomewid poag underpow biolog meaning snp modest curb fals discoveri purpos hypothesisdriven involv snp subset insight poag compar replic intern neighbor glaugen comt hpg intrigu polymorph estrogenmetabol poag caution warrant replic set estrogen snp poag discret glaucomat largest 6538 ass relat aggreg 903 estrogenmetabol snp relat poag snp poag shed epidemiolog basic scienc implic estrogen poag avenu estrogen poag genderspecif tailor makeup\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.750\testrogen polymorph relat angl glaucoma account gender circul estrogen glaucoma phenotyp trait estrogen nucleotid polymorph snp panel relat angl glaucoma poag account gender 3108 poag 3430 gender glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium genotyp illumina 660wquad platform relat snp panel repres estrogen poag genebas random incorpor pari softwar pari execut permut algorithm signific compar architectur metaanalyz glaugen neighbor set poag subtyp poag intraocular iop mmhg highpressur glaucoma hpg iop mmhg glaucoma npg gender separ jointli estrogen snp poag permut p0006 hpg permut 0001 npg permut p009 relat estrogen snp poag permut 099 genebas catecholomethyltransferas htg permut 0001 npg permut p001 estrogen snp poag  introductionmethodsdescript populationsophthalm participantsgenotyp datagen analysesdefin estrogen random incorpor analysisresultssignific estrogen relat openangl glaucoma poag glaugen neighbor dataset poag subtyp poag intraocular gendergen signific estrogen subdivid intraocular glaucoma diagnosisdiscuss accumul circul estrogen glaucoma reproduct postreproduct estrogen approxim intraocular iop concomit corneal thick estrogen throughout menstrual neuroretin rim confoc scan laser ophthalmoscopi wavelength autom perimetri ocular postmenopaus iop agematch menstruat postmenopaus hormon pmh iop ocular age pmh restor ocular indic premenopaus menopaus angl glaucoma rotterdam nurs nh age 65 enter menopaus 54 angl glaucoma poag nh pmh hightens poag 65 collect estrogen poag ioprel optic neuropathi convers hormon poag date estrogen poag restrict candid estrogen esr2 retin ganglion investig estrogen esr1 esr2 nucleotid polymorph snp poag conflict entir estrogen snp poag genderspecif hypothes estrogen glaucoma exist aggreg estrogen snp poag aris weak glaucomat research aggreg estrogen uterin yield encourag assembl throughput genotyp snp set glaucoma glaugen eye institut glaucoma genet collabor neighbor consortium estrogen snp panel random incorpor pari softwar packag panel poag similarli collect snp compris poag esr2 snp poag differ consider gender pmh poag candid ass estrogen snp candid poag estrogen snp poag genomewid estrogen poag notion modest glaucomat estrogen poag classifi hpg highlight sexual dimorph definit poag latter contribut null relat estrogen poag jointli esr1 code estrogen alpha retina sex 87 incid poag 3616 haplotyp esr1 snp angl glaucoma rotterdam 3108 3430 genotyp 127 esr1 snp collect esr1 snp contribut estrogen poag hpg permut 0001 esr1 modest esr1 permut poag 031 neighbor 2132 026 glaugen 976 reach signific esr1 modestli poag permut p0023 exogen estrogen protect neurodegener glaucoma rais question polymorph esr2 code estrogen retin ganglion alter affin estrogen retin ganglion viabil glaucoma japanes esr2 rs1256031 rs4986938 hpg 212 191 859 hpg 1937 contain genotyp 38 esr2 snp snp ld rs1256031 rs4986938 collect esr2 snp npg permut 0001 hpg permut p010 rs1256031 rs4986938 hpg rotterdam european caucasian esr2 snp angl glaucoma esr2 snp poag permut 099 rs1256031 rs4986938 snp 045 conflict stratif ass set evalu collect relat glaucoma exist estrogen polymorph poag esr1 snp play hpg esr2 snp play npg comt code catecholomethyltransferas catalyz methyl sadenosyl methionin hydroxyl estrogen dopamin epinephrin comt methyl deriv estradiol 2hydroxyestradiol 4hydroxyestradiol perhap estrogen bioavail comt hpg npg comt angl glaucoma saw intern set permut comt hpg 001 neighbor 002 glaugen robust comt differenti cytochrom p450 estrogen code contribut estrogen poag cyp3a4 htg cyp17a1 cypia1 cypia2 npg cyp1b1 snp poag metaanalysi cyp1bi snp poag consist 1953 1341 larg 3108 3430 cyp1b1 aggreg snp poag permut p0098 cytochrom p450 glaucoma intrigu specul estrogen cytochrom p450 alter estrogen angl glaucoma none snp estrogen poag gender strict bonferroni correct impos nonetheless exist genomewid poag underpow biolog meaning snp modest curb fals discoveri purpos hypothesisdriven involv snp subset insight poag compar replic intern neighbor glaugen comt hpg intrigu polymorph estrogenmetabol poag caution warrant replic set estrogen snp poag discret glaucomat largest 6538 ass relat aggreg 903 estrogenmetabol snp relat poag snp poag shed epidemiolog basic scienc implic estrogen poag avenu estrogen poag genderspecif tailor makeup\n",
            "\t-5.463\t3m cul7 distress gh 3m autosom recess cul7 obsl1 ccdc8 characteris dysmorph skelet abnorm gh statur emirati sibl 10yearold boy characterist prenat postnat triangular face philtrum full lip promin heel pval88ala cul7 parent firstdegre cousin nine die birth retard boy sibl reach height 117 cm 671 sd never gh start gh height 94 cm 53 sd 3m statur dysmorph skelet abnorm famili consanguin sibl infanc clue confirm counsel gh benefici improv statur 3m famili sibl statur consanguin help confirm sibl gh improv statur 3m  backgroundcas presentationinvestigationgenet testingtreatmentoutcom followupdiscussionconclusionpati consentauthor contribut statement 3m autosom recess initi miller name 3m characteris dysmorph skelet abnorm prenat postnat retard intellig subtl differenti dwarfism rais underdiagnos resembl silver russel syndrom achiev height descript 3m differenti silver russel classic 3m triangular face point chin philtrum full lip skelet hyperlordosi digit promin heel wing scapula pe planu joint hypermobl disloc classic radiolog typic slender bone foreshorten vertebr bodi defect 3m1 3m2 3m3 cul7 locat 6p211 obsl1 2q35 ccdc8 19q1332 huber cul7 29 famili 3m throughout cul7 3m prenat postnat child dysmorph skelet intrafamili degre compat view gh rhgh enabl counsel recess consent\n",
            "\t-6.162\tgynecomastia anti androgen gynecomastia bothersom take antiandrogen except distress physic mental man age 63 welltreat macroprolactinoma refer gynecomastia appear microsurgeri radiotherapi flutamid lesion suspect except huge enlarg breast mammographi breast mri suppos prostat phosphat rang hormon explor subclin hypogonad testosteron 74 ngml 39 fsh 149 muml 0711 lh 97 muml 0876 test ultrasound radiolog hormon adren explor cortisol 76 ngml 50250 dhea 59 gml 50560 e2402 pgml scan discus etiolog post subclin hypogonad anti androgen flutamid withdraw sign recurr gynecomastia disappear fibrosi agingantiandrogensgynecomastiaprost ntroduct ase eport iscuss gynecomastia present adolesc old imbal estrogen androgen sensibl estrogen antiandrogen antihypertens anticortisol antivirus iatrogen gynecomastia frequent antiandrogen vari hypertrophi mild moder giant huge pain bear physic psycholog \n",
            "short stature,GH,estrogen None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.419\tventricular diastol copd    sir ventricular diastol lvdd cophenomenon obstruct copd diastol vari cardiomyopathi mellitu hypothyroid restrict infiltr amyloidosi etc signific lvdd copd larg ischem appar investig implic lvdd copd larg recogn lvdd claim causal copd exacerb coexist lvdd frequent prolong hospit exacerb copd lvdd turn benefici lvdd nine consecut copd diltiazem bisoprolol cardioselect beta blocker note copd cat uniform follow look spirometri cat histor exacerb pharmacotherapi preced treat lvdd comorbid rest pul arteri satur done lvdd 6500 636 2246 338 fev rest pul rest arteri satur cat chart lvdd copd fev rest pul arteri satur lvdd pharmacotherapi copd chang cat score cat score valid copd talli copd version st georg questionnair infer lvdd copd benefici warrant immedi valid alongsid determin lvdd copd \n",
            "\t0.419\tventricular diastol copd    sir ventricular diastol lvdd cophenomenon obstruct copd diastol vari cardiomyopathi mellitu hypothyroid restrict infiltr amyloidosi etc signific lvdd copd larg ischem appar investig implic lvdd copd larg recogn lvdd claim causal copd exacerb coexist lvdd frequent prolong hospit exacerb copd lvdd turn benefici lvdd nine consecut copd diltiazem bisoprolol cardioselect beta blocker note copd cat uniform follow look spirometri cat histor exacerb pharmacotherapi preced treat lvdd comorbid rest pul arteri satur done lvdd 6500 636 2246 338 fev rest pul rest arteri satur cat chart lvdd copd fev rest pul arteri satur lvdd pharmacotherapi copd chang cat score cat score valid copd talli copd version st georg questionnair infer lvdd copd benefici warrant immedi valid alongsid determin lvdd copd \n",
            "\t0.327\ttwodimension echocardiographi arteri diastol arteri pah clarifi twodimension echocardiographi 2decho prognost pah pah wsph symposium classif catheter rhc monotherapi 2decho organ classif 6minut walk distanc 6mwd record echo 6mwd receiv oper characterist roc curv fiftyeight ventricular diastol lvdd rvdd 2decho 6mwd lvdd 0699 rvdd 0818 0001 lvdd 0701 rvdd 0666 0001 biventricular lvddrvdd 2decho 6mwd 0831 0771 0001 roc curv curv auc lvdd rvdd lvddrvdd 0823 00001 0737 00002 0825 00001 roc diastol accur predict pah lvdd rvdd lvddrvdd yield comprehens lv rv diastol moder pah  introductionmateri methodspatientsinstru methods2dechotissu doppler later septal wall mitral annulu doppler later wall tricuspid annulu doppler tei d6mwd borg dyspnea scaletreatmentfollowupstatist analysisresultsbaselinebaselin demograph patientsclin echocardiograph followupfollowup dataleft ventricular diastol functionth lvdd followupth lvdd rvdd lvdd rvdd 6mwd fleft ventricular diastol lvdd followupright ventricular diastol functionth rvdd followupright ventricular diastol rvdd followupbiventricular diastol functionoth ventricular echocardiograph parametersth tap tei fac 6mwd fclinic analysisroc curv rhc echocardiograph lv rv dresult roc curv compar rhc echocardiograph leftright ventricular lvdd rvdd lvdd rvdd predict unfavor followupdiscussioncardiac functionlimitationsconclus echocardiographi echo preliminari suspect arteri pah ventricular rv outflow tract obstruct systol arteri spap rv systol rvsp calcul tricuspid regurgit gradient atrial echo rv tricuspid annular plane systol excurs tap tei mitral valv peak veloc mitral valv peak veloc ea magnet reson mri gold echo predict pah cost complex mri routin noninvas echo suitabl tent pah echo evalu predict pah valuabl echo comprehens pah ventricular diastol superior 2decho predict pah biventricular diastol ventricular diastol predict pah lvddrvddlvddrvdd yield comprehens lvrv diastol moder pah\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.362\telectrocardiograph bundl branch block ischem nonischem ventricular differenti ischem ilvd nonischem ventricular nilvd prognost therapeut clinic differenti electrocardiograph ecg bundlebranch block lbbb debat differenti ilvd nilvd ecg differenti ilvd nilvd lbbb lbbb divid ventricular ilvd 49 65 nilvd 49 59 numer ecg ecg except ecg voltag wave v6 statist nilvd ilvd 003 stj 02 mv v6 nilvd ilvd 39 0001 notch ascend descend limb wave v14 ilvd 36 003 003 ecg ecg lbbb differenti ilvd nilvd bundl branch blockischem ventricular introductionmethodsresultsdiscuss bundl branch block lbbb idiopath dilat ischem ventricular differenti ilvd nilvd prognost therapeut clinic noninvas reliabl distinguish ventricular coronari arteri cad nonischem reason center coronari angiographi routin cost inher risk invas catheter prognost ecg increasingli recogn numer electrocardiograph ecg nilvd ilvd lbbb ecgbas diagnos myocardi infarct ventricular hypertrophi lbbb problemat alter time ventricular depolar differenti ecg lbbb debat differenti ilvd nilvd ecg lbbb object momiyama evalu ecg nilvd nilvd ecg sign ventricular hypertrophi sokolow criterion voltag wave v6 nilvd voltag wave wave di dii diii lowest nicmp rv6 voltag 78 nilvd cad 0001 wave ri rii riii nilvd voltag ratio rv6ri rii riii nilvd rv6 maximum wave rv6rmax nilvd cad ventricular dilat invers eject fraction 61 nilvd none cad abnorm wave 69 cad nilvd abnorm wave dii diii avf v2v4 61 cad nilvd abnorm wave bayesgeni voltag precordi v2 v3 sum v1 v2 v3 voltag promin nilvd v3 voltag 2100 microv ecg lbbb ventricular nonischem origin 85 73 voltag indic firstli bit modern era valid prospect secondli ilvd nilvd cad percutan coronari lvef nonischem reason cad sever depress ventricular beyond cad nonlad markedli eject fraction definit distinct complic circumfer vessel ilvd ecg coronari angiographi amplitud notori precordi serial ecg serial ecg ecg ecg differenti ilvd nilvd lbbb\n",
            "\t0.362\telectrocardiograph bundl branch block ischem nonischem ventricular differenti ischem ilvd nonischem ventricular nilvd prognost therapeut clinic differenti electrocardiograph ecg bundlebranch block lbbb debat differenti ilvd nilvd ecg differenti ilvd nilvd lbbb lbbb divid ventricular ilvd 49 65 nilvd 49 59 numer ecg ecg except ecg voltag wave v6 statist nilvd ilvd 003 stj 02 mv v6 nilvd ilvd 39 0001 notch ascend descend limb wave v14 ilvd 36 003 003 ecg ecg lbbb differenti ilvd nilvd bundl branch blockischem ventricular introductionmethodsresultsdiscuss bundl branch block lbbb idiopath dilat ischem ventricular differenti ilvd nilvd prognost therapeut clinic noninvas reliabl distinguish ventricular coronari arteri cad nonischem reason center coronari angiographi routin cost inher risk invas catheter prognost ecg increasingli recogn numer electrocardiograph ecg nilvd ilvd lbbb ecgbas diagnos myocardi infarct ventricular hypertrophi lbbb problemat alter time ventricular depolar differenti ecg lbbb debat differenti ilvd nilvd ecg lbbb object momiyama evalu ecg nilvd nilvd ecg sign ventricular hypertrophi sokolow criterion voltag wave v6 nilvd voltag wave wave di dii diii lowest nicmp rv6 voltag 78 nilvd cad 0001 wave ri rii riii nilvd voltag ratio rv6ri rii riii nilvd rv6 maximum wave rv6rmax nilvd cad ventricular dilat invers eject fraction 61 nilvd none cad abnorm wave 69 cad nilvd abnorm wave dii diii avf v2v4 61 cad nilvd abnorm wave bayesgeni voltag precordi v2 v3 sum v1 v2 v3 voltag promin nilvd v3 voltag 2100 microv ecg lbbb ventricular nonischem origin 85 73 voltag indic firstli bit modern era valid prospect secondli ilvd nilvd cad percutan coronari lvef nonischem reason cad sever depress ventricular beyond cad nonlad markedli eject fraction definit distinct complic circumfer vessel ilvd ecg coronari angiographi amplitud notori precordi serial ecg serial ecg ecg ecg differenti ilvd nilvd lbbb\n",
            "\t-1.250\tpolym thin film nitrogen nitrogendop thiophen polym nthiopp thin film deposit radio 1356 mhz plasmaenhanc vapor deposit thiophen organ precursor carbon hydrogen ga precursor bubbler ga nitrogen ga nitrogen dopant argon carrier ga asgrown polymer thin film ellipsometri fouriertransform infrar ftir spectroscopi raman spectroscopi contact angl ellipsometri refract nthiopp film ftir spectrum nthiopp film complet fragment polymer thiophen pecvdplasma polymernthioppopticalphysicaland introductionexperiment detailresult discussionconclusionscompet interestsauthor contribut exist semiconductor technolog let silicon integr topdown nano molecul technolog merg nanotechnolog biotechniqu technolog bottomup constitut circuit selfalign atom opinion expert spite basic consensu expert progress nano molecul slow wors reason recogn question choic molecul technolog selfalign technolog atom technolog molecul contact metal electrod realiz nanoscal electron expect bottomup self align atom selfassembl supramolecul fabric bioapplic diamondlik carbon film candid bloodcontact devic cellcontact excel mechan nitrogendop polym deposit nitrogen inject plasmaenhanc vapor deposit ammonia ga nthiopp thin film nthiopp thin film deposit si100 pecvd ir spectrum nitril band 2025 2200 cm fingerprint thiopp nthiopp nthiopp thin film fabric nitrogen ga inject pecvd nh definit raman spectrum nh decreas contact angl nthiopp thin film decreas contact angl indirect nitrogen amount nthiopp thin film nitrogen atom bond thiophen pecvd nitrogen disturb bond thiophen refract nthiopp thin film nitrogen hard nthiopp thin film nitrogen amount thin film uvvi spectrum 80 transmitt infrar transmitt visibl dramat chang nitrogen amount bandgap nthiopp nitrogen amount nitrogendop polym thin film fabric easili nitrogen inject pecvd ammonia toxic ga optic nthiopp thin film control nitrogen compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.419\tventricular diastol copd    sir ventricular diastol lvdd cophenomenon obstruct copd diastol vari cardiomyopathi mellitu hypothyroid restrict infiltr amyloidosi etc signific lvdd copd larg ischem appar investig implic lvdd copd larg recogn lvdd claim causal copd exacerb coexist lvdd frequent prolong hospit exacerb copd lvdd turn benefici lvdd nine consecut copd diltiazem bisoprolol cardioselect beta blocker note copd cat uniform follow look spirometri cat histor exacerb pharmacotherapi preced treat lvdd comorbid rest pul arteri satur done lvdd 6500 636 2246 338 fev rest pul rest arteri satur cat chart lvdd copd fev rest pul arteri satur lvdd pharmacotherapi copd chang cat score cat score valid copd talli copd version st georg questionnair infer lvdd copd benefici warrant immedi valid alongsid determin lvdd copd \n",
            "\t0.419\tventricular diastol copd    sir ventricular diastol lvdd cophenomenon obstruct copd diastol vari cardiomyopathi mellitu hypothyroid restrict infiltr amyloidosi etc signific lvdd copd larg ischem appar investig implic lvdd copd larg recogn lvdd claim causal copd exacerb coexist lvdd frequent prolong hospit exacerb copd lvdd turn benefici lvdd nine consecut copd diltiazem bisoprolol cardioselect beta blocker note copd cat uniform follow look spirometri cat histor exacerb pharmacotherapi preced treat lvdd comorbid rest pul arteri satur done lvdd 6500 636 2246 338 fev rest pul rest arteri satur cat chart lvdd copd fev rest pul arteri satur lvdd pharmacotherapi copd chang cat score cat score valid copd talli copd version st georg questionnair infer lvdd copd benefici warrant immedi valid alongsid determin lvdd copd \n",
            "\t0.327\ttwodimension echocardiographi arteri diastol arteri pah clarifi twodimension echocardiographi 2decho prognost pah pah wsph symposium classif catheter rhc monotherapi 2decho organ classif 6minut walk distanc 6mwd record echo 6mwd receiv oper characterist roc curv fiftyeight ventricular diastol lvdd rvdd 2decho 6mwd lvdd 0699 rvdd 0818 0001 lvdd 0701 rvdd 0666 0001 biventricular lvddrvdd 2decho 6mwd 0831 0771 0001 roc curv curv auc lvdd rvdd lvddrvdd 0823 00001 0737 00002 0825 00001 roc diastol accur predict pah lvdd rvdd lvddrvdd yield comprehens lv rv diastol moder pah  introductionmateri methodspatientsinstru methods2dechotissu doppler later septal wall mitral annulu doppler later wall tricuspid annulu doppler tei d6mwd borg dyspnea scaletreatmentfollowupstatist analysisresultsbaselinebaselin demograph patientsclin echocardiograph followupfollowup dataleft ventricular diastol functionth lvdd followupth lvdd rvdd lvdd rvdd 6mwd fleft ventricular diastol lvdd followupright ventricular diastol functionth rvdd followupright ventricular diastol rvdd followupbiventricular diastol functionoth ventricular echocardiograph parametersth tap tei fac 6mwd fclinic analysisroc curv rhc echocardiograph lv rv dresult roc curv compar rhc echocardiograph leftright ventricular lvdd rvdd lvdd rvdd predict unfavor followupdiscussioncardiac functionlimitationsconclus echocardiographi echo preliminari suspect arteri pah ventricular rv outflow tract obstruct systol arteri spap rv systol rvsp calcul tricuspid regurgit gradient atrial echo rv tricuspid annular plane systol excurs tap tei mitral valv peak veloc mitral valv peak veloc ea magnet reson mri gold echo predict pah cost complex mri routin noninvas echo suitabl tent pah echo evalu predict pah valuabl echo comprehens pah ventricular diastol superior 2decho predict pah biventricular diastol ventricular diastol predict pah lvddrvddlvddrvdd yield comprehens lvrv diastol moder pah\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.362\telectrocardiograph bundl branch block ischem nonischem ventricular differenti ischem ilvd nonischem ventricular nilvd prognost therapeut clinic differenti electrocardiograph ecg bundlebranch block lbbb debat differenti ilvd nilvd ecg differenti ilvd nilvd lbbb lbbb divid ventricular ilvd 49 65 nilvd 49 59 numer ecg ecg except ecg voltag wave v6 statist nilvd ilvd 003 stj 02 mv v6 nilvd ilvd 39 0001 notch ascend descend limb wave v14 ilvd 36 003 003 ecg ecg lbbb differenti ilvd nilvd bundl branch blockischem ventricular introductionmethodsresultsdiscuss bundl branch block lbbb idiopath dilat ischem ventricular differenti ilvd nilvd prognost therapeut clinic noninvas reliabl distinguish ventricular coronari arteri cad nonischem reason center coronari angiographi routin cost inher risk invas catheter prognost ecg increasingli recogn numer electrocardiograph ecg nilvd ilvd lbbb ecgbas diagnos myocardi infarct ventricular hypertrophi lbbb problemat alter time ventricular depolar differenti ecg lbbb debat differenti ilvd nilvd ecg lbbb object momiyama evalu ecg nilvd nilvd ecg sign ventricular hypertrophi sokolow criterion voltag wave v6 nilvd voltag wave wave di dii diii lowest nicmp rv6 voltag 78 nilvd cad 0001 wave ri rii riii nilvd voltag ratio rv6ri rii riii nilvd rv6 maximum wave rv6rmax nilvd cad ventricular dilat invers eject fraction 61 nilvd none cad abnorm wave 69 cad nilvd abnorm wave dii diii avf v2v4 61 cad nilvd abnorm wave bayesgeni voltag precordi v2 v3 sum v1 v2 v3 voltag promin nilvd v3 voltag 2100 microv ecg lbbb ventricular nonischem origin 85 73 voltag indic firstli bit modern era valid prospect secondli ilvd nilvd cad percutan coronari lvef nonischem reason cad sever depress ventricular beyond cad nonlad markedli eject fraction definit distinct complic circumfer vessel ilvd ecg coronari angiographi amplitud notori precordi serial ecg serial ecg ecg ecg differenti ilvd nilvd lbbb\n",
            "\t0.362\telectrocardiograph bundl branch block ischem nonischem ventricular differenti ischem ilvd nonischem ventricular nilvd prognost therapeut clinic differenti electrocardiograph ecg bundlebranch block lbbb debat differenti ilvd nilvd ecg differenti ilvd nilvd lbbb lbbb divid ventricular ilvd 49 65 nilvd 49 59 numer ecg ecg except ecg voltag wave v6 statist nilvd ilvd 003 stj 02 mv v6 nilvd ilvd 39 0001 notch ascend descend limb wave v14 ilvd 36 003 003 ecg ecg lbbb differenti ilvd nilvd bundl branch blockischem ventricular introductionmethodsresultsdiscuss bundl branch block lbbb idiopath dilat ischem ventricular differenti ilvd nilvd prognost therapeut clinic noninvas reliabl distinguish ventricular coronari arteri cad nonischem reason center coronari angiographi routin cost inher risk invas catheter prognost ecg increasingli recogn numer electrocardiograph ecg nilvd ilvd lbbb ecgbas diagnos myocardi infarct ventricular hypertrophi lbbb problemat alter time ventricular depolar differenti ecg lbbb debat differenti ilvd nilvd ecg lbbb object momiyama evalu ecg nilvd nilvd ecg sign ventricular hypertrophi sokolow criterion voltag wave v6 nilvd voltag wave wave di dii diii lowest nicmp rv6 voltag 78 nilvd cad 0001 wave ri rii riii nilvd voltag ratio rv6ri rii riii nilvd rv6 maximum wave rv6rmax nilvd cad ventricular dilat invers eject fraction 61 nilvd none cad abnorm wave 69 cad nilvd abnorm wave dii diii avf v2v4 61 cad nilvd abnorm wave bayesgeni voltag precordi v2 v3 sum v1 v2 v3 voltag promin nilvd v3 voltag 2100 microv ecg lbbb ventricular nonischem origin 85 73 voltag indic firstli bit modern era valid prospect secondli ilvd nilvd cad percutan coronari lvef nonischem reason cad sever depress ventricular beyond cad nonlad markedli eject fraction definit distinct complic circumfer vessel ilvd ecg coronari angiographi amplitud notori precordi serial ecg serial ecg ecg ecg differenti ilvd nilvd lbbb\n",
            "\t-1.250\tpolym thin film nitrogen nitrogendop thiophen polym nthiopp thin film deposit radio 1356 mhz plasmaenhanc vapor deposit thiophen organ precursor carbon hydrogen ga precursor bubbler ga nitrogen ga nitrogen dopant argon carrier ga asgrown polymer thin film ellipsometri fouriertransform infrar ftir spectroscopi raman spectroscopi contact angl ellipsometri refract nthiopp film ftir spectrum nthiopp film complet fragment polymer thiophen pecvdplasma polymernthioppopticalphysicaland introductionexperiment detailresult discussionconclusionscompet interestsauthor contribut exist semiconductor technolog let silicon integr topdown nano molecul technolog merg nanotechnolog biotechniqu technolog bottomup constitut circuit selfalign atom opinion expert spite basic consensu expert progress nano molecul slow wors reason recogn question choic molecul technolog selfalign technolog atom technolog molecul contact metal electrod realiz nanoscal electron expect bottomup self align atom selfassembl supramolecul fabric bioapplic diamondlik carbon film candid bloodcontact devic cellcontact excel mechan nitrogendop polym deposit nitrogen inject plasmaenhanc vapor deposit ammonia ga nthiopp thin film nthiopp thin film deposit si100 pecvd ir spectrum nitril band 2025 2200 cm fingerprint thiopp nthiopp nthiopp thin film fabric nitrogen ga inject pecvd nh definit raman spectrum nh decreas contact angl nthiopp thin film decreas contact angl indirect nitrogen amount nthiopp thin film nitrogen atom bond thiophen pecvd nitrogen disturb bond thiophen refract nthiopp thin film nitrogen hard nthiopp thin film nitrogen amount thin film uvvi spectrum 80 transmitt infrar transmitt visibl dramat chang nitrogen amount bandgap nthiopp nitrogen amount nitrogendop polym thin film fabric easili nitrogen inject pecvd ammonia toxic ga optic nthiopp thin film control nitrogen compet interest\n",
            "NVD None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.381\tletter editor   dear editor dear editor congratul articl entitl optim nausea vomit comprehens frequent complic letter arriv public think research clarif seemingli minor avoid confus point metoclopramid section statement subcutan metoclopramid nvp hg support observ continu subcutan metoclopramid distinct receiv 267 4432 unfavor comparison recommend expens altern explor subject extrem prudent perhap continu subcutan metoclopramid accident suggest reassur excess sleepi impli diclectin tire continu subcutan metoclopramid wast resourc reckless \n",
            "\t0.341\toverlap hepat hepat hepat lamivudin disappear hepat antigen hbsag hepat clearanc hepat hbv fals hbsag neg pres2 determin ymdd hbv escap hbsag overlap hbsag lamivudin 36 lamivudin 44yrold korean hepat hbsag turn hbv remain probe nucleotid hbv hbv genotyp subtyp adr regist ncbi af 286594 delet nucleotid 55 pres2 determin substitut i126 t131n m133t s136i methionin rtm204 substitut isoleucin yidd rtm204i hbv compos pres2 delet determin substitut ymdd fals hbsag neg overlap lamivudin hepat chronichepat antigenshepat viruslamivudinemut introductionmateri methodspatientmethodsresultsidentif pres2 delet mutantmut determinantyidd mutantdiscuss envelop hepat hbsag consist 226 code antigen determin epitop subtyp hbsag determin 124 147 antigen call hydrophil mhr epitop hbsag hepat hbv encount hbsag hepat chb detect hbv polymeras set occult hbv 94 chb occult hbv viremia progress hbv load implic hbsag neg occult hbv document vaccin hepat immunoglobulin hbig nucleotid substitut delet epitop escap hbsag determin vaccin person antigen hbsag kind variant hbsag evad protect antihb support suggest aris besid polymeras ymdd hbv escap variant hbsag induc seroneg ymdd lamivudin variant overlap chb whose turn hbsag hbv term lamivudin occult hbv ymdd lamivudin overlap chb nondetect hbsag persist hepat viremia term lamivudin hbsag hepat awar occult hbv confus antivir occult hbv unresolv nondetect hbsag aris alter hbv hbsag hbsag hbv persist hbv escap hbsag delet pre disrupt greatli dilat smooth vesicl endoplasm reticulum assembl branch filament particl trap endoplasm reticulum secret antigen cytoplasm endoplasm reticulum alter physiolog biolog hepatocyt phenomenon evas surveil occasion lifelong persist hbv discrep hbv hbsag substitut loop creat put glycosyl hbv make antigen hbsag undetect determin destroy antigen hbsag display antigen chaudhuri delet ymdd polymeras occult hbv ymdd occult hbv antivir hbv variant pres2 delet determin substitut ymdd lamivudin polymeras ymdd hbv escap ymdd happen circul hbsag synergist make hbsag imposs limit compar variat lamivudin preserv confirm ymdd exist lamivudin 29 emerg lamivudin confirm ymdd word decid pres2 delet determin substitut consequ creat lamivudin just coincid emerg ymdd antivir investig serial lamivudin warrant summari explan hbsag term lamivudin consist pres2 delet determin substitut alter antigen synergist ymdd emerg overlap antivir fals neg confus occult hbv antivir confirm concern hbv escap hbsag persist hbv seroneg hbv antivir understood\n",
            "\t0.325\theadach intracrani hypotens     \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.134\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t1.134\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t0.060\tlipas nausea vomit pancreat hyperemesi gravidarum hyperemesi gravidarum manifest nausea vomit abnorm abnorm mildli lipas hyperemesi gravidarum detail hyperemesi gravidarum lipas discus nausea vomit abdomin sever lipas 1000 unitslit pancreat conserv hyperemesi gravidarum eventu resolut lipas lipas pregnant nausea vomit concern pancreat lipas pancreat lipas quit hyperemesi gravidarum accur biochem pancreat establish pancreat  introduction2 report3 discus nausea vomit affect 85 gestat begin gestat peak resolv rang mild nausea vomit incapacit hyperemesi gravidarum exclus persist vomit percent prepregn dehydr electrolyt imbal nutrit defici rang 05 pregnanc repres hospit trimest hospit etiolog hyperemesi gravidarum multifactori involv endocrin neurobehavior placent gestat trophoblast person hyperemesi gravidarum motion sick migrain carri fetu hyperemesi gravidarum exclus nausea vomit gestat hydatidiform mole preeclampsia gastroenter dyspepsia gastroparesi gastroesophag reflux cholecyst pancreat migrain malign nervou pseudotumor cerebri hyperthyroid uremia addison ketoacidosi pyelonephr aid hyperemesi gravidarum 300 unitsl bilirubin mgdl amylas lipas thyroid stimul hormon thyroxin graviti ketonuria urinalysi hyperemesi gravidarum lipas sign pancreat hyperemesi gravidarum involv lipas nausea vomit elev lipas pancreat exclud pancreat 3000 pregnanc cholelithiasi heavi alcohol hypertriglyceridemia pancreat typic present persist abdomin midepigastr upper quadrant back chest flank abdomen abdomin tender fever tachycardia jaundic pancreat typic abdomin amylas lipas confirmatori pancreat abdomin present hyperemesi gravidarum nausea vomit complaint abdomin present abdomin fever lipas 94 96 diagnos pancreat amylas 83 88 resp pancreat cholelithiasi alcohol reliabl diagnos pancreat pancreat lipidinduc pancreat triglycerid triglycerid 300 mgdl 750 mgdl pancreat fast panel suspect pancreat ct scan modal choic confirm pancreat nonpregn abdomin ultrasound modal pregnant pancreat gallston pancreat sever lipas nausea vomit complaint nausea vomit hyperemesi gravidarum pancreat consider lipas meet neither abdomin typic pancreat ultrasound pancreat pancreat conserv bowel rest fluid hydrat endoscop retrograd cholangiopancreatographi attempt outsid trimest conserv hyperemesi gravidarum intraven fluid hydrat antiemet employ consider bowel rest sever lipas allow consum began hungri next outpati lipas return lipas pregnant nausea vomit workup pancreat lipas pancreat lipas quit hyperemesi gravidarum lipas accur biochem pancreat abstract gastroenterolog describ amylas lipas hyperemesi gravidarum elev amylas lipas mild elev lipas 171 unitsl 6fold upper limit rule nausea vomit pancreat present pancreat lipas question elev lipas physiolog nausea vomit trigger lipas besid pancrea frank gottlieb discus nonpancreat lipas cite organ gastrointestin tract tongu esophagu gastroesophag junction stomach duodenum bowel contain lipolyt obstruct bowel intestin infarct duoden ulcer abdomin trauma trigger lipas nonpancreat ketoacidosi asymptomat alcohol insuffici elev lipas asid pancreat elev lipas add hyperemesi gravidarum nonpancreat lipas hyperemesi gravidarum affect organ gastrointestin tract trigger lipas nonpancreat organ physiolog lipas hyperemesi gravidarum signific\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.381\tletter editor   dear editor dear editor congratul articl entitl optim nausea vomit comprehens frequent complic letter arriv public think research clarif seemingli minor avoid confus point metoclopramid section statement subcutan metoclopramid nvp hg support observ continu subcutan metoclopramid distinct receiv 267 4432 unfavor comparison recommend expens altern explor subject extrem prudent perhap continu subcutan metoclopramid accident suggest reassur excess sleepi impli diclectin tire continu subcutan metoclopramid wast resourc reckless \n",
            "\t0.341\toverlap hepat hepat hepat lamivudin disappear hepat antigen hbsag hepat clearanc hepat hbv fals hbsag neg pres2 determin ymdd hbv escap hbsag overlap hbsag lamivudin 36 lamivudin 44yrold korean hepat hbsag turn hbv remain probe nucleotid hbv hbv genotyp subtyp adr regist ncbi af 286594 delet nucleotid 55 pres2 determin substitut i126 t131n m133t s136i methionin rtm204 substitut isoleucin yidd rtm204i hbv compos pres2 delet determin substitut ymdd fals hbsag neg overlap lamivudin hepat chronichepat antigenshepat viruslamivudinemut introductionmateri methodspatientmethodsresultsidentif pres2 delet mutantmut determinantyidd mutantdiscuss envelop hepat hbsag consist 226 code antigen determin epitop subtyp hbsag determin 124 147 antigen call hydrophil mhr epitop hbsag hepat hbv encount hbsag hepat chb detect hbv polymeras set occult hbv 94 chb occult hbv viremia progress hbv load implic hbsag neg occult hbv document vaccin hepat immunoglobulin hbig nucleotid substitut delet epitop escap hbsag determin vaccin person antigen hbsag kind variant hbsag evad protect antihb support suggest aris besid polymeras ymdd hbv escap variant hbsag induc seroneg ymdd lamivudin variant overlap chb whose turn hbsag hbv term lamivudin occult hbv ymdd lamivudin overlap chb nondetect hbsag persist hepat viremia term lamivudin hbsag hepat awar occult hbv confus antivir occult hbv unresolv nondetect hbsag aris alter hbv hbsag hbsag hbv persist hbv escap hbsag delet pre disrupt greatli dilat smooth vesicl endoplasm reticulum assembl branch filament particl trap endoplasm reticulum secret antigen cytoplasm endoplasm reticulum alter physiolog biolog hepatocyt phenomenon evas surveil occasion lifelong persist hbv discrep hbv hbsag substitut loop creat put glycosyl hbv make antigen hbsag undetect determin destroy antigen hbsag display antigen chaudhuri delet ymdd polymeras occult hbv ymdd occult hbv antivir hbv variant pres2 delet determin substitut ymdd lamivudin polymeras ymdd hbv escap ymdd happen circul hbsag synergist make hbsag imposs limit compar variat lamivudin preserv confirm ymdd exist lamivudin 29 emerg lamivudin confirm ymdd word decid pres2 delet determin substitut consequ creat lamivudin just coincid emerg ymdd antivir investig serial lamivudin warrant summari explan hbsag term lamivudin consist pres2 delet determin substitut alter antigen synergist ymdd emerg overlap antivir fals neg confus occult hbv antivir confirm concern hbv escap hbsag persist hbv seroneg hbv antivir understood\n",
            "\t0.325\theadach intracrani hypotens     \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.134\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t1.134\tprotect gabapentin nausea vomit cesarean spinal anesthesia nausea vomit cesarean spinal anesthesia pneumonia delay discharg electrolyt abnorm dissatisfact gabapentin prevent nausea vomit spinal anesthesia cesarean doubleblind done 200 candid cesarean random american societi anesthesiologist divid 600 mg gabapentin placebo nausea vomit everi hour withdraw mother recoveri section demograph st nausea vomit nausea gabapentin cesarean decreas nausea vomit cesareangabapentinnauseaspin anesthesiavomit introductionpati methodsstudi populationstudi assessmentstatist analysisresultsdiscussionconclus caesarean section incis woman abdomen uteru deliv babi worldwid statist childbirth caesarean manag childbirth anesthesia mother fetu issu caesarean section spinal anesthesia cesarean sweden 90 caesarean section elect 80 emerg caesarian section spinal anesthesia caesarean section spinal anesthesia undesir anesthesia nausea vomit nausea vomit concern occur nausea vomit spinal anesthesia vagal sympathet systol 80 mmmercuri block fifth thorac segment retractor neostigmin opioid anesthet agent chanc nausea vomit hypotens brainstem ischemia vomit center hypotens bowel ischemia nauseacaus substanc serotonin total region anesthesia reason nausea vomit postop nausea vomit ponv pneumonia aspir dehydr delay discharg recoveri room electrolyt imbal postop hemorrhag intracrani mention ponv systemat myocardi ischemia gabapentin neurontin commerci analog gamma butyr action anticonvuls antinocicept psychoact gabapentin reflex sympathet dystrophi neuropathi vast spectrum pain neuropathi neuralgia preoper pain 300 mg gabapentin nausea vomit 600 mg gabapentin nausea vomit gabapentin recommend laparoscop cholecystectomi control nausea vomit gabapentin nausea vomit abdomin hysterectomi meperidin inject attempt 600 mg gabapentin caesarian postop vomit nausea gabapentin prevent nausea vomit spinal anesthesia cesarean prescrib gabapentin nausea vomit satisfact recoveri 600 mg gabapentin nausea vomit\n",
            "\t0.060\tlipas nausea vomit pancreat hyperemesi gravidarum hyperemesi gravidarum manifest nausea vomit abnorm abnorm mildli lipas hyperemesi gravidarum detail hyperemesi gravidarum lipas discus nausea vomit abdomin sever lipas 1000 unitslit pancreat conserv hyperemesi gravidarum eventu resolut lipas lipas pregnant nausea vomit concern pancreat lipas pancreat lipas quit hyperemesi gravidarum accur biochem pancreat establish pancreat  introduction2 report3 discus nausea vomit affect 85 gestat begin gestat peak resolv rang mild nausea vomit incapacit hyperemesi gravidarum exclus persist vomit percent prepregn dehydr electrolyt imbal nutrit defici rang 05 pregnanc repres hospit trimest hospit etiolog hyperemesi gravidarum multifactori involv endocrin neurobehavior placent gestat trophoblast person hyperemesi gravidarum motion sick migrain carri fetu hyperemesi gravidarum exclus nausea vomit gestat hydatidiform mole preeclampsia gastroenter dyspepsia gastroparesi gastroesophag reflux cholecyst pancreat migrain malign nervou pseudotumor cerebri hyperthyroid uremia addison ketoacidosi pyelonephr aid hyperemesi gravidarum 300 unitsl bilirubin mgdl amylas lipas thyroid stimul hormon thyroxin graviti ketonuria urinalysi hyperemesi gravidarum lipas sign pancreat hyperemesi gravidarum involv lipas nausea vomit elev lipas pancreat exclud pancreat 3000 pregnanc cholelithiasi heavi alcohol hypertriglyceridemia pancreat typic present persist abdomin midepigastr upper quadrant back chest flank abdomen abdomin tender fever tachycardia jaundic pancreat typic abdomin amylas lipas confirmatori pancreat abdomin present hyperemesi gravidarum nausea vomit complaint abdomin present abdomin fever lipas 94 96 diagnos pancreat amylas 83 88 resp pancreat cholelithiasi alcohol reliabl diagnos pancreat pancreat lipidinduc pancreat triglycerid triglycerid 300 mgdl 750 mgdl pancreat fast panel suspect pancreat ct scan modal choic confirm pancreat nonpregn abdomin ultrasound modal pregnant pancreat gallston pancreat sever lipas nausea vomit complaint nausea vomit hyperemesi gravidarum pancreat consider lipas meet neither abdomin typic pancreat ultrasound pancreat pancreat conserv bowel rest fluid hydrat endoscop retrograd cholangiopancreatographi attempt outsid trimest conserv hyperemesi gravidarum intraven fluid hydrat antiemet employ consider bowel rest sever lipas allow consum began hungri next outpati lipas return lipas pregnant nausea vomit workup pancreat lipas pancreat lipas quit hyperemesi gravidarum lipas accur biochem pancreat abstract gastroenterolog describ amylas lipas hyperemesi gravidarum elev amylas lipas mild elev lipas 171 unitsl 6fold upper limit rule nausea vomit pancreat present pancreat lipas question elev lipas physiolog nausea vomit trigger lipas besid pancrea frank gottlieb discus nonpancreat lipas cite organ gastrointestin tract tongu esophagu gastroesophag junction stomach duodenum bowel contain lipolyt obstruct bowel intestin infarct duoden ulcer abdomin trauma trigger lipas nonpancreat ketoacidosi asymptomat alcohol insuffici elev lipas asid pancreat elev lipas add hyperemesi gravidarum nonpancreat lipas hyperemesi gravidarum affect organ gastrointestin tract trigger lipas nonpancreat organ physiolog lipas hyperemesi gravidarum signific\n",
            "nausea and vomiting,Hb None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.428\tenalapril hyponatremia sensorium child enalapril angiotensin convert congest 5yearold boy hyponatremia sensorium enalapril sodium gradual becam sensorium correct hyponatremia highlight sodium enalapril enalaprilhyponatremiarenin angiotensin systemsyndrom inappropri antidiuret hormon introductioncas reportdiscussionconclus angiotensin convert ace congest renoprotect captopril enalapril offpat ace econom hyperkalemia cough angioedema hypoglycemia ace enalapril hyponatremia sensorium enalapril demonstr probabl hyponatremia enalapril awar highlight sodium enalapril\n",
            "\t0.425\tlightinduc limulu ventral photoreceptor rise sodium illumin limulu ventral photoreceptor sodium nai o2 delta qo2 1 flash take 480 nai return preillumin delta qo2 take 90 delta qo2 nai return rest inject na elev nai attain illumin rise nai return lightinduc rise nai inject na o2 conclud na pump rise nai lightinduc o2    \n",
            "\t0.417\tsodium ion irrig gill rainbow trout salmo gairdneri sodium rainbow trout gill smallvolum enabl success flux solut sodium influx obey michaelismenten relat 046 proce unimpair penetr counterion coupl cation exchang ammonia output na influx extern na na influx hold progress downward shift irrig medium na influx exchang cation hydrogen acetazolamid inhibit na prevent downward shift gill mv fluid nacl solut na locat ratelimit outer epithelium    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.595\tsodium traumat sodium poorli understood electrolyt neurolog sodium traumat injuri prospect 80 moder traumat injuri underw cerebr comput tomographi sodium injuri comput tomographi traumat conscious sodium trauma exclud sodium disturb 45 hypernatremia hyponatremia refer sodium disturb 53 record 125 meql hyponatremia sodium subdur intracerebr hematoma diffus axon sodium diffus contus 0022 sodium diffus traumat injuri focal sodium traumahypernatremiahyponatremia introductionmethodsresultsdiscuss sodium poorli understood electrolyt neurolog disturb manifest hypernatremia hyponatremia hypernatremia insipidu hyponatremia develop inappropri antidiuret hormon cerebr saltwast traumat tbi depend substanti homeostasi trauma hyponatremia electrolyt encount neurosurg intens unit icu address neuroendocrinolog cerebr ill address deal subarachnoid hemorrhag sodium tbi sodium hypernatremia hyponatremia tbi univers trauma center approv ethic committe da clinica univers paulo school paulo brazil sodium sodium tbi intracrani substanti admiss hypernatremia frequent headinjur hypernatremia sodium sodium remark swell infus manual headinjur unexpect excret hypoton urin hypernatrem dehydr loss filtrat aggrav hypernatremia hyponatremia arieff hyponatremia tbi neurolog sudden seizur coma apnea brainstem compress retrospect maggior verifi hypernatremia occur 515 31 icu stay hypernatremia threefold hazard icu adjust verifi hypernatremia 53 horn glenn screen head hormon disturb sodium diver morbid vari hyponatremia hyponatrem intracrani neurolog princip manifest hyponatremia exacerb patholog intracrani seriou alter occurr neuroendocrinolog insipidu inappropri antidiuret hormon cerebr salt wast intracrani occurr elucid insipidu insuffici pituitari sodium excret inappropri antidiuret hormon hypersecret hyponatremia hyponatremia unclear hyponatremia natriuret bnf secret thalamu exert ident hormon secret atrial cardiocyt bnf potent diuret natriuret vasodil agent aldosteron renin vasopressin decreas bnf subarachnoid hemorrhag hemorrhag base ventricl bnf equip special patholog substrat bnf except diffus edema sodium diffus tbi tbi sodium sodium diffus intracerebr hematoma disturb sodium warrant close craniocerebr injuri time exacerb eventu believ allow exclus confound restrict head trauma injuri deviat slightli realiti believ blind respond question answer\n",
            "\t-4.233\tsodium  hyponatremia thiazid diuret discus 63yearold admit heartburn vomit tired myalgia oneday abdomen distens jaundic episod preced consum alcohol week 60ml brandi alcohol bing suggest seizur antihypertens amlodepin metopronolol drowsi mild moder dehydr vital reveal clue abdomen soft organomegali tender clinic hemoglobin white count platelet limit fold rais sgot sgpt otherwis appear transabdomin ultrasonographi fatti mild prostomegali gastroscopi hiatu hernia sodium 101mmoll 136 145 mmoll antihypertens electrocardiogram done exclud event creatin phosphokinas cpk cpkmb troponin 5773 ul 170 ul 968 iul iul 0008ngml 0012ngml urin myoglobulin rhabdomyolysi cpk cpkmbtroponin meanwhil 100ml hyperton salin infus 10mlhour correct hyponatremia sodium cpk 124 mmoll 157 ul rd discharg th discus judgment hyponatremia nonspecif anorexia vomit weak headach confus convuls coma hyponatremia salt wast nephropathi cerebr salt wast excess fluid ex acetazolamid amphotericin thiazid diuret amiodaron angiotensin blocker bromocriptin carbamazepin event hyponatremia 120 mmoll treat immedi correct sodium mandatori avoid hyponatremia morbid rhabdomyolysi trauma seizur alcoholc withdraw seizur myopathi hereditari myopathi exclud detail biochem examin hyponatremia rhabdomyolysi uncommon phenomenon notic psychiatr polydipsia state thiazid diuret proton pump sulfamethoxazoletrimethoprim mannitol colonoscopi pvp photoselect vapor benign hypertrophi hyponatermia rhabdomyolysi pathophysiolog hyponatremia rhabdomyolysi obscur malfunct na pump rise protea lipas rhabdomyolysi state hypernatremia rhabdomyolysi rhabdomyolysi perfus toxic cast myoglobin delay inadequateov correct hyponatremia numer pontin myelinosi admit gastrointestin incident hyponatremia rhabdomyolysi promptli hyperton salin sodium cpk return limit rd discharg th stay correct hyponatremia myoglobulinuria highlight entiti hyponatremia rhabdomyolysi prompt correct hyponatremia rhabdomyolysi \n",
            "\t-4.233\tsodium  hyponatremia thiazid diuret discus 63yearold admit heartburn vomit tired myalgia oneday abdomen distens jaundic episod preced consum alcohol week 60ml brandi alcohol bing suggest seizur antihypertens amlodepin metopronolol drowsi mild moder dehydr vital reveal clue abdomen soft organomegali tender clinic hemoglobin white count platelet limit fold rais sgot sgpt otherwis appear transabdomin ultrasonographi fatti mild prostomegali gastroscopi hiatu hernia sodium 101mmoll 136 145 mmoll antihypertens electrocardiogram done exclud event creatin phosphokinas cpk cpkmb troponin 5773 ul 170 ul 968 iul iul 0008ngml 0012ngml urin myoglobulin rhabdomyolysi cpk cpkmbtroponin meanwhil 100ml hyperton salin infus 10mlhour correct hyponatremia sodium cpk 124 mmoll 157 ul rd discharg th discus judgment hyponatremia nonspecif anorexia vomit weak headach confus convuls coma hyponatremia salt wast nephropathi cerebr salt wast excess fluid ex acetazolamid amphotericin thiazid diuret amiodaron angiotensin blocker bromocriptin carbamazepin event hyponatremia 120 mmoll treat immedi correct sodium mandatori avoid hyponatremia morbid rhabdomyolysi trauma seizur alcoholc withdraw seizur myopathi hereditari myopathi exclud detail biochem examin hyponatremia rhabdomyolysi uncommon phenomenon notic psychiatr polydipsia state thiazid diuret proton pump sulfamethoxazoletrimethoprim mannitol colonoscopi pvp photoselect vapor benign hypertrophi hyponatermia rhabdomyolysi pathophysiolog hyponatremia rhabdomyolysi obscur malfunct na pump rise protea lipas rhabdomyolysi state hypernatremia rhabdomyolysi rhabdomyolysi perfus toxic cast myoglobin delay inadequateov correct hyponatremia numer pontin myelinosi admit gastrointestin incident hyponatremia rhabdomyolysi promptli hyperton salin sodium cpk return limit rd discharg th stay correct hyponatremia myoglobulinuria highlight entiti hyponatremia rhabdomyolysi prompt correct hyponatremia rhabdomyolysi \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.428\tenalapril hyponatremia sensorium child enalapril angiotensin convert congest 5yearold boy hyponatremia sensorium enalapril sodium gradual becam sensorium correct hyponatremia highlight sodium enalapril enalaprilhyponatremiarenin angiotensin systemsyndrom inappropri antidiuret hormon introductioncas reportdiscussionconclus angiotensin convert ace congest renoprotect captopril enalapril offpat ace econom hyperkalemia cough angioedema hypoglycemia ace enalapril hyponatremia sensorium enalapril demonstr probabl hyponatremia enalapril awar highlight sodium enalapril\n",
            "\t0.425\tlightinduc limulu ventral photoreceptor rise sodium illumin limulu ventral photoreceptor sodium nai o2 delta qo2 1 flash take 480 nai return preillumin delta qo2 take 90 delta qo2 nai return rest inject na elev nai attain illumin rise nai return lightinduc rise nai inject na o2 conclud na pump rise nai lightinduc o2    \n",
            "\t0.417\tsodium ion irrig gill rainbow trout salmo gairdneri sodium rainbow trout gill smallvolum enabl success flux solut sodium influx obey michaelismenten relat 046 proce unimpair penetr counterion coupl cation exchang ammonia output na influx extern na na influx hold progress downward shift irrig medium na influx exchang cation hydrogen acetazolamid inhibit na prevent downward shift gill mv fluid nacl solut na locat ratelimit outer epithelium    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.595\tsodium traumat sodium poorli understood electrolyt neurolog sodium traumat injuri prospect 80 moder traumat injuri underw cerebr comput tomographi sodium injuri comput tomographi traumat conscious sodium trauma exclud sodium disturb 45 hypernatremia hyponatremia refer sodium disturb 53 record 125 meql hyponatremia sodium subdur intracerebr hematoma diffus axon sodium diffus contus 0022 sodium diffus traumat injuri focal sodium traumahypernatremiahyponatremia introductionmethodsresultsdiscuss sodium poorli understood electrolyt neurolog disturb manifest hypernatremia hyponatremia hypernatremia insipidu hyponatremia develop inappropri antidiuret hormon cerebr saltwast traumat tbi depend substanti homeostasi trauma hyponatremia electrolyt encount neurosurg intens unit icu address neuroendocrinolog cerebr ill address deal subarachnoid hemorrhag sodium tbi sodium hypernatremia hyponatremia tbi univers trauma center approv ethic committe da clinica univers paulo school paulo brazil sodium sodium tbi intracrani substanti admiss hypernatremia frequent headinjur hypernatremia sodium sodium remark swell infus manual headinjur unexpect excret hypoton urin hypernatrem dehydr loss filtrat aggrav hypernatremia hyponatremia arieff hyponatremia tbi neurolog sudden seizur coma apnea brainstem compress retrospect maggior verifi hypernatremia occur 515 31 icu stay hypernatremia threefold hazard icu adjust verifi hypernatremia 53 horn glenn screen head hormon disturb sodium diver morbid vari hyponatremia hyponatrem intracrani neurolog princip manifest hyponatremia exacerb patholog intracrani seriou alter occurr neuroendocrinolog insipidu inappropri antidiuret hormon cerebr salt wast intracrani occurr elucid insipidu insuffici pituitari sodium excret inappropri antidiuret hormon hypersecret hyponatremia hyponatremia unclear hyponatremia natriuret bnf secret thalamu exert ident hormon secret atrial cardiocyt bnf potent diuret natriuret vasodil agent aldosteron renin vasopressin decreas bnf subarachnoid hemorrhag hemorrhag base ventricl bnf equip special patholog substrat bnf except diffus edema sodium diffus tbi tbi sodium sodium diffus intracerebr hematoma disturb sodium warrant close craniocerebr injuri time exacerb eventu believ allow exclus confound restrict head trauma injuri deviat slightli realiti believ blind respond question answer\n",
            "\t-4.233\tsodium  hyponatremia thiazid diuret discus 63yearold admit heartburn vomit tired myalgia oneday abdomen distens jaundic episod preced consum alcohol week 60ml brandi alcohol bing suggest seizur antihypertens amlodepin metopronolol drowsi mild moder dehydr vital reveal clue abdomen soft organomegali tender clinic hemoglobin white count platelet limit fold rais sgot sgpt otherwis appear transabdomin ultrasonographi fatti mild prostomegali gastroscopi hiatu hernia sodium 101mmoll 136 145 mmoll antihypertens electrocardiogram done exclud event creatin phosphokinas cpk cpkmb troponin 5773 ul 170 ul 968 iul iul 0008ngml 0012ngml urin myoglobulin rhabdomyolysi cpk cpkmbtroponin meanwhil 100ml hyperton salin infus 10mlhour correct hyponatremia sodium cpk 124 mmoll 157 ul rd discharg th discus judgment hyponatremia nonspecif anorexia vomit weak headach confus convuls coma hyponatremia salt wast nephropathi cerebr salt wast excess fluid ex acetazolamid amphotericin thiazid diuret amiodaron angiotensin blocker bromocriptin carbamazepin event hyponatremia 120 mmoll treat immedi correct sodium mandatori avoid hyponatremia morbid rhabdomyolysi trauma seizur alcoholc withdraw seizur myopathi hereditari myopathi exclud detail biochem examin hyponatremia rhabdomyolysi uncommon phenomenon notic psychiatr polydipsia state thiazid diuret proton pump sulfamethoxazoletrimethoprim mannitol colonoscopi pvp photoselect vapor benign hypertrophi hyponatermia rhabdomyolysi pathophysiolog hyponatremia rhabdomyolysi obscur malfunct na pump rise protea lipas rhabdomyolysi state hypernatremia rhabdomyolysi rhabdomyolysi perfus toxic cast myoglobin delay inadequateov correct hyponatremia numer pontin myelinosi admit gastrointestin incident hyponatremia rhabdomyolysi promptli hyperton salin sodium cpk return limit rd discharg th stay correct hyponatremia myoglobulinuria highlight entiti hyponatremia rhabdomyolysi prompt correct hyponatremia rhabdomyolysi \n",
            "\t-4.233\tsodium  hyponatremia thiazid diuret discus 63yearold admit heartburn vomit tired myalgia oneday abdomen distens jaundic episod preced consum alcohol week 60ml brandi alcohol bing suggest seizur antihypertens amlodepin metopronolol drowsi mild moder dehydr vital reveal clue abdomen soft organomegali tender clinic hemoglobin white count platelet limit fold rais sgot sgpt otherwis appear transabdomin ultrasonographi fatti mild prostomegali gastroscopi hiatu hernia sodium 101mmoll 136 145 mmoll antihypertens electrocardiogram done exclud event creatin phosphokinas cpk cpkmb troponin 5773 ul 170 ul 968 iul iul 0008ngml 0012ngml urin myoglobulin rhabdomyolysi cpk cpkmbtroponin meanwhil 100ml hyperton salin infus 10mlhour correct hyponatremia sodium cpk 124 mmoll 157 ul rd discharg th discus judgment hyponatremia nonspecif anorexia vomit weak headach confus convuls coma hyponatremia salt wast nephropathi cerebr salt wast excess fluid ex acetazolamid amphotericin thiazid diuret amiodaron angiotensin blocker bromocriptin carbamazepin event hyponatremia 120 mmoll treat immedi correct sodium mandatori avoid hyponatremia morbid rhabdomyolysi trauma seizur alcoholc withdraw seizur myopathi hereditari myopathi exclud detail biochem examin hyponatremia rhabdomyolysi uncommon phenomenon notic psychiatr polydipsia state thiazid diuret proton pump sulfamethoxazoletrimethoprim mannitol colonoscopi pvp photoselect vapor benign hypertrophi hyponatermia rhabdomyolysi pathophysiolog hyponatremia rhabdomyolysi obscur malfunct na pump rise protea lipas rhabdomyolysi state hypernatremia rhabdomyolysi rhabdomyolysi perfus toxic cast myoglobin delay inadequateov correct hyponatremia numer pontin myelinosi admit gastrointestin incident hyponatremia rhabdomyolysi promptli hyperton salin sodium cpk return limit rd discharg th stay correct hyponatremia myoglobulinuria highlight entiti hyponatremia rhabdomyolysi prompt correct hyponatremia rhabdomyolysi \n",
            "dizziness,Sodium None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.437\tembol arthroscop rotat cuff hipkne arthroplasti venou thromboembol vte postop complic vte arthroscop shoulder embol pe arthroscop rotat cuff recov sequela dvt limb deni contrastenhanc ct possibl pe deep vein thrombosi dvt upper limb desault fixat arthroscop surgeryrel swell postop  introduction2 report3 discussion4 hipkne arthroplasti venou thromboembol vte postop complic vte arthroscop shoulder reportedli 001 embol arthroscop rotat cuff gave inform consent public arthroscop shoulder pe\n",
            "\t0.435\tunexpect symptomat pneumon tangent symptomat pneumon rp rt uncommon 80yearold fatigu exert dyspnea fever cough 115 adjuv rt tangent field rp respond taper steroid  introductioncas presentationradi plan ct scan demonstr red inner cyan middl orang outer isodos pa chest xray complet rt patchi consolid aspect pa chest xray start prednison persist airspac consolid upper lobe anteriorli postrt ct simul scan fuse plan scan demonstr consolid axial coron sagittaldiscussionconclus pneumon rp wellrecogn irradi rp extern beam rt vari typic cough dyspnea lowgrad fever occasion chest rp typic complet rt ma20 rp locoregion rt axillari lymph node intern mammari 02 eortc 22922 rp locoregion rt imc medial supraclavicular field receiv 07 01 rp aris 115 adjuv describ symptomat rp occur 115 adjuv tangent dosimetr ipsilater v20 mld 432 gy rp uncommon rt real discus\n",
            "\t0.435\tunexpect symptomat pneumon tangent symptomat pneumon rp rt uncommon 80yearold fatigu exert dyspnea fever cough 115 adjuv rt tangent field rp respond taper steroid  introductioncas presentationradi plan ct scan demonstr red inner cyan middl orang outer isodos pa chest xray complet rt patchi consolid aspect pa chest xray start prednison persist airspac consolid upper lobe anteriorli postrt ct simul scan fuse plan scan demonstr consolid axial coron sagittaldiscussionconclus pneumon rp wellrecogn irradi rp extern beam rt vari typic cough dyspnea lowgrad fever occasion chest rp typic complet rt ma20 rp locoregion rt axillari lymph node intern mammari 02 eortc 22922 rp locoregion rt imc medial supraclavicular field receiv 07 01 rp aris 115 adjuv describ symptomat rp occur 115 adjuv tangent dosimetr ipsilater v20 mld 432 gy rp uncommon rt real discus\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.632\trho gdi osteoblast intermitt parathyroid hormon boneform intermitt parathyroid hormon pth search anabol pth cultur osteoblast rob divid intermitt pthtreat itm ctr imit pharmacokinet intermitt pth rob itm pth 24h incub rob ctr vehicl entir incub final itm ctr twodimension electrophoresi 2de coupl fingerprint assist laser desorptionion timeofflight spectrometri malditofm differenti valid immunohistochemistri ihc proteom downregul itm ctr success belong cytoskeleton chaperon famili antiapoptot rho gdpdissoci rhogdi vimentin chang ihc rhogdi rob pthtreat shamoper vehicletr shamoper pthtreat vehicletr ovx vimentin chang pthtreat shamoper pthtreat ovx intermitt pth rob rhogdi upregul rob estrogen upregul rhogdi synergist boneform pth estrogen parathyroid hormonerho gdpdissoci αosteoblastimmunohistochemistryproteom introductionmateri methodscel intermitt pth treatmentprotein extract 2de identificationanim modelsimmunohistochemistrystatist analysisresultsresult 2deprotein identificationihc rhogdi discussionauthor contribut osteoporosi depend antiresorpt bisphosphon bp calcitonin estrogen moder satisfactori consider osteoporosi pth osteotrop calcium homeostasi regul turnov pth posse bidirect action bonecatabol boneanabol continu pth decreas stimul net resorpt intermitt pth osteogenesi intermitt pth osteoblast pthmediat osteogenesi pth osteoclast osteoblast pth osteoblast studi anabol pth search osteoporosi microarray osteoblast umr 10601 pth 125 tag est twofold pth necessarili correl twodimension electrophoresi 2debas proteom power simultan analyz uncov anabol pth compar proteom research candid biomark distinguish osteosarcoma osteoblast proteom technolog pthregul osteoblast intermitt pth anabol document ten osteoblast intermitt pth chang rhogdi grp78 vimentin upregul greatest 10fold rhogdi vimentin secret spectrum call secretom valid rhogdi vimentin recombin pth intermitt inject immunohistochemistri observ rhogdi vimentin osteoblast proteom pthregul rob intermitt pth intermitt pth rob imit pharmacokinet pth pth stimul osteogenesi rob reason continu pth suppress osteogenesi rob 2de lysat success downregul itm6h upregul itm24h factin cap betaactin vimentin belong maintain morpholog stabil regul erp29 pdiprecursor grp78 precursor grpe grpelik grpe homolog rhogdi upregul itm24h belong chaperon biosynthesi transduct immunoregul igfbp3 member igfbp promot bind igf1 igfbp3 inhibit osteogenesi il22ralpha2 phenylalaninetrna synthetaselik subunit pp galactokinas refer play pthinduc osteogenesi fluctuat osteoblast deserv success categori differenti reason follow accret fast stimul pth incub pth pth remov delay pth remov pth anabol continu pth inhibit rob view support temporarili call pth delay trigger intermitt pth dramat rhogdi vimentin rob vimentin rob inconsist rhogdi vitr intermitt pth promot rhogdi rob shamoper rob note intermitt pth rhogdi ovariectom rob intermitt pth stimul rhogdi estrogen enough estrogen exist medium rob fetal bovin shamoper rhogdi osteoporosi ovx pth rhogdi cytoplasm origin regul rho gtpase ubiquit rho gtpase rac1 rhoa cdc42 actin cytoskeleton remodel therebi promot morpholog adhes motil rhogdi rho gtpase inhibit transgen lack rhogdi kidney reproduct organ rhogdi rhogdi rhogdi estrogen transactiv antagon rho crucial mainten estrogen estrogen stimul cancel bone elev rhogdi help partli pth estrogen ovariectom 29 osteoporot efficaci pth estrogen rhogdi antiapoptot molecul 31 inhibit osteoblast rhogdi pthinduc osteogenesi transactiv antiapoptot summari intermitt pth rhogdi rob estrogen support pth estrogen osteoporosi rhogdi differenti deserv indepth obtain treat osteoporosi author contribut\n",
            "\t-5.868\tintermitt parathyroid hormon improv repair calvaria defect histomorphometr radiodensitometr intermitt parathyroid hormon pth 134 regener criticallys calvari defect thirtytwo trephin 4mm fullthick diamet pariet bone divid pth subcutan inject pth 134 gkg week ctl vehicl regimen sacrif posttreat regimen pariet bone extract histomorphometri radiodensitometri histolog pth islandlik defect margin fibrou ctl pth exhibit histolog ctl 15mm 07 06 005 residu defect radiodensitometri pth ctl eq 004 18al eq 006 005 demonstr miner pth contribut miner fibrou ctl regener acceler heal calvari defect intermitt pth  introductionmateri methodsresultsdiscuss defect frequent sequela patholog cyst trauma slow regener defect pose stimul heal defect auto graft allograft polymer membran enamel deriv assist regener stimul anabol pth intermitt minim periodont heal fenestr defect mandibl pth mediat remodel regul calcium homeostasi produc remodel anabol remodel catabol continu pth osteoclast osteoclast turnov intermitt stimul osteoblast osteoblast pth success osteoporosi intermitt pth prove vertebr nonvertebr fractur femor vertebr absent intermitt pth enhanc fractur strength callu heal tibia fractur stiff ultim load newlyform osteogenesi distract pth osteoporosi fractur pth calvari heal andreassen cacciafesta intermitt pth mechan strength heal calvari defect cover expand polytetrafluoroethylen membran besid dri newlyform insid defect stancoven criticals 8mm recombin morphogenet protein2 soakload onto absorb collagen spong deminer additivesynergist exogen pth purpos intermitt pth criticallys calvari defect 4mm wistar histomorphometr radiodensitometr recombin pth 134 approv mono post menopaus osteoporosi pth approv osteoporosi question arisen pth antiresorpt osteoporosi pth enhanc acceler fractur surround dental implant fenestr mandibular defect critic ally defect osseou defect heal spontan lifetim aalami fullthick 5mm diamet calvari defect complet heal critic ally 4mm calvari defect ten old beg experi intermitt pth pth ctl incomplet heal defect observ islandslik margin 4mm defect pth intermitt possibl restor ovariectom shirota intermitt pth 134 heal placement titanium screw implant ovariectom implant pth sham oper 56 implant pth dental implant pth 134 gkg week protect tooth periodontitisinduc promot margin gingiv ovariectom team pth 134 callu form acceler callu reabsorpt osteoclast callu corrobor miner bmd alter balanc osteoblast osteoclast resorpt bmd radiograph densitometri radiograph densitometri lowcost dualenergi xray absorptiometri radiograph densitometri intermitt pth calvari defect pth 134 intermitt bmd calvaria criticallys defect reinforc histolog possibl specul collagen miner turnov corrobor collagen fiber periodont ligament visual polar microscopi garnero pth chang typei collagen isomer stancoven pth 134 administ gkg calvari defect 8mm radiograph histolog exam slightli pth pth andreassen cacciafesta pth 134 gkg mechan strength heal calvari defect 5mm cover expand polytetrafluoroethylen membran dri newlyform insid defect pth inject week pth gkg acceler heal isol defect 4mm optic miner pth pth contribut miner fibrou ctl frequent islandlik format pth organ collagen fiber reinforc anabol pth 134 intermitt util coadjuv regener acceler heal calvari defect\n",
            "\t-6.013\tjoint nigerian sickl anaemia highlight commonest manifest sickl scd set pain vasoocclus crisi voc progress debil avascular necrosi avn osteomyel fix flexion deform joint protract bilater femor humer osteomyel elbow knee humer septic arthriti avascular necrosi femor humer head coupl urinari tract uti decubitu ulcer scd unusu occurr morbid uninterrupt 29 hospit enjoy fairli microorgan sequenti cultur coli klebsiella urin klebsiella spp aspir knee joint elbow joint femor osteomyel screen nonreact multidisciplinari discharg home wheelchair reflect scd morbid attend highlight forestal voc predispos osteomyel organ wellequip subsid sickl rehabilit center nigeria scd  introductioncas presentationdiscuss pain vasoocclus crise voc osteomyel frequent requir admiss sickl scd crise exacerb morbid scd old hb scd walk crisi discharg home wheelchair 29 turbul admiss widespread marrow micro occlus haplotyp benin seneg nigeria belong showcas devast scd highlight pathophysiolog viz voc abdomin crise haematogen spread microorgan caus osteomyel septic arthriti cumul escal morbid scd musculoskelet manifest commonest manifest scd set pain voc progress disabl avn osteomyel septic arthriti scd typic haemolyt anemia period steadi interrupt pain vasoocclus crisi trigger psycholog infect equal osteomyel skelet complic scd distinct infarct osteomyel scd dilemma scd fever local local erythema swell tender characterist typic esr favor osteomyel background sepsi suspect ab initio took osteomyel becam obviou aspir grew coli klebsiella joint scd marrow hyperplasia caus distort disturb vasoocclus infarct metaphys diaphys osteonecrosi juxtaarticular bone haematogen osteomyel septic arthriti femor humer head necrosi haematogen take promin abdomin crisi seepag gut flora stream haematogen spread scd sluggish circul bone compromis attribut inher defect microbi opson infarct splenic hypofunct voc involv patholog pyrexia hypercoagul neutrophilia eosinophilia thrombocytosi red cytopath diarrhoea vomit singli concert red sickl sickl indirectli haemoglobin oxygen polymer hydrat viscos red procoagul intercellular adher aggreg culmin voc apart tender warmth swell bone joint persist grade fever discharg sinus leukocytosi shift aspir yield predominantli pathogen organ septic arthriti osteomyel haematogen spread spread contigu osteomyel tender joint swell warmth mark limit motion characterist septic arthriti differenti arthropathi synovi synov adjac necrosi nonspecif synov selflimit rare progress chondrolysi abdomin crisi microscop infarct bowel wall consequ sickl intestin vessel favor specul anaerob organ escap bowel stream spread infarct bone scd refractori osteomyel display adhes perivascul shoulder avascular necrosi femor humer head refer explain unabl walk discharg wheelchair commenc hydroxyurea th week admiss contribut speedi recoveri hydroxyurea hbf reduc leukocytosi thrombocytosi attend endothelium adhes reaction therebi curtail cascad progress radic antioxid lifethreaten morbid scd spectrum organ larg kind exist abnorm multidisciplinari exemplifi actual establish wellequip sickl center nigeria largest black heaviest scd burden integr rehabilit center assist scd heavi subsidi optim controlimmun inclus suspicion adequ potent antibiot great limit attend\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.437\tembol arthroscop rotat cuff hipkne arthroplasti venou thromboembol vte postop complic vte arthroscop shoulder embol pe arthroscop rotat cuff recov sequela dvt limb deni contrastenhanc ct possibl pe deep vein thrombosi dvt upper limb desault fixat arthroscop surgeryrel swell postop  introduction2 report3 discussion4 hipkne arthroplasti venou thromboembol vte postop complic vte arthroscop shoulder reportedli 001 embol arthroscop rotat cuff gave inform consent public arthroscop shoulder pe\n",
            "\t0.435\tunexpect symptomat pneumon tangent symptomat pneumon rp rt uncommon 80yearold fatigu exert dyspnea fever cough 115 adjuv rt tangent field rp respond taper steroid  introductioncas presentationradi plan ct scan demonstr red inner cyan middl orang outer isodos pa chest xray complet rt patchi consolid aspect pa chest xray start prednison persist airspac consolid upper lobe anteriorli postrt ct simul scan fuse plan scan demonstr consolid axial coron sagittaldiscussionconclus pneumon rp wellrecogn irradi rp extern beam rt vari typic cough dyspnea lowgrad fever occasion chest rp typic complet rt ma20 rp locoregion rt axillari lymph node intern mammari 02 eortc 22922 rp locoregion rt imc medial supraclavicular field receiv 07 01 rp aris 115 adjuv describ symptomat rp occur 115 adjuv tangent dosimetr ipsilater v20 mld 432 gy rp uncommon rt real discus\n",
            "\t0.435\tunexpect symptomat pneumon tangent symptomat pneumon rp rt uncommon 80yearold fatigu exert dyspnea fever cough 115 adjuv rt tangent field rp respond taper steroid  introductioncas presentationradi plan ct scan demonstr red inner cyan middl orang outer isodos pa chest xray complet rt patchi consolid aspect pa chest xray start prednison persist airspac consolid upper lobe anteriorli postrt ct simul scan fuse plan scan demonstr consolid axial coron sagittaldiscussionconclus pneumon rp wellrecogn irradi rp extern beam rt vari typic cough dyspnea lowgrad fever occasion chest rp typic complet rt ma20 rp locoregion rt axillari lymph node intern mammari 02 eortc 22922 rp locoregion rt imc medial supraclavicular field receiv 07 01 rp aris 115 adjuv describ symptomat rp occur 115 adjuv tangent dosimetr ipsilater v20 mld 432 gy rp uncommon rt real discus\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.632\trho gdi osteoblast intermitt parathyroid hormon boneform intermitt parathyroid hormon pth search anabol pth cultur osteoblast rob divid intermitt pthtreat itm ctr imit pharmacokinet intermitt pth rob itm pth 24h incub rob ctr vehicl entir incub final itm ctr twodimension electrophoresi 2de coupl fingerprint assist laser desorptionion timeofflight spectrometri malditofm differenti valid immunohistochemistri ihc proteom downregul itm ctr success belong cytoskeleton chaperon famili antiapoptot rho gdpdissoci rhogdi vimentin chang ihc rhogdi rob pthtreat shamoper vehicletr shamoper pthtreat vehicletr ovx vimentin chang pthtreat shamoper pthtreat ovx intermitt pth rob rhogdi upregul rob estrogen upregul rhogdi synergist boneform pth estrogen parathyroid hormonerho gdpdissoci αosteoblastimmunohistochemistryproteom introductionmateri methodscel intermitt pth treatmentprotein extract 2de identificationanim modelsimmunohistochemistrystatist analysisresultsresult 2deprotein identificationihc rhogdi discussionauthor contribut osteoporosi depend antiresorpt bisphosphon bp calcitonin estrogen moder satisfactori consider osteoporosi pth osteotrop calcium homeostasi regul turnov pth posse bidirect action bonecatabol boneanabol continu pth decreas stimul net resorpt intermitt pth osteogenesi intermitt pth osteoblast pthmediat osteogenesi pth osteoclast osteoblast pth osteoblast studi anabol pth search osteoporosi microarray osteoblast umr 10601 pth 125 tag est twofold pth necessarili correl twodimension electrophoresi 2debas proteom power simultan analyz uncov anabol pth compar proteom research candid biomark distinguish osteosarcoma osteoblast proteom technolog pthregul osteoblast intermitt pth anabol document ten osteoblast intermitt pth chang rhogdi grp78 vimentin upregul greatest 10fold rhogdi vimentin secret spectrum call secretom valid rhogdi vimentin recombin pth intermitt inject immunohistochemistri observ rhogdi vimentin osteoblast proteom pthregul rob intermitt pth intermitt pth rob imit pharmacokinet pth pth stimul osteogenesi rob reason continu pth suppress osteogenesi rob 2de lysat success downregul itm6h upregul itm24h factin cap betaactin vimentin belong maintain morpholog stabil regul erp29 pdiprecursor grp78 precursor grpe grpelik grpe homolog rhogdi upregul itm24h belong chaperon biosynthesi transduct immunoregul igfbp3 member igfbp promot bind igf1 igfbp3 inhibit osteogenesi il22ralpha2 phenylalaninetrna synthetaselik subunit pp galactokinas refer play pthinduc osteogenesi fluctuat osteoblast deserv success categori differenti reason follow accret fast stimul pth incub pth pth remov delay pth remov pth anabol continu pth inhibit rob view support temporarili call pth delay trigger intermitt pth dramat rhogdi vimentin rob vimentin rob inconsist rhogdi vitr intermitt pth promot rhogdi rob shamoper rob note intermitt pth rhogdi ovariectom rob intermitt pth stimul rhogdi estrogen enough estrogen exist medium rob fetal bovin shamoper rhogdi osteoporosi ovx pth rhogdi cytoplasm origin regul rho gtpase ubiquit rho gtpase rac1 rhoa cdc42 actin cytoskeleton remodel therebi promot morpholog adhes motil rhogdi rho gtpase inhibit transgen lack rhogdi kidney reproduct organ rhogdi rhogdi rhogdi estrogen transactiv antagon rho crucial mainten estrogen estrogen stimul cancel bone elev rhogdi help partli pth estrogen ovariectom 29 osteoporot efficaci pth estrogen rhogdi antiapoptot molecul 31 inhibit osteoblast rhogdi pthinduc osteogenesi transactiv antiapoptot summari intermitt pth rhogdi rob estrogen support pth estrogen osteoporosi rhogdi differenti deserv indepth obtain treat osteoporosi author contribut\n",
            "\t-5.868\tintermitt parathyroid hormon improv repair calvaria defect histomorphometr radiodensitometr intermitt parathyroid hormon pth 134 regener criticallys calvari defect thirtytwo trephin 4mm fullthick diamet pariet bone divid pth subcutan inject pth 134 gkg week ctl vehicl regimen sacrif posttreat regimen pariet bone extract histomorphometri radiodensitometri histolog pth islandlik defect margin fibrou ctl pth exhibit histolog ctl 15mm 07 06 005 residu defect radiodensitometri pth ctl eq 004 18al eq 006 005 demonstr miner pth contribut miner fibrou ctl regener acceler heal calvari defect intermitt pth  introductionmateri methodsresultsdiscuss defect frequent sequela patholog cyst trauma slow regener defect pose stimul heal defect auto graft allograft polymer membran enamel deriv assist regener stimul anabol pth intermitt minim periodont heal fenestr defect mandibl pth mediat remodel regul calcium homeostasi produc remodel anabol remodel catabol continu pth osteoclast osteoclast turnov intermitt stimul osteoblast osteoblast pth success osteoporosi intermitt pth prove vertebr nonvertebr fractur femor vertebr absent intermitt pth enhanc fractur strength callu heal tibia fractur stiff ultim load newlyform osteogenesi distract pth osteoporosi fractur pth calvari heal andreassen cacciafesta intermitt pth mechan strength heal calvari defect cover expand polytetrafluoroethylen membran besid dri newlyform insid defect stancoven criticals 8mm recombin morphogenet protein2 soakload onto absorb collagen spong deminer additivesynergist exogen pth purpos intermitt pth criticallys calvari defect 4mm wistar histomorphometr radiodensitometr recombin pth 134 approv mono post menopaus osteoporosi pth approv osteoporosi question arisen pth antiresorpt osteoporosi pth enhanc acceler fractur surround dental implant fenestr mandibular defect critic ally defect osseou defect heal spontan lifetim aalami fullthick 5mm diamet calvari defect complet heal critic ally 4mm calvari defect ten old beg experi intermitt pth pth ctl incomplet heal defect observ islandslik margin 4mm defect pth intermitt possibl restor ovariectom shirota intermitt pth 134 heal placement titanium screw implant ovariectom implant pth sham oper 56 implant pth dental implant pth 134 gkg week protect tooth periodontitisinduc promot margin gingiv ovariectom team pth 134 callu form acceler callu reabsorpt osteoclast callu corrobor miner bmd alter balanc osteoblast osteoclast resorpt bmd radiograph densitometri radiograph densitometri lowcost dualenergi xray absorptiometri radiograph densitometri intermitt pth calvari defect pth 134 intermitt bmd calvaria criticallys defect reinforc histolog possibl specul collagen miner turnov corrobor collagen fiber periodont ligament visual polar microscopi garnero pth chang typei collagen isomer stancoven pth 134 administ gkg calvari defect 8mm radiograph histolog exam slightli pth pth andreassen cacciafesta pth 134 gkg mechan strength heal calvari defect 5mm cover expand polytetrafluoroethylen membran dri newlyform insid defect pth inject week pth gkg acceler heal isol defect 4mm optic miner pth pth contribut miner fibrou ctl frequent islandlik format pth organ collagen fiber reinforc anabol pth 134 intermitt util coadjuv regener acceler heal calvari defect\n",
            "\t-6.013\tjoint nigerian sickl anaemia highlight commonest manifest sickl scd set pain vasoocclus crisi voc progress debil avascular necrosi avn osteomyel fix flexion deform joint protract bilater femor humer osteomyel elbow knee humer septic arthriti avascular necrosi femor humer head coupl urinari tract uti decubitu ulcer scd unusu occurr morbid uninterrupt 29 hospit enjoy fairli microorgan sequenti cultur coli klebsiella urin klebsiella spp aspir knee joint elbow joint femor osteomyel screen nonreact multidisciplinari discharg home wheelchair reflect scd morbid attend highlight forestal voc predispos osteomyel organ wellequip subsid sickl rehabilit center nigeria scd  introductioncas presentationdiscuss pain vasoocclus crise voc osteomyel frequent requir admiss sickl scd crise exacerb morbid scd old hb scd walk crisi discharg home wheelchair 29 turbul admiss widespread marrow micro occlus haplotyp benin seneg nigeria belong showcas devast scd highlight pathophysiolog viz voc abdomin crise haematogen spread microorgan caus osteomyel septic arthriti cumul escal morbid scd musculoskelet manifest commonest manifest scd set pain voc progress disabl avn osteomyel septic arthriti scd typic haemolyt anemia period steadi interrupt pain vasoocclus crisi trigger psycholog infect equal osteomyel skelet complic scd distinct infarct osteomyel scd dilemma scd fever local local erythema swell tender characterist typic esr favor osteomyel background sepsi suspect ab initio took osteomyel becam obviou aspir grew coli klebsiella joint scd marrow hyperplasia caus distort disturb vasoocclus infarct metaphys diaphys osteonecrosi juxtaarticular bone haematogen osteomyel septic arthriti femor humer head necrosi haematogen take promin abdomin crisi seepag gut flora stream haematogen spread scd sluggish circul bone compromis attribut inher defect microbi opson infarct splenic hypofunct voc involv patholog pyrexia hypercoagul neutrophilia eosinophilia thrombocytosi red cytopath diarrhoea vomit singli concert red sickl sickl indirectli haemoglobin oxygen polymer hydrat viscos red procoagul intercellular adher aggreg culmin voc apart tender warmth swell bone joint persist grade fever discharg sinus leukocytosi shift aspir yield predominantli pathogen organ septic arthriti osteomyel haematogen spread spread contigu osteomyel tender joint swell warmth mark limit motion characterist septic arthriti differenti arthropathi synovi synov adjac necrosi nonspecif synov selflimit rare progress chondrolysi abdomin crisi microscop infarct bowel wall consequ sickl intestin vessel favor specul anaerob organ escap bowel stream spread infarct bone scd refractori osteomyel display adhes perivascul shoulder avascular necrosi femor humer head refer explain unabl walk discharg wheelchair commenc hydroxyurea th week admiss contribut speedi recoveri hydroxyurea hbf reduc leukocytosi thrombocytosi attend endothelium adhes reaction therebi curtail cascad progress radic antioxid lifethreaten morbid scd spectrum organ larg kind exist abnorm multidisciplinari exemplifi actual establish wellequip sickl center nigeria largest black heaviest scd burden integr rehabilit center assist scd heavi subsidi optim controlimmun inclus suspicion adequ potent antibiot great limit attend\n",
            "bones and joints pain,PTH,Vit D None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.513\timmunoregulatori abil polymorphonuclear neutrophil sclerosi polymorphonuclear neutrophil pmn posse sclerosi m fluorescein isothiocyan fitc stain tnfalpha pmn cd11a cd11b cd18 beta2integrin cd10 neutral endopeptidasenep cd13 aminopeptidas apn antigen pmn m neurolog ond noninflammatori prove m exacerb progress m pmn reveal preactiv stainedtnfalpha cd11b cd18 cd10 cd13 antigen m remiss ond pmn m exacerb cpm pmn prime prove pmn    \n",
            "\t0.477\tpostop sore throat cough polyvinylchlorid tube armour tube   introductionmethodsresultsconclus postop sore throat cough name trauma airway endotrach tube mucos cuff hyperinfl complic minor distress otherwis intub endotrach tube cuff demonstr polyvinylchlorid endotrach tube postop sore throat cough\n",
            "\t0.457\tcyst cough copiou purul sputum   answer visit 40yearold woman chest fever cough purul sputum presum tract fever subsid continu 400500 ml purul sputum bloodting occas past unremark pale afebril pul chest palpat auscult breath sound infrascapular crepit abdomin enlarg investig hemoglobin gdl white count eosinophil bilirubin alkalin phosphatas transaminas chest xray hemidiaphragm zone consolid air fluid pleural effus abdomin ultrasonographi lobe cyst intern echo insid wall calcif contrastenhanc multidetectorrow ct mdct 64detector row ct transvers ct chest soft issu attenu consolid lobe involv later basal medial basal posterior basal segment round elong fluid attenu ct imag upper abdomen cystic segment vii air attenu anteriorli cyst wall curvilinear calcif bile duct dilat axial ct chest transvers ct imag chest soft attenu parenchym consolid later posterior medial basal segment lobe upward arrow round linear fluidattenu insid downward arrow axial ct abdomen transvers ct imag superior aspect cyst segment vii lobe upward arrow air anteriorli adjac wall downward arrow procedur precaut answer visit httpwwwsaudiannalsnet \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.571\tdiffus alveolar hemorrhag 39yearold woman unusu present microscop polyangi microscop polyangi mpa necrot vascul involv vessel granulomat mpa initi present initi present alveolar hemorrhag 39yearold progress cough dyspnea bloodting sputum mpa vat biopsi biopsi steroid chest mpa hemoptysislungvascular reportdiscuss 39yearold woman visit emerg room progress cough dyspnea bloodting sputum tobacco alcohol present 10754 mmhg pul 74 beat minut respir breath minut 368 awak orient suggest cbc count follow white count 8420mm 751 granulocyt 177 lymphocyt 56 monocyt 04 eosinophil hematocrit 252 mgdl platelet 374 kmm chemistri serolog hepat urin nonspecif chest pa opac throughout field chest ct extens groundglass opac field lymphadenopathi sputum acidfast bacillus bronchoscopi compat alveolar hemorrhag rml rll alveolar hemorrhag pneumonia conserv hemoptysi 5th admiss urin color chang abruptli bloodi simultan hematuria hemoptysi electrophoresi albumin immunotyp serolog hepat antinuclear antiglomerular basement antigbm mycoplasma pneumonia mycoplasma tuberculosi titer complement c3 c4 ch50 anti mpo panca 160 accur vat biopsi 9th biopsi 14th patholog lesion intraralveolar hemorrhag capillar lesion focal segment necrot glomerulonephr deposit capillari basement microscop polyangi present start steroid steroid chest hematuria remain hemoptysi diffus alveolar hemorrhag vascul rare encount thorac vascul destruct affect vessel surround diver microscop polyangi mpa necrot vascul involv vessel granulomat mpa antineutrophil cytoplasm ancaassoci vessel vascul deposit vessel mpa 100000 slight predomin organ 90 alveolar hemorrhag organ gi tract musculoskelet nervou mpa initi present initi present alveolar hemorrhag mpa research immunolog anca mpa chest radiograph consist groundglass opac consolid thicken bronchovascular bundl honeycomb appear alveolar hemorrhag anca aid monitor vacul mpa wegen granulomatosi churgstrauss 80 mpa anca biopsi aggrav critic ill follow biopsi recommend vasculitisassoci alveolar hemorrhag biopsi organ immunolog unusu present hemoptysi conserv biopsi accur specimen mpa necrosi nonspecif hemorrhag capillar specimen focal segment necrot glomerulonephr deposit specimen intraalveolar hemorrhag aggreg pigmentladen neutrophil capillar organ pneumonia specimen focal segment necrot glomerulonephr deposit basement specimen patholog mpa goodpastur goodpastur immunolog rapidli progress glomerulonephr diffus intraalveolar hemorrhag deposit capillari basement rule goodpastur mainstay mpa corticosteroid cyclophosphamid recommend empir paper mpa alveolar hemorrhag improv start steroid continu 39yearold woman present progress cough dyspnea hemoptysi mpa vat biopsi biopsi steroid chest mpa\n",
            "\t-4.571\tdiffus alveolar hemorrhag 39yearold woman unusu present microscop polyangi microscop polyangi mpa necrot vascul involv vessel granulomat mpa initi present initi present alveolar hemorrhag 39yearold progress cough dyspnea bloodting sputum mpa vat biopsi biopsi steroid chest mpa hemoptysislungvascular reportdiscuss 39yearold woman visit emerg room progress cough dyspnea bloodting sputum tobacco alcohol present 10754 mmhg pul 74 beat minut respir breath minut 368 awak orient suggest cbc count follow white count 8420mm 751 granulocyt 177 lymphocyt 56 monocyt 04 eosinophil hematocrit 252 mgdl platelet 374 kmm chemistri serolog hepat urin nonspecif chest pa opac throughout field chest ct extens groundglass opac field lymphadenopathi sputum acidfast bacillus bronchoscopi compat alveolar hemorrhag rml rll alveolar hemorrhag pneumonia conserv hemoptysi 5th admiss urin color chang abruptli bloodi simultan hematuria hemoptysi electrophoresi albumin immunotyp serolog hepat antinuclear antiglomerular basement antigbm mycoplasma pneumonia mycoplasma tuberculosi titer complement c3 c4 ch50 anti mpo panca 160 accur vat biopsi 9th biopsi 14th patholog lesion intraralveolar hemorrhag capillar lesion focal segment necrot glomerulonephr deposit capillari basement microscop polyangi present start steroid steroid chest hematuria remain hemoptysi diffus alveolar hemorrhag vascul rare encount thorac vascul destruct affect vessel surround diver microscop polyangi mpa necrot vascul involv vessel granulomat mpa antineutrophil cytoplasm ancaassoci vessel vascul deposit vessel mpa 100000 slight predomin organ 90 alveolar hemorrhag organ gi tract musculoskelet nervou mpa initi present initi present alveolar hemorrhag mpa research immunolog anca mpa chest radiograph consist groundglass opac consolid thicken bronchovascular bundl honeycomb appear alveolar hemorrhag anca aid monitor vacul mpa wegen granulomatosi churgstrauss 80 mpa anca biopsi aggrav critic ill follow biopsi recommend vasculitisassoci alveolar hemorrhag biopsi organ immunolog unusu present hemoptysi conserv biopsi accur specimen mpa necrosi nonspecif hemorrhag capillar specimen focal segment necrot glomerulonephr deposit specimen intraalveolar hemorrhag aggreg pigmentladen neutrophil capillar organ pneumonia specimen focal segment necrot glomerulonephr deposit basement specimen patholog mpa goodpastur goodpastur immunolog rapidli progress glomerulonephr diffus intraalveolar hemorrhag deposit capillari basement rule goodpastur mainstay mpa corticosteroid cyclophosphamid recommend empir paper mpa alveolar hemorrhag improv start steroid continu 39yearold woman present progress cough dyspnea hemoptysi mpa vat biopsi biopsi steroid chest mpa\n",
            "\t-4.571\tdiffus alveolar hemorrhag 39yearold woman unusu present microscop polyangi microscop polyangi mpa necrot vascul involv vessel granulomat mpa initi present initi present alveolar hemorrhag 39yearold progress cough dyspnea bloodting sputum mpa vat biopsi biopsi steroid chest mpa hemoptysislungvascular reportdiscuss 39yearold woman visit emerg room progress cough dyspnea bloodting sputum tobacco alcohol present 10754 mmhg pul 74 beat minut respir breath minut 368 awak orient suggest cbc count follow white count 8420mm 751 granulocyt 177 lymphocyt 56 monocyt 04 eosinophil hematocrit 252 mgdl platelet 374 kmm chemistri serolog hepat urin nonspecif chest pa opac throughout field chest ct extens groundglass opac field lymphadenopathi sputum acidfast bacillus bronchoscopi compat alveolar hemorrhag rml rll alveolar hemorrhag pneumonia conserv hemoptysi 5th admiss urin color chang abruptli bloodi simultan hematuria hemoptysi electrophoresi albumin immunotyp serolog hepat antinuclear antiglomerular basement antigbm mycoplasma pneumonia mycoplasma tuberculosi titer complement c3 c4 ch50 anti mpo panca 160 accur vat biopsi 9th biopsi 14th patholog lesion intraralveolar hemorrhag capillar lesion focal segment necrot glomerulonephr deposit capillari basement microscop polyangi present start steroid steroid chest hematuria remain hemoptysi diffus alveolar hemorrhag vascul rare encount thorac vascul destruct affect vessel surround diver microscop polyangi mpa necrot vascul involv vessel granulomat mpa antineutrophil cytoplasm ancaassoci vessel vascul deposit vessel mpa 100000 slight predomin organ 90 alveolar hemorrhag organ gi tract musculoskelet nervou mpa initi present initi present alveolar hemorrhag mpa research immunolog anca mpa chest radiograph consist groundglass opac consolid thicken bronchovascular bundl honeycomb appear alveolar hemorrhag anca aid monitor vacul mpa wegen granulomatosi churgstrauss 80 mpa anca biopsi aggrav critic ill follow biopsi recommend vasculitisassoci alveolar hemorrhag biopsi organ immunolog unusu present hemoptysi conserv biopsi accur specimen mpa necrosi nonspecif hemorrhag capillar specimen focal segment necrot glomerulonephr deposit specimen intraalveolar hemorrhag aggreg pigmentladen neutrophil capillar organ pneumonia specimen focal segment necrot glomerulonephr deposit basement specimen patholog mpa goodpastur goodpastur immunolog rapidli progress glomerulonephr diffus intraalveolar hemorrhag deposit capillari basement rule goodpastur mainstay mpa corticosteroid cyclophosphamid recommend empir paper mpa alveolar hemorrhag improv start steroid continu 39yearold woman present progress cough dyspnea hemoptysi mpa vat biopsi biopsi steroid chest mpa\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.513\timmunoregulatori abil polymorphonuclear neutrophil sclerosi polymorphonuclear neutrophil pmn posse sclerosi m fluorescein isothiocyan fitc stain tnfalpha pmn cd11a cd11b cd18 beta2integrin cd10 neutral endopeptidasenep cd13 aminopeptidas apn antigen pmn m neurolog ond noninflammatori prove m exacerb progress m pmn reveal preactiv stainedtnfalpha cd11b cd18 cd10 cd13 antigen m remiss ond pmn m exacerb cpm pmn prime prove pmn    \n",
            "\t0.477\tpostop sore throat cough polyvinylchlorid tube armour tube   introductionmethodsresultsconclus postop sore throat cough name trauma airway endotrach tube mucos cuff hyperinfl complic minor distress otherwis intub endotrach tube cuff demonstr polyvinylchlorid endotrach tube postop sore throat cough\n",
            "\t0.457\tcyst cough copiou purul sputum   answer visit 40yearold woman chest fever cough purul sputum presum tract fever subsid continu 400500 ml purul sputum bloodting occas past unremark pale afebril pul chest palpat auscult breath sound infrascapular crepit abdomin enlarg investig hemoglobin gdl white count eosinophil bilirubin alkalin phosphatas transaminas chest xray hemidiaphragm zone consolid air fluid pleural effus abdomin ultrasonographi lobe cyst intern echo insid wall calcif contrastenhanc multidetectorrow ct mdct 64detector row ct transvers ct chest soft issu attenu consolid lobe involv later basal medial basal posterior basal segment round elong fluid attenu ct imag upper abdomen cystic segment vii air attenu anteriorli cyst wall curvilinear calcif bile duct dilat axial ct chest transvers ct imag chest soft attenu parenchym consolid later posterior medial basal segment lobe upward arrow round linear fluidattenu insid downward arrow axial ct abdomen transvers ct imag superior aspect cyst segment vii lobe upward arrow air anteriorli adjac wall downward arrow procedur precaut answer visit httpwwwsaudiannalsnet \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.571\tdiffus alveolar hemorrhag 39yearold woman unusu present microscop polyangi microscop polyangi mpa necrot vascul involv vessel granulomat mpa initi present initi present alveolar hemorrhag 39yearold progress cough dyspnea bloodting sputum mpa vat biopsi biopsi steroid chest mpa hemoptysislungvascular reportdiscuss 39yearold woman visit emerg room progress cough dyspnea bloodting sputum tobacco alcohol present 10754 mmhg pul 74 beat minut respir breath minut 368 awak orient suggest cbc count follow white count 8420mm 751 granulocyt 177 lymphocyt 56 monocyt 04 eosinophil hematocrit 252 mgdl platelet 374 kmm chemistri serolog hepat urin nonspecif chest pa opac throughout field chest ct extens groundglass opac field lymphadenopathi sputum acidfast bacillus bronchoscopi compat alveolar hemorrhag rml rll alveolar hemorrhag pneumonia conserv hemoptysi 5th admiss urin color chang abruptli bloodi simultan hematuria hemoptysi electrophoresi albumin immunotyp serolog hepat antinuclear antiglomerular basement antigbm mycoplasma pneumonia mycoplasma tuberculosi titer complement c3 c4 ch50 anti mpo panca 160 accur vat biopsi 9th biopsi 14th patholog lesion intraralveolar hemorrhag capillar lesion focal segment necrot glomerulonephr deposit capillari basement microscop polyangi present start steroid steroid chest hematuria remain hemoptysi diffus alveolar hemorrhag vascul rare encount thorac vascul destruct affect vessel surround diver microscop polyangi mpa necrot vascul involv vessel granulomat mpa antineutrophil cytoplasm ancaassoci vessel vascul deposit vessel mpa 100000 slight predomin organ 90 alveolar hemorrhag organ gi tract musculoskelet nervou mpa initi present initi present alveolar hemorrhag mpa research immunolog anca mpa chest radiograph consist groundglass opac consolid thicken bronchovascular bundl honeycomb appear alveolar hemorrhag anca aid monitor vacul mpa wegen granulomatosi churgstrauss 80 mpa anca biopsi aggrav critic ill follow biopsi recommend vasculitisassoci alveolar hemorrhag biopsi organ immunolog unusu present hemoptysi conserv biopsi accur specimen mpa necrosi nonspecif hemorrhag capillar specimen focal segment necrot glomerulonephr deposit specimen intraalveolar hemorrhag aggreg pigmentladen neutrophil capillar organ pneumonia specimen focal segment necrot glomerulonephr deposit basement specimen patholog mpa goodpastur goodpastur immunolog rapidli progress glomerulonephr diffus intraalveolar hemorrhag deposit capillari basement rule goodpastur mainstay mpa corticosteroid cyclophosphamid recommend empir paper mpa alveolar hemorrhag improv start steroid continu 39yearold woman present progress cough dyspnea hemoptysi mpa vat biopsi biopsi steroid chest mpa\n",
            "\t-4.571\tdiffus alveolar hemorrhag 39yearold woman unusu present microscop polyangi microscop polyangi mpa necrot vascul involv vessel granulomat mpa initi present initi present alveolar hemorrhag 39yearold progress cough dyspnea bloodting sputum mpa vat biopsi biopsi steroid chest mpa hemoptysislungvascular reportdiscuss 39yearold woman visit emerg room progress cough dyspnea bloodting sputum tobacco alcohol present 10754 mmhg pul 74 beat minut respir breath minut 368 awak orient suggest cbc count follow white count 8420mm 751 granulocyt 177 lymphocyt 56 monocyt 04 eosinophil hematocrit 252 mgdl platelet 374 kmm chemistri serolog hepat urin nonspecif chest pa opac throughout field chest ct extens groundglass opac field lymphadenopathi sputum acidfast bacillus bronchoscopi compat alveolar hemorrhag rml rll alveolar hemorrhag pneumonia conserv hemoptysi 5th admiss urin color chang abruptli bloodi simultan hematuria hemoptysi electrophoresi albumin immunotyp serolog hepat antinuclear antiglomerular basement antigbm mycoplasma pneumonia mycoplasma tuberculosi titer complement c3 c4 ch50 anti mpo panca 160 accur vat biopsi 9th biopsi 14th patholog lesion intraralveolar hemorrhag capillar lesion focal segment necrot glomerulonephr deposit capillari basement microscop polyangi present start steroid steroid chest hematuria remain hemoptysi diffus alveolar hemorrhag vascul rare encount thorac vascul destruct affect vessel surround diver microscop polyangi mpa necrot vascul involv vessel granulomat mpa antineutrophil cytoplasm ancaassoci vessel vascul deposit vessel mpa 100000 slight predomin organ 90 alveolar hemorrhag organ gi tract musculoskelet nervou mpa initi present initi present alveolar hemorrhag mpa research immunolog anca mpa chest radiograph consist groundglass opac consolid thicken bronchovascular bundl honeycomb appear alveolar hemorrhag anca aid monitor vacul mpa wegen granulomatosi churgstrauss 80 mpa anca biopsi aggrav critic ill follow biopsi recommend vasculitisassoci alveolar hemorrhag biopsi organ immunolog unusu present hemoptysi conserv biopsi accur specimen mpa necrosi nonspecif hemorrhag capillar specimen focal segment necrot glomerulonephr deposit specimen intraalveolar hemorrhag aggreg pigmentladen neutrophil capillar organ pneumonia specimen focal segment necrot glomerulonephr deposit basement specimen patholog mpa goodpastur goodpastur immunolog rapidli progress glomerulonephr diffus intraalveolar hemorrhag deposit capillari basement rule goodpastur mainstay mpa corticosteroid cyclophosphamid recommend empir paper mpa alveolar hemorrhag improv start steroid continu 39yearold woman present progress cough dyspnea hemoptysi mpa vat biopsi biopsi steroid chest mpa\n",
            "\t-4.571\tdiffus alveolar hemorrhag 39yearold woman unusu present microscop polyangi microscop polyangi mpa necrot vascul involv vessel granulomat mpa initi present initi present alveolar hemorrhag 39yearold progress cough dyspnea bloodting sputum mpa vat biopsi biopsi steroid chest mpa hemoptysislungvascular reportdiscuss 39yearold woman visit emerg room progress cough dyspnea bloodting sputum tobacco alcohol present 10754 mmhg pul 74 beat minut respir breath minut 368 awak orient suggest cbc count follow white count 8420mm 751 granulocyt 177 lymphocyt 56 monocyt 04 eosinophil hematocrit 252 mgdl platelet 374 kmm chemistri serolog hepat urin nonspecif chest pa opac throughout field chest ct extens groundglass opac field lymphadenopathi sputum acidfast bacillus bronchoscopi compat alveolar hemorrhag rml rll alveolar hemorrhag pneumonia conserv hemoptysi 5th admiss urin color chang abruptli bloodi simultan hematuria hemoptysi electrophoresi albumin immunotyp serolog hepat antinuclear antiglomerular basement antigbm mycoplasma pneumonia mycoplasma tuberculosi titer complement c3 c4 ch50 anti mpo panca 160 accur vat biopsi 9th biopsi 14th patholog lesion intraralveolar hemorrhag capillar lesion focal segment necrot glomerulonephr deposit capillari basement microscop polyangi present start steroid steroid chest hematuria remain hemoptysi diffus alveolar hemorrhag vascul rare encount thorac vascul destruct affect vessel surround diver microscop polyangi mpa necrot vascul involv vessel granulomat mpa antineutrophil cytoplasm ancaassoci vessel vascul deposit vessel mpa 100000 slight predomin organ 90 alveolar hemorrhag organ gi tract musculoskelet nervou mpa initi present initi present alveolar hemorrhag mpa research immunolog anca mpa chest radiograph consist groundglass opac consolid thicken bronchovascular bundl honeycomb appear alveolar hemorrhag anca aid monitor vacul mpa wegen granulomatosi churgstrauss 80 mpa anca biopsi aggrav critic ill follow biopsi recommend vasculitisassoci alveolar hemorrhag biopsi organ immunolog unusu present hemoptysi conserv biopsi accur specimen mpa necrosi nonspecif hemorrhag capillar specimen focal segment necrot glomerulonephr deposit specimen intraalveolar hemorrhag aggreg pigmentladen neutrophil capillar organ pneumonia specimen focal segment necrot glomerulonephr deposit basement specimen patholog mpa goodpastur goodpastur immunolog rapidli progress glomerulonephr diffus intraalveolar hemorrhag deposit capillari basement rule goodpastur mainstay mpa corticosteroid cyclophosphamid recommend empir paper mpa alveolar hemorrhag improv start steroid continu 39yearold woman present progress cough dyspnea hemoptysi mpa vat biopsi biopsi steroid chest mpa\n",
            "dry cough,serum MPO-ANCA,corticosteroid None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.502\taflatrem tremorgen mycotoxin neurotox tremorgen mycotoxin neurolog rang confus tremor seizur appar mycotoxin nervou tremorgen implic neurolog cattl collect stagger syndrom pose agricultur cattl tremorgen transient perturb neurotransmitt reason believ exposur toxin synapt degener fiber tremorgen mgkg ip aflatrem kinet neurotransmitt hippocamp termin week inject gaba glutam interpret termin affin constant transmitt transient transmitt aflatrem degener hippocamp neurotransmitt repres threat    \n",
            "\t0.458\tcardiomyopathi defect myocellular copper defect rectifi dival copper chelat defect copper cardiomyopathi dcm sought myocardi copper copperprotein respond cu iiselect chelat triethylenetetramin teta dcm wistar streptozotocin stzinduc teta isolatedperfus work heart myocardi copper particleinduc xray emiss spectroscopi pix coupl rutherford backscatt spectrometri rb mediat lvtissuecopp rtqpcr western blot immunofluoresc microscopi student anova 005 leftventricular lv copper sever depress 16week unexpectedli normal 8week teta institut local myocardi copper defici accompani polymer copperrespons transitionmetalbind metallothionein mt1mt2 antioxid defenc prooxid highaffin copper transporter1 ctr1 depress copper modifi teta contrastingli renorm myocardi copper cellmembran local lowaffin copper transporter2 ctr2 lower index ic copper copper chaperon superoxid dismutas cc cuproenzym superoxid dismutase1 sod1 rectifi teta normal sod1 consequ bolster antioxid defens depress coppertransport antioxidantprotein1 atox1 coppertransportingatpase2 atp7b teta coppertransportingatpase1 atp7a myocardi copper defici defect copper transporttraffick defect lv impair tetamedi restor copper dcm cardiomyopathycopperdefici cardiomyopathyleftventricular dysfunctionmyocellular coppercopp transporterssuperoxid dismutas 1copper chaperonescu iichelationcopp metalationheart backgroundmethodsanim studieschoic teta dosagechoic valid modelmeasur ex functionmeasur copper contentmeasur rtqpcrwestern blot analysiscuznsod1 elisacuznsod1 assayimmunofluoresc lv freewal tissuestatist analysisresultsdiabet myocardi copper defici rectifi teta treatmentteta accentu diabetesevok upregul ctr2 modifi diabeteselicit lower ctr1 expressiondiabet lower mt1 mt2 lv myocardiumincreas polymer mt partial amelior teta treatmentteta rectifi diabetesmedi defect cc sod1diabet teta evok coppertransport atpas atp7a atp7bdiscussionconclusionsabbreviationscompet interestsauthor contributionssupplementari materialaddit file disabl mellitu accompani lv hyperglycemia cardiomyopathi dcm contribut substanti morbid dcm numer patholog myocellular hypertrophi interstiti fibrosi defect fuel util accompani myocellular organel contractil apparatu mitochondrion sarcoplasm reticulum defect cooper systol diastol progress overt defect poorli understood dcm pathogenet reflect defect superoxid anion exampl excess coupl diminish clearanc sod review alter ion homeostasi implic dcm myocellular efflux na exchang ncx atpas serca pump defect contractil calcium homeostasi contractil deficit dcm myocellular ic ic energyineffici dcm copper defici copper excess antioxid defens copper defici neurodegener hematolog copper overload accompani hepat neurolog copper homeostasi coordin chaperon deliv subcellular compart copperrequir releas copper atom otherwis exampl copper chaperon superoxid dismutas cc sod1 antioxid copper chaperon atox1 atp7a atp7b disturb copper homeostasi pronounc deleteri bodili menk wilson encod atp7a atp7b copper cofactor cuznsod sod1 ecsod sod3 cytochrom oxidas cox ceruloplasminferroxidas whereof defici implic causat local myocardi copper defici heartspecif knockout ctr1 cardiomyopathi geneticallymedi defect rodent sco2 encod chaperon copper metal cua coii subunit cox link myocardi copper defici copper metal causat cardiomyopathi copper defici cardiomyopathi wherein pathobiolog close resembl dcm index copper differ markedli cardiomyopathi insuffici copper exhibit sign copper defici hypocupremia hypoceruloplasminemia anemia neutropenia defici hepat copper allevi copper replac dcm sign copper excess elev urinari copper copper balanc copper ceruloplasmin markedli hepat copper copper defect copper cu chelat triethylenetetramin teta restor index copper homeostasi lv lv hypertrophi improv copper index myocellular copper transporttraffick contribut widelyaccept dcm teta amelior diabetesinduc dysregul copper homeostasi tetamedi myocardi coppertransport coordin copper homeostasi lv nondiabet tetatreateddiabet undertook tetatr nondiabet compar purpos teta transloc coppertransport copperenzym lvcopper teta relat alter expressionact copperregulatori dcm hemodynam perfus heart non teta teta teta teta wistar wistar wistar wistar enrol 67 67 67 67 2223 2223 2223 2223 573 562 220 290 58 020 51 015 298 065 270 120 158 004 163 005 103 006 118 009 heartweightbodyweight 276 001 277 013 466 013 408 017 output mlmin 792 750 533 81 780 lv dpdt max mmhg 4506 549 4667 417 2249 162 4082 196 lv dpdt min mmhg 4384 453 4245 413 1952 144 3366 125 steadyst cmh preload 75 mmhg afterload heart pace 300 beatsmin sem twoway anova post hoc tukey 005 005 diabetesinduc impair myocellular coppertransport local copper defici lvmyocardium myocardi copper defici elicit lv dcm revers teta employ parallel investig lv hypertrophi diastol type2 dcm sign copper overload excess lv markedli teta newlyrecogn serv discoveri teta normal myocardi copper mainten restor myocardi restor myocellular copper antioxid defens work newlyrecogn myocardi copper discoveri highlyselect cu chelat restor defect myocardi coppertraffick otherwis conspir dcm alter dcm abbrevi\n",
            "\t0.452\ttremor sclerosi patholog anatomi pharmacolog tremor preval disabl sclerosi m mileston tremor focus anatom search medlin search sclerosi tremor refer articl januari 1966 predomin m tremor largeamplitud postur kinet tremor affect arm tremor involv head neck vocal cord trunk tongu jaw palat anatom tremor m poorli understood link cerebellum msrelat tremor support unsuccess satisfactori treat disabl tremor tremor m consequ aggress m tremor disabl m tremor great dissoci tremor cerebellar issu success pathophysiolog biochemistri tremor m tremormultipl sclerosisreview introductionreview criteriapreval tremor sclerosismain tremor sclerosisclin featuresanatom basisassess tremor sclerosisoutcom tremor sclerosistreatmentgener considerationstreat option sclerosi tremorpharmacolog agentssurg tremor involuntari rhythmic movement involv oscil part repeat contract relax oppos sclerosi m nervou adulthood tremor featur m french neurologist jeanmartin charcot tremor defin m nystagmu scan speech tremor preval disabl m mileston relat m tremor focus anatom \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.312\twhite matter magnet reson neurodegen   commentari 14yearold sri lankan progress dysarthria dysmetria gait ataxia tremor bradykinesia declin ensu admiss sister ill parent nonconsanguin glasgow coma quadrihyperreflexia extensor plantar cerebellar cogwheel rigid note flap tremor hepatosplenomegali elicit abdomin kayserfleisch kf ring slit lamp magnet reson mri intens t2weight imag basal ganglion supratentori infratentori gray white matter magnet reson diffus abnorm intens cerebr white matter bilater white arrow cerebr atrophi extend involv grey matter abnorm t2 bilater extern slightli t2 intens putamen black arrow biochem follow ceruloplasmin mgdl 1845 urinari copper excret 45 mol24 aspart transaminas ast sgot 48 ul 1035 alanin transaminas alt sgpt 57 ul 1040 alkalin phosphatas 226 ul 100360 bilirubin 92 moll 521 70 gl albumin 39 gl globulin 31 gl prothrombin 128 intern normal inr aptt ammonia moll moll na 140 mmoll 45 mmoll creatinin 62 moll cerebrospin fluid commentari extrapyramid bradykinesia cogwheel rigid hepatosplenomegali kf ring ceruloplasmin urinari copper excret wilson wd symptomat wd neuroimag abnorm wd spectrum neuroimag abnorm conspicu atrophi abnorm basal ganglion nearli gray white matter t2 highlight strike white matter mri white matter diffus child present progress declin mri herit leukoencephalopathi diffus megalencephali differenti vanish white matter pelizaeusmerzbach unusu wd diffus white matter posterior wd diffus intens white matter t2weight imag demyelini soften spongi cavitari disintegr mri imag grey matter t2 intens edema gliosi necrosi cystic degener white matter penicillamin white matter white matter van wassenaervan hall 41 1995 indian white matter wd pauciti sri lanka highlight recogn white matter wd evalu neuropsychiatr \n",
            "\t-4.631\tcopper ion huntington huntington hd domin polyglutamin expans nterminu huntingtin energet insuffici striatal degener copper iron striata hd metal hd inductivelycoupledplasma spectroscopi elev copper iron hd reiter brain hd transgen copper copper export amyloid precursor hypothes amount copper bound affin prooxid neurodegener huntingtin central hd lactat dehydrogenas ldh document copper necess normox lactat hd 171 wildtyp huntingtin glutamin expand interact copper iron n171 cu copper stoichiometri fragment redox copper promot metal chelat inhibit aggreg cellfre huntingtin ldh lactat hd transgen ldh oxam neurodegener deliv intrastriati ldh neurodegener hd prooxid copperprotein hd offer pharmacotherapeut  introductionmateri methodsmaterialsntermin huntingtin synthesishuman tissueimmobil metal affin chromatographymet assayhuntingtin aggreg assaymic husbandrycopp iron analysessod1 assayldh lactat assaysoxam infusionswestern blotsquantit pcrstatist analysisresultscopp interact ntermin huntingtincopperhuntingtin involv histidin residuescopperii promot aggreg huntingtincopp iron hd brainlact dehydrogenas hd neurodegenerationdecreas copper export app hd braindiscussionsupport huntington hd neurodegen progress psychiatr deterior hd domin glutamin expans nterminu huntingtin initi primarili striatum cerebr fulllength huntingtin 350 kd smaller ntermin fragment mediat fragment aberr biomolecul hallmark hd aggreg repress copper iron striata postmortem hd brain ferritiniron striata hd mri metal hd basal ganglion copper iron wilson wd copper wd neurolog coppermedi striatal degener ferritin neuroferritinopathi accumul iron degener globu pallidu mechanist overlap hd basal ganglion copper iron copper iron hd potenti neurodegener copper hd affin diver biomolecul aberr copperprotein implic alzheim lou gehrig parkinson polyglutamin hd copper huntingtin conform aggreg redoxact analog betaamyloid copper betaamyloid oligomer alzheim glycolyt dehydrogenas lactat dehydrogenas ldh succin dehydrogenas sdh coppermedi inactiv ldh astrocyteneuron lactat shuttl wherebi lactat releas astrocyt substrat lactat hd striata magnet reson spectroscopi presymptomat n17182q hd metabol lactat succin excess copper hd energet insuffici inhibit ldh goal address aberr copperprotein hd address way copper hd modul huntingtin interf lactateenergi inhibit ldh copper hereto unappreci potenti hd huntingtin interf basal ganglion copper iron neurodegener 31 hd copper accumul promot prooxid huntingtin central hd lactat dehydrogenas ldh document copper necess normox lactat hd postmortem hd huntingtin fragment biochem transgen knockin hd express fulllength huntingtin excess copper potenti hd immobil metal affin chromatographi imac huntingtin interact copper imac copperprotein neurodegen n171 17q expand 68q glutamin tract interact copper iron zinc histidin 82 98 copper 2b coordin copper ion exon117q fragment n84 interact copper 2d copperntermin huntingtin neurodegen r62 hd express exon1 huntingtin n171 fragment h98f bind imac column exon1 n171 fragment coordin copper differ 2a glutamin expans affect copperbind flank polyglutamin tract profound influenc huntingtin 33 modul huntingtin invivo n17117q reduc copper copper n17117q huntingtin interact solut electron copper n17117q oxid copper 34 abeta1 42 n171 redox iron n17117q copper 3a iron interact ntermin huntingtin solut imac huntingtin aggreg center reactiv ro cultur implic iron ro inhibit metal chelat deferoxamin ad medium deferoxamin iron interpret agreement ntermin huntingtin redox hd insolubl huntingtin aggreg patholog hallmark hd copper promot metal chelat inhibit cellfre sd mercaptoethanol resist huntingtin aggreg 3c copper modul huntingtin aggreg invivo rais metal chelat neuroprotect hd inhibit silenc redox huntingtin permeabl copper iron chelat clioquinol neuroprotect decreas aggreg load r62 hd 36 epigallocatechingal green tea flavonoid copper chelat 37 modul huntingtin misfold reduc drosophila hd 38 microscop visibl aggreg hd controversi copper interact ntermin huntingtin monom copper modul aggreg influenc proxim huntingtin cascad monom oligom microscop aggreg exact unclear possibl coppermedi conform huntingtin oxid proteolysi copper iron brain 12week r62 hd correspond latestag hd iron brain 12month cag140 hd correspond preclin hd figur 4a r62 unlik shift advanc hd cortic zinc unalt copper iron homeostasi hd argu iron hd copper cag140 preclin copper potenti hd act iron cag140 copper r62 striatum hd cortic striatal degener 39 address distribut copper huntingtin biochem fraction compat occur distribut r62 iron aggreg huntingtin exclud biochem copper iron fraction 4a molar copper iron exon1 huntingtin copper bound huntingtin stoichiometri excess metal subcellular mediat copper inactiv ldh oxid activesit cystein residu forebrain 12weekold r62 ldh llactat disturb lactat ldh ldhb isoform n17182q hd ppar coactiv pgc1 n17182q util lactat substrat defect pgc1 r62 hd 41 decreas ldh monom western blot 6b unalt ldh monom biochem ingel ldh agedepend declin ldh r62 hd 6ab forebrain copper r62 12week 4e ldh coppermedi inactiv 6d ldh coppermedi enzymat interpret support fraction copper entir huntingtin ldh oxam striatal degener 6e defect ldh neurodegener hd copper interfer lactat hd inhibit ldh copper hd reason neuroprotect cuproprotein copperhomeostat huntingtin copperbind copper iron unalt r62 12week rule r62 hd mount compensatori antioxid sod1 antioxid repres shift copper r62 s1 implic copper homeostasi app aplp2 knockout cortic copper 29 r62 hd app aplp2 7ad explain copper r62 app knockout grip strength locomotor 42 app aplp2 transcript unalt r62 western blot translat copperexport app neuroprotect 43 neurotroph 44 45 app r62 hd neurodegener copperdepend copper huntingtin ldh hd ntermin huntingtin copper redoxmedi huntingtin compat huntingtin dysregul axon copper hd way hydrogen peroxid ion copper reactiv fold reactiv iron 46 47 abund oxid hd 48 neurotox metabolit 3hydroxykynurenin hd 49 invitro react readili copper iron gener hydrogen peroxid 51 copper iron hd quantifi affin specif metal ion ntermin huntingtin fragment redox chemistri underscor relev metalprotein chemistri hd neuroprotect stratagi\n",
            "\t-6.078\ttremor sclerosi tremor percent sclerosi m sever disabl embarrass manag isoniazid dose carbamazepin propranolol gluthetimid relief effect cannabinoid ineffect tremor stereotact thalamotomi thalam scarc physiotherapi tremor orthos limb cool achiev tremor m unmet requir basic  search criteriaintroductionepidemiologytremor subtypespathophysiolog tremorassess tremormed treatmentsurg treatmentstrategi selectionoutcom treatmentoth optionsconclus refer search pubm 1966 cochran librari issu search sclerosi tremor ataxia disabl thalamotomi deep articl search tabl paper search isi scienc citat articl cite paper articl english german public abstract tremor great everyon care m unsuccess pathophysiolog biochemistri tremor m stereotact treat tremor uncertain lesion db choic compar option physiotherapi tremor orthos limb cool valuabl improv live\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.502\taflatrem tremorgen mycotoxin neurotox tremorgen mycotoxin neurolog rang confus tremor seizur appar mycotoxin nervou tremorgen implic neurolog cattl collect stagger syndrom pose agricultur cattl tremorgen transient perturb neurotransmitt reason believ exposur toxin synapt degener fiber tremorgen mgkg ip aflatrem kinet neurotransmitt hippocamp termin week inject gaba glutam interpret termin affin constant transmitt transient transmitt aflatrem degener hippocamp neurotransmitt repres threat    \n",
            "\t0.458\tcardiomyopathi defect myocellular copper defect rectifi dival copper chelat defect copper cardiomyopathi dcm sought myocardi copper copperprotein respond cu iiselect chelat triethylenetetramin teta dcm wistar streptozotocin stzinduc teta isolatedperfus work heart myocardi copper particleinduc xray emiss spectroscopi pix coupl rutherford backscatt spectrometri rb mediat lvtissuecopp rtqpcr western blot immunofluoresc microscopi student anova 005 leftventricular lv copper sever depress 16week unexpectedli normal 8week teta institut local myocardi copper defici accompani polymer copperrespons transitionmetalbind metallothionein mt1mt2 antioxid defenc prooxid highaffin copper transporter1 ctr1 depress copper modifi teta contrastingli renorm myocardi copper cellmembran local lowaffin copper transporter2 ctr2 lower index ic copper copper chaperon superoxid dismutas cc cuproenzym superoxid dismutase1 sod1 rectifi teta normal sod1 consequ bolster antioxid defens depress coppertransport antioxidantprotein1 atox1 coppertransportingatpase2 atp7b teta coppertransportingatpase1 atp7a myocardi copper defici defect copper transporttraffick defect lv impair tetamedi restor copper dcm cardiomyopathycopperdefici cardiomyopathyleftventricular dysfunctionmyocellular coppercopp transporterssuperoxid dismutas 1copper chaperonescu iichelationcopp metalationheart backgroundmethodsanim studieschoic teta dosagechoic valid modelmeasur ex functionmeasur copper contentmeasur rtqpcrwestern blot analysiscuznsod1 elisacuznsod1 assayimmunofluoresc lv freewal tissuestatist analysisresultsdiabet myocardi copper defici rectifi teta treatmentteta accentu diabetesevok upregul ctr2 modifi diabeteselicit lower ctr1 expressiondiabet lower mt1 mt2 lv myocardiumincreas polymer mt partial amelior teta treatmentteta rectifi diabetesmedi defect cc sod1diabet teta evok coppertransport atpas atp7a atp7bdiscussionconclusionsabbreviationscompet interestsauthor contributionssupplementari materialaddit file disabl mellitu accompani lv hyperglycemia cardiomyopathi dcm contribut substanti morbid dcm numer patholog myocellular hypertrophi interstiti fibrosi defect fuel util accompani myocellular organel contractil apparatu mitochondrion sarcoplasm reticulum defect cooper systol diastol progress overt defect poorli understood dcm pathogenet reflect defect superoxid anion exampl excess coupl diminish clearanc sod review alter ion homeostasi implic dcm myocellular efflux na exchang ncx atpas serca pump defect contractil calcium homeostasi contractil deficit dcm myocellular ic ic energyineffici dcm copper defici copper excess antioxid defens copper defici neurodegener hematolog copper overload accompani hepat neurolog copper homeostasi coordin chaperon deliv subcellular compart copperrequir releas copper atom otherwis exampl copper chaperon superoxid dismutas cc sod1 antioxid copper chaperon atox1 atp7a atp7b disturb copper homeostasi pronounc deleteri bodili menk wilson encod atp7a atp7b copper cofactor cuznsod sod1 ecsod sod3 cytochrom oxidas cox ceruloplasminferroxidas whereof defici implic causat local myocardi copper defici heartspecif knockout ctr1 cardiomyopathi geneticallymedi defect rodent sco2 encod chaperon copper metal cua coii subunit cox link myocardi copper defici copper metal causat cardiomyopathi copper defici cardiomyopathi wherein pathobiolog close resembl dcm index copper differ markedli cardiomyopathi insuffici copper exhibit sign copper defici hypocupremia hypoceruloplasminemia anemia neutropenia defici hepat copper allevi copper replac dcm sign copper excess elev urinari copper copper balanc copper ceruloplasmin markedli hepat copper copper defect copper cu chelat triethylenetetramin teta restor index copper homeostasi lv lv hypertrophi improv copper index myocellular copper transporttraffick contribut widelyaccept dcm teta amelior diabetesinduc dysregul copper homeostasi tetamedi myocardi coppertransport coordin copper homeostasi lv nondiabet tetatreateddiabet undertook tetatr nondiabet compar purpos teta transloc coppertransport copperenzym lvcopper teta relat alter expressionact copperregulatori dcm hemodynam perfus heart non teta teta teta teta wistar wistar wistar wistar enrol 67 67 67 67 2223 2223 2223 2223 573 562 220 290 58 020 51 015 298 065 270 120 158 004 163 005 103 006 118 009 heartweightbodyweight 276 001 277 013 466 013 408 017 output mlmin 792 750 533 81 780 lv dpdt max mmhg 4506 549 4667 417 2249 162 4082 196 lv dpdt min mmhg 4384 453 4245 413 1952 144 3366 125 steadyst cmh preload 75 mmhg afterload heart pace 300 beatsmin sem twoway anova post hoc tukey 005 005 diabetesinduc impair myocellular coppertransport local copper defici lvmyocardium myocardi copper defici elicit lv dcm revers teta employ parallel investig lv hypertrophi diastol type2 dcm sign copper overload excess lv markedli teta newlyrecogn serv discoveri teta normal myocardi copper mainten restor myocardi restor myocellular copper antioxid defens work newlyrecogn myocardi copper discoveri highlyselect cu chelat restor defect myocardi coppertraffick otherwis conspir dcm alter dcm abbrevi\n",
            "\t0.452\ttremor sclerosi patholog anatomi pharmacolog tremor preval disabl sclerosi m mileston tremor focus anatom search medlin search sclerosi tremor refer articl januari 1966 predomin m tremor largeamplitud postur kinet tremor affect arm tremor involv head neck vocal cord trunk tongu jaw palat anatom tremor m poorli understood link cerebellum msrelat tremor support unsuccess satisfactori treat disabl tremor tremor m consequ aggress m tremor disabl m tremor great dissoci tremor cerebellar issu success pathophysiolog biochemistri tremor m tremormultipl sclerosisreview introductionreview criteriapreval tremor sclerosismain tremor sclerosisclin featuresanatom basisassess tremor sclerosisoutcom tremor sclerosistreatmentgener considerationstreat option sclerosi tremorpharmacolog agentssurg tremor involuntari rhythmic movement involv oscil part repeat contract relax oppos sclerosi m nervou adulthood tremor featur m french neurologist jeanmartin charcot tremor defin m nystagmu scan speech tremor preval disabl m mileston relat m tremor focus anatom \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-2.312\twhite matter magnet reson neurodegen   commentari 14yearold sri lankan progress dysarthria dysmetria gait ataxia tremor bradykinesia declin ensu admiss sister ill parent nonconsanguin glasgow coma quadrihyperreflexia extensor plantar cerebellar cogwheel rigid note flap tremor hepatosplenomegali elicit abdomin kayserfleisch kf ring slit lamp magnet reson mri intens t2weight imag basal ganglion supratentori infratentori gray white matter magnet reson diffus abnorm intens cerebr white matter bilater white arrow cerebr atrophi extend involv grey matter abnorm t2 bilater extern slightli t2 intens putamen black arrow biochem follow ceruloplasmin mgdl 1845 urinari copper excret 45 mol24 aspart transaminas ast sgot 48 ul 1035 alanin transaminas alt sgpt 57 ul 1040 alkalin phosphatas 226 ul 100360 bilirubin 92 moll 521 70 gl albumin 39 gl globulin 31 gl prothrombin 128 intern normal inr aptt ammonia moll moll na 140 mmoll 45 mmoll creatinin 62 moll cerebrospin fluid commentari extrapyramid bradykinesia cogwheel rigid hepatosplenomegali kf ring ceruloplasmin urinari copper excret wilson wd symptomat wd neuroimag abnorm wd spectrum neuroimag abnorm conspicu atrophi abnorm basal ganglion nearli gray white matter t2 highlight strike white matter mri white matter diffus child present progress declin mri herit leukoencephalopathi diffus megalencephali differenti vanish white matter pelizaeusmerzbach unusu wd diffus white matter posterior wd diffus intens white matter t2weight imag demyelini soften spongi cavitari disintegr mri imag grey matter t2 intens edema gliosi necrosi cystic degener white matter penicillamin white matter white matter van wassenaervan hall 41 1995 indian white matter wd pauciti sri lanka highlight recogn white matter wd evalu neuropsychiatr \n",
            "\t-4.631\tcopper ion huntington huntington hd domin polyglutamin expans nterminu huntingtin energet insuffici striatal degener copper iron striata hd metal hd inductivelycoupledplasma spectroscopi elev copper iron hd reiter brain hd transgen copper copper export amyloid precursor hypothes amount copper bound affin prooxid neurodegener huntingtin central hd lactat dehydrogenas ldh document copper necess normox lactat hd 171 wildtyp huntingtin glutamin expand interact copper iron n171 cu copper stoichiometri fragment redox copper promot metal chelat inhibit aggreg cellfre huntingtin ldh lactat hd transgen ldh oxam neurodegener deliv intrastriati ldh neurodegener hd prooxid copperprotein hd offer pharmacotherapeut  introductionmateri methodsmaterialsntermin huntingtin synthesishuman tissueimmobil metal affin chromatographymet assayhuntingtin aggreg assaymic husbandrycopp iron analysessod1 assayldh lactat assaysoxam infusionswestern blotsquantit pcrstatist analysisresultscopp interact ntermin huntingtincopperhuntingtin involv histidin residuescopperii promot aggreg huntingtincopp iron hd brainlact dehydrogenas hd neurodegenerationdecreas copper export app hd braindiscussionsupport huntington hd neurodegen progress psychiatr deterior hd domin glutamin expans nterminu huntingtin initi primarili striatum cerebr fulllength huntingtin 350 kd smaller ntermin fragment mediat fragment aberr biomolecul hallmark hd aggreg repress copper iron striata postmortem hd brain ferritiniron striata hd mri metal hd basal ganglion copper iron wilson wd copper wd neurolog coppermedi striatal degener ferritin neuroferritinopathi accumul iron degener globu pallidu mechanist overlap hd basal ganglion copper iron copper iron hd potenti neurodegener copper hd affin diver biomolecul aberr copperprotein implic alzheim lou gehrig parkinson polyglutamin hd copper huntingtin conform aggreg redoxact analog betaamyloid copper betaamyloid oligomer alzheim glycolyt dehydrogenas lactat dehydrogenas ldh succin dehydrogenas sdh coppermedi inactiv ldh astrocyteneuron lactat shuttl wherebi lactat releas astrocyt substrat lactat hd striata magnet reson spectroscopi presymptomat n17182q hd metabol lactat succin excess copper hd energet insuffici inhibit ldh goal address aberr copperprotein hd address way copper hd modul huntingtin interf lactateenergi inhibit ldh copper hereto unappreci potenti hd huntingtin interf basal ganglion copper iron neurodegener 31 hd copper accumul promot prooxid huntingtin central hd lactat dehydrogenas ldh document copper necess normox lactat hd postmortem hd huntingtin fragment biochem transgen knockin hd express fulllength huntingtin excess copper potenti hd immobil metal affin chromatographi imac huntingtin interact copper imac copperprotein neurodegen n171 17q expand 68q glutamin tract interact copper iron zinc histidin 82 98 copper 2b coordin copper ion exon117q fragment n84 interact copper 2d copperntermin huntingtin neurodegen r62 hd express exon1 huntingtin n171 fragment h98f bind imac column exon1 n171 fragment coordin copper differ 2a glutamin expans affect copperbind flank polyglutamin tract profound influenc huntingtin 33 modul huntingtin invivo n17117q reduc copper copper n17117q huntingtin interact solut electron copper n17117q oxid copper 34 abeta1 42 n171 redox iron n17117q copper 3a iron interact ntermin huntingtin solut imac huntingtin aggreg center reactiv ro cultur implic iron ro inhibit metal chelat deferoxamin ad medium deferoxamin iron interpret agreement ntermin huntingtin redox hd insolubl huntingtin aggreg patholog hallmark hd copper promot metal chelat inhibit cellfre sd mercaptoethanol resist huntingtin aggreg 3c copper modul huntingtin aggreg invivo rais metal chelat neuroprotect hd inhibit silenc redox huntingtin permeabl copper iron chelat clioquinol neuroprotect decreas aggreg load r62 hd 36 epigallocatechingal green tea flavonoid copper chelat 37 modul huntingtin misfold reduc drosophila hd 38 microscop visibl aggreg hd controversi copper interact ntermin huntingtin monom copper modul aggreg influenc proxim huntingtin cascad monom oligom microscop aggreg exact unclear possibl coppermedi conform huntingtin oxid proteolysi copper iron brain 12week r62 hd correspond latestag hd iron brain 12month cag140 hd correspond preclin hd figur 4a r62 unlik shift advanc hd cortic zinc unalt copper iron homeostasi hd argu iron hd copper cag140 preclin copper potenti hd act iron cag140 copper r62 striatum hd cortic striatal degener 39 address distribut copper huntingtin biochem fraction compat occur distribut r62 iron aggreg huntingtin exclud biochem copper iron fraction 4a molar copper iron exon1 huntingtin copper bound huntingtin stoichiometri excess metal subcellular mediat copper inactiv ldh oxid activesit cystein residu forebrain 12weekold r62 ldh llactat disturb lactat ldh ldhb isoform n17182q hd ppar coactiv pgc1 n17182q util lactat substrat defect pgc1 r62 hd 41 decreas ldh monom western blot 6b unalt ldh monom biochem ingel ldh agedepend declin ldh r62 hd 6ab forebrain copper r62 12week 4e ldh coppermedi inactiv 6d ldh coppermedi enzymat interpret support fraction copper entir huntingtin ldh oxam striatal degener 6e defect ldh neurodegener hd copper interfer lactat hd inhibit ldh copper hd reason neuroprotect cuproprotein copperhomeostat huntingtin copperbind copper iron unalt r62 12week rule r62 hd mount compensatori antioxid sod1 antioxid repres shift copper r62 s1 implic copper homeostasi app aplp2 knockout cortic copper 29 r62 hd app aplp2 7ad explain copper r62 app knockout grip strength locomotor 42 app aplp2 transcript unalt r62 western blot translat copperexport app neuroprotect 43 neurotroph 44 45 app r62 hd neurodegener copperdepend copper huntingtin ldh hd ntermin huntingtin copper redoxmedi huntingtin compat huntingtin dysregul axon copper hd way hydrogen peroxid ion copper reactiv fold reactiv iron 46 47 abund oxid hd 48 neurotox metabolit 3hydroxykynurenin hd 49 invitro react readili copper iron gener hydrogen peroxid 51 copper iron hd quantifi affin specif metal ion ntermin huntingtin fragment redox chemistri underscor relev metalprotein chemistri hd neuroprotect stratagi\n",
            "\t-6.078\ttremor sclerosi tremor percent sclerosi m sever disabl embarrass manag isoniazid dose carbamazepin propranolol gluthetimid relief effect cannabinoid ineffect tremor stereotact thalamotomi thalam scarc physiotherapi tremor orthos limb cool achiev tremor m unmet requir basic  search criteriaintroductionepidemiologytremor subtypespathophysiolog tremorassess tremormed treatmentsurg treatmentstrategi selectionoutcom treatmentoth optionsconclus refer search pubm 1966 cochran librari issu search sclerosi tremor ataxia disabl thalamotomi deep articl search tabl paper search isi scienc citat articl cite paper articl english german public abstract tremor great everyon care m unsuccess pathophysiolog biochemistri tremor m stereotact treat tremor uncertain lesion db choic compar option physiotherapi tremor orthos limb cool valuabl improv live\n",
            "tremors,serum caeruloplasmin,copper None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.525\tamyotroph later sclerosi polymorph deltaaminolevulin dehydratas vitamin amyotroph later sclerosi al polymorph deltaaminolevulin dehydratas alad vitamin vdr casecontrol england 1993 1996 al polymorph alad vdr polymorph al alad allel 177g k59n patella tibia imprecis al odd confid interv 06063 unreport polymorph alad msp1 intron ivs2299g imprecis al 035 01012 vdr allel al observ genotyp al occup confer polymorph alad al possibl intern    \n",
            "\t0.506\tfactora vegfa chemokin ligand2 ccl2 amyotroph later sclerosi al factora vegfa chemokn ligand2 ccl2 amyotroph later sclerosi al western north indian al display consider sporad al el escori vegfa ccl2 cerebrospin fluid csf al immunosorb elisa adjust confound cigarett alcohol meat contrari vegfa csf al ccl2 csf al csf definit al vegfa probabl al ccl2 unalt definit probabl al univari multivari alcohol meat vegfa ccl2 vegfa upregul compensatori al reflect north indian al intrathec ccl2 microgli al  introductionsubject methodsresultsdiscussionconclusionsabbreviationseth approvalcompet interestsauthor contribut amyotroph later sclerosi al neurodegen heterogen exist factora vegfa delay al superoxid dismutase1 sod1 mutat transgen activ pi3kakt anti apoptot vegfa progenitor chemokin ligand2 ccl2 proinflammatori molecul enhanc microgli recruit nervou cn exacerb al ccl2 knockout resist autoimmun encephalomyel vegfa 165 isoform vegfa ccl2 interact synergist mount hypothes vegfaccl2 axi crucial al al support vegfa ccl2 enhanc sporad al comprehens unveil abbrevi\n",
            "\t0.486\tvitamin sclerosi pathophysiolog implic sclerosi m aris interplay vitamin besid maintain calcium immunomodulatori nervou vitamin 99 152 nmoll m subgroup lowest 63 nmoll vitamin m hypovitaminosi m numer epidemiolog correct option debilit immunomodulatorymultipl sclerosisvitamin ntroduct basisexperiment immunolog basisepidemiolog studiesclin studiesc onclus vitamin besid maintain calcium vitamin vdr vitamin immunomodulatori nervou cn hypovitaminosi sclerosi m promis implic m aris interplay hypovitaminosi suspect m vitamin substanti protect m come diver epidemiolog \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.458\tacromegali neoplasia acromegali ghigf1 excess probabl pathophysiolog explan igf1 excess acromegalyassoci neoplasm comorbid acromegali unclear acromegal canadian referr center toronto montreal edmonton record percentag upper limit uln igf1 comorbid neoplasm benign malign 408 185 453 126 309 extrapituitari neoplasm 55 malign 71 benign frequent anatom gastrointestin tract 46 113 head neck 36 88 locat 34 106 260 igf1 38015 28478 0001 younger diabet igf1 38938 28527 0009 diabet 453 48106 extrapituitari neoplasm 243 71292 0001 2576 95ci 1615 4108 226 24106 malign 92 27292 0001 2873 95ci 1572 5250 acromegal extrapituitari neoplasm igf1 contribut igf1 extrapituitari neoplasm warrant  introductionpati methodsresultsloc extrapituitari malignancyextra pituitari neoplasm genderextra pituitari neoplasm groupsextra pituitari neoplasm gender groupdiabet gender groupextrapituitari neoplasm diabetesextrapituitari malign bothigf1initi final igf1 ulncanc acromegali populationnumb malign canadian groupsdiscuss acromegali excess hormon gh ghsecret pituitari adenoma acromegali ghinsulinlik factor1 igf1 pathophysiolog explan outsid acromegali set colorect igf1 acromegali debat epidemiolog confound report acromegali malign controversi nevertheless acromegali thyroid colon polyp urinari tract carcinoma particip ghigf1 axi neoplasm metastas igf1 affect cellcycl phosphatidylinositol 3kinas pi3kprotein akt signalregul kina erk instabl igf1 acromegali oncogen toler frequent acromegali comorbid igf1 hyperglycemia pituitari patholog acromegali acromegali multicent acromegali acromegal 58 124 acromegal extrapituitari twice nondiabet acromegal malign acromegal extrapituitari malign causal attribut hyperinsulinemia igf1 mediat metaanalys anatom pancreat 95ci colorect rr 95ci 120 140 rr 120 95ci 112 128 endometri rr 210 95ci 175 253 bladder rr 124 95ci 108 142 rr 250 95ci rr 222 95ci 104 470 note odd malign acromegali 2873 95ci 1572 5250 acromegali potenti mitogen transform ghigf1 axi igf1 igf1r crucial activ cascad substrate1 irs1 src homolog shc rack1 trigger prompt motil invas alter igf1 enhanc prolif close homolog igf1 share downstream effector hyperinsulinemia igf1 unclear question convers advantag metformin note igf1 ageadjust uln absolut igf1 agerel igf1 igf1 igf1 persist note igf1 malign neoplasm latter altern drive forc malign transform acromegal retrospect carcinogenesi neoplasm institut document mandatori refin conclus retrospect acromegali studi certainli malign colonoscopi thyroid ultrasound moment acromegali institut vari frequenc benign\n",
            "\t-4.488\tvitamin reduc cytotox hyperglycemia prediabet hyperglycemia radic glycat endproduct age antioxid glycat vitamin abund antioxid fast fpg glycat hemoglobin a1c cytotox prediabet fpg a1c micronuclei nucleoplasm bridg bud fpg a1c necrosi 0294 0013 0401 0001 resp vitamin neg necrosi 0246 0040 0276 0021 resp fpg a1c explain elimin necrosi cytotox vitamin appear cytotox lowdos vitamin supplement  introduction2 methods3 results4 discus mellitu dm includ hyperglycemia defici hormon 200 million diabet worldwid dm dm2 account 90 dm dm2 patholog macrovascular ischem encephalopathi microvascular coagul nephropathi neuropathi biochem dyslipidemia disturb dm disturb hyperglycemia glycat endproduct age form nonenzymat basic dm selfoxid radic latter occur radic antioxid dm glycat hemoglobin a1c hemoglobin age a1c correl dm antioxid defens compris endogen exogen enzymat nonenzymat vitamin exogen nonenzymat antioxid vitamin enzymat cofactor antioxid capabl shift oxid electron donor protect lipid aim dietari vitamin antioxid a1c prediabet dm2 grow dm micro macrovascular dm wellknown white diabet somewhat controversi document vitamin dysfunct dm antioxid document vitamin capabl affect inhibit facilit remov promot damag necrosi link vitamin cytotox vitamin requir ear repres adequ nutrient dietari dri portion inadequ vitamin vitamin intak 90 mg recommend carr frei nonsmok maximum 300 mgday substanti mgday institut iom maximum risk start fpg a1c correl endpoint fpg a1c dm2 micronuclei dm2 uncompens dm2 a1c 70 uncompens dm2 a1c 80 chromosom dm2 exhibit chromosom necrosi cytotox dm2 rodent dm2 necrosi necrosi prediabet explan cytotox dm2 selfoxid gener damag compart possibl iron particip redox reaction gener reactiv mediat link iron dm2 cycl hemoglobin aris halflif red exact link cytotox dm2 elucid vitamin reduc vitamin diabet deplet vitamin slightli recommend nondiabet choi fast vitamin lymphocyt comet a1c 427 dm2 vitamin dietari choi dietari recommend cytotox decreas ear met ear 75 mg vitamin mg vitamin reflect vitamin slightli dri vitamin dm2associ dietari lowdos vitamin supplement dm2 highlight vitamin dosag vitamin prooxid follow prediabet dm2 uncompens dm2 limit compar dietari recommend vitamin instead dietari subject recal error iv consid dose hypoglycemi dm2 cytotox vitamin modul cytotox vitamin cytotox design hyperglycemia dm2\n",
            "\t-4.488\tvitamin reduc cytotox hyperglycemia prediabet hyperglycemia radic glycat endproduct age antioxid glycat vitamin abund antioxid fast fpg glycat hemoglobin a1c cytotox prediabet fpg a1c micronuclei nucleoplasm bridg bud fpg a1c necrosi 0294 0013 0401 0001 resp vitamin neg necrosi 0246 0040 0276 0021 resp fpg a1c explain elimin necrosi cytotox vitamin appear cytotox lowdos vitamin supplement  introduction2 methods3 results4 discus mellitu dm includ hyperglycemia defici hormon 200 million diabet worldwid dm dm2 account 90 dm dm2 patholog macrovascular ischem encephalopathi microvascular coagul nephropathi neuropathi biochem dyslipidemia disturb dm disturb hyperglycemia glycat endproduct age form nonenzymat basic dm selfoxid radic latter occur radic antioxid dm glycat hemoglobin a1c hemoglobin age a1c correl dm antioxid defens compris endogen exogen enzymat nonenzymat vitamin exogen nonenzymat antioxid vitamin enzymat cofactor antioxid capabl shift oxid electron donor protect lipid aim dietari vitamin antioxid a1c prediabet dm2 grow dm micro macrovascular dm wellknown white diabet somewhat controversi document vitamin dysfunct dm antioxid document vitamin capabl affect inhibit facilit remov promot damag necrosi link vitamin cytotox vitamin requir ear repres adequ nutrient dietari dri portion inadequ vitamin vitamin intak 90 mg recommend carr frei nonsmok maximum 300 mgday substanti mgday institut iom maximum risk start fpg a1c correl endpoint fpg a1c dm2 micronuclei dm2 uncompens dm2 a1c 70 uncompens dm2 a1c 80 chromosom dm2 exhibit chromosom necrosi cytotox dm2 rodent dm2 necrosi necrosi prediabet explan cytotox dm2 selfoxid gener damag compart possibl iron particip redox reaction gener reactiv mediat link iron dm2 cycl hemoglobin aris halflif red exact link cytotox dm2 elucid vitamin reduc vitamin diabet deplet vitamin slightli recommend nondiabet choi fast vitamin lymphocyt comet a1c 427 dm2 vitamin dietari choi dietari recommend cytotox decreas ear met ear 75 mg vitamin mg vitamin reflect vitamin slightli dri vitamin dm2associ dietari lowdos vitamin supplement dm2 highlight vitamin dosag vitamin prooxid follow prediabet dm2 uncompens dm2 limit compar dietari recommend vitamin instead dietari subject recal error iv consid dose hypoglycemi dm2 cytotox vitamin modul cytotox vitamin cytotox design hyperglycemia dm2\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.525\tamyotroph later sclerosi polymorph deltaaminolevulin dehydratas vitamin amyotroph later sclerosi al polymorph deltaaminolevulin dehydratas alad vitamin vdr casecontrol england 1993 1996 al polymorph alad vdr polymorph al alad allel 177g k59n patella tibia imprecis al odd confid interv 06063 unreport polymorph alad msp1 intron ivs2299g imprecis al 035 01012 vdr allel al observ genotyp al occup confer polymorph alad al possibl intern    \n",
            "\t0.506\tfactora vegfa chemokin ligand2 ccl2 amyotroph later sclerosi al factora vegfa chemokn ligand2 ccl2 amyotroph later sclerosi al western north indian al display consider sporad al el escori vegfa ccl2 cerebrospin fluid csf al immunosorb elisa adjust confound cigarett alcohol meat contrari vegfa csf al ccl2 csf al csf definit al vegfa probabl al ccl2 unalt definit probabl al univari multivari alcohol meat vegfa ccl2 vegfa upregul compensatori al reflect north indian al intrathec ccl2 microgli al  introductionsubject methodsresultsdiscussionconclusionsabbreviationseth approvalcompet interestsauthor contribut amyotroph later sclerosi al neurodegen heterogen exist factora vegfa delay al superoxid dismutase1 sod1 mutat transgen activ pi3kakt anti apoptot vegfa progenitor chemokin ligand2 ccl2 proinflammatori molecul enhanc microgli recruit nervou cn exacerb al ccl2 knockout resist autoimmun encephalomyel vegfa 165 isoform vegfa ccl2 interact synergist mount hypothes vegfaccl2 axi crucial al al support vegfa ccl2 enhanc sporad al comprehens unveil abbrevi\n",
            "\t0.486\tvitamin sclerosi pathophysiolog implic sclerosi m aris interplay vitamin besid maintain calcium immunomodulatori nervou vitamin 99 152 nmoll m subgroup lowest 63 nmoll vitamin m hypovitaminosi m numer epidemiolog correct option debilit immunomodulatorymultipl sclerosisvitamin ntroduct basisexperiment immunolog basisepidemiolog studiesclin studiesc onclus vitamin besid maintain calcium vitamin vdr vitamin immunomodulatori nervou cn hypovitaminosi sclerosi m promis implic m aris interplay hypovitaminosi suspect m vitamin substanti protect m come diver epidemiolog \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.458\tacromegali neoplasia acromegali ghigf1 excess probabl pathophysiolog explan igf1 excess acromegalyassoci neoplasm comorbid acromegali unclear acromegal canadian referr center toronto montreal edmonton record percentag upper limit uln igf1 comorbid neoplasm benign malign 408 185 453 126 309 extrapituitari neoplasm 55 malign 71 benign frequent anatom gastrointestin tract 46 113 head neck 36 88 locat 34 106 260 igf1 38015 28478 0001 younger diabet igf1 38938 28527 0009 diabet 453 48106 extrapituitari neoplasm 243 71292 0001 2576 95ci 1615 4108 226 24106 malign 92 27292 0001 2873 95ci 1572 5250 acromegal extrapituitari neoplasm igf1 contribut igf1 extrapituitari neoplasm warrant  introductionpati methodsresultsloc extrapituitari malignancyextra pituitari neoplasm genderextra pituitari neoplasm groupsextra pituitari neoplasm gender groupdiabet gender groupextrapituitari neoplasm diabetesextrapituitari malign bothigf1initi final igf1 ulncanc acromegali populationnumb malign canadian groupsdiscuss acromegali excess hormon gh ghsecret pituitari adenoma acromegali ghinsulinlik factor1 igf1 pathophysiolog explan outsid acromegali set colorect igf1 acromegali debat epidemiolog confound report acromegali malign controversi nevertheless acromegali thyroid colon polyp urinari tract carcinoma particip ghigf1 axi neoplasm metastas igf1 affect cellcycl phosphatidylinositol 3kinas pi3kprotein akt signalregul kina erk instabl igf1 acromegali oncogen toler frequent acromegali comorbid igf1 hyperglycemia pituitari patholog acromegali acromegali multicent acromegali acromegal 58 124 acromegal extrapituitari twice nondiabet acromegal malign acromegal extrapituitari malign causal attribut hyperinsulinemia igf1 mediat metaanalys anatom pancreat 95ci colorect rr 95ci 120 140 rr 120 95ci 112 128 endometri rr 210 95ci 175 253 bladder rr 124 95ci 108 142 rr 250 95ci rr 222 95ci 104 470 note odd malign acromegali 2873 95ci 1572 5250 acromegali potenti mitogen transform ghigf1 axi igf1 igf1r crucial activ cascad substrate1 irs1 src homolog shc rack1 trigger prompt motil invas alter igf1 enhanc prolif close homolog igf1 share downstream effector hyperinsulinemia igf1 unclear question convers advantag metformin note igf1 ageadjust uln absolut igf1 agerel igf1 igf1 igf1 persist note igf1 malign neoplasm latter altern drive forc malign transform acromegal retrospect carcinogenesi neoplasm institut document mandatori refin conclus retrospect acromegali studi certainli malign colonoscopi thyroid ultrasound moment acromegali institut vari frequenc benign\n",
            "\t-4.488\tvitamin reduc cytotox hyperglycemia prediabet hyperglycemia radic glycat endproduct age antioxid glycat vitamin abund antioxid fast fpg glycat hemoglobin a1c cytotox prediabet fpg a1c micronuclei nucleoplasm bridg bud fpg a1c necrosi 0294 0013 0401 0001 resp vitamin neg necrosi 0246 0040 0276 0021 resp fpg a1c explain elimin necrosi cytotox vitamin appear cytotox lowdos vitamin supplement  introduction2 methods3 results4 discus mellitu dm includ hyperglycemia defici hormon 200 million diabet worldwid dm dm2 account 90 dm dm2 patholog macrovascular ischem encephalopathi microvascular coagul nephropathi neuropathi biochem dyslipidemia disturb dm disturb hyperglycemia glycat endproduct age form nonenzymat basic dm selfoxid radic latter occur radic antioxid dm glycat hemoglobin a1c hemoglobin age a1c correl dm antioxid defens compris endogen exogen enzymat nonenzymat vitamin exogen nonenzymat antioxid vitamin enzymat cofactor antioxid capabl shift oxid electron donor protect lipid aim dietari vitamin antioxid a1c prediabet dm2 grow dm micro macrovascular dm wellknown white diabet somewhat controversi document vitamin dysfunct dm antioxid document vitamin capabl affect inhibit facilit remov promot damag necrosi link vitamin cytotox vitamin requir ear repres adequ nutrient dietari dri portion inadequ vitamin vitamin intak 90 mg recommend carr frei nonsmok maximum 300 mgday substanti mgday institut iom maximum risk start fpg a1c correl endpoint fpg a1c dm2 micronuclei dm2 uncompens dm2 a1c 70 uncompens dm2 a1c 80 chromosom dm2 exhibit chromosom necrosi cytotox dm2 rodent dm2 necrosi necrosi prediabet explan cytotox dm2 selfoxid gener damag compart possibl iron particip redox reaction gener reactiv mediat link iron dm2 cycl hemoglobin aris halflif red exact link cytotox dm2 elucid vitamin reduc vitamin diabet deplet vitamin slightli recommend nondiabet choi fast vitamin lymphocyt comet a1c 427 dm2 vitamin dietari choi dietari recommend cytotox decreas ear met ear 75 mg vitamin mg vitamin reflect vitamin slightli dri vitamin dm2associ dietari lowdos vitamin supplement dm2 highlight vitamin dosag vitamin prooxid follow prediabet dm2 uncompens dm2 limit compar dietari recommend vitamin instead dietari subject recal error iv consid dose hypoglycemi dm2 cytotox vitamin modul cytotox vitamin cytotox design hyperglycemia dm2\n",
            "\t-4.488\tvitamin reduc cytotox hyperglycemia prediabet hyperglycemia radic glycat endproduct age antioxid glycat vitamin abund antioxid fast fpg glycat hemoglobin a1c cytotox prediabet fpg a1c micronuclei nucleoplasm bridg bud fpg a1c necrosi 0294 0013 0401 0001 resp vitamin neg necrosi 0246 0040 0276 0021 resp fpg a1c explain elimin necrosi cytotox vitamin appear cytotox lowdos vitamin supplement  introduction2 methods3 results4 discus mellitu dm includ hyperglycemia defici hormon 200 million diabet worldwid dm dm2 account 90 dm dm2 patholog macrovascular ischem encephalopathi microvascular coagul nephropathi neuropathi biochem dyslipidemia disturb dm disturb hyperglycemia glycat endproduct age form nonenzymat basic dm selfoxid radic latter occur radic antioxid dm glycat hemoglobin a1c hemoglobin age a1c correl dm antioxid defens compris endogen exogen enzymat nonenzymat vitamin exogen nonenzymat antioxid vitamin enzymat cofactor antioxid capabl shift oxid electron donor protect lipid aim dietari vitamin antioxid a1c prediabet dm2 grow dm micro macrovascular dm wellknown white diabet somewhat controversi document vitamin dysfunct dm antioxid document vitamin capabl affect inhibit facilit remov promot damag necrosi link vitamin cytotox vitamin requir ear repres adequ nutrient dietari dri portion inadequ vitamin vitamin intak 90 mg recommend carr frei nonsmok maximum 300 mgday substanti mgday institut iom maximum risk start fpg a1c correl endpoint fpg a1c dm2 micronuclei dm2 uncompens dm2 a1c 70 uncompens dm2 a1c 80 chromosom dm2 exhibit chromosom necrosi cytotox dm2 rodent dm2 necrosi necrosi prediabet explan cytotox dm2 selfoxid gener damag compart possibl iron particip redox reaction gener reactiv mediat link iron dm2 cycl hemoglobin aris halflif red exact link cytotox dm2 elucid vitamin reduc vitamin diabet deplet vitamin slightli recommend nondiabet choi fast vitamin lymphocyt comet a1c 427 dm2 vitamin dietari choi dietari recommend cytotox decreas ear met ear 75 mg vitamin mg vitamin reflect vitamin slightli dri vitamin dm2associ dietari lowdos vitamin supplement dm2 highlight vitamin dosag vitamin prooxid follow prediabet dm2 uncompens dm2 limit compar dietari recommend vitamin instead dietari subject recal error iv consid dose hypoglycemi dm2 cytotox vitamin modul cytotox vitamin cytotox design hyperglycemia dm2\n",
            "Acromegaly,IGF-1,vitamin D None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.570\tissu   overview alcohol revisitedstress alcohol epidemiolog evidencealcohol militarychildhood trauma posttraumat alcohol dependenceanxieti alcohol comorbid considerationshow alcohol relapseneur integr relev alcohol abuseeffect alcohol depend withdraw respons alcohol consumptionclin stressor alcohol relationshipsstress hpa axi glucocorticoid alcohol dependencegenet determin respondingstress epigenet alcoholismresili meet addict psychobiolog considerationstreat alcohol depend antagonist drink alcohol reliev creat sen doubleedg sword link alcohol drink alcohol ongo ultim alcohol anthenelli reaction vari makeup gender articl anthenelli review introduc articl issu pp 386 390 \n",
            "\t0.563\tinsulinlik myocardi decreas alcohol alcohol cardiomyopathi cmp excess alcohol pathogen implic diver induc myocardium insulinlik igf1 modul help inhibit igf1 alcoholinduc alcohol igf1 myocardi compar organ donor donor alcohol igf1 myocardi immunohistochemistri semiquantit igf1 myocardi compar donor igf1 myocardi donor alcohol cmp donor alcohol cmp igf1 donor alcohol cmp downward trend achiev signific alcohol reduc igf1 myocardi alcohol partial compens myocardi  backgroundresultsigf1 immunohistochem myocardi expressiondiscussionconclusionsmethodsselect controlsclin evaluationcardiac studiesmyocardium histolog studiesimmunohistochemistrymicroscop evaluationstatist  igf1 myocardi alcohol donor cmp donor igf1 promot improv contractil output eject fraction igf1 igf1 benefici myocardi excess alcohol reason igf1 alcohol avoid cmp\n",
            "\t0.532\torgan alcohol   alcohol healthwho alcohol healthprocess gisahalcohol caput consumptiondata validationfurth develop substanc abus alcohol databas 1996 creat largest alcohol consequ polici member alcohol larg collect alcohol polici moser 1974 1980 1992 establish alcohol databas secretariat start implement regular questionnair survey alcohol government offici member nomin alcohol alcoholrel harm polici staff collabor extern expert alcohol alcohol member alcohol harm alcohol polici latest alcohol contain newli countri profil indic alcohol consequ polici valuabl alcohol region contain estim alcoholattribut burden expert committe alcohol recommend establish alcohol alcohol databas continu effort collect compil analyz alcohol surveil compar agre definit \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.049\talcohol eventu type2 alcohol protect protect type2 alcohol protect type2 alcohol improv fed alcohol lean obes alcohol weight overlap adipos type2 alter epididym white adipos wat wat fed calori restrict cr lf hf diet ethanol drink screen homeostasi array compos 384 calori restrict alcohol obes cd68 il6 il1 downregul cr antiinflammatori il10 adrenerg beta adrbk1 obes cr alcohol kcnj11 potassium inwardlyrectifi channel subfamili member lpin2 lipin2 dusp9 dualspecif map phosphatas alcohol alter coupl alter alcohol upregul antiinflammatori indentifi transduc obesityrel calori restrict alcoholinduc  backgroundmateri methodsstudi designstellarraystellarray valid qpcrserum leptin levelsbodi levelsstatisticsresultsestablish weightsleptin alcohol consumptionglucos toler testshf cr opposit profilesproinflammatori il18 cr interventioncr upregul prostaglandin d2 synthas ptgdskatp channel subunit kcnj11 cr suppress hf dietbodi alcohol distinct lipin member expressionretinol protein4 rbp4 adipos tightli weightangiopoietinlik neg weightdual phosphatas dusp9mkp4 proteintyrosin phosphatas receptortyp alpha ptpra opposit cr hf dietdiscussionconclusioncompet interestsauthor contribut patholog type2 seriou morbid osteoarthr sleep apnea obes consum gener amount alcohol prone alcohol calori consum epidemiolog moder alcohol benefici decreas type2 alcohol type2 promot alcohol improv phenotyp lean overweight obes alcohol modifi excess calori adipocyt hypertrophi hyperplasia turn adipokin leptin adiponectin mediat interleukin adipokin theori theori excess adipos produc adipokin adiponectin adiponectin secret adipos close viscer subcutan type2 promot alcohol adiponectin white adipos obes secret mcp1 initi monocyt white adipos secret persist excess adipokin adipocyt skelet adipos excess lipid nonadipos caus lipotox eventu propos obesitydepend reactiv ro ro advers pancrea homeostasi array 384 white adipos fed calori restrict cr lf hf consum ethanol drink cr lf hf diet phenotyp lean bmi overweight bmi obes bmi allow alcohol lean cr lf obes hf calori restrict alcohol calori restrict drastic oppos pro antiinflammatori adipos lpin2 kcnj11 rbp4 alcohol reduc spectrum upregul antiinflammatori contribut modif alcohol summari lean obes alcohol calori restrict alcohol promot adipos type2 wat alcohol hf il6 il1 cd68 proinflammatori wat cr opposit il6 il1 alcohol oppress retnlb mif cr alcohol antiinflammatori il10 adrbk1 homeostasi ptgd lpin2 lpin3 dusp9 alcohol angptl6 kcnj11 ptpra gck ins1 pltp apob pck1 downregul hf upregul cr alcohol alcohol overlap regul foundat studi alcohol dietregul compet interest\n",
            "\t-0.837\talcohol drink relat colorect casecontrol newfoundland labrador canada substant epidemiolog alcohol drink colorect crc adequ explor casecontrol alcohol drink crc differ newli crc newfoundland labrador nl frequencymatch random digit dial 702 717 complet selfadminist questionnair ass lifestyl estim alcohol beverag drink alcohol drink odd ratio alcohol independ stratifi crc obes bmi alcohol crc 1240 nonalcohol categori obes drink 34fold crc nondrink crc drink drink obes alcohol drink crc modifi casecontrol studyalcoholobesitycolorect cancerinteractionlifestylesnewfoundland backgroundmethodsstudi participantsexposur datastatist analyseseth considerationsresultscharacterist controlscolorect alcohol intakecolorect alcohol sexcolorect alcohol statusdiscussionconclusioncompet interestsauthor contributionsprepubl colorect crc gastrointestin tract neoplasm account crc vari geograph western asia africa canada substanti crc provinc atlant provinc newfoundland labrador nl crc twice british columbia alberta unclear exist specul lifestyl crc carcinogenesi alcohol avoid lifestyl behavior crc epidemiolog alcohol crc occurr metaanalysi 34 casecontrol modestli crc compar moder 126499 gday rr121 heavi drinker gday rr152 nonoccasion drinker doserespons pool north america europ support report 141fold regular alcohol drinker 45 gday nondrink alcohol drink crc consider variat exist explain random error glutathion stransferas a4 gsta4 depred acetaldehyd carcinogen metabol alcohol expect modif alcohol hypothes alcohol drink crc vari histor provinc nl alcohol obes bmi nl alcohol crc joint alcohol crc object alcohol drink crc differ nl provinc nl canada alcohol crc valid prospect implic explor alcohol tailor alcohol polici obes compet interest\n",
            "\t-2.048\talcohol drink nutrit 1988 1994 alcohol protect explor alcohol nonsmok 8236 respond particip nutrit weightkgheightm height categor overweight obes alcohol drink bing drink quantiti drinksday drink drinksweek nonsmok 264 261 267 46 respond classifi drinker drinker odd adjust odd 073 055 097 nondrink odd overweight bing drinker consum drinksday drink drink 046 034 062 059 041 086 odd similarli odd drink consum drink week overweight alcohol pronounc explor moder alcohol drink control  backgroundmethodssampl selectionvariablesstatist analysisresultsdiscussionconclusioncompet interestsauthor contributionsprepubl overweight obes steadili nation continu rise concern agenc explos alcohol pastmonth consum drink fifti percent alcohol alcohol den macronutri consum oxid favor storag gain ad calori alcohol drinker gain extra nondrink jshape alcohol waisttohip moder drink benefici nondrink heavi riski drink opposit invers alcohol drink gain promin remain inconclus aim crosssect alcohol drink nation repres nonsmok alcohol benefici moder alcohol beverag prospect epidemiolog confirm benefici extend activ promot moder alcohol combat inappropri link alcohol note give advis nondrink start drink alcohol just argu promot abstent atleast regularli consum alcohol compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.570\tissu   overview alcohol revisitedstress alcohol epidemiolog evidencealcohol militarychildhood trauma posttraumat alcohol dependenceanxieti alcohol comorbid considerationshow alcohol relapseneur integr relev alcohol abuseeffect alcohol depend withdraw respons alcohol consumptionclin stressor alcohol relationshipsstress hpa axi glucocorticoid alcohol dependencegenet determin respondingstress epigenet alcoholismresili meet addict psychobiolog considerationstreat alcohol depend antagonist drink alcohol reliev creat sen doubleedg sword link alcohol drink alcohol ongo ultim alcohol anthenelli reaction vari makeup gender articl anthenelli review introduc articl issu pp 386 390 \n",
            "\t0.563\tinsulinlik myocardi decreas alcohol alcohol cardiomyopathi cmp excess alcohol pathogen implic diver induc myocardium insulinlik igf1 modul help inhibit igf1 alcoholinduc alcohol igf1 myocardi compar organ donor donor alcohol igf1 myocardi immunohistochemistri semiquantit igf1 myocardi compar donor igf1 myocardi donor alcohol cmp donor alcohol cmp igf1 donor alcohol cmp downward trend achiev signific alcohol reduc igf1 myocardi alcohol partial compens myocardi  backgroundresultsigf1 immunohistochem myocardi expressiondiscussionconclusionsmethodsselect controlsclin evaluationcardiac studiesmyocardium histolog studiesimmunohistochemistrymicroscop evaluationstatist  igf1 myocardi alcohol donor cmp donor igf1 promot improv contractil output eject fraction igf1 igf1 benefici myocardi excess alcohol reason igf1 alcohol avoid cmp\n",
            "\t0.532\torgan alcohol   alcohol healthwho alcohol healthprocess gisahalcohol caput consumptiondata validationfurth develop substanc abus alcohol databas 1996 creat largest alcohol consequ polici member alcohol larg collect alcohol polici moser 1974 1980 1992 establish alcohol databas secretariat start implement regular questionnair survey alcohol government offici member nomin alcohol alcoholrel harm polici staff collabor extern expert alcohol alcohol member alcohol harm alcohol polici latest alcohol contain newli countri profil indic alcohol consequ polici valuabl alcohol region contain estim alcoholattribut burden expert committe alcohol recommend establish alcohol alcohol databas continu effort collect compil analyz alcohol surveil compar agre definit \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.049\talcohol eventu type2 alcohol protect protect type2 alcohol protect type2 alcohol improv fed alcohol lean obes alcohol weight overlap adipos type2 alter epididym white adipos wat wat fed calori restrict cr lf hf diet ethanol drink screen homeostasi array compos 384 calori restrict alcohol obes cd68 il6 il1 downregul cr antiinflammatori il10 adrenerg beta adrbk1 obes cr alcohol kcnj11 potassium inwardlyrectifi channel subfamili member lpin2 lipin2 dusp9 dualspecif map phosphatas alcohol alter coupl alter alcohol upregul antiinflammatori indentifi transduc obesityrel calori restrict alcoholinduc  backgroundmateri methodsstudi designstellarraystellarray valid qpcrserum leptin levelsbodi levelsstatisticsresultsestablish weightsleptin alcohol consumptionglucos toler testshf cr opposit profilesproinflammatori il18 cr interventioncr upregul prostaglandin d2 synthas ptgdskatp channel subunit kcnj11 cr suppress hf dietbodi alcohol distinct lipin member expressionretinol protein4 rbp4 adipos tightli weightangiopoietinlik neg weightdual phosphatas dusp9mkp4 proteintyrosin phosphatas receptortyp alpha ptpra opposit cr hf dietdiscussionconclusioncompet interestsauthor contribut patholog type2 seriou morbid osteoarthr sleep apnea obes consum gener amount alcohol prone alcohol calori consum epidemiolog moder alcohol benefici decreas type2 alcohol type2 promot alcohol improv phenotyp lean overweight obes alcohol modifi excess calori adipocyt hypertrophi hyperplasia turn adipokin leptin adiponectin mediat interleukin adipokin theori theori excess adipos produc adipokin adiponectin adiponectin secret adipos close viscer subcutan type2 promot alcohol adiponectin white adipos obes secret mcp1 initi monocyt white adipos secret persist excess adipokin adipocyt skelet adipos excess lipid nonadipos caus lipotox eventu propos obesitydepend reactiv ro ro advers pancrea homeostasi array 384 white adipos fed calori restrict cr lf hf consum ethanol drink cr lf hf diet phenotyp lean bmi overweight bmi obes bmi allow alcohol lean cr lf obes hf calori restrict alcohol calori restrict drastic oppos pro antiinflammatori adipos lpin2 kcnj11 rbp4 alcohol reduc spectrum upregul antiinflammatori contribut modif alcohol summari lean obes alcohol calori restrict alcohol promot adipos type2 wat alcohol hf il6 il1 cd68 proinflammatori wat cr opposit il6 il1 alcohol oppress retnlb mif cr alcohol antiinflammatori il10 adrbk1 homeostasi ptgd lpin2 lpin3 dusp9 alcohol angptl6 kcnj11 ptpra gck ins1 pltp apob pck1 downregul hf upregul cr alcohol alcohol overlap regul foundat studi alcohol dietregul compet interest\n",
            "\t-0.837\talcohol drink relat colorect casecontrol newfoundland labrador canada substant epidemiolog alcohol drink colorect crc adequ explor casecontrol alcohol drink crc differ newli crc newfoundland labrador nl frequencymatch random digit dial 702 717 complet selfadminist questionnair ass lifestyl estim alcohol beverag drink alcohol drink odd ratio alcohol independ stratifi crc obes bmi alcohol crc 1240 nonalcohol categori obes drink 34fold crc nondrink crc drink drink obes alcohol drink crc modifi casecontrol studyalcoholobesitycolorect cancerinteractionlifestylesnewfoundland backgroundmethodsstudi participantsexposur datastatist analyseseth considerationsresultscharacterist controlscolorect alcohol intakecolorect alcohol sexcolorect alcohol statusdiscussionconclusioncompet interestsauthor contributionsprepubl colorect crc gastrointestin tract neoplasm account crc vari geograph western asia africa canada substanti crc provinc atlant provinc newfoundland labrador nl crc twice british columbia alberta unclear exist specul lifestyl crc carcinogenesi alcohol avoid lifestyl behavior crc epidemiolog alcohol crc occurr metaanalysi 34 casecontrol modestli crc compar moder 126499 gday rr121 heavi drinker gday rr152 nonoccasion drinker doserespons pool north america europ support report 141fold regular alcohol drinker 45 gday nondrink alcohol drink crc consider variat exist explain random error glutathion stransferas a4 gsta4 depred acetaldehyd carcinogen metabol alcohol expect modif alcohol hypothes alcohol drink crc vari histor provinc nl alcohol obes bmi nl alcohol crc joint alcohol crc object alcohol drink crc differ nl provinc nl canada alcohol crc valid prospect implic explor alcohol tailor alcohol polici obes compet interest\n",
            "\t-2.048\talcohol drink nutrit 1988 1994 alcohol protect explor alcohol nonsmok 8236 respond particip nutrit weightkgheightm height categor overweight obes alcohol drink bing drink quantiti drinksday drink drinksweek nonsmok 264 261 267 46 respond classifi drinker drinker odd adjust odd 073 055 097 nondrink odd overweight bing drinker consum drinksday drink drink 046 034 062 059 041 086 odd similarli odd drink consum drink week overweight alcohol pronounc explor moder alcohol drink control  backgroundmethodssampl selectionvariablesstatist analysisresultsdiscussionconclusioncompet interestsauthor contributionsprepubl overweight obes steadili nation continu rise concern agenc explos alcohol pastmonth consum drink fifti percent alcohol alcohol den macronutri consum oxid favor storag gain ad calori alcohol drinker gain extra nondrink jshape alcohol waisttohip moder drink benefici nondrink heavi riski drink opposit invers alcohol drink gain promin remain inconclus aim crosssect alcohol drink nation repres nonsmok alcohol benefici moder alcohol beverag prospect epidemiolog confirm benefici extend activ promot moder alcohol combat inappropri link alcohol note give advis nondrink start drink alcohol just argu promot abstent atleast regularli consum alcohol compet interest\n",
            "obese,CRP,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.353\tupper quadrant abdomin append mobil cecum present upper quadrant abdomin  leftsid append 58yearold constant upper quadrant luq deni fever chill anorexia eat bowel bladder nontox appear vital sign abdomen soft tender palpat luq bowel sound mass guard tender remaind white count 10600mm 749 neutrophil otherwis indic chemistri urinalysi lipas creactiv crp 217 mgl mgl computer tomographi ct intraven leftsid append ct mobil mesocecum upper quadrant inflam thickwal appendix append underw laparotomi colon cecum upper quadrant inflam enlarg appendix malrot congenit abnorm histolog gangren appendix toler discharg home leftsid append predominantli congenit anomali situ inversu totali midgut malrot quadrant luq hypermobil colon crp append crp concern obtain ct \n",
            "\t0.343\tgood migrant explor good migrant establish good migrant independ good good fit threefold good advantag nonconfront nonopposit selfinterest argument good migrant appeal move rightsbas argument  seek frameworksdefin goodsth environmentefficaci antibiot good migrantsconclus migrant right duti migrant use right framework justic claim delin right migrant duti owe caricatur debat collaps conflict right right true discours surround debat migrant draw right languag domin discus defend right immigr immigr polici instanc intern convent protect right migrant worker famili seek protect basic freedom document undocu migrant propos realiz right person hold univers declar right 1948 un 1990 similarli discus link tension fundament right right immigr polici liber ghoshray theorist tend compar interest migrant lowskil lowpaid citizen polici exacerb inequ poorest nation borja cafaro regard immigr debat couch teitelbaum 1980 compet narr right trump right assum grant right expens right discours migrant rhetor emot instanc migrant forc refuge flee conflict zone econom migrant seek escap grind poverti caricatur antimigr flood take job migrant qualifi migrant colloqui call drain critic leav origin certainli movement difficulti evidenc profession convers remitt incom emot languag make claim right migrant controversi right languag languag tend impli confront opposit confront right languag somewhat tent issu migrant perspect rightsbas focus commun good good abandon contrari consid ethicist endors right duti global individu theori crucial justic theoriz regard locu moral concern overli individualist theori fail recogn good harm theori priori good harm recogn widdow westoram intend replac rightsbas complement alongsid brief discus good migrant provid good justifi right ground ground protect endors good basic good accord migrant ground deni conflict right right good protect harm prevent conceptu simpli remov claim right resourc competit issu protect protect reason right migrant grant good final comment good migrant migrant protect good parallel migrant right argument right claim migrant right argument separ provis good migrant\n",
            "\t0.336\tright eastern myanmar polit transit populationbas multistag household cluster sampl myanmarburma humanitarian assist elect novemb foreign assist econom right preelect octob 2008januari communitybas organ household survey threestag cluster sampl shan kayin bago kayah mon tanintharyi myanmar 5592 head household household demograph reproduct diarrhea birth death malnutrit 59 age 49 right modul right violat hrv experienc household infant underf 77 56 98 139 107 171 death 1000 live birth crude death thousand person respondentreport diarrhea caus 212 165 258 166 118 214 123 87 158 household right violat preced 362 307 417 household forc labor infant rr 44 rr 36 moder malnutrit household displac pr 33 56 elect eastern myanmar experienc hrv populationbas monitor intern effort right situat burmamyanmarhuman rightshealthmortalitymalaria backgroundmethodsdesignimplementationanalysissampl sizeeth approvalresultsdemographicsmort morbidityhuman right violationsassoci right violat outcomesdiscussionmorbid mortalityhuman right violationslimitationsconclusioncompet interestsauthor contributionsprepubl  hrv poorer eastern myanmar conflict transit add grow demonstr right succeed complement concert effort elimin hrv intern domest actor polit econom invest eastern myanmar hrv compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-7.841\tright intern migrant worldwid migrat border intern migrant citizenship confront financi consequ right financi crisi exacerb vulner intern migrant face realiz right antiretrovir china russia intern migrant offici resid inelig receiv increasingli unabl afford privat india intern migrant face substanti logist cultur linguist barrier difficulti access return poorli serv rural interrupt consequ vulner undermin effort curb epidem univers emerg drugresist intern right law guarante law territori movement border guarante attain intern right treati fundament principl nondiscrimin creat duti core minimum intern migrant nondiscriminatori elimin restrict residencebas elig ensur intern migrant realiz equal right  introductionbarri hivaid face intern migrant china russia indiath peopl republ chinath russian federationrepubl indiaintern lawright attain healthprincipl equal nondiscriminationnondiscrimin healthdiscussionconclusionsummarycompet interestsauthor contribut worldwid migrat countri intern migrantsa oppos intern migrantsar resid civil divis countri origin reason vari typic polit financi disast urban manufactur east southeast asia circular ruralurban unpreced indonesia vietnam cambodia ruralrur ruralurban india lift restrict movementa south africa postapartheid erahav intern eastern europ commonwealth fall soviet union intrametropolitan increasingli latin america financi crisi serious spend hivaid march bank joint nation programm hivaid unaid organ face shortag disrupt hivaid crisi ill financi crisi thrown relief plight intern migrant exacerb inequ declin market migrant worker lose job februari china million migrant worker laid unabl fragil healthrel consequ unemploy dire return rural impoverish origin seek locat equal intern right law guarante law territori movement border commit legal parti intern coven civil polit right iccpr right committe iccpr note liberti movement indispens person intern convent elimin racial discrimin support freedom movement freedom movement assur intern law alway respect put restrict movement limit unoffici intern migrant margin subject stigma migrant hivaid doubli stigmat subject neglect exploit gap intern migrant hivaid serviceseith offici restrict logist cultur linguist barriershav consequ increasingli vulner realiz goal univers aid epidem face emerg drugresist interrupt articl describ barrier hivaidsrel face intern migrant move place origin highlight countrieschina russia indiathat intern restrict logist linguist cultur barrier hivaid success achiev goal burden provid univers recogn right intern migrant oblig elimin barrier intern realiti million precondit econom govern famili commun reli financi crisi serv engin econom protect keep pace realiti intern critic right research china hukou alway unfair migrant econom crisi make downright punit deni migrant liter built citi live welfar net gener wherev residencebas restrict place face transmiss serv intern migrant imper oblig govern intern right law commit attain univers intern effort systemwid wake econom crisi take right goal intern migrant next intern economi worker summari\n",
            "\t-8.035\tgood migrant explor good migrant establish good migrant independ good good fit threefold good advantag nonconfront nonopposit selfinterest argument good migrant appeal move rightsbas argument  seek frameworksdefin goodsth environmentefficaci antibiot good migrantsconclus migrant right duti migrant use right framework justic claim delin right migrant duti owe caricatur debat collaps conflict right right true discours surround debat migrant draw right languag domin discus defend right immigr immigr polici instanc intern convent protect right migrant worker famili seek protect basic freedom document undocu migrant propos realiz right person hold univers declar right 1948 un 1990 similarli discus link tension fundament right right immigr polici liber ghoshray theorist tend compar interest migrant lowskil lowpaid citizen polici exacerb inequ poorest nation borja cafaro regard immigr debat couch teitelbaum 1980 compet narr right trump right assum grant right expens right discours migrant rhetor emot instanc migrant forc refuge flee conflict zone econom migrant seek escap grind poverti caricatur antimigr flood take job migrant qualifi migrant colloqui call drain critic leav origin certainli movement difficulti evidenc profession convers remitt incom emot languag make claim right migrant controversi right languag languag tend impli confront opposit confront right languag somewhat tent issu migrant perspect rightsbas focus commun good good abandon contrari consid ethicist endors right duti global individu theori crucial justic theoriz regard locu moral concern overli individualist theori fail recogn good harm theori priori good harm recogn widdow westoram intend replac rightsbas complement alongsid brief discus good migrant provid good justifi right ground ground protect endors good basic good accord migrant ground deni conflict right right good protect harm prevent conceptu simpli remov claim right resourc competit issu protect protect reason right migrant grant good final comment good migrant migrant protect good parallel migrant right argument right claim migrant right argument separ provis good migrant\n",
            "\t-9.167\tupper quadrant abdomin append mobil cecum present upper quadrant abdomin  leftsid append 58yearold constant upper quadrant luq deni fever chill anorexia eat bowel bladder nontox appear vital sign abdomen soft tender palpat luq bowel sound mass guard tender remaind white count 10600mm 749 neutrophil otherwis indic chemistri urinalysi lipas creactiv crp 217 mgl mgl computer tomographi ct intraven leftsid append ct mobil mesocecum upper quadrant inflam thickwal appendix append underw laparotomi colon cecum upper quadrant inflam enlarg appendix malrot congenit abnorm histolog gangren appendix toler discharg home leftsid append predominantli congenit anomali situ inversu totali midgut malrot quadrant luq hypermobil colon crp append crp concern obtain ct \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.353\tupper quadrant abdomin append mobil cecum present upper quadrant abdomin  leftsid append 58yearold constant upper quadrant luq deni fever chill anorexia eat bowel bladder nontox appear vital sign abdomen soft tender palpat luq bowel sound mass guard tender remaind white count 10600mm 749 neutrophil otherwis indic chemistri urinalysi lipas creactiv crp 217 mgl mgl computer tomographi ct intraven leftsid append ct mobil mesocecum upper quadrant inflam thickwal appendix append underw laparotomi colon cecum upper quadrant inflam enlarg appendix malrot congenit abnorm histolog gangren appendix toler discharg home leftsid append predominantli congenit anomali situ inversu totali midgut malrot quadrant luq hypermobil colon crp append crp concern obtain ct \n",
            "\t0.343\tgood migrant explor good migrant establish good migrant independ good good fit threefold good advantag nonconfront nonopposit selfinterest argument good migrant appeal move rightsbas argument  seek frameworksdefin goodsth environmentefficaci antibiot good migrantsconclus migrant right duti migrant use right framework justic claim delin right migrant duti owe caricatur debat collaps conflict right right true discours surround debat migrant draw right languag domin discus defend right immigr immigr polici instanc intern convent protect right migrant worker famili seek protect basic freedom document undocu migrant propos realiz right person hold univers declar right 1948 un 1990 similarli discus link tension fundament right right immigr polici liber ghoshray theorist tend compar interest migrant lowskil lowpaid citizen polici exacerb inequ poorest nation borja cafaro regard immigr debat couch teitelbaum 1980 compet narr right trump right assum grant right expens right discours migrant rhetor emot instanc migrant forc refuge flee conflict zone econom migrant seek escap grind poverti caricatur antimigr flood take job migrant qualifi migrant colloqui call drain critic leav origin certainli movement difficulti evidenc profession convers remitt incom emot languag make claim right migrant controversi right languag languag tend impli confront opposit confront right languag somewhat tent issu migrant perspect rightsbas focus commun good good abandon contrari consid ethicist endors right duti global individu theori crucial justic theoriz regard locu moral concern overli individualist theori fail recogn good harm theori priori good harm recogn widdow westoram intend replac rightsbas complement alongsid brief discus good migrant provid good justifi right ground ground protect endors good basic good accord migrant ground deni conflict right right good protect harm prevent conceptu simpli remov claim right resourc competit issu protect protect reason right migrant grant good final comment good migrant migrant protect good parallel migrant right argument right claim migrant right argument separ provis good migrant\n",
            "\t0.336\tright eastern myanmar polit transit populationbas multistag household cluster sampl myanmarburma humanitarian assist elect novemb foreign assist econom right preelect octob 2008januari communitybas organ household survey threestag cluster sampl shan kayin bago kayah mon tanintharyi myanmar 5592 head household household demograph reproduct diarrhea birth death malnutrit 59 age 49 right modul right violat hrv experienc household infant underf 77 56 98 139 107 171 death 1000 live birth crude death thousand person respondentreport diarrhea caus 212 165 258 166 118 214 123 87 158 household right violat preced 362 307 417 household forc labor infant rr 44 rr 36 moder malnutrit household displac pr 33 56 elect eastern myanmar experienc hrv populationbas monitor intern effort right situat burmamyanmarhuman rightshealthmortalitymalaria backgroundmethodsdesignimplementationanalysissampl sizeeth approvalresultsdemographicsmort morbidityhuman right violationsassoci right violat outcomesdiscussionmorbid mortalityhuman right violationslimitationsconclusioncompet interestsauthor contributionsprepubl  hrv poorer eastern myanmar conflict transit add grow demonstr right succeed complement concert effort elimin hrv intern domest actor polit econom invest eastern myanmar hrv compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-7.841\tright intern migrant worldwid migrat border intern migrant citizenship confront financi consequ right financi crisi exacerb vulner intern migrant face realiz right antiretrovir china russia intern migrant offici resid inelig receiv increasingli unabl afford privat india intern migrant face substanti logist cultur linguist barrier difficulti access return poorli serv rural interrupt consequ vulner undermin effort curb epidem univers emerg drugresist intern right law guarante law territori movement border guarante attain intern right treati fundament principl nondiscrimin creat duti core minimum intern migrant nondiscriminatori elimin restrict residencebas elig ensur intern migrant realiz equal right  introductionbarri hivaid face intern migrant china russia indiath peopl republ chinath russian federationrepubl indiaintern lawright attain healthprincipl equal nondiscriminationnondiscrimin healthdiscussionconclusionsummarycompet interestsauthor contribut worldwid migrat countri intern migrantsa oppos intern migrantsar resid civil divis countri origin reason vari typic polit financi disast urban manufactur east southeast asia circular ruralurban unpreced indonesia vietnam cambodia ruralrur ruralurban india lift restrict movementa south africa postapartheid erahav intern eastern europ commonwealth fall soviet union intrametropolitan increasingli latin america financi crisi serious spend hivaid march bank joint nation programm hivaid unaid organ face shortag disrupt hivaid crisi ill financi crisi thrown relief plight intern migrant exacerb inequ declin market migrant worker lose job februari china million migrant worker laid unabl fragil healthrel consequ unemploy dire return rural impoverish origin seek locat equal intern right law guarante law territori movement border commit legal parti intern coven civil polit right iccpr right committe iccpr note liberti movement indispens person intern convent elimin racial discrimin support freedom movement freedom movement assur intern law alway respect put restrict movement limit unoffici intern migrant margin subject stigma migrant hivaid doubli stigmat subject neglect exploit gap intern migrant hivaid serviceseith offici restrict logist cultur linguist barriershav consequ increasingli vulner realiz goal univers aid epidem face emerg drugresist interrupt articl describ barrier hivaidsrel face intern migrant move place origin highlight countrieschina russia indiathat intern restrict logist linguist cultur barrier hivaid success achiev goal burden provid univers recogn right intern migrant oblig elimin barrier intern realiti million precondit econom govern famili commun reli financi crisi serv engin econom protect keep pace realiti intern critic right research china hukou alway unfair migrant econom crisi make downright punit deni migrant liter built citi live welfar net gener wherev residencebas restrict place face transmiss serv intern migrant imper oblig govern intern right law commit attain univers intern effort systemwid wake econom crisi take right goal intern migrant next intern economi worker summari\n",
            "\t-8.035\tgood migrant explor good migrant establish good migrant independ good good fit threefold good advantag nonconfront nonopposit selfinterest argument good migrant appeal move rightsbas argument  seek frameworksdefin goodsth environmentefficaci antibiot good migrantsconclus migrant right duti migrant use right framework justic claim delin right migrant duti owe caricatur debat collaps conflict right right true discours surround debat migrant draw right languag domin discus defend right immigr immigr polici instanc intern convent protect right migrant worker famili seek protect basic freedom document undocu migrant propos realiz right person hold univers declar right 1948 un 1990 similarli discus link tension fundament right right immigr polici liber ghoshray theorist tend compar interest migrant lowskil lowpaid citizen polici exacerb inequ poorest nation borja cafaro regard immigr debat couch teitelbaum 1980 compet narr right trump right assum grant right expens right discours migrant rhetor emot instanc migrant forc refuge flee conflict zone econom migrant seek escap grind poverti caricatur antimigr flood take job migrant qualifi migrant colloqui call drain critic leav origin certainli movement difficulti evidenc profession convers remitt incom emot languag make claim right migrant controversi right languag languag tend impli confront opposit confront right languag somewhat tent issu migrant perspect rightsbas focus commun good good abandon contrari consid ethicist endors right duti global individu theori crucial justic theoriz regard locu moral concern overli individualist theori fail recogn good harm theori priori good harm recogn widdow westoram intend replac rightsbas complement alongsid brief discus good migrant provid good justifi right ground ground protect endors good basic good accord migrant ground deni conflict right right good protect harm prevent conceptu simpli remov claim right resourc competit issu protect protect reason right migrant grant good final comment good migrant migrant protect good parallel migrant right argument right claim migrant right argument separ provis good migrant\n",
            "\t-9.167\tupper quadrant abdomin append mobil cecum present upper quadrant abdomin  leftsid append 58yearold constant upper quadrant luq deni fever chill anorexia eat bowel bladder nontox appear vital sign abdomen soft tender palpat luq bowel sound mass guard tender remaind white count 10600mm 749 neutrophil otherwis indic chemistri urinalysi lipas creactiv crp 217 mgl mgl computer tomographi ct intraven leftsid append ct mobil mesocecum upper quadrant inflam thickwal appendix append underw laparotomi colon cecum upper quadrant inflam enlarg appendix malrot congenit abnorm histolog gangren appendix toler discharg home leftsid append predominantli congenit anomali situ inversu totali midgut malrot quadrant luq hypermobil colon crp append crp concern obtain ct \n",
            "migratory pain in the right lower quadrant of None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.509\tcrosssect childhood asthma ahvaz citi iran childhood asthma dramat asthma isaac questionnair crosssect school populationbas carri 1803 school age ahvaz citi khuzestan south west iran intern asthma allergi childhood isaac questionnair asthma chisquar asthma logist regress asthma enter spss version softwar 005 asthma school 49 male 55 femal 43 asthma 61 age 37 wheez wheez play 181 139 84 dri cough night 176 asthma winter asthma male femal allerg air pollut asthma childhood asthma prevalenceasthmachildrenrisk factorsahvaz introductionaimmateri methodsmethodstudi populationresearch toolsstatist analysisresultsdiscussionconclus asthma affect childhood asthma morbid asthma pediatr childhood morbid airway wheez breathless chest tight nighttim morn cough revers spontan intern asthma allergi childhood isaac questionnair compar secular trend asthma demonstr ill base trend phase carri 70000 156 center 56 36 center explor protect indiffer took place asthma allergi implement hypothes isaac launch iran 1997 carri institut tuberculosi rashtand tehran citi iran citi shahrekord isfahan kashan zanjan birjand tabriz babol amor ahvazison iranian citi asthma hot humid weather overpopul industri center instal dust collector asthma male femal allerg air pollut asthma childhood asthma\n",
            "\t0.489\toccup asthma paroxysm atrial fibril diamond polish diamond polish occup asthma prolong potent wellrecogn asthmainduc cobalt dust profession ill attempt establish causal exposur illustr ultim fate retir job perman ill avoid illustr complic asthma arrhythmia contribut worsen practic avoid complic    \n",
            "\t0.489\toccup asthma paroxysm atrial fibril diamond polish diamond polish occup asthma prolong potent wellrecogn asthmainduc cobalt dust profession ill attempt establish causal exposur illustr ultim fate retir job perman ill avoid illustr complic asthma arrhythmia contribut worsen practic avoid complic    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t4.905\tzafirlukast improv obstruct zafirlukast select ltd4 antagonist obstruct copd zafirlukast shortact rescu agonist fewer exacerb asthma benefit asthma zafirlukast copd twenti moder copd particip intervent quasiexperiment mg zafirlukast pair ttest spss v16 6729 sd556 forc expiratori fev equal 4179 sd1496 improv forc vital fvc fev fev fvc 475 sd1318 371 sd919 933sd2708 zafirlukast nonsignific 005 bronchodil maximum fev 004 lit zafirlukast consider bronchodilatori copd consist extens possibl verifi leukoterien antagonist improv copd obstruct copdpulmonari testzafirlukast introductionmethodspatientsstudi designspirometrystatist analysisresultsdiscussionconclus obstruct copd prevent treatabl airflow limit revers progress abnorm lung noxiou particl gase morbid abnorm copd acceler declin forc expiratori fev1 fev1 declin ml copd declin nearli ml guidelin initi obstruct gold airflow limit copd fev1 80 percent fev1fvc 070 cysteinyl leukotrien cyslt proinflammatori mediat arachidon 5lypoxigenas 5lo bronchial smooth contract mucou enhanc permeabl recruit eosinophil cysteinyl leukotrien cyslt antagonist airflow limit cyslt potent bronchoconstrictor asthma mediat copd cyslt sputum bronchiti zafirlukast select ltd antagonist benefit antileukotrien 5lipoxygenas zileuton45 cyslt1 blockad montelukast zafirlukast asthma daytim nocturn shortact rescu agonist fewer exacerb asthma zafirlukast consider bronchodilatori copd zafirlukast consider bronchodilatori copd except fev1fvc zafirlukast mostli asthma copd controversi zafirlukast bronchodil copd cysteinyl leukotrien bronchospasm consist extens possibl verifi leukoterien antagonist improv copd confirm zafirlukast copd zafirlukast copd zafirlukast bronchodilatori copd\n",
            "\t4.905\tzafirlukast improv obstruct zafirlukast select ltd4 antagonist obstruct copd zafirlukast shortact rescu agonist fewer exacerb asthma benefit asthma zafirlukast copd twenti moder copd particip intervent quasiexperiment mg zafirlukast pair ttest spss v16 6729 sd556 forc expiratori fev equal 4179 sd1496 improv forc vital fvc fev fev fvc 475 sd1318 371 sd919 933sd2708 zafirlukast nonsignific 005 bronchodil maximum fev 004 lit zafirlukast consider bronchodilatori copd consist extens possibl verifi leukoterien antagonist improv copd obstruct copdpulmonari testzafirlukast introductionmethodspatientsstudi designspirometrystatist analysisresultsdiscussionconclus obstruct copd prevent treatabl airflow limit revers progress abnorm lung noxiou particl gase morbid abnorm copd acceler declin forc expiratori fev1 fev1 declin ml copd declin nearli ml guidelin initi obstruct gold airflow limit copd fev1 80 percent fev1fvc 070 cysteinyl leukotrien cyslt proinflammatori mediat arachidon 5lypoxigenas 5lo bronchial smooth contract mucou enhanc permeabl recruit eosinophil cysteinyl leukotrien cyslt antagonist airflow limit cyslt potent bronchoconstrictor asthma mediat copd cyslt sputum bronchiti zafirlukast select ltd antagonist benefit antileukotrien 5lipoxygenas zileuton45 cyslt1 blockad montelukast zafirlukast asthma daytim nocturn shortact rescu agonist fewer exacerb asthma zafirlukast consider bronchodilatori copd zafirlukast consider bronchodilatori copd except fev1fvc zafirlukast mostli asthma copd controversi zafirlukast bronchodil copd cysteinyl leukotrien bronchospasm consist extens possibl verifi leukoterien antagonist improv copd confirm zafirlukast copd zafirlukast copd zafirlukast bronchodilatori copd\n",
            "\t-4.558\toccup asthma gateway occup asthma asthma began asthma worsen period improv holiday suspicion sensitizerinduc occup asthma recogn sensit workplac allerg rhiniti conjunct accident irrit shortli rais irritantinduc occup asthma indic occup asthma investig confirm asthma relat workplac suspect   occup asthma oa asthma attribut occup encount outsid workplac adultonset asthma sensit workplac substanc immunoglobulin immunolog highlevel irrit irritantinduc asthma clearest reactiv airway articl discus workaggrav asthma aggrav asthma workplac exert cold air dust smoke fume oa sensit remov sensit asthma mild nevertheless socioeconom worker compens accur great facilit reloc compani retrain give worker chanc reentri workplac unfortun delay oa reach chart occup clinic ontario delay suspicion workrel asthma fear lose inquiri asthma incom oa suspect care oa ident nonoccupationrel asthmaepisod wheez dri cough short breath chest tightnessand singli ask question ass asthma start worsen work unusu workplac hour asthma asthma weekend away asthma holiday away question implic explain unusu worka spill highlevel irrit hour asthma enough worker seek emerg timewould rais suspicion irritantinduc asthma rad rad definit irritantinduc asthma brook colleagu hour highlevel irrit typic asthma asthma persist airflow limit bronchodil methacholin histamin rad stringent irritantinduc asthma irritantinduc asthma highlevel irrit week nonmass irrit exposur certainti becom stringent abovement question question asthma allerg object confirm asthma object ass accident review record exclud question list abovear asthma weekend away asthma holidaysar workrel asthma asthma relax beach elsewher weekend holiday work nevertheless away indic oa sensit workaggrav asthma object oa qu bec 88 object oa gave question holiday oppos 76 oa workaggrav asthma question oa question ontario worker compens claimant whose claim oa accept 70 weekend 88 holiday oppos 41 54 deem asthma unrel percentag final compens decis unrel asthma likelihood compens decis belgium qu bec vandenpla colleagu wheez oa occur 88 oa workrel eye nasal predict oa itch nose eye oa highmolecularweight sensit voic workattribut neg oa vandenpla colleagu 74 correct predict oppos gold detail occup workplac sensit exposur asthma start worsen worker whose occup sensitizerinduc oa worker diisocyan make polyurethan foam spray paint mould foundri manufactur particleboard worker veterinarian farmer worker baker worker grain farmer grain handler worker airborn worker wood dust carpent construct worker metal worker platinum salt solder flux metal salt irritantinduc oa accident spill highlevel exposur diisocyan chlorin chloron irrit alkalin dust smoke job titl give indic dust fume nearbi worker question job descript know help ask obtain copi sheet msdss workplac worker entitl receiv copi sheet list hazard ingredi workplac canada recogn sensit constitut 01 product list hazard ingredi requir provid note ask supervisor workplac committe msdss cowork assist obtain msdss list toxic hypersensit list contain sensit request product manufactur workplac permiss 250 workplac sensit oa workplac set sensit list onlin httpwwwasmanetcom sensit exclud oa oa highmolecularweight sensit oa igeantibodymedi allerg rhiniti conjunct sensit start concurr asthma asthma sensit actual presum latent irritantinduc asthma typic begin hour irrit sensitizerinduc oa asthma exposur immedi minut sensit typic 46 hour sensit lowmolecularweight agent dual asthmat immedi obviou worsen begin progress shift away evid away note weekend away holiday away oa worker oa remov subgroup worker whose asthma whose asthma worsen asthma emphas think oa ask asthmat make incorrect emphas detail guidelin review avoid unnecessari job oa unlik undergo object workplac \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.509\tcrosssect childhood asthma ahvaz citi iran childhood asthma dramat asthma isaac questionnair crosssect school populationbas carri 1803 school age ahvaz citi khuzestan south west iran intern asthma allergi childhood isaac questionnair asthma chisquar asthma logist regress asthma enter spss version softwar 005 asthma school 49 male 55 femal 43 asthma 61 age 37 wheez wheez play 181 139 84 dri cough night 176 asthma winter asthma male femal allerg air pollut asthma childhood asthma prevalenceasthmachildrenrisk factorsahvaz introductionaimmateri methodsmethodstudi populationresearch toolsstatist analysisresultsdiscussionconclus asthma affect childhood asthma morbid asthma pediatr childhood morbid airway wheez breathless chest tight nighttim morn cough revers spontan intern asthma allergi childhood isaac questionnair compar secular trend asthma demonstr ill base trend phase carri 70000 156 center 56 36 center explor protect indiffer took place asthma allergi implement hypothes isaac launch iran 1997 carri institut tuberculosi rashtand tehran citi iran citi shahrekord isfahan kashan zanjan birjand tabriz babol amor ahvazison iranian citi asthma hot humid weather overpopul industri center instal dust collector asthma male femal allerg air pollut asthma childhood asthma\n",
            "\t0.489\toccup asthma paroxysm atrial fibril diamond polish diamond polish occup asthma prolong potent wellrecogn asthmainduc cobalt dust profession ill attempt establish causal exposur illustr ultim fate retir job perman ill avoid illustr complic asthma arrhythmia contribut worsen practic avoid complic    \n",
            "\t0.489\toccup asthma paroxysm atrial fibril diamond polish diamond polish occup asthma prolong potent wellrecogn asthmainduc cobalt dust profession ill attempt establish causal exposur illustr ultim fate retir job perman ill avoid illustr complic asthma arrhythmia contribut worsen practic avoid complic    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t4.905\tzafirlukast improv obstruct zafirlukast select ltd4 antagonist obstruct copd zafirlukast shortact rescu agonist fewer exacerb asthma benefit asthma zafirlukast copd twenti moder copd particip intervent quasiexperiment mg zafirlukast pair ttest spss v16 6729 sd556 forc expiratori fev equal 4179 sd1496 improv forc vital fvc fev fev fvc 475 sd1318 371 sd919 933sd2708 zafirlukast nonsignific 005 bronchodil maximum fev 004 lit zafirlukast consider bronchodilatori copd consist extens possibl verifi leukoterien antagonist improv copd obstruct copdpulmonari testzafirlukast introductionmethodspatientsstudi designspirometrystatist analysisresultsdiscussionconclus obstruct copd prevent treatabl airflow limit revers progress abnorm lung noxiou particl gase morbid abnorm copd acceler declin forc expiratori fev1 fev1 declin ml copd declin nearli ml guidelin initi obstruct gold airflow limit copd fev1 80 percent fev1fvc 070 cysteinyl leukotrien cyslt proinflammatori mediat arachidon 5lypoxigenas 5lo bronchial smooth contract mucou enhanc permeabl recruit eosinophil cysteinyl leukotrien cyslt antagonist airflow limit cyslt potent bronchoconstrictor asthma mediat copd cyslt sputum bronchiti zafirlukast select ltd antagonist benefit antileukotrien 5lipoxygenas zileuton45 cyslt1 blockad montelukast zafirlukast asthma daytim nocturn shortact rescu agonist fewer exacerb asthma zafirlukast consider bronchodilatori copd zafirlukast consider bronchodilatori copd except fev1fvc zafirlukast mostli asthma copd controversi zafirlukast bronchodil copd cysteinyl leukotrien bronchospasm consist extens possibl verifi leukoterien antagonist improv copd confirm zafirlukast copd zafirlukast copd zafirlukast bronchodilatori copd\n",
            "\t4.905\tzafirlukast improv obstruct zafirlukast select ltd4 antagonist obstruct copd zafirlukast shortact rescu agonist fewer exacerb asthma benefit asthma zafirlukast copd twenti moder copd particip intervent quasiexperiment mg zafirlukast pair ttest spss v16 6729 sd556 forc expiratori fev equal 4179 sd1496 improv forc vital fvc fev fev fvc 475 sd1318 371 sd919 933sd2708 zafirlukast nonsignific 005 bronchodil maximum fev 004 lit zafirlukast consider bronchodilatori copd consist extens possibl verifi leukoterien antagonist improv copd obstruct copdpulmonari testzafirlukast introductionmethodspatientsstudi designspirometrystatist analysisresultsdiscussionconclus obstruct copd prevent treatabl airflow limit revers progress abnorm lung noxiou particl gase morbid abnorm copd acceler declin forc expiratori fev1 fev1 declin ml copd declin nearli ml guidelin initi obstruct gold airflow limit copd fev1 80 percent fev1fvc 070 cysteinyl leukotrien cyslt proinflammatori mediat arachidon 5lypoxigenas 5lo bronchial smooth contract mucou enhanc permeabl recruit eosinophil cysteinyl leukotrien cyslt antagonist airflow limit cyslt potent bronchoconstrictor asthma mediat copd cyslt sputum bronchiti zafirlukast select ltd antagonist benefit antileukotrien 5lipoxygenas zileuton45 cyslt1 blockad montelukast zafirlukast asthma daytim nocturn shortact rescu agonist fewer exacerb asthma zafirlukast consider bronchodilatori copd zafirlukast consider bronchodilatori copd except fev1fvc zafirlukast mostli asthma copd controversi zafirlukast bronchodil copd cysteinyl leukotrien bronchospasm consist extens possibl verifi leukoterien antagonist improv copd confirm zafirlukast copd zafirlukast copd zafirlukast bronchodilatori copd\n",
            "\t-4.558\toccup asthma gateway occup asthma asthma began asthma worsen period improv holiday suspicion sensitizerinduc occup asthma recogn sensit workplac allerg rhiniti conjunct accident irrit shortli rais irritantinduc occup asthma indic occup asthma investig confirm asthma relat workplac suspect   occup asthma oa asthma attribut occup encount outsid workplac adultonset asthma sensit workplac substanc immunoglobulin immunolog highlevel irrit irritantinduc asthma clearest reactiv airway articl discus workaggrav asthma aggrav asthma workplac exert cold air dust smoke fume oa sensit remov sensit asthma mild nevertheless socioeconom worker compens accur great facilit reloc compani retrain give worker chanc reentri workplac unfortun delay oa reach chart occup clinic ontario delay suspicion workrel asthma fear lose inquiri asthma incom oa suspect care oa ident nonoccupationrel asthmaepisod wheez dri cough short breath chest tightnessand singli ask question ass asthma start worsen work unusu workplac hour asthma asthma weekend away asthma holiday away question implic explain unusu worka spill highlevel irrit hour asthma enough worker seek emerg timewould rais suspicion irritantinduc asthma rad rad definit irritantinduc asthma brook colleagu hour highlevel irrit typic asthma asthma persist airflow limit bronchodil methacholin histamin rad stringent irritantinduc asthma irritantinduc asthma highlevel irrit week nonmass irrit exposur certainti becom stringent abovement question question asthma allerg object confirm asthma object ass accident review record exclud question list abovear asthma weekend away asthma holidaysar workrel asthma asthma relax beach elsewher weekend holiday work nevertheless away indic oa sensit workaggrav asthma object oa qu bec 88 object oa gave question holiday oppos 76 oa workaggrav asthma question oa question ontario worker compens claimant whose claim oa accept 70 weekend 88 holiday oppos 41 54 deem asthma unrel percentag final compens decis unrel asthma likelihood compens decis belgium qu bec vandenpla colleagu wheez oa occur 88 oa workrel eye nasal predict oa itch nose eye oa highmolecularweight sensit voic workattribut neg oa vandenpla colleagu 74 correct predict oppos gold detail occup workplac sensit exposur asthma start worsen worker whose occup sensitizerinduc oa worker diisocyan make polyurethan foam spray paint mould foundri manufactur particleboard worker veterinarian farmer worker baker worker grain farmer grain handler worker airborn worker wood dust carpent construct worker metal worker platinum salt solder flux metal salt irritantinduc oa accident spill highlevel exposur diisocyan chlorin chloron irrit alkalin dust smoke job titl give indic dust fume nearbi worker question job descript know help ask obtain copi sheet msdss workplac worker entitl receiv copi sheet list hazard ingredi workplac canada recogn sensit constitut 01 product list hazard ingredi requir provid note ask supervisor workplac committe msdss cowork assist obtain msdss list toxic hypersensit list contain sensit request product manufactur workplac permiss 250 workplac sensit oa workplac set sensit list onlin httpwwwasmanetcom sensit exclud oa oa highmolecularweight sensit oa igeantibodymedi allerg rhiniti conjunct sensit start concurr asthma asthma sensit actual presum latent irritantinduc asthma typic begin hour irrit sensitizerinduc oa asthma exposur immedi minut sensit typic 46 hour sensit lowmolecularweight agent dual asthmat immedi obviou worsen begin progress shift away evid away note weekend away holiday away oa worker oa remov subgroup worker whose asthma whose asthma worsen asthma emphas think oa ask asthmat make incorrect emphas detail guidelin review avoid unnecessari job oa unlik undergo object workplac \n",
            "asthma,Zafirlukast None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.503\tbiomark delay graft transplant transplant ensur advantag endstag allograft consequ graft transplant delay graft dgf unfortun dgf dgf modif immunosuppress creatinin biomark princip inabl inabl differenti urinari intens biomark set promis candid biomark dgf emerg biomark dgf ngal kim1 lfabp il18 random establish promis biomark dgf costeffect  creatininenovel biomarkersneutrophil gelatinaseassoci lipocalin ngalkidney molecul kim1interleukin18 il18 livertyp fattyacid ykl40clusterincystatin csummaryaddit histor formal urea nitrogen wast richard bright 1827 urea urin diseas kidney 1900 urea nitrogen bun quantif eventu introduc creatinin supplant bun mid1900 estim gfr today gold estim glomerular filtrat gfr creatinin imperfect gender hydrat creatinin creatinin estim gfr aki adulter stem creatinin creatinin reflect tubular creatinin preclud tubular creatinin widespread acknowledg creatinin definit aki continu reli substanc perhap histor valid biomark research creatinin gold use tubular biomark suboptim ideal gold creatinin imperfect silver \n",
            "\t0.491\tpair urinari creatinin neonat jaff enzymat idmstrac urinari creatinin quantifi jaff enzymat denomin urinari excret electrolyt pair pediatr document interassay 80 verifi interchang idmstrac jaff enzymat neonat urin neonat urinari creatinin idmstrac creatinin 84 neonat urin 46 neonat idm traceabl jaff enzymat roch diagnost coba c702 modul creatinin urinari creatinin covari explor wilcoxon blandaltman regress median jaff enzymat urinari creatinin 925 37422 915 38429 mgdl median 008 sd 06 096 mgdl regress urinari enzymat creatinin 045 postnat 059 remain adj 045 idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat urinari creatininenewbornjaffeenzymaticidm traceabl backgroundmethodsclin samplingbioanalysisstatisticsresultsdiscussionconclusionscompet interestsauthor contributionsprepubl includ glomerular filtrat gfr tubular necessit quantif urinari creatinin calcul creatinin clearanc gfr estim denomin quantifi tubular sodium potassium calcium phosphat neonat muscular creatinin display extens matur gfr phenomenon median urin creatinin 97 mgdl mgdl 154 269 mgdl tubular matur initi wast solut urinari diuresi elimin conjug bilirubin agerel glucuronid accur interchang adequ standard utmost histor creatinin great depend jaff enzymat manufactur consequ creatinin neonat depend idmstrac creatinin introduc solv idm recalibr extens verifi urin manufactur intern commun roch diagnost standard elimin jaff display interfer endogen pseudocreatinin bilirubin exogen cefalosporin substanc enzymat prone interfer bilirubin dopamin abovement matur frequent neonat urin interfer urinari creatinin vari neonat urin 80 describ compar jaff enzymat median urinari 69 75 mgdl depend take abovement remark interchang idmstrac jaff enzymat verifi neonat urin neonat urinari creatinin idmstrac idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat compet interest\n",
            "\t0.486\tcreatin heart genet creatin creatin cardiomyocyt accumul creatin creatin transport crt fail myocardi creatin gain insight crt sever myocardi creatin creatin heart creatinefre guanidinoacet methyl transferas knock gamt overexpress myocardi crt crtoe cradiolabel creatin crt real rtpcr creatin hplc heart gamt 7fold max creatin 14fold crt cr crt complet prevent fed creatin supplement creatin subject feedback creatin crtoe 27fold consider creatin crt myocardi creatin 067 00001 endogen crt correl myocardi creatin 001 096 creatin massiv upregul magnitud upregul subject feedback crt predominantli alter  introductionmethodsmicecreatin perfus heartmrna measurementswestern blottingbiochem measurementscalcul crt revers potentialstatist analysisresultscreatin uptakecrt levelssgk1 levelscreatin levelsfre creatin transportdiscuss demand myocardium creatin atp synthes mitochondrion react creatin creatin ck adp phosphocreatin atp consum revers take place replenish atp maintain adp creatin origin dietari biosynthesi predominantli kidney cardiomyocyt synthes creatin accumul gradient na creatin cotransport crt creatin lost cardiomyocyt spontan nonenzymat convers creatinin permeabl diffus possibl efflux creatin creatin tightli creatin supplement creatin downregul creatin myocardi creatin unchang myocardi creatin cr coronari ligat myocardi creatin explain myocardi creatin crt crt crt downregul upregul creatin analogu guanidinoproprion gpa act competit crt creatin regul crt upregul glucocorticoid sgk1 xenopu oocyt express crt crt genet manipul myocardi creatin guanidinoacet methyl transferas knock gamt unabl synthes creatin fed creatinefre entir creatinefre instead accumul creatin precursor guanidinoacet ga phosphoryl ck instead creatin partial take creatin ck veloc order magnitud ga substrat overexpress crt crtoe myocardi creatin creatin creatin extrem creatin forc creatin insight creatin hypothes creatin trigger upregul creatin myocardi crt creatin quantifi crt upregul creatin heart gamt crt overexpress crt heart sgk1 candid crt regul heart gamt creatinefre gamt heart creatin massiv 7fold wt crt 14fold feed creatin supplement essenti abolish heart creatin crt creatin endogen crt creatin crt crt domin crt patho intra creatin alter crt creatin creatin feed creatin kinet unalt myocardi creatin creatin heart wt fed creatin supplement similarli creatin deplet feed creatin analogu gpa creatin g8 myoblast creatin creatin creatin creatin wherebi creatin alter crt poorli understood crt interpret caution anticrt cross react pyruv dehydrogenas crt take place sandov crt compat housekeep crt heart creatinefre gamt revers creatin feed suscept chang crt heart 7fold creatin consid extrem stimulu zero creatin alter minor crt endogen crt downregul creatin heart crtoe crt feed wt creatin supplement crt heart crt heart crtoe heart creatinefre gamt creatin gamt heart crt primarili subject posttranscript posttranscript crt modif crt put pkc close transmembran dopamin transport downregul transloc dopamin transport sarcolemma pool conceiv regul exist crt xenopu oocyt express crt coexpress sgk1 creatin sgk1 stimul crt unalt sgk1 gamt sgk1 upregul creatin heart exclud sgk1 gamt heart undetect methodolog heart overexpress crt creatin creatin crt myc interest note ventricular rv creatin crtoe heart ventricular lv creatin transgen crt myc mlc2v normal ventricl ventricular transgen mlc2v mlc2v rv explain creatin ventricl myocardium rv lv creatin rv creatin lv creatin heart creatin rv crtoe lv actual creatin rv discrep attribut heart lv creatin heart greatest ventricular creatin discrep creatin lv creatin never wt altogeth creatin exce start determin myocardi creatin crt ever oper revers creatin calcul revers creatin becom thermodynam revers heart creatin revers plateau revers creatin thermodynam unpublish consciou ecg crtoe calcul qt interv reflect take theoret revers creatin take place substanti fraction heart creatin crt revers theori hypothes heart lv transgen crt revers creatin systol act creatin dissoci lv creatin creatin heart creatin ventricl creatin gamt accumul creatin precursor guanidinoacet capabl phosphoryl creatin substrat impli gamt heart phosphoryl creatin rapidli convert instant transport keep creatin facilit creatin experi limit exclud myocardium crt residu ccreatin unlik confound min washout heart coronari effluent min washout regardless residu absolut worst underestim creatinefre heart gamt creatin transsarcolemm creatin gradient revers experi passiv diffus creatin heart creatin heart impli gradient rapidli disappear experi unlik substanti ccreatin creatin heart gamt enorm creatin creatin smaller 7fold creatin heart fed gpa heart creatin max creatin 63 remov creatin crt upregul creatin revers creatin fail worthwhil unravel signal creatin pharmacolog manipul restor myocardi creatin fail\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.806\tpair urinari creatinin neonat jaff enzymat idmstrac urinari creatinin quantifi jaff enzymat denomin urinari excret electrolyt pair pediatr document interassay 80 verifi interchang idmstrac jaff enzymat neonat urin neonat urinari creatinin idmstrac creatinin 84 neonat urin 46 neonat idm traceabl jaff enzymat roch diagnost coba c702 modul creatinin urinari creatinin covari explor wilcoxon blandaltman regress median jaff enzymat urinari creatinin 925 37422 915 38429 mgdl median 008 sd 06 096 mgdl regress urinari enzymat creatinin 045 postnat 059 remain adj 045 idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat urinari creatininenewbornjaffeenzymaticidm traceabl backgroundmethodsclin samplingbioanalysisstatisticsresultsdiscussionconclusionscompet interestsauthor contributionsprepubl includ glomerular filtrat gfr tubular necessit quantif urinari creatinin calcul creatinin clearanc gfr estim denomin quantifi tubular sodium potassium calcium phosphat neonat muscular creatinin display extens matur gfr phenomenon median urin creatinin 97 mgdl mgdl 154 269 mgdl tubular matur initi wast solut urinari diuresi elimin conjug bilirubin agerel glucuronid accur interchang adequ standard utmost histor creatinin great depend jaff enzymat manufactur consequ creatinin neonat depend idmstrac creatinin introduc solv idm recalibr extens verifi urin manufactur intern commun roch diagnost standard elimin jaff display interfer endogen pseudocreatinin bilirubin exogen cefalosporin substanc enzymat prone interfer bilirubin dopamin abovement matur frequent neonat urin interfer urinari creatinin vari neonat urin 80 describ compar jaff enzymat median urinari 69 75 mgdl depend take abovement remark interchang idmstrac jaff enzymat verifi neonat urin neonat urinari creatinin idmstrac idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat compet interest\n",
            "\t-5.827\tcystatin albuminuria albuminuria glomerular filtrat gfr joint albuminuria gfr comprehens 78 gfr cystatin creatinin albumintocreatinin acr singlevoid urin 691 378 die cystatin gfr mlmin 173 creatininebas gfr mlmin 173 urin acr mgg hazard ratio 173 137 218 154 121 197 173 139 217 adjust race hypoglycem bmi cholesterol lipidlow preval cvd preval cystatin gfr urin acr addit cystatin gfr creatininebas gfr albuminuria gfr addit recommend regularli albuminuria gfr treat cvd albuminuria gfr consider cystatin  methodsmeasur diseaseascertain mortalitycovariatesstatist analysisresultsbaselin characteristicsmortalitycystatin creatininechang cystatin cystatin ccystatin albuminuriaconclusionssupplementari materialonlineonli appendix ch prospect communitybas cvd age 65 recruit commun forsyth counti north carolina sacramento counti california washington counti maryland pittsburgh pennsylvania elig sampl medicar elig list institution wheelchairbound home receiv hospic exclud origin ch 5201 enrol 1989 1990 687 predominantli african american enrol 1992 1993 urin albumin 1996 1997 includ ch 1996 1997 cystatin creatinin urin albumin 12h fast 75g load hypoglycem fast 126 mgdl 2h postchalleng 200 mgdl cystatin creatinin urin albumin 691 814 meet 85 full list princip ch investig institut httpwwwchsnhlbiorgpihtm albuminuria gfr addit gfr cystatin gfr creatinin recommend regularli albuminuria gfr sharp treat cvd albuminuria gfr consider cystatin addit prognost util albuminuria gfr demonstr suit regular complementari hong kong albuminuria gfr incid italian albuminuria gfr mlmin 173 differ italian owe particip cystatin estim gfr 53 gfr egfr cy mlmin 173 urin acr mgg nhane possibl ad gfr gfr cystatin gfr urin acr uk prospect addit support concept albuminuria gfr separ overlap complementari manifest concept emerg paradigm describ albuminuria gfr serial manifest linear albuminuria gfr reflect albuminuria reflect widespread identifi nonren bed gfr reflect nephron parenchym fibrosi cvd urem toxin abnorm albuminuria gfr cvd requir cystatin gfr modestli stronger gfr creatinin full ch cystatin gfr linearli mdrdestim gfr ushap cystatin mdrdestim gfr cystatin estim true gfr precis nearnorm cystatin suscept confound formula estim gfr cystatin cystatin formula perform differ cystatin gfr cystatin explain cystatin cystatin carri prognost longitudin avail urin acr ass glycem notabl hypoglycem reflect cumul hyperglycemia ch extrapol younger strength diver communitybas adjud cvd facilit\n",
            "\t-6.070\tvalproat creatin   introduct introduct manuscript valproat unusu creatin metabolit explain defect primarili affect creatin biosynthesi ammonia creatin precursor glycin arginin organ priori rule defect secondarili affect creatin etiolog origin valproat conclud abnorm combin elev urinari creatin guanidinoacet coher valproat metabolit 16yearold boy born consanguin parent perinat asphyxia ill age psychomotor delay gener tonic clonic seizur partial valproat mgkgday clonazepam 006 mgkgday facial dysmorph axial hypotonia spastic tetraparesi languag retard gener dystonia mri cerebellar hypoplasia auditori evok electromyographi urinari organ ammonemia karyotyp aminoacid redox coupl lactat pyruv 589 0339 mmoll lactatepyruv urin creatin guanidinoacet abnorm 734 molmmol creatinin 684 molmmol creatinin corrobor disturb creatin metabolit unusu partial differ creatin agat gamt slc6a8 defici exclud anapleuresi arginin glycin creatin biosynthesi etiolog search rise guanidinometabolit point toward link valproat creatin highlight valproat autism valproat hyperammonemia turn ammonia creatin defici valproat creatin besid ammoniabas guanidinobutyratebas link rest drugdriven gammaaminobutyr avail yield guanidinobutyr creatineform guanidinoacet methyltransferas transport slc6a8 recoveri guanidinoacet guanidinoacet methyltransferas creatin util urin concurr slc6a8 emphas creatin oper valproat abnorm creatin guanidinoacet suggest creatin defici metabolit unusu valproat valproat creatin coher urinari guanidinoacet creatin \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.503\tbiomark delay graft transplant transplant ensur advantag endstag allograft consequ graft transplant delay graft dgf unfortun dgf dgf modif immunosuppress creatinin biomark princip inabl inabl differenti urinari intens biomark set promis candid biomark dgf emerg biomark dgf ngal kim1 lfabp il18 random establish promis biomark dgf costeffect  creatininenovel biomarkersneutrophil gelatinaseassoci lipocalin ngalkidney molecul kim1interleukin18 il18 livertyp fattyacid ykl40clusterincystatin csummaryaddit histor formal urea nitrogen wast richard bright 1827 urea urin diseas kidney 1900 urea nitrogen bun quantif eventu introduc creatinin supplant bun mid1900 estim gfr today gold estim glomerular filtrat gfr creatinin imperfect gender hydrat creatinin creatinin estim gfr aki adulter stem creatinin creatinin reflect tubular creatinin preclud tubular creatinin widespread acknowledg creatinin definit aki continu reli substanc perhap histor valid biomark research creatinin gold use tubular biomark suboptim ideal gold creatinin imperfect silver \n",
            "\t0.491\tpair urinari creatinin neonat jaff enzymat idmstrac urinari creatinin quantifi jaff enzymat denomin urinari excret electrolyt pair pediatr document interassay 80 verifi interchang idmstrac jaff enzymat neonat urin neonat urinari creatinin idmstrac creatinin 84 neonat urin 46 neonat idm traceabl jaff enzymat roch diagnost coba c702 modul creatinin urinari creatinin covari explor wilcoxon blandaltman regress median jaff enzymat urinari creatinin 925 37422 915 38429 mgdl median 008 sd 06 096 mgdl regress urinari enzymat creatinin 045 postnat 059 remain adj 045 idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat urinari creatininenewbornjaffeenzymaticidm traceabl backgroundmethodsclin samplingbioanalysisstatisticsresultsdiscussionconclusionscompet interestsauthor contributionsprepubl includ glomerular filtrat gfr tubular necessit quantif urinari creatinin calcul creatinin clearanc gfr estim denomin quantifi tubular sodium potassium calcium phosphat neonat muscular creatinin display extens matur gfr phenomenon median urin creatinin 97 mgdl mgdl 154 269 mgdl tubular matur initi wast solut urinari diuresi elimin conjug bilirubin agerel glucuronid accur interchang adequ standard utmost histor creatinin great depend jaff enzymat manufactur consequ creatinin neonat depend idmstrac creatinin introduc solv idm recalibr extens verifi urin manufactur intern commun roch diagnost standard elimin jaff display interfer endogen pseudocreatinin bilirubin exogen cefalosporin substanc enzymat prone interfer bilirubin dopamin abovement matur frequent neonat urin interfer urinari creatinin vari neonat urin 80 describ compar jaff enzymat median urinari 69 75 mgdl depend take abovement remark interchang idmstrac jaff enzymat verifi neonat urin neonat urinari creatinin idmstrac idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat compet interest\n",
            "\t0.486\tcreatin heart genet creatin creatin cardiomyocyt accumul creatin creatin transport crt fail myocardi creatin gain insight crt sever myocardi creatin creatin heart creatinefre guanidinoacet methyl transferas knock gamt overexpress myocardi crt crtoe cradiolabel creatin crt real rtpcr creatin hplc heart gamt 7fold max creatin 14fold crt cr crt complet prevent fed creatin supplement creatin subject feedback creatin crtoe 27fold consider creatin crt myocardi creatin 067 00001 endogen crt correl myocardi creatin 001 096 creatin massiv upregul magnitud upregul subject feedback crt predominantli alter  introductionmethodsmicecreatin perfus heartmrna measurementswestern blottingbiochem measurementscalcul crt revers potentialstatist analysisresultscreatin uptakecrt levelssgk1 levelscreatin levelsfre creatin transportdiscuss demand myocardium creatin atp synthes mitochondrion react creatin creatin ck adp phosphocreatin atp consum revers take place replenish atp maintain adp creatin origin dietari biosynthesi predominantli kidney cardiomyocyt synthes creatin accumul gradient na creatin cotransport crt creatin lost cardiomyocyt spontan nonenzymat convers creatinin permeabl diffus possibl efflux creatin creatin tightli creatin supplement creatin downregul creatin myocardi creatin unchang myocardi creatin cr coronari ligat myocardi creatin explain myocardi creatin crt crt crt downregul upregul creatin analogu guanidinoproprion gpa act competit crt creatin regul crt upregul glucocorticoid sgk1 xenopu oocyt express crt crt genet manipul myocardi creatin guanidinoacet methyl transferas knock gamt unabl synthes creatin fed creatinefre entir creatinefre instead accumul creatin precursor guanidinoacet ga phosphoryl ck instead creatin partial take creatin ck veloc order magnitud ga substrat overexpress crt crtoe myocardi creatin creatin creatin extrem creatin forc creatin insight creatin hypothes creatin trigger upregul creatin myocardi crt creatin quantifi crt upregul creatin heart gamt crt overexpress crt heart sgk1 candid crt regul heart gamt creatinefre gamt heart creatin massiv 7fold wt crt 14fold feed creatin supplement essenti abolish heart creatin crt creatin endogen crt creatin crt crt domin crt patho intra creatin alter crt creatin creatin feed creatin kinet unalt myocardi creatin creatin heart wt fed creatin supplement similarli creatin deplet feed creatin analogu gpa creatin g8 myoblast creatin creatin creatin creatin wherebi creatin alter crt poorli understood crt interpret caution anticrt cross react pyruv dehydrogenas crt take place sandov crt compat housekeep crt heart creatinefre gamt revers creatin feed suscept chang crt heart 7fold creatin consid extrem stimulu zero creatin alter minor crt endogen crt downregul creatin heart crtoe crt feed wt creatin supplement crt heart crt heart crtoe heart creatinefre gamt creatin gamt heart crt primarili subject posttranscript posttranscript crt modif crt put pkc close transmembran dopamin transport downregul transloc dopamin transport sarcolemma pool conceiv regul exist crt xenopu oocyt express crt coexpress sgk1 creatin sgk1 stimul crt unalt sgk1 gamt sgk1 upregul creatin heart exclud sgk1 gamt heart undetect methodolog heart overexpress crt creatin creatin crt myc interest note ventricular rv creatin crtoe heart ventricular lv creatin transgen crt myc mlc2v normal ventricl ventricular transgen mlc2v mlc2v rv explain creatin ventricl myocardium rv lv creatin rv creatin lv creatin heart creatin rv crtoe lv actual creatin rv discrep attribut heart lv creatin heart greatest ventricular creatin discrep creatin lv creatin never wt altogeth creatin exce start determin myocardi creatin crt ever oper revers creatin calcul revers creatin becom thermodynam revers heart creatin revers plateau revers creatin thermodynam unpublish consciou ecg crtoe calcul qt interv reflect take theoret revers creatin take place substanti fraction heart creatin crt revers theori hypothes heart lv transgen crt revers creatin systol act creatin dissoci lv creatin creatin heart creatin ventricl creatin gamt accumul creatin precursor guanidinoacet capabl phosphoryl creatin substrat impli gamt heart phosphoryl creatin rapidli convert instant transport keep creatin facilit creatin experi limit exclud myocardium crt residu ccreatin unlik confound min washout heart coronari effluent min washout regardless residu absolut worst underestim creatinefre heart gamt creatin transsarcolemm creatin gradient revers experi passiv diffus creatin heart creatin heart impli gradient rapidli disappear experi unlik substanti ccreatin creatin heart gamt enorm creatin creatin smaller 7fold creatin heart fed gpa heart creatin max creatin 63 remov creatin crt upregul creatin revers creatin fail worthwhil unravel signal creatin pharmacolog manipul restor myocardi creatin fail\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-4.806\tpair urinari creatinin neonat jaff enzymat idmstrac urinari creatinin quantifi jaff enzymat denomin urinari excret electrolyt pair pediatr document interassay 80 verifi interchang idmstrac jaff enzymat neonat urin neonat urinari creatinin idmstrac creatinin 84 neonat urin 46 neonat idm traceabl jaff enzymat roch diagnost coba c702 modul creatinin urinari creatinin covari explor wilcoxon blandaltman regress median jaff enzymat urinari creatinin 925 37422 915 38429 mgdl median 008 sd 06 096 mgdl regress urinari enzymat creatinin 045 postnat 059 remain adj 045 idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat urinari creatininenewbornjaffeenzymaticidm traceabl backgroundmethodsclin samplingbioanalysisstatisticsresultsdiscussionconclusionscompet interestsauthor contributionsprepubl includ glomerular filtrat gfr tubular necessit quantif urinari creatinin calcul creatinin clearanc gfr estim denomin quantifi tubular sodium potassium calcium phosphat neonat muscular creatinin display extens matur gfr phenomenon median urin creatinin 97 mgdl mgdl 154 269 mgdl tubular matur initi wast solut urinari diuresi elimin conjug bilirubin agerel glucuronid accur interchang adequ standard utmost histor creatinin great depend jaff enzymat manufactur consequ creatinin neonat depend idmstrac creatinin introduc solv idm recalibr extens verifi urin manufactur intern commun roch diagnost standard elimin jaff display interfer endogen pseudocreatinin bilirubin exogen cefalosporin substanc enzymat prone interfer bilirubin dopamin abovement matur frequent neonat urin interfer urinari creatinin vari neonat urin 80 describ compar jaff enzymat median urinari 69 75 mgdl depend take abovement remark interchang idmstrac jaff enzymat verifi neonat urin neonat urinari creatinin idmstrac idmstrac interchang heterogen neonat urin neonat urinari creatinin fold postnat compet interest\n",
            "\t-5.827\tcystatin albuminuria albuminuria glomerular filtrat gfr joint albuminuria gfr comprehens 78 gfr cystatin creatinin albumintocreatinin acr singlevoid urin 691 378 die cystatin gfr mlmin 173 creatininebas gfr mlmin 173 urin acr mgg hazard ratio 173 137 218 154 121 197 173 139 217 adjust race hypoglycem bmi cholesterol lipidlow preval cvd preval cystatin gfr urin acr addit cystatin gfr creatininebas gfr albuminuria gfr addit recommend regularli albuminuria gfr treat cvd albuminuria gfr consider cystatin  methodsmeasur diseaseascertain mortalitycovariatesstatist analysisresultsbaselin characteristicsmortalitycystatin creatininechang cystatin cystatin ccystatin albuminuriaconclusionssupplementari materialonlineonli appendix ch prospect communitybas cvd age 65 recruit commun forsyth counti north carolina sacramento counti california washington counti maryland pittsburgh pennsylvania elig sampl medicar elig list institution wheelchairbound home receiv hospic exclud origin ch 5201 enrol 1989 1990 687 predominantli african american enrol 1992 1993 urin albumin 1996 1997 includ ch 1996 1997 cystatin creatinin urin albumin 12h fast 75g load hypoglycem fast 126 mgdl 2h postchalleng 200 mgdl cystatin creatinin urin albumin 691 814 meet 85 full list princip ch investig institut httpwwwchsnhlbiorgpihtm albuminuria gfr addit gfr cystatin gfr creatinin recommend regularli albuminuria gfr sharp treat cvd albuminuria gfr consider cystatin addit prognost util albuminuria gfr demonstr suit regular complementari hong kong albuminuria gfr incid italian albuminuria gfr mlmin 173 differ italian owe particip cystatin estim gfr 53 gfr egfr cy mlmin 173 urin acr mgg nhane possibl ad gfr gfr cystatin gfr urin acr uk prospect addit support concept albuminuria gfr separ overlap complementari manifest concept emerg paradigm describ albuminuria gfr serial manifest linear albuminuria gfr reflect albuminuria reflect widespread identifi nonren bed gfr reflect nephron parenchym fibrosi cvd urem toxin abnorm albuminuria gfr cvd requir cystatin gfr modestli stronger gfr creatinin full ch cystatin gfr linearli mdrdestim gfr ushap cystatin mdrdestim gfr cystatin estim true gfr precis nearnorm cystatin suscept confound formula estim gfr cystatin cystatin formula perform differ cystatin gfr cystatin explain cystatin cystatin carri prognost longitudin avail urin acr ass glycem notabl hypoglycem reflect cumul hyperglycemia ch extrapol younger strength diver communitybas adjud cvd facilit\n",
            "\t-6.070\tvalproat creatin   introduct introduct manuscript valproat unusu creatin metabolit explain defect primarili affect creatin biosynthesi ammonia creatin precursor glycin arginin organ priori rule defect secondarili affect creatin etiolog origin valproat conclud abnorm combin elev urinari creatin guanidinoacet coher valproat metabolit 16yearold boy born consanguin parent perinat asphyxia ill age psychomotor delay gener tonic clonic seizur partial valproat mgkgday clonazepam 006 mgkgday facial dysmorph axial hypotonia spastic tetraparesi languag retard gener dystonia mri cerebellar hypoplasia auditori evok electromyographi urinari organ ammonemia karyotyp aminoacid redox coupl lactat pyruv 589 0339 mmoll lactatepyruv urin creatin guanidinoacet abnorm 734 molmmol creatinin 684 molmmol creatinin corrobor disturb creatin metabolit unusu partial differ creatin agat gamt slc6a8 defici exclud anapleuresi arginin glycin creatin biosynthesi etiolog search rise guanidinometabolit point toward link valproat creatin highlight valproat autism valproat hyperammonemia turn ammonia creatin defici valproat creatin besid ammoniabas guanidinobutyratebas link rest drugdriven gammaaminobutyr avail yield guanidinobutyr creatineform guanidinoacet methyltransferas transport slc6a8 recoveri guanidinoacet guanidinoacet methyltransferas creatin util urin concurr slc6a8 emphas creatin oper valproat abnorm creatin guanidinoacet suggest creatin defici metabolit unusu valproat valproat creatin coher urinari guanidinoacet creatin \n",
            "urinary retention,Prostate-specific antigen,Creatinine None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.425\tiron sclerosi noninvas map iron sclerosi m iron accumul myeloid bloodbrain barrier bbb seal eventu neurodegener magnet reson mri wellestablish noninvas m mri map qsm iron immunohistochem investig help defin lesion iron m m histolog insight iron neurodegener m m lesionquantit map qsmdeep grey matter dgmmri introduction2 iron methods21 exvivo iron measurement211 qualit iron histology212 iron spectrometr techniques22 iron measurement221 qualit mri methods222 semiquantit mri methods23 map qsm3 iron brains4 iron sclerosis41 iron white matter m lesions42 iron cortic m lesions43 iron appear white matter nawm44 iron deep gray matter m patients5 investig iron ms51 exvivo iron ms511 immunohistochem ihc iron m 52 invivo iron ms521 qualit iron mri contrasts522 semiquantit iron mri contrasts53 map qsm531 shell solid 532 m lesion 533 qsm r2 detect m basal ganglion 534 qsm laser ablat induct coupl spectrometri laicpm immunohistochem ihc label myelin basic mbp myeloid cd68 535 iron white matter lesion unequivoc qsm6 ad qsm m mri protocol monitoring7 conclus iron electron facilit myelin neurotransmitt excess iron invari neurodegen alzheim amyotroph later sclerosi parkinson sclerosi m nervou neurodegen iron accumul deep grey matter dgm nucleus m white matter wm quantifi iron m noninvas magnet reson mri magnet iron mri detect measur iron bloom artifact nonloc magnet map qsm fieldtosourc deconvolut iron quantif overcom bloom artefact mri iron progress iron map mri contribut iron m pathophysiolog iron homeostasi m profoundli perturb ironoverload lesion myeloid deep nucleus diminish iron nawm cortic shift lowgrad neurodegener qsm iron monitor m ironsensit aid decis clinic radiograph ironposit microglia acceler resolut iron lowgrad\n",
            "\t0.396\tcontribut lactic acidif tumour variant lack lactat dehydrogenas solid tumour acid lactic lactic glycolysi assum acid lactat dehydrogenas ldhdefici rastransfect chine hamster ovarian undertaken address lactic acidif variant neglig quantiti lactic consum amount parent lactateproduc parent acidifi lightlybuff medium variant tumour parent variant implant nude phe 703 003 703 005 phe 743 003 0001 lactic variant tumour 450 90 microg g1 wet parent tumour 1880 140 microgg1 400 microgg1 discord phe lactat tumour newel 1993 lactic glycolysi acidif medium acid solid tumour    \n",
            "\t0.378\tiron ferritin transferrin predict intracerebr hemorrhag highserum ferritin iron detriment intracerebr hemorrhag ich iron ferritin transferrin tf ceruloplasmin cp ich admiss 75 hematoma edema volum ichpati admiss modifi rankin mr 59 41 90 ferritin iron tf markedli pooroutcom correspond goodoutcom ferritin edema hematoma iron tf hematoma conclud ferritin iron tf hematoma  resultsbaselin characteristicschang iron ferritin transferrin ceruloplasmin ich patientsgener tendencyiron transferrin ferritin ceruloplasmin ich goodoutcomeeffect intraventricular hemorrhag hematoma volum content iron ferritin transferrin ceruloplasmin serumcorrel analysisrel edema iron ferritin tf cp contentshematoma iron ferritin tf cp contentsserum iron ferritin cp tf ferritin tf contentsdiscussionconclusionsmethodssubjectsdata collectionradiolog measurementslaboratori determinationsevalu outcomestatist analysisaddit  analyz ich iron ironhandl ferritin tf cp biomark iron ich firstli platelet deep locat hematoma subtentori hematoma intraventricular extens hemorrhag secondli ferritin content hematoma edema predict ich thirdli impli ferritin iron tf hematoma ich fourthli intraventricular hemorrhag hematoma volum content iron ferritin tf cp ich cp ich cp unlik ich ich hepcidin\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.461\tiron defici anemia present congenit diaphragmat hernia toddler    editor 3yearold toddler refer pediatr emerg unit 2week fatigu anorexia progress pallor vomit iron defici anemia ironsulf intermitt vomit seem adequ ironrich food chest xray abdomin ultrasonograph center count follow hb gdl wbc count 80 anc 46 hct 69 rbc count 119 rdw 205 mcv 58 fl plt count 485 absolut reticulocyt count 455 50150 smear hypochrom microcyt red polychromasia nucleat red iron gdl iron 450 gdl ferritin ngml hospit pack red transfus suddenli distress breakfast chest xray radioluc lesion paracardiac congenit diaphragmat hernia cdh barium gastrointestin xray comput tomographi chest retrostern diaphragmat hernia sack excis stomach intestin transvers colon abdomin caviti nissen fundopl effort postop gastroesophag reflux defect note posterolater diaphragm defect repair thal anterior fundopl morgagni bochdalek defect post gastrointestin hb drop 79 gdl fecal occult hct 256 rbc count 363 mcv 705 fl mch 219 mchc 31 rdw wbc count 98 anc 43 plt count 453 absolut reticulocyt count smear hypochrom microcyt red esophagogastroduodenoscopi esophag biopsi eros gastroesophag reflux hyperplasia epithelium proton pump domperidon antiacid start iron sucros administ twice weekli hb hb 122 gdl htc 346 rbc count 476 mcv 72fl mch 256 mchc 351 rdw 174 wbc count 122 anc 82 plt count 348 absolut reticulocyt count 85 ferritin ngml smear red 2year gastrointestin anemia coexist morgagni bochdalek defect rare 530 cdh neonat pose vomit distress intermitt sometim volvulu spontan hernia abdomen asymptomat period abdomin ultrasound chest xray referr depart occult gastrointestin tract reflux esophag mechan trauma diaphragm sinaki monthold 6yearold gastrointestin hb 58 gdl gdl zaki 5yearold persist anemia respond adequ hematin transfus abdomin melena hb 48 gdl linear eros mucos fold lesser curv stomach cdh iron defici anemia obviou nutrit defici melena hematochezia malabsorpt awar intermitt vomit sudden distress indic upper gastrointestin tract thorax \n",
            "\t-5.609\tcalibr myocardi t2 t1 iron myocardi iron t2 magnet reson cmr valid calibr ass relax t1 t2 myocardi iron twelv heart transfusiondepend endstag transplant die iron load exvivo r1 r2 r1 1t1 r2 1t2 tesla myocardi iron induct coupl atom emiss spectroscopi myocardi slice formalin repeatedli modest t2 sd 237 093 m formalin fixat 185 141 m 566 0001 raw t2 adjust correct fall myocardi r2 iron fe 0566 0001 stronger lnr2 lnfe 0790 0001 relat fe 5081 t2 222 t2 m myocardi iron mgg dri t1 prove challeng dichotom t1 t1 723 258 m iron heart store formalin remain heart store scan lnr1 iron mark scatter 0517 0001 linear t1 t2 heart store 0657 0001 myocardi t2 correl myocardi iron rais t2 addit t2 myocardi siderosi exvivo t1 reliabl formalin t1 shorten t1 calibr practic invivo magnet resonanceheartiron overloadsiderosisthalassaemia backgroundmethodsstudi patientsstudi protocoleffect formalin relaxationmyocardi iron measurementstatisticsresultspati detailscomparison exvivo cmr iront1 measurementeffect formalin relaxationt2 measurementrel t2 t1discussionissu affect calibrationlimitationsconclusionscompet interestsauthor contribut iron transfusiondepend anaemia beta thalassaemia tm siderosi myocardi prevent revers modern chelat regim magnet reson cmr myocardi iron overload preclin iron load correl poorli myocardi iron ventricular siderosi myocardi iron overload t2 cmr prove reliabl reproduc clinic viabl measur myocardi iron load calibr myocardi iron predict t2 superior indic ferritin iron ventricular eject fraction doppler echocardiograph endomyocardi biopsi routin substanti death t2 particul iron relax t2 t1 shorten inhomogen magnet faster proton dephas t2 accur iron load give impress hepat fibrosi t1 t2 map relat t1 t2 iron extend myocardi iron mr relax t1 t2 biochem iron myocardi t2 correl iron logarithm fit t2 noniron load formalin fix t2 myocardium establish myocardi t2 addit t2 myocardi siderosi regard iron speciat iron mishandl exvivo t1 reliabl calibr t1 iron take invivo t1 t2 t2 calibr compet interest\n",
            "\t-5.668\tiron milk preterm term mother enugu urban assum preterm babi malnourish micronutri supplement iron compar iron milk mother preterm term babi nineti 96 lactat mother deliv babi term 68 lactat mother preterm deliveri recruit mother attend postnat clinic tertiari healthcar facil enugu milk iron atom absorpt spectrophotomet iron preterm term milk statist 3906 1078 3279 1417 moll 002 milk iron gradual lactat progress 00001 iron milk mother preterm babi mother term babi needle introduc exogen iron lactat iron concentrationbreast milkpreterm mothersterm mothersinf introductionsubject methodssubjectsmethodsbreast milk collectionsampl analysisstatist analysisresultsdiscuss organ american academi paediatr aap unequivoc recommend breastfeed ideal nutrit infant optim milk composit fluid load nutrient nonnutrit bioactiv nutrient newborn babi milk nonnutrit infant protect infant allergi preterm milk refer milk mother deliv babi 37 th week gestat term milk babi deliv term 37 th week gestat exist nutrient preterm term milk babi perfect nutrient milk iron replenish nutrit store iron conjunct zinc copper selenium fluorin miner element miik iron milk bound make babi prevent harm ecoli salmonella clostridium bacteroid escherichia staphylococcu utilis cow milk infant formula contain iron milk milk iron absorb effici babi milk uniform constitu lactat differ mother regul milk iron lactoferrin incomplet understood adequaci milk maintain optimum iron breastf babi iron preterm term milk remain controversi concern exclus breastf infant iron defici recommend advoc research recommend drop iron breastf infant birth weight 2500 3000 recommend breastf infant supplement iron iron mother milk vital optim newborn babi term preterm preterm uncommon wild spread suggest routin micronutri supplement iron rule parent preterm babi panic administ iron supplement supposit arbitrari import nigerian market numer vari micronutri composit regrett diminut term preterm milk iron consequ formul unscientif assumpt strang peculiar socioeconom situat purpos establish iron compar iron preterm term milk mother lactat milk ultim nutrit infant offer requir newborn eat digest food dilemma iron nutrit imbal truli issu infant lactat mother correct imbal vulner involv iron nutrit milk incongru capabl milk sustain optim iron breastf babi adequaci iron preterm milk disput milk iron preterm mother gave birth term milk iron preterm mother milk iron preterm term success lactat concord state full term infant ampl iron store birth enough ration possibl iron store preterm babi compens mother milk iron transfer preterm foetu trimest retain mother excret milk iron preterm term exclus breastfeed ebf adequ preterm term babi infant purpos iron nutrient indiscrimin iron supplement preterm babi discontinu avoid overload serv determin iron requir neonat iron supplement exclud iron food eaten hour longitudin address shortcom milk mother give birth preterm babi iron lactat mother term babi preterm babi iron supplement\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.425\tiron sclerosi noninvas map iron sclerosi m iron accumul myeloid bloodbrain barrier bbb seal eventu neurodegener magnet reson mri wellestablish noninvas m mri map qsm iron immunohistochem investig help defin lesion iron m m histolog insight iron neurodegener m m lesionquantit map qsmdeep grey matter dgmmri introduction2 iron methods21 exvivo iron measurement211 qualit iron histology212 iron spectrometr techniques22 iron measurement221 qualit mri methods222 semiquantit mri methods23 map qsm3 iron brains4 iron sclerosis41 iron white matter m lesions42 iron cortic m lesions43 iron appear white matter nawm44 iron deep gray matter m patients5 investig iron ms51 exvivo iron ms511 immunohistochem ihc iron m 52 invivo iron ms521 qualit iron mri contrasts522 semiquantit iron mri contrasts53 map qsm531 shell solid 532 m lesion 533 qsm r2 detect m basal ganglion 534 qsm laser ablat induct coupl spectrometri laicpm immunohistochem ihc label myelin basic mbp myeloid cd68 535 iron white matter lesion unequivoc qsm6 ad qsm m mri protocol monitoring7 conclus iron electron facilit myelin neurotransmitt excess iron invari neurodegen alzheim amyotroph later sclerosi parkinson sclerosi m nervou neurodegen iron accumul deep grey matter dgm nucleus m white matter wm quantifi iron m noninvas magnet reson mri magnet iron mri detect measur iron bloom artifact nonloc magnet map qsm fieldtosourc deconvolut iron quantif overcom bloom artefact mri iron progress iron map mri contribut iron m pathophysiolog iron homeostasi m profoundli perturb ironoverload lesion myeloid deep nucleus diminish iron nawm cortic shift lowgrad neurodegener qsm iron monitor m ironsensit aid decis clinic radiograph ironposit microglia acceler resolut iron lowgrad\n",
            "\t0.396\tcontribut lactic acidif tumour variant lack lactat dehydrogenas solid tumour acid lactic lactic glycolysi assum acid lactat dehydrogenas ldhdefici rastransfect chine hamster ovarian undertaken address lactic acidif variant neglig quantiti lactic consum amount parent lactateproduc parent acidifi lightlybuff medium variant tumour parent variant implant nude phe 703 003 703 005 phe 743 003 0001 lactic variant tumour 450 90 microg g1 wet parent tumour 1880 140 microgg1 400 microgg1 discord phe lactat tumour newel 1993 lactic glycolysi acidif medium acid solid tumour    \n",
            "\t0.378\tiron ferritin transferrin predict intracerebr hemorrhag highserum ferritin iron detriment intracerebr hemorrhag ich iron ferritin transferrin tf ceruloplasmin cp ich admiss 75 hematoma edema volum ichpati admiss modifi rankin mr 59 41 90 ferritin iron tf markedli pooroutcom correspond goodoutcom ferritin edema hematoma iron tf hematoma conclud ferritin iron tf hematoma  resultsbaselin characteristicschang iron ferritin transferrin ceruloplasmin ich patientsgener tendencyiron transferrin ferritin ceruloplasmin ich goodoutcomeeffect intraventricular hemorrhag hematoma volum content iron ferritin transferrin ceruloplasmin serumcorrel analysisrel edema iron ferritin tf cp contentshematoma iron ferritin tf cp contentsserum iron ferritin cp tf ferritin tf contentsdiscussionconclusionsmethodssubjectsdata collectionradiolog measurementslaboratori determinationsevalu outcomestatist analysisaddit  analyz ich iron ironhandl ferritin tf cp biomark iron ich firstli platelet deep locat hematoma subtentori hematoma intraventricular extens hemorrhag secondli ferritin content hematoma edema predict ich thirdli impli ferritin iron tf hematoma ich fourthli intraventricular hemorrhag hematoma volum content iron ferritin tf cp ich cp ich cp unlik ich ich hepcidin\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-5.461\tiron defici anemia present congenit diaphragmat hernia toddler    editor 3yearold toddler refer pediatr emerg unit 2week fatigu anorexia progress pallor vomit iron defici anemia ironsulf intermitt vomit seem adequ ironrich food chest xray abdomin ultrasonograph center count follow hb gdl wbc count 80 anc 46 hct 69 rbc count 119 rdw 205 mcv 58 fl plt count 485 absolut reticulocyt count 455 50150 smear hypochrom microcyt red polychromasia nucleat red iron gdl iron 450 gdl ferritin ngml hospit pack red transfus suddenli distress breakfast chest xray radioluc lesion paracardiac congenit diaphragmat hernia cdh barium gastrointestin xray comput tomographi chest retrostern diaphragmat hernia sack excis stomach intestin transvers colon abdomin caviti nissen fundopl effort postop gastroesophag reflux defect note posterolater diaphragm defect repair thal anterior fundopl morgagni bochdalek defect post gastrointestin hb drop 79 gdl fecal occult hct 256 rbc count 363 mcv 705 fl mch 219 mchc 31 rdw wbc count 98 anc 43 plt count 453 absolut reticulocyt count smear hypochrom microcyt red esophagogastroduodenoscopi esophag biopsi eros gastroesophag reflux hyperplasia epithelium proton pump domperidon antiacid start iron sucros administ twice weekli hb hb 122 gdl htc 346 rbc count 476 mcv 72fl mch 256 mchc 351 rdw 174 wbc count 122 anc 82 plt count 348 absolut reticulocyt count 85 ferritin ngml smear red 2year gastrointestin anemia coexist morgagni bochdalek defect rare 530 cdh neonat pose vomit distress intermitt sometim volvulu spontan hernia abdomen asymptomat period abdomin ultrasound chest xray referr depart occult gastrointestin tract reflux esophag mechan trauma diaphragm sinaki monthold 6yearold gastrointestin hb 58 gdl gdl zaki 5yearold persist anemia respond adequ hematin transfus abdomin melena hb 48 gdl linear eros mucos fold lesser curv stomach cdh iron defici anemia obviou nutrit defici melena hematochezia malabsorpt awar intermitt vomit sudden distress indic upper gastrointestin tract thorax \n",
            "\t-5.609\tcalibr myocardi t2 t1 iron myocardi iron t2 magnet reson cmr valid calibr ass relax t1 t2 myocardi iron twelv heart transfusiondepend endstag transplant die iron load exvivo r1 r2 r1 1t1 r2 1t2 tesla myocardi iron induct coupl atom emiss spectroscopi myocardi slice formalin repeatedli modest t2 sd 237 093 m formalin fixat 185 141 m 566 0001 raw t2 adjust correct fall myocardi r2 iron fe 0566 0001 stronger lnr2 lnfe 0790 0001 relat fe 5081 t2 222 t2 m myocardi iron mgg dri t1 prove challeng dichotom t1 t1 723 258 m iron heart store formalin remain heart store scan lnr1 iron mark scatter 0517 0001 linear t1 t2 heart store 0657 0001 myocardi t2 correl myocardi iron rais t2 addit t2 myocardi siderosi exvivo t1 reliabl formalin t1 shorten t1 calibr practic invivo magnet resonanceheartiron overloadsiderosisthalassaemia backgroundmethodsstudi patientsstudi protocoleffect formalin relaxationmyocardi iron measurementstatisticsresultspati detailscomparison exvivo cmr iront1 measurementeffect formalin relaxationt2 measurementrel t2 t1discussionissu affect calibrationlimitationsconclusionscompet interestsauthor contribut iron transfusiondepend anaemia beta thalassaemia tm siderosi myocardi prevent revers modern chelat regim magnet reson cmr myocardi iron overload preclin iron load correl poorli myocardi iron ventricular siderosi myocardi iron overload t2 cmr prove reliabl reproduc clinic viabl measur myocardi iron load calibr myocardi iron predict t2 superior indic ferritin iron ventricular eject fraction doppler echocardiograph endomyocardi biopsi routin substanti death t2 particul iron relax t2 t1 shorten inhomogen magnet faster proton dephas t2 accur iron load give impress hepat fibrosi t1 t2 map relat t1 t2 iron extend myocardi iron mr relax t1 t2 biochem iron myocardi t2 correl iron logarithm fit t2 noniron load formalin fix t2 myocardium establish myocardi t2 addit t2 myocardi siderosi regard iron speciat iron mishandl exvivo t1 reliabl calibr t1 iron take invivo t1 t2 t2 calibr compet interest\n",
            "\t-5.668\tiron milk preterm term mother enugu urban assum preterm babi malnourish micronutri supplement iron compar iron milk mother preterm term babi nineti 96 lactat mother deliv babi term 68 lactat mother preterm deliveri recruit mother attend postnat clinic tertiari healthcar facil enugu milk iron atom absorpt spectrophotomet iron preterm term milk statist 3906 1078 3279 1417 moll 002 milk iron gradual lactat progress 00001 iron milk mother preterm babi mother term babi needle introduc exogen iron lactat iron concentrationbreast milkpreterm mothersterm mothersinf introductionsubject methodssubjectsmethodsbreast milk collectionsampl analysisstatist analysisresultsdiscuss organ american academi paediatr aap unequivoc recommend breastfeed ideal nutrit infant optim milk composit fluid load nutrient nonnutrit bioactiv nutrient newborn babi milk nonnutrit infant protect infant allergi preterm milk refer milk mother deliv babi 37 th week gestat term milk babi deliv term 37 th week gestat exist nutrient preterm term milk babi perfect nutrient milk iron replenish nutrit store iron conjunct zinc copper selenium fluorin miner element miik iron milk bound make babi prevent harm ecoli salmonella clostridium bacteroid escherichia staphylococcu utilis cow milk infant formula contain iron milk milk iron absorb effici babi milk uniform constitu lactat differ mother regul milk iron lactoferrin incomplet understood adequaci milk maintain optimum iron breastf babi iron preterm term milk remain controversi concern exclus breastf infant iron defici recommend advoc research recommend drop iron breastf infant birth weight 2500 3000 recommend breastf infant supplement iron iron mother milk vital optim newborn babi term preterm preterm uncommon wild spread suggest routin micronutri supplement iron rule parent preterm babi panic administ iron supplement supposit arbitrari import nigerian market numer vari micronutri composit regrett diminut term preterm milk iron consequ formul unscientif assumpt strang peculiar socioeconom situat purpos establish iron compar iron preterm term milk mother lactat milk ultim nutrit infant offer requir newborn eat digest food dilemma iron nutrit imbal truli issu infant lactat mother correct imbal vulner involv iron nutrit milk incongru capabl milk sustain optim iron breastf babi adequaci iron preterm milk disput milk iron preterm mother gave birth term milk iron preterm mother milk iron preterm term success lactat concord state full term infant ampl iron store birth enough ration possibl iron store preterm babi compens mother milk iron transfer preterm foetu trimest retain mother excret milk iron preterm term exclus breastfeed ebf adequ preterm term babi infant purpos iron nutrient indiscrimin iron supplement preterm babi discontinu avoid overload serv determin iron requir neonat iron supplement exclud iron food eaten hour longitudin address shortcom milk mother give birth preterm babi iron lactat mother term babi preterm babi iron supplement\n",
            "breast cancer,HER2,iron None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.391\tinhal sodium cromoglyc treat cough cfibr final ace neoplast cough inhal sodium cromoglyc ace cough suppress affer unmyelin cfibr inhal sodium cromoglyc irrit neoplast cough twenti nonsmallcel nsclc complain cough resist randomis receiv doubleblind inhal sodium cromoglyc placebo record cough mannwhitney utest nonparametr compar intergroup summari calcul inhal sodium cromoglyc cough nsclc statist 0001 inhal sodium cromoglyc costeffect safe cancerrel cough    \n",
            "\t0.388\tehmti0057 anxieti migrain relat headach   introductionaimsmethodsresultsconclus evid anxieti preval headach hit6 valid reliabl questionnair evalu spectrum headach burden anxieti had valid reliabl psycholog anxieti 794 444 migrain depress migraineur express headach nondepress migaineur headach depress nondepress relat anxieti conflict\n",
            "\t0.386\tesophag mellitu esophag motil disturb diabet preval neuropathi autonom neuropathi usual amplitud esophag contract smooth portion frequent peristalsi simultan repetit contract veloc peristalsi radiograph manifest delay esophag empti dysphagia chest thoroughli ascrib candidiasi diabet    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-6.496\tglucosedepend insulinotrop polypeptid depend glucosedepend insulinotrop polypeptid gip glucagon sem age bmi kgm hba 1c 55 01 salin dose gip administ intraven random doubl blind 90 min insulininduc hypoglycemia euglycemia hyperglycemia hypoglycemia gip infus glucagon min salin 76 pmoll min 0008 peak glucagon reach min euglycemia gip infus elicit glucagon 62 pmoll 90 min 0005 hyperglycemia compar suppress glucagon 461 81 371 pmoll 90 min 026 gip salin infus hyperglycemia gip doubl 00001 gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip bifunct stabil diverg glucosedepend pancreat glucoregulatori hormon  methodsstudi protocolsubjectsdesign studypeptidesblood specimensanalyt proceduresstatist calculationsresultsglucosegipinsulin isrglucagondiscuss  action gip pancreat hormon glycem gip invert glucosedepend glucagon gip exhibit glucagonotrop fast hypoglycem exert hormon gip glucagon hyperglycemia robustli potenti glucoseinduc controversi exist glucagonotrop gip hyperglycem clamp glucagon glucagon earliest accord reexamin origin vilsb ll shortdur gip infus min glycem mmoll actual gave rise glucagon salin stepwis mmoll mmoll glucagon increasingli suppress nonsignific glucagon gip salin origin public collect glycem threshold 55 mmoll exist gip exert glucagonotrop action illustr bifunct glucosedepend gip pg interv mmoll bear resembl perfus pancrea pederson brown ago glucagon cpeptid relat glucagon dark blue curv squar cpeptid blue curv circl pg mmoll stimul gip broken fill symbol basal full symbol sem 005 pair glucagonotrop insulinotrop gip seem constitut preserv rodent alik relev dual hormon regul gip elucid gip physiolog interest respect note gip stimul depend ingest postprandi circumst alway alongsid coincretin glucagonlik glp1 glucosedepend insulinotrop hormon glp1 gip wellestablish suppress glucagon seemingli capabl hypoglycemia discern gip robustli rodent canin gip obes highfat diet relev gip elus 29 nervou reli hypothes gip glucagonotrop buffer reactiv hypoglycemia meal buffer compat gip anabol hormon adipos 29 regard pancreat islet hormon interest gip euglycemia glucagon concurr hyperinsulinem hypoglycemia glucagon min gip concomit presum pancreat intraislet wellknown paracrin amylin aminobutyr zinc ion etc director glucagon refer intraislet 31 domin gip glucagon presum pancreat secret neighbor euglycemia hypoglycemia demonstr suppress glucagon gip infus hyperglycemia depend concurr rise drawn cpeptid intraven arginin paracrin intraislet prevail glycemia glucagon consequ parallel glucagon euglycem slight lower pg probabl consequ nonhepat circumst certainli exclud buffer glucagon hepat excurs toward hypoglycemia pg complet superimpos gip salin nonphysiolog hyperinsulinemia inher clamp stimul glucagon min modifi downwardslop pg curv hyperinsulinem clamp glucagon concomit gip infus pg 55 mmoll maxim glucagon reach lowest pg gip salin maxim glucagon hypoglycemia autonom nervou clinic sweat glucagonotrop gip pathophysiolog consequ excess glucagon weigh postprandi fast determin hyperglycemia evid hyperglucagonemia sole explain intriguingli insulinotrop gip sever defici glucagonotrop gip ad mismatch insulintoglucagon maxim glucagon gip salin euglycemia amount pmoll relev insuffici oppos support pmoll fast glucagon 33 notion gip infus supraphysiolog dose worsen postprandi hyperglycemia 34 antagon glucagonsuppress glp1 36 gip glucagon hypoglycemia dipeptidyl peptidase4 vildagliptin 37 gip safeguard hypoglycemia pathophysiolog implic explor glucosedepend glucagonotrop gip gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip pancreat islet regul diverg pancreat glucoregulatori hormon glucagon\n",
            "\t-7.453\tglycaem cholesterol 629 diabet compar t2dm achiev haemoglobin 1c hba 1c bp ldl cholesterol ldlc databas medlin ovid pubm sabinet mellitu guidelin goal achiev 2014 629 hba 1c 70 445 192 705 352 74 663 bp 13080 mmhg 514 200 829 ldlc mmoll mgdl guidelin recommend lower hba 1c bp lipid t2dm morbid suboptim set mellitusguidelinesgo achiev objectivemethodsresultsstudi characteristicsdiscussionstudi limitationsconclus mellitu dm progress morbid prematur econom burden healthcar intern feder idf 366 million live 2035 half billion trend urbanis adopt unhealthi western lifestyl begun middleincom lmic prime south africa dubiou pleasur infecti today expans noncommunic ncd begin manifest deplet strain resourc glycaemia mellitu t2dm includ prioriti modifi accept t2dm cvd lifestyl lowdens lipoprotein cholesterol ldlc bp goal cvd t2dm diabetesrel microvascular retinopathi neuropathi nephropathi substanti reduct hyperglycaemia societi endocrinolog south africa semdsa recommend hba 1c 70 bp 14080 mmhg ldlc mmoll gap t2dm prove close differ t2dm reach guidelinerecommend way compar set compar achiev indic glycaem bp t2dm worldwid attempt benchmark success t2dm inadequ differ healthcar set substanti room t2dm manag effort multidisciplinari guidelin adher delay diabetesrel\n",
            "\t-7.458\tpdk1 myeloma utilis glycolyt adequ phenomenon warburg oper myeloma glycolysi modal purifi 59 cd138immunomagnet bead glycolysi cmyc glut1 ldha hif1a pyruv dehydrogenas kinase1 pdk1 realtim lactat analys oxam ldh dichloroacet dca pdk1 employ pdk1 sirna ldha indic posit pdk1 cmyc glut1 lactat ldha glycolysi oxam dca pdk1 sirna dca bortezomib addit cytotox warburg oper pdk1 overexpress pdk1 serv myelomaglycolysispdk1apoptosi methodscel culturepati samplescdna realtim pcrglycolysi inhibitorsmeasur concentrationldh assaymeasur lactat productionwestern blottinganalysi apoptosisevalu reactiv rosrna interfer experimentsstatist analysisresultsexpress glycolysisrel myeloma cellsanalysi glycolysi linesinduct ldha oxamateinduct pdk1 dcadiscuss  ldha ldh ldh prognost barlogi 1989 ldha ldh median 1559 331 001 pdk1 cmyc glut1 hif1a serv prognost ldha prognost s2 microarray databas refer tt2 ncbi gse2658 zhan margin possibl intens s3 subgroup tt2 classifi profil cd2 ldha s4 zhan cd2 longest ldha lowrisk myeloma classifi subgroup maf mmset ccnd1 frzb testi antigen moreaux subgroup s5 reflect somewhat uniform background extra medullar aggress ldh glycolyt convert pyruv lactat ldha glycolyt ldha glycolyt lactat signific ldh glycolyt prognost glycolysi interest issu myeloma accumul abnorm mgu kord zingon kuehl ldha mgu ldha myc mgu shou gabrea chng myc 67 rare mgu chng shou dysregul cmyc princip rearrang myc event myc interferon factor4 irf4 oncogen shaffer glycolysi ldha hk pdk1 irf4target shaffer aerob glycolysi upregul mgu possibl myc regard toward glycolyt reason smallmolecul ldha fx11 trigger necrot le ldha elev nadhnad ro ldha lactat xie le ldha fantin oxam competit ldh activ caspase3 ldh glycolysi modal ldh dichloroacet pdk bind ntermin pdk2 decreas pdk1 kato posse anticanc induc arrest depolaris hyperpolar inner michelaki wong madhok sun tong dca bioavail encourag nonsmal michelaki porporato select pdk1 azd7545 undergo kato pdk1 myeloma haematopoiet lineag shaffer jourdan pdk1 suitabl ldh basic exist kind pdk1 jourdan web atla httpamazoniatranscriptomeeu carrour dca ro pdk1 ro caspase3 pdk1 molecul myeloma bortezomib wellknown proteasom antimyeloma nf cytokin angiogenesi hideshima hideshima bortezomib bortezomib therapi glycolyt anticanc synergist additiveeffect zhou fium tong addit dca bortezomib accompani caspase3 ro dichloroacet bortezomibresist dosedepend addit dca bortezomib bortezomibresist pdk1 sensitis bortezomibresist bortezomib glycolysi pdk1 ldh\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.391\tinhal sodium cromoglyc treat cough cfibr final ace neoplast cough inhal sodium cromoglyc ace cough suppress affer unmyelin cfibr inhal sodium cromoglyc irrit neoplast cough twenti nonsmallcel nsclc complain cough resist randomis receiv doubleblind inhal sodium cromoglyc placebo record cough mannwhitney utest nonparametr compar intergroup summari calcul inhal sodium cromoglyc cough nsclc statist 0001 inhal sodium cromoglyc costeffect safe cancerrel cough    \n",
            "\t0.388\tehmti0057 anxieti migrain relat headach   introductionaimsmethodsresultsconclus evid anxieti preval headach hit6 valid reliabl questionnair evalu spectrum headach burden anxieti had valid reliabl psycholog anxieti 794 444 migrain depress migraineur express headach nondepress migaineur headach depress nondepress relat anxieti conflict\n",
            "\t0.386\tesophag mellitu esophag motil disturb diabet preval neuropathi autonom neuropathi usual amplitud esophag contract smooth portion frequent peristalsi simultan repetit contract veloc peristalsi radiograph manifest delay esophag empti dysphagia chest thoroughli ascrib candidiasi diabet    \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-6.496\tglucosedepend insulinotrop polypeptid depend glucosedepend insulinotrop polypeptid gip glucagon sem age bmi kgm hba 1c 55 01 salin dose gip administ intraven random doubl blind 90 min insulininduc hypoglycemia euglycemia hyperglycemia hypoglycemia gip infus glucagon min salin 76 pmoll min 0008 peak glucagon reach min euglycemia gip infus elicit glucagon 62 pmoll 90 min 0005 hyperglycemia compar suppress glucagon 461 81 371 pmoll 90 min 026 gip salin infus hyperglycemia gip doubl 00001 gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip bifunct stabil diverg glucosedepend pancreat glucoregulatori hormon  methodsstudi protocolsubjectsdesign studypeptidesblood specimensanalyt proceduresstatist calculationsresultsglucosegipinsulin isrglucagondiscuss  action gip pancreat hormon glycem gip invert glucosedepend glucagon gip exhibit glucagonotrop fast hypoglycem exert hormon gip glucagon hyperglycemia robustli potenti glucoseinduc controversi exist glucagonotrop gip hyperglycem clamp glucagon glucagon earliest accord reexamin origin vilsb ll shortdur gip infus min glycem mmoll actual gave rise glucagon salin stepwis mmoll mmoll glucagon increasingli suppress nonsignific glucagon gip salin origin public collect glycem threshold 55 mmoll exist gip exert glucagonotrop action illustr bifunct glucosedepend gip pg interv mmoll bear resembl perfus pancrea pederson brown ago glucagon cpeptid relat glucagon dark blue curv squar cpeptid blue curv circl pg mmoll stimul gip broken fill symbol basal full symbol sem 005 pair glucagonotrop insulinotrop gip seem constitut preserv rodent alik relev dual hormon regul gip elucid gip physiolog interest respect note gip stimul depend ingest postprandi circumst alway alongsid coincretin glucagonlik glp1 glucosedepend insulinotrop hormon glp1 gip wellestablish suppress glucagon seemingli capabl hypoglycemia discern gip robustli rodent canin gip obes highfat diet relev gip elus 29 nervou reli hypothes gip glucagonotrop buffer reactiv hypoglycemia meal buffer compat gip anabol hormon adipos 29 regard pancreat islet hormon interest gip euglycemia glucagon concurr hyperinsulinem hypoglycemia glucagon min gip concomit presum pancreat intraislet wellknown paracrin amylin aminobutyr zinc ion etc director glucagon refer intraislet 31 domin gip glucagon presum pancreat secret neighbor euglycemia hypoglycemia demonstr suppress glucagon gip infus hyperglycemia depend concurr rise drawn cpeptid intraven arginin paracrin intraislet prevail glycemia glucagon consequ parallel glucagon euglycem slight lower pg probabl consequ nonhepat circumst certainli exclud buffer glucagon hepat excurs toward hypoglycemia pg complet superimpos gip salin nonphysiolog hyperinsulinemia inher clamp stimul glucagon min modifi downwardslop pg curv hyperinsulinem clamp glucagon concomit gip infus pg 55 mmoll maxim glucagon reach lowest pg gip salin maxim glucagon hypoglycemia autonom nervou clinic sweat glucagonotrop gip pathophysiolog consequ excess glucagon weigh postprandi fast determin hyperglycemia evid hyperglucagonemia sole explain intriguingli insulinotrop gip sever defici glucagonotrop gip ad mismatch insulintoglucagon maxim glucagon gip salin euglycemia amount pmoll relev insuffici oppos support pmoll fast glucagon 33 notion gip infus supraphysiolog dose worsen postprandi hyperglycemia 34 antagon glucagonsuppress glp1 36 gip glucagon hypoglycemia dipeptidyl peptidase4 vildagliptin 37 gip safeguard hypoglycemia pathophysiolog implic explor glucosedepend glucagonotrop gip gip glucagon hyperglycemia potenti gip glucagon fast hypoglycem gip pancreat islet regul diverg pancreat glucoregulatori hormon glucagon\n",
            "\t-7.453\tglycaem cholesterol 629 diabet compar t2dm achiev haemoglobin 1c hba 1c bp ldl cholesterol ldlc databas medlin ovid pubm sabinet mellitu guidelin goal achiev 2014 629 hba 1c 70 445 192 705 352 74 663 bp 13080 mmhg 514 200 829 ldlc mmoll mgdl guidelin recommend lower hba 1c bp lipid t2dm morbid suboptim set mellitusguidelinesgo achiev objectivemethodsresultsstudi characteristicsdiscussionstudi limitationsconclus mellitu dm progress morbid prematur econom burden healthcar intern feder idf 366 million live 2035 half billion trend urbanis adopt unhealthi western lifestyl begun middleincom lmic prime south africa dubiou pleasur infecti today expans noncommunic ncd begin manifest deplet strain resourc glycaemia mellitu t2dm includ prioriti modifi accept t2dm cvd lifestyl lowdens lipoprotein cholesterol ldlc bp goal cvd t2dm diabetesrel microvascular retinopathi neuropathi nephropathi substanti reduct hyperglycaemia societi endocrinolog south africa semdsa recommend hba 1c 70 bp 14080 mmhg ldlc mmoll gap t2dm prove close differ t2dm reach guidelinerecommend way compar set compar achiev indic glycaem bp t2dm worldwid attempt benchmark success t2dm inadequ differ healthcar set substanti room t2dm manag effort multidisciplinari guidelin adher delay diabetesrel\n",
            "\t-7.458\tpdk1 myeloma utilis glycolyt adequ phenomenon warburg oper myeloma glycolysi modal purifi 59 cd138immunomagnet bead glycolysi cmyc glut1 ldha hif1a pyruv dehydrogenas kinase1 pdk1 realtim lactat analys oxam ldh dichloroacet dca pdk1 employ pdk1 sirna ldha indic posit pdk1 cmyc glut1 lactat ldha glycolysi oxam dca pdk1 sirna dca bortezomib addit cytotox warburg oper pdk1 overexpress pdk1 serv myelomaglycolysispdk1apoptosi methodscel culturepati samplescdna realtim pcrglycolysi inhibitorsmeasur concentrationldh assaymeasur lactat productionwestern blottinganalysi apoptosisevalu reactiv rosrna interfer experimentsstatist analysisresultsexpress glycolysisrel myeloma cellsanalysi glycolysi linesinduct ldha oxamateinduct pdk1 dcadiscuss  ldha ldh ldh prognost barlogi 1989 ldha ldh median 1559 331 001 pdk1 cmyc glut1 hif1a serv prognost ldha prognost s2 microarray databas refer tt2 ncbi gse2658 zhan margin possibl intens s3 subgroup tt2 classifi profil cd2 ldha s4 zhan cd2 longest ldha lowrisk myeloma classifi subgroup maf mmset ccnd1 frzb testi antigen moreaux subgroup s5 reflect somewhat uniform background extra medullar aggress ldh glycolyt convert pyruv lactat ldha glycolyt ldha glycolyt lactat signific ldh glycolyt prognost glycolysi interest issu myeloma accumul abnorm mgu kord zingon kuehl ldha mgu ldha myc mgu shou gabrea chng myc 67 rare mgu chng shou dysregul cmyc princip rearrang myc event myc interferon factor4 irf4 oncogen shaffer glycolysi ldha hk pdk1 irf4target shaffer aerob glycolysi upregul mgu possibl myc regard toward glycolyt reason smallmolecul ldha fx11 trigger necrot le ldha elev nadhnad ro ldha lactat xie le ldha fantin oxam competit ldh activ caspase3 ldh glycolysi modal ldh dichloroacet pdk bind ntermin pdk2 decreas pdk1 kato posse anticanc induc arrest depolaris hyperpolar inner michelaki wong madhok sun tong dca bioavail encourag nonsmal michelaki porporato select pdk1 azd7545 undergo kato pdk1 myeloma haematopoiet lineag shaffer jourdan pdk1 suitabl ldh basic exist kind pdk1 jourdan web atla httpamazoniatranscriptomeeu carrour dca ro pdk1 ro caspase3 pdk1 molecul myeloma bortezomib wellknown proteasom antimyeloma nf cytokin angiogenesi hideshima hideshima bortezomib bortezomib therapi glycolyt anticanc synergist additiveeffect zhou fium tong addit dca bortezomib accompani caspase3 ro dichloroacet bortezomibresist dosedepend addit dca bortezomib bortezomibresist pdk1 sensitis bortezomibresist bortezomib glycolysi pdk1 ldh\n",
            "dizziness,LDL-C,glucose None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.566\tissu   overview alcohol revisitedstress alcohol epidemiolog evidencealcohol militarychildhood trauma posttraumat alcohol dependenceanxieti alcohol comorbid considerationshow alcohol relapseneur integr relev alcohol abuseeffect alcohol depend withdraw respons alcohol consumptionclin stressor alcohol relationshipsstress hpa axi glucocorticoid alcohol dependencegenet determin respondingstress epigenet alcoholismresili meet addict psychobiolog considerationstreat alcohol depend antagonist drink alcohol reliev creat sen doubleedg sword link alcohol drink alcohol ongo ultim alcohol anthenelli reaction vari makeup gender articl anthenelli review introduc articl issu pp 386 390 \n",
            "\t0.562\tnhane 19992002 reveal noteworthi alcohol pandem sweep globe alcohol rise worldwid grow epidemiolog nhane registri 19992002 analyz alcohol multivari logist regress alcohol separ 9193 49 male 268 male 336 femal obes male femal never drinker drink lifetim adjust race marit spous countri origin annual household incom past odd never drinker ever drinker alcohol 45 bing drink drinksday 90 ever bing drinker odd gender drank shorter never bing drinker alcohol recommend limit moder drink drinksday femal drinksday male 1074 10721076 0970 95ci 09680972 femal male frequent heavi alcohol odd obes alcoholobesitybing drinkingdemographiceduc introductionmethodsresultscomparison demograph alcohol obes nonobes individualsfactor affect odd womendiscussionsummari box alcohol pandem sweep globe keen identifi lifestyl turn remedi unhealthi practic encourag alcohol 1001 cypriot instanc alcohol posit neg met nonalcohol fatti alcohol met trend drink goal alcohol nhane nutrit nhane start 1960 center statist nch center cdc examin repres 5000 counti goal alcohol past bing drink alcohol beverag odd obes separ ever drinker irrespect gender consum alcohol 45 engag bing drink 180 past odd obes answer question bing drink odd obes answer ye question alcohol bmi repres male 34 femal obes bmi alcohol constitut unhealthi lifestyl practic nearli million american 400 million worldwid obes worldwid excess alcohol hepat healthcar expens comorbid malign moder bmi 3035 morbid bmi annual expenditur 4050yearold bmi expenditur 5469 old 51 neither heavi alcohol independ healthcar expenditur alcohol synergist hepatocellular adjust gender habit hepat corrobor flore arif flore cowork mexican american note mexican american heavi bing drinker alcohol arif rohrer drinker odd odd bing drinker nonbing drinker male femal odd consum alcohol drink alcohol bing drink angl age 1218 concern muscular supplement enhanc physiqu bing drink felt lose tendenc indulg bing drink colleg enrol mexican american 194 alcohol heavi alcohol eat bing eat purg restrict fast excess bmi bmi calori restrict bing eat tobacco articl yeoman discus shortterm alcohol meal stimul reward moder alcohol note consum drink recommend limit moder alcohol odd alcohol occup instanc firefight department well fit bing drink highstress fireman jezewska articl discus excess process food alcohol eat bing drink coupl seafar longwork hour place korean worker jang colleagu note manual worker nonmanu worker femal work week odd obes 165 126215 psycholog appetit alcohol 20000 posttraumat ptsd adjust alcohol ptsd predictor psycholog ill psycholog peer eat drink turn instanc 700000 nonpregn age 1844 live 20032006 bing drink comorbid mellitu improv alcohol intens grow concern today youth spend indoor watch televis play video game 1219yearold canada watch frequent televis odd get obes adjust 110 odd bing alcohol drink alcohol depend investig alcohol nonu lee korean nhane iv genderspecif alcohol occurr met note odd met consum alcohol drink typic occas correspond drink bing drink week odd met gender consum drink indulg bing drink abdomin hyperglycemia engag bing drink notabl alcohol met italian age 5074 aim primarili psycholog bmi socioeconom gender psycholog influenc differ net imbal calori util cdc recommend 150 min week 600 min month note engag 600 min month 2030 odd hypothes likelihood get recommend alcohol bing drink contribut alcohol account nearli cost alcohol account cost nh uk 20062007 obes healthrel treat alcohol abus notic mexican american black gender report someon emot odd gender racial accept alcohol cultur dietari born outsid usa obes encourag emot alcohol cessat adopt dietari practic marit emerg determin divorc widow separ marri tend obes marri obes unmarri overweight obes prehypertens ugandan gender 69 marit wealth noncommunic alcohol overweightobes 13889 scottish molloy colleagu never marri separateddivorc marri conclud alcohol psycholog dysregul interact unmarri annual household incom 20000 dollar odd awar motiv engag contribut famili 13262 italian note incom adher mediterranean compris veget oliv oil obes 36 incom 00001 incom preced discus appar interplay alcohol situat gender next question come mind tackl apart counsel pharmacolog treat alcohol depend curb appetit promis agonist gamma butyr naloxon naltrexon baclofen pharmacolog bing eat review retrospect reli questionnair nhane unavoid pitfal recal bia nhane outsid usa socioeconom cultur emerg predictor numer registri nhane cumul view influenc extrapol alcohol gender odd never drinker gender ever drinker odd gender consum alcohol 45 past ever bing drinker odd obes never bing drinker bing drink 90 preced odd drink recommend limit moder alcohol odd male odd femal summari box\n",
            "\t0.558\talcohol alcohol immun explor alcohol simian immunodefici siv siv alcoholconsum oppos defens nutrit balanc consequ proinflammatori consum alcohol acceler siv possibl alcohol aod abus dependenceaod effectsdiseas factordiseas complicationimmun systemhuman immunodefici hivhiv infectionacquir defici syndromeantiretrovir therapysimian immunodefici virusanim modelsrhesu macaqu alcohol transmissionbehavior effectsphysiolog effectsalcohol pathogenesisviru entri replicationalcohol systemeffect alcohol exposureeffect alcohol exposurealcohol arv treatmentalcohol compliancealcohol metabolismeffect alcohol coinfectionsoth alcohol arv drugseffect alcohol systemanim studi alcohol infectionnhp pathogen siv infectionresearch applicationssiv pathogenesisimmun responsesadvantagesresearch siv alcohol modelalcohol progressionalcohol replicationalcohol tcell subsetssiv alcohol weightperspectivesalcohol intestin inflammationalcohol state alcohol review \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.348\tmoder alcohol protect mellitu overweight obes   introduction2 methods3 results4 discus strongest predictor mellitu t2dm lifestyl etiolog t2dm prevent modif healthier lifestyl dietari modif moder alcohol protect metaanalys conclud ushap jshape invers t2dm alcohol prospect alcohol t2dm initi drinker stratifi t2dm alcohol bmi ushap alcohol t2dm bmi kgm invers overweight obes newli t2dm invers incom maori pacif european moder alcohol t2dm separ middl highbmi crosssect middleag zealand moder alcohol past t2dm overweight alcohol t2dm obes full look alcohol alcohol statist bmi alcohol persist adjust probabl t2dm categoris alcohol appear approxim ushap alcohol t2dm full overweight obes cutoff point chosen classifi alcohol ushap alcohol t2dm overweight obes 84941 nurs ushap alcohol t2dm bmi kgm invers overweight obes carri 109690 nurs age 42 invers alcohol t2dm obes bmi kgm nonobes toler selfreport initi employ latter moder alcohol invers selfreport t2dm 16154 european stronger overweight obes alcohol 121 invers alcohol median bmi 244 kgm japanes 5636 selfreport t2dm bmi bmi kgm t2dm middlebmi 221 249 kgm highbmi kgm overweight obes bmi kgm categori japanes employ alcohol toler t2dm lean protect overweight japanes 28893 selfreport moder alcohol gday bmi kgm kgm alcohol fast t2dm overweight bmi kgm obes bmi 387 kgm 2500 korean male prospect carri drink alcohol drink beer wine drink vodka spirit contribut inconsist incomplet adjust confound error alcohol alcohol usual alcohol alcohol agreement 8700 micronesian mauritian alcohol toler igt 6362 japanes crosssect 3128 swedish age 56 igt moder alcohol alcohol igt overweight bmi kgm obes bmi 387 kgm korean male igt alcohol t2dm invers ushap moder alcohol t2dm hdlcholesterol antiinflammatori alcohol alcohol triglycerid moder alcohol inhibit lipolysi fatti explan invers ushap alcohol t2dm hypothes regular moder alcohol promot skelet protect t2dm report alcohol minim alcohol t2dm drink habit recal alcohol influenc reli selfreport alcohol alcoholrel epidemiolog practic use selfadminist questionnair reliabl estim alcohol indirectli valid hdlcholesterol unlik misclassif account error observ tend obscur true limit crosssect differenti strength ascertain toler selfreport invers moder alcohol t2dm overweight obes work consum moder amount alcohol moder alcohol modifi t2dm\n",
            "\t1.057\talcohol drink nutrit 1988 1994 alcohol protect explor alcohol nonsmok 8236 respond particip nutrit weightkgheightm height categor overweight obes alcohol drink bing drink quantiti drinksday drink drinksweek nonsmok 264 261 267 46 respond classifi drinker drinker odd adjust odd 073 055 097 nondrink odd overweight bing drinker consum drinksday drink drink 046 034 062 059 041 086 odd similarli odd drink consum drink week overweight alcohol pronounc explor moder alcohol drink control  backgroundmethodssampl selectionvariablesstatist analysisresultsdiscussionconclusioncompet interestsauthor contributionsprepubl overweight obes steadili nation continu rise concern agenc explos alcohol pastmonth consum drink fifti percent alcohol alcohol den macronutri consum oxid favor storag gain ad calori alcohol drinker gain extra nondrink jshape alcohol waisttohip moder drink benefici nondrink heavi riski drink opposit invers alcohol drink gain promin remain inconclus aim crosssect alcohol drink nation repres nonsmok alcohol benefici moder alcohol beverag prospect epidemiolog confirm benefici extend activ promot moder alcohol combat inappropri link alcohol note give advis nondrink start drink alcohol just argu promot abstent atleast regularli consum alcohol compet interest\n",
            "\t0.985\talcohol eventu type2 alcohol protect protect type2 alcohol protect type2 alcohol improv fed alcohol lean obes alcohol weight overlap adipos type2 alter epididym white adipos wat wat fed calori restrict cr lf hf diet ethanol drink screen homeostasi array compos 384 calori restrict alcohol obes cd68 il6 il1 downregul cr antiinflammatori il10 adrenerg beta adrbk1 obes cr alcohol kcnj11 potassium inwardlyrectifi channel subfamili member lpin2 lipin2 dusp9 dualspecif map phosphatas alcohol alter coupl alter alcohol upregul antiinflammatori indentifi transduc obesityrel calori restrict alcoholinduc  backgroundmateri methodsstudi designstellarraystellarray valid qpcrserum leptin levelsbodi levelsstatisticsresultsestablish weightsleptin alcohol consumptionglucos toler testshf cr opposit profilesproinflammatori il18 cr interventioncr upregul prostaglandin d2 synthas ptgdskatp channel subunit kcnj11 cr suppress hf dietbodi alcohol distinct lipin member expressionretinol protein4 rbp4 adipos tightli weightangiopoietinlik neg weightdual phosphatas dusp9mkp4 proteintyrosin phosphatas receptortyp alpha ptpra opposit cr hf dietdiscussionconclusioncompet interestsauthor contribut patholog type2 seriou morbid osteoarthr sleep apnea obes consum gener amount alcohol prone alcohol calori consum epidemiolog moder alcohol benefici decreas type2 alcohol type2 promot alcohol improv phenotyp lean overweight obes alcohol modifi excess calori adipocyt hypertrophi hyperplasia turn adipokin leptin adiponectin mediat interleukin adipokin theori theori excess adipos produc adipokin adiponectin adiponectin secret adipos close viscer subcutan type2 promot alcohol adiponectin white adipos obes secret mcp1 initi monocyt white adipos secret persist excess adipokin adipocyt skelet adipos excess lipid nonadipos caus lipotox eventu propos obesitydepend reactiv ro ro advers pancrea homeostasi array 384 white adipos fed calori restrict cr lf hf consum ethanol drink cr lf hf diet phenotyp lean bmi overweight bmi obes bmi allow alcohol lean cr lf obes hf calori restrict alcohol calori restrict drastic oppos pro antiinflammatori adipos lpin2 kcnj11 rbp4 alcohol reduc spectrum upregul antiinflammatori contribut modif alcohol summari lean obes alcohol calori restrict alcohol promot adipos type2 wat alcohol hf il6 il1 cd68 proinflammatori wat cr opposit il6 il1 alcohol oppress retnlb mif cr alcohol antiinflammatori il10 adrbk1 homeostasi ptgd lpin2 lpin3 dusp9 alcohol angptl6 kcnj11 ptpra gck ins1 pltp apob pck1 downregul hf upregul cr alcohol alcohol overlap regul foundat studi alcohol dietregul compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.566\tissu   overview alcohol revisitedstress alcohol epidemiolog evidencealcohol militarychildhood trauma posttraumat alcohol dependenceanxieti alcohol comorbid considerationshow alcohol relapseneur integr relev alcohol abuseeffect alcohol depend withdraw respons alcohol consumptionclin stressor alcohol relationshipsstress hpa axi glucocorticoid alcohol dependencegenet determin respondingstress epigenet alcoholismresili meet addict psychobiolog considerationstreat alcohol depend antagonist drink alcohol reliev creat sen doubleedg sword link alcohol drink alcohol ongo ultim alcohol anthenelli reaction vari makeup gender articl anthenelli review introduc articl issu pp 386 390 \n",
            "\t0.562\tnhane 19992002 reveal noteworthi alcohol pandem sweep globe alcohol rise worldwid grow epidemiolog nhane registri 19992002 analyz alcohol multivari logist regress alcohol separ 9193 49 male 268 male 336 femal obes male femal never drinker drink lifetim adjust race marit spous countri origin annual household incom past odd never drinker ever drinker alcohol 45 bing drink drinksday 90 ever bing drinker odd gender drank shorter never bing drinker alcohol recommend limit moder drink drinksday femal drinksday male 1074 10721076 0970 95ci 09680972 femal male frequent heavi alcohol odd obes alcoholobesitybing drinkingdemographiceduc introductionmethodsresultscomparison demograph alcohol obes nonobes individualsfactor affect odd womendiscussionsummari box alcohol pandem sweep globe keen identifi lifestyl turn remedi unhealthi practic encourag alcohol 1001 cypriot instanc alcohol posit neg met nonalcohol fatti alcohol met trend drink goal alcohol nhane nutrit nhane start 1960 center statist nch center cdc examin repres 5000 counti goal alcohol past bing drink alcohol beverag odd obes separ ever drinker irrespect gender consum alcohol 45 engag bing drink 180 past odd obes answer question bing drink odd obes answer ye question alcohol bmi repres male 34 femal obes bmi alcohol constitut unhealthi lifestyl practic nearli million american 400 million worldwid obes worldwid excess alcohol hepat healthcar expens comorbid malign moder bmi 3035 morbid bmi annual expenditur 4050yearold bmi expenditur 5469 old 51 neither heavi alcohol independ healthcar expenditur alcohol synergist hepatocellular adjust gender habit hepat corrobor flore arif flore cowork mexican american note mexican american heavi bing drinker alcohol arif rohrer drinker odd odd bing drinker nonbing drinker male femal odd consum alcohol drink alcohol bing drink angl age 1218 concern muscular supplement enhanc physiqu bing drink felt lose tendenc indulg bing drink colleg enrol mexican american 194 alcohol heavi alcohol eat bing eat purg restrict fast excess bmi bmi calori restrict bing eat tobacco articl yeoman discus shortterm alcohol meal stimul reward moder alcohol note consum drink recommend limit moder alcohol odd alcohol occup instanc firefight department well fit bing drink highstress fireman jezewska articl discus excess process food alcohol eat bing drink coupl seafar longwork hour place korean worker jang colleagu note manual worker nonmanu worker femal work week odd obes 165 126215 psycholog appetit alcohol 20000 posttraumat ptsd adjust alcohol ptsd predictor psycholog ill psycholog peer eat drink turn instanc 700000 nonpregn age 1844 live 20032006 bing drink comorbid mellitu improv alcohol intens grow concern today youth spend indoor watch televis play video game 1219yearold canada watch frequent televis odd get obes adjust 110 odd bing alcohol drink alcohol depend investig alcohol nonu lee korean nhane iv genderspecif alcohol occurr met note odd met consum alcohol drink typic occas correspond drink bing drink week odd met gender consum drink indulg bing drink abdomin hyperglycemia engag bing drink notabl alcohol met italian age 5074 aim primarili psycholog bmi socioeconom gender psycholog influenc differ net imbal calori util cdc recommend 150 min week 600 min month note engag 600 min month 2030 odd hypothes likelihood get recommend alcohol bing drink contribut alcohol account nearli cost alcohol account cost nh uk 20062007 obes healthrel treat alcohol abus notic mexican american black gender report someon emot odd gender racial accept alcohol cultur dietari born outsid usa obes encourag emot alcohol cessat adopt dietari practic marit emerg determin divorc widow separ marri tend obes marri obes unmarri overweight obes prehypertens ugandan gender 69 marit wealth noncommunic alcohol overweightobes 13889 scottish molloy colleagu never marri separateddivorc marri conclud alcohol psycholog dysregul interact unmarri annual household incom 20000 dollar odd awar motiv engag contribut famili 13262 italian note incom adher mediterranean compris veget oliv oil obes 36 incom 00001 incom preced discus appar interplay alcohol situat gender next question come mind tackl apart counsel pharmacolog treat alcohol depend curb appetit promis agonist gamma butyr naloxon naltrexon baclofen pharmacolog bing eat review retrospect reli questionnair nhane unavoid pitfal recal bia nhane outsid usa socioeconom cultur emerg predictor numer registri nhane cumul view influenc extrapol alcohol gender odd never drinker gender ever drinker odd gender consum alcohol 45 past ever bing drinker odd obes never bing drinker bing drink 90 preced odd drink recommend limit moder alcohol odd male odd femal summari box\n",
            "\t0.558\talcohol alcohol immun explor alcohol simian immunodefici siv siv alcoholconsum oppos defens nutrit balanc consequ proinflammatori consum alcohol acceler siv possibl alcohol aod abus dependenceaod effectsdiseas factordiseas complicationimmun systemhuman immunodefici hivhiv infectionacquir defici syndromeantiretrovir therapysimian immunodefici virusanim modelsrhesu macaqu alcohol transmissionbehavior effectsphysiolog effectsalcohol pathogenesisviru entri replicationalcohol systemeffect alcohol exposureeffect alcohol exposurealcohol arv treatmentalcohol compliancealcohol metabolismeffect alcohol coinfectionsoth alcohol arv drugseffect alcohol systemanim studi alcohol infectionnhp pathogen siv infectionresearch applicationssiv pathogenesisimmun responsesadvantagesresearch siv alcohol modelalcohol progressionalcohol replicationalcohol tcell subsetssiv alcohol weightperspectivesalcohol intestin inflammationalcohol state alcohol review \n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t1.348\tmoder alcohol protect mellitu overweight obes   introduction2 methods3 results4 discus strongest predictor mellitu t2dm lifestyl etiolog t2dm prevent modif healthier lifestyl dietari modif moder alcohol protect metaanalys conclud ushap jshape invers t2dm alcohol prospect alcohol t2dm initi drinker stratifi t2dm alcohol bmi ushap alcohol t2dm bmi kgm invers overweight obes newli t2dm invers incom maori pacif european moder alcohol t2dm separ middl highbmi crosssect middleag zealand moder alcohol past t2dm overweight alcohol t2dm obes full look alcohol alcohol statist bmi alcohol persist adjust probabl t2dm categoris alcohol appear approxim ushap alcohol t2dm full overweight obes cutoff point chosen classifi alcohol ushap alcohol t2dm overweight obes 84941 nurs ushap alcohol t2dm bmi kgm invers overweight obes carri 109690 nurs age 42 invers alcohol t2dm obes bmi kgm nonobes toler selfreport initi employ latter moder alcohol invers selfreport t2dm 16154 european stronger overweight obes alcohol 121 invers alcohol median bmi 244 kgm japanes 5636 selfreport t2dm bmi bmi kgm t2dm middlebmi 221 249 kgm highbmi kgm overweight obes bmi kgm categori japanes employ alcohol toler t2dm lean protect overweight japanes 28893 selfreport moder alcohol gday bmi kgm kgm alcohol fast t2dm overweight bmi kgm obes bmi 387 kgm 2500 korean male prospect carri drink alcohol drink beer wine drink vodka spirit contribut inconsist incomplet adjust confound error alcohol alcohol usual alcohol alcohol agreement 8700 micronesian mauritian alcohol toler igt 6362 japanes crosssect 3128 swedish age 56 igt moder alcohol alcohol igt overweight bmi kgm obes bmi 387 kgm korean male igt alcohol t2dm invers ushap moder alcohol t2dm hdlcholesterol antiinflammatori alcohol alcohol triglycerid moder alcohol inhibit lipolysi fatti explan invers ushap alcohol t2dm hypothes regular moder alcohol promot skelet protect t2dm report alcohol minim alcohol t2dm drink habit recal alcohol influenc reli selfreport alcohol alcoholrel epidemiolog practic use selfadminist questionnair reliabl estim alcohol indirectli valid hdlcholesterol unlik misclassif account error observ tend obscur true limit crosssect differenti strength ascertain toler selfreport invers moder alcohol t2dm overweight obes work consum moder amount alcohol moder alcohol modifi t2dm\n",
            "\t1.057\talcohol drink nutrit 1988 1994 alcohol protect explor alcohol nonsmok 8236 respond particip nutrit weightkgheightm height categor overweight obes alcohol drink bing drink quantiti drinksday drink drinksweek nonsmok 264 261 267 46 respond classifi drinker drinker odd adjust odd 073 055 097 nondrink odd overweight bing drinker consum drinksday drink drink 046 034 062 059 041 086 odd similarli odd drink consum drink week overweight alcohol pronounc explor moder alcohol drink control  backgroundmethodssampl selectionvariablesstatist analysisresultsdiscussionconclusioncompet interestsauthor contributionsprepubl overweight obes steadili nation continu rise concern agenc explos alcohol pastmonth consum drink fifti percent alcohol alcohol den macronutri consum oxid favor storag gain ad calori alcohol drinker gain extra nondrink jshape alcohol waisttohip moder drink benefici nondrink heavi riski drink opposit invers alcohol drink gain promin remain inconclus aim crosssect alcohol drink nation repres nonsmok alcohol benefici moder alcohol beverag prospect epidemiolog confirm benefici extend activ promot moder alcohol combat inappropri link alcohol note give advis nondrink start drink alcohol just argu promot abstent atleast regularli consum alcohol compet interest\n",
            "\t0.985\talcohol eventu type2 alcohol protect protect type2 alcohol protect type2 alcohol improv fed alcohol lean obes alcohol weight overlap adipos type2 alter epididym white adipos wat wat fed calori restrict cr lf hf diet ethanol drink screen homeostasi array compos 384 calori restrict alcohol obes cd68 il6 il1 downregul cr antiinflammatori il10 adrenerg beta adrbk1 obes cr alcohol kcnj11 potassium inwardlyrectifi channel subfamili member lpin2 lipin2 dusp9 dualspecif map phosphatas alcohol alter coupl alter alcohol upregul antiinflammatori indentifi transduc obesityrel calori restrict alcoholinduc  backgroundmateri methodsstudi designstellarraystellarray valid qpcrserum leptin levelsbodi levelsstatisticsresultsestablish weightsleptin alcohol consumptionglucos toler testshf cr opposit profilesproinflammatori il18 cr interventioncr upregul prostaglandin d2 synthas ptgdskatp channel subunit kcnj11 cr suppress hf dietbodi alcohol distinct lipin member expressionretinol protein4 rbp4 adipos tightli weightangiopoietinlik neg weightdual phosphatas dusp9mkp4 proteintyrosin phosphatas receptortyp alpha ptpra opposit cr hf dietdiscussionconclusioncompet interestsauthor contribut patholog type2 seriou morbid osteoarthr sleep apnea obes consum gener amount alcohol prone alcohol calori consum epidemiolog moder alcohol benefici decreas type2 alcohol type2 promot alcohol improv phenotyp lean overweight obes alcohol modifi excess calori adipocyt hypertrophi hyperplasia turn adipokin leptin adiponectin mediat interleukin adipokin theori theori excess adipos produc adipokin adiponectin adiponectin secret adipos close viscer subcutan type2 promot alcohol adiponectin white adipos obes secret mcp1 initi monocyt white adipos secret persist excess adipokin adipocyt skelet adipos excess lipid nonadipos caus lipotox eventu propos obesitydepend reactiv ro ro advers pancrea homeostasi array 384 white adipos fed calori restrict cr lf hf consum ethanol drink cr lf hf diet phenotyp lean bmi overweight bmi obes bmi allow alcohol lean cr lf obes hf calori restrict alcohol calori restrict drastic oppos pro antiinflammatori adipos lpin2 kcnj11 rbp4 alcohol reduc spectrum upregul antiinflammatori contribut modif alcohol summari lean obes alcohol calori restrict alcohol promot adipos type2 wat alcohol hf il6 il1 cd68 proinflammatori wat cr opposit il6 il1 alcohol oppress retnlb mif cr alcohol antiinflammatori il10 adrbk1 homeostasi ptgd lpin2 lpin3 dusp9 alcohol angptl6 kcnj11 ptpra gck ins1 pltp apob pck1 downregul hf upregul cr alcohol alcohol overlap regul foundat studi alcohol dietregul compet interest\n",
            "obese,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.528\thcv mellitu egyptian casecontrol hepat hcv egypt part 33 hcv mostli mellitu dm egypt dm 254 hcv magnitud optim hepat object casecontrol dm extrahepat eh manifest hcv morbid asymptomat hepat cirrhot 289 hcv 289 investig lft done serolog cryoglobulin rheumatoid antinuclear hcvpcr 289 hcv 1384 289 415 hcv 481 92 male urbanian repres 725 85 manifest 525 875 marri nondiabet hcv 407 104 male urbanian repres 715 655 attain 554 767 marri compar hcv non hcv resid alcohol drink affect sonar cirrhosi preval hcv fibrosi hcv non hcv hcv alcohol drink non hcv alcohol drink logist regress resid urban predict alcohol predict  backgroundpati methodsstudi designstatist analysisresultsihcv casesii mellitu hcv casesiii hcv non hcv controlsiv hcv diabet non hcv diabeticsdiscussionsociodemograph charact special habit controlsliv conditionconclusionabbreviationscompet interestsauthor contribut hepat hcv egypt reach person rural hcv genotyp predomin genotyp 91 hcvinfect person egypt origin hcv epidem egypt attribut intraven schistosomiasi rural 1960s70 hcv evid hcv organ cacoub 38 hcv manifest extrahepat manifest ill extrahepat eh manifest hcv endocrinolog manifest mellitu dm thyroid rheumatolog manifest arthralgia arthriti mix cryoglobulinemia clinic eh manifest morbid awar manifest paramount facilit t2d worldwid obes live sedentari lifestyl agreement t2d noninfect hcv genotyp t2d part 33 hcv mostli dm frequent cirrhosi hepat dm eh manifest hcv egypt dm 254 hcv hepat dm hcv seroneg magnitud optim hepat object dm eh manifest hcv morbid asymptomat hepat cirrhot match close hcv dm link hcv conjectur hepat hcv underli intoler hcv dm multisystem pathophysiolog includ defect hepat overt hyperglycemia age dm dm pathogen hcv dm fibrot dm hcv multifactori precirrhot abnorm act conjunct undefin pancreat occur genet prone explan explan caronia respons hcv possibl dysfunctionand presum ir hcv hcv alcohol drink non hcv logist regress resid urban predict alcohol abbrevi\n",
            "\t0.527\thepat cascad call address ongo barrier aim hepat hcv cascad hivinfect reason refer initi hcv complet hcv stage retrospect hivinfect univers california san diego ucsd screen hcv logist regress referr hcv electron record review ascertain reason initi hcv 4725 hivinfect ucsd owen clinic 4534 96 screen hcv 748 reactiv hcv 542 hcv engag predictor nonreferr hcv odd 508 confid interv 324 697 000001 predictor unstabl hous 226 aid 183 detect load 198 nonwhit 167 reason initi defer hcv ongo barrier hcv hivinfect half hcv refer hcv improv hcv benefit realiz unless deal barrier implement  introductionmethodspati hcv carestudi designstudi definitionsstatist analysisresultsdemograph count load refer nonref hepat considerationcommon provid decis referr hivinfect hepat considerationpredictor nonb refer hcv consider 562 unadjust adjust analysesth depict hepat cascad hivinfect attend univers california san diego owen clinic januari 31 decemb 2012discussionsupport person live immunodefici coinfect hepat hcv guidelin recommend hcv person establish diver clinic 85 hivinfect person hcv 3month enrol hcv hivinfect person advanc hcv hcv europ hcv liverrel morbid contribut cost urgent hcv hivinfect person advent act antivir hcv opportun cure hcv coinfect person influenc hcv referr disposit hcv establish reason nonreferr hcv initi hcv hivinfect refer hcv narrow gap hcv nonreferr hcv consider character reason start hcv complet hcv stage describ hcv cascad hcv owen clinic univers california san diego ucsd conclusions1 hivinfect screen hcv half hivinfect hcv coinfect refer hcv reason initi hcv ongo barrier compromis engag reflect extant dispar nonwhit engag unstabl hous uncontrol hivinfect refer hcv idu refer hcv msm idu want refer stigma hcv msm iud creat opportun awar provid rise hcv hivinfect msm idu coinfect ongo hcv refer hcv interferon contraind hcv referr neither unwilling receiv hcv interferonbas detail clinic note highlight interferon regimen cure immedi barrier referr address never receiv hcv unexpect ongo substanc abus neuropsychiatr predictor hcv referr ascertain bia explan refer hcv engag reliabl selfreport ongo alcohol abus uncertain similarli systemat evalu document alcohol abus neuropsychiatr electron record refer hcv noniniti hcv attribut alcohol abus neuropsychiatr engag refer hcv realworld challeng success hcv accomplish 4188 start attain sustain interferonfre therapi efficaci shorter approv emphasi place implement integr multidisciplinari hcv alcohol substanc stigma discrimin coinfect retain initi hcv cur insur incom influenc referr hcv hcv coinfect clinic oper clinic insur coverag allow univers hcv argu definit engag gold miss visit gap visit constanc comprehens descript engag chose hrsa hivaid bureau retent align updat guidelin highlight concept adher restrict reason initi hcv finish hcv stage critic 53 303 refer hcv never hcv appoint return hcv appoint 33 rule unmeasur travel distanc clinic hcv literaci neg impact hcv initi limit balanc strength complet hcv stage underw detail character logist barrier hcv initi generaliz fund geograph percentag coinfect ultim hcv sustain mirror cohort europ improv hcv benefit realiz unless deal barrier address\n",
            "\t0.522\thepat substanc user enrol communitybas hepat hcv frequent bloodborn epidemiolog hcv complet understood minor hcv substanc abus femal institut alcohol abus alcohol niaaa institut abus nida fund street recruit month interview substanc sexual behavior implement share practic tattoo pierc transfus share person hygien equip tweezer toothbrush razor urin hcv ab sexual transmit std 782 predominantli african american 162 hcv ab 0001 inject 0001 lifetim crack cocain 0004 tattoo 001 hcv ab posit hcv ab posit sexual behavior hcv ab predominantli african american substanc abus hcv ab posit awar hcv serostatu intraven idu hcv ab posit tattoo lifetim crack rout hcv  backgroundmethodssampl descriptionlaboratori testingstatist analysesresultsbaselin characteristicssubst sexual behaviourmultivari analysessubgroup analysesdiscussionconclusionscompet interestsauthor contribut hepat hcv frequent bloodborn caus morbid 4500 inhospit death hcv nutrit nhane hcv ab million person chronic hcv hcv endstag subsequ transplant hcv indic transplant transplant hcv hcv origin document nona nonb caus transfus hepat hcv spread parenter intraven idu introduct univers 1990 transfus hcv hcv vari depend race epidemiolog hcv african american reason hcv femal male regardless race hcv femal extens set coinfect vertic hcv inject predomin rout idu hcv rang 6090 carri morbid burden sexual hcv hepat sexual hcv vertic 67 viremia rout idu tattoo pierc share prepar equip share person hygien item hcv noninject user intranas cocain share drugus equip hcv virolog confirm hcv nasal secret support epidemiolog comprehens hcv underrepres hcv substanc abus predominantli african american femal epidemiolog eprg washington univers school highlight born reach understudi underreport epidemiolog inject contribut hcv ab posit predominantli african american substanc abus reveal awar hcv ab awar hcv ab implic perspect hcv counsel overcom barrier ensur referr comprehens incorpor address substanc idu hcv ab posit tattoo lifetim crack inject rout hcv largescal prospect compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.755\tintracerebr hemorrhag hepat explor hepat hcv intracerebr hemorrhag ich taiwan insur claim 9023 newli hcv 36092 sexfrequencymatch hcv randomli ich hcv comorbid ischem hyperlipidemia atrial fibril alcohol head ich hcv adjust hazard ahr 160 confid interv 124 206 multivari cox regress agespecif ich hcv younger ahr 192 118 311 245 152 398 55 56 64 ich hcv ahr 166 121 230 mild hcv 212 147 306 hcv comorbid ich 233 136 398 hcv hcv ich younger age  introductionmateri methodsdata sourcestudi subjectsoutcom variablesstatist analysisresultsdiscussioncomorbid intracerebr hemorrhagestrength limitationsconclus intracerebr hemorrhag ich debilit ich consum socioeconom resourc burden ischem ich compris stroke patholog cerebr arteriolar wall wall smooth ectasia arteriolar wall microaneurysm ruptur microaneurysm ich tradit ich hyperlipidemia ischem ihd atrial fibril af alcohol ald head trigger patholog cerebr arteriolar wall ich unclear younger arteri ectasia microaneurysm coronari arteri proven connect ich vascul cerebr arteriol immunodefici varicellazost vzv autoimmun lupu erythematosu sle rheumatoid arthriti ra nevertheless inflamm trigger cerebr arteriolar ectasia ruptur microaneurysm transmit inject transfus unsaf inject hepat hcv 130 million global worldwid issu hcv hepat cirrhosi hepatocellular therebi socioeconom burden hcv ich relev size taiwanes enrol insur nhi taiwan subset nhi claim databas hcv ich 12year ich hcv ich hcv confirm younger hcv prevent ich hcv younger\n",
            "\t-0.755\tintracerebr hemorrhag hepat explor hepat hcv intracerebr hemorrhag ich taiwan insur claim 9023 newli hcv 36092 sexfrequencymatch hcv randomli ich hcv comorbid ischem hyperlipidemia atrial fibril alcohol head ich hcv adjust hazard ahr 160 confid interv 124 206 multivari cox regress agespecif ich hcv younger ahr 192 118 311 245 152 398 55 56 64 ich hcv ahr 166 121 230 mild hcv 212 147 306 hcv comorbid ich 233 136 398 hcv hcv ich younger age  introductionmateri methodsdata sourcestudi subjectsoutcom variablesstatist analysisresultsdiscussioncomorbid intracerebr hemorrhagestrength limitationsconclus intracerebr hemorrhag ich debilit ich consum socioeconom resourc burden ischem ich compris stroke patholog cerebr arteriolar wall wall smooth ectasia arteriolar wall microaneurysm ruptur microaneurysm ich tradit ich hyperlipidemia ischem ihd atrial fibril af alcohol ald head trigger patholog cerebr arteriolar wall ich unclear younger arteri ectasia microaneurysm coronari arteri proven connect ich vascul cerebr arteriol immunodefici varicellazost vzv autoimmun lupu erythematosu sle rheumatoid arthriti ra nevertheless inflamm trigger cerebr arteriolar ectasia ruptur microaneurysm transmit inject transfus unsaf inject hepat hcv 130 million global worldwid issu hcv hepat cirrhosi hepatocellular therebi socioeconom burden hcv ich relev size taiwanes enrol insur nhi taiwan subset nhi claim databas hcv ich 12year ich hcv ich hcv confirm younger hcv prevent ich hcv younger\n",
            "\t-0.888\tinterferon alpha hepat complet substanc substanc sud hepat hcv explor empir object interferon alpha complet hcv comorbid sud inform guidelin record databas retrospect 307437 veteran veteran integr servic visn veteran healthcar vha 1998 regular pegyl ribavirin hcv genotyp complet sud sud sud sud odd sud sud equal genotyp 731 680 genotyp 395 399 began sud sud similarli achiev genotyp 528 543 genotyp 245 248 sustain genotyp 426 411 genotyp 160 223 sud respond antivir hcv collect comorbid sud hcv diagnos success antivir  backgroundresultshcv antivir demograph informationcomplet genotyp 3complet genotyp 4discussionconclusionmethodssampl selectionoper definitionssud groupsud grouphcv statusantivir therapyhcv genotypesifn completionifn responsestatist analysescompet interestsauthor contribut comorbid substanc sud psychiatr hepat hcv constitut vast person hcv hcv 90 inject user hcv noninject user 700 noninject user heroin cocain crack hcv rang 29 depend gender locat date complet ongo inject noninject affect hcv hcv pegyl interferon alpha ribavirin antivir ifnbas therapi neuropsychiatr 75 psychiatr anxieti insomnia meet ifninduc depress healthcar provid reluct treat comorbid sud concern neuropsychiatr relaps empir clinician concern sud noncompli jeopard withhold antivir hcvinfect alcohol user maintain abstin attitud disproportion sud particip antivir hcv prospect screen psychiatr ill sud seriou ill 68 inelig similarli 557 refer hcv clinic exclud psychiatr alcohol abus inject retrospect franc hcv receiv ongo hcv close receiv belong highrisk lifestyl nasal intraven 228 alcohol abus gday barrier clinician attitud sud sud preclud toler size adequ inject user activ concern antivir substanc user sustain svr adher nondrug user hcv heavi drink 70 80 gday svr mild moder alcohol abstain svr alcohol abus mild moder alcohol complianc hcv comorbid sud object antivir complet etr svr comorbid sud serv va healthcar empir facilit decis underserv emerg guidelin antivir feasibl ongo alcohol compli contraind polici edlin decis hcv illicit individu riskbenefit ass just decis thorough discus adher regimen risk reinfect agreement polici institut consensu statement hepat veteran recommend hepat guidelin hepat recommend decis hcv psychiatr sud inject user casebycas advis absolut contraind hcv\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.528\thcv mellitu egyptian casecontrol hepat hcv egypt part 33 hcv mostli mellitu dm egypt dm 254 hcv magnitud optim hepat object casecontrol dm extrahepat eh manifest hcv morbid asymptomat hepat cirrhot 289 hcv 289 investig lft done serolog cryoglobulin rheumatoid antinuclear hcvpcr 289 hcv 1384 289 415 hcv 481 92 male urbanian repres 725 85 manifest 525 875 marri nondiabet hcv 407 104 male urbanian repres 715 655 attain 554 767 marri compar hcv non hcv resid alcohol drink affect sonar cirrhosi preval hcv fibrosi hcv non hcv hcv alcohol drink non hcv alcohol drink logist regress resid urban predict alcohol predict  backgroundpati methodsstudi designstatist analysisresultsihcv casesii mellitu hcv casesiii hcv non hcv controlsiv hcv diabet non hcv diabeticsdiscussionsociodemograph charact special habit controlsliv conditionconclusionabbreviationscompet interestsauthor contribut hepat hcv egypt reach person rural hcv genotyp predomin genotyp 91 hcvinfect person egypt origin hcv epidem egypt attribut intraven schistosomiasi rural 1960s70 hcv evid hcv organ cacoub 38 hcv manifest extrahepat manifest ill extrahepat eh manifest hcv endocrinolog manifest mellitu dm thyroid rheumatolog manifest arthralgia arthriti mix cryoglobulinemia clinic eh manifest morbid awar manifest paramount facilit t2d worldwid obes live sedentari lifestyl agreement t2d noninfect hcv genotyp t2d part 33 hcv mostli dm frequent cirrhosi hepat dm eh manifest hcv egypt dm 254 hcv hepat dm hcv seroneg magnitud optim hepat object dm eh manifest hcv morbid asymptomat hepat cirrhot match close hcv dm link hcv conjectur hepat hcv underli intoler hcv dm multisystem pathophysiolog includ defect hepat overt hyperglycemia age dm dm pathogen hcv dm fibrot dm hcv multifactori precirrhot abnorm act conjunct undefin pancreat occur genet prone explan explan caronia respons hcv possibl dysfunctionand presum ir hcv hcv alcohol drink non hcv logist regress resid urban predict alcohol abbrevi\n",
            "\t0.527\thepat cascad call address ongo barrier aim hepat hcv cascad hivinfect reason refer initi hcv complet hcv stage retrospect hivinfect univers california san diego ucsd screen hcv logist regress referr hcv electron record review ascertain reason initi hcv 4725 hivinfect ucsd owen clinic 4534 96 screen hcv 748 reactiv hcv 542 hcv engag predictor nonreferr hcv odd 508 confid interv 324 697 000001 predictor unstabl hous 226 aid 183 detect load 198 nonwhit 167 reason initi defer hcv ongo barrier hcv hivinfect half hcv refer hcv improv hcv benefit realiz unless deal barrier implement  introductionmethodspati hcv carestudi designstudi definitionsstatist analysisresultsdemograph count load refer nonref hepat considerationcommon provid decis referr hivinfect hepat considerationpredictor nonb refer hcv consider 562 unadjust adjust analysesth depict hepat cascad hivinfect attend univers california san diego owen clinic januari 31 decemb 2012discussionsupport person live immunodefici coinfect hepat hcv guidelin recommend hcv person establish diver clinic 85 hivinfect person hcv 3month enrol hcv hivinfect person advanc hcv hcv europ hcv liverrel morbid contribut cost urgent hcv hivinfect person advent act antivir hcv opportun cure hcv coinfect person influenc hcv referr disposit hcv establish reason nonreferr hcv initi hcv hivinfect refer hcv narrow gap hcv nonreferr hcv consider character reason start hcv complet hcv stage describ hcv cascad hcv owen clinic univers california san diego ucsd conclusions1 hivinfect screen hcv half hivinfect hcv coinfect refer hcv reason initi hcv ongo barrier compromis engag reflect extant dispar nonwhit engag unstabl hous uncontrol hivinfect refer hcv idu refer hcv msm idu want refer stigma hcv msm iud creat opportun awar provid rise hcv hivinfect msm idu coinfect ongo hcv refer hcv interferon contraind hcv referr neither unwilling receiv hcv interferonbas detail clinic note highlight interferon regimen cure immedi barrier referr address never receiv hcv unexpect ongo substanc abus neuropsychiatr predictor hcv referr ascertain bia explan refer hcv engag reliabl selfreport ongo alcohol abus uncertain similarli systemat evalu document alcohol abus neuropsychiatr electron record refer hcv noniniti hcv attribut alcohol abus neuropsychiatr engag refer hcv realworld challeng success hcv accomplish 4188 start attain sustain interferonfre therapi efficaci shorter approv emphasi place implement integr multidisciplinari hcv alcohol substanc stigma discrimin coinfect retain initi hcv cur insur incom influenc referr hcv hcv coinfect clinic oper clinic insur coverag allow univers hcv argu definit engag gold miss visit gap visit constanc comprehens descript engag chose hrsa hivaid bureau retent align updat guidelin highlight concept adher restrict reason initi hcv finish hcv stage critic 53 303 refer hcv never hcv appoint return hcv appoint 33 rule unmeasur travel distanc clinic hcv literaci neg impact hcv initi limit balanc strength complet hcv stage underw detail character logist barrier hcv initi generaliz fund geograph percentag coinfect ultim hcv sustain mirror cohort europ improv hcv benefit realiz unless deal barrier address\n",
            "\t0.522\thepat substanc user enrol communitybas hepat hcv frequent bloodborn epidemiolog hcv complet understood minor hcv substanc abus femal institut alcohol abus alcohol niaaa institut abus nida fund street recruit month interview substanc sexual behavior implement share practic tattoo pierc transfus share person hygien equip tweezer toothbrush razor urin hcv ab sexual transmit std 782 predominantli african american 162 hcv ab 0001 inject 0001 lifetim crack cocain 0004 tattoo 001 hcv ab posit hcv ab posit sexual behavior hcv ab predominantli african american substanc abus hcv ab posit awar hcv serostatu intraven idu hcv ab posit tattoo lifetim crack rout hcv  backgroundmethodssampl descriptionlaboratori testingstatist analysesresultsbaselin characteristicssubst sexual behaviourmultivari analysessubgroup analysesdiscussionconclusionscompet interestsauthor contribut hepat hcv frequent bloodborn caus morbid 4500 inhospit death hcv nutrit nhane hcv ab million person chronic hcv hcv endstag subsequ transplant hcv indic transplant transplant hcv hcv origin document nona nonb caus transfus hepat hcv spread parenter intraven idu introduct univers 1990 transfus hcv hcv vari depend race epidemiolog hcv african american reason hcv femal male regardless race hcv femal extens set coinfect vertic hcv inject predomin rout idu hcv rang 6090 carri morbid burden sexual hcv hepat sexual hcv vertic 67 viremia rout idu tattoo pierc share prepar equip share person hygien item hcv noninject user intranas cocain share drugus equip hcv virolog confirm hcv nasal secret support epidemiolog comprehens hcv underrepres hcv substanc abus predominantli african american femal epidemiolog eprg washington univers school highlight born reach understudi underreport epidemiolog inject contribut hcv ab posit predominantli african american substanc abus reveal awar hcv ab awar hcv ab implic perspect hcv counsel overcom barrier ensur referr comprehens incorpor address substanc idu hcv ab posit tattoo lifetim crack inject rout hcv largescal prospect compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-0.755\tintracerebr hemorrhag hepat explor hepat hcv intracerebr hemorrhag ich taiwan insur claim 9023 newli hcv 36092 sexfrequencymatch hcv randomli ich hcv comorbid ischem hyperlipidemia atrial fibril alcohol head ich hcv adjust hazard ahr 160 confid interv 124 206 multivari cox regress agespecif ich hcv younger ahr 192 118 311 245 152 398 55 56 64 ich hcv ahr 166 121 230 mild hcv 212 147 306 hcv comorbid ich 233 136 398 hcv hcv ich younger age  introductionmateri methodsdata sourcestudi subjectsoutcom variablesstatist analysisresultsdiscussioncomorbid intracerebr hemorrhagestrength limitationsconclus intracerebr hemorrhag ich debilit ich consum socioeconom resourc burden ischem ich compris stroke patholog cerebr arteriolar wall wall smooth ectasia arteriolar wall microaneurysm ruptur microaneurysm ich tradit ich hyperlipidemia ischem ihd atrial fibril af alcohol ald head trigger patholog cerebr arteriolar wall ich unclear younger arteri ectasia microaneurysm coronari arteri proven connect ich vascul cerebr arteriol immunodefici varicellazost vzv autoimmun lupu erythematosu sle rheumatoid arthriti ra nevertheless inflamm trigger cerebr arteriolar ectasia ruptur microaneurysm transmit inject transfus unsaf inject hepat hcv 130 million global worldwid issu hcv hepat cirrhosi hepatocellular therebi socioeconom burden hcv ich relev size taiwanes enrol insur nhi taiwan subset nhi claim databas hcv ich 12year ich hcv ich hcv confirm younger hcv prevent ich hcv younger\n",
            "\t-0.755\tintracerebr hemorrhag hepat explor hepat hcv intracerebr hemorrhag ich taiwan insur claim 9023 newli hcv 36092 sexfrequencymatch hcv randomli ich hcv comorbid ischem hyperlipidemia atrial fibril alcohol head ich hcv adjust hazard ahr 160 confid interv 124 206 multivari cox regress agespecif ich hcv younger ahr 192 118 311 245 152 398 55 56 64 ich hcv ahr 166 121 230 mild hcv 212 147 306 hcv comorbid ich 233 136 398 hcv hcv ich younger age  introductionmateri methodsdata sourcestudi subjectsoutcom variablesstatist analysisresultsdiscussioncomorbid intracerebr hemorrhagestrength limitationsconclus intracerebr hemorrhag ich debilit ich consum socioeconom resourc burden ischem ich compris stroke patholog cerebr arteriolar wall wall smooth ectasia arteriolar wall microaneurysm ruptur microaneurysm ich tradit ich hyperlipidemia ischem ihd atrial fibril af alcohol ald head trigger patholog cerebr arteriolar wall ich unclear younger arteri ectasia microaneurysm coronari arteri proven connect ich vascul cerebr arteriol immunodefici varicellazost vzv autoimmun lupu erythematosu sle rheumatoid arthriti ra nevertheless inflamm trigger cerebr arteriolar ectasia ruptur microaneurysm transmit inject transfus unsaf inject hepat hcv 130 million global worldwid issu hcv hepat cirrhosi hepatocellular therebi socioeconom burden hcv ich relev size taiwanes enrol insur nhi taiwan subset nhi claim databas hcv ich 12year ich hcv ich hcv confirm younger hcv prevent ich hcv younger\n",
            "\t-0.888\tinterferon alpha hepat complet substanc substanc sud hepat hcv explor empir object interferon alpha complet hcv comorbid sud inform guidelin record databas retrospect 307437 veteran veteran integr servic visn veteran healthcar vha 1998 regular pegyl ribavirin hcv genotyp complet sud sud sud sud odd sud sud equal genotyp 731 680 genotyp 395 399 began sud sud similarli achiev genotyp 528 543 genotyp 245 248 sustain genotyp 426 411 genotyp 160 223 sud respond antivir hcv collect comorbid sud hcv diagnos success antivir  backgroundresultshcv antivir demograph informationcomplet genotyp 3complet genotyp 4discussionconclusionmethodssampl selectionoper definitionssud groupsud grouphcv statusantivir therapyhcv genotypesifn completionifn responsestatist analysescompet interestsauthor contribut comorbid substanc sud psychiatr hepat hcv constitut vast person hcv hcv 90 inject user hcv noninject user 700 noninject user heroin cocain crack hcv rang 29 depend gender locat date complet ongo inject noninject affect hcv hcv pegyl interferon alpha ribavirin antivir ifnbas therapi neuropsychiatr 75 psychiatr anxieti insomnia meet ifninduc depress healthcar provid reluct treat comorbid sud concern neuropsychiatr relaps empir clinician concern sud noncompli jeopard withhold antivir hcvinfect alcohol user maintain abstin attitud disproportion sud particip antivir hcv prospect screen psychiatr ill sud seriou ill 68 inelig similarli 557 refer hcv clinic exclud psychiatr alcohol abus inject retrospect franc hcv receiv ongo hcv close receiv belong highrisk lifestyl nasal intraven 228 alcohol abus gday barrier clinician attitud sud sud preclud toler size adequ inject user activ concern antivir substanc user sustain svr adher nondrug user hcv heavi drink 70 80 gday svr mild moder alcohol abstain svr alcohol abus mild moder alcohol complianc hcv comorbid sud object antivir complet etr svr comorbid sud serv va healthcar empir facilit decis underserv emerg guidelin antivir feasibl ongo alcohol compli contraind polici edlin decis hcv illicit individu riskbenefit ass just decis thorough discus adher regimen risk reinfect agreement polici institut consensu statement hepat veteran recommend hepat guidelin hepat recommend decis hcv psychiatr sud inject user casebycas advis absolut contraind hcv\n",
            "HCV,IFN None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.475\trelat hydroxi vitamin d3 hypovitaminosi mellitu dm relat vitamin 101 classifi diabet bodymass indic hdroxi vitamin d3 25o hd bmi 0001 023 classifi diabet indic overweight obes hydroxi vitamin d3 everi bmi hydroxi vitamin turkish dm vitamin correl bmi vitamin worsen vitamin lessen obesitytyp mellitusvitamin introductionmateri methodspatientslaboratori methodsmethodsstatist analysisresultsdiscussionconclus hyperglycemia independ vitamin vitamin defici hipovitaminosi note diabet reason state besid sun impair predisposit vitamin insuffici turkey vitamin defici vitamin turkish relat vitamin grave vitamin turkey vitamin bmi vitamin defici oh worsen\n",
            "\t0.475\trelat hydroxi vitamin d3 hypovitaminosi mellitu dm relat vitamin 101 classifi diabet bodymass indic hdroxi vitamin d3 25o hd bmi 0001 023 classifi diabet indic overweight obes hydroxi vitamin d3 everi bmi hydroxi vitamin turkish dm vitamin correl bmi vitamin worsen vitamin lessen obesitytyp mellitusvitamin introductionmateri methodspatientslaboratori methodsmethodsstatist analysisresultsdiscussionconclus hyperglycemia independ vitamin vitamin defici hipovitaminosi note diabet reason state besid sun impair predisposit vitamin insuffici turkey vitamin defici vitamin turkish relat vitamin grave vitamin turkey vitamin bmi vitamin defici oh worsen\n",
            "\t0.464\tnativ banana starch supplement obes diabet fiber supplement effect nativ banana starch nb soy milk obes diabet blind withinsubject crossov undertook phase 4week supplement nb soy milk nb lost homai nb nb dietari fiber supplement resist starchbananadiabetesobesityinsulin introductionmateri methodspatientsstudi designmateri proceduresclin assaysstatist analysisresultscharacterist patientsdietari compliancebodi weightglycem resistancelipid parametersdiscussionconclus worldwid project rise 171 million 366 million 2030 expect overweight statist 90 diabet obes ir unifi ir inabl take ir accompani dyslipidemia hyperglycemia discus necessarili style modif view dietari habit wholegrain dietari fiber institut iom dietari fiber nondigest carbohydr lignin intrins intact fiber consist nondigest carbohydr benefici be accordingli resist starch r fiber indigest benefici r escap digest intestin ferment colon metabol fatti scfa banana resist starch belong r consist nativ starch granul resist digest amylas nativ banana starch nb unrip banana musa cavendish aaa cheap tabasco mexico starch diver consequ enzymat hydrolysi grade digest starch correl amylos banana amylosecont digest glycem insulin nb hypothes nb obes diabet nb gday lower obes diabet nb supplement cheap homeostasi recommend\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.857\tvitamin b12 diabet attend tertiari preliminari cross section estim vitamin b12 vitamin b12 defici autoimmun controversi b12 defici south indian demonstr b12 type1 recommend regular supplement vitamin b12 cross section nineti 44 male 46 femal randomli inclus exclus registri bangalor centr vitamin b12 autom carri spss version 455 diabet b12 manufactur cut 180 pgml 54 b12 cut 148 pmoll 200pgml b12 male femal 143 005 vitamin b12 018 011 008 005 b12 diabet merit defici b12 supplement vitamin b12 deficiencytyp diabetesdur diabetesdiabet ntroduct ateri ethod oper definitionsintern validitystatist analysisr esult iscuss studyc onclus mellitu iddm autoimmun destruct produc beta insul beta auto autoimmun endocrin auto autoimmun polyglandular autoimmun gastriti pernici anemia autoimmun fold pariet pca intrins occurr b12 defici dietari habit vari defici vitamin b12 defici insuffici vitamin b12 defici south indian undertaken b12 diabet south indian attend tertiari consider diabet vitamin b12 worthwhil consid regular supplement vitamin b12 \n",
            "\t-3.857\tvitamin b12 diabet attend tertiari preliminari cross section estim vitamin b12 vitamin b12 defici autoimmun controversi b12 defici south indian demonstr b12 type1 recommend regular supplement vitamin b12 cross section nineti 44 male 46 femal randomli inclus exclus registri bangalor centr vitamin b12 autom carri spss version 455 diabet b12 manufactur cut 180 pgml 54 b12 cut 148 pmoll 200pgml b12 male femal 143 005 vitamin b12 018 011 008 005 b12 diabet merit defici b12 supplement vitamin b12 deficiencytyp diabetesdur diabetesdiabet ntroduct ateri ethod oper definitionsintern validitystatist analysisr esult iscuss studyc onclus mellitu iddm autoimmun destruct produc beta insul beta auto autoimmun endocrin auto autoimmun polyglandular autoimmun gastriti pernici anemia autoimmun fold pariet pca intrins occurr b12 defici dietari habit vari defici vitamin b12 defici insuffici vitamin b12 defici south indian undertaken b12 diabet south indian attend tertiari consider diabet vitamin b12 worthwhil consid regular supplement vitamin b12 \n",
            "\t-4.281\trelat hydroxi vitamin d3 hypovitaminosi mellitu dm relat vitamin 101 classifi diabet bodymass indic hdroxi vitamin d3 25o hd bmi 0001 023 classifi diabet indic overweight obes hydroxi vitamin d3 everi bmi hydroxi vitamin turkish dm vitamin correl bmi vitamin worsen vitamin lessen obesitytyp mellitusvitamin introductionmateri methodspatientslaboratori methodsmethodsstatist analysisresultsdiscussionconclus hyperglycemia independ vitamin vitamin defici hipovitaminosi note diabet reason state besid sun impair predisposit vitamin insuffici turkey vitamin defici vitamin turkish relat vitamin grave vitamin turkey vitamin bmi vitamin defici oh worsen\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.475\trelat hydroxi vitamin d3 hypovitaminosi mellitu dm relat vitamin 101 classifi diabet bodymass indic hdroxi vitamin d3 25o hd bmi 0001 023 classifi diabet indic overweight obes hydroxi vitamin d3 everi bmi hydroxi vitamin turkish dm vitamin correl bmi vitamin worsen vitamin lessen obesitytyp mellitusvitamin introductionmateri methodspatientslaboratori methodsmethodsstatist analysisresultsdiscussionconclus hyperglycemia independ vitamin vitamin defici hipovitaminosi note diabet reason state besid sun impair predisposit vitamin insuffici turkey vitamin defici vitamin turkish relat vitamin grave vitamin turkey vitamin bmi vitamin defici oh worsen\n",
            "\t0.475\trelat hydroxi vitamin d3 hypovitaminosi mellitu dm relat vitamin 101 classifi diabet bodymass indic hdroxi vitamin d3 25o hd bmi 0001 023 classifi diabet indic overweight obes hydroxi vitamin d3 everi bmi hydroxi vitamin turkish dm vitamin correl bmi vitamin worsen vitamin lessen obesitytyp mellitusvitamin introductionmateri methodspatientslaboratori methodsmethodsstatist analysisresultsdiscussionconclus hyperglycemia independ vitamin vitamin defici hipovitaminosi note diabet reason state besid sun impair predisposit vitamin insuffici turkey vitamin defici vitamin turkish relat vitamin grave vitamin turkey vitamin bmi vitamin defici oh worsen\n",
            "\t0.464\tnativ banana starch supplement obes diabet fiber supplement effect nativ banana starch nb soy milk obes diabet blind withinsubject crossov undertook phase 4week supplement nb soy milk nb lost homai nb nb dietari fiber supplement resist starchbananadiabetesobesityinsulin introductionmateri methodspatientsstudi designmateri proceduresclin assaysstatist analysisresultscharacterist patientsdietari compliancebodi weightglycem resistancelipid parametersdiscussionconclus worldwid project rise 171 million 366 million 2030 expect overweight statist 90 diabet obes ir unifi ir inabl take ir accompani dyslipidemia hyperglycemia discus necessarili style modif view dietari habit wholegrain dietari fiber institut iom dietari fiber nondigest carbohydr lignin intrins intact fiber consist nondigest carbohydr benefici be accordingli resist starch r fiber indigest benefici r escap digest intestin ferment colon metabol fatti scfa banana resist starch belong r consist nativ starch granul resist digest amylas nativ banana starch nb unrip banana musa cavendish aaa cheap tabasco mexico starch diver consequ enzymat hydrolysi grade digest starch correl amylos banana amylosecont digest glycem insulin nb hypothes nb obes diabet nb gday lower obes diabet nb supplement cheap homeostasi recommend\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-3.857\tvitamin b12 diabet attend tertiari preliminari cross section estim vitamin b12 vitamin b12 defici autoimmun controversi b12 defici south indian demonstr b12 type1 recommend regular supplement vitamin b12 cross section nineti 44 male 46 femal randomli inclus exclus registri bangalor centr vitamin b12 autom carri spss version 455 diabet b12 manufactur cut 180 pgml 54 b12 cut 148 pmoll 200pgml b12 male femal 143 005 vitamin b12 018 011 008 005 b12 diabet merit defici b12 supplement vitamin b12 deficiencytyp diabetesdur diabetesdiabet ntroduct ateri ethod oper definitionsintern validitystatist analysisr esult iscuss studyc onclus mellitu iddm autoimmun destruct produc beta insul beta auto autoimmun endocrin auto autoimmun polyglandular autoimmun gastriti pernici anemia autoimmun fold pariet pca intrins occurr b12 defici dietari habit vari defici vitamin b12 defici insuffici vitamin b12 defici south indian undertaken b12 diabet south indian attend tertiari consider diabet vitamin b12 worthwhil consid regular supplement vitamin b12 \n",
            "\t-3.857\tvitamin b12 diabet attend tertiari preliminari cross section estim vitamin b12 vitamin b12 defici autoimmun controversi b12 defici south indian demonstr b12 type1 recommend regular supplement vitamin b12 cross section nineti 44 male 46 femal randomli inclus exclus registri bangalor centr vitamin b12 autom carri spss version 455 diabet b12 manufactur cut 180 pgml 54 b12 cut 148 pmoll 200pgml b12 male femal 143 005 vitamin b12 018 011 008 005 b12 diabet merit defici b12 supplement vitamin b12 deficiencytyp diabetesdur diabetesdiabet ntroduct ateri ethod oper definitionsintern validitystatist analysisr esult iscuss studyc onclus mellitu iddm autoimmun destruct produc beta insul beta auto autoimmun endocrin auto autoimmun polyglandular autoimmun gastriti pernici anemia autoimmun fold pariet pca intrins occurr b12 defici dietari habit vari defici vitamin b12 defici insuffici vitamin b12 defici south indian undertaken b12 diabet south indian attend tertiari consider diabet vitamin b12 worthwhil consid regular supplement vitamin b12 \n",
            "\t-4.281\trelat hydroxi vitamin d3 hypovitaminosi mellitu dm relat vitamin 101 classifi diabet bodymass indic hdroxi vitamin d3 25o hd bmi 0001 023 classifi diabet indic overweight obes hydroxi vitamin d3 everi bmi hydroxi vitamin turkish dm vitamin correl bmi vitamin worsen vitamin lessen obesitytyp mellitusvitamin introductionmateri methodspatientslaboratori methodsmethodsstatist analysisresultsdiscussionconclus hyperglycemia independ vitamin vitamin defici hipovitaminosi note diabet reason state besid sun impair predisposit vitamin insuffici turkey vitamin defici vitamin turkish relat vitamin grave vitamin turkey vitamin bmi vitamin defici oh worsen\n",
            "type 1 diabetes,ACE,vitamin D None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.452\tpapillari thyroid hashimoto thyroid hashimoto thyroid ht autoimmun hypothyroid nonendem goitrou symmetr painless diffus sometim local swell thyroid gland hypothyroid papillari thyroid ptc aggress thyroid iodinedefici coexist 50yearold 10year huge goiter essenti symptomfre present start complain neck dysphagia product cough cold intoler focal cystic tender multinodular swell cervic lymphadenopathi neck thyroid stimul hormon subnorm t3 t4 fine needl aspir cytolog yield ml aspir pu admix microscopi suspici follicular nucleus admix neutrophil polymorph siderophag foam hemorrhag background incis biopsi display ptc ht hashimoto thyroiditishistopathologyhurthl cellpapillari thyroid introductionpati observationdiscussionconclusionfinanci sponsorshipconflict name hashimoto thyroid ht 1912 hashimoto describ goiter intens lymphocyt infiltr thyroid struma lymphomatosa ht hypothyroid iodinedefici papillari carcinoma thyroid ioniz papillari thyroid ptc ht subject debat dailey 1955 lee cipolla liu pino rivero singh conclud ht ptc microscop thyroid biopsi 50yearold focus ht ptc hurthl hyperplasia herebi suspicion establish coexist hashimoto thyroid ptc clinician thoroughli hashimoto thyroid pathologist alway thorough job painstakingli macroscop microscop thyroid specimen one suspect hashimoto thyroid financi sponsorship\n",
            "\t0.446\tadalimumab sarcoidosi   introductionaimmethodsresultsconclus hamper immunosuppress sarcoidosi adalimumab monoclon direct cytokin sarcoidosi immunolog advantag exponenti involv adalimumab sarcoidosi restrict 80 adalimumab sil2r il8 scan vegfc dcr3 cytokinedirect\n",
            "\t0.433\thashimoto thyroid chest reveal sickl anemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red hashimoto thyroid thyroid recogn autoimmun thyroid haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia woman whose sign goitr thyroid autoimmun hemolyt anemia unconjug bilirubin coomb igg thyroid stimul hormon tsh thyroid excess 45 hemolyt anemia atyp chest anguish search hemoglobinopathi haematolog pain attack childhood electrophoresis mother ultim sickl trait ignor pain crise childhood adolesc hashimoto′ thyroitidissickl anemiaacut introductionpati observationdiscussionconclus world carrier hemoglobin sickl anemia thalassemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red affect african mediterranean asian descent manifest haemolysi vasoocclus sickl scd manifest worsen leg ulcer sickl retinopathi nephropathi thromboembol transfusion iron overload necrosi chest ac present pneumonia vasoocclus vasculatur clinic hypoxia fever infiltr chest xray hypoxia fever coincid vasoocclus episod receiv narcot preced radiograph delay fetal hemoglobin hbf modifi sickl anemia hashimoto thyroid thyroid recogn autoimmun thyroid goitr lymphocyt infiltr thyroidspecif autoantibodi haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia unusu event discoveri sickl anteced cholecystectomi wit hyperhemolysi illustr probabl manifest otherwis hemolyt charact hemolysi forgotten sickl\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.470\thashimoto thyroid chest reveal sickl anemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red hashimoto thyroid thyroid recogn autoimmun thyroid haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia woman whose sign goitr thyroid autoimmun hemolyt anemia unconjug bilirubin coomb igg thyroid stimul hormon tsh thyroid excess 45 hemolyt anemia atyp chest anguish search hemoglobinopathi haematolog pain attack childhood electrophoresis mother ultim sickl trait ignor pain crise childhood adolesc hashimoto′ thyroitidissickl anemiaacut introductionpati observationdiscussionconclus world carrier hemoglobin sickl anemia thalassemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red affect african mediterranean asian descent manifest haemolysi vasoocclus sickl scd manifest worsen leg ulcer sickl retinopathi nephropathi thromboembol transfusion iron overload necrosi chest ac present pneumonia vasoocclus vasculatur clinic hypoxia fever infiltr chest xray hypoxia fever coincid vasoocclus episod receiv narcot preced radiograph delay fetal hemoglobin hbf modifi sickl anemia hashimoto thyroid thyroid recogn autoimmun thyroid goitr lymphocyt infiltr thyroidspecif autoantibodi haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia unusu event discoveri sickl anteced cholecystectomi wit hyperhemolysi illustr probabl manifest otherwis hemolyt charact hemolysi forgotten sickl\n",
            "\t0.470\tatrial fibril adrenocorticotrop hormon defici hashimoto thyroid 75yearold hashimoto thyroid congest atrial fibril adrenocorticotrop hormon acth defici acth defici hashimoto thyroid sometim establish simultan make proper atrial fibrillationheart failureisol acth defici introductioncas reportdiscussionconclus adrenocorticotrop hormon acth defici iad autoimmun hashimoto thyroid congest atrial fibril iad hashimoto thyroid atrial fibril ventricular iad exacerb iad hashimoto thyroid sometim establish make proper improv congest atrial fibril acth defici hashimoto thyroid pathophysiolog sometim easili explain appropri\n",
            "\t0.470\tatrial fibril adrenocorticotrop hormon defici hashimoto thyroid 75yearold hashimoto thyroid congest atrial fibril adrenocorticotrop hormon acth defici acth defici hashimoto thyroid sometim establish simultan make proper atrial fibrillationheart failureisol acth defici introductioncas reportdiscussionconclus adrenocorticotrop hormon acth defici iad autoimmun hashimoto thyroid congest atrial fibril iad hashimoto thyroid atrial fibril ventricular iad exacerb iad hashimoto thyroid sometim establish make proper improv congest atrial fibril acth defici hashimoto thyroid pathophysiolog sometim easili explain appropri\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.452\tpapillari thyroid hashimoto thyroid hashimoto thyroid ht autoimmun hypothyroid nonendem goitrou symmetr painless diffus sometim local swell thyroid gland hypothyroid papillari thyroid ptc aggress thyroid iodinedefici coexist 50yearold 10year huge goiter essenti symptomfre present start complain neck dysphagia product cough cold intoler focal cystic tender multinodular swell cervic lymphadenopathi neck thyroid stimul hormon subnorm t3 t4 fine needl aspir cytolog yield ml aspir pu admix microscopi suspici follicular nucleus admix neutrophil polymorph siderophag foam hemorrhag background incis biopsi display ptc ht hashimoto thyroiditishistopathologyhurthl cellpapillari thyroid introductionpati observationdiscussionconclusionfinanci sponsorshipconflict name hashimoto thyroid ht 1912 hashimoto describ goiter intens lymphocyt infiltr thyroid struma lymphomatosa ht hypothyroid iodinedefici papillari carcinoma thyroid ioniz papillari thyroid ptc ht subject debat dailey 1955 lee cipolla liu pino rivero singh conclud ht ptc microscop thyroid biopsi 50yearold focus ht ptc hurthl hyperplasia herebi suspicion establish coexist hashimoto thyroid ptc clinician thoroughli hashimoto thyroid pathologist alway thorough job painstakingli macroscop microscop thyroid specimen one suspect hashimoto thyroid financi sponsorship\n",
            "\t0.446\tadalimumab sarcoidosi   introductionaimmethodsresultsconclus hamper immunosuppress sarcoidosi adalimumab monoclon direct cytokin sarcoidosi immunolog advantag exponenti involv adalimumab sarcoidosi restrict 80 adalimumab sil2r il8 scan vegfc dcr3 cytokinedirect\n",
            "\t0.433\thashimoto thyroid chest reveal sickl anemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red hashimoto thyroid thyroid recogn autoimmun thyroid haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia woman whose sign goitr thyroid autoimmun hemolyt anemia unconjug bilirubin coomb igg thyroid stimul hormon tsh thyroid excess 45 hemolyt anemia atyp chest anguish search hemoglobinopathi haematolog pain attack childhood electrophoresis mother ultim sickl trait ignor pain crise childhood adolesc hashimoto′ thyroitidissickl anemiaacut introductionpati observationdiscussionconclus world carrier hemoglobin sickl anemia thalassemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red affect african mediterranean asian descent manifest haemolysi vasoocclus sickl scd manifest worsen leg ulcer sickl retinopathi nephropathi thromboembol transfusion iron overload necrosi chest ac present pneumonia vasoocclus vasculatur clinic hypoxia fever infiltr chest xray hypoxia fever coincid vasoocclus episod receiv narcot preced radiograph delay fetal hemoglobin hbf modifi sickl anemia hashimoto thyroid thyroid recogn autoimmun thyroid goitr lymphocyt infiltr thyroidspecif autoantibodi haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia unusu event discoveri sickl anteced cholecystectomi wit hyperhemolysi illustr probabl manifest otherwis hemolyt charact hemolysi forgotten sickl\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t2.470\thashimoto thyroid chest reveal sickl anemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red hashimoto thyroid thyroid recogn autoimmun thyroid haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia woman whose sign goitr thyroid autoimmun hemolyt anemia unconjug bilirubin coomb igg thyroid stimul hormon tsh thyroid excess 45 hemolyt anemia atyp chest anguish search hemoglobinopathi haematolog pain attack childhood electrophoresis mother ultim sickl trait ignor pain crise childhood adolesc hashimoto′ thyroitidissickl anemiaacut introductionpati observationdiscussionconclus world carrier hemoglobin sickl anemia thalassemia sickl anemia substitut encod globin subunit polymer deoxygen sickl hemoglobin deform red affect african mediterranean asian descent manifest haemolysi vasoocclus sickl scd manifest worsen leg ulcer sickl retinopathi nephropathi thromboembol transfusion iron overload necrosi chest ac present pneumonia vasoocclus vasculatur clinic hypoxia fever infiltr chest xray hypoxia fever coincid vasoocclus episod receiv narcot preced radiograph delay fetal hemoglobin hbf modifi sickl anemia hashimoto thyroid thyroid recogn autoimmun thyroid goitr lymphocyt infiltr thyroidspecif autoantibodi haemolyt autoimmun anemia old admit chest haemolysi anemia hashimoto thyroid sickl anemia unusu event discoveri sickl anteced cholecystectomi wit hyperhemolysi illustr probabl manifest otherwis hemolyt charact hemolysi forgotten sickl\n",
            "\t0.470\tatrial fibril adrenocorticotrop hormon defici hashimoto thyroid 75yearold hashimoto thyroid congest atrial fibril adrenocorticotrop hormon acth defici acth defici hashimoto thyroid sometim establish simultan make proper atrial fibrillationheart failureisol acth defici introductioncas reportdiscussionconclus adrenocorticotrop hormon acth defici iad autoimmun hashimoto thyroid congest atrial fibril iad hashimoto thyroid atrial fibril ventricular iad exacerb iad hashimoto thyroid sometim establish make proper improv congest atrial fibril acth defici hashimoto thyroid pathophysiolog sometim easili explain appropri\n",
            "\t0.470\tatrial fibril adrenocorticotrop hormon defici hashimoto thyroid 75yearold hashimoto thyroid congest atrial fibril adrenocorticotrop hormon acth defici acth defici hashimoto thyroid sometim establish simultan make proper atrial fibrillationheart failureisol acth defici introductioncas reportdiscussionconclus adrenocorticotrop hormon acth defici iad autoimmun hashimoto thyroid congest atrial fibril iad hashimoto thyroid atrial fibril ventricular iad exacerb iad hashimoto thyroid sometim establish make proper improv congest atrial fibril acth defici hashimoto thyroid pathophysiolog sometim easili explain appropri\n",
            "Hashimoto disease,TSH None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.524\talcohol alcohol polici intim partner violenc systemat intim partner violenc ipv issu alcohol partner contribut ipv alcohol ipv sought ipv alcohol organ ecolog framework violenc eleven databas medlin psycinfo cinahl embas search englishlanguag grey januari 1992 march investig alcohol interventionspolici ipv intim relationship eleven meet attribut ten mediat alcohol heterogen design preclud meta narr populationlevel price taxat weak alcohol price influenc ipv communitylevel polici hour sale alcohol outlet weak ipv couplesbas alcohol reduct alcohol reduct ipv design preclud attribut random alcohol violenc brief alcohol adjunct batter hazard drink ipv perpetr brief nondepend younger sustain associ problemat alcohol ipv alcohol ipv adequ possibl alcoholrel ipv rigor design ipv drink preval combin alcohol ipv interventionpolici individuallevel opportun onlin version articl doi1011861471245814881 author user  backgroundmethodsresultspopulationlevel interventionsalcohol pricingtax ipvcommunitylevel interventionsalcohol sale restrict ipvalcohol outlet ipvrelationshiplevel interventionscouplesbas treatmentindividuallevel interventionstreatmentdiscussionconclusionselectron  alcoholrel ipv multidimension neglect link alcohol ipv alcohol contribut ipv alcohol alcohol polici ipv allow ipv attribut appropri fund agenda urgent alcoholpolici ipv individuallevel answer gap base includ theoret link ipv alcohol price avail heavi episod drinker stronger design random groupcommun prospect longitudin design design mediat alcohol reliabl distinguish alcoholrel ipv ipv involv alcohol consist middl incom ipv link alcohol stronger employ problemat alcohol integr ecolog framework combin alcohol ipv ipv enhanc victim alcohol intertwin ipv perpetr electron\n",
            "\t0.504\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "\t0.481\tpai1 4g5g polymorph coronari arteri occlus myocardi infarct   introduction2 methods21 inclus criteria22 genotyp sequencing221 pcr222 purif product223 presequenc pcr224 purif product225 sequencing23 analysis3 results31 anthropometr characteristics32 coronari arteri occlusion33 coronari arteri occlusion4 discus myocardi infarct mi atherosclerot plaqu ruptur ruptur plaqu trigger coagul cascad occlus myocardi necrosi mellitu excess habit arteri mi thrombosi coronari arteri myocardi infarct plasminogen activ pai1 pai1 particip thrombu stabil wound heal pai1 secret store releas platelet pai1 downregul fibrinolysi stop convers plasminogen plasmin plasminogen activ tissueplasminogen activ urokinas pai1 atherosclerosi pai1 atherosclerosi mellitu pai1 cd 34 microvascular match nondiabet pai1 viscer pai1 ectop depot pai1 il8 leukotrien b4 monocyt pai1 prolong haemorrhag state pai1 member serpin serin protea superfamili protea pai1 polymorph research one pai1 rs1799889 675 4g5g insertiondelet polymorph 675 ga substitut 844 rs2227631 c43g pa15t rs6092 pi17v r 6090 state polymorph pai1 pai1675 4g5g pai1 special carri 4g4g genotyp polymorph name ga substitut 844 rs2227631 aa ag aa carri pai1 ag pai1 genotyp gg polymorph c43g pa15t rs6092 pai1 aa ag genotyp pai1 gg genotyp pai1 depend exact polymorph pai1 rs1799889 675 4g5g thoroughli thrombosi pai1 4g4g genotyp myocardi infarct confirm pai1 genotyp thrombolysi mi pai1675 4g5g polymorph coronari arteri occlus myocardi infarct gender pai1 4g5g genotyp coronari arteri occlus myocardi infarct pai1 4g5g genotyp sanger allelespecif rflp fragment label primer melt curv sanger 4g5g genotyp rare consist mi definit siano classifi occlus coronari arteri classifi follow coronari arteri occlus visibl occlus nonocclus coronari arteri narrow vessel thrombosi take narrow 99 vessel diamet thrombosi occlus coronari arteri vessel diamet thrombosi postobstruct antegrad visibl angiographi 2nd 3rd join twothird coronari arteri occlus coronari arteri lumen mi excess smoker differ coronari arteri occlus 3894 0048 coronari arteri occlus occlus occlud coronari arteri 005 resp concord ukrainian guid efimov coronari arteri occlus prove kgm dyslipidaemia coronari arteri occlus epidemiolog pai1 mi inhibit fibrinolysi clot dissolut mi pai1 upregul reninangiotensin recurr mi carrier 4g allel obes 4g4g genotyp thrombot recurr mi normolipidem postinfarct carri 4g allel 4g4g genotyp prevent stenosi half 4g5g genotyp onethird 4g4g onefifth genotyp 5g5g allel pai1 match hardyweinberg equilibrium 076 4g5g genotyp lithuanian european danish guid knudsen french guid collet belgian guid rapold italian guid castro norwegian guid liguori state pai1 genotyp mi coronari arteri occlus pai1 polymorph coronari occlus guid mehta univari pai1 4g5g genotyp independ coronari arteri occlus lithuanian 1656 1009 2718 0046 multivari coronari arteri occlus univari multivari individu one odd ratio coronari arteri occlus heterozyg pai1 4g5g genotyp carrier pai1 4g5g genotyp biomark individu fibrinolysi enhanc mi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.297\telectrophysiolog alcohol cue pavloviantoinstrument drinker pavlovian instrument pit refer behavior phenomenon instrument respond reinforc pavlovian condit separ pair reinforc pit substanc underli alcohol consum behavior electroencephalograph eeg drinker 31 pit chose instrument pursuit beer chocol reinforc eeg reactiv beer chocol neutral pictori cue record motiv salienc pictur p300 slow wave eventrel potenti erp behavior pit respond beer beer pictur erp amplitud slow potenti evok beer cue electrod cluster contrari hypothes correl behavior pit electrophysiolog reactiv cue drink behaviour pit beer accompani slow potenti beer cue drinker behavior eeg drink behaviour attribut methodolog pit  introductionmethodseth statementparticipantsmaterialsconcurr instrument trainingpavlovian instrument pitproceduredata acquisit analysiselectrod interestresultsparticip characteristicsbehavior pavlovian instrument effectsmean percentag instrument beer cue typeeegtanovatim point eeg contrastseventrel potenti erpserp anterior posterior midlin rightp300slow potentialsplan comparison erp amplitud nine electrod sp window 801 1357 m stimulu onsetassoci electrophysiolog behavior pit alcohol usediscussionsupport instrument pavlovian condit selfadministr ultim substanc drugseek reinforc pharmacolog action abus pleasur consequ allevi withdraw instrument condit develop synchron pavlovian condit repeat reward abus consist pair drugrel cue sight smell beer pair cue evok condit subject crave anticip arous behavior pavlovian instrument independ pavlovian instrument pit refer behavior phenomenon instrument respond reinforc condit c pair reinforc wellsupport explan pit pavlovian cue predict retriev belief responseoutcom stronger conting instrument reinforc addict drugrel cue evok expect turn activ instrument hogarth colleagu pit cigarett smoker instrument respond cigarett chocol cigarett cue respond chocol expens cigarett chocol cue pit maintain reinforc devalu instrument extinguish train extinguish instrument tobacco present tobacco cue reinstat instrument tobacco devalu reward cigarett chocol satieti suppress instrument respond reinforc attenu pit pit involv retriev represent reinforc represent encod incent reinforc pavlovian cue evok instrument automat irrespect strength motiv consum regardless user depend implic pit drugseek behaviour relaps drugtak abstin trigger cue former user motiv consum characteris underli pit reward consist striatum amygdala orbitofront mediodors thalamu electroencephalographi eeg electrophysiolog indic cue reactiv eventrel potenti erp regist motiv salienc drugrel pictori cue metaanalysi littel colleagu p300 slow wave sp sustain lpp erp reliabl substanc user view substancerel cue p300 transient deflect maxim medial pariet 300 800 m stimulu present sp sustain continu p300 last second amplitud modul attent captur taskrelev motivationallyrelev littel colleagu robust medium p300 sp substanc elicit drugrel cue neutral cue substanc nondepend substanc user drinker p300 sp indic motiv attent salienc drugrel cue amplitud erp alcoholrel cue enhanc instrument alcohol cue behavior pit learn instrument attempt win beer instrument attempt win chocol complet pit instrument pictur beer chocol neutral stimulu display electrophysiolog analys prerespons hypothes follow firstli behavior reveal pit instrument beer beer pictur neutral stimulu secondli amplitud p300 sp beer chocol pictur neutral stimulu reflect motiv salienc beer chocol pictur drank beer ate chocol regularli interrelationship behavior pit amplitud erp amplitud p300 sp beer cue amplitud neutral cue posit beer cue instrument respond beer typic alcohol hazard drink alcohol crave posit magnitud eventrel potenti evok alcoholrel cue drinker pavlovian instrument beer chocol pictur instrument respond beer chocol reinforc whilst eeg record behavior pit present nonconting beer pictur instrument beer reinforc present nonconting chocol pictur instrument chocol reinforc support demonstr pit alcohol cue drinker compar tobacco smoker metaanalysi alcoholrel chocol pictur evok electrophysiolog p300 slow potenti neutral stimulu grey squar partial pictur pronounc slow potenti p300 expect mix reward alcohol chocol pictur neutral grey squar electrod consider methodolog task littel al metaanalysi fail oddbal manual electrophysiolog record view pictur await prompt instrument p300 amplitud tend blunt engag paradigm unexpect review repeatedli imag imag pictur chocol bar bottl beer blank grey squar drugrel pictur pictur goal pit paradigm erp pictori cue paradigm insensit consider explan weak erp alcohol cue littel al metaanalysi abus substanc alcoholdepend drinker alcohol depend neither littel al metaanalysi amplitud p300 alcoholcu neutral cue drinker care read paper p300 alcohol cue robust drinker p300 alcohol cue subgroup drinker alcohol herrmann p300 alcohol cue heavi drinker drinker frontalmidlin electrod amplitud p300 pariet p300 promin alcoholdepend p300 alcohol cue consist research interest studi electrophysiolog correl pit addict advis tobacco smoker cocain user erp reactiv drugrel cue robust advis methodolog oddbal captur erp drugrel cue oppos modifi interrelationship behavior pit amplitud p300 sp beer chocol pictur amplitud p300 sp beer cue amplitud chocol neutral cue posit beer cue instrument respond beer behavior pit correl fail reach signific fail drink habit hazard drink audit alcohol crave daq erp indic cue reactiv repeat split audit median split audit moder strength behavior pit erp alcohol pictur pit fourth reject behavior pit drink habit hazard drink parallel cigarett smoker instrument respond tobacco nicotin depend magnitud tobacco pit discus introduct notion pit evok automat condit irrespect depend motiv correl erp indic alcohol cue reactiv audit perhap unsurpris robust p300 sp alcohol cue materi inconclus erp reactiv alcohol cue drinker alcohol discus audit erp reactiv instrument respond alcohol vast 81 score audit class hazard drinker maximum audit restrict 81 audit audit rang unabl sophist explor betweensubject moder withinsubject manipul recruit wider drink habit lighter infrequ drinker comprehens relationship hazard drink instrument respond alcohol erp alcohol pictur alcohol abstain suitabl inclus reason believ ever instrument pursuit alcohol uneth attempt pit crucial eeg correl behavior pit pit explicit expect paradox decoupl motiv perhap unsurpris behavior pit erp motiv cue name p300 sp fmri lesion remark pit nondrug reward striatum amygdala orbitofront mediodors thalamu eeg capabl detect notabl paradigm pit paradigm fmri resolv issu attempt obtain pit fmri scanner paradigm conduct erp paradigm close match pavlovian instrument evok alcohol chocol cue electrophysiolog correl drinker regularli consum chocol behavior pit p300 slow eventrel potenti reveal robust reactiv alcohol cue reflect limit attribut\n",
            "\t0.240\tpavloviancondit alcoholseek invigor discret contextu alcohol cue implic relaps crave independ stimul cue discret cue context contextu cue discret alcoholpredict cue experienc robustli cue stimul alcoholseek longevan pavlovian discrimin pdt session condit stimulu c trial pair ethanol 02 mlc stimulu c trial pdt entri fluid port ethanol deliv c next acclim altern nonalcohol cue ethanol withheld nonextinguish c c ethanol alcoholassoci pdt nonalcohol pdt c elicit port entri c indic pavlovian discrimin c elicit port entri c context alcohol seek driven c robust alcoholassoci separ experi extinguish contextalcohol c respond alcohol seek nonc interv spontan recoveri alcoholseek driven discret pavlovian alcohol cue invigor alcohol context excitatori pavlovian condit trigger alcoholseek alcoholismcontextethanollearningpavlovianconditioningreinstatementrenew introductionmateri methodssubjectsapparatusdrugsalcohol home cagepavlovian discrimin trainingexposur altern nonalcohol contexttestexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi extinct pavloviancondit alcoholseek behaviorstatist analysesresultsexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi extinct pavloviancondit alcoholseek behaviordiscuss crave term character addict subject urg consum relaps sinha omalley litt flanneri evren crave trigger repeat cooccurr abus come predict pharmacolog addict substanc ludwig 1986 duka uslan sensori alcohol sight smell tast evok crave reactiv alcohol abus turn drink ludwig wikler 1974 pomerleau 1983 litt cooney sensori oral consum alcohol typic encount tempor discret gain promin activ consum convers configur multimod background necessarili gain lose promin relat nonetheless discret cue context evok crave bordnick conklin pari seek crombag shaham zironi fuch chaudhri 2008b perri mcnalli acquir predict avail pavlovian janak chaudhri determin discret contextu cue independ relaps longstand empir question cooccur everyday user cooccurr crave seek litt cooney pari nee question behavior pavloviancondit alcohol seek train discrimin auditori condit c c pair alcohol c alcohol chaudhri 2008b entri fluid port alcohol deliv cue discrimin repeatedli neither cue alcohol acclim never alcohol avail pavloviancondit alcohol seek present nonextinguish c c alcohol alcoholassoci nonalcohol separ experi sought alcoholassoci respond elicit c alcohol excitatori pavloviancondit stimulu repeat alcohol pavloviancondit extinguish alcohol respond c receiv extinct reveal alcoholseek trigger discret pavloviancondit alcohol cue invigor alcoholassoci alcohol seek elicit alcoholpredict c consist robust alcohol familiar context alcohol never consum extinguish pdt alcohol diminish c respond markedli alcoholseek driven pdt spontan recoveri implic crave alcohol abus encount discret contextu alcoholpredict cue concurr acquir predict relat c alcohol pdt chaudhri 2008b altern cue alcohol establish alcohol never acrosssess spontan entri fluid port fig s1 respond cue context note cue respond extinguish therebi parallel crave reactiv discret cue systemat extinguish staiger white 1991 thoma continu discrimin c c cue alcohol nonalcohol chaudhri discrimin remain intact cue pdt alcohol consum alcoholseek driven c invigor alcoholassoci nonalcohol context separ ethanol pdt discret cue experienc determin seek elicit cue zironi tsiang janak chaudhri 2008a nee translat impli crave vigor discret cue encount drugassoci discret contextu cue potent trigger relaps cue independ alcohol seek driven c nonalcohol remov nonalcohol se invigor pavloviancondit alcohol seek c trigger alcohol seek parallel reactiv drugpredict cue evok set resembl environ normal consum litt cooney wit duka strength cue reactiv underestim environ extens cuereact estim accur drugus environ set incorpor contextu drugus environ virtual realiti creat context prove investig bordnick pari traylor alcohol port entri elicit c present experi rapidli extinct alcohol seek c respond alcohol nonalcohol throughout session conduct extinct uncondit stimulu alcohol experienc produc extinct bouton addict undergo drugpredict discret cue repeatedli effort dampen cue reactiv drummond glautier 1994 conklin tiffani extinct session influenc set turn longev extinct instrument alcohol selfadministr reveal modul respond discret cue train perform oper obtain alcohol alcohol pair discret tonelight cue acquisit respond extinguish withhold alcohol extinct context placement extinct renew respond invigor conting present discret tonelight cue cue absent tsiang janak train leverpress alcohol extinct drop alcohol trigger reinstat alcohol extinct chaudhri 2008a congruent instrument alcohol seek pavloviancondit alcoholseek invigor alcoholassoci context experi facilit cuedriven alcohol seek alcohol attribut summat condit excitatori c alcoholassoci context stimul crave context acquir condit excitatori conklin preclin neutral euphor morphin facilit sexual trigger mitchel stewart 1990 uncondit stimulu invigor respond elicit condit stimulu predict uncondit stimulu reason alcohol function excitatori pavlovian c extinguish alcohol respond c extinct extinct manipul context respond pavloviancondit cue predict avers bouton boll 1979 consequ pdt session experi repeatedli pdt alcohol extinct altern nonalcohol spontan entri fluid port session s1 extinct contextalcohol contrari predict extinct respond c fig immedi c trend port entri interv session signal c contextextinct neglig extinct c respond discret alcoholpredict cue drive alcoholseek unequ pdt contextextinct session contribut conduct equival pdt contextextinct session extinct c respond mark extinct spontan recoveri extinct modest c respond start spontan recoveri extinct fewer port entri interv signal c extinguish excitatori pdt appear effect alcoholseek trigger alcoholseek trigger c spontan recoveri c alcohol extinguish pdt extinct extinct c respond pdt unsign alcoholseek spontan recoveri extinct alcoholassoci pavlovian condit stimulu elicit alcoholseek extinct c respond condit excitatori discret contextu alcohol cue summat respond discret cue function occasionsett stimulu modul stimulu elicit elicit bouton crombag properti modest c spontan recoveri extinct c whose alcohol diminish c alcohol summari alcoholseek elicit discret alcohol cue robustli invigor alcoholassoci strongest trigger crave relaps discret cue drugassoci extinct alcoholseek trigger pdt context acquir condit excitatori pavlovian aim diminish drugpredict cue extinct addict consid discret contextu drugpredict cue\n",
            "\t-0.964\tdetermin populationlevel alcohol estim alcoholattribut harm goal alcohol burden analyz chosen alcohol estim alcohol attribut fraction paf character chosen alcohol explor lognorm gamma weibul distribut 41 survey gender alcohol intern genaci european compar alcohol distribut alcohol paf calcul alcohol paf pancreat abovenam distribut tradit categori deviat gamma 851 dataset 66 genaci stepwis surveil organ lognorm fit gamma weibul distribut provid fit mark alcohol paf estim gamma weibul distribut paf categor alcohol estim deviat alcohol unit alcohol unit 1258 1223 1293 09207 1171 1144 1197 9474 gamma weibul gamma recommend alcohol survey fit flexibl ea modifi varianc deviat alcohol gamma explain alcohol allow alcohol model gamma alcohol consumptionempir distributiongamma distributionlognorm distributionweibul distributionpopulationattribut fractionexposur distributionupestimationp caput consumptionmeanstandard deviat introductionmethodsdescript surveysmethod fit distributionsmethod deriv alcohol pafmethod character gamma distributionsregress analysisresultsmodel alcohol distributioncharacter alcohol gamma distributiondiscussionconclusioncompet interestsauthor contributionssupplementari materialaddit file alcohol 200 intern classif icd10 threedigit code word fraction call populationattribut fraction paf disappear causal elimin alcohol counterfactu scenario everi person lifetim abstain alcohol alcohol risk alcohol alcoholattribut pancreat cirrhosi alcohol adequ predictor injuri ischem unintent injuri intent injuri drink calcul alcohol paf involv threestag estim alcohol establish solv equat paf alcohol intern agre estim paf categor model mathemat continu mathemat followsformula categori rr th categori continu alcohol calcul repres formulaformula 150 150 lifetim abstain rr lifetim abstain ex former drinker rr ex former drinker alcohol px alcohol rrx drinker accur calcul paf alcohol attempt model alcohol lognorm critic reason lognorm adequ approxim adapt distribut gamma favor lognorm mix distribut separ drink quantiti alcohol consum instrument monitor alcohol intern organ survey estim caput caput aggreg record unrecord tourist caput alcohol sale econom statist instrument survey exist accur estim survey ask drink exist survey consider underestim real typic cover alcohol sale caput figur estim countri caput disaggreg statist genderspecif estim instanc alcohol diseasespecif gender alcohol gender estim paf calcul alcoholattribut burden note respect survey underestim burden attribut alcohol paf calcul adjust consequ triangul alcohol survey caput paf calcul categor estim alcohol correct multipli top alcohol categori invers undercoverag caput consumptionth caput categori alcohol doserespons nonlinear estim alcohol gender accur estim alcohol paf strengthen dissemin alcohol outlin organ harm alcohol alcohol easili model fit compat caput estim except estim abstent intern alcohol consist follow wellknown rightskew distribut lognorm gamma weibul chosen estim paf paf pancreat exampl exist alcohol alcohol compar lognorm weibul gamma distribut calcul alcohol gamma weibul outperform lognorm fit empir distribut gamma choic model easili shift fit compat caput make estim aggreg caput abstent shift upward gamma deviat empir varianc deviat alcohol gamma explain alcohol accur model alcohol upshift decisionmak accur alcohol aid determin prioriti alloc resourc compet interest\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.524\talcohol alcohol polici intim partner violenc systemat intim partner violenc ipv issu alcohol partner contribut ipv alcohol ipv sought ipv alcohol organ ecolog framework violenc eleven databas medlin psycinfo cinahl embas search englishlanguag grey januari 1992 march investig alcohol interventionspolici ipv intim relationship eleven meet attribut ten mediat alcohol heterogen design preclud meta narr populationlevel price taxat weak alcohol price influenc ipv communitylevel polici hour sale alcohol outlet weak ipv couplesbas alcohol reduct alcohol reduct ipv design preclud attribut random alcohol violenc brief alcohol adjunct batter hazard drink ipv perpetr brief nondepend younger sustain associ problemat alcohol ipv alcohol ipv adequ possibl alcoholrel ipv rigor design ipv drink preval combin alcohol ipv interventionpolici individuallevel opportun onlin version articl doi1011861471245814881 author user  backgroundmethodsresultspopulationlevel interventionsalcohol pricingtax ipvcommunitylevel interventionsalcohol sale restrict ipvalcohol outlet ipvrelationshiplevel interventionscouplesbas treatmentindividuallevel interventionstreatmentdiscussionconclusionselectron  alcoholrel ipv multidimension neglect link alcohol ipv alcohol contribut ipv alcohol alcohol polici ipv allow ipv attribut appropri fund agenda urgent alcoholpolici ipv individuallevel answer gap base includ theoret link ipv alcohol price avail heavi episod drinker stronger design random groupcommun prospect longitudin design design mediat alcohol reliabl distinguish alcoholrel ipv ipv involv alcohol consist middl incom ipv link alcohol stronger employ problemat alcohol integr ecolog framework combin alcohol ipv ipv enhanc victim alcohol intertwin ipv perpetr electron\n",
            "\t0.504\talcohol epidemiolog alcohol risk alcohol consist risk squamou carcinoma mouth pharynx larynx esophagu vari joint alcohol addit multipl synerg alcohol beverag casual implic genesi alcohol risk upper aerodigest tract person margin nutrit betternourish alcohol adenocarcinoma esophagu gastroesophag junction cardia squamou esophag carcinoma alcohol tobacco 80 squamou carcinoma mouth pharynx larynx esophagu risk distal stomach pancrea colon rectum consist alcohol relationship beer drink rectal heavi alcohol pancreat warrant alcohol confound hepat yield inconsist replic heavi alcohol control investig issu warrant    \n",
            "\t0.481\tpai1 4g5g polymorph coronari arteri occlus myocardi infarct   introduction2 methods21 inclus criteria22 genotyp sequencing221 pcr222 purif product223 presequenc pcr224 purif product225 sequencing23 analysis3 results31 anthropometr characteristics32 coronari arteri occlusion33 coronari arteri occlusion4 discus myocardi infarct mi atherosclerot plaqu ruptur ruptur plaqu trigger coagul cascad occlus myocardi necrosi mellitu excess habit arteri mi thrombosi coronari arteri myocardi infarct plasminogen activ pai1 pai1 particip thrombu stabil wound heal pai1 secret store releas platelet pai1 downregul fibrinolysi stop convers plasminogen plasmin plasminogen activ tissueplasminogen activ urokinas pai1 atherosclerosi pai1 atherosclerosi mellitu pai1 cd 34 microvascular match nondiabet pai1 viscer pai1 ectop depot pai1 il8 leukotrien b4 monocyt pai1 prolong haemorrhag state pai1 member serpin serin protea superfamili protea pai1 polymorph research one pai1 rs1799889 675 4g5g insertiondelet polymorph 675 ga substitut 844 rs2227631 c43g pa15t rs6092 pi17v r 6090 state polymorph pai1 pai1675 4g5g pai1 special carri 4g4g genotyp polymorph name ga substitut 844 rs2227631 aa ag aa carri pai1 ag pai1 genotyp gg polymorph c43g pa15t rs6092 pai1 aa ag genotyp pai1 gg genotyp pai1 depend exact polymorph pai1 rs1799889 675 4g5g thoroughli thrombosi pai1 4g4g genotyp myocardi infarct confirm pai1 genotyp thrombolysi mi pai1675 4g5g polymorph coronari arteri occlus myocardi infarct gender pai1 4g5g genotyp coronari arteri occlus myocardi infarct pai1 4g5g genotyp sanger allelespecif rflp fragment label primer melt curv sanger 4g5g genotyp rare consist mi definit siano classifi occlus coronari arteri classifi follow coronari arteri occlus visibl occlus nonocclus coronari arteri narrow vessel thrombosi take narrow 99 vessel diamet thrombosi occlus coronari arteri vessel diamet thrombosi postobstruct antegrad visibl angiographi 2nd 3rd join twothird coronari arteri occlus coronari arteri lumen mi excess smoker differ coronari arteri occlus 3894 0048 coronari arteri occlus occlus occlud coronari arteri 005 resp concord ukrainian guid efimov coronari arteri occlus prove kgm dyslipidaemia coronari arteri occlus epidemiolog pai1 mi inhibit fibrinolysi clot dissolut mi pai1 upregul reninangiotensin recurr mi carrier 4g allel obes 4g4g genotyp thrombot recurr mi normolipidem postinfarct carri 4g allel 4g4g genotyp prevent stenosi half 4g5g genotyp onethird 4g4g onefifth genotyp 5g5g allel pai1 match hardyweinberg equilibrium 076 4g5g genotyp lithuanian european danish guid knudsen french guid collet belgian guid rapold italian guid castro norwegian guid liguori state pai1 genotyp mi coronari arteri occlus pai1 polymorph coronari occlus guid mehta univari pai1 4g5g genotyp independ coronari arteri occlus lithuanian 1656 1009 2718 0046 multivari coronari arteri occlus univari multivari individu one odd ratio coronari arteri occlus heterozyg pai1 4g5g genotyp carrier pai1 4g5g genotyp biomark individu fibrinolysi enhanc mi\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t0.297\telectrophysiolog alcohol cue pavloviantoinstrument drinker pavlovian instrument pit refer behavior phenomenon instrument respond reinforc pavlovian condit separ pair reinforc pit substanc underli alcohol consum behavior electroencephalograph eeg drinker 31 pit chose instrument pursuit beer chocol reinforc eeg reactiv beer chocol neutral pictori cue record motiv salienc pictur p300 slow wave eventrel potenti erp behavior pit respond beer beer pictur erp amplitud slow potenti evok beer cue electrod cluster contrari hypothes correl behavior pit electrophysiolog reactiv cue drink behaviour pit beer accompani slow potenti beer cue drinker behavior eeg drink behaviour attribut methodolog pit  introductionmethodseth statementparticipantsmaterialsconcurr instrument trainingpavlovian instrument pitproceduredata acquisit analysiselectrod interestresultsparticip characteristicsbehavior pavlovian instrument effectsmean percentag instrument beer cue typeeegtanovatim point eeg contrastseventrel potenti erpserp anterior posterior midlin rightp300slow potentialsplan comparison erp amplitud nine electrod sp window 801 1357 m stimulu onsetassoci electrophysiolog behavior pit alcohol usediscussionsupport instrument pavlovian condit selfadministr ultim substanc drugseek reinforc pharmacolog action abus pleasur consequ allevi withdraw instrument condit develop synchron pavlovian condit repeat reward abus consist pair drugrel cue sight smell beer pair cue evok condit subject crave anticip arous behavior pavlovian instrument independ pavlovian instrument pit refer behavior phenomenon instrument respond reinforc condit c pair reinforc wellsupport explan pit pavlovian cue predict retriev belief responseoutcom stronger conting instrument reinforc addict drugrel cue evok expect turn activ instrument hogarth colleagu pit cigarett smoker instrument respond cigarett chocol cigarett cue respond chocol expens cigarett chocol cue pit maintain reinforc devalu instrument extinguish train extinguish instrument tobacco present tobacco cue reinstat instrument tobacco devalu reward cigarett chocol satieti suppress instrument respond reinforc attenu pit pit involv retriev represent reinforc represent encod incent reinforc pavlovian cue evok instrument automat irrespect strength motiv consum regardless user depend implic pit drugseek behaviour relaps drugtak abstin trigger cue former user motiv consum characteris underli pit reward consist striatum amygdala orbitofront mediodors thalamu electroencephalographi eeg electrophysiolog indic cue reactiv eventrel potenti erp regist motiv salienc drugrel pictori cue metaanalysi littel colleagu p300 slow wave sp sustain lpp erp reliabl substanc user view substancerel cue p300 transient deflect maxim medial pariet 300 800 m stimulu present sp sustain continu p300 last second amplitud modul attent captur taskrelev motivationallyrelev littel colleagu robust medium p300 sp substanc elicit drugrel cue neutral cue substanc nondepend substanc user drinker p300 sp indic motiv attent salienc drugrel cue amplitud erp alcoholrel cue enhanc instrument alcohol cue behavior pit learn instrument attempt win beer instrument attempt win chocol complet pit instrument pictur beer chocol neutral stimulu display electrophysiolog analys prerespons hypothes follow firstli behavior reveal pit instrument beer beer pictur neutral stimulu secondli amplitud p300 sp beer chocol pictur neutral stimulu reflect motiv salienc beer chocol pictur drank beer ate chocol regularli interrelationship behavior pit amplitud erp amplitud p300 sp beer cue amplitud neutral cue posit beer cue instrument respond beer typic alcohol hazard drink alcohol crave posit magnitud eventrel potenti evok alcoholrel cue drinker pavlovian instrument beer chocol pictur instrument respond beer chocol reinforc whilst eeg record behavior pit present nonconting beer pictur instrument beer reinforc present nonconting chocol pictur instrument chocol reinforc support demonstr pit alcohol cue drinker compar tobacco smoker metaanalysi alcoholrel chocol pictur evok electrophysiolog p300 slow potenti neutral stimulu grey squar partial pictur pronounc slow potenti p300 expect mix reward alcohol chocol pictur neutral grey squar electrod consider methodolog task littel al metaanalysi fail oddbal manual electrophysiolog record view pictur await prompt instrument p300 amplitud tend blunt engag paradigm unexpect review repeatedli imag imag pictur chocol bar bottl beer blank grey squar drugrel pictur pictur goal pit paradigm erp pictori cue paradigm insensit consider explan weak erp alcohol cue littel al metaanalysi abus substanc alcoholdepend drinker alcohol depend neither littel al metaanalysi amplitud p300 alcoholcu neutral cue drinker care read paper p300 alcohol cue robust drinker p300 alcohol cue subgroup drinker alcohol herrmann p300 alcohol cue heavi drinker drinker frontalmidlin electrod amplitud p300 pariet p300 promin alcoholdepend p300 alcohol cue consist research interest studi electrophysiolog correl pit addict advis tobacco smoker cocain user erp reactiv drugrel cue robust advis methodolog oddbal captur erp drugrel cue oppos modifi interrelationship behavior pit amplitud p300 sp beer chocol pictur amplitud p300 sp beer cue amplitud chocol neutral cue posit beer cue instrument respond beer behavior pit correl fail reach signific fail drink habit hazard drink audit alcohol crave daq erp indic cue reactiv repeat split audit median split audit moder strength behavior pit erp alcohol pictur pit fourth reject behavior pit drink habit hazard drink parallel cigarett smoker instrument respond tobacco nicotin depend magnitud tobacco pit discus introduct notion pit evok automat condit irrespect depend motiv correl erp indic alcohol cue reactiv audit perhap unsurpris robust p300 sp alcohol cue materi inconclus erp reactiv alcohol cue drinker alcohol discus audit erp reactiv instrument respond alcohol vast 81 score audit class hazard drinker maximum audit restrict 81 audit audit rang unabl sophist explor betweensubject moder withinsubject manipul recruit wider drink habit lighter infrequ drinker comprehens relationship hazard drink instrument respond alcohol erp alcohol pictur alcohol abstain suitabl inclus reason believ ever instrument pursuit alcohol uneth attempt pit crucial eeg correl behavior pit pit explicit expect paradox decoupl motiv perhap unsurpris behavior pit erp motiv cue name p300 sp fmri lesion remark pit nondrug reward striatum amygdala orbitofront mediodors thalamu eeg capabl detect notabl paradigm pit paradigm fmri resolv issu attempt obtain pit fmri scanner paradigm conduct erp paradigm close match pavlovian instrument evok alcohol chocol cue electrophysiolog correl drinker regularli consum chocol behavior pit p300 slow eventrel potenti reveal robust reactiv alcohol cue reflect limit attribut\n",
            "\t0.240\tpavloviancondit alcoholseek invigor discret contextu alcohol cue implic relaps crave independ stimul cue discret cue context contextu cue discret alcoholpredict cue experienc robustli cue stimul alcoholseek longevan pavlovian discrimin pdt session condit stimulu c trial pair ethanol 02 mlc stimulu c trial pdt entri fluid port ethanol deliv c next acclim altern nonalcohol cue ethanol withheld nonextinguish c c ethanol alcoholassoci pdt nonalcohol pdt c elicit port entri c indic pavlovian discrimin c elicit port entri c context alcohol seek driven c robust alcoholassoci separ experi extinguish contextalcohol c respond alcohol seek nonc interv spontan recoveri alcoholseek driven discret pavlovian alcohol cue invigor alcohol context excitatori pavlovian condit trigger alcoholseek alcoholismcontextethanollearningpavlovianconditioningreinstatementrenew introductionmateri methodssubjectsapparatusdrugsalcohol home cagepavlovian discrimin trainingexposur altern nonalcohol contexttestexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi extinct pavloviancondit alcoholseek behaviorstatist analysesresultsexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi pavloviancondit alcohol seek alcoholassoci nonalcohol contextexperi extinct pavloviancondit alcoholseek behaviordiscuss crave term character addict subject urg consum relaps sinha omalley litt flanneri evren crave trigger repeat cooccurr abus come predict pharmacolog addict substanc ludwig 1986 duka uslan sensori alcohol sight smell tast evok crave reactiv alcohol abus turn drink ludwig wikler 1974 pomerleau 1983 litt cooney sensori oral consum alcohol typic encount tempor discret gain promin activ consum convers configur multimod background necessarili gain lose promin relat nonetheless discret cue context evok crave bordnick conklin pari seek crombag shaham zironi fuch chaudhri 2008b perri mcnalli acquir predict avail pavlovian janak chaudhri determin discret contextu cue independ relaps longstand empir question cooccur everyday user cooccurr crave seek litt cooney pari nee question behavior pavloviancondit alcohol seek train discrimin auditori condit c c pair alcohol c alcohol chaudhri 2008b entri fluid port alcohol deliv cue discrimin repeatedli neither cue alcohol acclim never alcohol avail pavloviancondit alcohol seek present nonextinguish c c alcohol alcoholassoci nonalcohol separ experi sought alcoholassoci respond elicit c alcohol excitatori pavloviancondit stimulu repeat alcohol pavloviancondit extinguish alcohol respond c receiv extinct reveal alcoholseek trigger discret pavloviancondit alcohol cue invigor alcoholassoci alcohol seek elicit alcoholpredict c consist robust alcohol familiar context alcohol never consum extinguish pdt alcohol diminish c respond markedli alcoholseek driven pdt spontan recoveri implic crave alcohol abus encount discret contextu alcoholpredict cue concurr acquir predict relat c alcohol pdt chaudhri 2008b altern cue alcohol establish alcohol never acrosssess spontan entri fluid port fig s1 respond cue context note cue respond extinguish therebi parallel crave reactiv discret cue systemat extinguish staiger white 1991 thoma continu discrimin c c cue alcohol nonalcohol chaudhri discrimin remain intact cue pdt alcohol consum alcoholseek driven c invigor alcoholassoci nonalcohol context separ ethanol pdt discret cue experienc determin seek elicit cue zironi tsiang janak chaudhri 2008a nee translat impli crave vigor discret cue encount drugassoci discret contextu cue potent trigger relaps cue independ alcohol seek driven c nonalcohol remov nonalcohol se invigor pavloviancondit alcohol seek c trigger alcohol seek parallel reactiv drugpredict cue evok set resembl environ normal consum litt cooney wit duka strength cue reactiv underestim environ extens cuereact estim accur drugus environ set incorpor contextu drugus environ virtual realiti creat context prove investig bordnick pari traylor alcohol port entri elicit c present experi rapidli extinct alcohol seek c respond alcohol nonalcohol throughout session conduct extinct uncondit stimulu alcohol experienc produc extinct bouton addict undergo drugpredict discret cue repeatedli effort dampen cue reactiv drummond glautier 1994 conklin tiffani extinct session influenc set turn longev extinct instrument alcohol selfadministr reveal modul respond discret cue train perform oper obtain alcohol alcohol pair discret tonelight cue acquisit respond extinguish withhold alcohol extinct context placement extinct renew respond invigor conting present discret tonelight cue cue absent tsiang janak train leverpress alcohol extinct drop alcohol trigger reinstat alcohol extinct chaudhri 2008a congruent instrument alcohol seek pavloviancondit alcoholseek invigor alcoholassoci context experi facilit cuedriven alcohol seek alcohol attribut summat condit excitatori c alcoholassoci context stimul crave context acquir condit excitatori conklin preclin neutral euphor morphin facilit sexual trigger mitchel stewart 1990 uncondit stimulu invigor respond elicit condit stimulu predict uncondit stimulu reason alcohol function excitatori pavlovian c extinguish alcohol respond c extinct extinct manipul context respond pavloviancondit cue predict avers bouton boll 1979 consequ pdt session experi repeatedli pdt alcohol extinct altern nonalcohol spontan entri fluid port session s1 extinct contextalcohol contrari predict extinct respond c fig immedi c trend port entri interv session signal c contextextinct neglig extinct c respond discret alcoholpredict cue drive alcoholseek unequ pdt contextextinct session contribut conduct equival pdt contextextinct session extinct c respond mark extinct spontan recoveri extinct modest c respond start spontan recoveri extinct fewer port entri interv signal c extinguish excitatori pdt appear effect alcoholseek trigger alcoholseek trigger c spontan recoveri c alcohol extinguish pdt extinct extinct c respond pdt unsign alcoholseek spontan recoveri extinct alcoholassoci pavlovian condit stimulu elicit alcoholseek extinct c respond condit excitatori discret contextu alcohol cue summat respond discret cue function occasionsett stimulu modul stimulu elicit elicit bouton crombag properti modest c spontan recoveri extinct c whose alcohol diminish c alcohol summari alcoholseek elicit discret alcohol cue robustli invigor alcoholassoci strongest trigger crave relaps discret cue drugassoci extinct alcoholseek trigger pdt context acquir condit excitatori pavlovian aim diminish drugpredict cue extinct addict consid discret contextu drugpredict cue\n",
            "\t-0.964\tdetermin populationlevel alcohol estim alcoholattribut harm goal alcohol burden analyz chosen alcohol estim alcohol attribut fraction paf character chosen alcohol explor lognorm gamma weibul distribut 41 survey gender alcohol intern genaci european compar alcohol distribut alcohol paf calcul alcohol paf pancreat abovenam distribut tradit categori deviat gamma 851 dataset 66 genaci stepwis surveil organ lognorm fit gamma weibul distribut provid fit mark alcohol paf estim gamma weibul distribut paf categor alcohol estim deviat alcohol unit alcohol unit 1258 1223 1293 09207 1171 1144 1197 9474 gamma weibul gamma recommend alcohol survey fit flexibl ea modifi varianc deviat alcohol gamma explain alcohol allow alcohol model gamma alcohol consumptionempir distributiongamma distributionlognorm distributionweibul distributionpopulationattribut fractionexposur distributionupestimationp caput consumptionmeanstandard deviat introductionmethodsdescript surveysmethod fit distributionsmethod deriv alcohol pafmethod character gamma distributionsregress analysisresultsmodel alcohol distributioncharacter alcohol gamma distributiondiscussionconclusioncompet interestsauthor contributionssupplementari materialaddit file alcohol 200 intern classif icd10 threedigit code word fraction call populationattribut fraction paf disappear causal elimin alcohol counterfactu scenario everi person lifetim abstain alcohol alcohol risk alcohol alcoholattribut pancreat cirrhosi alcohol adequ predictor injuri ischem unintent injuri intent injuri drink calcul alcohol paf involv threestag estim alcohol establish solv equat paf alcohol intern agre estim paf categor model mathemat continu mathemat followsformula categori rr th categori continu alcohol calcul repres formulaformula 150 150 lifetim abstain rr lifetim abstain ex former drinker rr ex former drinker alcohol px alcohol rrx drinker accur calcul paf alcohol attempt model alcohol lognorm critic reason lognorm adequ approxim adapt distribut gamma favor lognorm mix distribut separ drink quantiti alcohol consum instrument monitor alcohol intern organ survey estim caput caput aggreg record unrecord tourist caput alcohol sale econom statist instrument survey exist accur estim survey ask drink exist survey consider underestim real typic cover alcohol sale caput figur estim countri caput disaggreg statist genderspecif estim instanc alcohol diseasespecif gender alcohol gender estim paf calcul alcoholattribut burden note respect survey underestim burden attribut alcohol paf calcul adjust consequ triangul alcohol survey caput paf calcul categor estim alcohol correct multipli top alcohol categori invers undercoverag caput consumptionth caput categori alcohol doserespons nonlinear estim alcohol gender accur estim alcohol paf strengthen dissemin alcohol outlin organ harm alcohol alcohol easili model fit compat caput estim except estim abstent intern alcohol consist follow wellknown rightskew distribut lognorm gamma weibul chosen estim paf paf pancreat exampl exist alcohol alcohol compar lognorm weibul gamma distribut calcul alcohol gamma weibul outperform lognorm fit empir distribut gamma choic model easili shift fit compat caput make estim aggreg caput abstent shift upward gamma deviat empir varianc deviat alcohol gamma explain alcohol accur model alcohol upshift decisionmak accur alcohol aid determin prioriti alloc resourc compet interest\n",
            "Pap smear,alcohol None\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.575\tnonlact lactat expressor septic shock   backgroundmethodsresultsconclus lactat sepsi septic shock express lactic acidosi object vasopressordepend septic shock lactic acidosi secondarili sought differenti lactat expressor nonlact expressor septic shock lactat face onehalf vasopressordepend septic shock express lactic acidosi present lactic acidosi indic perfus endpoint resuscit septic shock inadequ lactat expressor cultur\n",
            "\t0.548\tlactic acidosi septic shock metformin user lactat septic shock metformin alter lactat prognost metformin user nonus extrem lactat septic shock electron record emr admit emerg room januari june review compris septic shock lactat mmoll divid metformin user metformin nonus unexpos inhospit 44 metformin user 118 nonus metformin user nonus respect lactat hco admiss nonus inhospit metformintr 568 881 00001 lactat septic metformin clinician decid otherwis ill real  backgroundmethodsstatist analysisresultsdiscussionconclusionskey messag lactic acidosi lactat 735 emerg room intens unit icu lactic acidosi mark hypoperfus shock follow cardiopulmonari arrest serv indic lactat organ shock metformin choic interfer lactat metformin user nonus sepsi lactat unclear lactic acidosi divid obvious oxygen impair oxygen exist readili appar lactat pyruv pyruv convers carbon dioxid redox pyruvatelact shift toward lactat lactic acidosi metformin typic lactic acidosi term metformininduc lactic acidosi mila lactic acidosi metformin metformin overdos term metforminassoci lactic acidosi mala describ exact lactat metformin unclear metformin select inhibit isoform glycerophosph dehydrogenas catalyz convers glycerophosph dihydroxyaceton phosphat dhap cytosol dhap cytosol nad nadh nad inhibit convers lactat pyruv limit lactat gluconeogen precursor culmin lactat metformin interact dosedepend hepat extrahepat inhibit lactic acidosi metformin user nevertheless mala concern casefat mala predispos hypoperfus hypoxemia hypotens mila overdos metformin suicid attempt lactic acidosi unlik lactic acidosi easili correct remov mila lactat mmoll surviv compar metformin user nonus extrem lactat septic shock arriv lactat septic shock metformin user clinician decid otherwis ill real messag\n",
            "\t0.544\tinterpret lactat septic hyperlactatem distress   introductionmethodsresultsconclus lactat surrog hypoxia critic ill defin signific origin hyperlactatemia septic distress ard defin lactateproduc organ septic hyperlactatem ard patholog suppli depend outlin wrong interpret lactat surrog hypoxia\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.044\tlactat dehydrogenase5 ldh5 nonsmallcel hypoxia angiogen  lactat dehydrogenasehifca9nonsmallcel methodsldh5 immunohistochemistryassess hif ca9 expressionimmunohistochemistri angiogenesi angiogen expressioncomparison ldh immunohistochemistrystatist analysisresultsldh5 patternsdefinit cutoff pointslact dehydrogenas histopatholog variableslact dehydrogenas hif ca9lact dehydrogenas angiogenesisassoci hif vegf ca9ldh5 survivalserum ldh immunohistochemistrydiscuss archiv paraffinembed biopsi 76 squamou carcinoma 36 adenocarcinoma retriev section cut slide depart patholog univers oxford uk oper t12 n01 histolog grade nstage haematoxylin eosinstain section 87 age rang 74 median 63 104 54 112 dead median surviv 57 83 chosen peripheri hypoxia acid ldh5 adjac avoid bia ldh5 alveolar bronchial autopsi appar away underw pneumonectomi retreiv archiv depart patholog democritu univers alexandroupoli greec lactat dehydrogenas serum postop spectrum neoplast pancreat ta 2001a osteosarcoma ferrari testicular motzer voneyben melanoma hauschild metastat nasopharyng carcinoma ldh cheng 1998 clinicopatholog ldh radioresist head neck brizel metastat tumour kushner lutterbach lagerwaard ldh relaps lymphoma kondo wilder ovarian ryberg yuce argiri ta 2001b omin prognost signific ldh malign attribut reason ldh lactic acidif space featur vaupel 1989 stubb acid activ gelatinas cathepsin invas rozhin 1994 martinezzagulian 1996 macrophagemedi angiogenesi lactat facilit jensen 1986 zabel 1996 murray wilson protect mitochondrion hypoxiainduc bronk gore 1991 nemoto ldh intratumor hypoxia firth 1995 radiotherapi chemotherapeut ldh5 transcript hif ldh reflect upregul hifmolecular cascad firth 1995 semenza 1996 ebert bunn 1998 hypoxia induc stabilis hypoxia angiogenesi glycolysi semenza 1998 akakura harri ldh indirect hifdepend aggress cytotox regimen aebersold koukouraki 2001b koukouraki unlik reflect adequ intratumor ldh bulk neoplast variat ldh clearanc confound biochem ldh extract beasley give vari nonmalign stromal reactiv necrot compos obtain extract immunohistochem ldh5 ldh5 noncancer tumour intens ldh5 subcellular ldh5 localis relev immunohistochemistri characteris ldh adequ ldh ldh biochemistri compar ldh immunohistochemistri trend overlap ldh5 subcellular cytoplasm vari localis lactat dehydrogenas resid cytoplasm nucleus reddi shukla tumor stroma fibroblast vessel reactiv unreact ldh5 minor extens cytoplasm ldh5 stromal accompani ldh5 ldh posit ldh5 reactiv stroma reactiv ldh serum origin contribut stroma drop ldh confirm excess ldh subset nsclc origin ldh5 relat histolog mall ldh ovarian yuce ldh squamou hnc ross ewe sarcoma nasopharyng relat ldh cheng 1998 bacci ldh5 frequent tumour node statist histolog necrosi ldh5 ldh5 hif1 lesser hif2 note full accord ldh5 transcript hif semenza 1996 ebert bunn 1998 lactat dehydrogenase5 hif immunostain reactiv diffus necrot giatromanolaki 2001b ca9 necrosi localis layer proxim necrot giatromanolaki 2001a lactat dehydrogenase5 ca9 ca9 hif wykoff threshold hypoxia ca9 ldh5 differ giatromanolaki 2001a ldh ca9 discord relat necrosi nevertheless hif ldh5 oncogen diffus ca9 tumour hif1 accompani ldh5 defect hif1 polymorph alter hifdna exist ebert bunn 1998 ema ldh minor hif reactiv hypoxia ldh5 cmyc shim 1997 hif1 ldh5 predict intact defect hif hif postop nsclc ldh5 similarli doubl stratif hif1 hif2 ldh5 overexpress hif ldh5 potent prognost reflect downstream programm hif mediat ldh5 ca9 independ acidif explain aggress behaviour rozhin 1994 martinezzagulian 1996 stubb ldh5 angiogenesi angiogen ldh microvessel ldh5 vegf bfgf tp note coexpress ldh hif acidosi vegf upregul fukumura shi herein analys vegf hif1 hif2 ca9 margin hif1 giatromanolaki 2001b ldh vegf pleural fluid cheng ldh bfgf hifindepend reason acidif lactat bfgf darcangelo bfgf ldh riera immunohistochem ldh tumor lactat dehydrogenas immunohistochemistri predict ldh ldh biochemistri extract lactat dehydrogenas hif abund angiogen ldh repres predict aggress becom power prognost hif downregul ldh background hif subgroup tumour aggress hif prove hif kung endogen hypoxia predictor radiotherapi aebersold koukouraki 2001a 2001b hif ldh ldh acid hypoxia name ca9 omin ldh ca9 hif immunohistochemistri reliabl predict aggress acid hypoxia\n",
            "\t-1.226\tprognost lactat dehydrogenas colorect metaanalysi prognost lactat dehydrogenas colorect controversi heterogen comprehens review lactat dehydrogenas colorect databas search septemb 2014 prognost lactat dehydrogenas colorect pubm embas cochran regist extract hazard ratio hr confid interv ci randomeffect metaanalys o progressionfre pf thirtytwo cumul 8261 metaanalys lactat dehydrogenas o hr 175 152 202 colorect obviou o nonmetastat colorect hr 121 079 186 prognost lactat dehydrogenas pf hr 136 098 187 subgroup prognost signific lactat dehydrogenas locat antiangiogenesi bia lactat dehydrogenas o colorect predictor pf onlin version articl doi101186s1288501622763 author user  backgroundmethodssearch criteriadata extractionstudi assessmentstatist analysesresultsbaselin characteristicsth prognost lactat dehydrogenas levelssubgroup analysesdiscussionconclusionsavail colorect crc repres malign throughout crc extrem metastas advanc modern therapi crc adjuv set iv crc discov biomark atrisk recurr reli heavili aerob glycolysi warburg lactat dehydrogenas mediat convers pyruv lactat emerg anticanc lactat dehydrogenas consist prognost prospect etc sign serolog ldh predictor termin ldh hr 2087 0002 termin crc prognost lactat dehydrogenas crc controversi metaanalysi prognost lactat dehydrogenas crc lactat dehydrogenas crc subgroup prognost nonmetastat crc encourag effort subpopul lactat dehydrogenas put metastat avail\n",
            "\t-2.250\theat lactic acidemia sepsi lactat correl septic shock heat sepsi heat lactat protect decreas sepsi lactat septic heat lactic heattreat septic 005 septic heat pretreat myeloperoxidas heat pretreat neutrophil infiltr mediat heat amelior lactic acidemia sepsi heat attenu heatinduc protect lactic acidemia sepsi explor injuryheat stresslactatesept shocktumor necrosi introductionmateri methodsday 1heat groupsnormothermia groupsday 2cecal ligat perfor 2sham cecal ligat perfor 4day 3tumor necrosi interleukin1 macrophag protein2 assaysmyeloperoxidas assays6ketoprostaglandin thromboxan assaysstatisticsresultssurvivalcecumplasma lactatearteri gasespulmonari myeloperoxidas activitycytokin eicosanoid lavagediscuss septic shock continu spite newer antibiot support sepsi organ hypoperfus hypotens clinic hypoperfus manifest lactic acidosi oliguria arteri lactat reliabl perfus correl lactat mmoll indic inadequ perfus sepsi begin endotoxin monocyt necrosi interleukin il1 il1 numer mediat il6 il8 eicosanoid macrophag mip2 injuryacut distress ard consequ sepsi neutrophil sequestr histolog hallmark ard heat evolutionarili heat shock protect take beyond alter heat administ sepsi protect sepsisinduc cardiopulmonari protect heat sepsi proinflammatori cytokin object heat lactat protect decreas sepsi hypothes heat sepsi attenu lactic acidemia heatexpos sepsisinduc suppress heat amelior lactic acidemia sepsi attenu sepsi lactic acidemia suppli depend util favor anaerob organ perfus consequ pyruv dehydrogenas mitochondrion endotoxemia hyperlactatemia shock sepsisinduc ard heat attenu lactat clp lactic acidemia heat sepsi unclear lactat lactat clearanc lactat util lactic heatstress septic reflect organ perfus lactat clearanc util heat protect sepsi pretreat septic heat edema septic heat downregul attenu il1 septic sequestr neutrophil myeloperoxidas myeloperoxidas lung septic heat attenu lactic heat septic heat protect heat depend peak reach alveolar spleen heat shock heat 41 15min protocol util mediat lipopolysaccharid vari depend heat period heat temperatur attenu sepsi heat amelior lactic acidemia sepsi possibl preserv organ perfus improv prevent unabl attenu heat endotoxemia optim heat cardiopulmonari protect endotoxem\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.575\tnonlact lactat expressor septic shock   backgroundmethodsresultsconclus lactat sepsi septic shock express lactic acidosi object vasopressordepend septic shock lactic acidosi secondarili sought differenti lactat expressor nonlact expressor septic shock lactat face onehalf vasopressordepend septic shock express lactic acidosi present lactic acidosi indic perfus endpoint resuscit septic shock inadequ lactat expressor cultur\n",
            "\t0.548\tlactic acidosi septic shock metformin user lactat septic shock metformin alter lactat prognost metformin user nonus extrem lactat septic shock electron record emr admit emerg room januari june review compris septic shock lactat mmoll divid metformin user metformin nonus unexpos inhospit 44 metformin user 118 nonus metformin user nonus respect lactat hco admiss nonus inhospit metformintr 568 881 00001 lactat septic metformin clinician decid otherwis ill real  backgroundmethodsstatist analysisresultsdiscussionconclusionskey messag lactic acidosi lactat 735 emerg room intens unit icu lactic acidosi mark hypoperfus shock follow cardiopulmonari arrest serv indic lactat organ shock metformin choic interfer lactat metformin user nonus sepsi lactat unclear lactic acidosi divid obvious oxygen impair oxygen exist readili appar lactat pyruv pyruv convers carbon dioxid redox pyruvatelact shift toward lactat lactic acidosi metformin typic lactic acidosi term metformininduc lactic acidosi mila lactic acidosi metformin metformin overdos term metforminassoci lactic acidosi mala describ exact lactat metformin unclear metformin select inhibit isoform glycerophosph dehydrogenas catalyz convers glycerophosph dihydroxyaceton phosphat dhap cytosol dhap cytosol nad nadh nad inhibit convers lactat pyruv limit lactat gluconeogen precursor culmin lactat metformin interact dosedepend hepat extrahepat inhibit lactic acidosi metformin user nevertheless mala concern casefat mala predispos hypoperfus hypoxemia hypotens mila overdos metformin suicid attempt lactic acidosi unlik lactic acidosi easili correct remov mila lactat mmoll surviv compar metformin user nonus extrem lactat septic shock arriv lactat septic shock metformin user clinician decid otherwis ill real messag\n",
            "\t0.544\tinterpret lactat septic hyperlactatem distress   introductionmethodsresultsconclus lactat surrog hypoxia critic ill defin signific origin hyperlactatemia septic distress ard defin lactateproduc organ septic hyperlactatem ard patholog suppli depend outlin wrong interpret lactat surrog hypoxia\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-1.044\tlactat dehydrogenase5 ldh5 nonsmallcel hypoxia angiogen  lactat dehydrogenasehifca9nonsmallcel methodsldh5 immunohistochemistryassess hif ca9 expressionimmunohistochemistri angiogenesi angiogen expressioncomparison ldh immunohistochemistrystatist analysisresultsldh5 patternsdefinit cutoff pointslact dehydrogenas histopatholog variableslact dehydrogenas hif ca9lact dehydrogenas angiogenesisassoci hif vegf ca9ldh5 survivalserum ldh immunohistochemistrydiscuss archiv paraffinembed biopsi 76 squamou carcinoma 36 adenocarcinoma retriev section cut slide depart patholog univers oxford uk oper t12 n01 histolog grade nstage haematoxylin eosinstain section 87 age rang 74 median 63 104 54 112 dead median surviv 57 83 chosen peripheri hypoxia acid ldh5 adjac avoid bia ldh5 alveolar bronchial autopsi appar away underw pneumonectomi retreiv archiv depart patholog democritu univers alexandroupoli greec lactat dehydrogenas serum postop spectrum neoplast pancreat ta 2001a osteosarcoma ferrari testicular motzer voneyben melanoma hauschild metastat nasopharyng carcinoma ldh cheng 1998 clinicopatholog ldh radioresist head neck brizel metastat tumour kushner lutterbach lagerwaard ldh relaps lymphoma kondo wilder ovarian ryberg yuce argiri ta 2001b omin prognost signific ldh malign attribut reason ldh lactic acidif space featur vaupel 1989 stubb acid activ gelatinas cathepsin invas rozhin 1994 martinezzagulian 1996 macrophagemedi angiogenesi lactat facilit jensen 1986 zabel 1996 murray wilson protect mitochondrion hypoxiainduc bronk gore 1991 nemoto ldh intratumor hypoxia firth 1995 radiotherapi chemotherapeut ldh5 transcript hif ldh reflect upregul hifmolecular cascad firth 1995 semenza 1996 ebert bunn 1998 hypoxia induc stabilis hypoxia angiogenesi glycolysi semenza 1998 akakura harri ldh indirect hifdepend aggress cytotox regimen aebersold koukouraki 2001b koukouraki unlik reflect adequ intratumor ldh bulk neoplast variat ldh clearanc confound biochem ldh extract beasley give vari nonmalign stromal reactiv necrot compos obtain extract immunohistochem ldh5 ldh5 noncancer tumour intens ldh5 subcellular ldh5 localis relev immunohistochemistri characteris ldh adequ ldh ldh biochemistri compar ldh immunohistochemistri trend overlap ldh5 subcellular cytoplasm vari localis lactat dehydrogenas resid cytoplasm nucleus reddi shukla tumor stroma fibroblast vessel reactiv unreact ldh5 minor extens cytoplasm ldh5 stromal accompani ldh5 ldh posit ldh5 reactiv stroma reactiv ldh serum origin contribut stroma drop ldh confirm excess ldh subset nsclc origin ldh5 relat histolog mall ldh ovarian yuce ldh squamou hnc ross ewe sarcoma nasopharyng relat ldh cheng 1998 bacci ldh5 frequent tumour node statist histolog necrosi ldh5 ldh5 hif1 lesser hif2 note full accord ldh5 transcript hif semenza 1996 ebert bunn 1998 lactat dehydrogenase5 hif immunostain reactiv diffus necrot giatromanolaki 2001b ca9 necrosi localis layer proxim necrot giatromanolaki 2001a lactat dehydrogenase5 ca9 ca9 hif wykoff threshold hypoxia ca9 ldh5 differ giatromanolaki 2001a ldh ca9 discord relat necrosi nevertheless hif ldh5 oncogen diffus ca9 tumour hif1 accompani ldh5 defect hif1 polymorph alter hifdna exist ebert bunn 1998 ema ldh minor hif reactiv hypoxia ldh5 cmyc shim 1997 hif1 ldh5 predict intact defect hif hif postop nsclc ldh5 similarli doubl stratif hif1 hif2 ldh5 overexpress hif ldh5 potent prognost reflect downstream programm hif mediat ldh5 ca9 independ acidif explain aggress behaviour rozhin 1994 martinezzagulian 1996 stubb ldh5 angiogenesi angiogen ldh microvessel ldh5 vegf bfgf tp note coexpress ldh hif acidosi vegf upregul fukumura shi herein analys vegf hif1 hif2 ca9 margin hif1 giatromanolaki 2001b ldh vegf pleural fluid cheng ldh bfgf hifindepend reason acidif lactat bfgf darcangelo bfgf ldh riera immunohistochem ldh tumor lactat dehydrogenas immunohistochemistri predict ldh ldh biochemistri extract lactat dehydrogenas hif abund angiogen ldh repres predict aggress becom power prognost hif downregul ldh background hif subgroup tumour aggress hif prove hif kung endogen hypoxia predictor radiotherapi aebersold koukouraki 2001a 2001b hif ldh ldh acid hypoxia name ca9 omin ldh ca9 hif immunohistochemistri reliabl predict aggress acid hypoxia\n",
            "\t-1.226\tprognost lactat dehydrogenas colorect metaanalysi prognost lactat dehydrogenas colorect controversi heterogen comprehens review lactat dehydrogenas colorect databas search septemb 2014 prognost lactat dehydrogenas colorect pubm embas cochran regist extract hazard ratio hr confid interv ci randomeffect metaanalys o progressionfre pf thirtytwo cumul 8261 metaanalys lactat dehydrogenas o hr 175 152 202 colorect obviou o nonmetastat colorect hr 121 079 186 prognost lactat dehydrogenas pf hr 136 098 187 subgroup prognost signific lactat dehydrogenas locat antiangiogenesi bia lactat dehydrogenas o colorect predictor pf onlin version articl doi101186s1288501622763 author user  backgroundmethodssearch criteriadata extractionstudi assessmentstatist analysesresultsbaselin characteristicsth prognost lactat dehydrogenas levelssubgroup analysesdiscussionconclusionsavail colorect crc repres malign throughout crc extrem metastas advanc modern therapi crc adjuv set iv crc discov biomark atrisk recurr reli heavili aerob glycolysi warburg lactat dehydrogenas mediat convers pyruv lactat emerg anticanc lactat dehydrogenas consist prognost prospect etc sign serolog ldh predictor termin ldh hr 2087 0002 termin crc prognost lactat dehydrogenas crc controversi metaanalysi prognost lactat dehydrogenas crc lactat dehydrogenas crc subgroup prognost nonmetastat crc encourag effort subpopul lactat dehydrogenas put metastat avail\n",
            "\t-2.250\theat lactic acidemia sepsi lactat correl septic shock heat sepsi heat lactat protect decreas sepsi lactat septic heat lactic heattreat septic 005 septic heat pretreat myeloperoxidas heat pretreat neutrophil infiltr mediat heat amelior lactic acidemia sepsi heat attenu heatinduc protect lactic acidemia sepsi explor injuryheat stresslactatesept shocktumor necrosi introductionmateri methodsday 1heat groupsnormothermia groupsday 2cecal ligat perfor 2sham cecal ligat perfor 4day 3tumor necrosi interleukin1 macrophag protein2 assaysmyeloperoxidas assays6ketoprostaglandin thromboxan assaysstatisticsresultssurvivalcecumplasma lactatearteri gasespulmonari myeloperoxidas activitycytokin eicosanoid lavagediscuss septic shock continu spite newer antibiot support sepsi organ hypoperfus hypotens clinic hypoperfus manifest lactic acidosi oliguria arteri lactat reliabl perfus correl lactat mmoll indic inadequ perfus sepsi begin endotoxin monocyt necrosi interleukin il1 il1 numer mediat il6 il8 eicosanoid macrophag mip2 injuryacut distress ard consequ sepsi neutrophil sequestr histolog hallmark ard heat evolutionarili heat shock protect take beyond alter heat administ sepsi protect sepsisinduc cardiopulmonari protect heat sepsi proinflammatori cytokin object heat lactat protect decreas sepsi hypothes heat sepsi attenu lactic acidemia heatexpos sepsisinduc suppress heat amelior lactic acidemia sepsi attenu sepsi lactic acidemia suppli depend util favor anaerob organ perfus consequ pyruv dehydrogenas mitochondrion endotoxemia hyperlactatemia shock sepsisinduc ard heat attenu lactat clp lactic acidemia heat sepsi unclear lactat lactat clearanc lactat util lactic heatstress septic reflect organ perfus lactat clearanc util heat protect sepsi pretreat septic heat edema septic heat downregul attenu il1 septic sequestr neutrophil myeloperoxidas myeloperoxidas lung septic heat attenu lactic heat septic heat protect heat depend peak reach alveolar spleen heat shock heat 41 15min protocol util mediat lipopolysaccharid vari depend heat period heat temperatur attenu sepsi heat amelior lactic acidemia sepsi possibl preserv organ perfus improv prevent unabl attenu heat endotoxemia optim heat cardiopulmonari protect endotoxem\n",
            "septicemia,lactate dehydrogenase,lactate None\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "Exception ignored in: <generator object tqdm_notebook.__iter__ at 0x7f562094a150>\n",
            "Traceback (most recent call last):\n",
            "  File \"/usr/local/lib/python3.7/dist-packages/tqdm/notebook.py\", line 220, in __iter__\n",
            "    self.sp(bar_style='danger')\n",
            "AttributeError: 'tqdm_notebook' object has no attribute 'sp'\n"
          ],
          "name": "stderr"
        },
        {
          "output_type": "error",
          "ename": "TypeError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-25-69f2924ce8c5>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      3\u001b[0m   \u001b[0moutput1\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m{\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      4\u001b[0m   \u001b[0moutput2\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m{\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 5\u001b[0;31m   \u001b[0moutput1\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mq2\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msearch\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mq2\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      6\u001b[0m   \u001b[0moutput2\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mq1\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msearch\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mq2\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      7\u001b[0m   \u001b[0;32mfor\u001b[0m \u001b[0mk\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mv\u001b[0m \u001b[0;32min\u001b[0m \u001b[0moutput1\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mitems\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m<ipython-input-20-1353fdef0ac4>\u001b[0m in \u001b[0;36msearch\u001b[0;34m(query)\u001b[0m\n\u001b[1;32m      5\u001b[0m     \u001b[0;31m##### Sematic Search #####\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      6\u001b[0m     \u001b[0;31m# Encode the query using the bi-encoder and find potentially relevant passages\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 7\u001b[0;31m     \u001b[0mquestion_embedding\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mbi_encoder\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mencode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mquery\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert_to_tensor\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      8\u001b[0m     \u001b[0mquestion_embedding\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mquestion_embedding\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcuda\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      9\u001b[0m     \u001b[0mhits\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mutil\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msemantic_search\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mquestion_embedding\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcorpus_embeddings\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtop_k\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtop_k\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.7/dist-packages/sentence_transformers/SentenceTransformer.py\u001b[0m in \u001b[0;36mencode\u001b[0;34m(self, sentences, batch_size, show_progress_bar, output_value, convert_to_numpy, convert_to_tensor, device, normalize_embeddings)\u001b[0m\n\u001b[1;32m    154\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mstart_index\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mtrange\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msentences\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbatch_size\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdesc\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"Batches\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdisable\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mnot\u001b[0m \u001b[0mshow_progress_bar\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    155\u001b[0m             \u001b[0msentences_batch\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msentences_sorted\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mstart_index\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0mstart_index\u001b[0m\u001b[0;34m+\u001b[0m\u001b[0mbatch_size\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 156\u001b[0;31m             \u001b[0mfeatures\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtokenize\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msentences_batch\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    157\u001b[0m             \u001b[0mfeatures\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mbatch_to_device\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfeatures\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdevice\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    158\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.7/dist-packages/sentence_transformers/SentenceTransformer.py\u001b[0m in \u001b[0;36mtokenize\u001b[0;34m(self, texts)\u001b[0m\n\u001b[1;32m    307\u001b[0m         \u001b[0mTokenizes\u001b[0m \u001b[0mthe\u001b[0m \u001b[0mtexts\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    308\u001b[0m         \"\"\"\n\u001b[0;32m--> 309\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_first_module\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtokenize\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtexts\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    310\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    311\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mget_sentence_features\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0mfeatures\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.7/dist-packages/sentence_transformers/models/Transformer.py\u001b[0m in \u001b[0;36mtokenize\u001b[0;34m(self, texts)\u001b[0m\n\u001b[1;32m     86\u001b[0m             \u001b[0mbatch1\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbatch2\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     87\u001b[0m             \u001b[0;32mfor\u001b[0m \u001b[0mtext_tuple\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mtexts\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 88\u001b[0;31m                 \u001b[0mbatch1\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtext_tuple\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     89\u001b[0m                 \u001b[0mbatch2\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtext_tuple\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     90\u001b[0m             \u001b[0mto_tokenize\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mbatch1\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbatch2\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mTypeError\u001b[0m: 'float' object is not subscriptable"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 606
        },
        "id": "w7XnubSxIfzo",
        "outputId": "b6e97b61-4184-411b-92b9-4dbff70e70b6"
      },
      "source": [
        "top_relevance = queries['summary'].apply(lambda x:search(query = x ))\n",
        "top_relevance"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Bi-Encoder Retrieval hits\n",
            "\t0.361\t 70 year age schedul joint replac surgeri random tramacet naloxon plu morphin pca morphin pca ass qualiti analgesia postop period primari object determin opioid use combin use oral tramacet naloxon infus periop elderli 70 yr older elect knee hip arthroplasti spinal anesthesia secondari object determin incid va score ≥4 advers effect nausea vomit sedat respiratori depress pruritu confus time independ mobil hypothesi periop naloxon infus tramacet provid adequ analgesia elderli undergo total kneehip arthroplasti associ 80 reduct opioid use reduc opioidinduc side effect\n",
            "\t0.330\t purpos examin variat physic physiolog characterist accord sport age adolesc adult male team handbal th player adolesc n19 age 181±14 yr adult n23 286±57 yr player examin anthropometr characterist somatotyp bodi composit perform physic work capac forceveloc later scapular slide lsst shark skill davi squat jump sj countermov vertic jump without cmj\n",
            "\t0.321\t child 712 year age function abdomin pain n42 determin aim examin character threshold exposur pk v respons pd relationship pmo menthol aim pd pmo ass microbiom composit 16 rna sequenc transit ratecontractil activ use smartpill® aim evalu potenti associ pd respons clinic abdomin pain stool pattern via valid diari psychosoci distress anxieti depress somat character potenti side effect questionnair\n",
            "\n",
            "-------------------------\n",
            "\n",
            "Top-3 Cross-Encoder Re-ranker hits\n",
            "\t-6.979\t safeti dosimetri bfpet™ evalu healthi volunt coronari arteri cad male femal age rang 2080 year old\n",
            "\t-6.979\t safeti dosimetri bfpet™ evalu healthi volunt coronari arteri cad male femal age rang 2080 year old\n",
            "\t-8.591\t cross section banha univers hospit among employe age subject 2060 year old male femal investig done plu abdomin ultrasound grade fatti liver dopler carotid intima medium thick\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "error",
          "ename": "TypeError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-17-dac34e67a790>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mtop_relevance\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mqueries\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'summary'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0msearch\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mquery\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mx\u001b[0m \u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m \u001b[0mtop_relevance\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.7/dist-packages/pandas/core/series.py\u001b[0m in \u001b[0;36mapply\u001b[0;34m(self, func, convert_dtype, args, **kwds)\u001b[0m\n\u001b[1;32m   4211\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4212\u001b[0m                 \u001b[0mvalues\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mastype\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mobject\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_values\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 4213\u001b[0;31m                 \u001b[0mmapped\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mlib\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmap_infer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mf\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mconvert_dtype\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   4214\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4215\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmapped\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmapped\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mSeries\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32mpandas/_libs/lib.pyx\u001b[0m in \u001b[0;36mpandas._libs.lib.map_infer\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32m<ipython-input-17-dac34e67a790>\u001b[0m in \u001b[0;36m<lambda>\u001b[0;34m(x)\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mtop_relevance\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mqueries\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'summary'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0msearch\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mquery\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mx\u001b[0m \u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m \u001b[0mtop_relevance\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m<ipython-input-15-351647bc3e6c>\u001b[0m in \u001b[0;36msearch\u001b[0;34m(query)\u001b[0m\n\u001b[1;32m     32\u001b[0m     \u001b[0;32mfor\u001b[0m \u001b[0mhit\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mhits_re\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;36m3\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     33\u001b[0m         \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"\\t{:.3f}\\t{}\"\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mhit\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'cross-score'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdoc_sum\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mhit\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'corpus_id'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreplace\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"\\n\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\" \"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 34\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0mhits_re\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'cross-score'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdoc_sum\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mhits_re\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'corpus_id'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     35\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     36\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mTypeError\u001b[0m: list indices must be integers or slices, not str"
          ]
        }
      ]
    }
  ]
}